PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chicurel, M				Chicurel, M			Bioinformatics: Bringing it all together	NATURE			English	Article																			0	28	30	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					751	+		10.1038/419751a	http://dx.doi.org/10.1038/419751a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384708	Bronze			2022-12-28	WOS:000178615200047
J	Madsen, KM; Hviid, A; Vestergaard, M; Schendel, D; Wohlfahrt, J; Thorsen, P; Olsen, J; Melbye, M				Madsen, KM; Hviid, A; Vestergaard, M; Schendel, D; Wohlfahrt, J; Thorsen, P; Olsen, J; Melbye, M			A population-based study of measles, mumps, and rubella vaccination and autism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MMR IMMUNIZATION; FOLLOW-UP; DISORDERS; PREVALENCE; DIAGNOSIS; REGISTER	Background: It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism. Methods: We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR-vaccination status was obtained from the Danish National Board of Health. Information on the children's autism status was obtained from the Danish Psychiatric Central Register, which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark. We obtained information on potential confounders from the Danish Medical Birth Registry, the National Hospital Registry, and Statistics Denmark. Results: Of the 537,303 children in the cohort (representing 2,129,864 person-years), 440,655 (82.0 percent) had received the MMR vaccine. We identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders. After adjustment for potential confounders, the relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group, was 0.92 (95 percent confidence interval, 0.68 to 1.24), and the relative risk of another autistic-spectrum disorder was 0.83 (95 percent confidence interval, 0.65 to 1.07). There was no association between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autistic disorder. Conclusions: This study provides strong evidence against the hypothesis that MMR vaccination causes autism.	Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, DK-8000 Aarhus C, Denmark; Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabilities, Atlanta, GA USA	Aarhus University; Aarhus University; Statens Serum Institut; Centers for Disease Control & Prevention - USA	Madsen, KM (corresponding author), Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, Vennelyst Blvd 6, DK-8000 Aarhus C, Denmark.	kmm@dadlnet.dk	Hviid, Anders/AAH-4319-2020; Vestergaard, Mogens/M-9333-2014	Hviid, Anders/0000-0002-7509-9127; Vestergaard, Mogens/0000-0001-8830-2174; Schendel, Diana/0000-0002-8588-1227; melbye, mads/0000-0001-8264-6785				Andersen TF, 1999, DAN MED BULL, V46, P263; [Anonymous], 2001, Wkly Epidemiol Rec, V76, P85; Baird G, 2000, J AM ACAD CHILD PSY, V39, P694, DOI 10.1097/00004583-200006000-00007; Bertrand J, 2001, PEDIATRICS, V108, P1155, DOI 10.1542/peds.108.5.1155; BURD L, 1987, J AM ACAD CHILD PSY, V26, P700, DOI 10.1097/00004583-198709000-00014; *CDCP, 2002, EP PREV VACC PREV DI; Croen LA, 2002, J AUTISM DEV DISORD, V32, P207, DOI 10.1023/A:1015453830880; Dales L, 2001, JAMA-J AM MED ASSOC, V285, P1183, DOI 10.1001/jama.285.9.1183; *DEP DEV SERV, 1999, CHANG POP PERS AUT P; Edwardes M, 2001, JAMA-J AM MED ASSOC, V285, P2852, DOI 10.1001/jama.285.22.2852; Filipek PA, 2000, J AUTISM DEV DISORD, V30, P81; Filipek PA, 1999, J AUTISM DEV DISORD, V29, P439, DOI 10.1023/A:1021943802493; Fombonne E, 1997, J AM ACAD CHILD PSY, V36, P1561, DOI 10.1016/S0890-8567(09)66566-7; Fombonne E, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e58; GRIFFIN DE, 1989, NEW ENGL J MED, V320, P1667, DOI 10.1056/NEJM198906223202506; Hill A, 2001, PSYCHOPATHOLOGY, V34, P187, DOI 10.1159/000049305; Hills, 1993, STAT MODELS EPIDEMIO; JOHNSON RT, 1984, NEW ENGL J MED, V310, P137, DOI 10.1056/NEJM198401193100301; Kaye JA, 2001, BRIT MED J, V322, P460, DOI 10.1136/bmj.322.7284.460; Knudsen LB, 1998, DAN MED BULL, V45, P320; MALIG C, 1996, 66 IIVRS; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Patja A, 2000, PEDIATR INFECT DIS J, V19, P1127, DOI 10.1097/00006454-200012000-00002; Peltola H, 1998, LANCET, V351, P1327, DOI 10.1016/S0140-6736(98)24018-9; Singh VK, 2002, J BIOMED SCI, V9, P359, DOI 10.1007/BF02256592; Smeeth L, 2001, BRIT MED J, V323, P163, DOI 10.1136/bmj.323.7305.163; Stratton K, 2001, IMMUNIZATION SAFETY; Taylor B, 2002, BRIT MED J, V324, P393, DOI 10.1136/bmj.324.7334.393; Taylor B, 1999, LANCET, V353, P2026, DOI 10.1016/S0140-6736(99)01239-8; Uhlmann V, 2002, J CLIN PATHOL-MOL PA, V55, P84, DOI 10.1136/mp.55.2.84; Vellinga A, 2002, ACTA PAEDIATR, V91, P599, DOI 10.1080/080352502753711759; VOLKMAR FR, 1994, AM J PSYCHIAT, V151, P1361; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Wakefield Andrew J., 2000, Adverse Drug Reactions and Toxicological Reviews, V19, P265; WHO, 2012, ICD 10 CLASS MENT BE; 2000, US HOUS REPR 106 C 2; 2000, LANCET, V355, P1379	37	403	417	1	316	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2002	347	19					1477	1482		10.1056/NEJMoa021134	http://dx.doi.org/10.1056/NEJMoa021134			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	611XG	12421889				2022-12-28	WOS:000179042700002
J	Carter, RC				Carter, RC			The impact of public schools on childhood obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA	Johns Hopkins University	Carter, RC (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.							Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; Cullen KW, 2000, J AM DIET ASSOC, V100, P1482, DOI 10.1016/S0002-8223(00)00414-4; Dwyer JT, 1996, PREV MED, V25, P413, DOI 10.1006/pmed.1996.0073; Edmunds L, 2001, BMJ-BRIT MED J, V323, P916, DOI 10.1136/bmj.323.7318.916; *FOOD NUTR SERV, 2002, NUTR PROGR FACTS NAT; Munoz KA, 1997, PEDIATRICS, V100, P323, DOI 10.1542/peds.100.3.323; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Sallis JF, 2001, AM J PUBLIC HEALTH, V91, P618, DOI 10.2105/AJPH.91.4.618; Story M, 1999, INT J OBESITY, V23, pS43, DOI 10.1038/sj.ijo.0800859; Wang YF, 2001, INT J EPIDEMIOL, V30, P1129, DOI 10.1093/ije/30.5.1129; 1995, FED REG, V60, P31188	11	37	38	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2180	2180		10.1001/jama.288.17.2180	http://dx.doi.org/10.1001/jama.288.17.2180			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413386	Green Published			2022-12-28	WOS:000179048100036
J	Fried, EJ; Nestle, M				Fried, EJ; Nestle, M			The growing political movement against soft drinks in schools	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD		NYU, Dept Nutr & Food Studies, New York, NY 10011 USA	New York University	Fried, EJ (corresponding author), NYU, Dept Nutr & Food Studies, New York, NY 10011 USA.							Borzekowski DLG, 2001, J AM DIET ASSOC, V101, P42, DOI 10.1016/S0002-8223(01)00012-8; *BRUN COMM, 2002, ADV PROM KIDS; Cullen KW, 2000, J AM DIET ASSOC, V100, P1482, DOI 10.1016/S0002-8223(00)00414-4; Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1; Munoz KA, 1997, PEDIATRICS, V100, P323, DOI 10.1542/peds.100.3.323; NESTLE M, 2013, FOOD POLITICS FOOD I; SEVERSON K, 2002, SAN FRANCISCO C 0828, pA1; STARKE AM, 2001, OREGONIAN       0911, pFD1	8	40	40	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2181	2181		10.1001/jama.288.17.2181	http://dx.doi.org/10.1001/jama.288.17.2181			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413387	hybrid			2022-12-28	WOS:000179048100037
J	Salpeter, SR; Ormiston, TM; Salpeter, EE				Salpeter, SR; Ormiston, TM; Salpeter, EE			Cardioselective beta-blockers in patients with reactive airway disease: A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; HYPERTENSIVE PATIENTS; ADRENERGIC-BLOCKADE; ADRENOCEPTOR ANTAGONISTS; RESPIRATORY-FUNCTION; VENTILATORY FUNCTION; ASTHMATIC-PATIENTS; BETA-1-ADRENOCEPTOR ANTAGONIST; INTRAVENOUS METOPROLOL; PULMONARY-FUNCTION	Objective: To assess the effect of cardioselective beta-blockers on respiratory function of patients with reactive airway disease. Data Sources: Comprehensive searches of the EMBASE, MEDLINE, and CINAHL databases from 1966 to May 2001 and scanning of references of the identified articles and related reviews. Study Selection: Randomized, blinded, placebo-controlled trials that studied the effects of cardioselective beta-blockers on FEV, symptoms, and the use of inhaled beta(2)-agonists in patients with reactive airway disease were selected. Interventions studied were the administration of a cardioselective beta-blocker and administration of beta(2)-agonist after the study drug. Data Extraction: Outcomes measured were the change in FEV, from baseline, the number of patients with respiratory symptoms, and the use of inhaled beta(2)-agonists with active treatment compared with placebo. Data Synthesis: Nineteen studies on single-dose treatment and 10 studies on continued treatment were included. Administration of a single dose of a cardioselective p-blocker was associated with a 7.46% (95% Cl, 5.59% to 9.32%) decrease in FEV1 and a 4.63% (Cl, 2.47% to 6.78%) increase in FEV1 response to beta-agonist compared with placebo, with no increase in symptoms. Trials lasting from 3 days to 4 weeks produced no significant change in FEV1 (-0.42% [Cl, -3.74% to 2.91%]), symptoms, or inhaler use compared with placebo but maintained an 8.74% (Cl, 1.96% to 15.52%) increase in beta-agonist response. No significant treatment effect in terms of FEV, was found in patients with concomitant chronic obstructive pulmonary disease, whether single doses (change in FEV1, -5.28% [Cl, -10.03% to -0.54%]) or continued treatment (change in FEV1, 1.07% [Cl, -3.3% to 5.44%]) was given. Conclusions: Cardioselective beta-blockers do not produce clinically significant adverse respiratory effects in patients with mild to moderate reactive airway disease. The results were similar for patients with concomitant chronic airways obstruction. Given their demonstrated benefit in such conditions as heart failure, cardiac arrhythmias, and hypertension, cardioselective beta-blockers; should not be withheld from patients with mild to moderate reactive airway disease.	Santa Clara Valley Med Ctr, Dept Med, San Jose, CA 95128 USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; Cornell Univ, Ithaca, NY USA	Santa Clara Valley Medical Center; Stanford University; Cornell University	Salpeter, SR (corresponding author), Santa Clara Valley Med Ctr, Dept Med, 751 S Bascom Ave, San Jose, CA 95128 USA.	shelley.salpeter@hhs.co.santa-clara.ca.us						ABRAHAM TA, 1981, CLIN PHARMACOL THER, V29, P582, DOI 10.1038/clpt.1981.81; ADAM WR, 1982, CLIN EXP HYPERTENS A, V4, P1419, DOI 10.3109/10641968209060799; ANDERSON EG, 1979, BRIT J DIS CHEST, V73, P407, DOI 10.1016/S0007-0971(79)80181-3; [Anonymous], 1985, J Hypertens, V3, P379; BASSO A, 1985, PHARMACOLOGY, V31, P278, DOI 10.1159/000138132; BAUER K, 1994, HYPERTENSION, V24, P339, DOI 10.1161/01.HYP.24.3.339; Belli G, 1995, CONT INTERN MED, V7, P51; BENSON MK, 1978, BRIT J CLIN PHARMACO, V5, P415, DOI 10.1111/j.1365-2125.1978.tb01647.x; BETO JA, 1992, AM J HYPERTENS, V5, P125, DOI 10.1093/ajh/5.3.125; BEUMER HM, 1978, INT J CLIN PHARM BI, V16, P249; BLAIVE B, 1988, Allergie et Immunologie (Paris), V20, P161; BORST SE, 1990, PHARMACOLOGY, V40, P325, DOI 10.1159/000138681; BOYE NP, 1977, EUR J CLIN PHARMACOL, V11, P11, DOI 10.1007/BF00561781; BRIGHT RA, 1992, JAMA-J AM MED ASSOC, V267, P1783; BRODDE OE, 1990, CLIN PHYSIOL BIOCH, V8, P11; BUTLAND RJA, 1983, J APPL PHYSIOL, V54, P1368, DOI 10.1152/jappl.1983.54.5.1368; Cazzola M, 2000, CHEST, V118, P1322, DOI 10.1378/chest.118.5.1322; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Chafin CC, 1999, CARDIOLOGY, V92, P99, DOI 10.1159/000006955; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; CHATTERJEE SS, 1986, J CARDIOVASC PHARM, V8, pS74; CHODOSH S, 1988, J CARDIOVASC PHARM, V11, pS18, DOI 10.1097/00005344-198800000-00005; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; Craig Timothy, 1996, Comprehensive Therapy, V22, P339; DECALMER PBS, 1978, BRIT HEART J, V40, P184; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Devereux G, 1998, BRIT J CLIN PHARMACO, V46, P79, DOI 10.1046/j.1365-2125.1998.00039.x; DOROW P, 1986, EUR J CLIN PHARMACOL, V31, P143, DOI 10.1007/BF00606650; DOROW P, 1986, J CARDIOVASC PHARM, V8, pS102, DOI 10.1097/00005344-198608004-00022; DOSHAN HD, 1986, J CARDIOVASC PHARM, V8, pS105, DOI 10.1097/00005344-198608004-00023; DOSHAN HD, 1986, J CARDIOVASC PHARM, V8, pS109, DOI 10.1097/00005344-198608004-00024; Doughty RN, 1997, EUR HEART J, V18, P560; ELLIS ME, 1981, EUR J CLIN PHARMACOL, V21, P173, DOI 10.1007/BF00627916; FALLIERS C J, 1985, Journal of Clinical Hypertension, V1, P70; FALLIERS CJ, 1986, J ASTHMA, V23, P251, DOI 10.3109/02770908609073169; FENSTER PE, 1983, CLIN CARDIOL, V6, P125, DOI 10.1002/clc.4960060305; FITZ GERALD JD, 1991, CARDIOVASC DRUG THER, V5, P561, DOI 10.1007/BF03029726; FOGARI R, 1990, CARDIOVASC DRUG THER, V4, P1145, DOI 10.1007/BF01856511; FORMGREN H, 1976, BRIT J CLIN PHARMACO, V3, P1007, DOI 10.1111/j.1365-2125.1976.tb00350.x; FORMGREN H, 1977, SCAND J RESPIR DIS, P1; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; FRISHMAN WH, 1984, NEW ENGL J MED, V310, P830; GEORGE RB, 1983, CHEST, V83, P457, DOI 10.1378/chest.83.3.457; GIULEKAS D, 1986, RESPIRATION, V50, P158, DOI 10.1159/000194923; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; Greefhorst A P, 1984, Eur J Respir Dis Suppl, V135, P147; HALL J, 1989, BR J PHARM P S, V87, pP391; HALL J, 1983, BR J PHARM P S, V93, pP116; Heidenreich PA, 1999, JAMA-J AM MED ASSOC, V281, P1927, DOI 10.1001/jama.281.20.1927; Heller DA, 2000, AM HEART J, V140, P663, DOI 10.1067/mhj.2000.109650; Jakubetz J, 1999, J CARDIOVASC PHARM, V33, P461, DOI 10.1097/00005344-199903000-00017; JOHNSSON G, 1975, EUR J CLIN PHARMACOL, V8, P175, DOI 10.1007/BF00567111; Jonas M, 1996, AM J CARDIOL, V77, P1273, DOI 10.1016/S0002-9149(96)00191-9; JONES MK, 1980, CLIN ENDOCRINOL, V13, P343, DOI 10.1111/j.1365-2265.1980.tb03394.x; Kendall MJ, 1997, AM J CARDIOL, V80, pJ15, DOI 10.1016/S0002-9149(97)00833-3; KENNEDY HL, 1995, J AM COLL CARDIOL, V26, P547, DOI 10.1016/0735-1097(95)80035-F; KJEKSHUS J, 1990, EUR HEART J, V11, P43, DOI 10.1093/oxfordjournals.eurheartj.a059591; KLEIN I, 1994, ANN INTERN MED, V121, P281, DOI 10.7326/0003-4819-121-4-199408150-00010; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; KRAUSS S, 1984, ANGIOLOGY, V35, P773, DOI 10.1177/000331978403501204; Krumholz HM, 1999, ANN INTERN MED, V131, P648, DOI 10.7326/0003-4819-131-9-199911020-00003; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; LAMMERS JWJ, 1988, EUR RESPIR J, V1, P453; LAMMERS JWJ, 1986, BRIT J CLIN PHARMACO, V22, P595, DOI 10.1111/j.1365-2125.1986.tb02940.x; LAMMERS JWJ, 1984, EUR J CLIN PHARMACOL, V27, P141, DOI 10.1007/BF00544036; LAMMERS JWJ, 1985, BRIT J CLIN PHARMACO, V20, P205, DOI 10.1111/j.1365-2125.1985.tb05062.x; LARSSON K, 1982, EUR J RESPIR DIS, V63, P221; LAWRENCE DS, 1982, EUR J CLIN PHARMACOL, V22, P501, DOI 10.1007/BF00609622; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; LIGHT RW, 1983, AM J MED, V75, P109, DOI 10.1016/0002-9343(83)90143-2; LOFDAHL CG, 1983, CLIN PHARMACOL THER, V33, P1; LOFDAHL CG, 1981, EUR J RESPIR DIS, V62, P396; LOIS M, 1997, J RESP DIS, V18, P568; LOIS M, 1999, J RESP DIS, V20, P31; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCNEILL RS, 1964, LANCET, V2, P1101; MOLINOFF PB, 1983, J CARDIOVASC PHARM, V5, pS63, DOI 10.1097/00005344-198300051-00010; MOOSS AN, 1994, ANN PHARMACOTHER, V28, P701, DOI 10.1177/106002809402800601; MOTOMURA S, 1990, BRIT J PHARMACOL, V101, P363, DOI 10.1111/j.1476-5381.1990.tb12715.x; MUE S, 1979, INT J CLIN PHARM BI, V17, P346; NICOLAESCU V, 1972, RESPIRATION, V29, P139, DOI 10.1159/000192867; NICOLAESCU V, 1973, EUR J CLIN PHARMACOL, V6, P3, DOI 10.1007/BF00561793; OMALLEY K, 1991, AM J MED, V90, pS27, DOI 10.1016/0002-9343(91)90433-X; OPIE LH, 1991, CARDIOVASC DRUGS T S, V6, P1273; PALMER KNV, 1969, LANCET, V2, P1092; PUJET JC, 1992, EUR RESPIR J, V5, P196; QUAN SF, 1983, J CLIN PHARMACOL, V23, P341, DOI 10.1002/j.1552-4604.1983.tb02746.x; RADACK K, 1991, ARCH INTERN MED, V151, P1769, DOI 10.1001/archinte.151.9.1769; RAINE JM, 1981, BRIT MED J, V282, P548, DOI 10.1136/bmj.282.6263.548; Rosenson RS, 1993, J AMB MONIT, V6, P163; RUFFIN RE, 1979, CLIN PHARMACOL THER, V25, P536; SALPETER S, 2001, CARDIOSELECTIVE BETA, P2; SALPETER S, 2002, CARDIOSELECTIVE BETA, P2; SBIRRAZZUOLI V, 1989, DRUG EXP CLIN RES, V15, P223; SCHINDL R, 1986, J CARDIOVASC PHARM, V8, pS99, DOI 10.1097/00005344-198608004-00021; SIAL SH, 1994, J GEN INTERN MED, V9, P599, DOI 10.1007/BF02600301; SINGH BN, 1976, CLIN PHARMACOL THER, V19, P493; SKINNER C, 1975, BRIT MED J, V2, P59, DOI 10.1136/bmj.2.5962.59; SKINNER C, 1975, BRIT J CLIN PHARMACO, V2, P417, DOI 10.1111/j.1365-2125.1975.tb00550.x; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; STEINBECK G, 1992, NEW ENGL J MED, V327, P987, DOI 10.1056/NEJM199210013271404; SUR DY, 1981, CHEST, V80, P537, DOI 10.1378/chest.80.5.537; TANTUCCI C, 1990, AM HEART J, V120, P467, DOI 10.1016/0002-8703(90)90106-8; TATTERSFIELD A E, 1991, Cardiovascular Drugs and Therapy, V4, P1229, DOI 10.1007/BF00114225; TATTERSFIELD AE, 1986, J CARDIOVASC PHARM, V8, pS35, DOI 10.1097/00005344-198608004-00007; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; VANDENBERGH JHAM, 1981, EUR J RESPIR DIS, V62, P168; VANZYL AI, 1989, CHEST, V95, P209, DOI 10.1378/chest.95.1.209; VILSVIK JS, 1976, BRIT MED J, V2, P453, DOI 10.1136/bmj.2.6033.453; Viskin S, 1996, AM J CARDIOL, V78, P821, DOI 10.1016/S0002-9149(96)00428-6; WADWORTH AN, 1991, DRUGS, V42, P468, DOI 10.2165/00003495-199142030-00007; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; Wang TJ, 1998, ARCH INTERN MED, V158, P1901, DOI 10.1001/archinte.158.17.1901; WELLSTEIN A, 1987, EUR HEART J SUPPL, P3; WICKLMAYR M, 1990, HORM METAB RES, V22, P29; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103; 1997, ARCH INTERN MED, V157, P2413	119	175	187	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2002	137	9					715	725		10.7326/0003-4819-137-9-200211050-00035	http://dx.doi.org/10.7326/0003-4819-137-9-200211050-00035			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612BA	12416945				2022-12-28	WOS:000179052400002
J	Groner, JI				Groner, JI			Lethal injection: a stain on the face of medicine	BRITISH MEDICAL JOURNAL			English	Article									Childrens Hosp, Dept Surg, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Groner, JI (corresponding author), Childrens Hosp, Dept Surg, 700 Childrens Dr, Columbus, OH 43205 USA.		Groner, Jonathan/E-3156-2011	Groner, Jonathan/0000-0002-0998-593X				*AM COLL PHYS HUM, 1994, BREACH TRUST PHYS PA; *AM MED ASS, 2000, COD MED ETH CURR OP, P15; ANDERSON K, 1982, TIME            1220, P28; Christen A G, 2000, J Hist Dent, V48, P117; COLBURN D, 1990, WASHINGTON POST 1211, pZ14; COOK R, 2002, ATLANTA J CONST 0125, pC3; Emanuel LL, 2001, ANN INTERN MED, V135, P922, DOI 10.7326/0003-4819-135-10-200111200-00013; Farber NJ, 2001, ANN INTERN MED, V135, P884, DOI 10.7326/0003-4819-135-10-200111200-00008; Gallagher H.G., 1995, TRUST BETRAYED PATIE; *GEORG DEP CORR, 2000, ADM EX PROC LETH INJ; HOBSON S, 2002, AUGUSTA CHRNICL 0125; Lifton Robert Jay, 2000, WHO OWNS DEATH CAPIT; PRICE J, 1991, WASHINGTON TIME 0103, pA4; SHULL RK, 1996, INDIANAPOLIS NE 0813, pA9; TROMBLEY S, 1992, EXECUTION PROTOCOL I; WEINER DB, 1972, J AMER MED ASSOC, V220, P85, DOI 10.1001/jama.220.1.85	16	18	18	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					1026	1028		10.1136/bmj.325.7371.1026	http://dx.doi.org/10.1136/bmj.325.7371.1026			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411367	Green Published			2022-12-28	WOS:000179415600029
J	Gossett, JM				Gossett, JM			Fishing for microbes	SCIENCE			English	Editorial Material							TETRACHLOROETHENE; BACTERIUM		Cornell Univ, Sch Civil & Environm Engn, Ithaca, NY 14853 USA	Cornell University	Gossett, JM (corresponding author), Cornell Univ, Sch Civil & Environm Engn, Ithaca, NY 14853 USA.							Coleman NV, 2002, APPL ENVIRON MICROB, V68, P2726, DOI 10.1128/AEM.68.6.2726-2730.2002; HOLLIGER C, 1994, ANTON LEEUW INT J G, V66, P239, DOI 10.1007/BF00871642; MaymoGatell X, 1997, SCIENCE, V276, P1568, DOI 10.1126/science.276.5318.1568; SCHOLZMURAMATSU H, 1995, ARCH MICROBIOL, V163, P48, DOI 10.1007/BF00262203; Squillace PJ, 1999, ENVIRON SCI TECHNOL, V33, P4176, DOI 10.1021/es990234m; Sun BL, 2002, SCIENCE, V298, P1023, DOI 10.1126/science.1074675	6	8	8	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					974	975		10.1126/science.1078715	http://dx.doi.org/10.1126/science.1078715			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411690				2022-12-28	WOS:000178932000039
J	Martianov, I; Viville, S; Davidson, I				Martianov, I; Viville, S; Davidson, I			RNA polymerase II transcription in murine cells lacking the TATA binding protein	SCIENCE			English	Article							TBP-LIKE FACTOR; GENE; MITOSIS; UBF	Inactivation of the murine TATA binding protein (TBP) gene by homologous recombination leads to growth arrest and apoptosis at the embryonic blastocyst stage. However, after loss of TBP, RNA polymerase II (pol II) remains in a transcriptionally active phosphorylation state, and in situ run-on experiments showed high levels of pol II transcription comparable to those of wild-type cells. In contrast, pol I and pol III transcription was arrested. Our results show a differential dependency of the RNA polymerases on TBP and provide evidence for TBP-independent pol II transcriptional mechanisms that allow reinitiation and maintenance of gene transcription in vivo.	IGBMC, CNRS, INSERM, ULP, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Davidson, I (corresponding author), IGBMC, CNRS, INSERM, ULP, BP 163, F-67404 Illkirch Graffenstaden, France.			Viville, Stephane/0000-0002-5088-3003; Davidson, Irwin/0000-0001-5533-1171; Martiyanov, Igor/0000-0001-6108-2036				BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Dantonel JC, 1999, TRENDS BIOCHEM SCI, V24, P335, DOI 10.1016/S0968-0004(99)01436-X; GebraneYounes J, 1997, J CELL SCI, V110, P2429; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Martianov I, 2001, MOL CELL, V7, P509, DOI 10.1016/S1097-2765(01)00198-8; MARTIANOV I, UNPUB; Masson C, 1996, EXP CELL RES, V226, P114, DOI 10.1006/excr.1996.0209; Muller F, 2001, CURR BIOL, V11, P282, DOI 10.1016/S0960-9822(01)00076-8; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Um M, 2001, MOL CELL BIOL, V21, P2435, DOI 10.1128/MCB.21.7.2435-2448.2001; Veenstra GJC, 2000, SCIENCE, V290, P2312, DOI 10.1126/science.290.5500.2312; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZATSEPINA OV, 1993, CHROMOSOMA, V102, P599, DOI 10.1007/BF00352307	16	96	101	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					1036	1039		10.1126/science.1076327	http://dx.doi.org/10.1126/science.1076327			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411709				2022-12-28	WOS:000178932000060
J	Reznick, DN; Mateos, M; Springer, MS				Reznick, DN; Mateos, M; Springer, MS			Independent origins and rapid evolution of the placenta in the fish genus Poeciliopsis	SCIENCE			English	Article							LIFE-HISTORY; POECILIIDAE	The evolution of complex organs is a source of controversy because they require the contributions of many adaptations to function properly. We argue that placentas are complex, that they have evolved multiple times in Poeciliopsis, and that there are closely related sister taxa that have either no placentas or intermediate stages in the evolution of a placenta. Furthermore, placentas can evolve in 750,000 years or less, on the same time scale as suggested by theoretical calculations for the evolution of complex eyes. Independent origins of such complexity, accompanied by sister taxa that either lack or have intermediate stages in the evolution of the trait, present an opportunity to study the evolution of novelty and complexity from a comparative, evolutionary perspective.	Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; Univ Calif Riverside, Ctr Conservat Biol, Riverside, CA 92521 USA; Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; Monterey Bay Aquarium Research Institute	Reznick, DN (corresponding author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.		Mateos, Mariana/B-5235-2008	Mateos, Mariana/0000-0001-5738-0145; reznick, david/0000-0002-1144-0568				[Anonymous], 1861, ORIGIN SPECIES MEANS; Arias AL, 2000, COPEIA, P792, DOI 10.1643/0045-8511(2000)000[0792:LHOPCA]2.0.CO;2; BLACKBURN DG, 1999, ENCY REPROD, V3, P840; Goldman N, 2000, SYST BIOL, V49, P652, DOI 10.1080/106351500750049752; HAIG D, 1993, Q REV BIOL, V68, P495, DOI 10.1086/418300; HANDWERGER S, 1999, ENCY REPROD, V3, P855; HAYNES JL, 1995, COPEIA, P147; Kishino H, 2001, MOL BIOL EVOL, V18, P352, DOI 10.1093/oxfordjournals.molbev.a003811; Mateos M, 2002, EVOLUTION, V56, P972; NILSSON DE, 1994, P ROY SOC B-BIOL SCI, V256, P53, DOI 10.1098/rspb.1994.0048; Randall D.J., 1988, FISH PHYSIOL, P2; Reznick D.N., 1989, P125; Rosen D. E., 1963, Bulletin of the American Museum of Natural History, V126, P1; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; Sadler TW, 1995, LANGMANS MED EMBRYOL; Schultz R.J., 1989, P69; Sokal R. R, 1981, BIOMETRY; THIBAULT RE, 1978, EVOLUTION, V32, P320, DOI 10.1111/j.1558-5646.1978.tb00648.x; Thorne JL, 1998, MOL BIOL EVOL, V15, P1647, DOI 10.1093/oxfordjournals.molbev.a025892; Turner CL, 1940, J MORPHOL, V67, P59, DOI 10.1002/jmor.1050670103; VRIJENHOEK RC, 1993, J HERED, V84, P388, DOI 10.1093/oxfordjournals.jhered.a111359; WETHERINGTON D, 1989, ECOLOGY EVOLUTION LI, P259	22	161	164	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					1018	1020		10.1126/science.1076018	http://dx.doi.org/10.1126/science.1076018			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411703				2022-12-28	WOS:000178932000054
J	Birnbaum, Y; Fishbein, MC; Blanche, C; Siegel, RJ				Birnbaum, Y; Fishbein, MC; Blanche, C; Siegel, RJ			Current concepts - Ventricular septal rupture after acute myocardial infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SHOCK TRIAL REGISTRY; FREE-WALL RUPTURE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; SURGICAL CONSIDERATIONS; TRANSCATHETER CLOSURE; MITRAL REGURGITATION; CARDIOGENIC-SHOCK; CARDIAC RUPTURE; CORONARY-ARTERY; EARLY REPAIR		Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA; Univ Calif Los Angeles, Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA; Cedars Sinai Med Ctr, Dept Cardiol, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Div Cardiothorac Surg, Los Angeles, CA 90048 USA	University of Texas System; University of Texas Medical Branch Galveston; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Birnbaum, Y (corresponding author), Univ Texas, Med Branch, Div Cardiol, 5106 John Sealy Annex,301 Univ Blvd, Galveston, TX 77555 USA.							AMICO A, 1989, AM HEART J, V117, P195, DOI 10.1016/0002-8703(89)90679-0; ARAVOT DJ, 1989, J THORAC CARDIOV SUR, V97, P815; BALLAL RS, 1993, AM J CARDIOL, V71, P367, DOI 10.1016/0002-9149(93)90814-S; BARRON JV, 1984, J AM COLL CARDIOL, V3, P169, DOI 10.1016/S0735-1097(84)80445-3; BECKER A E, 1975, European Journal of Cardiology, V3, P349; Birnbaum Y, 2000, AM J CARDIOL, V86, P830, DOI 10.1016/S0002-9149(00)01101-2; BLANCHE C, 1994, ANN THORAC SURG, V57, P1244, DOI 10.1016/0003-4975(94)91366-8; BLANCHE C, 1992, J THORAC CARDIOV SUR, V104, P961; BLANCHE C, 2001, CARDIOLOGY, P171; Crenshaw BS, 2000, CIRCULATION, V101, P27, DOI 10.1161/01.CIR.101.1.27; CUMMINGS RG, 1988, CIRCULATION, V77, P33, DOI 10.1161/01.CIR.77.1.33; DAGGETT WM, 1977, ANN SURG, V186, P260, DOI 10.1097/00000658-197709000-00004; DAVIES RH, 1993, J THORAC CARDIOV SUR, V106, P592, DOI 10.1016/S0022-5223(19)33699-2; EDWARDS BS, 1984, AM J CARDIOL, V54, P1201, DOI 10.1016/S0002-9149(84)80067-3; Figueras J, 1998, AM J CARDIOL, V81, P495, DOI 10.1016/S0002-9149(97)00928-4; FORTIN DF, 1991, AM HEART J, V121, P25, DOI 10.1016/0002-8703(91)90951-D; FOX AC, 1979, PROG CARDIOVASC DIS, V21, P461, DOI 10.1016/0033-0620(79)90026-4; FUCHS RM, 1982, AM J CARDIOL, V49, P849, DOI 10.1016/0002-9149(82)91968-3; GIULIANI ER, 1974, CIRCULATION, V49, P455, DOI 10.1161/01.CIR.49.3.455; GOWDA KS, 1976, AM HEART J, V92, P234, DOI 10.1016/S0002-8703(76)80260-8; GRAY RJ, 1983, AM HEART J, V106, P723, DOI 10.1016/0002-8703(83)90094-7; HARPAZ D, 1993, CHEST, V103, P1884, DOI 10.1378/chest.103.6.1884; HEITMILLER R, 1986, ANN THORAC SURG, V41, P683, DOI 10.1016/S0003-4975(10)63093-7; HELD AC, 1988, AM HEART J, V116, P1330, DOI 10.1016/0002-8703(88)90458-9; Hochman JS, 2000, J AM COLL CARDIOL, V36, P1063, DOI 10.1016/S0735-1097(00)00879-2; HUTCHINS GM, 1979, AM HEART J, V97, P165, DOI 10.1016/0002-8703(79)90351-X; Landzberg M J, 1998, Semin Thorac Cardiovasc Surg, V10, P128; Lee EM, 1998, HEART, V80, P522, DOI 10.1136/hrt.80.5.522; LEMERY R, 1992, AM J CARDIOL, V70, P147, DOI 10.1016/0002-9149(92)91266-7; LOISANCE DY, 1991, ANN THORAC SURG, V52, P474, DOI 10.1016/0003-4975(91)90908-9; MANN JM, 1988, AM J CARDIOL, V62, P8, DOI 10.1016/0002-9149(88)91357-4; MANN JM, 1987, AM J CARDIOL, V60, P722, DOI 10.1016/0002-9149(87)90390-0; Massetti M, 2000, J THORAC CARDIOV SUR, V119, P784, DOI 10.1016/S0022-5223(00)70014-6; Menon V, 2000, J AM COLL CARDIOL, V36, P1110, DOI 10.1016/S0735-1097(00)00878-0; MOORE CA, 1986, CIRCULATION, V74, P45, DOI 10.1161/01.CIR.74.1.45; Obarski T P, 1995, J Am Soc Echocardiogr, V8, P728, DOI 10.1016/S0894-7317(05)80388-8; Oskoui R, 1996, AM J CARDIOL, V78, P953, DOI 10.1016/S0002-9149(96)00476-6; PERLOFF J K, 1971, Progress in Cardiovascular Diseases, V13, P437, DOI 10.1016/0033-0620(71)90011-9; Pesonen E, 2000, SCAND CARDIOVASC J, V34, P446; POHJOLASINTONEN S, 1989, AM HEART J, V117, P809, DOI 10.1016/0002-8703(89)90617-0; Pretre R, 1999, AM J CARDIOL, V84, P785, DOI 10.1016/S0002-9149(99)00438-5; Pretre R, 2000, AM J CARDIOL, V85, P497, DOI 10.1016/S0002-9149(99)00780-8; RADFORD MJ, 1981, CIRCULATION, V64, P545, DOI 10.1161/01.CIR.64.3.545; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; SCANLON PJ, 1985, CIRCULATION, V72, P185; SHAPIRA I, 1987, CHEST, V92, P219, DOI 10.1378/chest.92.2.219; SKEHAN JD, 1989, BRIT HEART J, V62, P268; SMYLLIE JH, 1990, J AM COLL CARDIOL, V15, P1449, DOI 10.1016/S0735-1097(10)80038-5; TATOOLES CJ, 1968, AM HEART J, V75, P102, DOI 10.1016/0002-8703(68)90121-X; TOPAZ O, 1992, AM J MED, V93, P683, DOI 10.1016/0002-9343(92)90203-N; WESTABY S, 1992, J THORAC CARDIOV SUR, V104, P1506, DOI 10.1016/S0022-5223(19)33876-0; WYNNE J, 1978, CATHETER CARDIO DIAG, V4, P189, DOI 10.1002/ccd.1978.4.2.189	52	199	239	1	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1426	1432		10.1056/NEJMra020228	http://dx.doi.org/10.1056/NEJMra020228			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12409546				2022-12-28	WOS:000178888400007
J	Eccles, M; McColl, E; Steen, N; Rousseau, N; Grimshaw, J; Parkin, D; Purves, I				Eccles, M; McColl, E; Steen, N; Rousseau, N; Grimshaw, J; Parkin, D; Purves, I			Effect of computerised evidence based guidelines on management of asthma and angina in adults in primary care: cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DECISION-SUPPORT; DESIGN	Objective To evaluate the use of a computerised support system for decision making for implementing evidence based clinical guidelines for the management of asthma and angina in adults in primary care. Design A before and after pragmatic cluster randomised controlled trial utilising a two by two incomplete block design. Setting 60 general practices in north east England. Participants General practitioners and practice nurses in the study practices and their patients aged 18 or over with angina or asthma. Main outcome measures Adherence to the guidelines, based on review of case notes and patient reported generic and condition specific outcome measures. Results The computerised decision support system had no significant effect on consultation rates, process of care measures (including prescribing), or any patient reported outcomes for either condition. Levels of use of the software were low. Conclusions No effect was found of computerised evidence based guidelines on the management of asthma or angina in adults in primary care. This was probably due to low levels of use of the software, despite the system being optimised as far as was technically possible. Even if the technical problems of producing a system that fully supports the management of chronic disease were solved, there remains the challenge of integrating the systems into clinical encounters where busy practitioners manage patients with complex, multiple conditions.	Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland; City Univ London, Dept Econ, London EC1V 0HB, England; Newcastle Univ, Sowerby Ctr Hlth Informat, Newcastle Upon Tyne NE4 2AB, Tyne & Wear, England	Newcastle University - UK; University of Aberdeen; City University London; Newcastle University - UK	Eccles, M (corresponding author), Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	martin.eccles@ncl.ac.uk	McColl, Elaine/V-9906-2019; Eccles, Martin P/AAD-4029-2020; Grimshaw, Jeremy/D-8726-2013; Greiver, Michelle/N-8764-2015	McColl, Elaine/0000-0001-8300-3204; Greiver, Michelle/0000-0001-8957-0285; Grimshaw, Jeremy/0000-0001-8015-8243; Rousseau, Nikki/0000-0001-8826-3515				Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Donner A, 1998, J R STAT SOC C-APPL, V47, P95, DOI 10.1111/1467-9876.00100; Eccles M, 2001, FAM PRACT, V18, P223, DOI 10.1093/fampra/18.2.223; Eccles M, 2001, FAM PRACT, V18, P217, DOI 10.1093/fampra/18.2.217; Eccles M, 2000, FAM PRACT, V17, P180, DOI 10.1093/fampra/17.2.180; ECCLES M, 2002, EVALUATION COMPUTERI; Foy R, 2001, FAM PRACT, V18, P353, DOI 10.1093/fampra/18.4.353; Friedman C.P., 1997, EVALUATION METHODS M, P41; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; Hetlevik I, 2000, INT J TECHNOL ASSESS, V16, P210, DOI 10.1017/S0266462300161185; Hetlevik Irene, 1998, Blood Pressure, V7, P270; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Purves IN, 1998, BRIT J GEN PRACT, V48, P1552; SPERTUS JA, 1995, J AM COLL CARDIOL, V25, P333, DOI 10.1016/0735-1097(94)00397-9; STEEN N, 1994, BRIT MED J, V309, P1065, DOI 10.1136/bmj.309.6961.1065; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	18	219	221	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 26	2002	325	7370					941	944		10.1136/bmj.325.7370.941	http://dx.doi.org/10.1136/bmj.325.7370.941			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399345	Bronze, Green Published			2022-12-28	WOS:000178986300018
J	Myerburg, RJ; Castellanos, A				Myerburg, RJ; Castellanos, A			Electrode positioning for cardioversion of atrial fibrillation	LANCET			English	Editorial Material									Univ Miami, Sch Med, Div Cardiol, Miami, FL 33101 USA	University of Miami	Myerburg, RJ (corresponding author), Univ Miami, Sch Med, Div Cardiol, Miami, FL 33101 USA.	rmyerbur@med.miami.edu						[Anonymous], 2001, CIRCULATION, V104, P2118; CASTELLANOS A, 1969, ELECTROPHYSIOLOGY PA, P193; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; Joglar JA, 2000, AM J CARDIOL, V86, P348, DOI 10.1016/S0002-9149(00)00932-2; Kerber R E, 1996, Am J Cardiol, V78, P22, DOI 10.1016/S0002-9149(96)00562-0; MYERBURG RJ, 2001, HEART; PaganCarlo LA, 1996, J AM COLL CARDIOL, V27, P449, DOI 10.1016/0735-1097(95)00487-4; Page RL, 2002, J AM COLL CARDIOL, V39, P1956, DOI 10.1016/S0735-1097(02)01898-3; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; Sopher SM, 1998, J CARDIOVASC ELECTR, V9, pS211	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 26	2002	360	9342					1263	1264		10.1016/S0140-6736(02)11354-7	http://dx.doi.org/10.1016/S0140-6736(02)11354-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414196				2022-12-28	WOS:000178827200003
J	Fiebig, M; Lottermoser, T; Frohlich, D; Goltsev, AV; Pisarev, RV				Fiebig, M; Lottermoser, T; Frohlich, D; Goltsev, AV; Pisarev, RV			Observation of coupled magnetic and electric domains	NATURE			English	Article							2ND-HARMONIC GENERATION; HEXAGONAL MANGANITES; YMNO3	Ferroelectromagnets are an interesting group of compounds that complement purely (anti-)ferroelectric or (anti-)ferromagnetic materials-they display simultaneous electric and magnetic order(1-3). With this coexistence they supplement materials in which magnetization can be induced by an electric field and electrical polarization by a magnetic field, a property which is termed the magnetoelectric effect(4). Aside from its fundamental importance, the mutual control of electric and magnetic properties is of significant interest for applications in magnetic storage media and 'spintronics'(2,3). The coupled electric and magnetic ordering in ferroelectromagnets is accompanied by the formation of domains and domain walls. However, such a cross-correlation between magnetic and electric domains has so far not been observed. Here we report spatial maps of coupled antiferromagnetic and ferroelectric domains in YMnO(3), obtained by imaging with optical second harmonic generation. The coupling originates from an interaction between magnetic and electric domain walls, which leads to a configuration that is dominated by the ferroelectromagnetic product of the order parameters.	Univ Dortmund, Inst Phys, D-44221 Dortmund, Germany; Max Born Inst, D-12489 Berlin, Germany; Russian Acad Sci, AF Ioffe Phys Tech Inst, St Petersburg 194021, Russia	Dortmund University of Technology; Max Born Institute for Nonlinear Optics & Short Term Spectroscopy; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Ioffe Physical Technical Institute	Fiebig, M (corresponding author), Univ Dortmund, Inst Phys, D-44221 Dortmund, Germany.	fiebig@mbi-berlin.de	Lottermoser, Thomas/G-2828-2011; Goltsev, Alexander V/J-4305-2013	Lottermoser, Thomas/0000-0002-2941-7446; Goltsev, Alexander V/0000-0001-9397-8419				AIZU K, 1970, PHYS REV B, V2, P754, DOI 10.1103/PhysRevB.2.754; BERTAUT EF, 1963, PHYS LETT, V5, P27, DOI 10.1016/S0375-9601(63)80014-6; Birss R. R., 1966, SYMMETRY MAGNETISM; Fiebig M, 2000, PHYS REV LETT, V84, P5620, DOI 10.1103/PhysRevLett.84.5620; Fiebig M, 1998, APPL PHYS B-LASERS O, V66, P265, DOI 10.1007/s003400050387; Filippetti A, 2001, J MAGN MAGN MATER, V236, P176, DOI 10.1016/S0304-8853(01)00445-0; Fujimura N, 1996, APPL PHYS LETT, V69, P1011, DOI 10.1063/1.117969; Hill NA, 2000, J PHYS CHEM B, V104, P6694, DOI [10.1021/jp000114x, 10.1021/jpc00114x]; Iizuka-Sakano T, 2001, J PHYS-CONDENS MAT, V13, P3031, DOI 10.1088/0953-8984/13/13/316; Leute S, 1999, OPT LETT, V24, P1520, DOI 10.1364/OL.24.001520; O'Dell T.H., 1970, ELECTRODYNAMICS MAGN; Sa D, 2000, EUR PHYS J B, V14, P301, DOI 10.1007/s100510050133; Schmid H., 1994, Ferroelectrics, V162, P317, DOI 10.1080/00150199408245120; Smolenskii G. A., 1982, Soviet Physics - Uspekhi, V25, P475, DOI 10.1070/PU1982v025n07ABEH004570; Soboleva T. K., 1983, Soviet Physics - Solid State, V25, P1637; van Aken BB, 2001, ACTA CRYSTALLOGR C, V57, P230, DOI 10.1107/S0108270100015663; VANAKEN BB, 2001, THESIS REIKSUNIVERSI; YAKEL HL, 1963, ACTA CRYSTALLOGR, V16, P957, DOI 10.1107/S0365110X63002589	18	1281	1322	14	509	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					818	820		10.1038/nature01077	http://dx.doi.org/10.1038/nature01077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397352				2022-12-28	WOS:000178769800040
J	Grimes, DA				Grimes, DA			Uncertainty	LANCET			English	Editorial Material									Family Hlth Int, Res Triangle Pk, NC 27709 USA		Grimes, DA (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.								0	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1242	1242		10.1016/S0140-6736(02)11275-X	http://dx.doi.org/10.1016/S0140-6736(02)11275-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401269				2022-12-28	WOS:000178708100031
J	Fields, RD; Stevens-Graham, B				Fields, RD; Stevens-Graham, B			Neuroscience - New insights into neuron-glia communication	SCIENCE			English	Review							OLIGODENDROCYTE PRECURSOR CELLS; MYELIN-ASSOCIATED GLYCOPROTEIN; TRANSMITTER RELEASE; ADHESION MOLECULE; SYNAPTIC EFFICACY; SODIUM-CHANNELS; CALCIUM WAVES; SCHWANN-CELLS; GLUTAMATE RELEASE; ACTION-POTENTIALS	Two-way communication between neurons and nonneural cells called glia is essential for axonal conduction, synaptic transmission, and information processing and thus is required for normal functioning of the nervous system during development and throughout adult life. The signals between neurons and glia include ion fluxes, neurotransmitters, cell adhesion molecules, and specialized signaling molecules released from synaptic and nonsynaptic regions of the neuron. In contrast to the serial flow of information along chains of neurons, glia communicate with other glial cells through intracellular waves of calcium and via intercellular diffusion of chemical messengers. By releasing neurotransmitters and other extracellular signaling molecules, glia can affect neuronal excitability and synaptic transmission and perhaps coordinate activity across networks of neurons.	NICHHD, Neurocytol & Physiol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Fields, RD (corresponding author), NICHHD, Neurocytol & Physiol Sect, Bethesda, MD 20892 USA.	elds@helix.nih.gov			NICHD NIH HHS [Z01 HD000713-11] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000713] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000713, K04HD000713] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Araque A, 1998, J NEUROSCI, V18, P6822; Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Atkins CM, 1999, J NEUROCHEM, V73, P1090, DOI 10.1046/j.1471-4159.1999.0731090.x; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Bergles DE, 1997, NEURON, V19, P1297, DOI 10.1016/S0896-6273(00)80420-1; Bergles DE, 1998, J NEUROSCI, V18, P7709; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; Bjartmar C, 2001, NEUROLOGY, V57, P1248, DOI 10.1212/WNL.57.7.1248; Blondel O, 2000, J NEUROSCI, V20, P8012; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Castonguay A, 2001, J NEUROSCI, V21, P1911, DOI 10.1523/JNEUROSCI.21-06-01911.2001; Charles P, 2002, CURR BIOL, V12, P217, DOI 10.1016/S0960-9822(01)00680-7; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399; Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; De Pina-Benabou MH, 2001, J NEUROSCI, V21, P6635; Deerinck TJ, 1997, J NEUROSCI, V17, P5080; Demerens C, 1996, P NATL ACAD SCI USA, V93, P9887, DOI 10.1073/pnas.93.18.9887; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DUGANDZIJANOVAKOVIC S, 1995, J NEUROSCI, V15, P492; Fields RD, 2000, TRENDS NEUROSCI, V23, P625, DOI 10.1016/S0166-2236(00)01674-X; FINKBEINER SM, 1993, GLIA, V9, P83, DOI 10.1002/glia.440090202; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; GAIANO N, 2000, NEURON, V361, P258; Gallo V, 2000, TRENDS PHARMACOL SCI, V21, P252, DOI 10.1016/S0165-6147(00)01494-2; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Gollan L, 2002, J CELL BIOL, V157, P1247, DOI 10.1083/jcb.200203050; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; HAYDON PG, 2001, SOC NEUR ABSTR; Hidalgo A, 2000, DEVELOPMENT, V127, P393; HUTCHINS JB, 1990, J COMP NEUROL, V298, P113, DOI 10.1002/cne.902980109; Innocenti B, 2000, J NEUROSCI, V20, P1800; ITOH K, 1995, SCIENCE, V270, P1369, DOI 10.1126/science.270.5240.1369; JAHROMI BS, 1992, NEURON, V8, P1069, DOI 10.1016/0896-6273(92)90128-Z; JESSEN K, 1999, ANN NY ACAD SCI, V14, P883; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; Kaur C, 2001, MICROSC RES TECHNIQ, V54, P2, DOI 10.1002/jemt.1114; Liu QY, 2000, J NEUROPHYSIOL, V84, P1392, DOI 10.1152/jn.2000.84.3.1392; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; MULLER CM, 1992, INT REV NEUROBIOL, V34, P215, DOI 10.1016/S0074-7742(08)60099-9; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; Newman EA, 1998, J NEUROSCI, V18, P4022; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; Peles E, 2000, CURR OPIN NEUROBIOL, V10, P558, DOI 10.1016/S0959-4388(00)00122-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Porter JT, 1996, J NEUROSCI, V16, P5073; Queiroz G, 1999, NEUROSCIENCE, V91, P1171, DOI 10.1016/S0306-4522(98)00644-7; Rasband MN, 1999, J NEUROSCI, V19, P7516, DOI 10.1523/JNEUROSCI.19-17-07516.1999; REIST NE, 1992, P NATL ACAD SCI USA, V89, P7625, DOI 10.1073/pnas.89.16.7625; Robitaille R, 1998, NEURON, V21, P847, DOI 10.1016/S0896-6273(00)80600-5; Rochon D, 2001, J NEUROSCI, V21, P3819, DOI 10.1523/JNEUROSCI.21-11-03819.2001; Rossler W, 1999, J NEUROSCI, V19, P9865; SCEMES E, 2001, AM SOC CELL BIOL ABS; SEILHEIMER B, 1989, J CELL BIOL, V109, P3095, DOI 10.1083/jcb.109.6.3095; Shulman RG, 2001, P NATL ACAD SCI USA, V98, P6417, DOI 10.1073/pnas.101129298; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Stevens B, 1998, J NEUROSCI, V18, P9303; Stevens B, 2000, SCIENCE, V287, P2267, DOI 10.1126/science.287.5461.2267; STEVENS B, 2001, SOC NEUR ABSTR; Tait S, 2000, J CELL BIOL, V150, P657, DOI 10.1083/jcb.150.3.657; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Thomas S, 2001, J NEUROSCI, V21, P1087; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Urazaev AK, 2001, NEUROSCIENCE, V106, P237, DOI 10.1016/S0306-4522(01)00270-6; Verhratsky A, 1996, TRENDS NEUROSCI, V19, P346; Wang ZQ, 2000, ANAL CHEM, V72, P2001, DOI 10.1021/ac9912146; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Waxman SG, 2000, BRAIN RES, V886, P5, DOI 10.1016/S0006-8993(00)02774-8; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Yin XH, 1998, J NEUROSCI, V18, P1953, DOI 10.1523/jneurosci.18-06-01953.1998; Zalc B, 2000, NEUROSCIENTIST, V6, P5, DOI 10.1177/107385840000600109	95	695	740	3	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	2002	298	5593					556	562		10.1126/science.298.5593.556	http://dx.doi.org/10.1126/science.298.5593.556			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386325	Green Accepted			2022-12-28	WOS:000178634800030
J	Pecina, A; Smith, KN; Mezard, C; Murakami, H; Ohta, K; Nicolas, A				Pecina, A; Smith, KN; Mezard, C; Murakami, H; Ohta, K; Nicolas, A			Targeted stimulation of meiotic recombination	CELL			English	Article							DOUBLE-STRAND BREAKS; DNA-REPLICATION; HOT-SPOT; CHROMATIN-STRUCTURE; HIS4 LOCUS; WILD-TYPE; GENE; SITES; CHROMOSOMES; INITIATION	Meiotic recombination in Saccharomyces cerevisiae is initiated by programmed DNA double-strand breaks (DSBs), a process that requires the Spo11 protein. DSBs usually occur in intergenic regions that display open chromatin accessibility, but other determinants that control their frequencies and non-random chromosomal distribution remain obscure. We report that a Spo11 construct bearing the Ga14 DNA binding domain not only rescues spo11Delta spore inviability and catalyzes DSb formation at natural sites but also strongly stimulates DSb formation near Ga14 binding sites. At GAL2, a naturally DSb-cold locus, GaL4bd-Spo11 creates a recombinational hotspot that depends on all the other DSB gene functions, showing that the targeting of Spo11 to a specific site is sufficient to stimulate meiotic recombination that is under normal physiological control.	Inst Curie, Sect Rech, CNRS, UMR 144, F-75248 Paris 05, France; Saitama Univ, Grad Sch Sci & Engn, Urawa, Saitama 3388570, Japan; RIKEN, Inst Phys & Chem Res, Genet Dynam Res Unit Lab, Wako, Saitama 35101, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Saitama University; RIKEN	Nicolas, A (corresponding author), Inst Curie, Sect Rech, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.	alain.nicolas@curie.fr		Pecina, Ana/0000-0002-6243-9313; Murakami, Hajime/0000-0002-7022-6887				ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; [Anonymous], 1997, NATURE, V387, pS; ATCHESON CL, 1987, P NATL ACAD SCI USA, V84, P8035, DOI 10.1073/pnas.84.22.8035; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Bateson W., 1905, REPORTS EVOLUTION CO, V2, P80; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Baudat F, 2001, CURR BIOL, V11, pR45, DOI 10.1016/S0960-9822(01)00013-6; Beretta GL, 1999, CANCER RES, V59, P3689; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Borde V, 2000, SCIENCE, V290, P806, DOI 10.1126/science.290.5492.806; Borde V, 1999, MOL CELL BIOL, V19, P4832; Bullard SA, 1996, P NATL ACAD SCI USA, V93, P13054, DOI 10.1073/pnas.93.23.13054; Cha RS, 2000, GENE DEV, V14, P493; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DEVRIES H, 1903, FERTILIZATION HYBRID, P217; Diaz RL, 2002, MOL CELL BIOL, V22, P1106, DOI 10.1128/MCB.22.4.1106-1115.2002; Dirick L, 1998, SCIENCE, V281, P1854, DOI 10.1126/science.281.5384.1854; Fan QQ, 1996, MOL CELL BIOL, V16, P2037; Forsburg SL, 2002, MOL CELL, V9, P703, DOI 10.1016/S1097-2765(02)00508-7; Gerton JL, 2000, P NATL ACAD SCI USA, V97, P11383, DOI 10.1073/pnas.97.21.11383; HUIBREGTSE JM, 1993, J BIOL CHEM, V268, P22219; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; Keeney S, 1996, GENES CELLS, V1, P475, DOI 10.1046/j.1365-2443.1996.d01-257.x; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kim YG, 1998, BIOL CHEM, V379, P489, DOI 10.1515/bchm.1998.379.4-5.489; KLAPHOLZ S, 1985, GENETICS, V110, P187; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; Malkova A, 2000, P NATL ACAD SCI USA, V97, P14500, DOI 10.1073/pnas.97.26.14500; Moore CS, 1999, GENOMICS, V59, P1, DOI 10.1006/geno.1999.5812; Morgan TH, 1912, J EXP ZOOL, V13, P79, DOI 10.1002/jez.1400130105; Mozo T, 1999, NAT GENET, V22, P271, DOI 10.1038/10334; Neale MJ, 2002, MOL CELL, V9, P835, DOI 10.1016/S1097-2765(02)00498-7; Noor MAF, 2001, GENETICS, V159, P581; OHTA K, 1994, EMBO J, V13, P5754, DOI 10.1002/j.1460-2075.1994.tb06913.x; Ohta K, 1999, NUCLEIC ACIDS RES, V27, P2175, DOI 10.1093/nar/27.10.2175; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith KN, 1998, CURR OPIN GENET DEV, V8, P200, DOI 10.1016/S0959-437X(98)80142-1; Smith KN, 2001, CURR BIOL, V11, P88, DOI 10.1016/S0960-9822(01)00026-4; Steiner WW, 2002, MOL CELL, V9, P847, DOI 10.1016/S1097-2765(02)00489-6; Stuart D, 1998, GENE DEV, V12, P2698, DOI 10.1101/gad.12.17.2698; Sturtevant AH, 1913, J EXP ZOOL, V14, P43, DOI 10.1002/jez.1400140104; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Vedel M, 1999, GENETICS, V151, P1245; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WHITEHOUSE HLK, 1982, UNDERSTANDING MECH; WU TC, 1995, GENETICS, V140, P55; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; Xu F, 1996, GENETICS, V143, P1115; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619	58	78	83	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	2002	111	2					173	184		10.1016/S0092-8674(02)01002-4	http://dx.doi.org/10.1016/S0092-8674(02)01002-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408862	Bronze			2022-12-28	WOS:000178753500007
J	Smothers, JF; Henikoff, S; Carter, P				Smothers, JF; Henikoff, S; Carter, P			Affinity selection from biological libraries	SCIENCE			English	Article							PHAGE DISPLAY; ANTIBODY; LIGANDS		Amgen Inc, Dept Antibody Technol, Seattle, WA 98101 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA	Amgen; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Smothers, JF (corresponding author), Amgen Inc, Dept Antibody Technol, Seattle, WA 98101 USA.	SmotherJ@amgen.com; steveh@fhcrc.org; CarterP@amgen.com		Henikoff, Steven/0000-0002-7621-8685				Adda CG, 2002, COMB CHEM HIGH T SCR, V5, P1; Amstutz P, 2001, CURR OPIN BIOTECH, V12, P400, DOI 10.1016/S0958-1669(00)00234-2; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Crameri R, 2002, Methods Mol Biol, V185, P461; Ghosh AK, 2001, P NATL ACAD SCI USA, V98, P13278, DOI 10.1073/pnas.241491198; Hoess RH, 2001, CHEM REV, V101, P3205, DOI 10.1021/cr000056b; Ito J, 2002, NATURE, V417, P452, DOI 10.1038/417452a; Manoutcharian K., 2001, Current Pharmaceutical Biotechnology, V2, P217; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; QUAN MP, 2002, ANTIIGE ALLERGIC DIS, V164, P427; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Smothers JF, 2001, COMB CHEM HIGH T SCR, V4, P585; Trepel M, 2002, CURR OPIN CHEM BIOL, V6, P399, DOI 10.1016/S1367-5931(02)00336-8; Weiss GA, 2000, P NATL ACAD SCI USA, V97, P8950, DOI 10.1073/pnas.160252097; Whaley SR, 2000, NATURE, V405, P665, DOI 10.1038/35015043; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626	19	57	66	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	2002	298	5593					621	622		10.1126/science.298.5593.621	http://dx.doi.org/10.1126/science.298.5593.621			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386335				2022-12-28	WOS:000178634800046
J	Barland, S; Tredicce, JR; Brambilla, M; Lugiato, LA; Balle, S; Giudici, M; Maggipinto, T; Spinelli, L; Tissoni, G; Knodl, T; Miller, M; Jager, R				Barland, S; Tredicce, JR; Brambilla, M; Lugiato, LA; Balle, S; Giudici, M; Maggipinto, T; Spinelli, L; Tissoni, G; Knodl, T; Miller, M; Jager, R			Cavity solitons as pixels in semiconductor microcavities	NATURE			English	Article							LOCALIZED STRUCTURES; SPATIAL SOLITONS; PATTERNS; RESONATORS; DYNAMICS; SYSTEM	Cavity solitons are localized intensity peaks that can form in a homogeneous background of radiation. They are generated by shining laser pulses into optical cavities that contain a nonlinear medium driven by a coherent field (holding beam). The ability to switch cavity solitons on and off(1,2) and to control their location and motion(3) by applying laser pulses makes them interesting as potential 'pixels' for reconfigurable arrays or all-optical processing units. Theoretical work on cavity solitons(2-7) has stimulated a variety of experiments in macroscopic cavities(8-10) and in systems with optical feedback(11-13). But for practical devices, it is desirable to generate cavity solitons in semiconductor structures, which would allow fast response and miniaturization. The existence of cavity solitons in semiconductor microcavities has been predicted theoretically(14-17), and precursors of cavity solitons have been observed, but clear experimental realization has been hindered by boundary-dependence of the resulting optical patterns (18,19)-cavity solitons should be self-confined. Here we demonstrate the generation of cavity solitons in vertical cavity semiconductor microresonators that are electrically pumped above transparency but slightly below lasing threshold(20).We show that the generated optical spots can be written, erased and manipulated as objects independent of each other and of the boundary. Numerical simulations allow for a clearer interpretation of experimental results.	Univ Insubria, Dipartimento Sci, INFM, I-22100 Como, Italy; Inst Non Lineaire Nice, F-06560 Valbonne, France; Poltecn & Univ Bari, Dipartimento Fis Interateneo, INFM, I-70126 Bari, Italy; IMEDEA, Esporles 07190, Islas Baleares, Spain; Univ Ulm, Dept Optoelect, D-89069 Ulm, Germany	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Insubria; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Politecnico di Bari; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Mediterraneo de Estudios Avanzados (IMEDEA); Ulm University	Lugiato, LA (corresponding author), Univ Insubria, Dipartimento Sci, INFM, Via Valleggio 11, I-22100 Como, Italy.		Giudici, Massimo/A-8569-2012; Tredicce, Jorge/ABE-4960-2021; Brambilla, Massimo/E-2053-2017; Balle, Salvador/F-8575-2013; SPINELLI, LORENZO CLEMENTE/AAW-6564-2020; Spinelli, Lorenzo/ABC-9163-2020; tissoni, giovanna/AAD-1912-2022	Giudici, Massimo/0000-0002-7600-4927; Brambilla, Massimo/0000-0002-0985-8965; Balle, Salvador/0000-0002-7026-1391; SPINELLI, LORENZO CLEMENTE/0000-0002-4414-4351; Maggipinto, Tommaso/0000-0003-4156-5377; Tissoni, Giovanna/0000-0002-5491-8082				Ackemann T, 2000, OPT LETT, V25, P814, DOI 10.1364/OL.25.000814; Brambilla M, 1997, PHYS REV LETT, V79, P2042, DOI 10.1103/PhysRevLett.79.2042; Brambilla M, 1996, EUROPHYS LETT, V34, P109, DOI 10.1209/epl/i1996-00424-4; Fedorov S, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.036610; Firth WJ, 1996, PHYS REV LETT, V76, P1623, DOI 10.1103/PhysRevLett.76.1623; Grabherr M, 1998, IEEE PHOTONIC TECH L, V10, P1061, DOI 10.1109/68.701502; Lugiato L.A., 1999, ADV ATOM MOL OPT PHY, V40, P229, DOI [10.1016/S1049-250X(08)60114-7, DOI 10.1016/S1049-250X(08)60114-7]; MCDONALD GS, 1990, J OPT SOC AM B, V7, P1328, DOI 10.1364/JOSAB.7.001328; MCDONALD GS, 1993, J OPT SOC AM B, V10, P1081, DOI 10.1364/JOSAB.10.001081; MCLAUGHLIN DW, 1983, PHYS REV LETT, V51, P75, DOI 10.1103/PhysRevLett.51.75; Michaelis D, 1997, PHYS REV A, V56, pR3366, DOI 10.1103/PhysRevA.56.R3366; Ramazza PL, 2000, J OPT B-QUANTUM S O, V2, P399, DOI 10.1088/1464-4266/2/3/329; Rosanov N. N., 1988, OPT SPECTROSC, V65, P449; SAFFMAN M, 1994, OPT LETT, V19, P518, DOI 10.1364/OL.19.000518; Schapers B, 2000, PHYS REV LETT, V85, P748, DOI 10.1103/PhysRevLett.85.748; Schreiber A, 1997, OPT COMMUN, V136, P415, DOI 10.1016/S0030-4018(96)00722-5; Spinelli L, 1998, PHYS REV A, V58, P2542, DOI 10.1103/PhysRevA.58.2542; Spinelli L, 2001, EUR PHYS J D, V15, P257, DOI 10.1007/s100530170174; Taranenko VB, 1997, PHYS REV A, V56, P1582, DOI 10.1103/PhysRevA.56.1582; Taranenko VB, 2001, APPL PHYS B-LASERS O, V72, P377, DOI 10.1007/s003400000527; Taranenko VB, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.063818; THUAL O, 1988, J PHYS-PARIS, V49, P1829, DOI 10.1051/jphys:0198800490110182900; TLIDI M, 1994, PHYS REV LETT, V73, P640, DOI 10.1103/PhysRevLett.73.640; Weiss CO, 1999, APPL PHYS B-LASERS O, V68, P151, DOI 10.1007/s003400050601	24	491	492	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					699	702		10.1038/nature01049	http://dx.doi.org/10.1038/nature01049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384692				2022-12-28	WOS:000178615200034
J	Palmer, BF				Palmer, BF			Current concepts: Renal dysfunction complicating the treatment of hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GLOMERULAR-FILTRATION-RATE; CALCIUM-CHANNEL BLOCKERS; TERM ANTIHYPERTENSIVE TREATMENT; IMPAIRED AUTOREGULATION; ACE-INHIBITOR; INDUCED FALL; BLOOD-FLOW; PRESSURE; FAILURE; KIDNEY		Univ Texas, SW Med Sch, Div Nephrol, Dept Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Palmer, BF (corresponding author), Univ Texas, SW Med Sch, Div Nephrol, Dept Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	biff.palmer@utsouthwestern.edu						Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Apperloo AJ, 1997, KIDNEY INT, V51, P793, DOI 10.1038/ki.1997.111; Arima S, 1997, J CLIN INVEST, V100, P2816, DOI 10.1172/JCI119829; Bakris GL, 2000, ARCH INTERN MED, V160, P685, DOI 10.1001/archinte.160.5.685; Bakris GL, 2000, KIDNEY INT, V58, P2084, DOI 10.1111/j.1523-1755.2000.00381.x; Bakris GL, 1998, KIDNEY INT, V54, P1283, DOI 10.1046/j.1523-1755.1998.00083.x; Bakris GL, 1996, KIDNEY INT, V50, P1641, DOI 10.1038/ki.1996.480; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; Bidani AK, 2002, CURR OPIN NEPHROL HY, V11, P73, DOI 10.1097/00041552-200201000-00011; BIDANI AK, 1994, HYPERTENSION, V24, P309, DOI 10.1161/01.HYP.24.3.309; Black HR, 1998, ARCH INTERN MED, V158, P573; CHAPMAN AB, 1991, ANN INTERN MED, V115, P769, DOI 10.7326/0003-4819-115-10-769; Christensen PK, 1999, KIDNEY INT, V56, P1517, DOI 10.1046/j.1523-1755.1999.00676.x; Christensen PK, 1997, KIDNEY INT, V52, P1369, DOI 10.1038/ki.1997.463; CORDINGLEY FT, 1980, CLIN NEPHROL, V14, P98; CURTIS JJ, 1993, J AM SOC NEPHROL, V3, P1570; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; Demeilliers B, 1998, J HYPERTENS, V16, P1023, DOI 10.1097/00004872-199816070-00017; DITSCHERLEIN G, 1985, HYPERTENSION, V7, P29; GOLDFARB DA, 1994, J UROLOGY, V151, P208, DOI 10.1016/S0022-5347(17)34918-2; Griffin KA, 1999, KIDNEY INT, V55, P1849, DOI 10.1046/j.1523-1755.1999.00434.x; GRIFFIN KA, 1995, J CLIN INVEST, V96, P793, DOI 10.1172/JCI118125; HANSEN HP, 1995, KIDNEY INT, V47, P1726, DOI 10.1038/ki.1995.238; Hayashi K, 1996, J HYPERTENS, V14, P1387, DOI 10.1097/00004872-199612000-00002; IVERSEN BM, 1987, AM J PHYSIOL, V252, pF480, DOI 10.1152/ajprenal.1987.252.3.F480; Johnson RJ, 2002, NEW ENGL J MED, V346, P913, DOI 10.1056/NEJMra011078; Kang DH, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133806; Kitiyakara C, 1998, J AM SOC NEPHROL, V9, P133; KON V, 1993, KIDNEY INT, V44, P545, DOI 10.1038/ki.1993.279; Kvam FI, 1998, AM J PHYSIOL-RENAL, V275, pF576, DOI 10.1152/ajprenal.1998.275.4.F576; MAMDANI BH, 1974, NEW ENGL J MED, V291, P1343, DOI 10.1056/NEJM197412192912509; NAVAR LG, 1978, AM J PHYSIOL, V234, pF357, DOI 10.1152/ajprenal.1978.234.5.F357; Palmer BF, 1995, J INVEST MED, V43, P516; Palmer BF, 2001, AM J MED SCI, V321, P388; PELAYO JC, 1991, J CLIN INVEST, V88, P101, DOI 10.1172/JCI115264; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Ruggenenti P, 1998, J AM SOC NEPHROL, V9, P2096; Schnermann J, 1998, AM J PHYSIOL-REG I, V274, pR263, DOI 10.1152/ajpregu.1998.274.2.R263; Schor N, 2002, KIDNEY INT, V61, P764, DOI 10.1046/j.1523-1755.2002.00178.x; SEELIG CB, 1990, SOUTHERN MED J, V83, P1144, DOI 10.1097/00007611-199010000-00007; Stearne MR, 1998, BRIT MED J, V317, P713; STRANDGAARD S, 1976, CIRCULATION, V53, P720, DOI 10.1161/01.CIR.53.4.720; STRANDGAARD S, 1978, ACTA NEUROL SCAND, V57, P11; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zhuo J, 1996, Clin Exp Pharmacol Physiol Suppl, V3, pS147	46	225	238	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1256	1261		10.1056/NEJMra020676	http://dx.doi.org/10.1056/NEJMra020676			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393824				2022-12-28	WOS:000178598300008
J	Ray, WA; Stein, CM; Daugherty, JR; Hall, K; Arbogast, PG; Griffin, MR				Ray, WA; Stein, CM; Daugherty, JR; Hall, K; Arbogast, PG; Griffin, MR			COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease	LANCET			English	Article								Results of premarketing and postmarketing trials have raised doubts about the cardiovascular safety of the non-steroidal anti-inflammatory drug (NSAID) rofecoxib, especially at doses greater than 25 mg. Between Jan 1, 1999, and June 30, 2001, we did a retrospective cohort study of individuals on the expanded Tennessee Medicaid programme (TennCare), in which we assessed occurrence of serious coronary heart disease (CHD) in non-users (n=202 916) and in users of rofecoxib and other NSAIDs (rofecoxib n=24 132, other n=151 728). Participants were aged 50-84 years, lived in the community, and had no life-threatening non-cardiovascular illness. Users of high-dose rofecoxib were 1-70 (95% CI 0.98-2.95, p=0.058) times more likely than non-users to have CHD; among new users this rate increased to 1.93 (1.09-3.42, p=0.024). By contrast, there was no evidence of raised risk of CHD among users of rofecoxib at doses of 25 mg or less or among users of other NSAIDs.	Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Nashville Vet Adm Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN USA; Vanderbilt Univ, Ctr Educ & Res Therapeut, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; Vanderbilt University	Ray, WA (corresponding author), Vanderbilt Univ, Sch Med, Dept Prevent Med, 221 Kirkland Hall, Nashville, TN 37232 USA.				AHRQ HHS [HS1-0384] Funding Source: Medline; NHLBI NIH HHS [HL 67964] Funding Source: Medline; FDA HHS [FD-U-001641] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010384] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067964] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FDA HHS; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; *FOOD DRUG ADM, 1999, MED OFF REV; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Ray WA, 2002, LANCET, V359, P118, DOI 10.1016/S0140-6736(02)07370-1; Solomon DH, 2002, ARCH INTERN MED, V162, P1099, DOI 10.1001/archinte.162.10.1099	5	415	428	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1071	1073		10.1016/S0140-6736(02)11131-7	http://dx.doi.org/10.1016/S0140-6736(02)11131-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383990				2022-12-28	WOS:000178485200015
J	Kennedy, RD; Quinn, JE; Johnston, PG; Harkin, DP				Kennedy, RD; Quinn, JE; Johnston, PG; Harkin, DP			BRCA1: mechanisms of inactivation and implications for management of patients	LANCET			English	Review							BILATERAL PROPHYLACTIC MASTECTOMY; SURGICAL ADJUVANT BREAST; OVARIAN-CANCER; HEREDITARY BREAST; MUTATION CARRIERS; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; TUMOR CHARACTERISTICS; DECREASED EXPRESSION; ORAL-CONTRACEPTIVES	The BRCA1 gene was cloned in 1994 as one of the genes that conferred genetic predisposition to early-onset breast and ovarian cancer. Since then, a genetic test for identification of high-risk individuals has been developed. Despite being implicated in many important cellular pathways, including DNA repair and regulation of transcription, the exact mechanism by which inactivation of BRCA1 might lead to malignant transformation of cells remains unknown. We examine the mechanisms that underlie inactivation of BRCA1 and assess how they affect management of patients, in terms of both primary and secondary cancer prevention strategies. Furthermore, we look at the potential usefulness of BRCA1 as a prognostic tool and as a predictive marker of response to different classes of drugs. Finally, throughout this review, we draw links between the functional consequences of BRCA1 inactivation, in terms of key cellular signalling pathways, and how they might explain specific clinical observations in individuals who carry mutations in the gene.	Queens Univ Belfast, Dept Oncol, Canc Res Ctr, Belfast BT9 7AB, Antrim, North Ireland	Queens University Belfast	Harkin, DP (corresponding author), Queens Univ Belfast, Dept Oncol, Canc Res Ctr, Belfast BT9 7AB, Antrim, North Ireland.	d.harkin@qub.ac.uk	Kennedy, Richard/J-3489-2012	Kennedy, Richard/0000-0003-4737-6163	Breast Cancer Now [2000:119] Funding Source: Medline	Breast Cancer Now		[Anonymous], 1995, JAMA, V273, P491; Armstrong K, 2001, J CLIN ONCOL, V19, P919, DOI 10.1200/JCO.2001.19.4.919; Bahar AY, 2001, CANCER-AM CANCER SOC, V92, P440, DOI 10.1002/1097-0142(20010715)92:2<440::AID-CNCR1340>3.0.CO;2-O; Barton DL, 2002, ONCOLOGY-NY, V16, P67; Ben David Y, 2002, J CLIN ONCOL, V20, P463, DOI 10.1200/JCO.20.2.463; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brunet JS, 1997, NEW ENGL J MED, V336, P1256; *CANC RES UK PRIM, 2001, FAM BREAST OV CANC M; Cappelli M, 1999, CLIN GENET, V55, P419, DOI 10.1034/j.1399-0004.1999.550605.x; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chappuis PO, 2000, J CLIN ONCOL, V18, P4045, DOI 10.1200/JCO.2000.18.24.4045; Colgan TJ, 2001, AM J SURG PATHOL, V25, P1283, DOI 10.1097/00000478-200110000-00009; Couch FJ, 1998, JAMA-J AM MED ASSOC, V279, P955, DOI 10.1001/jama.279.12.955; *EARL BREAST CANC, 2001, COCHR LIB; Egawa C, 2001, INT J CANCER, V95, P255, DOI 10.1002/1097-0215(20010720)95:4<255::AID-IJC1043>3.0.CO;2-O; Einhorn N, 2000, GYNECOL ONCOL, V79, P466, DOI 10.1006/gyno.2000.5983; Eisen A, 2000, J CLIN ONCOL, V18, P1980, DOI 10.1200/JCO.2000.18.9.1980; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FORD D, 1995, AM J HUM GENET, V57, P1457; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Geisler JP, 2002, JNCI-J NATL CANCER I, V94, P61; Haffty BG, 2002, LANCET, V359, P1471, DOI 10.1016/S0140-6736(02)08434-9; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hamann U, 2000, BREAST CANCER RES TR, V59, P185, DOI 10.1023/A:1006350518190; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hartmann LC, 2001, JNCI-J NATL CANCER I, V93, P1633, DOI 10.1093/jnci/93.21.1633; Hatcher MB, 2001, BRIT MED J, V322, P76, DOI 10.1136/bmj.322.7278.76; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; HENDERSON IC, 1998, P ANN M AM SOC CLIN; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jernstrom H, 1999, LANCET, V354, P1846, DOI 10.1016/S0140-6736(99)04336-6; Johannsson OT, 1998, J CLIN ONCOL, V16, P397, DOI 10.1200/JCO.1998.16.2.397; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; KLOOS I, 2001, P ANN M AM SOC CLIN; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1997, LANCET, V349, P1505; MAMOUMAS E, 2000, NAT I HLTH CONS DEV; MARESCO DL, 2001, P ANN M AM SOC CLIN; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Modan B, 2001, NEW ENGL J MED, V345, P235, DOI 10.1056/NEJM200107263450401; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Mullan PB, 2001, BIOCHEM SOC T, V29, P678, DOI 10.1042/BST0290678; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; MUTO MG, 1993, GYNECOL ONCOL, V51, P12, DOI 10.1006/gyno.1993.1239; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Narod SA, 2002, NAT REV CANCER, V2, P113, DOI 10.1038/nrc726; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Paley PJ, 2001, GYNECOL ONCOL, V80, P176, DOI 10.1006/gyno.2000.6071; Peshkin BN, 1999, LANCET, V353, P2176, DOI 10.1016/S0140-6736(99)90078-8; Phillips KA, 1999, J CLIN ONCOL, V17, P3653, DOI 10.1200/JCO.1999.17.11.3653; Pierce LJ, 2000, J CLIN ONCOL, V18, P3360, DOI 10.1200/JCO.2000.18.19.3360; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P2751, DOI 10.1002/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J; Powles TJ, 2001, ANN NY ACAD SCI, V949, P109; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Robson M, 1998, J CLIN ONCOL, V16, P1642, DOI 10.1200/JCO.1998.16.5.1642; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shannon KM, 2002, CANCER-AM CANCER SOC, V94, P305, DOI 10.1002/cncr.10223; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Ursin G, 1997, CANCER RES, V57, P3678; van Nagell JR, 2000, GYNECOL ONCOL, V77, P350, DOI 10.1006/gyno.2000.5816; van Roosmalen MS, 2002, J CLIN ONCOL, V20, P2092, DOI 10.1200/jco.2002.08.035; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang QF, 2001, CANCER-AM CANCER SOC, V92, P54, DOI 10.1002/1097-0142(20010701)92:1<54::AID-CNCR1291>3.0.CO;2-8	81	84	89	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	2002	360	9338					1007	1014		10.1016/S0140-6736(02)11087-7	http://dx.doi.org/10.1016/S0140-6736(02)11087-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383682				2022-12-28	WOS:000178249000025
J	Milad, MR; Quirk, GJ				Milad, MR; Quirk, GJ			Neurons in medial prefrontal cortex signal memory for fear extinction	NATURE			English	Article							CONDITIONED FEAR; POTENTIATED STARTLE; FRONTAL-CORTEX; AMYGDALA; RAT; STIMULATION; BRAIN; PROJECTIONS; ACQUISITION	Conditioned fear responses to a tone previously paired with a shock diminish if the tone is repeatedly presented without the shock, a process known as extinction. Since Pavlov(1) it has been hypothesized that extinction does not erase conditioning, but forms a new memory. Destruction of the ventral medial prefrontal cortex, which consists of infralimbic and prelimbic cortices, blocks recall of fear extinction(2,3), indicating that medial prefrontal cortex might store long-term extinction memory. Here we show that infralimbic neurons recorded during fear conditioning and extinction fire to the tone only when rats are recalling extinction on the following day. Rats that froze the least showed the greatest increase in infralimbic tone responses. We also show that conditioned tones paired with brief electrical stimulation of infralimbic cortex elicit low freezing in rats that had not been extinguished. Thus, stimulation resembling extinction-induced infralimbic tone responses is able to simulate extinction memory. We suggest that consolidation of extinction learning potentiates infralimbic activity, which inhibits fear during subsequent encounters with fear stimuli.	Ponce Sch Med, Dept Physiol, Ponce, PR 00732 USA		Quirk, GJ (corresponding author), Ponce Sch Med, Dept Physiol, Ponce, PR 00732 USA.		anand, amit/A-7222-2009; Milad, Mohammed R/O-4553-2018					ALMASKATI HA, 1989, J AUTONOM NERV SYST, V28, P117, DOI 10.1016/0165-1838(89)90084-2; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; CONDE F, 1995, J COMP NEUROL, V352, P567, DOI 10.1002/cne.903520407; Eschweiler GW, 2000, PSYCHIAT RES-NEUROIM, V99, P161, DOI 10.1016/S0925-4927(00)00062-7; FALLS WA, 1992, J NEUROSCI, V12, P854; Fendt M, 1999, NEUROSCI BIOBEHAV R, V23, P743, DOI 10.1016/S0149-7634(99)00016-0; Garcia R, 1999, NATURE, V402, P294, DOI 10.1038/46286; Gewirtz JC, 1997, BEHAV NEUROSCI, V111, P712, DOI 10.1037/0735-7044.111.4.712; Herry C, 2002, J NEUROSCI, V22, P577, DOI 10.1523/JNEUROSCI.22-02-00577.2002; Herry C, 1999, J NEUROPHYSIOL, V82, P2827, DOI 10.1152/jn.1999.82.5.2827; Konorski J., 1967, INTEGRATIVE ACTIVITY; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lu KT, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0005.2001; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; McDonald AJ, 1996, NEUROSCIENCE, V71, P55, DOI 10.1016/0306-4522(95)00417-3; MCDONALD AJ, 1991, NEUROSCIENCE, V44, P1, DOI 10.1016/0306-4522(91)90247-L; MORGAN MA, 1993, NEUROSCI LETT, V163, P109, DOI 10.1016/0304-3940(93)90241-C; MORGAN MA, 1995, BEHAV NEUROSCI, V109, P681, DOI 10.1037/0735-7044.109.4.681; Morrow BA, 1999, NEUROSCIENCE, V92, P553, DOI 10.1016/S0306-4522(99)00014-7; Pavlov I.P., 1927, CONDITIONED REFLEXES; PEREZJARANAY JM, 1991, BRAIN RES, V564, P97, DOI 10.1016/0006-8993(91)91357-7; Quirk GJ, 2000, J NEUROSCI, V20, P6225, DOI 10.1523/JNEUROSCI.20-16-06225.2000; QUIRK GJ, 1995, NEURON, V15, P1029, DOI 10.1016/0896-6273(95)90092-6; Repa JC, 2001, NAT NEUROSCI, V4, P724, DOI 10.1038/89512; ROBERTSON A, 1982, PHYSIOL BEHAV, V28, P869, DOI 10.1016/0031-9384(82)90206-2; Royer S, 1999, J NEUROSCI, V19, P10575; Royer S, 2000, J NEUROSCI, V20, P9034; Santini E, 2001, J NEUROSCI, V21, P9009, DOI 10.1523/JNEUROSCI.21-22-09009.2001; Semple WE, 2000, PSYCHIATRY, V63, P65, DOI 10.1080/00332747.2000.11024895; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X	30	1295	1325	1	130	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					70	74		10.1038/nature01138	http://dx.doi.org/10.1038/nature01138			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422216				2022-12-28	WOS:000179068100038
J	Pronovost, PJ; Angus, DC; Dorman, T; Robinson, KA; Dremsizov, TT; Young, TL				Pronovost, PJ; Angus, DC; Dorman, T; Robinson, KA; Dremsizov, TT; Young, TL			Physician staffing patterns and clinical outcomes in critically ill patients - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-of-Critical-Care-Medicine	FEB 12-22, 2000	ORLANDO, FL	Soc Crit Care Med			INTENSIVE-CARE-UNIT; MIX-ADJUSTED MORTALITY; ORGANIZATIONAL-CHANGE; RESOURCE UTILIZATION; PEDIATRIC RISK; CAVE UNIT; IMPACT; QUALITY; COST; METAANALYSIS	Context Intensive care unit (ICU) physician staffing varies widely, and its association with patient outcomes remains unclear. Objective To evaluate the association between ICU physician staffing and patient outcomes. Data Sources We searched MEDLINE (January 1, 1965, through September 30, 2001) for the following medical subject heading (MeSH) terms: intensive care units, ICU, health resources/utilization, hospitalization, medical staff hospital organization and administration, personnel staffing and scheduling, length of stay, and LOS. We also used the following text words: staffing, intensivist, critical, care, and specialist. To identify observational studies, we added the MeSH terms case-control study and retrospective study. Although we searched for non-English-language citations, we reviewed only English-language articles. We also searched EMBASE, HealthStar (Health Services, Technology, Administration, and Research), and HSRPROJ (Health Services Research Projects in Progress) via Internet Grateful Med and The Cochrane Library and hand searched abstract proceedings from intensive care national scientific meetings (January 1, 1994, through December 31, 2001). Study Selection We selected randomized and observational controlled trials of critically ill adults or children. Studies examined ICU attending physician staffing strategies and the outcomes of hospital and ICU mortality and length of stay (LOS). Studies were selected and critiqued by 2 reviewers. We reviewed 2590 abstracts and identified 26 relevant observational studies (of which 1 included 2 comparisons), resulting in 27 comparisons of alternative staffing strategies. Twenty studies focused on a single ICU. Data Synthesis We grouped ICU physician staffing into low-intensity (no intensivist or elective intensivist consultation) or high-intensity (mandatory intensivist consultation or closed ICU [all care directed by intensivist]) groups. High-intensity staffing was associated with lower hospital mortality in 16 of 17 studies (94%) and with a pooled estimate of the relative risk for hospital mortality of 0.71 (95% confidence interval [CI], 0.62-0.82). High-intensity staffing was associated with a lower ICU mortality in 14 of 15 studies (93%) and with a pooled estimate of the relative risk for ICU mortality of 0.61 (95 % CI, 0.50-0.75). High-intensity staffing reduced hospital LOS in 10 of 13 studies and reduced ICU LOS in 14 of 18 studies without case-mix adjustment. Conclusions High-intensity staffing was associated with reduced hospital LOS in 2 of 4 studies and ICU LOS in both studies that adjusted for case mix. No study found increased LOS with high-intensity staffing after case-mix adjustment.	Univ Pittsburgh, Dept Crit Care Med, CRISMA Lab, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA; Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA; Johns Hopkins Univ, Dept Surg, Baltimore, MD USA; Johns Hopkins Univ, Dept Med, Baltimore, MD USA; Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Angus, DC (corresponding author), Univ Pittsburgh, Dept Crit Care Med, CRISMA Lab, 604 Scaife Hall,200 Lothrop St, Pittsburgh, PA 15213 USA.	angusdc@ccm.upmc.edu	Angus, Derek C/E-9671-2012	dorman, todd/0000-0002-8616-8677				Al-Asadi L, 1996, AM J RESP CRIT CARE, V153, pA360; Audit Commission, 1999, CRIT SUCC PLAC EFF E; Baldock G, 2001, INTENS CARE MED, V27, P865, DOI 10.1007/s001340100938; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Berlin J, 1996, AHCPR9720; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BIRKMEYER JD, 2002, LEAPFROG SAFETY STAN; Blunt MC, 2000, LANCET, V356, P735, DOI 10.1016/S0140-6736(00)02634-9; Brilli RJ, 2001, CRIT CARE MED, V29, P2007, DOI 10.1097/00003246-200110000-00026; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BROWN JJ, 1989, CHEST, V96, P127, DOI 10.1378/chest.96.1.127; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; Cole L, 2000, AM J RESP CRIT CARE, V162, P191, DOI 10.1164/ajrccm.162.1.9907016; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Cowen J, 1999, CRIT CARE MED, V27, pA35, DOI 10.1097/00003246-199901001-00029; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DiCosmo BF, 1999, CHEST, V116, pS238; Dimick JB, 2001, CRIT CARE MED, V29, P753, DOI 10.1097/00003246-200104000-00012; Dimick JB, 2000, CRIT CARE MED, V28, pA77; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; EAGLE KA, 1991, MED CARE, V29, P1237, DOI 10.1097/00005650-199112000-00006; Ferdinande P, 1997, INTENS CARE MED, V23, P226, DOI 10.1007/s001340050321; Ghorra S, 1999, ANN SURG, V229, P163, DOI 10.1097/00000658-199902000-00001; Goh AYT, 2001, LANCET, V357, P445, DOI 10.1016/S0140-6736(00)04014-9; GROEGER JS, 1992, CRIT CARE MED, V20, P846, DOI 10.1097/00003246-199206000-00024; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; JACOBS MC, 1998, CHEST, V114, pS276; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kuo H, 2000, CRIT CARE SHOCK, V3, P57; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; Lima C, 1995, CRIT CARE MED, V23, pA238; Manthous CA, 1997, MAYO CLIN PROC, V72, P391, DOI 10.4065/72.5.391; Marini CP NI, 1995, CRIT CARE MED, V23, pA235; Mark D H, 1997, Fam Med, V29, P132; Milstein A, 2000, Eff Clin Pract, V3, P313; Mirski MA, 2001, J NEUROSURG ANESTH, V13, P83, DOI 10.1097/00008506-200104000-00004; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; MOHER D, 2002, DOES LANGUAGE PUBLIC; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; Park CA, 2001, AM SURGEON, V67, P665; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Pollack MM, 1997, CRIT CARE MED, V25, P1637, DOI 10.1097/00003246-199710000-00011; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Pronovost P J, 2001, Eff Clin Pract, V4, P199; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; REICH HS, 1998, CRIT CARE MED, V25, pA44; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150; Rosenfeld BA, 2000, CRIT CARE MED, V28, P3925, DOI 10.1097/00003246-200012000-00034; SCHMITZ R, 1999, FUTURE WORKFORCE NEE; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tai D. Y. H., 1998, Annals Academy of Medicine Singapore, V27, P309; TEASDALE G, 1974, LANCET, V2, P81; Teres D, 1983, Inquiry, V20, P282; Topeli A, 2000, AM J RESP CRIT CARE, V161, pA397; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vincent JL, 2000, LANCET, V356, P695, DOI 10.1016/S0140-6736(00)02622-2; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; YEH TS, 1984, PEDIATR RES, V18, P445, DOI 10.1203/00006450-198405000-00011	68	1009	1040	1	68	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2151	2162		10.1001/jama.288.17.2151	http://dx.doi.org/10.1001/jama.288.17.2151			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	611ZJ	12413375	Bronze			2022-12-28	WOS:000179048100026
J	Ranta, E; Lundberg, P; Kaitala, V; Stenseth, NC				Ranta, E; Lundberg, P; Kaitala, V; Stenseth, NC			On the crest of a population wave	SCIENCE			English	Editorial Material							TRAVELING WAVES; SPATIAL ASYNCHRONY; DYNAMICS		Univ Helsinki, Dept Systemat & Ecol, FIN-00014 Helsinki, Finland; Univ Calif Santa Barbara, Ctr Ecol Anal & Synth, Santa Barbara, CA 93101 USA; Univ Oslo, Dept Zool, N-0316 Oslo, Norway	University of Helsinki; National Center for Ecological Analysis & Synthesis; University of California System; University of California Santa Barbara; University of Oslo	Ranta, E (corresponding author), Univ Helsinki, Dept Systemat & Ecol, FIN-00014 Helsinki, Finland.		Stenseth, Nils Chr./G-5212-2016	Stenseth, Nils Chr./0000-0002-1591-5399; Lundberg, Per/0000-0002-9609-726X				Bascompte J., 1997, MODELING SPATIOTEMPO; Bjornstad ON, 2002, SCIENCE, V298, P1020, DOI 10.1126/science.1075182; BUTLER L., 1953, CANADIAN JOUR ZOOL, V31, P242, DOI 10.1139/z53-021; Elton CS, 1924, BR J EXP BIOL, V2, P119; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; Kaitala V, 2001, P ROY SOC B-BIOL SCI, V268, P1655, DOI 10.1098/rspb.2001.1721; Lambin X, 1998, P ROY SOC B-BIOL SCI, V265, P1491, DOI 10.1098/rspb.1998.0462; Lindstrom J, 2001, BIOL REV, V76, P129, DOI 10.1017/S1464793100005637; Moss R, 2000, ECOLOGY, V81, P981, DOI 10.2307/177172; Ranta E, 1997, NATURE, V390, P456, DOI 10.1038/37261; SHIKESADA N, 1997, BIOL INVASIONS THEOR	12	2	2	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					973	974		10.1126/science.1078707	http://dx.doi.org/10.1126/science.1078707			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411689				2022-12-28	WOS:000178932000038
J	Roth, M; Johnson, PRA; Rudiger, JJ; King, GG; Ge, Q; Burgess, JK; Anderson, G; Tamm, M; Black, JL				Roth, M; Johnson, PRA; Rudiger, JJ; King, GG; Ge, Q; Burgess, JK; Anderson, G; Tamm, M; Black, JL			Interaction between glucocorticoids and beta(2) agonists on bronchial airway smooth muscle cells through synchronised cellular signalling	LANCET			English	Article							RAT HEPATOMA-CELLS; BINDING PROTEIN; RECEPTOR; ASTHMA; PROLIFERATION; SALMETEROL; BUDESONIDE; FORMOTEROL; GENE; BETA(2)-ADRENOCEPTOR	Background Increased airway smooth muscle bulk is a pathological feature of asthma. Asthma is well controlled by the combined inhalation of glucocorticoids and beta(2)-adrenoceptor agonists. The basic molecular mechanism of the interaction of the two drugs on proliferation of airway smooth muscle cells is yet to be identified. Our aim was to elucidate how glucocorticoids and beta(2) agonists affect the growth of human bronchial airway smooth muscle cells. Methods We assessed the effect of formoterol and budesonide on the activation and function of transcription factors by immunohistochemistry, western blotting, DNA mobility shift assay, and a luciferase reporter gene assay. The effect of the drugs and the involvement of specific transcription factors on cell proliferation was ascertained by direct cell count and confirmed by thymidine incorporation. Findings Both classes of drugs (10(-8) mol/L) activated C/EBP-alpha and the glucocorticoid receptor with different kinetic profiles, and inhibited proliferation. The combination of lower doses of drugs (10(-12) to 10(-9) mol/L) resulted in a synchronised activation of the transcription factors and an enhanced antiproliferative effect. The action of the drugs alone or in combination on transcription-factor activity and proliferation was suppressed by either depletion of C/EBP-alpha or in the presence of a glucocorticoid-receptor blocker. Interpretation Our findings could provide one explanation for the interaction of beta(2)-agonists and glucocorticoids at a molecular level, and indicate that the concentration of inhaled glucocorticoids can be reduced when combined with beta(2) agonists, minimising the side-effects of the drugs.	Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia; Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Univ Basel Hosp, Dept Pulm Cell Res, CH-4031 Basel, Switzerland; Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia	University of Sydney; University of Sydney; Woolcock Institute of Medical Research; University of Basel; University of Basel; University of Melbourne	Roth, M (corresponding author), Woolcock Inst Med Res, POB M77, Camperdown, NSW 2050, Australia.		Ge, Qi/D-3988-2013; Roth, Michael/H-8657-2019; Black, Judith L/C-6559-2008; Burgess, Janette/M-7117-2019; Burgess, Janette K/A-3597-2010	Roth, Michael/0000-0002-8139-2821; Anderson, Gary/0000-0001-6580-3398; Burgess, Janette/0000-0001-9868-9966				Adamson DL, 2000, J MOL CELL CARDIOL, V32, P1353, DOI 10.1006/jmcc.2000.1171; ANDERSON GP, 1994, EUR RESPIR J, V7, P569, DOI 10.1183/09031936.94.07030569; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214, DOI 10.1164/ajrccm.150.1.7912988; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Esmailpour N, 1997, EUR RESPIR J, V10, P1496, DOI 10.1183/09031936.97.10071496; Fernandes D, 1999, AM J RESP CELL MOL, V21, P77, DOI 10.1165/ajrcmb.21.1.3396; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056; Korn SH, 2001, EUR RESPIR J, V17, P1070, DOI 10.1183/09031936.01.00073301; Koukouritaki SB, 1996, J CELL BIOCHEM, V62, P251, DOI 10.1002/(SICI)1097-4644(199608)62:2<251::AID-JCB13>3.0.CO;2-O; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Ramos RA, 1999, FASEB J, V13, P169, DOI 10.1096/fasebj.13.1.169; Rudiger JJ, 2002, FASEB J, V16, P177, DOI 10.1096/fj.01-0226com; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Spoelstra FM, 2002, THORAX, V57, P237, DOI 10.1136/thorax.57.3.237; Stewart AG, 1995, BRIT J PHARMACOL, V116, P3219, DOI 10.1111/j.1476-5381.1995.tb15127.x; Stewart AG, 1997, BRIT J PHARMACOL, V121, P361, DOI 10.1038/sj.bjp.0701128; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TOMLINSON PR, 1995, BIOCHEM PHARMACOL, V49, P1809, DOI 10.1016/0006-2952(94)00532-Q; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; van der Velden VHJ, 1998, MEDIAT INFLAMM, V7, P229, DOI 10.1080/09629359890910; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	33	218	226	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1293	1299		10.1016/S0140-6736(02)11319-5	http://dx.doi.org/10.1016/S0140-6736(02)11319-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414205				2022-12-28	WOS:000178827200012
J	Noren, AJ; Bierman, PR; Steig, EJ; Lini, A; Southon, J				Noren, AJ; Bierman, PR; Steig, EJ; Lini, A; Southon, J			Millennial-scale storminess variability in the northeastern United States during the Holocene epoch	NATURE			English	Article							NORTH-ATLANTIC; YR RECORD; CLIMATE; ICE; CIRCULATION; SEDIMENTS; EROSION; EVENTS; NORWAY; CORES		Univ Vermont, Dept Geol, Burlington, VT 05405 USA; Univ Washington, Quaternary Res Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94551 USA	University of Vermont; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Noren, AJ (corresponding author), Univ Vermont, Dept Geol, Burlington, VT 05405 USA.		Steig, Eric J/G-9088-2015; Bierman, Paul/AAA-9466-2020; Lini, Andrea/F-9020-2016	Steig, Eric J/0000-0002-8191-5549; Bierman, Paul/0000-0001-9627-4601; Noren, Anders/0000-0002-5604-1085; Lini, Andrea/0000-0002-2920-570X				Bierman P., 1997, GSA TODAY, V7, P1; Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; BOSLEY AC, 2001, GEOL SOC AM ABSTR, V33, P15; BOULTON GS, 1997, GLACIER FLUCTUATIONS, P5; Brown P, 1999, PALEOCEANOGRAPHY, V14, P498, DOI 10.1029/1999PA900017; Brown SL, 2000, GEOLOGY, V28, P335, DOI 10.1130/0091-7613(2000)28<335:YROEHE>2.0.CO;2; CONLAN A, 2001, VERMONT GEOLOGICAL S; Eden DN, 1998, PALAEOGEOGR PALAEOCL, V139, P37, DOI 10.1016/S0031-0182(97)00136-3; Fischer H, 2001, J GEOPHYS RES-ATMOS, V106, P23977, DOI 10.1029/2000JD000175; Grove JM, 1988, LITTLE ICE AGE; Hormes A, 2001, HOLOCENE, V11, P255, DOI 10.1191/095968301675275728; Houghton J. T., 2001, CLIMATE CHANGE 2001; JENNINGS KL, IN PRESS GEOL SOC AM; Karlen W, 1996, HOLOCENE, V6, P359, DOI 10.1177/095968369600600311; Knox JC, 2000, QUATERNARY SCI REV, V19, P439, DOI 10.1016/S0277-3791(99)00074-8; LAMB HH, 1979, QUATERNARY RES, V11, P1, DOI 10.1016/0033-5894(79)90067-X; Lamoureux S, 2000, WATER RESOUR RES, V36, P309, DOI 10.1029/1999WR900271; Liu KB, 2000, QUATERNARY RES, V54, P238, DOI 10.1006/qres.2000.2166; Mann ME, 1996, CLIMATIC CHANGE, V33, P409, DOI 10.1007/BF00142586; Matthews JA, 2000, QUATERNARY SCI REV, V19, P1625, DOI 10.1016/S0277-3791(00)00008-1; MAYEWSKI PA, 1994, SCIENCE, V263, P1747, DOI 10.1126/science.263.5154.1747; Nesje A, 2001, J PALEOLIMNOL, V25, P329, DOI 10.1023/A:1011197507174; OBRIEN SR, 1995, SCIENCE, V270, P1962, DOI 10.1126/science.270.5244.1962; Rodbell DT, 1999, SCIENCE, V283, P516, DOI 10.1126/science.283.5401.516; Shindell DT, 2001, SCIENCE, V294, P2149, DOI 10.1126/science.1064363; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Thompson DWJ, 2001, SCIENCE, V293, P85, DOI 10.1126/science.1058958; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Thorndycraft V, 1998, HOLOCENE, V8, P741, DOI 10.1191/095968398668590504; Zong YQ, 1999, QUATERN INT, V55, P43, DOI 10.1016/S1040-6182(98)00022-6	30	139	149	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					821	824		10.1038/nature01132	http://dx.doi.org/10.1038/nature01132			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397353				2022-12-28	WOS:000178769800041
J	Hersh, WR				Hersh, WR			Medical informatics - Improving health care through information	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHYSICIAN ORDER ENTRY; DECISION-SUPPORT-SYSTEMS; IMPLEMENTATION; PAPER		Oregon Hlth & Sci Univ, Sch Med, Div Med Informat & Outcomes Res, BICC, Portland, OR 97201 USA	Oregon Health & Science University	Hersh, WR (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Div Med Informat & Outcomes Res, BICC, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	hersh@ohsu.edu	Frisse, Mark E/B-3824-2016; Tao, Youyou/D-2367-2014	Frisse, Mark E/0000-0003-0382-6222; Hersh, William/0000-0002-4114-5148				Ahmad A, 2002, J AM MED INFORM ASSN, V9, P16, DOI 10.1136/jamia.2002.0090016; *AM COLL PHYS, 2002, ACP ASIM SURV FINDS; [Anonymous], 2001, CROSSING QUALITY CHA; Bates DW, 2001, J AM MED INFORM ASSN, V8, P299, DOI 10.1136/jamia.2001.0080299; BATES DW, 1994, J AM MED INFORM ASSN, P996; Berg M, 2001, INT J MED INFORM, V64, P143, DOI 10.1016/S1386-5056(01)00200-3; Chueh H, 1997, ACAD MED, V72, P512, DOI 10.1097/00001888-199706000-00016; Cimino JJ, 1998, METHOD INFORM MED, V37, P394; Committee on Maintaining Privacy and Security in Health Care Applications of the National Information Infrastructure NRC, 1997, RECORD PROTECTING EL; Criswell DF, 2002, J AM MED INFORM ASSN, V9, P80, DOI 10.1136/jamia.2002.0090080; Dick RS, 1997, COMPUTER BASED PATIE; Dolin RH, 2001, J AM MED INFORM ASSN, V8, P552, DOI 10.1136/jamia.2001.0080552; Fox S, ONLINE HLTH CARE REV; GANDHI TK, 2001, MAKING HLTH CARE SAF, P79; Gostin LO, 2001, JAMA-J AM MED ASSOC, V285, P3015, DOI 10.1001/jama.285.23.3015; Haynes R B, 2001, ACP J Club, V134, pA11; HERSCH WR, 2002, INFORMATION RETRIEVA; Hersh WR, 2000, J AM MED INFORM ASSN, V7, P324, DOI 10.1136/jamia.2000.0070324; Hersh WR, 1998, JAMA-J AM MED ASSOC, V280, P1347, DOI 10.1001/jama.280.15.1347; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; KAUSHAL R, 2001, MAKING HLTH CARE SAF, P59; KOHN LT, 2000, ERR OS HUMAN BUILDIN; Kukafka R, 2001, J Public Health Manag Pract, V7, P31; Lovis C, 2001, J AM MED INFORM ASSN, V8, P486, DOI 10.1136/jamia.2001.0080486; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; McDonald CJ, 1997, J AM MED INFORM ASSN, V4, P213, DOI 10.1136/jamia.1997.0040213; MILLER RA, 1994, J AM MED INFORM ASSN, V1, P8, DOI 10.1136/jamia.1994.95236141; Overhage JM, 2001, J AM MED INFORM ASSN, V8, P361, DOI 10.1136/jamia.2001.0080361; Overhage JM, 2002, J AM MED INFORM ASSN, V9, P199, DOI 10.1197/jamia.M1081; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; Shiffman RN, 1999, J AM MED INFORM ASSN, V6, P104, DOI 10.1136/jamia.1999.0060104; Shu K, 2001, ST HEAL T, V84, P1207; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Taylor H., INCREASING IMPACT EH; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Wager K A, 2000, J Am Board Fam Pract, V13, P338; WOOD EH, 1994, J AM MED INFORM ASSN, V1, P372, DOI 10.1136/jamia.1994.95153425	37	114	118	2	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	2002	288	16					1955	1958		10.1001/jama.288.16.1955	http://dx.doi.org/10.1001/jama.288.16.1955			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	606QW	12387634				2022-12-28	WOS:000178745500001
J	Beich, A; Gannik, D; Malterud, K				Beich, A; Gannik, D; Malterud, K			Screening and brief intervention for excessive alcohol use: qualitative interview study of the experiences of general practitioners	BRITISH MEDICAL JOURNAL			English	Article							DRINKING; METAANALYSIS; STRATEGIES; DRINKERS; HEALTH	Objective To explore the suitability of a screening based intervention for excessive alcohol use by describing the experiences of general practitioners who tried such an intervention in their everyday practice. Design Qualitative interviews with general practitioners who had participated in a pragmatic study of a combined programme of screening and a brief intervention for excessive alcohol use. Doctors were interviewed either individually or in focus groups. A computer based, descriptive, phenomenological method was used to directly analyse the digitally recorded interviews. Setting and participants 24 of 39 general practitioners in four Danish counties who volunteered to take part in the pragmatic study were interviewed. Results The doctors were surprised at how difficult it was to establish rapport with the patients who had a positive result on the screening and to ensure compliance with die intervention. Although the doctors considered the doctor-patient relationship robust enough to sustain targeting of alcohol use, they often failed to follow up on initial interventions, and some expressed a lack of confidence in their ability to counsel patients effectively on lifestyle issues. The doctors questioned the rationale of screening in young drinkers who may grow out of excessive drinking behaviour. The programme needed considerable resources, and it interrupted the natural course of consultations and was inflexible. The doctors could not recommend the screening and brief intervention programme, although they thought it important to counsel their patients on drinking. Conclusions Screening for excessive alcohol use created more problems than it solved for the participating doctors. The results underline the value of carrying out pragmatic studies on the suitability of seemingly efficacious healthcare programmes.	Univ Copenhagen, Panum Inst, Cent Res Unit, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Panum Inst, Dept Gen Practice, DK-2200 Copenhagen, Denmark; Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Sect Gen Practice, N-5009 Bergen, Norway	University of Copenhagen; University of Copenhagen; University of Bergen	Beich, A (corresponding author), Univ Copenhagen, Panum Inst, Cent Res Unit, DK-2200 Copenhagen, Denmark.							Babor TF, 2000, ADDICTION, V95, P677, DOI 10.1046/j.1360-0443.2000.9556773.x; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; Edwards AGK, 1997, ADDICTION, V92, P1699, DOI 10.1111/j.1360-0443.1997.tb02890.x; FILLMORE KM, 1991, BRIT J ADDICT, V86, P1221, DOI 10.1111/j.1360-0443.1991.tb01702.x; FILLMORE KM, 1987, BRIT J ADDICT, V82, P77; Giorgi A, 1985, PHENOMENOLOGY PSYCHO; Hansen LJ, 1999, FAM PRACT, V16, P551, DOI 10.1093/fampra/16.6.551; Harnett R, 1999, ALCOHOL ALCOHOLISM, V34, P672, DOI 10.1093/alcalc/34.5.672; HEATHER N, 1995, ALCOHOL ALCOHOLISM, V30, P287; Hollnagel H, 2000, Med Health Care Philos, V3, P257; Kaner EFS, 1999, BRIT J GEN PRACT, V49, P699; Lawlor DA, 2000, BRIT J GEN PRACT, V50, P455; MALTERUD K, 1993, FAM PRACT, V10, P201, DOI 10.1093/fampra/10.2.201; Powell RA, 1996, INT J QUAL HEALTH C, V8, P499, DOI 10.1093/intqhc/8.5.499; Rollnick S, 1997, ADDICT RES, V5, P331, DOI 10.3109/16066359709004347; Rollnick S., 1999, HLTH BEHAV CHANGE GU, V1st; Saunders JB, 1987, WHO COLLABORATIVE ST; Tesch R, 1991, USING COMPUTERS QUAL; THOM B, 1986, BRIT J ADDICT, V81, P405; *WHO COLL PROJ ID, DEV COUNTR WID STRAT; Wilk AI, 1997, J GEN INTERN MED, V12, P274; WILLIAMS SJ, 1994, SOCIOL HEALTH ILL, V16, P372, DOI 10.1111/1467-9566.ep11348775	22	200	201	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 19	2002	325	7369					870	872B		10.1136/bmj.325.7369.870	http://dx.doi.org/10.1136/bmj.325.7369.870			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	607LL	12386040	Green Published, Bronze			2022-12-28	WOS:000178793000022
J	Wimalasundera, RC; Larbalestier, N; Smith, JN; de Ruiter, A; Thom, SAM; Hughes, AD; Poulter, N; Regan, L; Taylor, GP				Wimalasundera, RC; Larbalestier, N; Smith, JN; de Ruiter, A; Thom, SAM; Hughes, AD; Poulter, N; Regan, L; Taylor, GP			Pre-eclampsia, antiretroviral therapy, and immune reconstitution	LANCET			English	Article							PREGNANCY	Antiretrovirals are standard treatment for HIV-1-positive women during pregnancy in the UK, but little is known about maternal or fetal safety. In our cohort study of 2:14 pregnant women with HIV-1 infection, those who received no antiretroviral therapy had a rate of pre-eclampsia significantly lower (none of 61) than those on triple antiretroviral therapy (8 of 76; odds ratio 15.3, 95% CI 0.9-270, p=0.0087). However, the rate of pre-eclampsia in HIV-1-positive women on treatment did not differ from that in uninfected controls (12 of 214; p=0.2). The association of HIV-1-related immune deficiency with a low rate of pre-eclampsia, and the restoration of this rate in women treated with triple antiretroviral therapy to the expected rate Indicates a pivotal role of the immune system in the pathogenesis of pre-eclampsia. The clinical presentation of pre-eclampsia and toxic effects of antiretroviral therapy could overlap and complicate diagnosis and management in these patients.	St Marys Hosp, Imperial Coll Sch Med, Dept Obstet & Gynaecol, London, England; St Marys Hosp, Imperial Coll Sch Med, Dept Clin Pharmacol, London, England; St Marys Hosp, Imperial Coll Sch Med, Dept Genitourinary Med & Communicable Dis, London, England; Guys & St Thomas NHS Trust, Dept Genitourinary Med, London, England	Imperial College London; Imperial College London; Imperial College London; Guy's & St Thomas' NHS Foundation Trust	Wimalasundera, RC (corresponding author), Queen Charlottes & Chelsea Hosp, Ctr Fetal Care, London W12 0HS, England.		Hughes, Alun David/N-3781-2013; Sandall, Jane/D-4146-2009; Hughes, Alun D/C-6636-2009	Hughes, Alun David/0000-0001-5432-5271; Sandall, Jane/0000-0003-2000-743X; 				Higgins JR, 2001, LANCET, V357, P131, DOI 10.1016/S0140-6736(00)03552-2; Knapen MFCM, 1998, BRIT J OBSTET GYNAEC, V105, P1208, DOI 10.1111/j.1471-0528.1998.tb09977.x; Lyall E G, 2001, HIV Med, V2, P314, DOI 10.1046/j.1464-2662.2001.00082.x; SMITH AC, 2001, IMPORTANT DRUG WARNI; Stratton P, 1999, J ACQ IMMUN DEF SYND, V20, P179, DOI 10.1097/00042560-199902010-00011	5	132	136	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1152	1154		10.1016/S0140-6736(02)11195-0	http://dx.doi.org/10.1016/S0140-6736(02)11195-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387967				2022-12-28	WOS:000178632000019
J	van Weel, C				van Weel, C			Biomedical science matters for people - so its impact should be better assessed	LANCET			English	Editorial Material							HEALTH-CARE		Univ Med Ctr Nijmegen, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Weel, C (corresponding author), Univ Med Ctr Nijmegen, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				CHALMERS I, 1993, ANN NY ACAD SCI, V703, P156, DOI 10.1111/j.1749-6632.1993.tb26345.x; Royal Netherlands Academy of Arts and Sciences Council for Medical Sciences, 2002, SOC IMP APPL HLTH RE; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Smith R, 1998, BRIT MED J, V316, P1036	4	12	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1034	1035		10.1016/S0140-6736(02)11175-5	http://dx.doi.org/10.1016/S0140-6736(02)11175-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383979				2022-12-28	WOS:000178485200004
J	Reis, S; Hermoni, D; Livingstone, P; Borkan, J				Reis, S; Hermoni, D; Livingstone, P; Borkan, J			Integrated narrative and evidence based case report - Case report of paroxysmal atrial fibrillation and anticoagulation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PRIMARY-CARE; MEDICINE; STROKE		Technion Israel Inst Technol, Bruce Rappaport Fac Med, Sect Family Med, IL-31096 Haifa, Israel; Rappaport Fac Med, Dept Family Med, Haifa, Israel; Clalit Hlth Serv, Haifa, Israel; Western Galilee Dist, Haifa, Israel; R Sieff Hosp, Dept Child & Adolescent Psychiat, Safed, Israel; Tel Aviv Univ, Sackler Fac Med, Div Behav Sci, IL-69978 Tel Aviv, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Tel Aviv University; Sackler Faculty of Medicine	Reis, S (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Sect Family Med, POB 9649, IL-31096 Haifa, Israel.	Reis@netvision.net.il						Bensing J, 2000, PATIENT EDUC COUNS, V39, P17, DOI 10.1016/S0738-3991(99)00087-7; *BMJ, 1995, CLIN EV, P510; BORKAN J, 2001, FAM SYST HEALTH, V19, P121; Cantley P, 1999, BRIT J GEN PRACT, V49, P219; Elwyn G, 1999, BRIT J GEN PRACT, V49, P477; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; Falk RH, 2001, NEW ENGL J MED, V344, P1067, DOI 10.1056/NEJM200104053441407; Frank A.W., 1998, FAM SYST HEALTH, V16, P197, DOI [https://doi.org/10.1037/h0089849, DOI 10.1037/H0089849, 10.1037/h0089849]; Greenhalgh T, 1999, BRIT MED J, V318, P48; Greenhalgh T, 1999, BMJ-BRIT MED J, V318, P323, DOI 10.1136/bmj.318.7179.323; *HAIF, 2001, ANT LON ATR LIBR; Hankey GJ, 2001, MED J AUSTRALIA, V174, P234; Hardman SMC, 1999, BMJ-BRIT MED J, V318, P238; Harrison DA, 2001, AM J CARDIOL, V87, P584, DOI 10.1016/S0002-9149(00)01435-1; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hellemons BSP, 1999, BMJ-BRIT MED J, V319, P958, DOI 10.1136/bmj.319.7215.958; Herxheimer A, 2000, LANCET, V355, P1540, DOI 10.1016/S0140-6736(00)02174-7; McAlister FA, 2000, JAMA-J AM MED ASSOC, V283, P2829, DOI 10.1001/jama.283.21.2829; Oswald N, 1999, FAM PRACT, V16, P414, DOI 10.1093/fampra/16.4.414; Protheroe J, 2000, BRIT MED J, V320, P1380, DOI 10.1136/bmj.320.7246.1380; Stern S, 2000, JAMA-J AM MED ASSOC, V283, P2901, DOI 10.1001/jama.283.22.2901	21	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	2002	325	7371					1018	1020		10.1136/bmj.325.7371.1018	http://dx.doi.org/10.1136/bmj.325.7371.1018			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411364	Green Published			2022-12-28	WOS:000179415600026
J	Tappin, D; Brooke, H; Ecob, R; Gibson, A				Tappin, D; Brooke, H; Ecob, R; Gibson, A			Used infant mattresses and sudden infant death syndrome in Scotland: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To examine the proposition that a used infant mattress is associated with an increased risk of sudden infant death syndrome. Design Case-control study. Setting Scotland (population 5.1 million, with about 53000 births a year). Participants 131 infants who died of sudden infant death syndrome between I January 1996 and 31 May 2000 and 278 age, season, and obstetric unit matched control infants. Main outcome measures Routine use of an infant mattress previously used by another child and place of last sleep. Results Routine use of an infant mattress previously used by another child was significantly associated with an increased risk of sudden infant death syndrome (multivariate odds ratio 3.07,95% confidence interval 1.51 to 6.22). Use of a used infant mattress for last sleep was also associated with increased risk (6.10, 2.31 to 16.12). The association was significantly stronger if the mattress was from another home (4.78, 2.08 to 11.0) than if it was from the same home (1.64, 0.64 to 4.2). Conclusion A valid significant association exists between use of a used infant mattress and an increased risk of sudden infant death syndrome, particularly if the mattress is from another home. Insufficient evidence is available to judge whether this relation is cause and effect.	Royal Hosp Sick Children, Dept Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland; Royal Hosp Sick Children, Scottish Cot Death Trust, Glasgow G3 8SJ, Lanark, Scotland	University of Glasgow; University of Glasgow	Tappin, D (corresponding author), Royal Hosp Sick Children, Dept Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland.	goda11@udcf.gla.ac.uk						BLACKWELL CC, 1992, J CLIN PATHOL, V45, P20; BLACKWELL CC, 1999, FEMS IMMUNOL MED MIC, V25, P199; Brooke H, 1997, BMJ-BRIT MED J, V314, P1516, DOI 10.1136/bmj.314.7093.1516; Carstairs V., 1991, DEPRIVATION HLTH SCO; FLEMING P, 2000, SUDDEN UNEXPECTED DE, P50; GIBSON AAM, 1994, 3 SIDS INT C STAV NO; JENKINS R, 2002, P SCOTT COT DEATH TR; *STATA, 2001, STATA7 US GUID	8	65	65	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	2002	325	7371					1007	1009		10.1136/bmj.325.7371.1007	http://dx.doi.org/10.1136/bmj.325.7371.1007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411359	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000179415600021
J	Biragyn, A; Ruffini, PA; Leifer, CA; Klyushnenkova, E; Shakhov, A; Chertov, O; Shirakawa, AK; Farber, JM; Segal, DM; Oppenheim, JJ; Kwak, LW				Biragyn, A; Ruffini, PA; Leifer, CA; Klyushnenkova, E; Shakhov, A; Chertov, O; Shirakawa, AK; Farber, JM; Segal, DM; Oppenheim, JJ; Kwak, LW			Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2	SCIENCE			English	Article							INNATE IMMUNITY; BETA-DEFENSINS; LIPOPOLYSACCHARIDE; COMPLEXES; CD14	beta-Defensins are small antimicrobial peptides of the innate immune system produced in response to microbial infection of mucosal tissue and skin. We demonstrate that murine beta-defensin 2 (mDF2beta) acts directly on immature dendritic cells as an endogenous ligand for Toll-like receptor 4 (TLR-4), inducing up-regulation of costimulatory molecules and dendritic cell maturation. These events, in turn, trigger robust, type 1 polarized adaptive immune responses in vivo, suggesting that mDF2beta may play an important role in immunosurveillance against pathogens and, possibly, self antigens or tumor antigens.	NCI, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA; NCI, Expt Immunol Branch, Bethesda, MD 20892 USA; Sci Applicat Int Corp, Intramural Res Support Program, Frederick, MD 21702 USA; Sci Applicat Int Corp, Prot Chem Lab, Frederick, MD 21702 USA; NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; NCI, Mol Immunoregulat Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Biragyn, A (corresponding author), NCI, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA.	arya@mail.ncifcrf.gov	Ruffini, Pier Adelchi/GLU-1933-2022	Kwak, Larry/0000-0002-1884-5349	NCI NIH HHS [N0L-CO-12400] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000725, ZIAAI000725] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Biragyn A, 2002, BLOOD, V100, P1153, DOI 10.1182/blood-2002-01-0086; Biragyn A, 1999, NAT BIOTECHNOL, V17, P253, DOI 10.1038/6995; Biragyn A, 2001, J IMMUNOL, V167, P6644, DOI 10.4049/jimmunol.167.11.6644; BIRAGYN A, UNPUB; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Jarvis BW, 1997, INFECT IMMUN, V65, P3011, DOI 10.1128/IAI.65.8.3011-3016.1997; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Schutte BC, 2002, ANNU REV PHYSIOL, V64, P709, DOI 10.1146/annurev.physiol.64.081501.134340; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Tsutsumi-Ishii Y, 2002, J LEUKOCYTE BIOL, V71, P154; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Wiese A, 1998, J MEMBRANE BIOL, V162, P127, DOI 10.1007/s002329900350; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	20	735	810	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	2002	298	5595					1025	1029		10.1126/science.1075565	http://dx.doi.org/10.1126/science.1075565			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411706				2022-12-28	WOS:000178932000057
J	Thwaites, GE; Chau, TTH; Stepniewska, K; Phu, NH; Chuong, LV; Sinh, DX; White, NJ; Parry, CM; Farrar, JJ				Thwaites, GE; Chau, TTH; Stepniewska, K; Phu, NH; Chuong, LV; Sinh, DX; White, NJ; Parry, CM; Farrar, JJ			Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features	LANCET			English	Article							INFECTION; COUNTRIES; PROGNOSIS; CHILDREN	Background The diagnosis of tuberculous meningitis is difficult. Discrimination of cases from those of bacterial meningitis by clinical features alone is often impossible, and current laboratory methods remain inadequate or inaccessible in developing countries. We aimed to create a simple diagnostic aid for tuberculous meningitis in adults on the basis of clinical and basic laboratory features. Methods We compared the clinical and laboratory features on admission of 251 adults at an infectious disease hospital in Vietnam who satisfied diagnostic criteria for tuberculous (n=143) or bacterial (n=108) meningitis. Features independently predictive of tuberculous meningitis were modelled by multivariate logistic regression to create a diagnostic rule, and by a classification-tree method. The performance of both diagnostic aids was assessed by resubstitution and prospective test data methods. Findings Five features were predictive of a diagnosis of tuberculous meningitis: age, length of history, white-blood-cell count, total cerebrospinal fluid white-cell count, and cerebrospinal fluid neutrophil proportion. A diagnostic rule developed from these features was 97% sensitive and 91% specific by resubstitution, and 86% sensitive and 79% specific when applied prospectively to a further 42 adults with tuberculous meningitis, and 33 with bacterial meningitis. The corresponding values for the classification tree were 99% and 93% by resubstitution, and 88% and 70% with prospective test data. Interpretation This study suggests that simple, clinical and laboratory data can help in the diagnosis of adults with tuberculous meningitis. Although the usefulness of the diagnostic rule will vary depending on the prevalence of tuberculosis and HIV-1 infection, we suggest it be applied to adults with meningitis and a low cerebrospinal fluid glucose, particularly in settings with limited microbiological resources.	Univ Oxford, Wellcome Trust Clin Res Unit, Ctr Trop Dis, Ho Chi Minh City, Vietnam; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Dis, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Thwaites, GE (corresponding author), Univ Oxford, Wellcome Trust Clin Res Unit, Ctr Trop Dis, 190 Ben Ham Tu, Ho Chi Minh City, Vietnam.	gthwaites@hcm.vnn.vn	Farrar, Jeremy J./HGA-7610-2022; White, Nicholas J/I-4629-2012; Thwaites, Guy E/R-4993-2019; White, Nick/AAC-6527-2019	Thwaites, Guy E/0000-0002-2858-2087; White, Nick/0000-0002-1897-1978; Farrar, Jeremy/0000-0002-2700-623X; Stepniewska, Kasia/0000-0002-1713-6209				AHUJA GK, 1994, TUBERCLE LUNG DIS, V75, P149, DOI 10.1016/0962-8479(94)90045-0; BERENGUER J, 1992, NEW ENGL J MED, V326, P668, DOI 10.1056/NEJM199203053261004; FALLON RJ, 1981, J INFECTION, V3, P39, DOI 10.1016/S0163-4453(81)80007-2; Foulds J, 1998, INT J TUBERC LUNG D, V2, P778; Girgis NI, 1998, AM J TROP MED HYG, V58, P28, DOI 10.4269/ajtmh.1998.58.28; Hosoglu S, 1998, INT J TUBERC LUNG D, V2, P553; HUMPHRIES MJ, 1990, TUBERCLE, V71, P161, DOI 10.1016/0041-3879(90)90069-K; Kalita J, 1999, INT J TUBERC LUNG D, V3, P261; Karstaedt AS, 1998, QJM-INT J MED, V91, P743, DOI 10.1093/qjmed/91.11.743; KAY R, 1995, QJM-INT J MED, V88, P39; KENNEDY DH, 1979, JAMA-J AM MED ASSOC, V241, P264, DOI 10.1001/jama.241.3.264; Kumar R, 1999, ARCH DIS CHILD, V81, P221, DOI 10.1136/adc.81.3.221; LINCOLN EM, 1960, J PEDIATR-US, V57, P807, DOI 10.1016/S0022-3476(60)80132-1; Misra UK, 1996, J NEUROL SCI, V137, P57, DOI 10.1016/0022-510X(95)00334-X; NGUYEN TH, 1999, J ACQ IMMUN DEF SYND, V21, P338; Pfyffer GE, 1999, J INFECTION, V39, P21, DOI 10.1016/S0163-4453(99)90097-X; Thwaites G, 2000, J NEUROL NEUROSUR PS, V68, P289, DOI 10.1136/jnnp.68.3.289; Verdon R, 1996, CLIN INFECT DIS, V22, P982, DOI 10.1093/clinids/22.6.982; Wilson SM, 1998, T ROY SOC TROP MED H, V92, P241, DOI 10.1016/S0035-9203(98)90996-8; Yechoor VK, 1996, ARCH INTERN MED, V156, P1710, DOI 10.1001/archinte.156.15.1710	20	267	299	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 26	2002	360	9342					1287	1292		10.1016/S0140-6736(02)11318-3	http://dx.doi.org/10.1016/S0140-6736(02)11318-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414204				2022-12-28	WOS:000178827200011
J	Milo, R; Shen-Orr, S; Itzkovitz, S; Kashtan, N; Chklovskii, D; Alon, U				Milo, R; Shen-Orr, S; Itzkovitz, S; Kashtan, N; Chklovskii, D; Alon, U			Network motifs: Simple building blocks of complex networks	SCIENCE			English	Article							SMALL-WORLD; TRANSCRIPTIONAL REGULATION; DYNAMICS	Complex networks are studied across many fields of science. To uncover their structural design principles, we defined network motifs, patterns of interconnections occurring in complex networks at numbers that are significantly higher than those in randomized networks. We found such motifs in networks from biochemistry, neurobiology, ecology, and engineering. The motifs shared by ecological food webs were distinct from the motifs shared by the genetic networks of Escherichia coli and Saccharomyces cerevisiae or from those found in the World Wide Web. Similar motifs were found in networks that perform information processing, even though they describe elements as different as biomolecules within a cell and synaptic connections between neurons in Caenorhabditis elegans. Motifs may thus define universal classes of networks. This approach may uncover the basic building blocks of most networks.	Weizmann Inst Sci, Dept Phys, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Complex Syst, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Cold Spring Harbor Laboratory	Alon, U (corresponding author), Weizmann Inst Sci, Dept Phys, IL-76100 Rehovot, Israel.	urialon@weizmann.ac.il	Yang, Chen/G-1379-2010	Shen-Orr, Shai/0000-0002-6991-7736; Milo, Ron/0000-0003-1641-2299; Kashtan, Nadav/0000-0002-7475-1363				Amaral LAN, 2000, P NATL ACAD SCI USA, V97, P11149, DOI 10.1073/pnas.200327197; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bollobas B., 1985, RANDOM GRAPHS; BRGLEZ F, 1989, 1989 IEEE INTERNATIONAL SYMPOSIUM ON CIRCUITS AND SYSTEMS, VOLS 1-3, P1929, DOI 10.1109/ISCAS.1989.100747; Callaway DS, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.041902; Cancho RFI, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.046119; Cancho RFI, 2001, P ROY SOC B-BIOL SCI, V268, P2261, DOI 10.1098/rspb.2001.1800; Cohen J.E., 1990, COMMUNITY FOOD WEBS; Costanzo MC, 2001, NUCLEIC ACIDS RES, V29, P75, DOI 10.1093/nar/29.1.75; Guelzim N, 2002, NAT GENET, V31, P60, DOI 10.1038/ng873; HOLLAND PW, 1975, SOCIOL METHODOL, P1, DOI DOI 10.2307/270703; Huberman BA, 1999, NATURE, V401, P131, DOI 10.1038/43604; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Newman MEJ, 2001, P NATL ACAD SCI USA, V98, P404, DOI 10.1073/pnas.021544898; Newman MEJ, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.016131; PIMM SL, 1991, NATURE, V350, P669, DOI 10.1038/350669a0; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; Wasserman, 1994, SOCIAL NETWORK ANAL, DOI DOI 10.1017/CBO9780511815478; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Williams RJ, 2000, NATURE, V404, P180, DOI 10.1038/35004572	24	4416	4575	39	798	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					824	827		10.1126/science.298.5594.824	http://dx.doi.org/10.1126/science.298.5594.824			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399590				2022-12-28	WOS:000178791200058
J	Blessmann, J; Tannich, E				Blessmann, J; Tannich, E			Treatment of asymptomatic intestinal Entamoeba histolytica infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin	Blessmann, J (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.							DIAMOND LS, 1993, J EUKARYOT MICROBIOL, V40, P340, DOI 10.1111/j.1550-7408.1993.tb04926.x; MCAULEY JB, 1992, CLIN INFECT DIS, V15, P464, DOI 10.1093/clind/15.3.464; MCAULEY JB, 1992, CLIN INFECT DIS, V14, P1161, DOI 10.1093/clinids/14.5.1161; Verweij JJ, 2000, EUR J CLIN MICROBIOL, V19, P358, DOI 10.1007/s100960050494; WHO, 1997, WKLY EPIDEMIOL REC R, V72, P97	5	33	34	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1384	1384		10.1056/NEJM200210243471722	http://dx.doi.org/10.1056/NEJM200210243471722			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397207	Bronze			2022-12-28	WOS:000178781300035
J	Gasse, F				Gasse, F			Kilimanjaro's secrets revealed	SCIENCE			English	Editorial Material							ISOTOPE RECORD; CLIMATE-CHANGE; EAST-AFRICA; TROPICS; VARIABILITY; HOLOCENE; OXYGEN; FUTURE; KENYA		CEREGE, UMR 6635, F-13545 Aix En Provence 04, France	UDICE-French Research Universities; PSL Research University Paris; College de France; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD)	Gasse, F (corresponding author), CEREGE, UMR 6635, BP 80, F-13545 Aix En Provence 04, France.							Barker PA, 2001, SCIENCE, V292, P2307, DOI 10.1126/science.1059612; Black DE, 2002, SCIENCE, V297, P528, DOI 10.1126/science.1074379; Claussen M, 1999, GEOPHYS RES LETT, V26, P2037, DOI 10.1029/1999GL900494; deMenocal PB, 2001, SCIENCE, V292, P667, DOI 10.1126/science.1059827; Gasse F, 2000, QUATERNARY SCI REV, V19, P189, DOI 10.1016/S0277-3791(99)00061-X; HOELZMAN P, IN PRESS CLIMATE VAR; Johnson TC, 2001, GEOLOGY, V29, P83, DOI 10.1130/0091-7613(2001)029<0083:DROCVS>2.0.CO;2; Karlen W, 1999, AMBIO, V28, P409; Lamb AL, 2000, HOLOCENE, V10, P167, DOI 10.1191/095968300677444611; Neff U, 2001, NATURE, V411, P290, DOI 10.1038/35077048; Raynaud D, 2000, QUATERNARY SCI REV, V19, P9, DOI 10.1016/S0277-3791(99)00082-7; Rozanski K., 1993, GEOPHYS MONOGR SER, V78, P1, DOI DOI 10.1029/GM078P0001; Thompson LG, 2002, SCIENCE, V298, P589, DOI 10.1126/science.1073198; Thompson LG, 2000, QUATERNARY SCI REV, V19, P19, DOI 10.1016/S0277-3791(99)00052-9; Verschuren D, 2000, NATURE, V403, P410, DOI 10.1038/35000179	15	26	26	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					548	549		10.1126/science.1078561	http://dx.doi.org/10.1126/science.1078561			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386320				2022-12-28	WOS:000178634800025
J	Blum, R; Kafitz, KW; Konnerth, A				Blum, R; Kafitz, KW; Konnerth, A			Neurotrophin-evoked depolarization requires the sodium channel Na(V)1.9	NATURE			English	Article							HIGH-FREQUENCY STIMULATION; LONG-TERM POTENTIATION; RETINOIC ACID; BDNF; TRKB; HIPPOCAMPUS; EXPRESSION; SAXITOXIN; RECEPTORS; INDUCTION	Brain-derived neurotrophic factor (BDNF) and other neurotrophins are essential for normal brain function. Many types of neurons in the central nervous system are excited by BDNF or neurotrophin-4/5, an action that has recently been implicated in synaptic plasticity. The mechanisms involved in this transmitter-like action of neurotrophins remains unclear. Here, by screening candidate genes with an antisense messenger RNA expression approach and by co-expressing the receptor tyrosine kinase TrkB and various sodium channels, we demonstrate that the tetrodotoxin-insensitive sodium channel Na(V)1.9 underlies the neurotrophin-evoked excitation. These results establish the molecular basis of neurotrophin-evoked depolarization and reveal a mechanism of ligand-mediated sodium channel activation.	Univ Munich, Inst Physiol, D-80336 Munich, Germany	University of Munich	Konnerth, A (corresponding author), Univ Munich, Inst Physiol, D-80336 Munich, Germany.	konnerth@lrz.uni-muenchen.de	Blum, Robert/E-8899-2013	Blum, Robert/0000-0002-5270-3854				BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Coward K, 2000, PAIN, V85, P41, DOI 10.1016/S0304-3959(99)00251-1; Cummins TR, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-24-j0001.1999; Dib-Hajj SD, 1999, FEBS LETT, V462, P117, DOI 10.1016/S0014-5793(99)01519-7; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; FAVRE I, 1995, J GEN PHYSIOL, V106, P203, DOI 10.1085/jgp.106.2.203; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Hartmann M, 2001, EMBO J, V20, P5887, DOI 10.1093/emboj/20.21.5887; Herzog RI, 2001, J NEUROPHYSIOL, V86, P1351, DOI 10.1152/jn.2001.86.3.1351; HOEHN K, 1993, NEURON, V10, P543, DOI 10.1016/0896-6273(93)90341-N; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jeong SY, 2000, BIOCHEM BIOPH RES CO, V267, P262, DOI 10.1006/bbrc.1999.1916; Kafitz K. W., 2001, Pfluegers Archiv European Journal of Physiology, V441, pR125; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KLUGBAUER N, 1995, EMBO J, V14, P1084, DOI 10.1002/j.1460-2075.1995.tb07091.x; Kohara K, 2001, SCIENCE, V291, P2419, DOI 10.1126/science.1057415; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; Kossel AH, 2001, P NATL ACAD SCI USA, V98, P14702, DOI 10.1073/pnas.251326998; Kovalchuk Y, 2002, SCIENCE, V295, P1729, DOI 10.1126/science.1067766; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; Penzotti JL, 1998, BIOPHYS J, V75, P2647, DOI 10.1016/S0006-3495(98)77710-0; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Tate S, 1998, NAT NEUROSCI, V1, P653, DOI 10.1038/3652; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000; Yiangou Y, 2000, FEBS LETT, V467, P249, DOI 10.1016/S0014-5793(00)01166-2	45	205	215	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	2002	419	6908					687	693		10.1038/nature01085	http://dx.doi.org/10.1038/nature01085			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384689				2022-12-28	WOS:000178615200031
J	Rajagopol, J; Shepard, JAO; Mark, EJ; Malhotra, A				Rajagopol, J; Shepard, JAO; Mark, EJ; Malhotra, A			A 58-year-old man with interstitial pulmonary disease. Eosinophilic granuloma, late (burned-out) stage.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LANGERHANS CELL HISTIOCYTOSIS; LUNG; FEATURES; ADULT; RESOLUTION; CARCINOMA; LESIONS; THERAPY		Massachusetts Gen Hosp, Pulm & Crit Care Dept, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Howard Hughes Medical Institute; Harvard University	Rajagopol, J (corresponding author), Massachusetts Gen Hosp, Pulm & Crit Care Dept, Boston, MA 02114 USA.							*AM CANC SOC, 1990, CANC SOC; ARONCHICK JM, 1987, RADIOLOGY, V163, P677, DOI 10.1148/radiology.163.3.3575713; Asakura S, 1996, AM J RESP CRIT CARE, V154, P1525, DOI 10.1164/ajrccm.154.5.8912775; Banks DE, 1997, CHEST, V111, P837, DOI 10.1378/chest.111.4.837; BASSET F, 1978, AM REV RESPIR DIS, V118, P811; Brauner MW, 1997, RADIOLOGY, V204, P497, DOI 10.1148/radiology.204.2.9240543; CORRIN B, 1979, INVEST CELL PATHOL, V2, P137; Crans CA, 1999, CRIT REV DIAGN IMAG, V40, P251; DAIL DH, 1994, PULMONARY PATHOLOGY; Fauci AS, 2015, HARRISONS PRINCIPLES; FRIEDMAN PJ, 1981, MEDICINE, V60, P385, DOI 10.1097/00005792-198111000-00001; Hayashi T, 1997, ARCH PATHOL LAB MED, V121, P930; HIROSE M, 1995, ACTA PAEDIATR, V84, P1204, DOI 10.1111/j.1651-2227.1995.tb13529.x; HOFFMAN L, 1962, NEW ENGL J MED, V267, P577, DOI 10.1056/NEJM196209202671201; HOUSINI I, 1994, ARCH PATHOL LAB MED, V118, P523; HUGHES WT, 1975, CANCER, V36, P2004, DOI 10.1002/cncr.2820360912; James D G, 1989, Sarcoidosis, V6, P7; Kohalmi Ferenc, 1996, Pathol Oncol Res, V2, P184; Kubota H, 1996, ANN THORAC SURG, V61, P708, DOI 10.1016/0003-4975(95)00744-X; LACRONIQUE J, 1982, THORAX, V37, P104, DOI 10.1136/thx.37.2.104; Malpas JS, 1998, HEMATOL ONCOL CLIN N, V12, P259, DOI 10.1016/S0889-8588(05)70509-8; Mogulkoc N, 1999, CHEST, V115, P1452, DOI 10.1378/chest.115.5.1452; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Nezelof C, 1998, HEMATOL ONCOL CLIN N, V12, P385, DOI 10.1016/S0889-8588(05)70518-9; NUNEZ D, 1977, BRIT J RADIOL, V50, P142, DOI 10.1259/0007-1285-50-590-142; POWERS MA, 1984, AM REV RESPIR DIS, V129, P503; SCHONFELD N, 1993, RESPIRATION, V60, P38; SCHWARZ MI, 1998, INTERSTITIAL LUNG DI; STRIEDER DJ, 1978, NEW ENGL J MED, V298, P327; Tazi A, 1998, AM J RESP CRIT CARE, V157, P2007, DOI 10.1164/ajrccm.157.6.9709026; Vassallo R, 2002, NEW ENGL J MED, V346, P484, DOI 10.1056/NEJMoa012087; VONESSEN S, 1990, CHEST, V98, P765, DOI 10.1378/chest.98.3.765; WALLACH J, 1992, INTERPRETATION DIAGN	33	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1262	1268		10.1056/NEJMcpc020013	http://dx.doi.org/10.1056/NEJMcpc020013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393825				2022-12-28	WOS:000178598300009
J	Steel, Z; Silove, D; Phan, T; Bauman, A				Steel, Z; Silove, D; Phan, T; Bauman, A			Long-term effect of psychological trauma on the mental health of Vietnamese refugees resettled in Australia: a population-based study	LANCET			English	Article							POSTTRAUMATIC-STRESS-DISORDER; NATIONAL-COMORBIDITY-SURVEY; DOSE-EFFECT RELATIONSHIPS; PSYCHIATRIC-DISORDERS; ORGANIZED VIOLENCE; BOSNIAN REFUGEES; WAR TRAUMA; SYMPTOMS; PREVALENCE; PREDICTORS	Background What are the deleterious effects of mass trauma on the psychological wellbeing of refugees and other war-affected populations? Most epidemiological data are for short-to-medium term effects, leaving the possibility that early psychological reactions could reduce naturally over time. We aimed to assess the long-term effects of trauma on mental health and disability in Vietnamese refugees resettled in Australia. Methods In a population-based study, we identified a community sample of 1413 adult Vietnamese from census collection areas in Sydney, Australia. Participants were interviewed by trained bilingual workers who administered questionnaires to assess the frequency of international classification of disease, version 10 (ICD-10) mental disorders in the 12 months before interview; psychiatric symptoms, by use of a culturally-sensitive symptom measure; exposure to psychologically traumatic events; disability and use of health services; and social, economic, and cultural factors since migration. We did multivariate analyses with adjustment for stressors since migration to establish the risk factors for mental illness. Findings 1161 (82%) adults completed the interview. Mean length of residence in Australia was 11.2 years (SD 14.4) and mean time since the most severe traumatic event was 14.8 years (SD 10.8). 95 (8%) and 75 (7%) of participants had mental disorders defined by ICD-10 and the culturally-sensitive measure, respectively. Trauma exposure was the most important predictor of mental health status. Risk of mental illness fell consistently across time. However, people who had been exposed to more than three trauma events (199) had heightened risk of mental illness (23, [12%]) after 10 years compared with people with no trauma exposure (13, [3%]) (odds ratio 4.7, p<0.0001, 95% CI 2.3-9.5). Interpretation Most Vietnamese refugees were free from overt mental ill health. Trauma-related mental illness seemed to reduce steadily over time, but a subgroup of people with a high degree of exposure to trauma had long-term psychiatric morbidity. Our findings support the need to develop specialised mental health services to reduce disability in refugees whose exposure to extreme trauma puts them at risk of chronic psychiatric disability.	Univ New S Wales, Sch Psychiat, Psychiat Res & Teaching Unit, Sydney, NSW, Australia; Flinders Univ S Australia, Fac Hlth Sci, Adelaide, SA 5001, Australia; Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia	University of New South Wales Sydney; Flinders University South Australia; University of New South Wales Sydney	Silove, D (corresponding author), Liverpool Hosp, Psychiat Res & Teaching Unit, Level 4,Hlth Serv Bldg, Liverpool, NSW 2170, Australia.			Steel, Zachary/0000-0002-5048-2920				Andrews G, 1998, SOC PSYCH PSYCH EPID, V33, P80, DOI 10.1007/s001270050026; Andrews G, 1999, MENTAL HLTH AUSTR NA; BRACKEN PJ, 1995, SOC SCI MED, V40, P1073, DOI 10.1016/0277-9536(94)00181-R; Brackett WW, 1999, AM J DENT, V12, P119; Cardozo BL, 2000, JAMA-J AM MED ASSOC, V284, P569, DOI 10.1001/jama.284.5.569; Cheung P, 1994, Int J Soc Psychiatry, V40, P17, DOI 10.1177/002076409404000102; CHUNG RCY, 1993, SOC SCI MED, V36, P631, DOI 10.1016/0277-9536(93)90060-H; de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; *DEP IMM MULT AFF, 2000, MULT AUSTR VIET NAM; EITINGER L, 1959, J MENT SCI, V105, P326, DOI 10.1192/bjp.105.439.326; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Gorst-Unsworth C, 1998, BRIT J PSYCHIAT, V172, P90, DOI 10.1192/bjp.172.1.90; HAUFF E, 1993, ACTA PSYCHIAT SCAND, V88, P162, DOI 10.1111/j.1600-0447.1993.tb03432.x; HAUFF E, 1995, BRIT J PSYCHIAT, V166, P360, DOI 10.1192/bjp.166.3.360; HAUFF E, 1994, J NERV MENT DIS, V182, P85, DOI 10.1097/00005053-199402000-00004; Herlihy J, 2002, BMJ-BRIT MED J, V324, P324, DOI 10.1136/bmj.324.7333.324; Hinton L, 1998, J NERV MENT DIS, V186, P677, DOI 10.1097/00005053-199811000-00003; HINTON WL, 1993, J NERV MENT DIS, V181, P113, DOI 10.1097/00005053-199302000-00007; Hinton WL, 1997, J NERV MENT DIS, V185, P39, DOI 10.1097/00005053-199701000-00007; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KISH L, 1949, J AM STAT ASSOC, V44, P380, DOI 10.2307/2280236; KRUPINSKI J, 1973, SOC SCI MED, V7, P31, DOI 10.1016/0037-7856(73)90134-0; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; Mollica RF, 1998, J NERV MENT DIS, V186, P543, DOI 10.1097/00005053-199809000-00005; Mollica RF, 1998, BRIT J PSYCHIAT, V173, P482, DOI 10.1192/bjp.173.6.482; Mollica RF, 1999, JAMA-J AM MED ASSOC, V282, P433, DOI 10.1001/jama.282.5.433; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; Mollica RH, 2001, JAMA-J AM MED ASSOC, V286, P546, DOI 10.1001/jama.286.5.546; MURPHY HBM, 1955, FLIGHT RESETTLEMENT; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; PHAN T, 1997, ETHNOGRAPHIC W BASED; RANIERI NF, 1994, PSYCHOL REP, V74, P735, DOI 10.2466/pr0.1994.74.3.735; SOMASUNDARAM DJ, 1994, BRIT J PSYCHIAT, V165, P524, DOI 10.1192/bjp.165.4.524; Southwick SM, 1997, AM J PSYCHIAT, V154, P173; Steel Z, 1999, J TRAUMA STRESS, V12, P421, DOI 10.1023/A:1024710902534; Stubbs P, 1996, Med Confl Surviv, V12, P303, DOI 10.1080/13623699608409300; Summerfield D, 2000, BRIT MED J, V321, P232, DOI 10.1136/bmj.321.7255.232; Summerfield D, 1999, SOC SCI MED, V48, P1449, DOI 10.1016/S0277-9536(98)00450-X	39	335	337	2	36	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1056	1062		10.1016/S0140-6736(02)11142-1	http://dx.doi.org/10.1016/S0140-6736(02)11142-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	602BN	12383986				2022-12-28	WOS:000178485200011
J	Equi, A; Balfour-Lynn, IM; Bush, A; Rosenthal, M				Equi, A; Balfour-Lynn, IM; Bush, A; Rosenthal, M			Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial	LANCET			English	Article							RECOMBINANT HUMAN DNASE; PULMONARY-FUNCTION; ERYTHROMYCIN; MACROLIDES; INFLAMMATION; VARIABILITY; INFANTS; SPUTUM; ALPHA; IL-8	Background The macrolide antibiotic azithromycin has anti-inflammatory properties potentially beneficial in cystic fibrosis. Since findings of open pilot studies seemed to show clinical benefit, we undertook a formal trial. Method 41 children with cystic fibrosis, aged 8-18 years, and with a median forced expiratory volume in 1 s (FEV1) of 61% (range 33-80%) participated in a 15-month randomised double-blind, placebo-controlled crossover trial. They received either azithromycin (bodyweight less than or equal to40 kg: 250 mg daily, >40 kg: 500 mg daily) or placebo for 6 months. After 2 months of washout, the treatments were crossed over. The primary outcome was median relative difference in FEV1 between azithromycin and placebo treatment periods. Sputum cultures, sputum interleukin 8 and neutrophil elastase, exercise testing, quality of life, antibiotic use, and pulmonary exacerbation rates were secondary outcome measures. Side-effects were assessed by pure tone audiometry and liver function tests. Analysis was by intention-to-treat. Findings Median relative difference in FEV1 between azithromycin and placebo was 5.4% (95% CI 0.8-10.5). 13 of 41 patients improved by more than 13% and five of 41 deteriorated by more than 13% (p=0.059). Forced vital capacity and mid-expiratory flow did not significantly change overall. 17 of 41 patients had 24 fewer oral antibiotic courses when on azithromycin than when taking placebo, and five had six extra courses (p=0.005). Sputum bacterial densities, inflammatory markers, exercise tolerance, and subjective well-being did not change. There were no noticeable side-effects. Interpretation A 4-6-month trial of azithromycin is justified in children with cystic fibrosis who do not respond to conventional treatment. The mechanism of action remains unknown.	Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6NP, England; Queen Marys Childrens Hosp, Dept Paediat Resp Med, Sutton, Surrey, England	Royal Brompton Hospital	Rosenthal, M (corresponding author), Royal Brompton Hosp, Dept Paediat Resp Med, Sydney St, London SW3 6NP, England.	m.rosenthal@rbh.nthames.nhs.uk						[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Armstrong DS, 1997, AM J RESP CRIT CARE, V156, P1197, DOI 10.1164/ajrccm.156.4.96-11058; Balfour-Lynn IM, 1998, PEDIATR PULM, V25, P278, DOI 10.1002/(SICI)1099-0496(199804)25:4<278::AID-PPUL8>3.0.CO;2-G; BalfourLynn IM, 1997, ARCH DIS CHILD, V77, P124, DOI 10.1136/adc.77.2.124; CAMPBELL MJ, 1988, BRIT MED J, V296, P1454, DOI 10.1136/bmj.296.6634.1454; COOPER PJ, 1990, PEDIATR PULM, V8, P16, DOI 10.1002/ppul.1950080107; Davies J, 1997, PEDIATR PULM, V23, P243, DOI 10.1002/(SICI)1099-0496(199704)23:4<243::AID-PPUL1>3.0.CO;2-N; DUPONT MJ, 1990, DRUG EXP CLIN RES, V16, P597; Emre U, 1996, CLIN INFECT DIS, V22, P819, DOI 10.1093/clinids/22.5.819; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GANT TW, 1995, TOXICOL APPL PHARM, V133, P269, DOI 10.1006/taap.1995.1151; HOIBY N, 1994, THORAX, V49, P531, DOI 10.1136/thx.49.6.531; Jaffe A, 1998, LANCET, V351, P420, DOI 10.1016/S0140-6736(05)78360-4; Jaffe A, 2001, PEDIATR PULM, V31, P464, DOI 10.1002/ppul.1076; KADOTA J, 1993, AM REV RESPIR DIS, V147, P153, DOI 10.1164/ajrccm/147.1.153; KHAIR OA, 1995, EUR RESPIR J, V8, P1451; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; Kobayashi H, 1995, AM J MED, V99, pS26, DOI 10.1016/S0002-9343(99)80282-4; NAGAI H, 1991, RESPIRATION, V58, P145, DOI 10.1159/000195915; NICKERSON BG, 1980, AM REV RESPIR DIS, V122, P859; ORENSTEIN DM, 1989, CHEST, V95, P344, DOI 10.1378/chest.95.2.344; Ripoll L, 1996, J ANTIMICROB CHEMOTH, V37, P987, DOI 10.1093/jac/37.5.987; Salva PS, 1996, PEDIATR PULM, V21, P11, DOI 10.1002/(SICI)1099-0496(199601)21:1<11::AID-PPUL2>3.0.CO;2-T; SHAH PL, 1995, RESP MED, V89, P499, DOI 10.1016/0954-6111(95)90126-4; Tateda K, 1996, ANTIMICROB AGENTS CH, V40, P2271, DOI 10.1128/AAC.40.10.2271	25	399	412	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	2002	360	9338					978	984		10.1016/S0140-6736(02)11081-6	http://dx.doi.org/10.1016/S0140-6736(02)11081-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383667				2022-12-28	WOS:000178249000010
J	Shin, CS; Manley, JL				Shin, CS; Manley, JL			The SR protein SRp38 represses splicing in M phase cells	CELL			English	Article							PRE-MESSENGER-RNA; PREMESSENGER RNA; POLYMERASE-II; DEPENDENT TRANSCRIPTION; SITE SELECTION; FACTOR ASF/SF2; PHOSPHORYLATION; INHIBITION; DEPHOSPHORYLATION; LOCALIZATION	SR proteins constitute a family of pre-mRNA splicing factors that play important roles in both constitutive and regulated splicing. Here, we describe one member of the family, which we call SRp38, with unexpected properties. Unlike other SR proteins, SRp38 cannot activate splicing and is essentially inactive in splicing assays. However, dephosphorylation converts SRp38 to a potent, general repressor that inhibits splicing at an early step. To investigate the cellular function of SRp38, we examined its possible role in cell cycle control. We show first that splicing, like other steps in gene expression, is inhibited in extracts of mitotic cells. Strikingly, SRp38 was found to be dephosphorylated specifically in mitotic cells, and we show that dephosphorylated SRp38 is required for the observed splicing repression.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Manley, James/0000-0002-8341-1459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048259] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM48259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akoulitchev S, 1998, GENE DEV, V12, P3541, DOI 10.1101/gad.12.22.3541; Barnard DC, 2000, MOL CELL BIOL, V20, P3049, DOI 10.1128/MCB.20.9.3049-3057.2000; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Cowper AE, 2001, J BIOL CHEM, V276, P48908, DOI 10.1074/jbc.M103967200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Grabowski PJ, 2001, PROG NEUROBIOL, V65, P289, DOI 10.1016/S0301-0082(01)00007-7; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Hanamura A, 1998, RNA, V4, P430; Harlow E., 1988, ANTIBODIES LAB MANUA; Hertel KJ, 1999, P NATL ACAD SCI USA, V96, P2651, DOI 10.1073/pnas.96.6.2651; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Hirose Y, 2000, GENE DEV, V14, P1415; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Komatsu M, 1999, GENES CELLS, V4, P593, DOI 10.1046/j.1365-2443.1999.00286.x; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Labourier E, 1999, GENE DEV, V13, P740, DOI 10.1101/gad.13.6.740; Labourier E, 2001, MOL CELL, V8, P363, DOI 10.1016/S1097-2765(01)00311-2; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Prasad J, 1999, MOL CELL BIOL, V19, P6991; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Schaal TD, 1999, MOL CELL BIOL, V19, P261; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Van Hooser A, 1998, J CELL SCI, V111, P3497; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	53	159	163	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 1	2002	111	3					407	417		10.1016/S0092-8674(02)01038-3	http://dx.doi.org/10.1016/S0092-8674(02)01038-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419250	Bronze			2022-12-28	WOS:000179010100012
J	Coates, JC; de Bono, M				Coates, JC; de Bono, M			Antagonistic pathways in neurons exposed to body fluid regulate social feeding in Caenorhabditis elegans	NATURE			English	Article							NUCLEOTIDE-GATED CHANNEL; NEUROPEPTIDE-Y RECEPTOR; C-ELEGANS; NATURAL VARIATION; NERVOUS-SYSTEM; BEHAVIOR; FAMILY; EXPRESSION; ENCODES; PROTEIN	Wild isolates of Caenorhabditis elegans can feed either alone or in groups(1,2). This natural variation in behaviour is associated with a single residue difference in NPR-1, a predicted G-protein-coupled neuropeptide receptor related to Neuropeptide Y receptors(2). Here we show that the NPR-1 isoform associated with solitary feeding acts in neurons exposed to the body fluid to inhibit social feeding. Furthermore, suppressing the activity of these neurons, called AQR, PQR and URX, using an activated K+ channel, inhibits social feeding. NPR-1 activity in AQR, PQR and URX neurons seems to suppress social feeding by antagonizing signalling through a cyclic GMP-gated ion channel encoded by tax-2 and tax-4. We show that mutations in tax-2 or tax-4 disrupt social feeding, and that tax-4 is required in several neurons for social feeding, including one or more of AQR, PQR and URX. The AQR, PQR and URX neurons are unusual in C. elegans because they are directly exposed to the pseudocoelomic body fluid(3). Our data suggest a model in which these neurons integrate antagonistic signals to control the choice between social and solitary feeding behaviour.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	de Bono, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Coates, Juliet C/A-3608-2013	Coates, Juliet C/0000-0002-2381-0298; de Bono, Mario/0000-0001-8347-0443				Ben-Shahar Y, 2002, SCIENCE, V296, P741, DOI 10.1126/science.1069911; CLARK SG, 1994, GENETICS, V137, P987; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; Hodgkin J, 1997, GENETICS, V146, P149; Komatsu H, 1999, BRAIN RES, V821, P160, DOI 10.1016/S0006-8993(99)01111-7; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; Lee DL, 1976, PHYSL NEMATODES; Li C, 1999, ANN NY ACAD SCI, V897, P239, DOI 10.1111/j.1749-6632.1999.tb07895.x; Li C, 1999, BRAIN RES, V848, P26, DOI 10.1016/S0006-8993(99)01972-1; Marsh DJ, 1999, P NATL ACAD SCI USA, V96, P13518, DOI 10.1073/pnas.96.23.13518; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mori I, 1999, ANNU REV GENET, V33, P399, DOI 10.1146/annurev.genet.33.1.399; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Robinson GE, 1997, BIOESSAYS, V19, P1099, DOI 10.1002/bies.950191209; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; Wang Q, 2002, J NEUROSCI, V22, P2274, DOI 10.1523/JNEUROSCI.22-06-02274.2002; Weinshenker D, 1999, J NEUROSCI, V19, P9831; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; [No title captured]	28	146	155	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					925	929		10.1038/nature01170	http://dx.doi.org/10.1038/nature01170			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410311				2022-12-28	WOS:000178909700044
J	Barberger-Gateau, P; Letenneur, L; Deschamps, V; Peres, K; Dartigues, JF; Renaud, S				Barberger-Gateau, P; Letenneur, L; Deschamps, V; Peres, K; Dartigues, JF; Renaud, S			Fish, meat, and risk of dementia: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Barberger-Gateau, P (corresponding author), Univ Bordeaux 2, INSERM, U330, 2 Case 11,146 Rue Leo Saignat, F-33076 Bordeaux, France.		DARTIGUES, Jean François/T-4513-2019; PERES, Karine/T-4128-2019; LETENNEUR, Luc/T-4424-2019; Robles-Sardin, Alma E/M-7714-2015	PERES, Karine/0000-0002-0720-0684; LETENNEUR, Luc/0000-0002-3274-937X; Robles-Sardin, Alma E/0000-0003-2044-7793				Barberger-Gateau P, 1999, J AM GERIATR SOC, V47, P456, DOI 10.1111/j.1532-5415.1999.tb07239.x; Grant W B, 1999, J Alzheimers Dis, V1, P197; Kalmijn S, 2000, J Nutr Health Aging, V4, P202; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Letenneur L, 1999, J NEUROL NEUROSUR PS, V66, P177, DOI 10.1136/jnnp.66.2.177	5	362	378	0	34	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					932	+		10.1136/bmj.325.7370.932	http://dx.doi.org/10.1136/bmj.325.7370.932			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399342	Bronze, Green Published			2022-12-28	WOS:000178986300015
J	Bent, N; Tennant, A; Swift, T; Posnett, J; Scuffham, P; Chamberlain, MA				Bent, N; Tennant, A; Swift, T; Posnett, J; Scuffham, P; Chamberlain, MA			Team approach versus ad hoc health services for young people with physical disabilities: a retrospective cohort study	LANCET			English	Article							TRANSITION; CARE; PARTICIPATION; ADULTS; SCHOOL	Background Young people with physical disabilities often have difficulty attaining independence in adult life and consequently need lifelong support from parents and from health-care and social-care services. There are concerns about the organisation and cost-effectiveness of such services and their ability to meet the independence training and serious health needs of these young people. Our aim was to compare a young adult team (YAT) approach with the ad hoc service approach in four locations in England, in terms of their ability to enhance the participation in society of these young people and their cost. Methods We did a retrospective cohort study, in which we interviewed 254 physically disabled young people. 124 healthy controls were given a questionnaire. We interviewed with standardised measures and used logistic regression analysis to test for effects of ad hoc and YAT services. The Mantel-Haenszel chi(2) statistic was used to test for differences in resource use between areas in which the YAT and ad hoc services were available. Findings The absence of pain, fatigue, and stress increased the odds of participation two-fold to four-fold. After adjustment for these factors, young people cared for by multidisciplinary YAT teams were 2.54 times (95% CI 1.30-4.98) more likely than those who used ad hoc services to participate in society. Resource use did not differ between the two service types. Interpretation A YAT approach costs no more to implement than an ad hoc approach, and is more likely to enhance participation in society of young people with physical disabilities.	Univ Leeds, Acad Unit Musculoskeletal & Rehabil Med, Leeds LS2 9NZ, W Yorkshire, England; Univ Bristol, Ctr Eth Med, Bristol BS8 1TH, Avon, England; Univ York, Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England	University of Leeds; University of Bristol; University of York - UK	Tennant, A (corresponding author), Univ Leeds, Acad Unit Musculoskeletal & Rehabil Med, Leeds LS2 9NZ, W Yorkshire, England.	AlanTennant@compuserve.com	Scuffham, Paul/B-3066-2014; Scuffham, Paul/AAS-8084-2021	Scuffham, Paul/0000-0001-5931-642X; Scuffham, Paul/0000-0001-5931-642X				BAINES P, 1994, MATERN CHILD HLT JAN, P11; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BAX MCO, 1988, BRIT MED J, V296, P1153, DOI 10.1136/bmj.296.6630.1153; Bent N, 2001, CLIN REHABIL, V15, P552, DOI 10.1191/026921501680425270; Chamberlain MA, 1996, BRIT J RHEUMATOL, V35, P84; CHAMBERLAIN MA, 1996, SERVICES YOUNG PEOPL, P75; CHAMBERLAIN MA, 1993, ASSESSMENT HLTH RELA; Clark A, 1989, DISABILITY HANDICAP, V4, P271, DOI DOI 10.1080/02674648966780291; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; CRAIG J, 1985, 1981 SOCIOECONOMIC C; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; EISER C, 1990, J CHILD PSYCHOL PSYC, V31, P85, DOI 10.1111/j.1469-7610.1990.tb02274.x; Eiser C, 1993, GROWING CHRONIC DIS; Fiorentino L, 1998, ARCH DIS CHILD, V79, P306, DOI 10.1136/adc.79.4.306; Gompertz P., 1994, CLIN REHABIL, V8, P233, DOI [DOI 10.1177/026921559400800308, 10.1177/026921559400800308]; Hair J., 1988, MULTIVARIATE DATA AN; Hallum A, 1995, Curr Probl Pediatr, V25, P12, DOI 10.1016/S0045-9380(06)80013-7; HanleyMaxwell C, 1995, J ASSOC PERS SEVERE, V20, P3, DOI 10.1177/154079699502000102; HARDOFF D, 1991, Pediatrician, V18, P157; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; HIRST M, 1994, UNEQUAL OPPORTUNITIE; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; KURTZ Z, 1996, SERVICES YOUNG PEOPL; McConachie H, 1996, SERVICES YOUNG PEOPL, P9; MORRIS J, 1999, RES PRACTICE HURTLIN; *NAT AUD OFF, 1992, HLTH SERV PHYS DIS P; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI DOI 10.1515/9781400876136; Schmitz G.S., 1999, Z F R EMPIRISCHE P D, V13, P3; Schwarzer R., 1993, MEASUREMENT PERCEIVE; SINNEMA G, 1992, J ADOLESCENT HEALTH, V13, P369, DOI 10.1016/1054-139X(92)90030-F; Tennant A, 1997, DISABIL REHABIL, V19, P278, DOI 10.3109/09638289709166539; THOMAS A, 1987, PROVISION SUPPORT SE; Viner R, 1999, ARCH DIS CHILD, V81, P271, DOI 10.1136/adc.81.3.271; *WHO, 1980, WHO INT CLASS IMP DI; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; World Health Organization, 2001, INT CLASS FUNCT DIS; 2000, UNIT COSTS HLTH SOCI	37	85	86	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 26	2002	360	9342					1280	1286		10.1016/S0140-6736(02)11316-X	http://dx.doi.org/10.1016/S0140-6736(02)11316-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	608CH	12414202				2022-12-28	WOS:000178827200009
J	Cohen-Cory, S				Cohen-Cory, S			The developing synapse: Construction and modulation of synaptic structures and circuits	SCIENCE			English	Review							DEVELOPING NEUROMUSCULAR SYNAPSES; OCULAR DOMINANCE COLUMNS; NMDA RECEPTOR ACTIVATION; DEVELOPING VISUAL-CORTEX; DENDRITES IN-VIVO; NEUROTROPHIC FACTOR; HIPPOCAMPAL-NEURONS; EXCITATORY SYNAPSES; TRKB RECEPTORS; AXON ARBORS	Synapse formation and stabilization in the vertebrate central nervous system is a dynamic process, requiring bi-directional communication between pre- and postsynaptic partners. Numerous mechanisms coordinate where and when synapses are made in the developing brain. This review discusses cellular and activity-dependent mechanisms that control the development of synaptic connectivity.	Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Mental Retardat Res Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Cohen-Cory, S (corresponding author), Univ Calif Irvine, Dept Neurol & Behav, Irvine, CA 92697 USA.	scohenco@ucla.edu			NATIONAL EYE INSTITUTE [R01EY011912] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011912] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Ahmari SE, 2002, NEURON, V34, P333, DOI 10.1016/S0896-6273(02)00685-2; Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Aloyz R, 1999, LEARN MEMORY, V6, P216; Alsina B, 2001, NAT NEUROSCI, V4, P1093, DOI 10.1038/nn735; ANTONINI A, 1993, J NEUROSCI, V13, P3549; Antonini A, 1996, J COMP NEUROL, V369, P64; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; Aoki C, 2000, J NEUROSCI RES, V59, P454, DOI 10.1002/(SICI)1097-4547(20000201)59:3<454::AID-JNR21>3.0.CO;2-H; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; Boulanger L, 1999, NAT NEUROSCI, V2, P346, DOI 10.1038/7258; Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; Bruses JL, 2000, CURR OPIN CELL BIOL, V12, P593, DOI 10.1016/S0955-0674(00)00137-X; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; CAMPBELL G, 1992, J NEUROSCI, V12, P1847; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; Chavis P, 2001, NATURE, V411, P317, DOI 10.1038/35077101; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; Cline HT, 2001, CURR OPIN NEUROBIOL, V11, P118, DOI 10.1016/S0959-4388(00)00182-3; Cohen-Cory S, 1999, J NEUROSCI, V19, P9996; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Colicos MA, 2001, CELL, V107, P605, DOI 10.1016/S0092-8674(01)00579-7; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; Crowley JC, 2002, CURR OPIN NEUROBIOL, V12, P104, DOI 10.1016/S0959-4388(02)00297-0; Crowley JC, 1999, NAT NEUROSCI, V2, P1125, DOI 10.1038/16051; Dailey ME, 1996, J NEUROSCI, V16, P2983; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Debski EA, 2002, CURR OPIN NEUROBIOL, V12, P93, DOI 10.1016/S0959-4388(02)00295-7; Eaton BA, 2002, NEURON, V34, P729, DOI 10.1016/S0896-6273(02)00721-3; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Feller MB, 1996, SCIENCE, V272, P1182, DOI 10.1126/science.272.5265.1182; Feller MB, 1999, NEURON, V22, P653, DOI 10.1016/S0896-6273(00)80724-2; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; Gnuegge L, 2001, J NEUROSCI, V21, P3542, DOI 10.1523/JNEUROSCI.21-10-03542.2001; Gonzalez M, 1999, NEURON, V24, P567, DOI 10.1016/S0896-6273(00)81113-7; Hanover JL, 1999, J NEUROSCI, V19, part. no.; Hartmann M, 2001, EMBO J, V20, P5887, DOI 10.1093/emboj/20.21.5887; Hopf FW, 2002, J NEUROSCI, V22, P775, DOI 10.1523/JNEUROSCI.22-03-00775.2002; Horch HW, 1999, NEURON, V23, P353; Inoue A, 1997, SCIENCE, V276, P1428, DOI 10.1126/science.276.5317.1428; Itami C, 2000, BRAIN RES, V857, P141, DOI 10.1016/S0006-8993(99)02352-5; Iwasato T, 2000, NATURE, V406, P726, DOI 10.1038/35021059; Jontes JD, 2000, NEURON, V27, P11, DOI 10.1016/S0896-6273(00)00003-9; Jontes JD, 2000, NAT NEUROSCI, V3, P231, DOI 10.1038/72936; Kaas JH, 2002, BIOESSAYS, V24, P334, DOI 10.1002/bies.10076; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Keller-Peck CR, 2001, NEURON, V31, P381, DOI 10.1016/S0896-6273(01)00383-X; Kovalchuk Y, 2002, SCIENCE, V295, P1729, DOI 10.1126/science.1067766; Leary JA, 1999, GLYCOBIOLOGY, V9, P1117; Lee SH, 2000, CURR OPIN NEUROBIOL, V10, P125, DOI 10.1016/S0959-4388(99)00046-X; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; Loeb JA, 1997, J NEUROSCI, V17, P1416; Loeb JA, 2002, J NEUROSCI, V22, P2206, DOI 10.1523/JNEUROSCI.22-06-02206.2002; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; Lom B, 1999, J NEUROSCI, V19, P9928; Luthi A, 2001, NAT NEUROSCI, V4, P1102, DOI 10.1038/nn744; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Marrs GS, 2001, NAT NEUROSCI, V4, P1006, DOI 10.1038/nn717; Martinez A, 1998, J NEUROSCI, V18, P7336; Matsuzaki M, 2001, NAT NEUROSCI, V4, P1086, DOI 10.1038/nn736; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; McAllister AK, 2000, CEREB CORTEX, V10, P963, DOI 10.1093/cercor/10.10.963; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Ming GL, 2001, NEURON, V29, P441, DOI 10.1016/S0896-6273(01)00217-3; Miskevich F, 2002, J NEUROSCI, V22, P226, DOI 10.1523/JNEUROSCI.22-01-00226.2002; Narisawa-Saito M, 1999, NEUROSCIENCE, V88, P1009, DOI 10.1016/S0306-4522(98)00496-5; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Okabe S, 2001, J NEUROSCI, V21, P6105, DOI 10.1523/JNEUROSCI.21-16-06105.2001; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; Personius KE, 2001, NEURON, V31, P395, DOI 10.1016/S0896-6273(01)00369-5; Pinches EM, 1998, J NEUROBIOL, V35, P426, DOI 10.1002/(SICI)1097-4695(19980615)35:4<426::AID-NEU8>3.0.CO;2-0; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Prakash N, 1996, NATURE, V381, P702, DOI 10.1038/381702a0; Rajan I, 1998, J NEUROSCI, V18, P7836; Rajan I, 1999, J NEUROBIOL, V38, P357, DOI 10.1002/(SICI)1097-4695(19990215)38:3<357::AID-NEU5>3.0.CO;2-#; Ranscht B, 2000, INT J DEV NEUROSCI, V18, P643, DOI 10.1016/S0736-5748(00)00030-7; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; REH TA, 1985, J NEUROSCI, V5, P1132; Rico B, 2002, NAT NEUROSCI, V5, P225, DOI 10.1038/nn808; Roos J, 2000, NAT NEUROSCI, V3, P415, DOI 10.1038/74773; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Schinder AF, 2000, TRENDS NEUROSCI, V23, P639, DOI 10.1016/S0166-2236(00)01672-6; Schinder AF, 2000, NEURON, V25, P151, DOI 10.1016/S0896-6273(00)80879-X; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Seil FJ, 2000, J NEUROSCI, V20, P5367, DOI 10.1523/JNEUROSCI.20-14-05367.2000; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Sheng M, 2001, CELL, V105, P825, DOI 10.1016/S0092-8674(01)00406-8; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Shimada A, 1998, J NEUROSCI, V18, P8559; Silver MA, 1999, J NEUROSCI, V19, P10829, DOI 10.1523/JNEUROSCI.19-24-10829.1999; Snider WD, 1996, MOL CELL NEUROSCI, V7, P433, DOI 10.1006/mcne.1996.0031; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SRETAVAN DW, 1986, J NEUROSCI, V6, P990; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; Stellwagen D, 2002, NEURON, V33, P357, DOI 10.1016/S0896-6273(02)00577-9; Sur M, 2001, NAT REV NEUROSCI, V2, P251, DOI 10.1038/35067562; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Tanaka H, 2000, NEURON, V25, P93, DOI 10.1016/S0896-6273(00)80874-0; Trachtenberg JT, 2001, J NEUROSCI, V21, P3476, DOI 10.1523/JNEUROSCI.21-10-03476.2001; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Vicario-Abejon C, 1998, J NEUROSCI, V18, P7256; von Bartheld CS, 2001, MOL NEUROBIOL, V24, P1, DOI 10.1385/MN:24:1-3:001; Wang XH, 1997, NEURON, V19, P825, DOI 10.1016/S0896-6273(00)80964-2; Washbourne P, 2002, NAT NEUROSCI, V5, P751, DOI 10.1038/nn883; Witte S, 1996, J NEUROBIOL, V31, P219, DOI 10.1002/(SICI)1097-4695(199610)31:2<219::AID-NEU7>3.0.CO;2-E; Wong ROL, 1999, ANNU REV NEUROSCI, V22, P29, DOI 10.1146/annurev.neuro.22.1.29; Wong WT, 2001, NAT NEUROSCI, V4, P351, DOI 10.1038/85987; Wong WT, 2000, CURR OPIN NEUROBIOL, V10, P118, DOI 10.1016/S0959-4388(99)00059-8; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222; Wu K, 1996, MOL BRAIN RES, V43, P286, DOI 10.1016/S0169-328X(96)00211-2; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; Xu BJ, 2000, NEURON, V26, P233, DOI 10.1016/S0896-6273(00)81153-8; Yacoubian TA, 2000, NAT NEUROSCI, V3, P342, DOI 10.1038/73911; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2; YEN LS, 1995, J NEUROSCI, V15, P4712; Zhang WD, 2001, J NEUROSCI, V21, P5169, DOI 10.1523/JNEUROSCI.21-14-05169.2001; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4; Zou DJ, 1999, J NEUROSCI, V19, P8909, DOI 10.1523/JNEUROSCI.19-20-08909.1999	137	335	359	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					770	776		10.1126/science.1075510	http://dx.doi.org/10.1126/science.1075510			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399577	Green Submitted			2022-12-28	WOS:000178791200044
J	Meissner, M; Schluter, D; Soldati, D				Meissner, M; Schluter, D; Soldati, D			Role of Toxoplasma gondii myosin A in powering parasite gliding and host cell invasion	SCIENCE			English	Article							MAMMALIAN-CELLS; EXPRESSION; MOTILITY; EGRESS; SYSTEM	Obligate intracellular apicomplexan parasites rely on gliding motion powered by their actomyosin system to disperse throughout tissues and to penetrate host cells. Toxoplasma gondii myosin A has been implicated in this process, but direct proof has been lacking. We designed a genetic screen to generate a tetracycline-inducible transactivator system in T. gondii. The MyoA gene was disrupted in the presence of a second regulatable copy of MyoA. Conditional removal of this myosin caused severe impairment in host cell invasion and parasite spreading in cultured cells, and unambiguously established the pathogenic function of this motor in an animal model.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Heidelberg Univ, Klinikum Mannheim, Inst Med Mikrobiol & Hyg, D-68167 Mannheim, Germany	Imperial College London; Ruprecht Karls University Heidelberg	Soldati, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Imperial Coll Rd, London SW7 2AZ, England.	d.soldati@ic.ac.uk	Soldati-Favre, Dominique/A-2999-2009	Meissner, Markus/0000-0002-5341-5969; Soldati-Favre, Dominique/0000-0003-4156-2109				Black MW, 2000, MOL CELL BIOL, V20, P9399, DOI 10.1128/MCB.20.24.9399-9408.2000; Brecht S, 2001, J BIOL CHEM, V276, P4119, DOI 10.1074/jbc.M008294200; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 1999, BIOCHEM J, V342, P379, DOI 10.1042/0264-6021:3420379; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hakansson S, 1999, MOL BIOL CELL, V10, P3539, DOI 10.1091/mbc.10.11.3539; Heintzelman MB, 1997, J MOL BIOL, V271, P139, DOI 10.1006/jmbi.1997.1167; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; Hettmann C, 2000, MOL BIOL CELL, V11, P1385, DOI 10.1091/mbc.11.4.1385; Hoff EF, 2002, TRENDS PARASITOL, V18, P251, DOI 10.1016/S1471-4922(02)02240-7; Meissner M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.22.e115; Moudy R, 2001, J BIOL CHEM, V276, P41492, DOI 10.1074/jbc.M106154200; PFEFFERKORN ER, 1976, EXP PARASITOL, V36, P365, DOI 10.1016/0014-4894(76)90040-0; Sibley LD, 1998, CURR BIOL, V8, pR12, DOI 10.1016/S0960-9822(98)70008-9; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	17	356	377	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					837	840		10.1126/science.1074553	http://dx.doi.org/10.1126/science.1074553			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399593	Green Accepted			2022-12-28	WOS:000178791200062
J	Oltvai, ZN; Barabasi, AL				Oltvai, ZN; Barabasi, AL			Life's complexity pyramid	SCIENCE			English	Editorial Material							REGULATORY NETWORKS; ORGANIZATION; MOTIFS		Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA	Northwestern University; University of Notre Dame	Oltvai, ZN (corresponding author), Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA.	zno008@nwu.edu; alb@nd.edu	Barabasi, Albert-Laszlo/S-6474-2017	Barabasi, Albert/0000-0002-4028-3522				Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hasty J, 2001, NAT REV GENET, V2, P268, DOI 10.1038/35066056; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881	10	324	343	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					763	764		10.1126/science.1078563	http://dx.doi.org/10.1126/science.1078563			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399572				2022-12-28	WOS:000178791200040
J	Sabeti, PC; Reich, DE; Higgins, JM; Levine, HZP; Richter, DJ; Schaffner, SF; Gabriel, SB; Platko, JV; Patterson, NJ; McDonald, GJ; Ackerman, HC; Campbell, SJ; Altshuler, D; Cooper, R; Kwiatkowski, D; Ward, R; Lander, ES				Sabeti, PC; Reich, DE; Higgins, JM; Levine, HZP; Richter, DJ; Schaffner, SF; Gabriel, SB; Platko, JV; Patterson, NJ; McDonald, GJ; Ackerman, HC; Campbell, SJ; Altshuler, D; Cooper, R; Kwiatkowski, D; Ward, R; Lander, ES			Detecting recent positive selection in the human genome from haplotype structure	NATURE			English	Article							LINKAGE DISEQUILIBRIUM; EVOLUTION; DIVERSITY; ALLELE; ORIGIN	The ability to detect recent natural selection in the human population would have profound implications for the study of human history and for medicine. Here, we introduce a framework for detecting the genetic imprint of recent positive selection by analysing long-range haplotypes in human populations. We first identify haplotypes at a locus of interest (core haplotypes). We then assess the age of each core haplotype by the decay of its association to alleles at various distances from the locus, as measured by extended haplotype homozygosity (EHH). Core haplotypes that have unusually high EHH and a high population frequency indicate the presence of a mutation that rose to prominence in the human gene pool faster than expected under neutral evolution. We applied this approach to investigate selection at two genes carrying common variants implicated in resistance to malaria: G6PD(1) and CD40 ligand(2). At both loci, the core haplotypes carrying the proposed protective mutation stand out and show significant evidence of selection. More generally, the method could be used to scan the entire genome for evidence of recent positive selection.	Whitehead Inst MIT Ctr Genome Res, Cambridge, MA 02142 USA; Univ Oxford, Inst Biol Anthropol, Oxford OX2 6QS, England; Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Loyola Univ, Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60143 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Loyola University Chicago; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Lander, ES (corresponding author), Whitehead Inst MIT Ctr Genome Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lander@genome.wi.mit.edu	Schaffner, Stephen F/D-1189-2011; Sabeti, Pardis/GQH-8610-2022; Ackerman, Hans/U-9621-2019; Altshuler, David M/A-4476-2009	Ackerman, Hans/0000-0003-4940-3305; Altshuler, David M/0000-0002-7250-4107; Pickett, Sarah/0000-0002-1242-2927; Kwiatkowski, Dominic/0000-0002-5023-0176; Schaffner, Stephen/0000-0001-6699-3568; Richter, Daniel/0000-0002-9238-5571				Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Fay JC, 2000, GENETICS, V155, P1405; FU YX, 1993, GENETICS, V133, P693; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; HUDSON RR, 1987, GENETICS, V116, P153; HUDSON RR, 1983, THEOR POPUL BIOL, V23, P183, DOI 10.1016/0040-5809(83)90013-8; HUDSON RR, 1985, GENETICS, V111, P147; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Kimura M., 1983, NEUTRAL THEORY MOL E; LEWONTIN RC, 1964, GENETICS, V49, P49; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Nei M., 1987, MOL EVOLUTIONARY GEN; Raymond M, 1995, EVOLUTION, V49, P1280, DOI 10.1111/j.1558-5646.1995.tb04456.x; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; REICH DE, 1999, MICROSATELLITES EVOL, P128; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; Ruwende C, 1998, J MOL MED, V76, P581, DOI 10.1007/s001090050253; Sabeti P, 2002, GENES IMMUN, V3, P286, DOI 10.1038/sj.gene.6363877; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; TAJIMA F, 1989, GENETICS, V123, P585; Tang K, 1999, P NATL ACAD SCI USA, V96, P10016, DOI 10.1073/pnas.96.18.10016; Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573; Vulliamy T J, 1991, Gene Geogr, V5, P13; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813; [No title captured]	26	1354	1399	9	264	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	2002	419	6909					832	837		10.1038/nature01140	http://dx.doi.org/10.1038/nature01140			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397357				2022-12-28	WOS:000178769800045
J	Francis, CW; Davidson, BL; Berkowitz, SD; Lotke, PA; Ginsberg, JS; Lieberman, JR; Webster, AK; Whipple, JP; Peters, GR; Colwell, CW				Francis, CW; Davidson, BL; Berkowitz, SD; Lotke, PA; Ginsberg, JS; Lieberman, JR; Webster, AK; Whipple, JP; Peters, GR; Colwell, CW			Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty - A randomized, double-blind trial	ANNALS OF INTERNAL MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; TOTAL HIP-REPLACEMENT; RECOMBINANT HIRUDIN; PULMONARY-EMBOLISM; UNFRACTIONATED HEPARIN; ENOXAPARIN; INHIBITOR; SURGERY; PROPHYLAXIS	Background: Warfarin is used for prophylaxis of venous thromboembolism in patients undergoing total knee arthroplasty. However, it is associated with rates of deep venous thrombosis (DVT) of approximately 38% to 55% and requires routine coagulation monitoring and frequent dose adjustment. Ximelagatran, an oral direct thrombin inhibitor, has shown promising efficacy and tolerability in patients undergoing total hip or knee arthroplasty. Objective: To compare the efficacy and safety of ximelagatran and warfarin for prophylaxis of venous thromboembolism after total knee arthroplasty. Design: Randomized, double-blind, parallel-group trial. Setting: 74 North American hospitals. Patients: 680 patients who had undergone total knee arthroplasty. Intervention: 7 to 12 days of treatment with oral ximelagatran, 24 ring twice daily, starting on the morning after surgery, or warfarin (target international normalized ratio, 2.5 [range, 1.8 to 3.0]), starting on the evening of the day of surgery. Measurements: Principal end points were asymptomatic DVT on mandatory venography; symptomatic DVT confirmed by ultrasonography or venography; symptomatic, objectively proven pulmonary embolism; and bleeding. All were assessed by blinded adjudication locally and at a central study laboratory. Results: On central adjudication, incidence of venous thromboembolism was 19.2% (53 of 276 patients) in the ximelagatran group and 25.7% (67 of 261 patients) in the warfarin group (difference, -6.5 percentage points [95% Cl, -13.5 to 0.6 percentage points]; P = 0.070). On local assessment, incidence was 25.4% in the ximelagatran group and 33.5% in the warfarin group (P = 0.043). In the ximelagatran and warfarin groups, respectively, major bleeding occurred in 1.7% and 0.9% of patients and minor bleeding occurred in 7.8% and 6.4% of patients. No variables related to bleeding differed significantly between the two groups. Conclusions: For prophylaxis of venous thromboembolism, fixed-dose ximelagatran started the morning after total knee arthroplasty is well tolerated and at least as effective, as warfarin, but it does not require coagulation monitoring or dose adjustment. For author affiliations, see end of text.	Univ Rochester, Sch Med & Dent, Rochester, NY USA; Univ Washington, Sch Med, Seattle, WA USA; Swedish Med Ctr, Seattle, WA USA; AstraZeneca, Wilmington, DE USA; Univ Penn, Philadelphia, PA 19104 USA; McMaster Univ, Hamilton, ON, Canada; Univ Calif Los Angeles, Los Angeles, CA USA; Scripps Res Inst, La Jolla, CA 92037 USA	University of Rochester; University of Washington; University of Washington Seattle; Swedish Medical Center; AstraZeneca; University of Pennsylvania; McMaster University; University of California System; University of California Los Angeles; Scripps Research Institute	Francis, CW (corresponding author), Univ Rochester, Med Ctr, Dept Med, Hematol Oncol Unit, Box 610,601 Elmwood Ave, Rochester, NY 14642 USA.	charles_francis@urmc.rochester.edu	ginsberg, jeffrey s/ABC-1065-2020; Berkowitz, Scott Darrell/AAS-9397-2021	Berkowitz, Scott Darrell/0000-0002-9428-4408				[Anonymous], 1994, J Bone Joint Surg Am, V76, P1174; Bauer KA, 2001, NEW ENGL J MED, V345, P1305, DOI 10.1056/NEJMoa011099; Bredberg U, 1999, BLOOD, V94, p28A; Clagett GP, 1998, CHEST, V114, p531S, DOI 10.1378/chest.114.5_Supplement.531S; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Elg M, 1997, THROMB HAEMOSTASIS, V78, P1286; Elg M, 1999, THROMB RES, V94, P187, DOI 10.1016/S0049-3848(98)00213-8; Eriksson BI, 1997, J BONE JOINT SURG AM, V79A, P326, DOI 10.2106/00004623-199703000-00002; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; Eriksson BI, 1997, THROMB HAEMOSTASIS, V78, P1404; Eriksson BI, 1997, NEW ENGL J MED, V337, P1329, DOI 10.1056/NEJM199711063371901; Eriksson BI, 1996, LANCET, V347, P635, DOI 10.1016/S0140-6736(96)91200-3; Eriksson BI, 2001, NEW ENGL J MED, V345, P1298, DOI 10.1056/NEJMoa011100; ERIKSSON BI, IN PRESS LANCET; Eriksson UG, 1999, BLOOD, V94, p26A; Eriksson UG, 2000, BLOOD, V96, p93B; ERIKSSON UG, 2001, CLIN PHARMACOL THER, V69, P24; ERIKSSON UG, 2001, 18 C INT SOC THROMB; ERIKSSONLIPKOWS.M, 2001, 18 C INT SOC THROMB; Fitzgerald RH, 2001, J BONE JOINT SURG AM, V83A, P900, DOI 10.2106/00004623-200106000-00012; Francis CW, 1997, J BONE JOINT SURG AM, V79A, P1365, DOI 10.2106/00004623-199709000-00011; Francis CW, 1996, THROMB HAEMOSTASIS, V75, P706; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; GINSBERG JS, 1994, CIRCULATION, V90, P2385, DOI 10.1161/01.CIR.90.5.2385; Gross M, 1999, CAN J SURG, V42, P457; Hamulyak K, 1995, THROMB HAEMOSTASIS, V74, P1428; HAVIG O, 1977, ACTA CHIR SCAND, P1; Heit JA, 2001, ARCH INTERN MED, V161, P2215, DOI 10.1001/archinte.161.18.2215; Heit JA, 1997, THROMB HAEMOSTASIS, V77, P32; Hirsh J, 1998, CHEST, V114, p445S, DOI 10.1378/chest.114.5_Supplement.445S; Howard AW, 1998, THROMB HAEMOSTASIS, V79, P902; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; Iobst C A, 1999, Am J Knee Surg, V12, P55; Johansson L, 2000, BLOOD, V96, p57A; JOHANSSON S, 2001, 18 C INT SOC THROMB; Kalebo P, 1996, THROMB HAEMOSTASIS, V76, P893; Leclerc JR, 1996, ANN INTERN MED, V124, P619, DOI 10.7326/0003-4819-124-7-199604010-00001; MAYNARD MJ, 1991, CLIN ORTHOP RELAT R, V273, P125; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; Peters G, 2001, CLIN PHARMACOL THER, V69, pP35; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134	41	177	187	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2002	137	8					648	655		10.7326/0003-4819-137-8-200210150-00008	http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604WL	12379064				2022-12-28	WOS:000178644000003
J	Giordano, SH; Buzdar, AU; Hortobagyi, GN				Giordano, SH; Buzdar, AU; Hortobagyi, GN			Breast cancer in men	ANNALS OF INTERNAL MEDICINE			English	Review							GERM-LINE MUTATIONS; LONG-TERM SURVIVAL; HORMONE RECEPTOR STATUS; PROGNOSTIC-FACTORS; FAMILY-HISTORY; PROLIFERATIVE ACTIVITY; ADJUVANT CHEMOTHERAPY; KLINEFELTERS-SYNDROME; ESTROGEN-RECEPTORS; STEROID-RECEPTORS	Purpose: Breast cancer in men is uncommon; 1500 new cases are diagnosed in the United States yearly. Optimal management of breast cancer in men is unknown because the rarity of the disease precludes large randomized trials. A review of the literature was undertaken with emphasis on articles published over a 10-year period. Data Sources: Articles published between 1942 and 2000 on breast cancer in men were identified by using CancerLit, MEDLINE, and study bibliographies. Study Selection: All retrospective series and studies focusing on the epidemiology, risk factors, genetics, and pathology of breast cancer in men. Data Extraction: Data on the epidemiology, risk factors, genetics, pathology, molecular markers, prognostic factors, therapy, and outcomes of breast cancer in men. Data Synthesis: Carcinoma of the male breast accounts for 0.8% of all breast cancers. Risk factors include testicular disease, benign breast conditions, age, Jewish ancestry, family history, and the Klinefelter syndrome. BRCA2 mutations predispose men to breast cancer and may account for 4% to 14% of all cases. Pathology data were reviewed: 81% of tumors were estrogen receptor positive, 74% were progesterone receptor positive, 37% overexpressed c-erbB-2, 30% overexpressed p53, 79% overexpressed Bcl-2, 51% overexpressed cyclin D1, and 39% overexpressed epidermal growth factor receptor. Prognostic factors include tumor size, histologic grade, and lymph node status; survival is similar to that of breast cancer in women when patients are matched for age and stage. Adjuvant hormonal therapy and chemotherapy, using the same guidelines as for women, are recommended for men. Hormonal therapy is the primary therapy for metastatic disease; chemotherapy should be reserved for hormone-refractory disease. Conclusion: Breast cancer is similar in men and women; however, breast cancer in men is more frequently hormone receptor positive and may be more sensitive to hormonal therapy.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Giordano, SH (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd,Box 424, Houston, TX 77030 USA.	sgiordano@mdanderson.org		Giordano, Sharon H./0000-0002-8700-2767				ADAMI HO, 1985, BRIT J CANCER, V52, P99, DOI 10.1038/bjc.1985.155; Amir H, 1996, E AFR MED J, V73, P187; ANELLI A, 1995, CANCER, V75, P2233, DOI 10.1002/1097-0142(19950501)75:9<2233::AID-CNCR2820750907>3.0.CO;2-S; [Anonymous], 1997, AJCC CANC STAGING MA; ARBER N, 1995, P ANN M AM ASS CANC, V36, pA1350; BAGLEY CS, 1987, AM J CLIN ONCOL-CANC, V10, P55, DOI 10.1097/00000421-198702000-00013; BEZWODA WR, 1987, CANCER, V60, P1337, DOI 10.1002/1097-0142(19870915)60:6<1337::AID-CNCR2820600629>3.0.CO;2-C; BINES J, 1997, P ASCO, V16, P558; BLIN N, 1993, ONCOLOGY, V50, P408; Bloom K. J., 2000, Breast Cancer Research and Treatment, V64, P127; BORGEN PI, 1992, ANN SURG, V215, P451, DOI 10.1097/00000658-199205000-00007; Borgen PI, 1997, ANN SURG ONCOL, V4, P385, DOI 10.1007/BF02305550; BRAUNSTEIN GD, 1993, NEW ENGL J MED, V328, P490; Bruce DM, 1996, EUR J SURG ONCOL, V22, P42, DOI 10.1016/S0748-7983(96)91418-3; *CANC STAT BRANCH, 2000, SEER PROGR PUBL US D; Carmalt HL, 1998, AUST NZ J SURG, V68, P712, DOI 10.1111/j.1445-2197.1998.tb04657.x; CIATTO S, 1990, TUMORI, V76, P555, DOI 10.1177/030089169007600608; CLARK G, 2000, DIS BREAST, V2, P489; Clark JL, 2000, AM SURGEON, V66, P502; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; CRICHLOW RW, 1972, SURG GYNECOL OBSTETR, V134, P1011; Csokay B, 1999, CANCER RES, V59, P995; Cutuli B, 1995, EUR J CANCER, V31A, P1960, DOI 10.1016/0959-8049(95)00366-5; Dawson PJ, 1996, MODERN PATHOL, V9, P367; DAWSON PJ, 1992, MODERN PATHOL, V5, P621; de Toro MMM, 1998, J STEROID BIOCHEM, V67, P333, DOI 10.1016/S0960-0760(98)00124-1; DICKSON RB, 2000, DIS BREAST, P281; Diez O, 2000, ANN ONCOL, V11, P81, DOI 10.1023/A:1008339009528; DIGENIS AG, 1990, SOUTHERN MED J, V83, P1162, DOI 10.1097/00007611-199010000-00011; Donegan WL, 1998, CANCER-AM CANCER SOC, V83, P498, DOI 10.1002/(SICI)1097-0142(19980801)83:3<498::AID-CNCR19>3.0.CO;2-R; ERLICHMAN C, 1984, J CLIN ONCOL, V2, P903, DOI 10.1200/JCO.1984.2.8.903; EVERSON RB, 1980, CANCER RES, V40, P991; EWERTZ M, 1989, INT J CANCER, V43, P27, DOI 10.1002/ijc.2910430107; FARROW JOSEPH H., 1942, SCIENCE, V95, P654, DOI 10.1126/science.95.2478.654; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FOX SB, 1992, J PATHOL, V166, P13, DOI 10.1002/path.1711660104; FOX SB, 1991, J CLIN PATHOL, V44, P960, DOI 10.1136/jcp.44.11.960; Friedman LS, 1997, AM J HUM GENET, V60, P313; FRIEDMAN MA, 1981, CANCER, V47, P134, DOI 10.1002/1097-0142(19810101)47:1<134::AID-CNCR2820470122>3.0.CO;2-M; Gattuso P, 1995, INT J SURG PATHOL, V2, P199; Goss PE, 1999, CANCER-AM CANCER SOC, V85, P629, DOI 10.1002/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V; GOUGH DB, 1993, SURG ONCOL, V2, P325, DOI 10.1016/0960-7404(93)90063-5; GUINEE VF, 1993, CANCER-AM CANCER SOC, V71, P154, DOI 10.1002/1097-0142(19930101)71:1<154::AID-CNCR2820710125>3.0.CO;2-#; GUPTA N, 1980, CANCER, V46, P1781, DOI 10.1002/1097-0142(19801015)46:8<1781::AID-CNCR2820460814>3.0.CO;2-F; Hakansson S, 1997, AM J HUM GENET, V60, P1068; Haraldsson K, 1998, CANCER RES, V58, P1367; HECHT JR, 1994, AM J CLIN PATHOL, V102, pS25; HELLER KS, 1978, ANN SURG, V188, P60, DOI 10.1097/00000658-197807000-00010; Hill A, 1999, CANCER, V86, P821, DOI 10.1002/(SICI)1097-0142(19990901)86:5<821::AID-CNCR18>3.0.CO;2-I; Hiort O, 1996, J CLIN ENDOCR METAB, V81, P3404, DOI 10.1210/jc.81.9.3404; Hittmair AP, 1998, CANCER-AM CANCER SOC, V83, P2139, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2139::AID-CNCR12>3.0.CO;2-F; HOLLEB AI, 1968, NEW YORK STATE J MED, V68, P656; Hsing AW, 1998, CANCER CAUSE CONTROL, V9, P269, DOI 10.1023/A:1008869003012; Hultborn R, 1997, ANTICANCER RES, V17, P4293; IZQUIERDO MA, 1994, ACTA ONCOL, V33, P767, DOI 10.3109/02841869409083946; JAIYESIMI IA, 1992, ANN INTERN MED, V117, P771, DOI 10.7326/0003-4819-117-9-771; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; JOENSUU H, 1994, AM J PATHOL, V145, P1191; Joshi A, 1999, ACTA CYTOL, V43, P334, DOI 10.1159/000331077; Joshi MG, 1996, CANCER, V77, P490; KANTARJIAN H, 1983, ARCH INTERN MED, V143, P237, DOI 10.1001/archinte.143.2.237; KRAYBILL WG, 1981, CANCER, V47, P2185, DOI 10.1002/1097-0142(19810501)47:9<2185::AID-CNCR2820470913>3.0.CO;2-B; LAVECCHIA C, 1992, INT J CANCER, V51, P62, DOI 10.1002/ijc.2910510113; LEACH IH, 1992, J CLIN PATHOL, V45, P942, DOI 10.1136/jcp.45.10.942-c; LOPEZ M, 1985, ONCOLOGY, V42, P345, DOI 10.1159/000226061; Mavraki E, 1997, BRIT J CANCER, V76, P1428, DOI 10.1038/bjc.1997.574; McCarthy PL, 1999, BONE MARROW TRANSPL, V24, P365, DOI 10.1038/sj.bmt.1701926; McLachlan SA, 1996, BREAST CANCER RES TR, V40, P225, DOI 10.1007/BF01806810; MIES C, 1994, LAB INVEST, V70, pA19; MOORE J, 1994, LAB INVEST, V70, pA19; MORIMOTO T, 1990, J SURG ONCOL, V44, P180, DOI 10.1002/jso.2930440311; NORRIS HJ, 1969, CANCER, V23, P1428, DOI 10.1002/1097-0142(196906)23:6<1428::AID-CNCR2820230626>3.0.CO;2-4; Osorio A, 2000, BRIT J CANCER, V82, P1266, DOI 10.1054/bjoc.1999.1089; OURIEL K, 1984, SURG GYNECOL OBSTET, V159, P373; PATEL HZ, 1989, CANCER, V64, P1583, DOI 10.1002/1097-0142(19891015)64:8<1583::AID-CNCR2820640804>3.0.CO;2-Q; Pich A, 1998, VIRCHOWS ARCH, V433, P229, DOI 10.1007/s004280050241; Pich A, 2000, J CLIN ONCOL, V18, P2948, DOI 10.1200/JCO.2000.18.16.2948; Pich A, 1996, HUM PATHOL, V27, P676, DOI 10.1016/S0046-8177(96)90397-4; Ramantanis G, 1980, World J Surg, V4, P621; Rayson D, 1998, CANCER, V83, P1947, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1947::AID-CNCR10>3.0.CO;2-J; RIBEIRO G, 1985, BRIT J CANCER, V51, P115, DOI 10.1038/bjc.1985.16; RIBEIRO G, 1992, BRIT J CANCER, V65, P252, DOI 10.1038/bjc.1992.50; Ribeiro GG, 1996, BREAST, V5, P141, DOI 10.1016/S0960-9776(96)90058-2; RIBEIRO GG, 1977, BRIT J SURG, V64, P381, DOI 10.1002/bjs.1800640602; RIBEIRO GG, 1983, CLIN RADIOL, V34, P625, DOI 10.1016/S0009-9260(83)80408-5; ROBISON R, 1982, CANCER, V49, P403, DOI 10.1002/1097-0142(19820115)49:2<403::AID-CNCR2820490232>3.0.CO;2-T; ROSENBLATT KA, 1991, JNCI-J NATL CANCER I, V83, P849, DOI 10.1093/jnci/83.12.849; Rudan Igor, 1997, Acta Medica Croatica, V51, P135; SALVADORI B, 1994, EUR J CANCER, V30A, P930, DOI 10.1016/0959-8049(94)90117-1; SANCHEZ AG, 1986, CANCER-AM CANCER SOC, V57, P1181, DOI 10.1002/1097-0142(19860315)57:6<1181::AID-CNCR2820570619>3.0.CO;2-T; SANDLER B, 1994, AM SURGEON, V60, P816; Sasano H, 1996, J CLIN ENDOCR METAB, V81, P3063, DOI 10.1210/jc.81.8.3063; SASCO AJ, 1993, INT J CANCER, V53, P538, DOI 10.1002/ijc.2910530403; SCHEIKE O, 1974, BRIT J CANCER, V30, P261, DOI 10.1038/bjc.1974.190; SCHEIKE O, 1973, BRIT J CANCER, V28, P552, DOI 10.1038/bjc.1973.185; Sorensen HT, 1998, AM J GASTROENTEROL, V93, P231, DOI 10.1016/S0002-9270(97)00050-6; SPENCE RAJ, 1985, CANCER, V55, P648, DOI 10.1002/1097-0142(19850201)55:3<648::AID-CNCR2820550329>3.0.CO;2-3; STALSBERG H, 1993, CANCER CAUSE CONTROL, V4, P143, DOI 10.1007/BF00053155; STIERER M, 1995, WORLD J SURG, V19, P687, DOI 10.1007/BF00295904; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; Tan PH, 1997, PATHOLOGY, V29, P2, DOI 10.1080/00313029700169444; THOMAS DB, 1992, AM J EPIDEMIOL, V135, P734, DOI 10.1093/oxfordjournals.aje.a116360; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; VANGEEL AN, 1985, BRIT J SURG, V72, P724, DOI 10.1002/bjs.1800720918; WeberChappuis K, 1996, EUR J CANCER, V32A, P1686, DOI 10.1016/0959-8049(96)00154-2; Wick MR, 1999, AM J CLIN PATHOL, V111, P59; WIECZOREK R, 1994, LAB INVEST, V70, pA24; WILLIAMS MJ, 1963, AM J MED, V34, P103, DOI 10.1016/0002-9343(63)90044-5; Williams WL, 1996, J NATL MED ASSOC, V88, P439; Willsher PC, 1997, AM J SURG, V173, P185, DOI 10.1016/S0002-9610(97)89592-X; Willsher PC, 1997, ANTICANCER RES, V17, P2335; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; YAP HY, 1979, CANCER, V44, P748, DOI 10.1002/1097-0142(197908)44:2<748::AID-CNCR2820440248>3.0.CO;2-9; Yildirim E, 1998, EUR J SURG ONCOL, V24, P548, DOI 10.1016/S0748-7983(98)93608-3	114	307	332	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2002	137	8					678	687		10.7326/0003-4819-137-8-200210150-00013	http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00013			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604WL	12379069				2022-12-28	WOS:000178644000008
J	Brenner, H				Brenner, H			Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis	LANCET			English	Article							RECENT TRENDS; CHILDHOOD-CANCER; UNITED-STATES; MORTALITY; SAARLAND; GERMANY	Background Long-term survival rates for many types of cancer have substantially improved in past decades because of advances in early detection and treatment. However, much of this improvement is only seen many years later with traditional cohort-based methods of survival analysis. I aimed to assess achievements in cancer patients' survival by an alternative method of survival analysis, known as period analysis, which provides more up-to-date estimates of long-term survival rates than do conventional methods. Methods The 1973-98 database of the Surveillance, Epidemiology, and End Results (SEER) programme of the US National Cancer Institute was analysed by period analysis. Findings Estimates of 5-year, 10-year, 15-year, and 20-year relative survival rates for all types of cancer were 63%, 57%, 53%, and 51%, respectively, by period analysis. These estimates were 1%, 7%, 11%, and 11% higher, respectively, than corresponding estimates by cohort-based survival analysis. By period analysis, 20-year relative survival rates were close to 90% for thyroid and testis cancer, exceeded 80% for melanomas and prostate cancer, were about 80% for endometrial cancer, and almost 70% for bladder cancer and Hodgkin's disease. A 20-year relative survival rate of 65% was estimated for breast cancer, of 60% for cervical cancer, and of about 50% for colorectal, ovarian, and renal cancer. Interpretation Timely detection of improvements in long-term survival rates might help to prevent clinicians and their patients from undue discouragement or depression by outdated and often overly pessimistic survival expectations. It also adds to the value of cancer surveillance as a basis for appropriate public-health decisions.	German Ctr Res Ageing, Dept Epidemiol, D-69115 Heidelberg, Germany		Brenner, H (corresponding author), German Ctr Res Ageing, Dept Epidemiol, Bergheimer Str 20, D-69115 Heidelberg, Germany.	brenner@dzfa.uni-heidelberg.de	Brenner, Hermann/ABE-6383-2020; Brenner, Hermann/B-4627-2017	Brenner, Hermann/0000-0002-6129-1572; Brenner, Hermann/0000-0002-6129-1572				Berrino F, 1995, IARC SCI PUBLICATION, V132; Berrino F, 1999, IARC SCI PUBLICATION, V151; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Brandt L, 2001, ACTA ONCOL, V40, P185, DOI 10.1080/02841860151116240; Brenner H, 2002, INT J EPIDEMIOL, V31, P456, DOI 10.1093/ije/31.2.456; Brenner H, 2002, J CLIN ONCOL, V20, P826, DOI 10.1200/JCO.20.3.826; Brenner H, 2002, EUR J CANCER, V38, P690, DOI 10.1016/S0959-8049(02)00003-5; Brenner H, 2001, CANCER, V92, P1977, DOI 10.1002/1097-0142(20011001)92:7<1977::AID-CNCR1717>3.0.CO;2-W; Brenner H, 2001, BRIT J CANCER, V85, P367, DOI 10.1054/bjoc.2001.1905; Brenner H, 1997, J CLIN EPIDEMIOL, V50, P211, DOI 10.1016/S0895-4356(97)00280-1; Brenner H, 1996, CANCER-AM CANCER SOC, V78, P2004, DOI 10.1002/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#; Brenner H, 2001, METHOD INFORM MED, V40, P248; Brenner H, 1998, BRIT J CANCER, V78, P694, DOI 10.1038/bjc.1998.562; Brenner H, 1999, J CANCER RES CLIN, V125, P109, DOI 10.1007/s004320050250; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Coleman MP, 2001, CANCER, V91, P208, DOI 10.1002/1097-0142(20010101)91:1+<208::AID-CNCR6>3.0.CO;2-E; Cox D. R., 1984, ANAL SURVIVAL DATA; CUTLER SJ, 1958, J CHRON DIS, V8, P699; Dennis LK, 2000, PROSTATE, V42, P247; Dickman PW, 1999, ACTA ONCOL, V38, P1; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; Gatta G, 2000, CANCER-AM CANCER SOC, V89, P893, DOI 10.1002/1097-0142(20000815)89:4<893::AID-CNCR24>3.3.CO;2-0; Greenwood M., 1926, REPORT NATURAL DURAT; HAKULINEN T, 1982, BIOMETRICS, V38, P933, DOI 10.2307/2529873; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Linet MS, 1999, JNCI-J NATL CANCER I, V91, P1051, DOI 10.1093/jnci/91.12.1051; *NCI DCCPS CANC SU, 2001, SURV EP END RES SEER; ROBERTSON CM, 1994, BRIT MED J, V309, P162, DOI 10.1136/bmj.309.6948.162; Sankaranarayanan R, 1996, CANCER-AM CANCER SOC, V78, P2461, DOI 10.1002/(SICI)1097-0142(19961215)78:12<2461::AID-CNCR2>3.0.CO;2-N; Wingo PA, 1998, CANCER EPIDEM BIOMAR, V7, P271	30	384	399	3	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	2002	360	9340					1131	1135		10.1016/S0140-6736(02)11199-8	http://dx.doi.org/10.1016/S0140-6736(02)11199-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387961				2022-12-28	WOS:000178632000013
J	Schneider, JG; Schaefer, S; Lettgen, B; Keiper, T; Nawroth, PP; Dugi, KA				Schneider, JG; Schaefer, S; Lettgen, B; Keiper, T; Nawroth, PP; Dugi, KA			Siblings with hepatosplenomegaly and lipoprotein lipase deficiency	LANCET			English	Editorial Material									Univ Heidelberg, Dept Internal Med 4, D-69115 Heidelberg, Germany; Darmstaedte Kinderkliniken, D-64287 Darmstadt, Germany	Ruprecht Karls University Heidelberg	Dugi, KA (corresponding author), Univ Heidelberg, Dept Internal Med 4, Bergheimer Str 58, D-69115 Heidelberg, Germany.							Brunzell JD, 2000, METABOLIC MOL BASIS, P2789; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; Wolf A D, 2000, Pediatr Rev, V21, P303, DOI 10.1542/pir.21-9-303	4	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1150	1150		10.1016/S0140-6736(02)11202-5	http://dx.doi.org/10.1016/S0140-6736(02)11202-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387965				2022-12-28	WOS:000178632000017
J	Jewkes, R				Jewkes, R			Preventing sexual violence: a rights-based approach	LANCET			English	Editorial Material									MRC, ZA-0001 Pretoria, South Africa		Jewkes, R (corresponding author), MRC, Private Bag X385, ZA-0001 Pretoria, South Africa.			Jewkes, Rachel/0000-0002-4330-6267				Hargreaves S, 2001, LANCET, V357, P737, DOI 10.1016/S0140-6736(00)04180-5; JEWKES R, 2002, SOC SCI MED, V55, P153; MALAMUTH NM, 1998, ANN NY ACAD SCI, V528, P113; World Health Organization, 2002, WORLD REPORT VIOLENC	4	17	17	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1092	1093		10.1016/S0140-6736(02)11135-4	http://dx.doi.org/10.1016/S0140-6736(02)11135-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	602BN	12384005				2022-12-28	WOS:000178485200030
J	Ma, JY; Lindquist, S				Ma, JY; Lindquist, S			Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol	SCIENCE			English	Article							PRION PROTEIN; CELLS	A rare conformation of the prion protein, PrPSc, is found only in mammals with transmissible prion diseases and represents either the infectious agent itself or a major component of it. The mechanism for initiating PrPSc formation is unknown. We report that PrP retrogradely transported out of the endoplasmic reticulum produced both amorphous aggregates and a PrPSc-like conformation in the cytosol. The distribution between these forms correlated with the rate of appearance in the cytosol. Once conversion to the PrPSc-like conformation occurred, it was sustained. Thus, PrP has an inherent capacity to promote its own conformational conversion in mammalian cells. These observations might explain the origin of PrPSc.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			Ma, Jiyan/0000-0001-7150-1898	NIGMS NIH HHS [GMS 25874] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; KIMBERLIN RH, 1982, NATURE, V297, P107, DOI 10.1038/297107a0; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LANSBURY PT, 1995, CHEM BIOL, V2, P1, DOI 10.1016/1074-5521(95)90074-8; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Piccardo P, 1998, J NEUROPATH EXP NEUR, V57, P979, DOI 10.1097/00005072-199810000-00010; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Wigley WC, 1999, J CELL BIOL, V145, P481; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383	22	228	240	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1785	1788		10.1126/science.1073619	http://dx.doi.org/10.1126/science.1073619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12386336				2022-12-28	WOS:000179494800044
J	Furukawa, TA; McGuire, H; Barbui, C				Furukawa, TA; McGuire, H; Barbui, C			Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GENERAL-PRACTICE; ASSOCIATION	Objective To compare the effects and side effects of low dosage tricyclic antidepressants with placebo and with standard dosage tricyclics in acute phase treatment of depression. Design Systematic review of randomised trials comparing low dosage tricyclics (less than or equal to100 mg/day) with placebo or with standard dosage tricyclics in adults with depression. Main outcome measures Relative risk of response in depression (random effects model), according to the original authors' definition but usually defined as 50% or greater reduction in severity of depression. Relative risks of overall dropouts and dropouts due to side effects. Results 35 studies (2013 participants) compared low dosage tricyclics with placebo, and six studies (551 participants) compared low dosage tricyclics with standard dosage tricyclics. Low dosage tricyclics, mostly between 75 and 100 mg/day, were 1.65 (95% confidence interval 1.36 to 2.0) and 1.47 (1.12 to 1.94) times more likely than placebo to bring about response at 4 weeks and 6-8 weeks, respectively. Standard dosage tricyclics failed, however, to bring about more response but produced more dropouts due to side effects than low dosage tricyclics. Conclusions Treatment of depression in adults with low dose tricyclics is justified. However, more rigorous studies are needed to definitively establish the relative benefits and harms of varying dosages.	Nagoya City Univ, Sch Med, Dept Psychiat, Nagoya, Aichi 4678601, Japan; Kings Coll London, Inst Psychiat, Cochrane Collaborat Depress Anxiety & Neurosis Hl, London SE5 8AF, England; Univ Verona, Dept Med & Publ Hlth, Sect Psychiat, OSped Policlin, I-37134 Verona, Italy	Nagoya City University; University of London; King's College London; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Furukawa, TA (corresponding author), Nagoya City Univ, Sch Med, Dept Psychiat, Nagoya, Aichi 4678601, Japan.	furukawa@med.nagoya-cu.ac.jp	Barbui, Corrado/E-7146-2010; Furukawa, Toshi A./B-9259-2011	Furukawa, Toshi A./0000-0003-2159-3776				Anderson IM, 2000, J PSYCHOPHARMACOL, V14, P3, DOI 10.1177/026988110001400101; [Anonymous], 2000, Am J Psychiatry, V157, P1; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; Donoghue J, 2000, CNS DRUGS, V13, P365, DOI 10.2165/00023210-200013050-00006; Furukawa TA, 2000, J AFFECT DISORDERS, V60, P173, DOI 10.1016/S0165-0327(99)00175-5; Furukawa TA, 2002, INT J EPIDEMIOL, V31, P72, DOI 10.1093/ije/31.1.72; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; Lawrenson RA, 2000, J AFFECT DISORDERS, V59, P149, DOI 10.1016/S0165-0327(99)00147-0; MULROW CD, 1997, COCHRANE LIB, V4; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; Pincus HA, 1998, JAMA-J AM MED ASSOC, V279, P526, DOI 10.1001/jama.279.7.526; Roberts E, 2001, NEW ZEAL MED J, V114, P25; Sleath BL, 2001, ANN PHARMACOTHER, V35, P419; *US DEP HHS, 1993, AHCPR PUBL	14	101	104	2	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	2002	325	7371					991	995		10.1136/bmj.325.7371.991	http://dx.doi.org/10.1136/bmj.325.7371.991			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411354	Bronze, Green Published			2022-12-28	WOS:000179415600016
J	Atwood, JL; Barbour, LJ; Jerga, A; Schottel, BL				Atwood, JL; Barbour, LJ; Jerga, A; Schottel, BL			Guest transport in a nonporous organic solid via dynamic van der Waals cooperativity	SCIENCE			English	Article							SINGLE-CRYSTAL; INTERCALATION; INCLUSION; COMPLEXES; FRAMEWORK	A well-known organic host compound undergoes single-crystal to single-crystal phase transitions upon guest uptake and release. Despite a lack of porosity of the material, guest transport through the solid occurs readily until a thermodynamically stable structure is achieved. In order to actively facilitate this dynamic process, the host molecules undergo significant positional and/or orientational rearrangement. This transformation of the host lattice is triggered by weak van der Waals interactions between the molecular components. In order for the material to maintain its macroscopic integrity, extensive cooperativity must exist between the molecules throughout the crystal, such that rearrangement can occur in a well-orchestrated fashion. We demonstrate here that even weak dispersive forces can exert a profound influence over solid-state dynamics.	Univ Missouri, Dept Chem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Atwood, JL (corresponding author), Univ Missouri, Dept Chem, Columbia, MO 65211 USA.	atwoodj@missouri.edu; barbourl@missouri.edu	atwood, jerry/ABA-8947-2021					Albrecht M, 2000, NATURE, V406, P970, DOI 10.1038/35023107; Atwood J. L., 1996, COMPREHENSIVE SUPRAM, V1; Atwood JL, 2002, SCIENCE, V296, P2367, DOI 10.1126/science.1072252; Brouwer EB, 2001, CHEM COMMUN, P565, DOI 10.1039/b009133m; Caira M. R., 1996, COMPREHENSIVE SUPRAM, V6, P825; COLEMAN AW, 1988, ANGEW CHEM INT EDIT, V27, P1361, DOI 10.1002/anie.198813611; Dunitz J., 1996, CRYSTAL SUPRAMOLECUL, P1; ENDO K, 1995, J AM CHEM SOC, V117, P8341, DOI 10.1021/ja00137a007; Fletcher AJ, 2001, J AM CHEM SOC, V123, P10001, DOI 10.1021/ja0109895; Hertzsch T, 2002, ANGEW CHEM INT EDIT, V41, P2281, DOI 10.1002/1521-3773(20020703)41:13<2281::AID-ANIE2281>3.0.CO;2-N; IBRAGIMOV BT, 1994, J INCLUS PHENOM MOL, V17, P317, DOI 10.1007/BF00707127; Kepert CJ, 1998, ANGEW CHEM INT EDIT, V37, P3158, DOI 10.1002/(SICI)1521-3773(19981204)37:22<3158::AID-ANIE3158>3.0.CO;2-8; Kepert CJ, 1999, CHEM COMMUN, P375, DOI 10.1039/a809746a; Kitaigorodsky A., 1973, MOL CRYSTALS MOL; Kitaigorodsky A., 1984, MIXED CRYSTALS; MIYATA M, 1990, NATURE, V343, P446, DOI 10.1038/343446a0; Steed J.W., 2022, SUPRAMOL CHEM; Steed JW, 2000, NATURE, V406, P943, DOI 10.1038/35023194; Takahashi S, 2002, J AM CHEM SOC, V124, P10944, DOI 10.1021/ja026564f	19	452	456	4	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	2002	298	5595					1000	1002		10.1126/science.1077591	http://dx.doi.org/10.1126/science.1077591			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411698				2022-12-28	WOS:000178932000048
J	Cremer, S; Sledge, MF; Heinze, J				Cremer, S; Sledge, MF; Heinze, J			Chemical mimicry - Male ants disguised by the queen's bouquet	NATURE			English	Article							HYDROCARBONS; RECOGNITION		Univ Regensburg, D-93040 Regensburg, Germany; Univ Florence, Dept Anim Biol & Genet, I-50125 Florence, Italy	University of Regensburg; University of Florence	Cremer, S (corresponding author), Univ Copenhagen, Inst Zool, Dept Populat Ecol, DK-2100 Copenhagen, Denmark.	sylvia.cremer@biologie.uni-regensburg.de	Cremer, Sylvia/B-2199-2013	Cremer, Sylvia/0000-0002-2193-3868				ANDERSON C, IN PRESS BEHAV ECOL; Andersson Malte, 1994; DETTNER K, 1994, ANNU REV ENTOMOL, V39, P129, DOI 10.1146/annurev.en.39.010194.001021; Heinze J, 1998, BEHAV ECOL SOCIOBIOL, V42, P239, DOI 10.1007/s002650050435; Heinze J, 2002, BEHAV ECOL SOCIOBIOL, V52, P59, DOI 10.1007/s00265-002-0491-1; Holldobler B, 1985, EXPT BEHAV ECOLOGY S, P167; KINOMURA K, 1987, J ETHOL, V5, P75, DOI 10.1007/BF02347897; Lahav S, 1999, NATURWISSENSCHAFTEN, V86, P246, DOI 10.1007/s001140050609; Lenoir A, 2001, ANNU REV ENTOMOL, V46, P573, DOI 10.1146/annurev.ento.46.1.573; PESCHKE K, 1987, J CHEM ECOL, V13, P1993, DOI 10.1007/BF01041727; Shine R, 2000, ANIM BEHAV, V59, P349, DOI 10.1006/anbe.1999.1321; Singer TL, 1998, AM ZOOL, V38, P394; Turillazzi S., 2002, Insect Social Life, V4, P169	13	48	48	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					897	897		10.1038/419897a	http://dx.doi.org/10.1038/419897a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410300				2022-12-28	WOS:000178909700032
J	Elbert, T; Schauer, M				Elbert, T; Schauer, M			Burnt into memory	NATURE			English	Editorial Material									Univ Konstanz, Dept Psychol, D-78457 Constance, Germany; Vivo, I-60032 Ancona, Italy	University of Konstanz	Elbert, T (corresponding author), Univ Konstanz, Dept Psychol, D-78457 Constance, Germany.		Elbert, Thomas/C-8556-2009	Elbert, Thomas/0000-0003-1332-4939				FRIEDMAN MJ, 2001, POST TRAUMATIC STRES; Kaldor Mary., 1999, NEW OLD WARS ORG VIO; LANG PJ, 1994, EMOTIONS: ESSAYS ON EMOTION THEORY, P61; Metcalfe J., 1996, PTSD RES Q, V7, P1; Neuner F, 2002, BEHAV COGN PSYCHOTH, V30, P205, DOI 10.1017/S1352465802002072	5	82	84	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					883	883		10.1038/419883a	http://dx.doi.org/10.1038/419883a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410289	Green Published			2022-12-28	WOS:000178909700022
J	Levy, D; Kenchaiah, S; Larson, MG; Benjamin, EJ; Kupka, MJ; Ho, KKL; Murabito, JM; Vasan, RS				Levy, D; Kenchaiah, S; Larson, MG; Benjamin, EJ; Kupka, MJ; Ho, KKL; Murabito, JM; Vasan, RS			Long-term trends in the incidence of and survival with heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; CASE-FATALITY; MORTALITY; HYPERTENSION; PREVALENCE; MORBIDITY; PROGNOSIS; COMMUNITY; THERAPY; DISEASE	Background: Heart failure is a major public health problem. Long-term trends in the incidence of heart failure and survival after its onset in the community have not been characterized. Methods: We used statistical models to assess temporal trends in the incidence of heart failure and Cox proportional-hazards regression to evaluate survival after the onset of heart failure among subjects in the Framingham Heart Study. Cases of heart failure were classified according to the date of onset: 1950 through 1969 (223 cases), 1970 through 1979 (222), 1980 through 1989 (307), and 1990 through 1999 (323). We also calculated 30-day, 1-year, and 5-year age-adjusted mortality rates for each period. Results: Heart failure occurred in 1075 subjects (51 percent of whom were women). As compared with the rate for the period from 1950 through 1969, the incidence of heart failure remained virtually unchanged among men in the three subsequent periods but declined by 31 to 40 percent among women (rate ratio for the period from 1990 through 1999, 0.69; 95 percent confidence interval, 0.51 to 0.93). The 30-day, 1-year, and 5-year age-adjusted mortality rates among men declined from 12 percent, 30 percent, and 70 percent, respectively, in the period from 1950 through 1969 to 11 percent, 28 percent, and 59 percent, respectively, in the period from 1990 through 1999. The corresponding rates among women were 18 percent, 28 percent, and 57 percent for the period from 1950 through 1969 and 10 percent, 24 percent, and 45 percent for the period from 1990 through 1999. Overall, there was an improvement in the survival rate after the onset of heart failure of 12 percent per decade (P=0.01 for men and P=0.02 for women). Conclusions: Over the past 50 years, the incidence of heart failure has declined among women but not among men, whereas survival after the onset of heart failure has improved in both sexes. Factors contributing to these trends need further clarification.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Boston Univ, Sch Med, Sect Prevent Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Clin Res Inst, Boston, MA USA; NHLBI, Bethesda, MD 20892 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levy, D (corresponding author), NHLBI, Framingham Heart Study, Framingham, MA 01702 USA.		Kenchaiah, Satish/A-1519-2016; Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021; Ramachandran, Vasan/Y-2527-2019; Benjamin, Emelia/E-7103-2011	Kenchaiah, Satish/0000-0002-8731-8702; Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Murabito, Joanne/0000-0002-0192-7516; Benjamin, Emelia/0000-0003-4076-2336; Rocha, Evangelista Casimiro/0000-0002-8716-5259; Ho, Kalon/0000-0001-5946-6428; Larson, Martin/0000-0002-9631-1254	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004334] Funding Source: NIH RePORTER; NHLBI NIH HHS [1K24 HL04334, N01-HC-25195] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM HEART ASS, 2001, 2002 HEART STROK STA; [Anonymous], 1991, JAMA, V265, P3255; BAKER DW, 1994, JAMA-J AM MED ASSOC, V272, P1528, DOI 10.1001/jama.272.19.1528; Black HR, 1998, ARCH INTERN MED, V158, P573; BROPHY JM, 1992, CAN J CARDIOL, V8, P495; Burt VL, 1996, HYPERTENSION, V27, P1192; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COX DR, 1972, J R STAT SOC B, V34, P187; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DILENARDA A, 1994, BRIT HEART J, V72, pS46; Hjalmarson A, 1999, LANCET, V353, P2001; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1994, BRIT HEART J, V72, P3; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1987, NIH PUBLICATION; Lechat P, 1999, LANCET, V353, P9; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; MORRISON AS, 1982, INT J EPIDEMIOL, V11, P261, DOI 10.1093/ije/11.3.261; Mosterd A, 1999, NEW ENGL J MED, V340, P1221, DOI 10.1056/NEJM199904223401601; Murdoch DR, 1998, EUR HEART J, V19, P1829, DOI 10.1053/euhj.1998.1269; *NAT HEART LUNG BL, 2002, FACT BOOK FISC YEAR; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Philbin EF, 1998, CLIN CARDIOL, V21, P103, DOI 10.1002/clc.4960210208; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; RodriguezArtalejo F, 1997, EUR HEART J, V18, P1771; SAS Institute, 1997, SAS STAT SOFTW CHANG; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Senni M, 1999, ARCH INTERN MED, V159, P29, DOI 10.1001/archinte.159.1.29; SHURTLEFF D, 1974, SOME CHARACTERISTICS, P7; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; STEVENSON R, 1993, BRIT MED J, V307, P909; STEVENSON WG, 1995, J AM COLL CARDIOL, V26, P1417, DOI 10.1016/0735-1097(95)00341-X; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1997, ARCH INTERN MED, V157, P2413	43	1480	1557	3	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1397	1402		10.1056/NEJMoa020265	http://dx.doi.org/10.1056/NEJMoa020265			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12409541	Bronze			2022-12-28	WOS:000178888400002
J	Liston, C; Kagan, J				Liston, C; Kagan, J			Brain development - Memory enhancement in early childhood	NATURE			English	Article							HUMAN PREFRONTAL CORTEX; BEHAVIORAL-DEVELOPMENT; NEUROBIOLOGICAL BASES; RETRIEVAL; EXPLICIT; INFANCY		Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Harvard University	Liston, C (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.	cliston@post.harvard.edu	, Conor Liston/GQH-8931-2022					BACHEVALIER J, 1993, NEUROREPORT, V4, P77, DOI 10.1097/00001756-199301000-00020; Barr R, 1996, INFANT BEHAV DEV, V19, P159, DOI 10.1016/S0163-6383(96)90015-6; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Carver LJ, 2001, J EXP PSYCHOL GEN, V130, P726, DOI 10.1037//0096-3445.130.4.726; Herschkowitz N, 1997, NEUROPEDIATRICS, V28, P296, DOI 10.1055/s-2007-973720; Herschkowitz N, 1999, NEUROPEDIATRICS, V30, P221, DOI 10.1055/s-2007-973495; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; KOENDERINK MJT, 1994, BRAIN RES, V653, P173, DOI 10.1016/0006-8993(94)90387-5; MRZLJAK L, 1990, PROG BRAIN RES, V85, P185; Nyberg L, 1996, P NATL ACAD SCI USA, V93, P11280, DOI 10.1073/pnas.93.20.11280; Piaget J., 1952, ORIGINS INTELLIGENCE; SERESS L, 1992, HIPPOCAMPUS, V2, P127, DOI 10.1002/hipo.450020205; Van Buren JM, 1972, VARIATIONS CONNECTIO	13	25	25	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					896	896		10.1038/419896a	http://dx.doi.org/10.1038/419896a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410299				2022-12-28	WOS:000178909700031
J	Farmer, P				Farmer, P			Can transnational research be ethical in the developing world?	LANCET			English	Editorial Material									Harvard Univ, Sch Med, Boston, MA 02115 USA; Partners Hlth, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Partners Healthcare System	Farmer, P (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Churchill Larry R., 1997, SOCIAL MED READER, P310; Farmer P, 1996, EMERG INFECT DIS, V2, P259, DOI 10.3201/eid0204.960402; Farmer P.E, 2001, INFECT INEQUALITIES; *WHO, 2001, WORLD HLTH REP 2001, P144	4	32	32	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1266	1266		10.1016/S0140-6736(02)11357-2	http://dx.doi.org/10.1016/S0140-6736(02)11357-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414199				2022-12-28	WOS:000178827200006
J	Kirchhof, P; Eckardt, L; Loh, P; Weber, K; Fischer, RJ; Seidl, KH; Bocker, D; Breithardt, G; Haverkamp, W; Borggrefe, M				Kirchhof, P; Eckardt, L; Loh, P; Weber, K; Fischer, RJ; Seidl, KH; Bocker, D; Breithardt, G; Haverkamp, W; Borggrefe, M			Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial	LANCET			English	Article							TRANS-THORACIC IMPEDANCE; VENTRICULAR DEFIBRILLATION; DC CARDIOVERSION; FLUTTER; ENERGY; PREVALENCE; CARDIOLOGY; MECHANISM; STATEMENT; SUCCESS	Background External cardioversion is a readily available treatment for persistent atrial fibrillation. Although anatomical and electrophysiological considerations suggest that an anterior-posterior electrode position should create a more homogeneous shock-field gradient throughout the atria than an anterior-lateral position, both electrode positions are equally recommended for external cardioversion in current guidelines. We undertook a randomised trial comparing the two positions with the endpoint of successful cardioversion. Methods 108 consecutive patients (mean age 60 years [SD 16]) with persistent atrial fibrillation (median duration 5 months, range 0.1-120) underwent elective external cardioversion by a standardised step-up protocol with increasing shock strengths (50-360 J). Electrode positions were randomly assigned as anterior-lateral or anterior-posterior. If sinus rhythm was not achieved with 360 J energy, a single cross-over shock (360 J) was applied with the other electrode configuration. A planned interim analysis was done after these patients had been recruited; it was by intention to treat. Findings Cardioversion was successful in a higher proportion of the anterior-posterior than the anterior-lateral group (50 of 52 [96%] vs 44 of 56 [78%], difference 23.7% (95% CI 9.1-37.8, p=0.009). Cross-over from the anterior-lateral to the anterior-posterior electrode position was successful in eight of 12 patients, whereas cross-over in the other direction was not successful (two patients). After cross-over, cardioversion was successful in 102 of 108 randomised patients (94%). Interpretation An anterior-posterior electrode position is more effective than the anterior-lateral position for external cardioversion of persistent atrial fibrillation. These results should be considered in clinical practice, for the design of defibrillation electrode pads, and when guidelines for cardioversion of atrial fibrillation are updated.	Univ Munster, Dept Cardiol & Angiol, D-4400 Munster, Germany; Univ Munster, Inst Arteriosclerosis Res, D-4400 Munster, Germany; Univ Munster, Dept Med Informat & Biomath, D-4400 Munster, Germany; City Hosp Ludwigshafen, Dept Cardiol, Ludwigshafen, Germany; Univ Mannheim, Dept Cardiol & Angiol, Mannheim, Germany	University of Munster; University of Munster; University of Munster; Ludwigshafen Hospital; University of Mannheim	Kirchhof, P (corresponding author), Univ Kliniken Munster, Med Klin & Poliklin, D-48129 Munster, Germany.		Kirchhof, Paulus/AAT-7074-2021	Kirchhof, Paulus/0000-0002-1881-0197				Alp NJ, 2000, INT J CARDIOL, V75, P211, DOI 10.1016/S0167-5273(00)00326-0; [Anonymous], 1997, Cardiovasc Res, V35, P2; AYLWARD PE, 1985, J AM COLL CARDIOL, V6, P682, DOI 10.1016/S0735-1097(85)80131-5; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Botto GL, 1999, HEART, V82, P726, DOI 10.1136/hrt.82.6.726; Chen PS, 1998, J CARDIOVASC ELECTR, V9, P553, DOI 10.1111/j.1540-8167.1998.tb01848.x; Cox JL, 1996, ANN SURG, V224, P267, DOI 10.1097/00000658-199609000-00003; DILLON SM, 1999, CARDIAC ELECTROPHYSI, P423; EWY GA, 1992, CIRCULATION, V86, P1645, DOI 10.1161/01.CIR.86.5.1645; FELD GK, 1992, CIRCULATION, V86, P1233, DOI 10.1161/01.CIR.86.4.1233; Franz MR, 1997, J AM COLL CARDIOL, V30, P1785, DOI 10.1016/S0735-1097(97)00385-9; Gray RA, 1997, CIRCULATION, V95, P1038; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; Joglar JA, 2000, AM J CARDIOL, V86, P348, DOI 10.1016/S0002-9149(00)00932-2; Kannel WB, 1998, AM J CARDIOL, V82, p2N, DOI 10.1016/S0002-9149(98)00583-9; Kerber R E, 1996, Am J Cardiol, V78, P22, DOI 10.1016/S0002-9149(96)00562-0; KERBER RE, 1981, CIRCULATION, V63, P676, DOI 10.1161/01.CIR.63.3.676; KERBER RE, 1984, CIRCULATION, V70, P303, DOI 10.1161/01.CIR.70.2.303; KERBER RE, 1981, NEW ENGL J MED, V305, P658, DOI 10.1056/NEJM198109173051202; Levy S, 1998, EUR HEART J, V19, P1294, DOI 10.1053/euhj.1998.1050; LOWN B, 1962, JAMA-J AM MED ASSOC, V182, P548; Mathew TP, 1999, HEART, V81, P576, DOI 10.1136/hrt.81.6.576; Newton JC, 1999, J CARDIOVASC ELECTR, V10, P234, DOI 10.1111/j.1540-8167.1999.tb00666.x; PANTRIDGE JF, 1965, BRIT HEART J, V27, P128; Ricard P, 1997, AM J CARDIOL, V79, P815, DOI 10.1016/S0002-9149(96)00879-X; Saoudi N, 2001, J CARDIOVASC ELECTR, V12, P852, DOI 10.1046/j.1540-8167.2001.00852.x; Shah DC, 1997, CIRCULATION, V96, P3904; Walcott GP, 1997, PACE, V20, P422, DOI 10.1111/j.1540-8159.1997.tb06201.x; Wolf PA, 1996, AM HEART J, V131, P790, DOI 10.1016/S0002-8703(96)90288-4; YURCHAK PM, 1993, CIRCULATION, V88, P342, DOI 10.1161/01.CIR.88.1.342	31	154	160	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1275	1279		10.1016/S0140-6736(02)11315-8	http://dx.doi.org/10.1016/S0140-6736(02)11315-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414201				2022-12-28	WOS:000178827200008
J	Molyneux, A; Kerr, R; Stratton, I; Sandercock, P; Clarke, M; Shrimpton, J; Holman, R				Molyneux, A; Kerr, R; Stratton, I; Sandercock, P; Clarke, M; Shrimpton, J; Holman, R		ISAT Collaborative Grp	International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial	LANCET			English	Article							UNRUPTURED CEREBRAL ANEURYSMS; DOSE TIRILAZAD MESYLATE; SURGICAL-TREATMENT; DOUBLE-BLIND; COMMUNICATING ANEURYSMS; HEMORRHAGE; EMBOLIZATION; OUTCOMES; STROKE; ARTERY	Background Endovascular detachable coil treatment is being increasingly used as an alternative to craniotomy and clipping for some ruptured intracranial aneurysms, although the relative benefits of these two approaches have yet to be established. We undertook a randomised, multicentre trial to compare the safety and efficacy of endovascular coiling with standard neurosurgical clipping for such aneurysms judged to be suitable for both treatments. Methods We enrolled 2143 patients with ruptured intracranial aneurysms and randomly assigned them to neurosurgical clipping (n=1070) or endovascular treatment by detachable platinum coils (n=1073). Clinical outcomes were assessed at 2 months and at 1 year with interim ascertainment of rebleeds and death. The primary outcome was the proportion of patients with a modified Rankin scale score of 3-6 (dependency or death) at 1 year. Trial recruitment was stopped by the steering committee after a planned interim analysis. Analysis was per protocol. Findings 190 of 801 (23.7%) patients allocated endovascular treatment were dependent or dead at 1 year compared with 243 of 793 (30.6%) allocated neurosurgical treatment (p=0.0019). The relative and absolute risk reductions in dependency or death after allocation to an endovascular versus neurosurgical treatment were 22.6% (95% CI 8.9-34-2) and 6.9% (2.5-11.3), respectively. The risk of rebleeding from the ruptured aneurysm after 1 year was two per 1276 and zero per 1081 patient-years for patients allocated endovascular and neurosurgical treatment, respectively. Interpretation In patients with a ruptured intracranial aneurysm, for which endovascular coiling and neurosurgical clipping are therapeutic options, the outcome in terms of survival free of disability at 1 year is significantly better with endovascular coiling. The data available to date suggest that the long-term risks of further bleeding from the treated aneurysm are low with either therapy, although somewhat more frequent with endovascular coiling.	Radcliffe Infirm, Neurovasc Res Unit, ISAT, Oxford OX2 6HE, England	Radcliffe Infirmary	Molyneux, A (corresponding author), Radcliffe Infirm, Neurovasc Res Unit, ISAT, Oxford OX2 6HE, England.	isat@radiology.ox.ac.uk; isat@radiology.ox.ac.uk	sandercock, peter/GQI-3167-2022; stratton, irene/AAZ-3627-2020	sandercock, peter/0000-0001-8484-0135; stratton, irene/0000-0003-1172-7865				Alexander MJ, 2002, NEUROSURGERY, V50, P899, DOI 10.1097/00006123-200204000-00045; Bardach NS, 2002, STROKE, V33, P1851, DOI 10.1161/01.STR.0000019126.43079.7B; Brilstra EH, 1999, STROKE, V30, P470, DOI 10.1161/01.STR.30.2.470; BYRNE JV, 1995, J NEUROL NEUROSUR PS, V59, P616, DOI 10.1136/jnnp.59.6.616; Byrne JV, 1999, J NEUROSURG, V90, P656, DOI 10.3171/jns.1999.90.4.0656; Dorman PJ, 1997, STROKE, V28, P1883, DOI 10.1161/01.STR.28.10.1883; DRAKE CG, 1988, J NEUROSURG, V68, P985; FEUERBERG I, 1987, J NEUROSURG, V66, P30, DOI 10.3171/jns.1987.66.1.0030; GUGLIELMI G, 1991, J NEUROSURG, V75, P8, DOI 10.3171/jns.1991.75.1.0008; Haley EC, 1997, J NEUROSURG, V86, P467, DOI 10.3171/jns.1997.86.3.0467; Johnston SC, 1999, NEUROLOGY, V52, P1799, DOI 10.1212/WNL.52.9.1799; Johnston SC, 2001, STROKE, V32, P597, DOI 10.1161/01.STR.32.3.597; Koivisto T, 2000, STROKE, V31, P2369, DOI 10.1161/01.STR.31.10.2369; Lanzino G, 1999, J NEUROSURG, V90, P1011, DOI 10.3171/jns.1999.90.6.1011; Lanzino G, 1999, J NEUROSURG, V90, P1018, DOI 10.3171/jns.1999.90.6.1018; Lempert TE, 2000, STROKE, V31, P100, DOI 10.1161/01.STR.31.1.100; LINDLEY RI, 1994, CEREBROVASC DIS, V4, P314, DOI 10.1159/000108501; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; MCKISSOC.W, 1965, LANCET, V1, P873; MCKISSOCK W, 1962, LANCET, V2, P417; MCKISSOCK W, 1960, LANCET, V1, P1203; Molyneux AJ, PROTOCOL 99PRT18 INT; Moret J, 1997, J NEURORADIOLOGY, V24, P30; NICHOLS DA, 1993, J NEUROSURG, V79, P1, DOI 10.3171/jns.1993.79.1.0001; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P772, DOI 10.1136/jnnp.72.6.772; RANKIN J, 1957, Scott Med J, V2, P200; Regli L, 1999, J NEUROSURG, V90, P1025, DOI 10.3171/jns.1999.90.6.1025; Vanninen R, 1999, RADIOLOGY, V211, P325, DOI 10.1148/radiology.211.2.r99ap06325; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	30	2470	2614	5	102	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 26	2002	360	9342					1267	1274		10.1016/S0140-6736(02)11314-6	http://dx.doi.org/10.1016/S0140-6736(02)11314-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414200				2022-12-28	WOS:000178827200007
J	Atlas, RM				Atlas, RM			Public health - National security and the biological research community	SCIENCE			English	Editorial Material									Univ Louisville, Ctr Deterrence Biowarfare & Bioterrorism, Louisville, KY 40292 USA	University of Louisville	Atlas, RM (corresponding author), Univ Louisville, Ctr Deterrence Biowarfare & Bioterrorism, Louisville, KY 40292 USA.							BACON F, 1901, IDEAL COMMONWEALTHS; Block SM, 2002, SCIENCE, V297, P769; CARD AH, 2002, COMMUNICATION   0319; Cello J, 2002, SCIENCE, V297, P1016, DOI 10.1126/science.1072266; Couzin J, 2002, SCIENCE, V297, P749, DOI 10.1126/science.297.5582.749; FAUCI T, 2002, EXPANDED BIODEFENSE; Fredrickson DS., 2001, RECOMBINANT DNA CONT; Jackson RJ, 2001, J VIROL, V75, P1205, DOI 10.1128/JVI.75.3.1205-1210.2001; KIMBERLY L, 2002, COMMUNICATION   0319; LANE N, 2000, SCI COMM NAT SEC WOR; LEO A, 2002, TECHNOL REV     0620, P60; MIT, 2002, PUBL INT REP AD HOC; *NAT SEC DEC DIR 1, 1985, NAT POL TRANSF SCI T; PETSKO GA, 2002, GENOME SCI, V3; POSTE G, 2002, PROSPECT         MAY, P48; RICE C, 2001, COMMUNICATION   1101; *SCI COMM NAT SEC, 1982, REP; SKOLNIKOFF EB, 2002, CHRON HIGH ED   0510; 2002, ECONOMIST       0309, P75	19	16	18	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					753	754		10.1126/science.1078329	http://dx.doi.org/10.1126/science.1078329			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399568				2022-12-28	WOS:000178791200031
J	Lee, TI; Rinaldi, NJ; Robert, F; Odom, DT; Bar-Joseph, Z; Gerber, GK; Hannett, NM; Harbison, CT; Thompson, CM; Simon, I; Zeitlinger, J; Jennings, EG; Murray, HL; Gordon, DB; Ren, B; Wyrick, JJ; Tagne, JB; Volkert, TL; Fraenkel, E; Gifford, DK; Young, RA				Lee, TI; Rinaldi, NJ; Robert, F; Odom, DT; Bar-Joseph, Z; Gerber, GK; Hannett, NM; Harbison, CT; Thompson, CM; Simon, I; Zeitlinger, J; Jennings, EG; Murray, HL; Gordon, DB; Ren, B; Wyrick, JJ; Tagne, JB; Volkert, TL; Fraenkel, E; Gifford, DK; Young, RA			Transcriptional regulatory networks in Saccharomyces cerevisiae	SCIENCE			English	Article							YEAST-CELL-CYCLE; GENE-EXPRESSION; BUDDING YEAST; ENVIRONMENTAL-CHANGES; PROTEINS; BINDING; BIOSYNTHESIS; ASSOCIATION; PROFILES; PROGRAM	We have determined how most of the transcriptional regulators encoded in the eukaryote Saccharomyces cerevisiae associate with genes across the genome in living cells. Just as maps of metabolic networks describe the potential pathways that may be used by a cell to accomplish metabolic processes, this network of regulator-gene interactions describes potential pathways yeast cells can use to regulate global gene expression programs. We use this information to identify network motifs, the simplest units of network architecture, and demonstrate that an automated process can use motifs to assemble a transcriptional regulatory network structure. Our results reveal that eukaryotic cellular functions are highly connected through networks of transcriptional regulators that regulate other transcriptional regulators.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Comp Sci Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	young@wi.mit.edu	Young, Richard A/F-6495-2012; Bar-Joseph, Ziv/GWN-2754-2022; Rinaldi, Nicola J/J-5858-2017; Robert, Francois/D-2316-2012; Yang, Chen/G-1379-2010; Pillay, Nischalan/F-9536-2012	Young, Richard A/0000-0001-8855-8647; Rinaldi, Nicola J/0000-0002-0358-0747; Simon, Itamar/0000-0002-8517-1903; Odom, Duncan/0000-0001-6201-5599; Fraenkel, Ernest/0000-0001-9249-8181; Tagne, Jean-Bosco/0000-0003-1830-9156; Bar-Joseph, Ziv/0000-0003-3430-6051				BARJOSEPH Z, 2002, 6 ANN INT C RES COMP, P39; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Bouquin N, 1999, MOL BIOL CELL, V10, P3389, DOI 10.1091/mbc.10.10.3389; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Devaux F, 2002, FEBS LETT, V515, P25, DOI 10.1016/S0014-5793(02)02387-6; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Garvie CW, 2001, MOL CELL, V8, P937, DOI 10.1016/S1097-2765(01)00392-6; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GOLDBETER A, 1984, J BIOL CHEM, V259, P14441; Guelzim N, 2002, NAT GENET, V31, P60, DOI 10.1038/ng873; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; Ho W, 1999, MOL CELL BIOL, V19, P5267; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; KAWASAKI Y, 1990, J BACTERIOL, V172, P6145, DOI 10.1128/jb.172.10.6145-6147.1990; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Lopez MC, 2000, J BACTERIOL, V182, P4970, DOI 10.1128/JB.182.17.4970-4978.2000; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; Madhani HD, 1999, P NATL ACAD SCI USA, V96, P12530, DOI 10.1073/pnas.96.22.12530; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; NISHIMURA H, 1992, FEBS LETT, V297, P155, DOI 10.1016/0014-5793(92)80349-L; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; PTASHNE M, 2002, GENES SIGNALS; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101	45	2192	2296	6	143	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					799	804		10.1126/science.1075090	http://dx.doi.org/10.1126/science.1075090			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399584				2022-12-28	WOS:000178791200051
J	Adam, D				Adam, D			Fatal rocket accident puts question mark over Soyuz's safety	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					766	766		10.1038/419766a	http://dx.doi.org/10.1038/419766a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397313	Bronze			2022-12-28	WOS:000178769800003
J	Steiner, TJ; Fontebasso, M				Steiner, TJ; Fontebasso, M			Headache	BMJ-BRITISH MEDICAL JOURNAL			English	Review							EPIDEMIOLOGY; WITHDRAWAL; POPULATION; FEATURES		Univ London Imperial Coll Sci Technol & Med, Div Neurosci, London W6 8RP, England; Front St Surg, York YO24 3BZ, N Yorkshire, England	Imperial College London	Steiner, TJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Neurosci, London W6 8RP, England.	t.steiner@ic.ac.uk						Amer Assoc Study Headache, 1998, HEADACHE, V38, P736; [Anonymous], 2000, HEADACHES; *BRIT ASS STUD HEA, 2001, GUID ALL DOCT DIAGN; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; DIENER HC, 1989, J NEUROL, V236, P9, DOI 10.1007/BF00314210; DUARTE RA, 1995, AM FAM PHYSICIAN, V51, P203; Ferrari MD, 1998, LANCET, V351, P1043, DOI 10.1016/S0140-6736(97)11370-8; Frishberg BM, 2000, EVIDENCE BASED GUIDE; HERING R, 1991, LANCET, V337, P1442, DOI 10.1016/0140-6736(91)93129-W; HOPKINS A, 1989, J NEUROL NEUROSUR PS, V52, P436, DOI 10.1136/jnnp.52.4.436; *INT HEAD SOC HEAD, 1988, CEPHALALGIA S7, V8, pS1; KRYST S, 1994, HEADACHE, V34, P344, DOI 10.1111/j.1526-4610.1994.hed3406344.x; LANCE F, 1988, HEADACHE, V28, P61, DOI 10.1111/j.1526-4610.1988.hed2801060_2.x; Limmroth V, 1999, LANCET, V353, P378, DOI 10.1016/S0140-6736(05)74950-3; MacGregor EA, 1997, NEUROL CLIN, V15, P125, DOI 10.1016/S0733-8619(05)70299-1; Mulleners WM, 1998, CEPHALALGIA, V18, P52, DOI 10.1046/j.1468-2982.1998.1801052.x; Osterhaus J T, 1992, Pharmacoeconomics, V2, P67, DOI 10.2165/00019053-199202010-00008; Ramadan NM, 1997, CEPHALALGIA, V17, P73, DOI 10.1046/j.1468-2982.1997.1702073.x; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; Schnider P, 1996, CEPHALALGIA, V16, P481, DOI 10.1046/j.1468-2982.1996.1607481.x; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1007/s11916-010-0146-2; SILBERSTEIN SD, 1994, HEADACHE, V34, P1, DOI 10.1111/j.1526-4610.1994.hed3401001.x; Smetana GW, 2000, ARCH INTERN MED, V160, P2729, DOI 10.1001/archinte.160.18.2729; Srikiatkhachorn A, 1997, HEADACHE, V37, P277, DOI 10.1046/j.1526-4610.1997.3705277.x; STEINER T, 2000, CHEM DRUGGIST S, V253, pR5; WHO, 2001, WORLD HLTH REPORT 20; Wiles CM, 1996, J ROY COLL PHYS LOND, V30, P426	27	14	14	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 19	2002	325	7369					881	886		10.1136/bmj.325.7369.881	http://dx.doi.org/10.1136/bmj.325.7369.881			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386043	Green Published			2022-12-28	WOS:000178793000025
J	Kroger, N; Lorenz, S; Brunner, E; Sumper, M				Kroger, N; Lorenz, S; Brunner, E; Sumper, M			Self-assembly of highly phosphorylated silaffins and their function in biosilica morphogenesis	SCIENCE			English	Article							DIATOM BIOSILICA; SILICA; DEPOSITION; PROTEINS; PEPTIDES	Silaffins are uniquely modified peptides that have been implicated in the biogenesis of diatom biosilica. A method that avoids the harsh anhydrous hydrogen fluoride treatment commonly used to dissolve biosilica allows the extraction of silaffins in their native state. The native silaffins carry further posttranslational modifications in addition to their polyamine moieties. Each serine residue was phosphorylated, and this high level of phosphorylation is essential for biological activity. The zwitterionic structure of native silaffins enables the formation of supramolecular assemblies. Time-resolved analysis of silica morphogenesis in vitro detected a plastic silaffin-silica phase, which may represent a building material for diatom biosilica.	Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany; Univ Regensburg, Inst Biophys & Phys Biochem, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg	Sumper, M (corresponding author), Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany.		Lorenz, Sonja/AAL-4499-2020	Lorenz, Sonja/0000-0002-9639-2381				Bencini A, 1999, COORDIN CHEM REV, V188, P97, DOI 10.1016/S0010-8545(98)00243-4; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHIAPPINO ML, 1977, PROTOPLASMA, V93, P205, DOI 10.1007/BF01275654; Crawford CG, 2001, J AM WATER RESOUR AS, V37, P1, DOI 10.1111/j.1752-1688.2001.tb05470.x; Kroger N, 1999, SCIENCE, V286, P1129, DOI 10.1126/science.286.5442.1129; Kroger N, 2000, P NATL ACAD SCI USA, V97, P14133, DOI 10.1073/pnas.260496497; Kroger N, 2001, J BIOL CHEM, V276, P26066, DOI 10.1074/jbc.M102093200; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; NAKAJIMA T, 1970, BIOCHEM BIOPH RES CO, V39, P28, DOI 10.1016/0006-291X(70)90752-7; Noll F, 2002, NANO LETT, V2, P91, DOI 10.1021/nl015581k; Parkinson J, 1999, TRENDS BIOTECHNOL, V17, P190, DOI 10.1016/S0167-7799(99)01321-9; Pickett-Heaps J., 1990, PROGR PHYCOLOGICAL R, V7, P1; Round F.E., 1990, DIATOMS; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID AMM, 1979, PROTOPLASMA, V100, P267, DOI 10.1007/BF01279316; Sumper M, 2002, SCIENCE, V295, P2430, DOI 10.1126/science.1070026; SWIFT DM, 1992, J PHYCOL, V28, P202, DOI 10.1111/j.0022-3646.1992.00202.x; Vrieling EG, 1999, J PHYCOL, V35, P548, DOI 10.1046/j.1529-8817.1999.3530548.x	20	612	641	8	207	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					584	586		10.1126/science.1076221	http://dx.doi.org/10.1126/science.1076221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386330				2022-12-28	WOS:000178634800036
J	Gottdiener, JS; McClelland, RL; Marshall, R; Shemanski, L; Furberg, CD; Kitzman, DW; Cushman, M; Polak, J; Gardin, JM; Gersh, BJ; Aurigemma, GP; Manolio, TA				Gottdiener, JS; McClelland, RL; Marshall, R; Shemanski, L; Furberg, CD; Kitzman, DW; Cushman, M; Polak, J; Gardin, JM; Gersh, BJ; Aurigemma, GP; Manolio, TA			Outcome of congestive heart failure in elderly persons: Influence of left ventricular systolic function - The cardiovascular health study	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM PROGNOSIS; EJECTION FRACTION; MYOCARDIAL-INFARCTION; PULMONARY-EDEMA; MORTALITY; PREVALENCE; DYSFUNCTION; MASS; AGE; HYPERTENSION	Background: Most persons with congestive heart failure are elderly, and many elderly persons with congestive heart failure have normal left ventricular systolic function. Objective: To evaluate the relationship between left ventricular systolic function and outcome of congestive heart failure in elderly persons. Design: Population-based longitudinal study of coronary heart disease and stroke. Setting: Four U.S. sites: Forsyth County, North Carolina; Sacramento County, California; Allegheny County, Pennsylvania; and Washington County, Maryland. Participants: 5888 persons who were at least 65 years of age and were recruited from the community. Measurements: Total mortality and cardiovascular morbidity and mortality. Results: Of 5532 participants, 269 (4.9%) had congestive heart failure. Among these, left ventricular function was normal in 63%, borderline decreased in 15%, and overtly impaired in 22%. The mortality rate was 25 deaths per 1000 person-years in the reference group (no congestive heart failure and normal left ventricular function at baseline); 154 deaths per 1000 person-years in participants with congestive heart failure and impaired left ventricular systolic function; 87 and 115 deaths per 1000 person-years in participants with congestive heart failure and normal or borderline systolic function, respectively; and 89 deaths per 1000 person-years in persons with impaired left ventricular function but no congestive heart failure. Although the risk for death from congestive heart failure was lower in persons with normal systolic function than in those with impaired function, more deaths were associated with normal systolic function because more persons with heart failure fall into this category. Conclusions: Community-dwelling elderly persons, especially those with impaired left ventricular function, have a substantial risk for death from congestive heart failure. However, more deaths occur from heart failure in persons with normal systolic function because left ventricular function is more often normal than impaired in elderly persons with heart failure.	St Francis Hosp, Div Cardiol, Roslyn, NY 11576 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Georgetown Univ Hosp, Washington, DC 20007 USA; Univ Washington, Seattle, WA 98195 USA; Wake Forest Univ, Winston Salem, NC 27109 USA; Univ Vermont, Burlington, VT USA; Tufts Univ New England Med Ctr, Boston, MA USA; St John Hosp & Med Ctr, Detroit, MI USA; Univ Massachusetts, Med Ctr, Worcester, MA USA; NHLBI, Bethesda, MD 20892 USA	Mayo Clinic; Georgetown University; University of Washington; University of Washington Seattle; Wake Forest University; University of Vermont; Tufts Medical Center; St. John Hospital & Medical Center; University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Gottdiener, JS (corresponding author), St Francis Hosp, Div Cardiol, 100 Port Washington Blvd, Roslyn, NY 11576 USA.	gottdien@ziplink.net			DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085085, N01HC085083, N01HC085080, N01HC085081, N01HC085079, N01HC085086, N01HC085084, N01HC085082, N01HC015103] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85086, N01-HC-15103, N01-HC-85079-85086, N01-HC-85085, N01-HC-85084, N01-HC-85083, N01-HC-85082, N01-HC-85081, N01-HC-85080] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON B, 1993, AM HEART J, V126, P632, DOI 10.1016/0002-8703(93)90414-5; Aurigemma GP, 2001, J AM COLL CARDIOL, V37, P1042, DOI 10.1016/S0735-1097(01)01110-X; BONOW RO, 1992, ANN INTERN MED, V117, P502, DOI 10.7326/0003-4819-117-6-502; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; BRAUNWALD E, 1992, HEART DISEASE, P1179; Carson P, 1996, J AM COLL CARDIOL, V27, P642, DOI 10.1016/0735-1097(95)00503-X; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; COHN JN, 1990, CIRCULATION, V81, P48; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; GAASCH WH, 1994, JAMA-J AM MED ASSOC, V271, P1276; Gandhi SK, 2001, NEW ENGL J MED, V344, P17, DOI 10.1056/NEJM200101043440103; Gardin J M, 1992, J Am Soc Echocardiogr, V5, P63; Gardin JM, 1997, HYPERTENSION, V29, P1095, DOI 10.1161/01.HYP.29.5.1095; GARDIN JM, 1995, CIRCULATION, V91, P1739, DOI 10.1161/01.CIR.91.6.1739; Gottdiener JS, 2000, J AM COLL CARDIOL, V35, P1628, DOI 10.1016/S0735-1097(00)00582-9; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAMBARA H, 1993, CLIN CARDIOL, V16, P872, DOI 10.1002/clc.4960161207; KITZMAN DW, 1991, J AM COLL CARDIOL, V17, P1065, DOI 10.1016/0735-1097(91)90832-T; Kitzman DW, 2001, AM J CARDIOL, V87, P413, DOI 10.1016/S0002-9149(00)01393-X; KITZMAN DW, 1991, J AM COLL CARDIOL, V18, P1243, DOI 10.1016/0735-1097(91)90542-H; Kitzman OW, 1994, DIASTOLIC RELAXATION, P295; Kramer K, 2000, AM HEART J, V140, P451, DOI 10.1067/mhj.2000.108828; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; LILIENFELD AM, 1980, F EPIDEMIOLOGY, P217; MITTELMARK MB, 1993, AM J EPIDEMIOL, V137, P311, DOI 10.1093/oxfordjournals.aje.a116678; *MMWR, 1994, MMWR-MORBID MORTAL W, V43, P77; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; Mosterd A, 1999, EUR HEART J, V20, P447, DOI 10.1053/euhj.1998.1239; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; Opasich C, 2000, AM J CARDIOL, V86, P353, DOI 10.1016/S0002-9149(00)00934-6; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pernenkil R, 1997, AM J CARDIOL, V79, P216, DOI 10.1016/S0002-9149(96)00719-9; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; POWELL AC, 1993, CIRCULATION, V88, P1083, DOI 10.1161/01.CIR.88.3.1083; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; Rautaharju PM, 1996, HYPERTENSION, V28, P8, DOI 10.1161/01.HYP.28.1.8; Rich MW, 1997, J AM GERIATR SOC, V45, P968, DOI 10.1111/j.1532-5415.1997.tb02968.x; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282; Senni M, 1997, MAYO CLIN PROC, V72, P453, DOI 10.4065/72.5.453; SETARO JF, 1992, AM J CARDIOL, V69, P1212, DOI 10.1016/0002-9149(92)90938-U; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Vasan RS, 2000, CIRCULATION, V101, P2118, DOI 10.1161/01.CIR.101.17.2118; Vasan RS, 1999, J AM COLL CARDIOL, V33, P1948, DOI 10.1016/S0735-1097(99)00118-7; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; WEI JY, 1992, NEW ENGL J MED, V327, P1735, DOI 10.1056/NEJM199212103272408; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	53	346	358	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2002	137	8					631	639		10.7326/0003-4819-137-8-200210150-00006	http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604WL	12379062				2022-12-28	WOS:000178644000001
J	Lucas, A; Morley, R; Stephenson, T; Elias-Jones, A				Lucas, A; Morley, R; Stephenson, T; Elias-Jones, A			Long-chain polyunsaturated fatty acids and infant formula	LANCET			English	Letter									MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England; Univ Melbourne, Dept Paediat, Clin Epidemiol & Biostat Unit, Parkville, Vic 3052, Australia; Nottingham Univ NHS Trust, Queens Med Ctr, Dept Child Hlth, Nottingham, England; Leicester Royal Infirm, Dept Paediat, Leicester, Leics, England	University of London; University College London; University of Melbourne; Nottingham University Hospital NHS Trust; University of Nottingham; University of Leicester	Lucas, A (corresponding author), MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England.							Lucas A, 1999, LANCET, V354, P1948, DOI 10.1016/S0140-6736(99)02314-4	1	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1178	1178		10.1016/S0140-6736(02)11228-1	http://dx.doi.org/10.1016/S0140-6736(02)11228-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387988				2022-12-28	WOS:000178632000040
J	Bloxham, J; Zatman, S; Dumberry, M				Bloxham, J; Zatman, S; Dumberry, M			The origin of geomagnetic jerks	NATURE			English	Article							SECULAR VARIATION; CORE; FLUID; FIELD	Geomagnetic jerks, which in the second half of the twentieth century occurred in 1969 (refs 1, 2), 1978 (refs 3, 4), 1991 (ref. 5) and 1999 (ref. 6), are abrupt changes in the second time-derivative (secular acceleration) of the Earth's magnetic field. Jerks separate periods of almost steady secular acceleration, so that the first time-derivative (secular variation) appears as a series of straight-line segments separated by geomagnetic jerks. The fact that they represent a reorganization of the secular variation implies that they are of internal origin (as has been established through spherical harmonic analysis(7)), and their short timescale implies that they are due to a change in the fluid flow at the surface of the Earth's core (as has also been established through mapping the time-varying flow at the core surface(8)). However, little is understood of their physical origin. Here we show that geomagnetic jerks can be explained by the combination of a steady flow and a simple time-varying, axisymmetric, equatorially symmetric, toroidal zonal flow. Such a flow is consistent with torsional oscillations in the Earth's core, which are simple oscillatory flows in the core that are expected on theoretical grounds(9), and observed in both core flow models(10) and numerical dynamo models(11).	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA	Harvard University; Washington University (WUSTL)	Bloxham, J (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.	Jeremy_Bloxham@harvard.edu		Bloxham, Jeremy/0000-0001-8556-2675				BLOXHAM J, 1992, J GEOPHYS RES-SOL EA, V97, P19565, DOI 10.1029/92JB01469; Bullard E., 1954, PHILOS T R SOC A, V247, P213; COURTILLOT V, 1978, CR ACAD SCI D NAT, V287, P1095; COURTILLOT V, 1984, NATURE, V311, P709, DOI 10.1038/311709a0; Davis RG, 1997, PHYS EARTH PLANET IN, V103, P181, DOI 10.1016/S0031-9201(97)00032-0; GAVORET J, 1986, J GEOPHYS RES-SOLID, V91, P4787, DOI 10.1029/JB091iB05p04787; GUBBINS D, 1986, GEOPHYS J INT, V86, P603, DOI 10.1111/j.1365-246X.1986.tb03846.x; Jackson A, 1997, PHYS EARTH PLANET IN, V103, P293, DOI 10.1016/S0031-9201(97)00039-3; Kuang WJ, 1999, PHYS EARTH PLANET IN, V116, P65, DOI 10.1016/S0031-9201(99)00116-8; Le Huy M, 2000, EARTH PLANETS SPACE, V52, P163, DOI 10.1186/BF03351625; Macmillan S, 1996, EARTH PLANET SC LETT, V137, P189, DOI 10.1016/0012-821X(95)00214-W; Malin S.R.C., 1983, SCI CONTRIBUTIONS CO; MALIN SRC, 1982, NATURE, V296, P726, DOI 10.1038/296726a0; Mandea M, 2000, EARTH PLANET SC LETT, V183, P369, DOI 10.1016/S0012-821X(00)00284-3; ROBERTS PH, 1965, J GEOMAGN GEOELECTR, V17, P137, DOI 10.5636/jgg.17.137; TAYLOR JB, 1963, PROC R SOC LON SER-A, V274, P274, DOI 10.1098/rspa.1963.0130; WADDINGTON R, 1995, GEOPHYS J INT, V122, P326, DOI 10.1111/j.1365-246X.1995.tb03556.x; Zatman S, 1997, NATURE, V388, P760, DOI 10.1038/41987; Zatman S, 1998, GEODYNAMICS, V28, P183	19	115	117	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	2002	420	6911					65	68		10.1038/nature01134	http://dx.doi.org/10.1038/nature01134			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422214				2022-12-28	WOS:000179068100036
J	Kitzman, DW; Little, WC; Brubaker, PH; Anderson, RT; Hundley, WG; Marburger, CT; Brosnihan, B; Morgan, TM; Stewart, KP				Kitzman, DW; Little, WC; Brubaker, PH; Anderson, RT; Hundley, WG; Marburger, CT; Brosnihan, B; Morgan, TM; Stewart, KP			Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRAIN NATRIURETIC PEPTIDE; PATIENTS GREATER-THAN-OR-EQUAL-TO-65 YEARS; PLASMA NOREPINEPHRINE; EJECTION FRACTION; ELDERLY-PATIENTS; EXERCISE; DYSFUNCTION; MINNESOTA; QUESTIONNAIRE; PREVALENCE	Context Many older patients with symptoms of congestive heart failure have a preserved left ventricular ejection fraction (LVEF). However, the pathophysiology of this disorder, presumptively termed diastolic heart failure (DHF), is not well characterized and it is unknown whether it represents true heart failure. Objective To assess the 4 key pathophysiological domains that characterize classic heart failure by systematically performing measurements in older patients with presumed DHF and comparing these results with those from age-matched healthy volunteers and patients with classic systolic heart failure (SHF). Design and Setting Observational clinical investigation conducted in 1998 in a general community and teaching hospital in Winston-Salem, NC. Participants A total of 147 subjects aged at least 60 years. Fifty-nine had isolated DHF defined as clinically presumed heart failure, LVEF of at least 50%, and no evidence of significant coronary, valvular, or pulmonary disease. Sixty had typical SHF (LVEF :less than or equal to35%). Twenty-eight were age-matched healthy volunteer controls. Main Outcome Measures Left ventricular structure and function, exercise capacity, neuroendocrine function, and quality of life. Results By echocardiography, mean (SE) LVEF was 60% (2%) inpatients with DHF vs 31% (2%) in those with SHF and 54% (2%) in controls. Mean (SE) LV mass-volume ratio was markedly increased in patients with DHF (2.12 [0.14] g/mL) vs those with SHF (1.22 [0.14] g/mL) (P<.001) and vs controls (1.49 [0.17] g/mL) (P=.002). Peak oxygen consumption by expired gas analysis during cycle ergometry was similar in the DHF and SHF groups (14.2 [0.5] and 13.1 [0.5] mL/kg per minute, respectively; P=.40) and in both was markedly reduced compared with healthy controls (19.9 [0.7] mL/kg per minute) (P=.001 for both). Ventilatory anaerobic threshold was similar in the DHF and SHF groups (9.1 [0.3] and 8.7 [0.3] mL/kg per minute, respectively; P<.001) and in both was reduced compared with healthy controls (11.5 [0.4] mL/kg per minute) (P<.001). Norepinephrine levels were similar in the DHF (306 [64] pg/mL) and SHF (287 [62] pg/mL) groups (P=.56) and in both were markedly increased vs healthy controls (169 [80] pg/mL) (P=.007 and .03, respectively). Brain natriuretic peptide was substantially increased in both the DHF (56 [30] pg/mL) and the SHF (154 [28] pg/mL) groups compared with healthy controls (3 [38] pg/mL) (P=.02 and .001, respectively). Quality-of-life decrement score as assessed by the Minnesota Living with Heart Failure Questionnaire was substantially increased from the benchmark score of 10 in both groups (SHF: 43.8 [3.9]; DHF: 24.8 [4.4]). Conclusion Patients with isolated DHF have similar though not as severe pathophysiologic characteristics compared with patients with typical SHF, including severely reduced exercise capacity, neuroendocrine activation, and impaired quality of life.	Wake Forest Univ, Bowman Gray Sch Med, Cardiol Sect, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Sect Gerontol, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Div Surg, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University	Kitzman, DW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Cardiol Sect, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dkitzman@wfubmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018915, P60AG010484, R01AG012257, R37AG018915, P30AG021332] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR07122] Funding Source: Medline; NIA NIH HHS [P60AG10484, P30 AG021332, AG18915, AG12257] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aurigemma GP, 2001, J AM COLL CARDIOL, V37, P1042, DOI 10.1016/S0735-1097(01)01110-X; Banerjee P, 2002, J AM COLL CARDIOL, V39, P138, DOI 10.1016/S0735-1097(01)01704-1; Benedict CR, 1996, CIRCULATION, V94, P690, DOI 10.1161/01.CIR.94.4.690; Bettencourt P, 2000, CARDIOLOGY, V93, P19, DOI 10.1159/000006997; BRAUNWALD E, 1991, NEW ENGL J MED, V325, P351, DOI 10.1056/NEJM199108013250508; Caruana L, 2000, BRIT MED J, V321, P215, DOI 10.1136/bmj.321.7255.215; Chen CH, 1998, J AM COLL CARDIOL, V32, P1221, DOI 10.1016/S0735-1097(98)00374-X; Clarkson PBM, 1996, CIRCULATION, V93, P2037, DOI 10.1161/01.CIR.93.11.2037; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Cowie MR, 1999, EUR HEART J, V20, P421, DOI 10.1053/euhj.1998.1280; Devereux RB, 2000, AM J CARDIOL, V86, P1090, DOI 10.1016/S0002-9149(00)01165-6; EISENACH JC, 1992, ANESTHESIOLOGY, V77, P522, DOI 10.1097/00000542-199209000-00018; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; Gandhi SK, 2001, NEW ENGL J MED, V344, P17, DOI 10.1056/NEJM200101043440103; Gottdiener JS, 2000, J AM COLL CARDIOL, V35, P1628, DOI 10.1016/S0735-1097(00)00582-9; Grossman W, 2000, CIRCULATION, V101, P2020, DOI 10.1161/01.CIR.101.17.2020; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Hundley WG, 2001, J AM COLL CARDIOL, V38, P796, DOI 10.1016/S0735-1097(01)01447-4; Kaminsky LA, 2000, AM J CARDIOL, V85, P1385, DOI 10.1016/S0002-9149(00)00778-5; KITZMAN DW, 1991, J AM COLL CARDIOL, V17, P1065, DOI 10.1016/0735-1097(91)90832-T; Kitzman DW, 2001, AM J CARDIOL, V87, P413, DOI 10.1016/S0002-9149(00)01393-X; KITZMAN DW, 1991, J AM COLL CARDIOL, V18, P1243, DOI 10.1016/0735-1097(91)90542-H; Kitzman DW, 2000, CLIN GERIATR MED, V16, P489, DOI 10.1016/S0749-0690(05)70025-2; LANG CC, 1994, AM HEART J, V127, P1635, DOI 10.1016/0002-8703(94)90401-4; Lubien E, 2002, CIRCULATION, V105, P595, DOI 10.1161/hc0502.103010; Marburger CT, 1998, AM J CARDIOL, V82, P905, DOI 10.1016/S0002-9149(98)00502-5; Mars F, 1998, CAH PSYCHOL COGN, V17, P1064; RECTOR TS, 1993, AM J CARDIOL, V71, P1106, DOI 10.1016/0002-9149(93)90582-W; RECTOR TS, 1992, AM HEART J, V124, P1017, DOI 10.1016/0002-8703(92)90986-6; Rector TS, 1987, HEART FAIL, V3, P198; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; ROSS RD, 1987, AM J CARDIOL, V60, P1411, DOI 10.1016/0002-9149(87)90635-7; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282; Vasan RS, 2001, NEW ENGL J MED, V344, P56, DOI 10.1056/NEJM200101043440111; Vasan RS, 2000, CIRCULATION, V101, P2118, DOI 10.1161/01.CIR.101.17.2118; Vasan RS, 1999, J AM COLL CARDIOL, V33, P1948, DOI 10.1016/S0735-1097(99)00118-7; Warner JG, 1999, J AM COLL CARDIOL, V33, P1567, DOI 10.1016/S0735-1097(99)00048-0; Zile MR, 2001, CIRCULATION, V104, P779, DOI 10.1161/hc3201.094226	39	609	640	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2144	2150		10.1001/jama.288.17.2144	http://dx.doi.org/10.1001/jama.288.17.2144			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413374	Bronze			2022-12-28	WOS:000179048100025
J	Esson, ML; Schrier, RW				Esson, ML; Schrier, RW			Diagnosis and treatment of acute tubular necrosis	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE-RENAL-FAILURE; INTENSIVE-CARE-UNIT; LOW FRACTIONAL EXCRETION; CRITICALLY-ILL PATIENTS; LOW-DOSE DOPAMINE; RIGHT HEART CATHETERIZATION; PARENTERAL-NUTRITION; DOUBLE-BLIND; CONTINUOUS HEMOFILTRATION; DAILY HEMODIALYSIS	Background: Acute tubular necrosis (ATN) is common in hospitalized patients, particularly in the intensive care unit Over the past four decades, the mortality rate from ATN has remained at 50% to 80%. Purpose: To review recent studies of diagnosis and treatment strategies for ATN. Data Sources: MEDLINE search for all clinical studies of therapies for ATN, supplemented by a review of the references of the identified articles. Study Selection: Prospective studies and major retrospective studies evaluating therapies for ATN. Data Extraction: Data on the study sample, interventions performed, results, side effects, and duration of follow-up. Data Synthesis: Early diagnosis of ATN by exclusion of prerenal and postreral causes of acute renal failure, examination of urinary sediment, and analysis of urine measures (for example, fractional excretion of sodium in the absence of diuretics) can allow the early involvement of rephrologists and improve survival. Enteral rather than parenteral hyperalimentation in severely malnourished patients may improve survival. Sepsis causes 30% to 70% of deaths in patients with ATN; therefore, avoidance of intravenous lines, bladder catheters, and respirators is recommended. Because septic patients are vasodilated, large volumes of administered fluid accumulate in the lung interstitium of these patients. This condition necessitates ventilatory support, which when prolonged leads to acute respiratory distress syndrome, multiorgan failure, and increased mortality. More aggressive dialysis (for example, given daily) with biocompatible membranes may improve survival in some patients with acute renal failure. Conclusions: New information about the importance of early diagnosis and supportive care for patients with ATN has emerged, However, randomized trials of these interventions are needed to test their effect on the morbidity and mortality of ATN.	Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Schrier, RW (corresponding author), Univ Colorado, Hlth Sci Ctr, 4200 E 9th Ave,Box B178, Denver, CO 80262 USA.	robert.schrier@uchsc.edu			NIDDK NIH HHS [DK52599, DK07135] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052599, T32DK007135] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEL RM, 1973, NEW ENGL J MED, V288, P695, DOI 10.1056/NEJM197304052881401; Abizaid AS, 1999, AM J CARDIOL, V83, P260, DOI 10.1016/S0002-9149(98)00833-9; Acker CG, 2000, KIDNEY INT, V57, P293, DOI 10.1046/j.1523-1755.2000.00827.x; ADAMS PL, 1980, KIDNEY INT, V18, P68, DOI 10.1038/ki.1980.111; ALCARAZ A, 1991, TRANSPLANT P, V23, P2383; Alkhunaizi AM, 1996, AM J KIDNEY DIS, V28, P315, DOI 10.1016/S0272-6386(96)90487-4; Allgren RL, 1997, NEW ENGL J MED, V336, P828, DOI 10.1056/NEJM199703203361203; Anderson  R., 2001, DIS KIDNEY URINARY T; Battistella FD, 1997, J TRAUMA, V43, P52, DOI 10.1097/00005373-199707000-00013; Bellomo R, 1997, RENAL FAILURE, V19, P111, DOI 10.3109/08860229709026265; Bellomo R, 2000, LANCET, V356, P2139; BONOMINI V, 1984, NEPHRON, V36, P169, DOI 10.1159/000183147; Bonventre JV, 2002, NEW ENGL J MED, V346, P362, DOI 10.1056/NEJM200201313460512; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; BROWN CB, 1981, CLIN NEPHROL, V15, P90; Cerra FB, 1997, CHEST, V111, P769, DOI 10.1378/chest.111.3.769; Chan C, 1997, TRANSPLANTATION, V63, P1435, DOI 10.1097/00007890-199705270-00012; Chertow GM, 1996, AM J MED, V101, P49, DOI 10.1016/S0002-9343(96)00075-7; Chertow GM, 1998, J AM SOC NEPHROL, V9, P692; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; Chiao H, 1998, KIDNEY INT, V54, P765, DOI 10.1046/j.1523-1755.1998.00075.x; Chiao H, 1997, J CLIN INVEST, V99, P1165, DOI 10.1172/JCI119272; Conger J, 1998, SEMIN NEPHROL, V18, P533; CONGER JD, 1988, J CLIN INVEST, V82, P532, DOI 10.1172/JCI113628; CONGER JD, 1994, KIDNEY INT, V46, P318, DOI 10.1038/ki.1994.277; CONGER JD, 1975, J TRAUMA, V15, P1056, DOI 10.1097/00005373-197512000-00003; CONGER JD, 1995, AM J KIDNEY DIS, V26, P565, DOI 10.1016/0272-6386(95)90590-1; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; CORWIN HL, 1984, ARCH INTERN MED, V144, P981, DOI 10.1001/archinte.144.5.981; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; DAWIDSON I, 1991, J AM SOC NEPHROL, V2, P983; Denton MD, 1996, KIDNEY INT, V50, P4, DOI 10.1038/ki.1996.280; DONNELLY PK, 1993, TRANSPLANT P, V25, P600; Douma CE, 1997, J AM SOC NEPHROL, V8, P111; DRUML W, 1994, CLIN NEPHROL, V41, P342; DuBose TD, 1997, AM J KIDNEY DIS, V29, P793, DOI 10.1016/S0272-6386(97)90136-0; DUGGAN KA, 1985, CLIN NEPHROL, V24, P289; EPSTEIN M, 1975, AM J MED, V58, P510, DOI 10.1016/0002-9343(75)90124-2; FANG LST, 1980, ARCH INTERN MED, V140, P531, DOI 10.1001/archinte.140.4.531; FEEST TG, 1993, BMJ-BRIT MED J, V306, P481, DOI 10.1136/bmj.306.6876.481; FEINSTEIN EI, 1981, MEDICINE, V60, P124, DOI 10.1097/00005792-198103000-00005; FEINSTEIN EI, 1983, KIDNEY INT S16, V26, pS319; FLANCBAUM L, 1994, CRIT CARE MED, V22, P61, DOI 10.1097/00003246-199401000-00014; Forni LG, 1997, NEW ENGL J MED, V336, P1303, DOI 10.1056/NEJM199705013361807; Gastaldello K, 2000, NEPHROL DIAL TRANSPL, V15, P224, DOI 10.1093/ndt/15.2.224; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; GILLUM DM, 1986, CLIN NEPHROL, V25, P249; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; HAKIM RM, 1993, KIDNEY INT, V44, P484, DOI 10.1038/ki.1993.272; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HENDERSON IS, 1980, LANCET, V2, P827; Heyland DK, 1996, CRIT CARE MED, V24, P517, DOI 10.1097/00003246-199603000-00025; Heyland DK, 1998, JAMA-J AM MED ASSOC, V280, P2013, DOI 10.1001/jama.280.23.2013; Himmelfarb J, 1998, J AM SOC NEPHROL, V9, P257; Hirschberg R, 1999, KIDNEY INT, V55, P2423, DOI 10.1046/j.1523-1755.1999.00463.x; Jones CH, 1997, J AM SOC NEPHROL, V8, pA1218; Jorres A, 1999, LANCET, V354, P1337, DOI 10.1016/S0140-6736(99)01213-1; KELLEHER SP, 1984, AM J PHYSIOL, V246, pF379, DOI 10.1152/ajprenal.1984.246.4.F379; Kelly KJ, 2000, SEMIN NEPHROL, V20, P4; KJELLSTRAND CM, 1981, T AM SOC ART INT ORG, V27, P45; KLEINKNECHT D, 1972, KIDNEY INT, V1, P190, DOI 10.1038/ki.1972.26; KLEINKNECHT D, 1976, NEPHRON, V17, P51, DOI 10.1159/000180710; Kopple Joel D., 1996, Journal of Parenteral and Enteral Nutrition, V20, P3, DOI 10.1177/014860719602000103; KURTAL H, 1995, ARTIF ORGANS, V19, P391, DOI 10.1111/j.1525-1594.1995.tb02347.x; Lameire N, 1998, KIDNEY INT, V53, pS110; Lassnigg A, 2000, J AM SOC NEPHROL, V11, P97, DOI 10.1681/ASN.V11197; Leverve X, 1998, KIDNEY INT, V53, pS62; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; Lewis J, 2000, AM J KIDNEY DIS, V36, P767, DOI 10.1053/ajkd.2000.17659; Liano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380; LIANO F, 1993, NEPHRON, V63, P21, DOI 10.1159/000187139; Liano F, 1998, KIDNEY INT, V53, pS16; Lieberthal W, 2000, AM J PHYSIOL-RENAL, V278, pF1, DOI 10.1152/ajprenal.2000.278.1.F1; LINDNER A, 1983, NEPHRON, V33, P121, DOI 10.1159/000182925; Lustig S, 1996, ISRAEL J MED SCI, V32, P1249; MARIK PE, 1993, HEART LUNG, V22, P171; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; Mehta R, 1996, J AM SOC NEPHROL, V7, pA1044; Mehta RL, 1996, AM J KIDNEY DIS, V28, pS74, DOI 10.1016/S0272-6386(96)90083-9; MILLER TR, 1978, ANN INTERN MED, V89, P47, DOI 10.7326/0003-4819-89-1-47; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MORAN SM, 1985, KIDNEY INT, V27, P928, DOI 10.1038/ki.1985.101; MYERS BD, 1986, NEW ENGL J MED, V314, P97; NAKAMOTO M, 1987, J CLIN INVEST, V80, P698, DOI 10.1172/JCI113124; NEUMAYER HH, 1987, J CARDIOVASC PHARM, V10, pS170, DOI 10.1097/00005344-198706110-00058; Neveu H, 1996, NEPHROL DIAL TRANSPL, V11, P293, DOI 10.1093/oxfordjournals.ndt.a027256; Paganini EP, 1996, AM J KIDNEY DIS, V28, pS81, DOI 10.1016/S0272-6386(96)90084-0; Pagnini EP, 1996, CLIN NEPHROL, V46, P206; PARKER S, 1981, CRIT CARE MED, V9, P630, DOI 10.1097/00003246-198109000-00002; Pavoni V, 1998, KIDNEY INT, V53, pS75; Polanczyk CA, 2001, JAMA-J AM MED ASSOC, V286, P309, DOI 10.1001/jama.286.3.309; RAHMAN SN, 1994, KIDNEY INT, V45, P1731, DOI 10.1038/ki.1994.225; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; Rudis MI, 1996, CRIT CARE MED, V24, P525, DOI 10.1097/00003246-199603000-00026; RUDNICK MR, 1995, KIDNEY INT, V47, P254, DOI 10.1038/ki.1995.32; SANDSTROM R, 1993, ANN SURG, V217, P185, DOI 10.1097/00000658-199302000-00013; SCHAFFERHANS K, 1986, NEPHRON, V44, P240, DOI 10.1159/000183994; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; Schiffl H, 1997, J AM SOC NEPHROL, V8, pA1333; SCHRIER RW, 1995, HOSP PRACT, V30, P19, DOI 10.1080/21548331.1995.11443205; Shilliday IR, 1997, NEPHROL DIAL TRANSPL, V12, P2592, DOI 10.1093/ndt/12.12.2592; SOLEZ K, 1979, MEDICINE, V58, P362, DOI 10.1097/00005792-197909000-00003; SPONSEL H, 1995, AM J KIDNEY DIS, V25, P96, DOI 10.1016/0272-6386(95)90634-7; Star RA, 1998, KIDNEY INT, V54, P1817, DOI 10.1046/j.1523-1755.1998.00210.x; Swartz RD, 1999, AM J KIDNEY DIS, V34, P424, DOI 10.1016/S0272-6386(99)70068-5; TENSCHERT W, 1991, TRANSPLANT P, V23, P1334; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; VANVALENBERG PLJ, 1987, TRANSPLANTATION, V44, P784, DOI 10.1097/00007890-198712000-00012; VAZ AJ, 1983, ARCH INTERN MED, V143, P738, DOI 10.1001/archinte.143.4.738; WAGNER K, 1987, AM J NEPHROL, V7, P287, DOI 10.1159/000167487; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; WU AW, 1990, J AM GERIATR SOC, V38, P621, DOI 10.1111/j.1532-5415.1990.tb01419.x; ZARICH S, 1985, ARCH INTERN MED, V145, P108, DOI 10.1001/archinte.145.1.108; ZION MM, 1990, CHEST, V98, P1331, DOI 10.1378/chest.98.6.1331	117	153	168	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2002	137	9					744	752		10.7326/0003-4819-137-9-200211050-00010	http://dx.doi.org/10.7326/0003-4819-137-9-200211050-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612BA	12416948	Green Published			2022-12-28	WOS:000179052400006
J	Smith, R				Smith, R			A POEM a week for the BMJ - A POEM is patient-oriented evidence that matters	BRITISH MEDICAL JOURNAL			English	Editorial Material							INFORMATION											SHAUGHNESSY AF, 1994, J FAM PRACTICE, V39, P489; Slawson DC, 1997, BRIT MED J, V314, P947, DOI 10.1136/bmj.314.7085.947; Smith R, 1996, BRIT MED J, V313, P1062	3	25	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					983	983		10.1136/bmj.325.7371.983	http://dx.doi.org/10.1136/bmj.325.7371.983			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411333	Green Published			2022-12-28	WOS:000179415600004
J	Sorensen, HT; Norgard, B; Pedersen, L; Larsen, H; Johnsen, SP				Sorensen, HT; Norgard, B; Pedersen, L; Larsen, H; Johnsen, SP			Maternal smoking and risk of hypertrophic infantile pyloric stenosis: 10-year population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark; Aalborg Hosp, Dept Obstet & Gynaecol, DK-9000 Aalborg, Denmark	Aarhus University; Aalborg University; Aalborg University Hospital	Sorensen, HT (corresponding author), Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark.	hts@soci.au.dk	Nørgård, Bente M/F-9563-2013; Sorensen, Henrik Toft/Z-6181-2019; Johnsen, Søren P/K-1724-2013	Nørgård, Bente M/0000-0002-9514-3033; Sorensen, Henrik Toft/0000-0003-4299-7040; 				APPLEGATE MS, 1995, ARCH PEDIAT ADOL MED, V149, P1123, DOI 10.1001/archpedi.1995.02170230077011; MITCHELL LE, 1993, AM J DIS CHILD, V147, P1203, DOI 10.1001/archpedi.1993.02160350077012; Nielsen JP, 2000, DAN MED BULL, V47, P223; Persson S, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e70; Wisborg K, 1998, ACTA OBSTET GYN SCAN, V77, P836	5	38	40	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	2002	325	7371					1011	1012		10.1136/bmj.325.7371.1011	http://dx.doi.org/10.1136/bmj.325.7371.1011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411361	Bronze, Green Published			2022-12-28	WOS:000179415600023
J	Weenig, RH; Davis, MDP; Dahl, PR; Su, WPD				Weenig, RH; Davis, MDP; Dahl, PR; Su, WPD			Skin ulcers misdiagnosed as pyoderma gangrenosum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the European-Academy-of-Dermatology-amd-Venerology	OCT, 2001	MUNICH, GERMANY	Euro Acad Dermatol Venerol			CUTANEOUS MANIFESTATIONS; LUPUS ANTICOAGULANT; CELL LYMPHOMA; ANTIPHOSPHOLIPID SYNDROME; WEGENERS GRANULOMATOSIS; LYMPHOCYTIC-LEUKEMIA; PATIENT; SPOROTRICHOSIS; ANTIBODIES; VASCULITIS	Background: Pyoderma gangrenosum is a diagnosis of exclusion, and the misdiagnosis of pyoderma gangrenosum can result in substantial complications in patients who have other causes of severe cutaneous ulceration. Methods: We reviewed the charts of 240 patients with a diagnosis of pyoderma gangrenosum who were evaluated at our institution from 1975 through 2000, including 157 consecutive patients treated for presumed pyoderma gangrenosum from 1984 through 1992. We also reviewed the English-language literature. Results: Ninety-five patients (49 from our institution and 46 described in the literature) had skin ulcers with a clinical resemblance to pyoderma gangrenosum. The final diagnoses were vascular occlusive or venous disease, vasculitis, cancer, primary infection, drug-induced or exogenous tissue injury, and other inflammatory disorders. Of the 95 patients studied, 64 had been treated for pyoderma gangrenosum for a median of 10 months (range, 3 to 180). These 64 included 15 of the 157 consecutive patients treated for pyoderma gangrenosum at our institution (10 percent). Of the ulcers in the 64 patients treated for pyoderma gangrenosum, it was clear that those in 23 patients (36 percent) did not respond to treatment directed at pyoderma gangrenosum, those in 8 (12 percent) were exacerbated by such treatment, and those in 15 (23 percent) improved with such treatment. Conclusions: The misdiagnosis of pyoderma gangrenosum is not uncommon and exposes patients to risks associated with its treatment. A thorough evaluation is required in all patients suspected of having pyoderma gangrenosum in order to rule out alternative diagnoses.	Mayo Clin, Dept Dermatol, Rochester, MN 55905 USA	Mayo Clinic	Davis, MDP (corresponding author), Mayo Clin, Dept Dermatol, 200 1st St SW, Rochester, MN 55905 USA.		Stienstra, Ymkje/F-2222-2010	Stienstra, Ymkje/0000-0002-8844-8859				Adachi Y, 1998, J INVEST DERMATOL, V111, P259, DOI 10.1046/j.1523-1747.1998.00311.x; AlRimawi HS, 1996, EUR J PEDIATR, V155, P759, DOI 10.1007/s004310050482; BABE KS, 1992, INT J DERMATOL, V31, P588, DOI 10.1111/j.1365-4362.1992.tb02726.x; BARRETT AP, 1988, ORAL SURG ORAL MED O, V65, P685, DOI 10.1016/0030-4220(88)90010-2; Brown TS, 1999, CUTIS, V64, P123; Brunsting LA, 1930, ARCH DERMATOL SYPH, V22, P655, DOI 10.1001/archderm.1930.01440160053009; BURGESS NA, 1991, BRIT J CLIN PRACT, V45, P223; CAMISA C, 1993, J AM ACAD DERMATOL, V29, P696, DOI 10.1016/0190-9622(93)70233-J; Chacek S, 1998, ANGIOLOGY, V49, P157, DOI 10.1177/000331979804900209; Chiewchanvit Siri, 1998, Journal of the Medical Association of Thailand, V81, P923; DAVID M, 1983, BIOMED PHARMACOTHER, V37, P298; FRANCES C, 1990, DERMATOLOGICA, V181, P266, DOI 10.1159/000247820; Freedman AM, 1997, INT J DERMATOL, V36, P205; Gibson LE, 1997, MAYO CLIN PROC, V72, P734; GRAHAM JA, 1994, PEDIATR DERMATOL, V11, P10, DOI 10.1111/j.1525-1470.1994.tb00065.x; GROB JJ, 1986, J AM ACAD DERMATOL, V15, P211, DOI 10.1016/S0190-9622(86)70159-X; HANDFIELDJONES SE, 1992, CLIN EXP DERMATOL, V17, P197, DOI 10.1111/j.1365-2230.1992.tb00206.x; HARMON CB, 1993, J AM ACAD DERMATOL, V29, P656, DOI 10.1016/S0190-9622(08)81879-8; HELM KF, 1992, J AM ACAD DERMATOL, V27, P868, DOI 10.1016/0190-9622(92)70269-L; Ho KKL, 2000, BRIT J DERMATOL, V142, P124, DOI 10.1046/j.1365-2133.2000.03253.x; HOOVER EL, 1990, SOUTHERN MED J, V83, P243, DOI 10.1097/00007611-199002000-00029; KITAHAMA A, 1991, ANGIOLOGY, V42, P498, DOI 10.1177/000331979104200610; LESHER JL, 1994, CUTIS, V53, P128; LIAO WQ, 1991, MYCOPATHOLOGIA, V116, P165, DOI 10.1007/BF00436831; LIAO WQ, 1995, MYCOSES, V38, P75, DOI 10.1111/j.1439-0507.1995.tb00011.x; Lindor NM, 1997, MAYO CLIN PROC, V72, P611; Maessen-Visch MB, 1999, INT J DERMATOL, V38, P161, DOI 10.1046/j.1365-4362.1999.00581.x; MASSA MC, 1981, J AM ACAD DERMATOL, V5, P32, DOI 10.1016/S0190-9622(81)70074-4; Matsui M, 2000, INT J DERMATOL, V39, P38, DOI 10.1046/j.1365-4362.2000.00843.x; MICALI G, 1994, INT J DERMATOL, V33, P477, DOI 10.1111/j.1365-4362.1994.tb02858.x; NORRIS JFB, 1984, CLIN EXP DERMATOL, V9, P388, DOI 10.1111/j.1365-2230.1984.tb00822.x; Oka M, 2000, LAB INVEST, V80, P595, DOI 10.1038/labinvest.3780064; Papi M, 1998, ARCH DERMATOL, V134, P447, DOI 10.1001/archderm.134.4.447; PARENT DJ, 1994, J AM ACAD DERMATOL, V31, P1072, DOI 10.1016/S0190-9622(09)80093-5; PERNICIARO CV, 1987, J AM ACAD DERMATOL, V17, P998, DOI 10.1016/S0190-9622(87)70289-8; PERRY HO, 1968, ARCH DERMATOL, V98, P561, DOI 10.1001/archderm.98.6.561; PETERSON LL, 1984, J AM ACAD DERMATOL, V10, P379, DOI 10.1016/S0190-9622(84)80011-0; REES RS, 1985, SOUTHERN MED J, V78, P283, DOI 10.1097/00007611-198503000-00012; SCHEINMAN PL, 1995, INT J DERMATOL, V34, P717, DOI 10.1111/j.1365-4362.1995.tb04662.x; Schlesinger I H, 1995, J La State Med Soc, V147, P357; Schmid MH, 1998, EUR J DERMATOL, V8, P45; SELVA A, 1994, DERMATOLOGY, V189, P182, DOI 10.1159/000246828; Smith JB, 1996, J AM ACAD DERMATOL, V34, P901, DOI 10.1016/S0190-9622(96)90076-6; SPIERS EM, 1986, ARCH DERMATOL, V122, P691, DOI 10.1001/archderm.122.6.691; STEPHANSSON EA, 1991, ACTA DERM-VENEREOL, V71, P416; STROUD JD, 1968, ARCH DERMATOL, V97, P667, DOI 10.1001/archderm.97.6.667; SUNARWAN I, 1975, DERMATOLOGICA, V151, P253, DOI 10.1159/000251344; THOMAS R, 1994, J RHEUMATOL, V21, P760; THOMAS RHM, 1982, CLIN EXP DERMATOL, V7, P523, DOI 10.1111/j.1365-2230.1982.tb02470.x; Torok L, 2000, EUR J DERMATOL, V10, P463; VOSE JM, 1988, CUTIS, V42, P335; WAHBA A, 1979, DERMATOLOGICA, V158, P373, DOI 10.1159/000250783; WHITE JC, 1976, J PATHOL, V120, P25, DOI 10.1002/path.1711200104; Yeon HB, 2000, AM J HUM GENET, V66, P1443, DOI 10.1086/302866	54	257	262	0	10	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1412	1418		10.1056/NEJMoa013383	http://dx.doi.org/10.1056/NEJMoa013383			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12409543	Bronze			2022-12-28	WOS:000178888400004
J	Weingarten, SR; Henning, JM; Badamgarav, E; Knight, K; Hasselblad, V; Gano, A; Ofman, JJ				Weingarten, SR; Henning, JM; Badamgarav, E; Knight, K; Hasselblad, V; Gano, A; Ofman, JJ			Interventions used in disease management programmes for patients with chronic illness - which ones work? Meta-analysis of published reports	BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED TRIAL; COMPREHENSIVE REHABILITATION PROGRAM; OBSTRUCTIVE PULMONARY-DISEASE; DEPENDENT DIABETES-MELLITUS; IMPROVE GLYCEMIC CONTROL; DECISION-SUPPORT SYSTEM; PRIMARY-CARE PATIENTS; LATE-LIFE DEPRESSION; CLINICAL-PRACTICE; CHOLESTEROL REDUCTION	Objective To systematically evaluate the published evidence regarding the characteristics and effectiveness of disease management programmes. Design Meta-analysis. Data sources Computerised databases for English language articles during 1987-2001. Study selection 102 articles evaluating 118 disease management programmes. Main outcome measures Pooled effect sizes calculated with a random effects model. Results Patient education was the most commonly used intervention (92/118 programmes), followed by education of healthcare providers (47/118) and provider feedback (32/118). Most programmes' (70/118) used more than one intervention. Provider education, feedback, and reminders were associated with significant improvements in provider adherence to guidelines (effect sizes (95% confidence intervals) 0.44 (0.19 to 0.68), 0.61 (0.28 to 0.93), and 0.52 (0.35 to 0.69) respectively) and with significant improvements in patient disease control (effect sizes 0.35 (0.19 to 0.51), 0.17 (0.10 to 0.25), and 0.22 (0.1 to 0.37) respectively). Patient education, reminders, and financial incentives were all associated with improvements in patient disease control (effect sizes 0.24 (0.07 to 0.40), 0.27 (0.17 to 0.36), and 0.40 (0.26 to 0.54) respectively). Conclusions All studied interventions were associated with improvements in provider adherence to practice guidelines and disease control. The type and number of interventions varied greatly, and future studies should directly compare different types of intervention to find the most effective.	Zynx Hlth, Beverly Hills, CA 90212 USA; TAP Pharmaceut Prod, Lake Forest, IL USA; Duke Univ, Duke Clin Res Inst, Durham, NC USA	Abbott Laboratories; Takeda Pharmaceutical Company Ltd; TAP Pharmaceuticals; Duke University	Weingarten, SR (corresponding author), Zynx Hlth, 9100 Wilshire Blvd 665E, Beverly Hills, CA 90212 USA.							Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; Banerjee S, 1996, BRIT MED J, V313, P1058; Bell MJ, 1998, J RHEUMATOL, V25, P231; Benjamin EM, 1999, DIABETES CARE, V22, P1672, DOI 10.2337/diacare.22.10.1672; Bogden PE, 1997, J GEN INTERN MED, V12, P158, DOI 10.1007/s11606-006-5023-7; Bogden PE, 1998, J GEN INTERN MED, V13, P740, DOI 10.1046/j.1525-1497.1998.00225.x; BROWN KE, 1994, CRIT REV ONCOL HEMAT, V16, P1, DOI 10.1016/1040-8428(94)90040-X; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P839, DOI 10.1111/j.1532-5415.1994.tb06555.x; *COCHR EFF PRACT O, 2000, COCHR DAT SYST REV W; *COMM ADV PUBL HLT, 1990, CLIN PRACT GUID DIR; Davis DA, 1997, CAN MED ASSOC J, V157, P408; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P111; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; DERAMOMELKUS GA, 1992, DIABETES CARE, V15, P864, DOI 10.2337/diacare.15.7.864; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; deSonnaville JJJ, 1997, DIABETOLOGIA, V40, P1334, DOI 10.1007/s001250050829; DEWEERDT I, 1991, DIABETIC MED, V8, P338; DOMENECH MI, 1995, ACTA DIABETOL, V32, P143, DOI 10.1007/BF00838482; Donohoe ME, 2000, DIABETIC MED, V17, P581, DOI 10.1046/j.1464-5491.2000.00336.x; DRUMMOND N, 1994, BRIT MED J, V308, P559, DOI 10.1136/bmj.308.6928.559; Ellis SL, 2000, PHARMACOTHERAPY, V20, P1508, DOI 10.1592/phco.20.19.1508.34852; Ellrodt G, 1997, JAMA-J AM MED ASSOC, V278, P1687, DOI 10.1001/jama.278.20.1687; EPSTEIN WA, 1985, ARCH DERMATOL, V121, P838, DOI 10.1001/archderm.1985.01660070026010; Erickson SR, 1997, PHARMACOTHERAPY, V17, P140; FIELDING JE, 1995, AM J PREV MED, V11, P120, DOI 10.1016/S0749-3797(18)30487-2; FIELDING JE, 1994, J OCCUP ENVIRON MED, V36, P743; FRANZ MJ, 1995, J AM DIET ASSOC, V95, P1009, DOI 10.1016/S0002-8223(95)00276-6; Gattis WA, 1999, ARCH INTERN MED, V159, P1939, DOI 10.1001/archinte.159.16.1939; GLASS G, 1980, SUMMARIZING EFFECT S; Gourley G A, 1998, J Am Pharm Assoc (Wash), V38, P586; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Harris LE, 1998, AM J MED, V105, P464, DOI 10.1016/S0002-9343(98)00329-5; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; HEDBACK B, 1993, EUR HEART J, V14, P831, DOI 10.1093/eurheartj/14.6.831; Hedges LV, 2014, STAT METHODS META AN; Heller RF, 2001, MED J AUSTRALIA, V174, P217, DOI 10.5694/j.1326-5377.2001.tb143238.x; Hetlevik I, 1999, SCAND J PRIM HEALTH, V17, P35; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; Hyman DJ, 1998, AM J PREV MED, V15, P139, DOI 10.1016/S0749-3797(98)00038-5; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353, DOI 10.1164/ajrccm.151.2.7842191; Jaber LA, 1996, ANN PHARMACOTHER, V30, P238, DOI 10.1177/106002809603000305; Katon W, 2001, ARCH GEN PSYCHIAT, V58, P241, DOI 10.1001/archpsyc.58.3.241; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KATZ S, 1968, J AMER MED ASSOC, V206, P1249, DOI 10.1001/jama.206.6.1249; Katzelnick DJ, 2000, ARCH FAM MED, V9, P345, DOI 10.1001/archfami.9.4.345; KAZIS LE, 1989, MED CARE S, V27, P178; Keyserling TC, 1997, ARCH FAM MED, V6, P135, DOI 10.1001/archfami.6.2.135; Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202; Kulkarni K, 1998, J AM DIET ASSOC, V98, P62, DOI 10.1016/S0002-8223(98)00017-0; Lidell E, 1996, SCAND J CARING SCI, V10, P67, DOI 10.1111/j.1471-6712.1996.tb00314.x; Lin EHB, 1999, AM J PSYCHIAT, V156, P643; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; Llewellyn-Jones RH, 1999, BMJ-BRIT MED J, V319, P676, DOI 10.1136/bmj.319.7211.676; MAGRUDERHABIB K, 1990, MED CARE, V28, P239, DOI 10.1097/00005650-199003000-00004; MAZZUCA SA, 1986, DIABETES CARE, V9, P1, DOI 10.2337/diacare.9.1.1; Montgomery AA, 2000, BRIT MED J, V320, P686, DOI 10.1136/bmj.320.7236.686; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; Muller C, 1996, SOC WORK HEALTH CARE, V22, P1, DOI 10.1300/J010v22n04_01; NAJI S, 1994, BRIT MED J, V308, P1208; OConnor PJ, 1996, ARCH FAM MED, V5, P502, DOI 10.1001/archfami.5.9.502; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PETERS JL, 1990, PAIN, V41, P283, DOI 10.1016/0304-3959(90)90005-X; Piette JD, 2001, DIABETES CARE, V24, P202, DOI 10.2337/diacare.24.2.202; Ray NF, 1998, DIABETES CARE, V21, P296; Ridgeway NA, 1999, SOUTHERN MED J, V92, P667, DOI 10.1097/00007611-199907000-00004; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; ROSENTHAL R, 1978, PSYCHOL BULL, V85, P185, DOI 10.1037/0033-2909.85.1.185; ROSENTHAL R, 1984, METAANAL PROCEDURES; Rost K, 2001, J GEN INTERN MED, V16, P143, DOI 10.1111/j.1525-1497.2001.00537.x; SCHNED ES, 1995, J RHEUMATOL, V22, P1141; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Smith JL, 2000, J RURAL HEALTH, V16, P313, DOI 10.1111/j.1748-0361.2000.tb00482.x; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Thompson C, 2000, LANCET, V355, P185, DOI 10.1016/S0140-6736(99)03171-2; Troosters T, 2000, AM J MED, V109, P207, DOI 10.1016/S0002-9343(00)00472-1; Tutty S, 2000, Eff Clin Pract, V3, P170; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; Vlieland TPMV, 1996, BRIT J RHEUMATOL, V35, P475; Walker EA, 2000, J GEN INTERN MED, V15, P859, DOI 10.1046/j.1525-1497.2000.91142.x; WEHRWEIN P, 1997, MANAG CARE, V6, P28; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Whooley MA, 2000, J GEN INTERN MED, V15, P293, DOI 10.1046/j.1525-1497.2000.04319.x; Worrall G, 1999, CAN MED ASSOC J, V161, P37; 1979, JAMA-J AM MED ASSOC, V242, P2572	92	465	470	1	45	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					925	928F		10.1136/bmj.325.7370.925	http://dx.doi.org/10.1136/bmj.325.7370.925			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	610XB	12399340	Bronze, Green Published			2022-12-28	WOS:000178986300013
J	Chenn, A				Chenn, A			Eppendorf & Science Prize - Making a bigger brain by regulating cell cycle exit	SCIENCE			English	Editorial Material							BETA-CATENIN; MICE LACKING; MAMMALIAN BRAINS; EMBRYOGENESIS; EVOLUTION; HYPERPLASIA; HIPPOCAMPUS; EXPRESSION; CASPASE-9; P27(KIP1)		Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Chenn, A (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA.							Barton RA, 2000, NATURE, V405, P1055, DOI 10.1038/35016580; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Brault V, 2001, DEVELOPMENT, V128, P1253; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; Cho EA, 1998, MECH DEVELOP, V77, P9; Clark DA, 2001, NATURE, V411, P189, DOI 10.1038/35075564; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; ELIAS H, 1969, SCIENCE, V166, P111, DOI 10.1126/science.166.3901.111; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FINLAY BL, 1995, SCIENCE, V268, P1578, DOI 10.1126/science.7777856; Galceran J, 2000, DEVELOPMENT, V127, P469; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HAUG H, 1987, AM J ANAT, V180, P126, DOI 10.1002/aja.1001800203; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lee SMK, 2000, DEVELOPMENT, V127, P457; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; PARR BA, 1993, DEVELOPMENT, V119, P247; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, TRENDS NEUROSCI, V18, P383, DOI 10.1016/0166-2236(95)93934-P; Yaworsky PJ, 1999, DEV BIOL, V205, P309, DOI 10.1006/dbio.1998.9035; Zurawel RH, 1998, CANCER RES, V58, P896	28	6	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					766	767		10.1126/science.1079328	http://dx.doi.org/10.1126/science.1079328			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399574				2022-12-28	WOS:000178791200042
J	Bernard, P; Chosidow, O; Vaillant, L				Bernard, P; Chosidow, O; Vaillant, L		French Erysipelas Study Grp	Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CELLULITIS; THERAPY	Objective To assess the efficacy and safety of oral pristinamycin versus intravenous then oral penicillin to treat erysipelas in patients in hospital. Design Multicentre, parallel group, open labelled, randomised non-inferiority trial. Setting 22 French hospitals. Participants 289 adults admitted to hospital with erysipelas. Results At follow up (day 25-45) the cure rate (primary efficacy end point) for the per protocol populations was 81% (83/102) for pristinamycin and 67% (68/102) for penicillin. The planned interim analysis (global one sided type 1 error 5%) showed that the one sided 97.06% confidence interval of the observed difference (pristinamycin - penicillin) between cure rates (3.3% to infinity) exceeded the - 10% non-inferiority threshold. For the intention to treat populations the cure rate at follow up was 65% (90/138) for pristinamycin and 53% (79/150) for penicillin, with the one sided 97.06% confidence interval of the observed difference between cure rates (1.7%) to infinity) exceeding the - 10% non-inferiority threshold. That the lower limit of the confidence interval exceeded the -10% threshold and was also > 0 supports the hypothesis that pristinamycin is significantly superior at the 5% level. More adverse events related to treatment, as assessed by the investigators, were reported in the pristinamycin group than in the penicillin group. Most adverse events involved the gastrointestinal tract (nausea, vomiting, and-diarrhoea) but were minor and usually did riot require discontinuation of treatment. Conclusion Pristinamycin could be an alternative to the standard intravenous then oral penicillin regimen used to treat erysipelas in adults in hospital, with the advantages of oral first line therapy.	Hop Robert Debre, Dept Dermatol, F-51092 Reims, France; Hop La Pitie Salpetriere, Dept Internal Med, F-75013 Paris, France; Hop Trousseau, Dept Dermatol, F-37044 Tours, France	CHU de Reims; Universite de Reims Champagne-Ardenne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Tours	Bernard, P (corresponding author), Hop Robert Debre, Dept Dermatol, F-51092 Reims, France.	pbernard@chu-reims.fr						[Anonymous], 2000, Ann Dermatol Venereol, V127, P1118; Bergkvist PI, 1997, SCAND J INFECT DIS, V29, P377, DOI 10.3109/00365549709011834; BERNARD P, 1989, ARCH DERMATOL, V125, P779, DOI 10.1001/archderm.125.6.779; Bernard P, 1997, ANN DERMATOL VENER, V124, P384; BERNARD P, 1992, BRIT J DERMATOL, V127, P155, DOI 10.1111/j.1365-2133.1992.tb08048.x; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; CHARTIER C, 1990, INT J DERMATOL, V29, P459, DOI 10.1111/j.1365-4362.1990.tb04833.x; Chartier C, 1996, INT J DERMATOL, V35, P779, DOI 10.1111/j.1365-4362.1996.tb02971.x; Committee for Proprietary Medicinal Products, 2000, POINTS CONS SWITCH S; Dupuy A, 1999, BRIT MED J, V318, P1591, DOI 10.1136/bmj.318.7198.1591; DUVANEL T, 1989, ARCH INTERN MED, V149, P293, DOI 10.1001/archinte.149.2.293; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; JORUPRONSTROM C, 1986, SCAND J INFECT DIS, V18, P519, DOI 10.3109/00365548609021656; JORUPRONSTROM C, 1984, INFECTION, V12, P390, DOI 10.1007/BF01645222; Kopp M, 2001, ANN DERMATOL VENER, V128, P338; RONNEN M, 1985, INT J DERMATOL, V24, P169, DOI 10.1111/j.1365-4362.1985.tb05415.x; Schmit JL, 2001, ANN DERMATOL VENER, V128, P334; Siegel JP, 2000, AM HEART J, V139, pS166, DOI 10.1016/S0002-8703(00)90066-8; [No title captured]	19	40	41	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 19	2002	325	7369					864	866		10.1136/bmj.325.7369.864	http://dx.doi.org/10.1136/bmj.325.7369.864			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386036	Green Published, Bronze			2022-12-28	WOS:000178793000018
J	Kivimaki, M; Leino-Arjas, P; Luukkonen, R; Riihimaki, H; Vahtera, J; Kirjonen, J				Kivimaki, M; Leino-Arjas, P; Luukkonen, R; Riihimaki, H; Vahtera, J; Kirjonen, J			Work stress and risk of cardiovascular mortality: prospective cohort study of industrial employees	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; JOB STRAIN; DECISION LATITUDE; SWEDISH MEN; INEQUALITIES; WOMEN	Objective To examine the association between work stress, according to the job strain model and the effort-reward imbalance model, and the risk of death from cardiovascular disease. Design Prospective cohort study. Baseline examination in 1973 determined cases of cardiovascular disease, behavioural and biological risks, and stressful characteristics of work. Biological risks were measured at 5 year and 10 year follow up. Setting Staff of a company in the metal industry in Finland. Participants 812 employees (545 men, 267 women) who were free from cardiovascular diseases at baseline. Main outcome measure Cardiovascular mortality 1973-2001 from the national mortality register. Results Mean length of follow up was 25.6 years. After adjustment for age and sex, employees with high job strain, a combination of high demands at work and low job control, had a 2.2-fold (95% confidence interval 1.2 to 4.2) cardiovascular mortality risk compared with their colleagues with low job strain. The corresponding risk ratio for employees with effort-reward imbalance (low salary, lack of social approval, and few career opportunities relative to efforts required at work) was 2.4 (1.3 to 4.4). These ratios remained significant after additional adjustment for occupational group and biological and behavioural risks at baseline. High job strain was associated with increased serum total cholesterol at the 5-year follow up. Effort-reward imbalance predicted increased body mass index at the 10 year follow up. Conclusions High job strain and effort-reward imbalance seem to increase the risk of cardiovascular mortality. The evidence froth industrial employees suggests that attention should be paid to the prevention of work stress.	Univ Helsinki, Dept Psychol, FIN-00014 Helsinki, Finland; Univ Jyvaskyla, Dept Educ Phys, Jyvaskyla, Finland	University of Helsinki; University of Jyvaskyla	Kivimaki, M (corresponding author), Univ Helsinki, Dept Psychol, POB 13, FIN-00014 Helsinki, Finland.		Vahtera, Jussi/J-3271-2013; Kivimaki, Mika/B-3607-2012	Kivimaki, Mika/0000-0002-4699-5627; Leino-Arjas, Paivi/0000-0001-9534-7071				ALTERMAN T, 1994, AM J EPIDEMIOL, V139, P620, DOI 10.1093/oxfordjournals.aje.a117051; Bosma H, 1998, AM J PUBLIC HEALTH, V88, P68, DOI 10.2105/AJPH.88.1.68; Hemingway H, 1999, BMJ-BRIT MED J, V318, P1460, DOI 10.1136/bmj.318.7196.1460; Karasek R, 1990, STRESS PRODUCTIVITY; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Lynch J, 1997, AM J PUBLIC HEALTH, V87, P617, DOI 10.2105/AJPH.87.4.617; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; *METELI, 1975, 9 METELL RES I PHYS; Peter R, 1998, J EPIDEMIOL COMMUN H, V52, P540, DOI 10.1136/jech.52.9.540; REED DM, 1989, AM J EPIDEMIOL, V129, P495, DOI 10.1093/oxfordjournals.aje.a115160; Siegrist J, 1996, J Occup Health Psychol, V1, P27, DOI 10.1037/1076-8998.1.1.27; Sokejima S, 1998, BRIT MED J, V317, P775, DOI 10.1136/bmj.317.7161.775; Steenland K, 1997, AM J IND MED, V31, P256, DOI 10.1002/(SICI)1097-0274(199702)31:2<256::AID-AJIM16>3.0.CO;2-0; SUADICANI P, 1993, ATHEROSCLEROSIS, V101, P165, DOI 10.1016/0021-9150(93)90113-9; Theorell T, 1996, J Occup Health Psychol, V1, P9, DOI 10.1037/1076-8998.1.1.9; Theorell T, 1998, AM J PUBLIC HEALTH, V88, P382, DOI 10.2105/AJPH.88.3.382; Vrijkotte TGM, 1999, PSYCHOSOM MED, V61, P796, DOI 10.1097/00006842-199911000-00012; Vrijkotte TGM, 2000, HYPERTENSION, V35, P880, DOI 10.1161/01.HYP.35.4.880	19	546	571	0	49	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 19	2002	325	7369					857	860		10.1136/bmj.325.7369.857	http://dx.doi.org/10.1136/bmj.325.7369.857			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	607LL	12386034	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000178793000016
J	Doukov, TI; Iverson, TM; Seravalli, J; Ragsdale, SW; Drennan, CL				Doukov, TI; Iverson, TM; Seravalli, J; Ragsdale, SW; Drennan, CL			A Ni-Fe-Cu center in a bifunctional carbon monoxide dehydrogenase/acetyl-CoA synthase	SCIENCE			English	Article							IRON-SULFUR PROTEIN; ACETYL-COENZYME-A; CLOSTRIDIUM-THERMOACETICUM; CRYSTAL-STRUCTURE; ELECTRON-DENSITY; ACTIVE-SITE; CRYSTALLOGRAPHY; MECHANISM; COORDINATION; METHYLATION	A metallocofactor containing iron, sulfur, copper, and nickel has been discovered in the enzyme carbon monoxide dehydrogenase/acetyl-CoA ( coenzyme A) synthase from Moorella thermoacetica (f. Clostridium thermoaceticum). Our structure at 2.2 angstrom resolution reveals that the cofactor responsible for the assembly of acetyl-CoA contains a [Fe4S4] cubane bridged to a copper-nickel binuclear site. The presence of these three metals together in one cluster was unanticipated and suggests a newly discovered role for copper in biology. The different active sites of this bifunctional enzyme complex are connected via a channel, 138 angstroms long, that provides a conduit for carbon monoxide generated at the C-cluster on one subunit to be incorporated into acetyl-CoA at the A-cluster on the other subunit.	MIT, Dept Chem, Cambridge, MA 02139 USA; Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA	Massachusetts Institute of Technology (MIT); University of Nebraska System; University of Nebraska Lincoln	Drennan, CL (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.			Doukov, Tzanko/0000-0001-8625-2572	NIGMS NIH HHS [R01-GM39451] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREESE.JR, 1973, J BACTERIOL, V114, P743, DOI 10.1128/JB.114.2.743-751.1973; Barondeau DP, 1997, J AM CHEM SOC, V119, P3959, DOI 10.1021/ja963597k; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CHRISTOPHER JA, 1998, THESIS TEXASS A M U; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Dobbek H, 2001, SCIENCE, V293, P1281, DOI 10.1126/science.1061500; Drennan CL, 2001, P NATL ACAD SCI USA, V98, P11973, DOI 10.1073/pnas.211429998; Ermler U, 1997, SCIENCE, V278, P1457, DOI 10.1126/science.278.5342.1457; Harford C, 1997, ACCOUNTS CHEM RES, V30, P123, DOI 10.1021/ar9501535; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; HU SI, 1982, J BACTERIOL, V149, P440, DOI 10.1128/JB.149.2.440-448.1982; Huang WJ, 1997, STRUCTURE, V5, P691, DOI 10.1016/S0969-2126(97)00223-2; Jaron S, 1999, BIOCHEMISTRY-US, V38, P15086, DOI 10.1021/bi991341w; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KUMAR M, 1992, J AM CHEM SOC, V114, P8713, DOI 10.1021/ja00048a062; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lindahl PA, 2002, BIOCHEMISTRY-US, V41, P2097, DOI 10.1021/bi015932+; Maynard EL, 1999, J AM CHEM SOC, V121, P9221, DOI 10.1021/ja992120g; Maynard EL, 2001, J AM CHEM SOC, V123, P4697, DOI 10.1021/ja004017t; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Menon S, 1999, J BIOL CHEM, V274, P11513, DOI 10.1074/jbc.274.17.11513; Montet Y, 1997, NAT STRUCT BIOL, V4, P523, DOI 10.1038/nsb0797-523; Nagashima S, 1998, NAT STRUCT BIOL, V5, P347, DOI 10.1038/nsb0598-347; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; Ragsdale SW, 1996, CHEM REV, V96, P2515, DOI 10.1021/cr950058+; RAGSDALE SW, 1983, J BIOL CHEM, V258, P2364; RAGSDALE SW, 2000, ENZYME CATALYZED ELE, V35, P487; Russell WK, 1998, J AM CHEM SOC, V120, P7502, DOI 10.1021/ja981165z; Seravalli J, 2000, BIOCHEMISTRY-US, V39, P1274, DOI 10.1021/bi991812e; Seravalli J, 2002, BIOCHEMISTRY-US, V41, P1807, DOI 10.1021/bi011687i; SHANMUGASUNDARAM T, 1992, J BIOL CHEM, V267, P897; SHANMUGASUNDARAM T, 1988, BIOCHEMISTRY-US, V27, P6499, DOI 10.1021/bi00417a045; Strop P, 2001, BIOCHEMISTRY-US, V40, P651, DOI 10.1021/bi0016467; Szulc A, 1998, INORG CHIM ACTA, V270, P440, DOI 10.1016/S0020-1693(97)06001-5; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; VOLBEDA A, 1999, ECOLES PHYSIQUE CHIM, V1, P47; YOUNGBLOOD MP, 1980, INORG CHEM, V19, P3068, DOI 10.1021/ic50212a048	45	423	432	12	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					567	572		10.1126/science.1075843	http://dx.doi.org/10.1126/science.1075843			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386327				2022-12-28	WOS:000178634800032
J	Keimer, B; Sackmann, E; Withers, PJ				Keimer, B; Sackmann, E; Withers, PJ			Neutron scattering - The case for neutron sources	SCIENCE			English	Editorial Material									Max Planck Inst Solid State Res, D-70569 Stuttgart, Germany; Tech Univ Munich, Dept Phys, D-85747 Garching, Germany; Univ Manchester, Manchester Mat Sci Ctr, Manchester M1 7HS, Lancs, England	Max Planck Society; Technical University of Munich; University of Manchester	Keimer, B (corresponding author), Max Planck Inst Solid State Res, D-70569 Stuttgart, Germany.		Withers, Phil/A-6760-2009	Withers, Phil/0000-0002-1946-5647				Birgeneau RJ, 2000, SCIENCE, V288, P437, DOI 10.1126/science.288.5465.437; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43	2	0	0	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					543	543		10.1126/science.1077970	http://dx.doi.org/10.1126/science.1077970			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386318				2022-12-28	WOS:000178634800021
J	Groh, V; Wu, J; Yee, C; Spies, T				Groh, V; Wu, J; Yee, C; Spies, T			Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation	NATURE			English	Article							RECEPTOR; RECOGNITION; ENGAGEMENT; PEPTIDE	Engagement of the NKG2D receptor by tumour-associated ligands may promote tumour rejection by stimulating innate and adaptive lymphocyte responses(1-5). In humans, NKG2D is expressed on most natural killer cells, gammadelta T cells and CD8alphabeta T cells(1). Ligands of NKG2D include the major histocompatibility complex class I homologues MICA and MICB, which function as signals of cellular stress(6,7). These molecules are absent from most cells and tissues but can be induced by viral and bacterial infections and are frequently expressed in epithelial tumours(8-11). MIC engagement of NKG2D triggers natural killer cells and costimulates antigen-specific effector T cells(1,10). Here we show that binding of MIC induces endocytosis and degradation of NKG2D. Expression of NKG2D is reduced markedly on large numbers of tumour-infiltrating and matched peripheral blood T cells from individuals with cancer. This systemic deficiency is associated with circulating tumour-derived soluble MICA, causing the downregulation of NKG2D and in turn severe impairment of the responsiveness of tumour-antigen-specific effector T cells. This mode of T-cell silencing may promote tumour immune evasion and, by inference, compromise host resistance to infections.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Groh, V (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N, Seattle, WA 98109 USA.	vgroh@fhcrc.org						Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Cerwenka A, 2001, P NATL ACAD SCI USA, V98, P11521, DOI 10.1073/pnas.201238598; Das H, 2001, IMMUNITY, V15, P83, DOI 10.1016/S1074-7613(01)00168-6; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Huard B, 2000, NATURE, V403, P325, DOI 10.1038/35002105; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; Li PW, 2001, NAT IMMUNOL, V2, P443, DOI 10.1038/87757; LINSLEY PS, 1993, J IMMUNOL, V150, P3161; Long EO, 2002, SEMIN CANCER BIOL, V12, P57, DOI 10.1006/scbi.2001.0398; Pardoll DM, 2001, SCIENCE, V294, P534, DOI 10.1126/science.1066284; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; Tieng V, 2002, P NATL ACAD SCI USA, V99, P2977, DOI 10.1073/pnas.032668099; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; Yee C, 1999, J IMMUNOL, V162, P2227	20	1182	1272	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	2002	419	6908					734	738		10.1038/nature01112	http://dx.doi.org/10.1038/nature01112			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384702				2022-12-28	WOS:000178615200044
J	Heinrich, AJ; Lutz, CP; Gupta, JA; Eigler, DM				Heinrich, AJ; Lutz, CP; Gupta, JA; Eigler, DM			Molecule cascades	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPE; VIBRATIONAL SPECTROSCOPY; ADSORBATE INTERACTIONS; CELLULAR-AUTOMATA; QUANTUM DIFFUSION; HYDROGEN; CO; TEMPERATURE; ADSORPTION; DEUTERIUM	Carbon monoxide molecules were arranged in atomically precise configurations, which we call "molecule cascades," where the motion of one molecule causes the subsequent motion of another, and so on in a cascade of motion similar to a row of toppling dominoes. Isotopically pure cascades were assembled on a copper (111) surface with a low-temperature scanning tunneling microscope. The hopping rate of carbon monoxide molecules in cascades was found to be independent of temperature below 6 kelvin and to exhibit a pronounced isotope effect, hallmarks of a quantum tunneling process. At higher temperatures, we observed a thermally activated hopping rate with an anomalously low Arrhenius prefactor that we interpret as tunneling from excited vibrational states. We present a cascade-based computation scheme that has all of the devices and interconnects required for the one-time computation of an arbitrary logic function. Logic gates and other devices were implemented by engineered arrangements of molecules at the intersections of cascades. We demonstrate a three-input sorter that uses several AND gates and OR gates, as well as the crossover and fan-out units needed to connect them.	IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA	International Business Machines (IBM)	Heinrich, AJ (corresponding author), IBM Corp, Almaden Res Ctr, Div Res, 650 Harry Rd, San Jose, CA 95120 USA.		Gupta, Jay/AGK-0162-2022	Gupta, Jay/0000-0002-3908-7719				Amlani I, 1999, SCIENCE, V284, P289, DOI 10.1126/science.284.5412.289; Baer R, 1998, SURF SCI, V411, pL783, DOI 10.1016/S0039-6028(98)00322-7; BAER R, 1996, PHYS REV B, V54; Bartels L, 1999, SURF SCI, V432, pL621, DOI 10.1016/S0039-6028(99)00640-8; Bartels L, 1997, APPL PHYS LETT, V71, P213, DOI 10.1063/1.119503; Barth JV, 2000, PHYS REV LETT, V84, P1732, DOI 10.1103/PhysRevLett.84.1732; Barth JV, 2000, SURF SCI REP, V40, P75, DOI 10.1016/S0167-5729(00)00002-9; Braich RS, 2002, SCIENCE, V296, P499, DOI 10.1126/science.1069528; Braun J, 1996, J CHEM PHYS, V105, P3258, DOI 10.1063/1.471841; Briner BG, 1997, SCIENCE, V278, P257, DOI 10.1126/science.278.5336.257; Cao GX, 1997, PHYS REV LETT, V79, P3696, DOI 10.1103/PhysRevLett.79.3696; Cowburn RP, 2000, SCIENCE, V287, P1466, DOI 10.1126/science.287.5457.1466; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; DREXLER KE, 1992, NANOSYSTEMS; EIGLER DM, 1991, NATURE, V352, P600, DOI 10.1038/352600a0; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Goldhaber-Gordon D, 1997, P IEEE, V85, P521, DOI 10.1109/5.573739; Huang Y, 2001, SCIENCE, V294, P1313, DOI 10.1126/science.1066192; Knorr N, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.115420; Kua J, 2001, J CHEM PHYS, V115, P5620, DOI 10.1063/1.1396815; LANDAUER R, 1990, PHYSICA A, V168, P75, DOI 10.1016/0378-4371(90)90359-Z; Lauhon LJ, 2000, PHYS REV LETT, V85, P4566, DOI 10.1103/PhysRevLett.85.4566; Lauhon LJ, 1999, PHYS REV B, V60, pR8525, DOI 10.1103/PhysRevB.60.R8525; Lent CS, 1997, P IEEE, V85, P541, DOI 10.1109/5.573740; Meindl JD, 2001, SCIENCE, V293, P2044, DOI 10.1126/science.293.5537.2044; Okawa Y, 2001, J CHEM PHYS, V115, P2317, DOI 10.1063/1.1384554; Ovesson S, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.125423; Pascual JI, 2002, SURF SCI, V502, P1, DOI 10.1016/S0039-6028(01)01890-8; Price PJ, 1998, AM J PHYS, V66, P1119, DOI 10.1119/1.19053; RAVAL R, 1988, SURF SCI, V203, P353, DOI 10.1016/0039-6028(88)90088-X; Seitz Charles L., 1980, INTRO VLSI SYSTEMS, P218; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; SWADE DD, 1993, SCI AM, V268, P86, DOI 10.1038/scientificamerican0293-86; Tseng GY, 2001, SCIENCE, V294, P1293, DOI 10.1126/science.1066920; Wind SJ, 2002, APPL PHYS LETT, V80, P3817, DOI 10.1063/1.1480877; Witte G, 2002, SURF SCI, V502, P405, DOI 10.1016/S0039-6028(01)01986-0; WITTL F, 1993, J CHEM PHYS, V98, P9554, DOI 10.1063/1.464386	37	398	410	1	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1381	1387		10.1126/science.1076768	http://dx.doi.org/10.1126/science.1076768			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12399543				2022-12-28	WOS:000179223100042
J	Atkinson, L; Milligan, CJ; Buckley, NJ; Deuchars, J				Atkinson, L; Milligan, CJ; Buckley, NJ; Deuchars, J			Purinergic receptors - An ATP-gated ion channel at the cell nucleus	NATURE			English	Article							P2X(7) RECEPTOR; PERMEABILITY; INTERNEURONS; HIPPOCAMPUS		Univ Leeds, Sch Biomed Sci, Leeds LS2 9NQ, W Yorkshire, England; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Atkinson, L (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9NQ, W Yorkshire, England.		Buckley, Noel J/B-9675-2012; Deuchars, Jim/L-3740-2019	Buckley, Noel J/0000-0003-1152-0653; Deuchars, Jim/0000-0002-4445-654X				Assandri R, 1997, J MEMBRANE BIOL, V157, P301, DOI 10.1007/s002329900237; Bading H, 2000, EUR J BIOCHEM, V267, P5280, DOI 10.1046/j.1432-1327.2000.01565.x; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; Du J, 1996, J NEUROSCI, V16, P506; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; MAZZANTI M, 1994, FASEB J, V8, P231, DOI 10.1096/fasebj.8.2.7509760; Sperlagh B, 2002, J NEUROCHEM, V81, P1196, DOI 10.1046/j.1471-4159.2002.00920.x; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735	10	45	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					42	42		10.1038/420042a	http://dx.doi.org/10.1038/420042a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422208				2022-12-28	WOS:000179068100030
J	Blumenthal, SJ; Hendi, JM; Marsillo, L				Blumenthal, SJ; Hendi, JM; Marsillo, L			A public health approach to decreasing obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US Dept HHS, Washington, DC 20201 USA		Blumenthal, SJ (corresponding author), US Dept HHS, Washington, DC 20201 USA.							Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P986; Division of Adult and Community Health National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention, 2002, BEH RISK FACT SURV S; LEE T, 2002, KSG FACULTY RES WORK; *NAT CTR CHRON DIS, 2002, YOUTH RISK BEH SURV; *NAT I DIAB DIG KI, 2002, CHOOS SAF SUCC WEIGH; Putnam J., 2000, FoodReview, V23, P2; SPAKE A, 2002, US NEWS WORLD RE AUG; *US DHHS, 2001, SURG GEN CALL ACT PR; Variyam J. N., 2002, FoodReview, V25, P13	9	17	17	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2178	2178		10.1001/jama.288.17.2178	http://dx.doi.org/10.1001/jama.288.17.2178			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413384	hybrid			2022-12-28	WOS:000179048100034
J	Zandi, PP; Carlson, MC; Plassman, BL; Welsh-Bohmer, KA; Mayer, LS; Steffens, DC; Breitner, JCS				Zandi, PP; Carlson, MC; Plassman, BL; Welsh-Bohmer, KA; Mayer, LS; Steffens, DC; Breitner, JCS		Cache County Memory Study Investig	Hormone replacement therapy and incidence of Alzheimer disease in older women - The Cache County Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COGNITIVE DECLINE; CONTROLLED TRIAL; ESTROGEN; RISK; DEMENTIA; AD; POPULATION; PREVALENCE; AGE	Context Previous studies have shown a sex-specific increased risk of Alzheimer disease (AD) in women older than 80 years. Basic neuroscience findings suggest that hormone replacement therapy (HRT) could reduce a woman's risk of AD. Epidemiologic findings on AD and HRT are mixed. Objective To examine the relationship between use of HRT and risk of AD among elderly women. Design, Setting, and Participants Prospective study of incident dementia among 1357 men (mean age, 73.2 years) and 1889 women (mean age, 74.5 years) residing in a single county in Utah. Participants were first assessed in 1995-1997, with follow-up conducted in 1998-2000. History of women's current and former use of HRT, as well as of calcium and multivitamin supplements, was ascertained at the initial contact. Main Outcome Measure Diagnosis of incident AD. Results Thirty-five men (2.6%) and 88 women (4.7%) developed AD between the initial interview and time of the follow-up Q years). Incidence among women increased after age 80 years and exceeded the risk among men of similar age (adjusted hazard ratio [HR], 2.11.; 95% confidence interval [CI], 1.22-3.86). Women who used HRT had a reduced risk of AD (26 cases among 1066 women) compared with non-HRT users (58 cases among 800 women) (adjusted HR, 0.59; 95% CI, 0.36-0.96). Risk varied with duration of HRT use, so that a woman's sex-specific increase in risk disappeared entirely with more than 10 years of treatment Q cases among 427 women). Adjusted HRs were 0.41 (95% CI, 0.17-0.86) for HRT users compared with non users and 0.77 (95% CI, 0.31-1.67) compared with men. No similar effect was seen with calcium or multivitamin use. Almost all of the HRT-related reduction in incidence reflected former use of HRT (9 cases among 490 women; adjusted HR, 0.33 [95% CI, 0.15-0.65]). There was no effect with current HRT use (17 cases among 576 women; adjusted HR, 1.08 [95% CI, 0.59-1.91]) unless duration of treatment exceeded 10 years (6 cases among 344 women; adjusted HR, 0.55 [95% CI, 0.21-1.23]). Conclusions Prior HRT use is associated with reduced risk of AD, but there is no apparent benefit with current HRT use unless such use has exceeded 10 years.	VA Puget Sound Hlth Care Syst, GRECC S182, Seattle, WA 98108 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Ment Hyg, Baltimore, MD USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA; Banner Hlth Syst, Phoenix, AZ USA; Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Johns Hopkins University; Duke University; Duke University; Banner Research; Banner Health; University of Washington; University of Washington Seattle	Breitner, JCS (corresponding author), VA Puget Sound Hlth Care Syst, GRECC S182, 1660 S Columbian Way, Seattle, WA 98108 USA.	jcsb@u.washington.edu	Welsh-Bohmer, Kathleen/AAA-3178-2020; Plassman, Brenda L/K-2620-2015		NATIONAL INSTITUTE ON AGING [R01AG011380] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG-11380] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allison P.D., 1984, EVENT HIST ANAL REGR; AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; Andersen K, 1999, NEUROLOGY, V53, P1992, DOI 10.1212/WNL.53.9.1992; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; Baldereschi M, 1998, NEUROLOGY, V50, P996, DOI 10.1212/WNL.50.4.996; Breitner JCS, 1999, NEUROLOGY, V53, P321, DOI 10.1212/WNL.53.2.321; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Lerner A, 1997, LANCET, V349, P403, DOI 10.1016/S0140-6736(97)80025-6; Marder K, 2000, NEUROLOGY, V54, P2035, DOI 10.1212/WNL.54.11.2035; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Miech RA, 2002, NEUROLOGY, V58, P209, DOI 10.1212/WNL.58.2.209; MORTEL KF, 1995, J NEUROPSYCH CLIN N, V7, P334; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; RINCH CE, 2000, CHANCE DEV AGING; Seshadri S, 2001, ARCH NEUROL-CHICAGO, V58, P435, DOI 10.1001/archneur.58.3.435; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; SILVERMAN JM, 1986, AM J PSYCHIAT, V143, P1279; Skoog I, 1999, J Epidemiol Biostat, V4, P227; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965	32	694	710	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2123	2129		10.1001/jama.288.17.2123	http://dx.doi.org/10.1001/jama.288.17.2123			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413371	Bronze			2022-12-28	WOS:000179048100022
J	Freeman, MP; Watkins, NW				Freeman, MP; Watkins, NW			The heavens in a pile of sand	SCIENCE			English	Editorial Material							SELF-ORGANIZED CRITICALITY; DYNAMICS		British Antarctic Survey, NERC, Cambridge CB3 0ET, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey	Freeman, MP (corresponding author), British Antarctic Survey, NERC, Cambridge CB3 0ET, England.		Freeman, Mervyn/E-5687-2019; Watkins, Nick/GPX-7439-2022; Watkins, Nicholas Wynn/C-5140-2008	Freeman, Mervyn/0000-0002-8653-8279; Watkins, Nick/0000-0003-4484-6588; Watkins, Nicholas Wynn/0000-0003-4484-6588				Angelopoulos V, 1999, PHYS PLASMAS, V6, P4161, DOI 10.1063/1.873681; BAK P, 1987, PHYS REV LETT, V59, P381, DOI 10.1103/PhysRevLett.59.381; BOROVSKY JE, 1993, J GEOPHYS RES-SPACE, V98, P6101, DOI 10.1029/92JA02242; Chapman S, 2001, SPACE SCI REV, V95, P293, DOI 10.1023/A:1005236717469; Consolini G, 2001, SPACE SCI REV, V95, P309, DOI 10.1023/A:1005252807049; Freeman MP, 2000, GEOPHYS RES LETT, V27, P1087, DOI 10.1029/1999GL017042; Frette V, 1996, NATURE, V379, P49, DOI 10.1038/379049a0; Gorney D. J., 1991, AURORAL PHYSICS, P325; GOULD SJ, 2001, STRUCTURE EVOLUTIONA; Jensen Henrik Jeldtoft., 1998, SELF ORG CRITICALITY; KADANOFF LP, 1986, PHYS TODAY, V39, P6, DOI 10.1063/1.2814878; Lui ATY, 2000, GEOPHYS RES LETT, V27, P911, DOI 10.1029/1999GL010752; NICOLIS G, 1984, PHYS REV A, V29, P2845, DOI 10.1103/PhysRevA.29.2845; TAKALO J, 1993, GEOPHYS RES LETT, V20, P1527, DOI 10.1029/93GL01596; Uritsky VM, 2001, GEOPHYS RES LETT, V28, P3809, DOI 10.1029/2001GL013026; URITSKY VM, IN PRESS J GEOPHYS R; 1999, SCIENCE, V284	17	17	17	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					979	980		10.1126/science.1075555	http://dx.doi.org/10.1126/science.1075555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411694				2022-12-28	WOS:000178932000043
J	Militzer, M				Militzer, M			A synchrotron look at steel	SCIENCE			English	Editorial Material							FE-C; NUCLEATION; AUSTENITE; KINETICS; FERRITE		Univ British Columbia, Ctr Met Proc Engn, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Militzer, M (corresponding author), Univ British Columbia, Ctr Met Proc Engn, Vancouver, BC V6T 1Z4, Canada.	militzer@cmpe.ubc.ca						Brux U, 2002, STEEL RES, V73, P294; Eldis GT, 1978, HARDENABILITY CONCEP, P126; ENOMOTO M, 1986, METALL TRANS A, V17, P1399, DOI 10.1007/BF02650121; ENOMOTO M, 1986, METALL TRANS A, V17, P1385, DOI 10.1007/BF02650120; Heimbuch RA, 1998, ISS MWSP CONF P, V36, P3; Jones SJ, 1997, ACTA MATER, V45, P2911, DOI 10.1016/S1359-6454(96)00392-8; Militzer M, 2000, METALL MATER TRANS A, V31, P1247, DOI 10.1007/s11661-000-0120-4; Offerman SE, 2002, SCIENCE, V298, P1003, DOI 10.1126/science.1076681; Pichler A, 2001, ISS MWSP CONF P, V39, P411; Shaw J., 2002, SAE, P63; Speer JG, 2002, JOM-J MIN MET MAT S, V54, P19, DOI 10.1007/BF02700981	11	69	69	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	2002	298	5595					975	976		10.1126/science.1078210	http://dx.doi.org/10.1126/science.1078210			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411691				2022-12-28	WOS:000178932000040
J	Xu, WH; Liu, YG; Wang, S; McDonald, T; Van Eyk, JE; Sidor, A; O'Rourke, B				Xu, WH; Liu, YG; Wang, S; McDonald, T; Van Eyk, JE; Sidor, A; O'Rourke, B			Cytoprotective role of Ca2+-activated K+ channels in the cardiac inner mitochondrial membrane	SCIENCE			English	Article							RAT-LIVER; POSSIBLE MECHANISM; MATRIX VOLUME; POTASSIUM; DIAZOXIDE; RECONSTITUTION; TRANSPORT; PURIFICATION; INHIBITION; ISCHEMIA	Ion channels on the mitochondrial inner membrane influence cell function in specific ways that can be detrimental or beneficial to cell survival. At least one type of potassium (K+) channel, the mitochondrial adenosine triphosphate sensitive K+ channel (mitoK(ATP)), is an important effector of protection against necrotic and apoptotic cell injury after ischemia. Here another channel with properties similar to the surface membrane calcium-activated K+ channel was found on the mitochondrial inner membrane (mitoK(Ca)) of guinea pig ventricular cells. MitoK(Ca) significantly contributed to mitochondrial K+ uptake of the myocyte, and an opener of mitoK(Ca) protected hearts against infarction.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA; Otsuka Maryland Res Inst, Maryland Res Labs, Rockville, MD 20850 USA; Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada	Johns Hopkins University; Queens University - Canada	O'Rourke, B (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA.	bor@jhmi.edu		O'Rourke, Brian/0000-0002-5548-4853	NHLBI NIH HHS [NIHR01HL54598] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akao M, 2001, CIRC RES, V88, P1267, DOI 10.1161/hh1201.092094; DIWAN JJ, 1988, BIOCHEM BIOPH RES CO, V153, P224, DOI 10.1016/S0006-291X(88)81212-9; DIWAN JJ, 1985, J MEMBRANE BIOL, V84, P165, DOI 10.1007/BF01872214; Forbes RA, 2001, CIRC RES, V88, P802, DOI 10.1161/hh0801.089342; Garlid KD, 1997, CIRC RES, V81, P1072; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; GIANGIACOMO KM, 1993, BIOCHEMISTRY-US, V32, P2363, DOI 10.1021/bi00060a030; Gribkoff VK, 1996, MOL PHARMACOL, V50, P206; Grimmsmann T, 1998, BRIT J PHARMACOL, V123, P781, DOI 10.1038/sj.bjp.0701663; HALESTRAP AP, 1986, BIOCHEM J, V236, P779, DOI 10.1042/bj2360779; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; HANSFORD RG, 1972, BIOCHEM J, V126, P689, DOI 10.1042/bj1260689; JUNG DW, 1977, ARCH BIOCHEM BIOPHYS, V183, P452, DOI 10.1016/0003-9861(77)90380-0; KIMMICH GA, 1967, BIOCHIM BIOPHYS ACTA, V131, P413, DOI 10.1016/0005-2728(67)90001-1; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; LIU Y, 1998, CIRCULATION, V97, P2413; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Miura T, 2000, J AM COLL CARDIOL, V35, P238, DOI 10.1016/S0735-1097(99)00493-3; Murata M, 2001, CIRC RES, V89, P891, DOI 10.1161/hh2201.100205; Pain T, 2000, CIRC RES, V87, P460; PALIWAL R, 1992, BIOCHEMISTRY-US, V31, P2223, DOI 10.1021/bi00123a003; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; Ransom CB, 2001, J NEUROPHYSIOL, V85, P790, DOI 10.1152/jn.2001.85.2.790; SELWYN MJ, 1970, FEBS LETT, V10, P1, DOI 10.1016/0014-5793(70)80402-1; Shake JG, 2001, ANN THORAC SURG, V72, P1849, DOI 10.1016/S0003-4975(01)03192-7; Siemen D, 1999, BIOCHEM BIOPH RES CO, V257, P549, DOI 10.1006/bbrc.1999.0496; Wang LG, 2001, AM J PHYSIOL-HEART C, V280, pH2321, DOI 10.1152/ajpheart.2001.280.5.H2321; Yao ZH, 1999, AM J PHYSIOL-HEART C, V277, pH2504	29	386	402	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	2002	298	5595					1029	1033		10.1126/science.1074360	http://dx.doi.org/10.1126/science.1074360			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411707				2022-12-28	WOS:000178932000058
J	Eichhorn, EJ; Gheorghiade, M				Eichhorn, EJ; Gheorghiade, M			Perspective - New perspective on an old drug	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Med City Dallas Hosp, Dallas, TX 75230 USA; Northwestern Univ, Sch Med, Chicago, IL 60611 USA	Medical City Dallas Hospital; Northwestern University	Eichhorn, EJ (corresponding author), Med City Dallas Hosp, Dallas, TX 75230 USA.								0	29	30	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1394	1395		10.1056/NEJMp020118	http://dx.doi.org/10.1056/NEJMp020118			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12409540				2022-12-28	WOS:000178888400001
J	Nichols, DA; Brown, RD; Meyer, FB				Nichols, DA; Brown, RD; Meyer, FB			Coils or clips in subarachnoid haemorrhage?	LANCET			English	Editorial Material							INTRACRANIAL ANEURYSMS; HEMORRHAGE; STROKE		Mayo Clin & Mayo Fdn, Dept Radiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Neurol Surg, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Nichols, DA (corresponding author), Mayo Clin & Mayo Fdn, Dept Radiol, 200 1st St SW, Rochester, MN 55905 USA.							David CA, 1999, J NEUROSURG, V91, P396, DOI 10.3171/jns.1999.91.3.0396; de Gans K, 2002, NEUROSURGERY, V50, P336, DOI 10.1097/00006123-200202000-00018; HALEY EC, 1992, STROKE, V23, P205, DOI 10.1161/01.STR.23.2.205; International Study of Unruptured Intracranial Aneurysms Investigators, 1999, NEW ENGL J MED, V340, P1725; LINDLEY RI, 1994, CEREBROVASC DIS, V4, P314, DOI 10.1159/000108501; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; Mahoney FI, 1965, MD STATE MED J, V14, P56; Malisch TW, 1997, J NEUROSURG, V87, P176, DOI 10.3171/jns.1997.87.2.0176; Menghini VV, 1998, NEUROLOGY, V51, P405, DOI 10.1212/WNL.51.2.405; SUNDT TM, 1978, NEW ENGL J MED, V299, P116, DOI 10.1056/NEJM197807202990303	10	32	34	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1262	1263		10.1016/S0140-6736(02)11353-5	http://dx.doi.org/10.1016/S0140-6736(02)11353-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414195				2022-12-28	WOS:000178827200002
J	Scott, J; Thorne, A; Horn, P				Scott, J; Thorne, A; Horn, P			Quality improvement report - Effect of a multifaceted approach to detecting and managing depression in primary care	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; ILLNESS; PRACTITIONER; MANAGEMENT	Problem Need to improve the detection and management of depression in primary care. Design Prospective, before and after study of changes in detection and management following attempts to introduce a chronic disease management approach. Background and setting Two representative general practices in the north east of England that differed markedly in resources available and populations served. Key measures of improvement Number of cases on a depression register, number of cases accurately diagnosed, adherence to own clinical management guidelines. Strategies for change Multifaceted intervention to meet the needs of each practice modified by in-house steering group, including resources to develop a case register, an education and training programme on detection and management agreed by consensus, facilitation of meetings with secondary care staff, and support in developing a practice guideline. Effects of change Practice A (with six partners and serving a predominantly affluent white British population) improved case detection rate by 23%, reduced prescribing of sub-therapeutic doses of antidepressants by 36%, and adhered to the preferred treatment regimens. At Practice B (with three partners and two surgeries located in deprived urban inner city areas with high levels of unemployment and large ethnic minority populations) improvement in the sensitivity of case detection was accompanied by a reduction in specificity The practice did not reach consensus on its own guideline and was unable to sustain the model. Lessons learnt A simple practice based approach improved the detection and management of depression in a team familiar with the philosophy of chronic disease management, with the capacity to commit to the programme, and with a critical mass of team members being open to change. This model failed to affect depression management when staff engagement with the project was passive rather than active and die practice was less well resourced and served an economically deprived and ethnically diverse population.	Inst Psychiat, Dept Psychol Med, London SE5 8AF, England; Whole Syst Mental Hlth Project, N Tyneside NE29 0DW, England; Friarage Hosp, Northallerton DL6 1JG, England	University of London; King's College London	Scott, J (corresponding author), Inst Psychiat, Dept Psychol Med, PO 96,De Crespigny Pk, London SE5 8AF, England.		Scott, Jan/F-2966-2010	Scott, Jan/0000-0002-7203-8601				*AHCPR DEPR GUID P, 1993, AHCPR PUBL, V1; *AHCPR DEPR GUID P, 1993, AHCPR PUBL, V2; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Bashir K, 2000, BRIT J GEN PRACT, V50, P626; Cornwall PL, 2000, BRIT J GEN PRACT, V50, P908; GOLDBERG D, 1987, J ROY COLL GEN PRACT, V37, P15; Katon W, 2001, GEN HOSP PSYCHIAT, V23, P138, DOI 10.1016/S0163-8343(01)00136-0; Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6; LESSER AL, 1985, MED EDUC, V19, P299, DOI 10.1111/j.1365-2923.1985.tb01325.x; *N ENGL EV BAS GUI, 1998, 91 CHSR U NEWC; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; Scott J, 1999, BRIT J GEN PRACT, V49, P441; SOLBERG L, 2001, EFF CLIN PRACT, V6, P128; Thompson C, 2000, LANCET, V355, P185, DOI 10.1016/S0140-6736(99)03171-2; Von Korff M, 2001, BRIT MED J, V323, P948, DOI 10.1136/bmj.323.7319.948; Wagner E H, 1998, Eff Clin Pract, V1, P2; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	17	22	22	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					951	954		10.1136/bmj.325.7370.951	http://dx.doi.org/10.1136/bmj.325.7370.951			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399349	Green Published			2022-12-28	WOS:000178986300022
J	Wennberg, JE				Wennberg, JE			Unwarranted variations in healthcare delivery: implications for academic medical centres	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIAL; FOLLOW-UP; NEW-HAVEN; CARE; VISITS; BOSTON		Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH 03755 USA	Dartmouth College	Wennberg, JE (corresponding author), Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, 7251 Strasenburgh, Hanover, NH 03755 USA.							Beck A, 1997, J AM GERIATR SOC, V45, P543, DOI 10.1111/j.1532-5415.1997.tb03085.x; Coleman E A, 2001, Eff Clin Pract, V4, P49; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; Trento M, 2001, DIABETES CARE, V24, P995, DOI 10.2337/diacare.24.6.995; Wagner EH, 2001, DIABETES CARE, V24, P695, DOI 10.2337/diacare.24.4.695; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1163; Wennberg JE, 2002, HLTH AFFAIRS, DOI p.hlthaff.w2.96; 2001, US NEWS WORLD R 1011, V131, P44	11	487	498	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					961	964		10.1136/bmj.325.7370.961	http://dx.doi.org/10.1136/bmj.325.7370.961			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399352	Green Published			2022-12-28	WOS:000178986300025
J	Hochstrasser, M				Hochstrasser, M			New proteases in a ubiquitin stew	SCIENCE			English	Editorial Material							COP9 SIGNALOSOME; 26S PROTEASOME; DEGRADATION; DEUBIQUITINATION; METALLOPROTEASE; CLEAVAGE		Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Hochstrasser, M (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.	hochstrasser@yale.edu		Hochstrasser, Mark/0000-0002-1131-5484				Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Brinke A, 1996, HUM MOL GENET, V5, P1945, DOI 10.1093/hmg/5.12.1945; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; EYTAN E, 1993, J BIOL CHEM, V268, P4668; Lohi O, 2001, FEBS LETT, V508, P287, DOI 10.1016/S0014-5793(01)03079-4; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2001, MOL CELL, V8, P439, DOI 10.1016/S1097-2765(01)00308-2; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	10	15	15	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					549	+		10.1126/science.1078097	http://dx.doi.org/10.1126/science.1078097			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386321				2022-12-28	WOS:000178634800026
J	Lee, FJS; Xue, S; Pei, L; Vukusic, B; Chery, N; Wang, YS; Wang, YT; Niznik, HB; Yu, XM; Liu, F				Lee, FJS; Xue, S; Pei, L; Vukusic, B; Chery, N; Wang, YS; Wang, YT; Niznik, HB; Yu, XM; Liu, F			Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor	CELL			English	Article							CALMODULIN; CALCIUM; KINASE; NEUROTOXICITY; APOPTOSIS; EXCITOTOXICITY; PHOSPHATASE-1; MITOCHONDRIA; NEOSTRIATUM; INHIBITION	Dopamine D1-like receptors, composed of D1 and D5 receptors, have been documented to modulate glutamate-mediated fast excitatory synaptic neurotransmission. Here, we report that dopamine D1 receptors modulate NMDA glutamate receptor-mediated functions through direct protein-protein interactions. Two regions in the D1 receptor carboxyl tail can directly and selectively couple to NMDA glutamate receptor subunits NR1-1a and NR2A. While one interaction is involved in the inhibition of NMDA receptor-gated currents, the other is implicated in the attenuation of NMDA receptor-mediated excitotoxicity through a PI-3 kinase-dependent pathway.	Univ Toronto, Ctr Addict & Mental Hlth, Dept Neurosci, Clarke Div, Toronto, ON M5T 1R8, Canada; Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada; Univ Toronto, Fac Dent, Toronto, ON M5T 1R8, Canada; Univ British Columbia, Vancouver, BC V6T 1Z3, Canada; Vancouver Gen Hosp, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Vancouver Gen Hosp, Dept Med, Vancouver, BC V6T 1Z3, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; University of British Columbia; University of British Columbia; University of British Columbia	Liu, F (corresponding author), Univ Toronto, Ctr Addict & Mental Hlth, Dept Neurosci, Clarke Div, 100 Coll St, Toronto, ON M5T 1R8, Canada.		Wang, Yu Tian/A-4729-2008; Lee, Frank J.S./D-5899-2017; Wang, Yu Tian/J-8255-2015; Shin, Jung Hoon/C-9566-2012	Lee, Frank J.S./0000-0002-5768-3776; 				Blank T, 1997, P NATL ACAD SCI USA, V94, P14859, DOI 10.1073/pnas.94.26.14859; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; Cepeda C, 1998, DEV NEUROSCI-BASEL, V20, P1, DOI 10.1159/000017294; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Dingledine R, 1999, PHARMACOL REV, V51, P7; Duchen MR, 2000, CELL CALCIUM, V28, P339, DOI 10.1054/ceca.2000.0170; Egea J, 2001, J CELL BIOL, V154, P585, DOI 10.1083/jcb.200101023; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FELDMAN DS, 2002, J BIOL CHEM, V29, P29; Fischer R, 1998, FEBS LETT, V425, P175, DOI 10.1016/S0014-5793(98)00225-7; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Harvey J, 1997, J NEUROSCI, V17, P5271; HAWES BE, 1994, J BIOL CHEM, V269, P15776; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lei G, 2002, EMBO J, V21, P2977, DOI 10.1093/emboj/cdf292; Levine MS, 1996, J NEUROSCI, V16, P5870; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Lipton SA, 1998, CELL CALCIUM, V23, P165, DOI 10.1016/S0143-4160(98)90115-4; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Snyder GL, 1998, J NEUROSCI, V18, P10297; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Yu XM, 1998, NATURE, V396, P469, DOI 10.1038/24877; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZEEVALK GD, 1993, J NEUROCHEM, V61, P386, DOI 10.1111/j.1471-4159.1993.tb03585.x	47	393	416	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 18	2002	111	2					219	230		10.1016/S0092-8674(02)00962-5	http://dx.doi.org/10.1016/S0092-8674(02)00962-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408866	Bronze			2022-12-28	WOS:000178753500011
J	Nelson, D				Nelson, D			Violence against elderly people: a neglected problem	LANCET			English	Editorial Material																			0	6	6	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1094	1094		10.1016/S0140-6736(02)11137-8	http://dx.doi.org/10.1016/S0140-6736(02)11137-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12384007				2022-12-28	WOS:000178485200032
J	Grizzard, T				Grizzard, T			Undertreatment of obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Grizzard, T (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							*CDCP, 2000, MMWR-MORBID MORTAL W, V49, P797; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P854; Galuska DA, 1999, JAMA-J AM MED ASSOC, V282, P1576, DOI 10.1001/jama.282.16.1576; KUSHNER RF, 1995, PREV MED, V24, P546, DOI 10.1006/pmed.1995.1087; Miller LA, 2002, J PEDIATR-US, V141, P121, DOI 10.1067/mpd.2002.124382; OCKENE JK, 1988, ARCH INTERN MED, V148, P1039, DOI 10.1001/archinte.148.5.1039; OCKENE JK, 1991, J GEN INTERN MED, V6, P1, DOI 10.1007/BF02599381; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; Stafford RS, 2000, ARCH FAM MED, V9, P631, DOI 10.1001/archfami.9.7.631; Tershakovec AM, 1999, J PEDIATR-US, V134, P573, DOI 10.1016/S0022-3476(99)70243-X; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586	11	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2177	2177		10.1001/jama.288.17.2177	http://dx.doi.org/10.1001/jama.288.17.2177			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413383	hybrid			2022-12-28	WOS:000179048100033
J	Offerman, SE; van Dijk, NH; Sietsma, J; Grigull, S; Lauridsen, EM; Margulies, L; Poulsen, HF; Rekveldt, MT; van der Zwaag, S				Offerman, SE; van Dijk, NH; Sietsma, J; Grigull, S; Lauridsen, EM; Margulies, L; Poulsen, HF; Rekveldt, MT; van der Zwaag, S			Grain nucleation and growth during phase transformations	SCIENCE			English	Article							INDIVIDUAL GRAINS; FE; KINETICS; BOUNDARIES; AUSTENITE	The mechanical properties of polycrystalline materials are largely determined by the kinetics of the phase transformations during the production process. Progress in x-ray diffraction instrumentation at synchrotron sources has created an opportunity to study the transformation kinetics at the level of individual grains. Our measurements show that the activation energy for grain nucleation is at least two orders of magnitude smaller than that predicted by thermodynamic models. The observed growth curves of the newly formed grains confirm the parabolic growth model but also show three fundamentally different types of growth. Insight into the grain nucleation and growth mechanisms during phase transformations contributes to the development of materials with optimal mechanical properties.	Delft Univ Technol, Interfac Reactor Inst, NL-2629 JB Delft, Netherlands; Delft Univ Technol, Dept Mat Sci, NL-2628 AL Delft, Netherlands; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Riso Natl Lab, Mat Res Dept, Ctr Fundamental Res Met Struct 4D, DK-4000 Roskilde, Denmark	Delft University of Technology; Delft University of Technology; European Synchrotron Radiation Facility (ESRF); Technical University of Denmark	Offerman, SE (corresponding author), Delft Univ Technol, Interfac Reactor Inst, Mekelweg 15, NL-2629 JB Delft, Netherlands.		Lauridsen, Erik/ABF-3961-2021; Poulsen, Henning F/A-4131-2012; Sietsma, Jilt/E-8123-2013	Lauridsen, Erik/0000-0002-4923-8373; Poulsen, Henning F/0000-0001-7876-4113; Offerman, Erik/0000-0002-6157-453X				AGREN J, 1986, SCRIPTA METALL MATER, V20, P1507, DOI 10.1016/0036-9748(86)90384-4; Auer S, 2001, NATURE, V409, P1020, DOI 10.1038/35059035; Christian J., 1981, THEORY TRANSFORMATIO; CLEMM PJ, 1955, ACTA METALL MATER, V3, P70, DOI 10.1016/0001-6160(55)90014-6; Krill CE, 2001, PHYS REV LETT, V86, P842, DOI 10.1103/PhysRevLett.86.842; KUCERA J, 1982, MATER SCI ENG, V52, P1, DOI 10.1016/0025-5416(82)90067-2; LANGE WF, 1988, METALL TRANS A, V19, P427, DOI 10.1007/BF02649256; Larson BC, 2002, NATURE, V415, P887, DOI 10.1038/415887a; Lauridsen EM, 2000, SCRIPTA MATER, V43, P561, DOI 10.1016/S1359-6462(00)00430-9; Margulies L, 2001, SCIENCE, V291, P2392, DOI 10.1126/science.1057956; Onink M, 1995, J MATER SCI, V30, P6223, DOI 10.1007/BF00369670; Porter D. A., 1981, PHASE TRANSFORMATION; Poulsen HF, 2001, J APPL CRYSTALLOGR, V34, P751, DOI 10.1107/S0021889801014273; THOMPSON SW, 1988, SCRIPTA METALL MATER, V22, P1775, DOI 10.1016/S0036-9748(88)80282-5; ZENER C, 1949, J APPL PHYS, V20, P950, DOI 10.1063/1.1698258	15	311	323	7	303	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					1003	1005		10.1126/science.1076681	http://dx.doi.org/10.1126/science.1076681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411699				2022-12-28	WOS:000178932000049
J	Khatri, GR; Frieden, TR				Khatri, GR; Frieden, TR			Controlling tuberculosis in India	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY; TRANSMISSION; DYNAMICS	Background: Tuberculosis kills nearly 500,000 people in India each year. Until recently, less than half of patients with tuberculosis received an accurate diagnosis, and less than half of those received effective treatment. Methods: We analyzed the effects of new policies introduced in 1993 that have resulted in increased resources, improved laboratory-based diagnosis, direct observation of treatment, and the use of standardized antituberculosis regimens and reporting methods. Results: By September 2001, more than 200,000 health workers had been trained, and 436 million people (more than 40 percent of the entire population) had access to services. About 3.4 million patients had been evaluated for tuberculosis, and nearly 800,000 had received treatment, with a success rate greater than 80 percent. More than half of all those treated in the past 8 years were treated in the past 12 months. Conclusions: India's tuberculosis-control program has been successful in improving access to care, the quality of diagnosis, and the likelihood of successful treatment. We estimate that the improved program has prevented 200,000 deaths, with indirect savings of more than $400 million - more than eight times the cost of implementation. It will be a substantial challenge to sustain and expand the program, given the country's level of economic development, limited primary health care system, and large and mostly unregulated private health care system, as well as the dual threats of the human immunodeficiency virus and multidrug-resistant tuberculosis.	Govt India, Minist Hlth & Family Welf, Directorate Gen Hlth Serv, New Delhi, India; WHO, Reg Off SE Asia, New Delhi, India; Ctr Dis Control & Prevent, Atlanta, GA USA	World Health Organization; Centers for Disease Control & Prevention - USA	Frieden, TR (corresponding author), 125 Worth St,CN 28, New York, NY 10013 USA.			Frieden, Thomas/0000-0002-4759-2256				BANERJI D, 1963, B WORLD HEALTH ORGAN, V29, P665; De Cock KM, 2000, TROP MED INT HEALTH, V5, pA3; *DIR GEN HLTH SERV, 2002, TUB CONTR IND; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; FOX W, 1962, Bull Int Union Tuberc, V32, P307; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; Gilks CF, 1997, AIDS, V11, P911, DOI 10.1097/00002030-199707000-00011; Grzybowski S, 1991, Bull Int Union Tuberc Lung Dis, V66, P193; MADRAS TUBERCULOSIS CHEMOTHERAPY CENTRE., 1964, Bulletin of the World Health Organization, V31, P247; Palittapongarnpim P, 1997, INT J TUBERC LUNG D, V1, P370; Paramasivan C. N., 2000, Indian Journal of Tuberculosis, V47, P27; Raviglione M, 2001, INT J TUBERC LUNG D, V5, P213; Suarez PG, 2001, J INFECT DIS, V184, P473, DOI 10.1086/322777; Swaminathan S, 2000, INT J TUBERC LUNG D, V4, P839; *TUB CHEM CTR, 1959, B WORLD HEALTH ORGAN, V21, P51; UPLEKAR MW, 1993, TUBERCLE LUNG DIS, V74, P332, DOI 10.1016/0962-8479(93)90108-A; *WHO, 2000, WHOCDSTB2000278; *WHO REG OFF SE AS, 2000, WHOSEATB224 REG OFF; Wilkinson D, 1997, TROP MED INT HEALTH, V2, P747, DOI 10.1046/j.1365-3156.1997.d01-386.x; World Bank, 1997, WORLD DEV REP STAT C; World Health Organization, 1997, WHOTB97220	21	100	103	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1420	1425		10.1056/NEJMsa020098	http://dx.doi.org/10.1056/NEJMsa020098			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12409545				2022-12-28	WOS:000178888400006
J	Chinnery, PF; Samuels, DC; Elson, J; Turnbull, DM				Chinnery, PF; Samuels, DC; Elson, J; Turnbull, DM			Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism?	LANCET			English	Article							MTDNA; REPLICATION; INCREASE; MUSCLE; TUMORS; MOUSE	In man, cells accumulate somatic mutations of mitochondrial DNA (mtDNA) as part of normal ageing. Although the overall concentration of mutant mtDNA is low in tissue as a whole, very high numbers of various mtDNA mutations develop in individual cells within the same person, which causes age-associated mitochondrial dysfunction. Some tumours contain high numbers of mtDNA mutations that are not present in healthy tissues from the same individual. The proportion of mutant mtDNA also rises in patients with progressive neurological disease due to inherited mtDNA mutations. This increase parallels the relentless clinical progression seen in these disorders. Mathematical models suggest that the same basic cellular mechanisms are responsible for the amplification of mutant mtDNA in ageing, in tumours, and in mtDNA disease. The accumulation of cells that contain high levels of mutant mtDNA may be an inevitable result of the normal mechanisms that maintain cellular concentrations of mtDNA.	Newcastle Univ, Dept Neurol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Newcastle Univ, Dept Math, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Chinnery, PF (corresponding author), Newcastle Univ, Dept Neurol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	p.f.chinnery@ncl.ac.uk	Samuels, David/AHC-8381-2022; Samuels, David/C-1365-2012; Samuels, David C/A-5393-2008	Samuels, David/0000-0003-3529-7791; Samuels, David C/0000-0003-3529-7791; Chinnery, Patrick/0000-0002-7065-6617; /0000-0002-3551-5624				Augenlicht LH, 2001, NAT GENET, V28, P104, DOI 10.1038/88800; BIRKY CW, 1994, J HERED, V85, P355, DOI 10.1093/oxfordjournals.jhered.a111480; BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0; Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212; Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.0.CO;2-P; Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; CORTOPASSI G, 1990, NUCLEIC ACIDS RES, V275, P169; Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392; Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Moraes CT, 2001, TRENDS GENET, V17, P199, DOI 10.1016/S0168-9525(01)02238-7; MORGANHUGHES JA, 1994, MYOLOGY, P1610; Nakayama T, 2000, IPAP CONFERENCE SER, V1, P7, DOI 10.1109/ROMAN.2000.892461; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; Turnbull DM, 1998, NAT GENET, V18, P199, DOI 10.1038/ng0398-199; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Weber K, 1997, AM J HUM GENET, V60, P373	23	165	180	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 26	2002	360	9342					1323	1325		10.1016/S0140-6736(02)11310-9	http://dx.doi.org/10.1016/S0140-6736(02)11310-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414225				2022-12-28	WOS:000178827200031
J	Sheng, M; Kim, MJ				Sheng, M; Kim, MJ			Postsynaptic signaling and plasticity mechanisms	SCIENCE			English	Review							AMPA RECEPTOR TRAFFICKING; PROTEIN-KINASE-C; LONG-TERM POTENTIATION; SYNAPTIC-TRANSMISSION; GLUTAMATE RECEPTORS; NMDA RECEPTORS; PDZ DOMAINS; DEPENDENT REGULATION; GLUR1 SUBUNIT; RAS	In excitatory synapses of the brain, specific receptors in the postsynaptic membrane lie ready to respond to the release of the neurotransmitter glutamate from the presynaptic terminal. Upon stimulation, these glutamate receptors activate multiple biochemical pathways that transduce signals into the postsynaptic neuron. Different kinds of synaptic activity elicit different patterns of postsynaptic signals that lead to short- or long-lasting strengthening or weakening of synaptic transmission. The complex molecular mechanisms that underlie postsynaptic signaling and plasticity are beginning to emerge.	MIT, Howard Hughes Med Inst, RIKEN MIT Neurosci Res Ctr, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN	Sheng, M (corresponding author), MIT, Howard Hughes Med Inst, RIKEN MIT Neurosci Res Ctr, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA.	msheng@mit.edu		Sheng, Morgan/0000-0002-8703-5366				Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; AEL DE, 2002, CELL, V108, P849; Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Bi GQ, 2001, ANNU REV NEUROSCI, V24, P139, DOI 10.1146/annurev.neuro.24.1.139; Borgdorff AJ, 2002, NATURE, V417, P649, DOI 10.1038/nature00780; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Choi S, 2000, NAT NEUROSCI, V3, P330, DOI 10.1038/73895; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; El-Hussein AE, 2000, SCIENCE, V290, P1364; Fong DK, 2002, J NEUROSCI, V22, P2153, DOI 10.1523/JNEUROSCI.22-06-02153.2002; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hanley JG, 2002, NEURON, V34, P53, DOI 10.1016/S0896-6273(02)00638-4; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Heynen AJ, 2000, NEURON, V28, P527, DOI 10.1016/S0896-6273(00)00130-6; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kameyama K, 1998, NEURON, V21, P1163, DOI 10.1016/S0896-6273(00)80633-9; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim CH, 2001, P NATL ACAD SCI USA, V98, P11725, DOI 10.1073/pnas.211132798; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; LEE SH, IN PRESS NEURON; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Manabe T, 2000, J NEUROSCI, V20, P2504; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; Morishita W, 2001, NEURON, V32, P1133, DOI 10.1016/S0896-6273(01)00554-2; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Renger JJ, 2001, NEURON, V29, P469, DOI 10.1016/S0896-6273(01)00219-7; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Sala C, 2000, J NEUROSCI, V20, P3529, DOI 10.1523/JNEUROSCI.20-10-03529.2000; Sanna PP, 2002, J NEUROSCI, V22, P3359; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Shen L, 2000, J NEUROSCI, V20, P7932; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Sheng M, 2001, CELL, V105, P825, DOI 10.1016/S0092-8674(01)00406-8; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Silva AJ, 1997, NAT GENET, V15, P281, DOI 10.1038/ng0397-281; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Steigerwald F, 2000, J NEUROSCI, V20, P4573, DOI 10.1523/JNEUROSCI.20-12-04573.2000; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tovar KR, 2002, NEURON, V34, P253; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Winder DG, 2001, NAT REV NEUROSCI, V2, P461, DOI 10.1038/35081514; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773; Zakharenko SS, 2001, NAT NEUROSCI, V4, P711, DOI 10.1038/89498; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	87	559	586	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					776	780		10.1126/science.1075333	http://dx.doi.org/10.1126/science.1075333			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399578				2022-12-28	WOS:000178791200045
J	Urquhart, K				Urquhart, K			European research - Directive could give postdocs permanency	SCIENCE			English	News Item																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					724	724						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399558				2022-12-28	WOS:000178791200009
J	Honma, S; Kawamoto, T; Takagi, Y; Fujimoto, K; Sato, F; Noshiro, M; Kato, Y; Honma, K				Honma, S; Kawamoto, T; Takagi, Y; Fujimoto, K; Sato, F; Noshiro, M; Kato, Y; Honma, K			Dec1 and Dec2 are regulators of the mammalian molecular clock	NATURE			English	Article							CIRCADIAN CLOCK; LOOP; TRANSCRIPTION; PROTEINS; RHYTHM; GENE; PATHWAYS; PERIOD; BMAL1; MOUSE	The circadian rhythms in mammals are regulated by a pacemaker located in the suprachiasmatic nucleus of the hypothalamus(1,2). Four clock-gene families have been found to be involved in a transcription-translation feedback loop that generates the circadian rhythm at the intracellular level(3). The proteins Clock and Bmal1 form a heterodimer which activates the transcription of the Per gene from the E-box elements in its promoter region(4,5). Protein products of Per act together with Cry proteins to inhibit Per transcription(6,7), thus closing the autoregulatory feedback loop. We found that Dec1 and Dec2, basic helix-loop-helix transcription factors, repressed Clock/Bmal1-induced transactivation of the mouse Per1 promoter through direct protein-protein interactions with Bmal1 and/or competition for E-box elements. Dec1 and Dec2 are expressed in the suprachiasmic nucleus in a circadian fashion, with a peak in the subjective day. A brief light pulse induced Dec1 but not Dec2 expression in the suprachiasmic nucleus in a phase-dependent manner. Dec1 and Dec2 are regulators of the mammalian molecular clock, and form a fifth clock-gene family.	Hokkaido Univ, Grad Sch Med, Dept Physiol, Sapporo, Hokkaido 0608638, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Hiroshima 7348553, Japan	Hokkaido University; Hiroshima University	Honma, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Physiol, Sapporo, Hokkaido 0608638, Japan.	sathonma@med.hokudai.ac.jp	, 河本健/D-7938-2015	, 河本健/0000-0003-3337-1775				Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hida A, 2000, GENOMICS, V65, P224, DOI 10.1006/geno.2000.6166; HONMA K, 1985, JPN J PHYSIOL, V35, P643, DOI 10.2170/jjphysiol.35.643; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Masubuchi S, 2000, EUR J NEUROSCI, V12, P4206, DOI 10.1046/j.1460-9568.2000.01313.x; Mitsui S, 2001, GENE DEV, V15, P995, DOI 10.1101/gad.873501; MOORE RY, 1985, ANN NY ACAD SCI, V453, P123, DOI 10.1111/j.1749-6632.1985.tb11805.x; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Stephan F.K., 1972, P NATL ACAD SCI USA, V54, P1521; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Teramoto M, 2001, J BIOCHEM-TOKYO, V129, P391, DOI 10.1093/oxfordjournals.jbchem.a002869; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; Yagita K, 2000, GENE DEV, V14, P1353; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yu WJ, 2002, BIOCHEM BIOPH RES CO, V290, P933, DOI 10.1006/bbrc.2001.6300; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	29	485	507	1	45	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 24	2002	419	6909					841	+		10.1038/nature01123	http://dx.doi.org/10.1038/nature01123			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397359				2022-12-28	WOS:000178769800047
J	Koskinen, MT; Haugen, TO; Primmer, CR				Koskinen, MT; Haugen, TO; Primmer, CR			Contemporary fisherian life-history evolution in small salmonid populations	NATURE			English	Article							NATURAL-SELECTION; DIFFERENTIATION; DIVERGENCE; THYMALLUS; GENETICS; LOCI	The relative importance of natural selection(1) and random drift(2) in phenotypic evolution has been discussed since the introduction of the first population genetic models(3-5). The empirical evidence used to evaluate the evolutionary theories of Fisher(1) and Wright(2) remains obscure because formal tests for neutral divergence(6-8) or sensitive attempts to separate the effects of selection and drift are scarce, subject to error, and have not been interpreted in the light of well-known population demography. We combined quantitative genetic and microsatellite DNA analyses to investigate the determinants of contemporary life-history evolution in isolated populations of grayling (Thymallus thymallus, Salmonidae) that originated from a common source 80-120 years ago. Here we show that natural selection was the dominant diversifying agent in the evolution of the quantitative traits. However, the populations were founded by a small number of individuals, exhibit very low microsatellite-based effective sizes and show genetic imprints of severe 'bottlenecks'; which are conditions often suggested to constrain selection and favour drift(6,8,9). This study demonstrates a very clear case of fisherian evolution in small natural populations across a contemporary timescale.	Univ Helsinki, Dept Systemat & Ecol, Div Populat Biol, FIN-00014 Helsinki, Finland; Univ Oslo, Dept Biol, Div Zool, N-0316 Oslo, Norway	University of Helsinki; University of Oslo	Koskinen, MT (corresponding author), Univ Helsinki, Dept Systemat & Ecol, Div Populat Biol, POB 65,Viikinkaari 1, FIN-00014 Helsinki, Finland.	mtkoskin@cc.helsinki.fi	Primmer, Craig R/B-8179-2008; Peng, Bo/A-6920-2009	Primmer, Craig R/0000-0002-3687-8435; Peng, Bo/0000-0001-8225-2284				BAKER AJ, 1992, EVOLUTION, V46, P1784, DOI 10.1111/j.1558-5646.1992.tb01169.x; Balloux F, 2001, J HERED, V92, P301, DOI 10.1093/jhered/92.3.301; Beaumont MA, 1999, GENETICS, V153, P2013; CARSON HL, 1984, ANNU REV ECOL SYST, V15, P97, DOI 10.1146/annurev.es.15.110184.000525; Fisher R.A., 1930, GENETICAL THEORY NAT; FRY JD, 1992, EVOLUTION, V46, P540, DOI 10.1111/j.1558-5646.1992.tb02057.x; Gillespie J.H., 1992, CAUSES MOL EVOLUTION; Goudet J, 1995, J HERED, V86, P485, DOI 10.1093/oxfordjournals.jhered.a111627; Grant PR, 2002, SCIENCE, V296, P707, DOI 10.1126/science.1070315; Haugen TO, 2001, GENETICA, V112, P475, DOI 10.1023/A:1013315116795; Haugen TO, 2000, J EVOLUTION BIOL, V13, P897, DOI 10.1046/j.1420-9101.2000.00242.x; Hendry AP, 1999, EVOLUTION, V53, P1637, DOI 10.1111/j.1558-5646.1999.tb04550.x; Hendry AP, 2001, GENETICA, V112, P515, DOI 10.1023/A:1013367100865; Kimura M., 1983, NEUTRAL THEORY MOL E; Kingsolver JG, 2001, AM NAT, V157, P245, DOI 10.1086/319193; Koskinen MT, 2001, CONSERV GENET, V2, P173, DOI 10.1023/A:1011886412830; Koskinen MT, 2002, HEREDITY, V88, P391, DOI 10.1038/sj.hdy.6800072; LANDE R, 1976, EVOLUTION, V30, P314, DOI [10.1111/j.1558-5646.1976.tb00911.x, 10.2307/2407703]; LANDE R, 1977, EVOLUTION, V31, P442, DOI 10.1111/j.1558-5646.1977.tb01025.x; Losos JB, 1997, NATURE, V387, P70, DOI 10.1038/387070a0; LYNCH M, 1990, AM NAT, V136, P727, DOI 10.1086/285128; LYNCH M, 1998, GENETICS ANAL QUANTI, P328; Majerus M, 1998, MELANISM EVOLUTION A; Merila J, 2001, J EVOLUTION BIOL, V14, P892, DOI 10.1046/j.1420-9101.2001.00348.x; O'Ryan C, 1998, ANIM CONSERV, V1, P85, DOI 10.1111/j.1469-1795.1998.tb00015.x; RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573; Reznick DN, 1997, SCIENCE, V275, P1934, DOI 10.1126/science.275.5308.1934; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; Wright S, 1931, GENETICS, V16, P0097; WRIGHT S, 1951, ANN EUGENIC, V15, P323	30	212	217	1	78	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 24	2002	419	6909					826	830		10.1038/nature01029	http://dx.doi.org/10.1038/nature01029			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397355				2022-12-28	WOS:000178769800043
J	Zacchi, P; Gostissa, M; Uchida, T; Salvagno, C; Avolio, F; Volinia, S; Ronai, Z; Blandino, G; Schneider, C; Del Sal, G				Zacchi, P; Gostissa, M; Uchida, T; Salvagno, C; Avolio, F; Volinia, S; Ronai, Z; Blandino, G; Schneider, C; Del Sal, G			The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults	NATURE			English	Article							CYCLIN-DEPENDENT KINASES; BETA-CATENIN; APOPTOSIS; PHOSPHORYLATION; DEATH; ACCUMULATION; MITOSIS; DOMAINS; BINDING; AGENTS	The tumour suppressor p53 is important in the cell decision to either arrest cell cycle progression or induce apoptosis in response to a variety of stimuli. p53 post-translational modifications and association with other proteins have been implicated in the regulation of its stability and transcriptional activities(1,2). Here we report that, on DNA damage, p53 interacts with Pin1, a peptidyl-prolyl isomerase 3, which regulates the function of many proteins involved in cell cycle control and apoptosis(4-6). The interaction is strictly dependent on p53 phosphorylation, and requires Ser 33, Thr 81 and Ser 315. On binding, Pin1 generates conformational changes in p53, enhancing its transactivation activity. Stabilization of p53 is impaired in UV-treated Pin1(-/-) cells owing to its inability to efficiently dissociate from Mdm2. As a consequence, a reduced p53-dependent response was detected in Pin1(-/-) cells, and this correlates with a diminished transcriptional activation of some p53-regulated genes. Our results suggest that, following stress-induced phosphorylation, p53 needs to form a complex with Pin1 and to undergo a conformational change to fulfil its biological roles.	Lab Nazl CIB, I-34012 Trieste, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34100 Trieste, Italy; Tohoku Univ, Inst Dev Aging & Canc, Dept Pathol, Sendai, Miyagi 9808575, Japan; Univ Ferrara, Sez Istol & Embriol, Dipartimento Morfol & Embriol, I-44100 Ferrara, Italy; CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	University of Trieste; Tohoku University; University of Ferrara; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Del Sal, G (corresponding author), Lab Nazl CIB, AREA Sci Pk,Padriciano 99, I-34012 Trieste, Italy.		Volinia, Stefano/AAA-9264-2019; Volinia, Stefano/A-3029-2010; Blandino, Giovanni/B-1137-2013	Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Blandino, Giovanni/0000-0002-6970-2241; Uchida, Takafumi/0000-0003-3665-4906; RONAI, ZEEV/0000-0002-3859-0400; DEL SAL, GIANNINO/0000-0003-2185-6003; Avolio, Fabio/0000-0003-2067-5315				Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; KWONSEOP K, 2000, MOL BIOL CELL, V11, P3509; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Pathan N, 2001, NEOPLASIA, V3, P70, DOI 10.1038/sj.neo.7900131; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459	28	357	367	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					853	857		10.1038/nature01120	http://dx.doi.org/10.1038/nature01120			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397362				2022-12-28	WOS:000178769800050
J	Levinson, W; Linzer, M				Levinson, W; Linzer, M			What is an academic general internist? Career options and training pathways	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTEGRATING CLINICIAN-EDUCATORS; MEDICAL-CENTERS; HOSPITALIST MOVEMENT; RACIAL DISPARITIES; CHALLENGES; PROMOTION; FUTURE	Academic divisions of general internal medicine have developed and flourished in the last 2 decades. Young faculty can join these divisions in 1 of 3 possible career paths: clinical educator, clinical researcher, and, most recently, the "hospitalist." This article describes the typical job description, training pathway, and rewards and challenges for each path for students and residents considering a career in academic general internal medicine.	Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; Univ Wisconsin, Sch Med, Madison, WI USA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Wisconsin System; University of Wisconsin Madison	Levinson, W (corresponding author), Univ Toronto, 190 Elizabeth St,Suite 3-805, Toronto, ON M5B 1W8, Canada.	wendy.levinson@utoronto.ca						BARDES CL, 1995, ACAD MED, V70, P111, DOI 10.1097/00001888-199502000-00013; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Beasley BW, 1997, JAMA-J AM MED ASSOC, V278, P723, DOI 10.1001/jama.278.9.723; BECKETT W, 1994, J GEN INTERN MED, V9, P513; Chertow GM, 2001, JAMA-J AM MED ASSOC, V286, P2839, DOI 10.1001/jama.286.22.2839; EISENBERG JM, 1985, AM J MED, V78, P283, DOI 10.1016/0002-9343(85)90439-5; Epstein AM, 2000, NEW ENGL J MED, V343, P1537, DOI 10.1056/NEJM200011233432106; Epstein AM, 2001, NEW ENGL J MED, V344, P1471, DOI 10.1056/NEJM200105103441911; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES; FRIEDMAN RH, 1982, ANN INTERN MED, V96, P233, DOI 10.7326/0003-4819-96-2-233; FRIEDMAN RH, 1986, J GEN INTERN MED, V1, P134, DOI 10.1007/BF02599820; FRIEDMAN RH, 1985, ANN INTERN MED, V103, P439, DOI 10.7326/0003-4819-103-3-439; Gerrity MS, 1997, J GEN INTERN MED, V12, pS90, DOI 10.1046/j.1525-1497.12.s2.13.x; GOLDMAN L, 1991, J GEN INTERN MED, V6, P341, DOI 10.1007/BF02597435; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; Guyatt G., 2015, USERS GUIDES MED LIT; Hauer KE, 1999, WESTERN J MED, V171, P367; Hoff TH, 2001, ARCH INTERN MED, V161, P851, DOI 10.1001/archinte.161.6.851; Levinson W, 1999, NEW ENGL J MED, V341, P840, DOI 10.1056/NEJM199909093411111; Levinson W, 1998, ANN INTERN MED, V129, P59, DOI 10.7326/0003-4819-129-1-199807010-00013; Levinson W, 2000, ACAD MED, V75, P906, DOI 10.1097/00001888-200009000-00012; LIPKIN M, 1990, ANN INTERN MED, V112, P371, DOI 10.7326/0003-4819-112-5-371; Lipkin MJ, 1995, MED INTERVIEW CLIN C; Litzelman DK, 1998, ACAD MED, V73, P688, DOI 10.1097/00001888-199806000-00016; Lubitz RM, 1997, J GEN INTERN MED, V12, pS71, DOI 10.1046/j.1525-1497.12.s2.10.x; Lurie JD, 1999, AM J MED, V106, P441, DOI 10.1016/S0002-9343(99)00045-5; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; Speer AJ, 1999, AM J MED, V106, P381; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487; Wachter RM, 1998, J GEN INTERN MED, V13, P783, DOI 10.1046/j.1525-1497.1998.00234.x; Zakowski LJ, 1998, J GEN INTERN MED, V13, P410, DOI 10.1046/j.1525-1497.1998.00121.x; Zinn WM, 1998, J GEN INTERN MED, V13, P186, DOI 10.1046/j.1525-1497.1998.00055.x	33	22	22	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	2002	288	16					2045	2048		10.1001/jama.288.16.2045	http://dx.doi.org/10.1001/jama.288.16.2045			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	606QW	12387659	Bronze			2022-12-28	WOS:000178745500030
J	Donaldson, C; Currie, G; Mitton, C				Donaldson, C; Currie, G; Mitton, C			Cost effectiveness analysis in health care: contraindications	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; ECONOMIC-EVALUATION; DECISION-MAKING; MANAGED CARE; THERAPY; DISEASE		Univ Newcastle Upon Tyne, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Business, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Calgary, Dept Community Hlth Sci, Calgary, AB 52N 4N1, Canada; Univ Calgary, Dept Econ, Calgary, AB 52N 4N1, Canada; Univ Calgary, Ctr Hlth & Policy Studies, Calgary, AB T2N 1N4, Canada	Newcastle University - UK; Newcastle University - UK; University of Calgary; University of Calgary; University of Calgary	Donaldson, C (corresponding author), Univ Newcastle Upon Tyne, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.			Donaldson, Cam/0000-0003-4670-5340				Donaldson C, 1996, HEALTH ECON, V5, P267, DOI 10.1002/(SICI)1099-1050(199605)5:3<267::AID-HEC209>3.0.CO;2-X; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; El-Serag HB, 2000, ANN INTERN MED, V132, P261, DOI 10.7326/0003-4819-132-4-200002150-00003; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; GAFNI A, 1993, CAN MED ASSOC J, V148, P913; Garcia-Altes A, 2001, HEALTH ECON, V10, P715, DOI 10.1002/hec.608; GOLD MR, 2001, PHARMACOECONOMICS, V19, P609; Gould MK, 1999, ANN INTERN MED, V130, P789, DOI 10.7326/0003-4819-130-10-199905180-00002; Hoffmann C, 2000, HEALTH POLICY, V52, P179, DOI 10.1016/S0168-8510(00)00076-2; James M, 2000, BRIT MED J, V320, P1627, DOI 10.1136/bmj.320.7250.1627; JOHANNESSON M, 1991, HEALTH POLICY, V17, P1, DOI 10.1016/0168-8510(91)90114-D; Johnston K, 1999, BRIT MED J, V319, P1097, DOI 10.1136/bmj.319.7217.1097; KERLIKOWSKE K, 1999, JAMA-J AM MED ASSOC, V282, P2157; Litvak E, 2000, AM J MANAG CARE, V6, P254; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; NEUHAUSER D, 1975, NEW ENGL J MED, V293, P255; Neumann PJ, 2000, ANN INTERN MED, V132, P964, DOI 10.7326/0003-4819-132-12-200006200-00007; Newby LK, 2000, NEW ENGL J MED, V342, P749, DOI 10.1056/NEJM200003163421101; Palmer S, 1999, BRIT MED J, V318, P1349, DOI 10.1136/bmj.318.7194.1349; Prosser LA, 2000, AM J MANAG CARE, V6, P173; Sonnenberg A, 2000, ANN INTERN MED, V133, P573, DOI 10.7326/0003-4819-133-8-200010170-00007; Stolk EA, 2000, BRIT MED J, V320, P1165, DOI 10.1136/bmj.320.7243.1165; Trueman P, 2001, PHARMACOECONOMICS, V19, P609, DOI 10.2165/00019053-200119060-00001; WEINSTEIN MC, 1977, N ENGL MED, V296, P715	24	74	76	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 19	2002	325	7369					891	894		10.1136/bmj.325.7369.891	http://dx.doi.org/10.1136/bmj.325.7369.891			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	607LL	12386045	Green Published			2022-12-28	WOS:000178793000028
J	Seoane, J; Le, HV; Massague, J				Seoane, J; Le, HV; Massague, J			Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage	NATURE			English	Article							HUMAN CANCER-CELLS; TGF-BETA; C-MYC; CYCLE ARREST; G(1) ARREST; GROWTH; EXPRESSION; TRANSCRIPTION; P15(INK4B); MIZ-1	Activation of the tumour suppressor p53 by DNA damage induces either cell cycle arrest or apoptotic cell death(1). The cytostatic effect of p53 is mediated by transcriptional activation of the cyclin-dependent kinase (CDK) inhibitor p21(Cip1), whereas the apoptotic effect is mediated by transcriptional activation of mediators including PUMA and PIG3 (ref. 2). What determines the choice between cytostasis and apoptosis is not clear(3). Here we show that the transcription factor Myc is a principal determinant of this choice. Myc is directly recruited to the p21(Cip1) promoter by the DNA-binding protein Miz-1. This interaction blocks p21(Cip1) induction by p53 and other activators. As a result Myc switches, from cytostatic to apoptotic, the p53-dependent response of colon cancer cells to DNA damage. Myc does not modify the ability of p53 to bind to the p21(Cip1) or PUMA promoters, but selectively inhibits bound p53 from activating p21(Cip1) transcription. By inhibiting p21(Cip1) expression Myc favours the initiation of apoptosis, thereby influencing the outcome of a p53 response in favour of cell death.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.		Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974; Massague, Joan/0000-0001-9324-8408				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Lane D, 2001, NATURE, V414, P25, DOI 10.1038/35102132; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALDMAN T, 1995, CANCER RES, V55, P5187; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557; Ziegelbauer J, 2001, MOL CELL, V8, P339, DOI 10.1016/S1097-2765(01)00313-6; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	30	535	560	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					729	734		10.1038/nature01119	http://dx.doi.org/10.1038/nature01119			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384701				2022-12-28	WOS:000178615200043
J	Gerberding, JL				Gerberding, JL			Hospital-onset infections: A patient safety issue	ANNALS OF INTERNAL MEDICINE			English	Article							URINARY-TRACT-INFECTION; INADEQUATE ANTIMICROBIAL TREATMENT; BLOOD-STREAM INFECTIONS; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE UNITS; RISK-FACTORS; NOSOCOMIAL PNEUMONIA; ATTRIBUTABLE MORTALITY; CATHETERIZED PATIENTS; VENTILATED PATIENTS	Hospital-onset infections, particularly those involving the urinary tract, lung, and bloodstream, are common and costly and cause substantial morbidity. This article analyzes the case of a 78-year-old man with lung cancer who died after developing hospitalonset pneumonia and urinary catheter-related infection during hospitalization for elective removal of a cerebellar metastasis. The field of infection control could benefit by adopting several approaches advocated by patient safety adherents, such as root-cause analysis. For example, hospital-onset infections that are implicated as attributable causes of death should perhaps be reviewed by local infection control teams regardless of the institution's overall infection rates. The patient safety movement can also learn from the traditions of infection control and hospital epidemiology. Specifically, applying infection control-based practices to safety problems may enhance safety. Such practices include establishing clear definitions of adverse events, standardizing methods for detecting and reporting events, creating appropriate rate adjustments for case-mix differences, instituting evidence-based intervention programs, and relying on skilled professionals to promote ongoing improvements in care.	Ctr Dis Control & Prevent, Off Director, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Gerberding, JL (corresponding author), 1600 Clifton Rd MS A07, Atlanta, GA 30333 USA.	Jgerberding@cdc.gov						BARKER FG, 1994, NEUROSURGERY, V35, P484, DOI 10.1227/00006123-199409000-00017; *CDCP, 2002, NAT NOS INF SURV SYS; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; D'Addario V, 1991, J Qual Assur, V13, P34; DADDARIO V, 1991, J QUAL ASSUR, V13, P52; Darouiche RO, 1999, UROLOGY, V54, P976, DOI 10.1016/S0090-4295(99)00288-5; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; Fridkin SK, 1996, INFECT CONT HOSP EP, V17, P150; GARIBALDI RA, 1974, NEW ENGL J MED, V291, P215, DOI 10.1056/NEJM197408012910501; GEORGE D, 1996, HOSP EPIDEMIOLOGY IN, P139; Gerberding J, 2000, AM J INFECT CONTROL, V28, P429, DOI 10.1067/mic.2000.110544; Goldspiel BR, 2000, AM J HEALTH-SYST PH, V57, pS4, DOI 10.1093/ajhp/57.suppl_4.S4; HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988; HALEY RW, 1981, AM J MED, V70, P947, DOI 10.1016/0002-9343(81)90561-1; HAMPTON AA, 1988, SURG CLIN N AM, V68, P57; HARTSTEIN AI, 1981, INFECT CONT HOSP EP, V2, P380, DOI 10.1017/S0195941700055533; Ibrahim EH, 2000, CHEST, V118, P146, DOI 10.1378/chest.118.1.146; JAIN P, 1995, ARCH INTERN MED, V155, P1425, DOI 10.1001/archinte.155.13.1425; Karchmer TB, 2000, ARCH INTERN MED, V160, P3294, DOI 10.1001/archinte.160.21.3294; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, DOI 10.17226/9728; Kollef MH, 1999, CHEST, V115, P462, DOI 10.1378/chest.115.2.462; Kollef MH, 1999, NEW ENGL J MED, V340, P627, DOI 10.1056/NEJM199902253400807; Kollef MH, 1999, CLIN CHEST MED, V20, P653, DOI 10.1016/S0272-5231(05)70242-2; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Kortbeek JB, 1999, J TRAUMA, V46, P992, DOI 10.1097/00005373-199906000-00002; Leape L L, 2000, Jt Comm J Qual Improv, V26, P321; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Maki DG, 1998, INFECT CONT HOSP EP, V19, P682; Mathus-Vliegen LMH, 1999, GASTROINTEST ENDOSC, V50, P746, DOI 10.1016/S0016-5107(99)70153-7; Nagy KK, 1999, J TRAUMA, V46, P996; Nakajoh K, 2000, J INTERN MED, V247, P39, DOI 10.1046/j.1365-2796.2000.00565.x; Ott L, 1999, J NEUROTRAUM, V16, P233, DOI 10.1089/neu.1999.16.233; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; PLATT R, 1986, AM J EPIDEMIOL, V124, P977, DOI 10.1093/oxfordjournals.aje.a114487; Plowman R, 2001, J HOSP INFECT, V48, P33, DOI 10.1053/jhin.2001.0938; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Saint S, 2000, ARCH INTERN MED, V160, P2670, DOI 10.1001/archinte.160.17.2670; Saint S, 2000, AM J MED, V109, P476, DOI 10.1016/S0002-9343(00)00531-3; Saint S, 1998, AM J MED, V105, P236, DOI 10.1016/S0002-9343(98)00240-X; Saint S, 1999, ARCH INTERN MED, V159, P800, DOI 10.1001/archinte.159.8.800; SHAPIRO M, 1984, INFECT CONT HOSP EP, V5, P525, DOI 10.1017/S019594170006104X; SHIKE M, 1991, GASTROINTEST ENDOSC, V37, P62, DOI 10.1016/S0016-5107(91)70625-1; SLAUGHTER MS, 1993, ANN THORAC SURG, V56, P1063, DOI 10.1016/0003-4975(95)90014-4; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; STUCK AE, 1989, REV INFECT DIS, V11, P954; TABLAN OC, 1994, INFECT CONT HOSP EP, V15, P588, DOI 10.1086/646989; *VA NAT CTR PAT SA, 2001, VA NAT CTR PAT SAF; WELTZ CR, 1992, ANN SURG, V215, P140, DOI 10.1097/00000658-199202000-00008; Whitby M, 2000, BRIT J NEUROSURG, V14, P13	51	74	81	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2002	137	8					665	670		10.7326/0003-4819-137-8-200210150-00011	http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604WL	12379067				2022-12-28	WOS:000178644000006
J	Mafart, B				Mafart, B			Goundou: a historical form of yaws	LANCET			English	Review									Mediterranee Univ, Fac Med Marseille, Lab Anthropol, UMR 6569, F-13916 Marseille 20, France; Serv Sante Armees, Inst Trop Med, Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite	Mafart, B (corresponding author), Mediterranee Univ, Fac Med Marseille, Lab Anthropol, UMR 6569, F-13916 Marseille 20, France.							BOTREAUROUSSEL P, 1925, OSTEITES PIANIQUES; BOTREAUROUSSEL P, 1938, CLIN CHIRURG PAYS CH; BRADDON W, 2001, J TROP MED, V4, P170; BRANCH CW, 1909, J TROP MED, V5, P63; *CANN, 1904, ARCH MED NAVALE, V31, P89; Chalmers AJ, 1900, LANCET, V1, P20; DRAWS J, 1988, HNO, V36, P426; ELANGO S, 1989, EUR NOSE THROAT J, V68, P873; FRIEDRICHSEN, 2003, J TROP MED, V6, P62; HACKETT CJ, 1963, B WORLD HEALTH ORGAN, V29, P7; Lamprey J J, 1887, Br Med J, V2, P1273; MACALISTER A, 1883, ROYAL IRISH ACAD, V2, P771; MACLAUD, 1895, ARCH MED NAVALE, V63, P25; Meheus A., 1992, World Health Statistics Quarterly, V45, P228; MENDES P, 2001, REV CHIR, V21, P445; Seheult R, 1915, LANCET, V1, P72; SHIRCORE JO, 1910, BMJ             0226, P503; STRACHAN H, 1894, BRIT MED J, V1, P189; TRENOUTH MJ, 1975, BRIT J ORAL SURG, V13, P166, DOI 10.1016/0007-117X(75)90005-0; WELLMAN FC, 1905, J TROP MED, V7, P286; *WHO ORG, WORLD HLTH REP 1998; Zimmer C, 2001, SCIENCE, V292, P1093, DOI 10.1126/science.292.5519.1093	22	4	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1168	1170		10.1016/S0140-6736(02)11205-0	http://dx.doi.org/10.1016/S0140-6736(02)11205-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387970				2022-12-28	WOS:000178632000022
J	Sulo, J; Chimpeni, P; Hatcher, J; Kublin, JG; Plowe, CV; Molyneux, ME; Marsh, K; Taylor, TE; Watkins, WM; Winstanley, PA				Sulo, J; Chimpeni, P; Hatcher, J; Kublin, JG; Plowe, CV; Molyneux, ME; Marsh, K; Taylor, TE; Watkins, WM; Winstanley, PA			Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial	LANCET			English	Article							PLASMODIUM-FALCIPARUM; DIHYDROFOLATE-REDUCTASE; DIHYDROPTEROATE SYNTHASE; SELECTIVE PRESSURE; IN-VITRO; RESISTANCE; AFRICA; GENE; COMBINATIONS; MORTALITY	Background Chlorproguanil-dapsone exerts lower resistance pressure on Plasmodium falciparum than does sulfadoxine-pyrimethamine, but is rapidly eliminated, We aimed to find out whether chlorproguanil-dapsone results in a higher retreatment rate for malaria than sulfadoxine-pyrimethamine. Methods In a randomised trial of paediatric outpatients with uncomplicated falciparum malaria, patients received either chlorproguanil-dapsone or sulfadoxine-pyrimethamine and were followed up for up to 1 year. Sites were in Kenya (n=410) and Malawi (n=500). We used per-protocol analysis to assess the primary outcome of annual malaria incidence. Findings Drop-outs were 117 of 410 (28.5%) in Kenya, and 342 of 500 (68.4%) in Malawi. Follow-up was for a median of 338 days (IQR 128-360) and 342 days (152-359) in Kilifi (chlorproguanil-dapsone and sulfadoxine-pyrimethamine, respectively), and for 120 days (33-281) and 84 days (26-224) in Blantyre, Mean annual malaria incidence was 2.5 versus 2.1 in Kenya (relative risk 1.16, 95% CI 0.98-1.37), and 2.2 versus 2.8 in Malawi (0.77, 0.63-0.94). 4.3% versus 12.8%, and 5.4% versus 20.1%, of patients were withdrawn for treatment failure in Kenya and Malawi, respectively. In Kenya haemoglobin concentration of 50 g/L or less caused exit in 6.9% of chlorproguanil-dapsone patients and 1.5% of sulfadoxine-pyrimethamine patients, but most anaemia occurred before re-treatment. In Malawi only one patient exited because of anaemia. Interpretation Despite the rapid elimination of chlorproguanil-dapsone, children treated with this drug did not have a higher incidence of malaria episodes than those treated with sulfadoxine-pyrimethamine. Treatment failure was more common with sulfadoxine-pyrimethamine. Cause of anaemia in Kenya was probably not adverse reaction to chlorproguanil-dapsone, but this observation requires further study.	Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England; Kenya Govt Med Res Ctr, Ctr Geog Med, Kilifi, Kenya; Malawi Liverpool Wellcome Trust Programme Trop Me, Blantyre, Malawi; Alberta Canc Board, Div Epidemiol Prevent & Screening, Calgary, AB, Canada; Univ Maryland, Sch Med, Ctr Vaccine Dev, Malaria Sect, Baltimore, MD 21201 USA; Univ Liverpool Liverpool Sch Trop Med, Div Trop Med, Liverpool, Merseyside, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Michigan State Univ, Coll Osteopath Med, Dept Med, E Lansing, MI 48824 USA	University of Liverpool; Kenya Medical Research Institute; University of Malawi; Alberta Cancer Board; University System of Maryland; University of Maryland Baltimore; Liverpool School of Tropical Medicine; University of Oxford; Michigan State University; Michigan State University College of Osteopathic Medicine	Winstanley, PA (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England.	peterwin@liv.ac.uk						Amukoye E, 1997, ANTIMICROB AGENTS CH, V41, P2261, DOI 10.1128/AAC.41.10.2261; Brockman A, 2000, T ROY SOC TROP MED H, V94, P537, DOI 10.1016/S0035-9203(00)90080-4; BROOKS DR, 1994, EUR J BIOCHEM, V224, P397, DOI 10.1111/j.1432-1033.1994.00397.x; BYRD SR, 1991, LEPROSY REV, V62, P171; FOOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014, DOI 10.1073/pnas.87.8.3014; Goodman CA, 1999, LANCET, V354, P378, DOI 10.1016/S0140-6736(99)02141-8; HASTINGS MD, IN PRESS T R SOC TRO; Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566; Mookherjee S, 1999, AM J TROP MED HYG, V61, P131, DOI 10.4269/ajtmh.1999.61.131; Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; NOSTEN F, 1993, LANCET, V341, P1054, DOI 10.1016/0140-6736(93)92412-M; Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520; Nzila-Mounda A, 1998, ANTIMICROB AGENTS CH, V42, P164, DOI 10.1128/AAC.42.1.164; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; SNEWIN VA, 1989, GENE, V76, P41, DOI 10.1016/0378-1119(89)90006-1; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; WATKINS WM, 1993, T ROY SOC TROP MED H, V87, P75, DOI 10.1016/0035-9203(93)90431-O; Watkins WM, 1997, PARASITOL TODAY, V13, P459, DOI 10.1016/S0169-4758(97)01124-1; WHO, 2000, T R SOC TROP MED S1, V94; WHO, 1996, WHOMAL961077; Winstanley P, 1997, T ROY SOC TROP MED H, V91, P322, DOI 10.1016/S0035-9203(97)90093-6; WINSTANLEY PA, 1995, ANTIMICROB AGENTS CH, V39, P948, DOI 10.1128/AAC.39.4.948; Winstanley PA, 2000, PARASITOL TODAY, V16, P146, DOI 10.1016/S0169-4758(99)01622-1	25	51	51	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	2002	360	9340					1136	1143		10.1016/S0140-6736(02)11198-6	http://dx.doi.org/10.1016/S0140-6736(02)11198-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387962				2022-12-28	WOS:000178632000014
J	Krug, EG; Mercy, JA; Dahlberg, LL; Zwi, AB				Krug, EG; Mercy, JA; Dahlberg, LL; Zwi, AB			The world report on violence and health	LANCET			English	Article							CHILD SEXUAL ABUSE; ELDER ABUSE; COMMUNITY; PREVALENCE	In 1996, the World Health Assembly declared violence a major public health issue. To follow up on this resolution, on Oct 3 this year, WHO released the first World Report on Violence and Health. The report analyses different types of violence including child abuse and neglect, youth violence, intimate partner violence, sexual violence, elder abuse, self-directed violence, and collective violence. For all these types of violence, the report explores the magnitude of the health and social effects, the risk and protective factors, and the types of prevention efforts that have been initiated. The launch of the report will be followed by a 1-year Global Campaign on Violence Prevention, focusing on implementation of the recommendations. This article summarises some of the main points of the world report.	WHO, Injuries & Violence Prevent Dept, Non Communicable Dis & Mental Hlth, CH-1211 Geneva, Switzerland; Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia	World Health Organization; Centers for Disease Control & Prevention - USA; University of New South Wales Sydney	Krug, EG (corresponding author), WHO, Injuries & Violence Prevent Dept, Non Communicable Dis & Mental Hlth, Av Appia 20, CH-1211 Geneva, Switzerland.		Zwi, Anthony/AAP-8731-2020; Zwi, Anthony/AAP-7026-2021	Zwi, Anthony/0000-0001-6902-6602				Bronfenbrenner, 1979, ECOLOGY HUMAN DEV EX; Carp R. M., 2000, ELDER ABUSE FAMILY I; Comijs HC, 1998, J AM GERIATR SOC, V46, P885, DOI 10.1111/j.1532-5415.1998.tb02724.x; Committee for the Study of the Future of Public Health, 1988, FUT PUBL HLTH; Davidson JRT, 1996, ARCH GEN PSYCHIAT, V53, P550; FAJNZYLBER P, 1999, INEQUALITY VIOLENT C; Farrington D. P., 1978, AGGRESSION ANTISOCIA, P73; Farrington D.P., 1998, SERIOUS VIOLENT JUVE; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Fergusson DM, 1996, J AM ACAD CHILD PSY, V35, P1365, DOI 10.1097/00004583-199610000-00024; FINKELHOR D, 1994, CHILD ABUSE NEGLECT, V18, P409, DOI 10.1016/0145-2134(94)90026-4; Finkelhor D, 1994, Future Child, V4, P31, DOI 10.2307/1602522; GARBARINO J, 1978, CHILD DEV, V49, P604, DOI 10.2307/1128227; Garbarino J., 1985, ADOLESCENT DEV ECOLO; GOMEZ HA, 1962, TRIBUNA MED, V2, P1; GORDON JE, 1949, AJPH, V39, P504; GREENWOOD PW, 1996, DIVERTING CHILDREN L; HEISE L, 1999, POPULATION REPORTS L, V11; Heise L L, 1998, Violence Against Women, V4, P262, DOI 10.1177/1077801298004003002; Kivela S. L., 1992, J ELDER ABUSE NEGL, V4, P1; KRUG EG, 2002, STAT ANNEX WORLD VIO; McCord J, 1983, Child Abuse Negl, V7, P265, DOI 10.1016/0145-2134(83)90003-0; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; OGG J, 1992, BRIT MED J, V305, P998, DOI 10.1136/bmj.305.6860.998; Paolucci EO, 2001, J PSYCHOL, V135, P17, DOI 10.1080/00223980109603677; PILLEMER K, 1988, GERONTOLOGIST, V28, P51, DOI 10.1093/geront/28.1.51; Podnieks E., 1992, J ELDER ABUSE NEGL, V4, P5, DOI [DOI 10.1300/J084V04N01_02, 10.1300/j084v04n01_02]; Schiamberg LB, 1999, J ELDER ABUSE NEGL, V11, P79, DOI 10.1300/J084v11n01_05; THORNBERRY T, 1995, SERIOUS VIOLENT CHRO; Tolan P., 1994, WHAT WORKS REDUCING; Villaveces A, 2000, JAMA-J AM MED ASSOC, V283, P1205, DOI 10.1001/jama.283.9.1205; WARD E, IN PRESS J INJURY CO; WHO Global Consultation on Violence and Health, 1996, WHOEHASPIPOA2 WHO GL; WIDOM CS, 1989, CRIMINOLOGY, V27, P251, DOI 10.1111/j.1745-9125.1989.tb01032.x; Wiederman M W, 1998, Violence Vict, V13, P3; World Health Assembly, 1996, PREV VIOL PUBL HLTH; World Health Organization, 2002, WORLD REPORT VIOLENC; World Health Organization [WHO], 2002, WHONMHVIP0205	38	1981	2026	10	178	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1083	1088		10.1016/S0140-6736(02)11133-0	http://dx.doi.org/10.1016/S0140-6736(02)11133-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	602BN	12384003	Green Published			2022-12-28	WOS:000178485200028
J	Brandt, TL; Romme, CR; LaRusso, NF; Lindor, KD				Brandt, TL; Romme, CR; LaRusso, NF; Lindor, KD			A novel incentive system for faculty in an academic medical center	ANNALS OF INTERNAL MEDICINE			English	Article							FINANCIAL INCENTIVES; PHYSICIANS	The need to contain health care costs has led some physicians to become salaried employees of health care organizations. However, the use of nonfinancial incentives for physicians in such an environment has not been broadly explored. The authors describe a novel incentive system that is designed to promote continuing high-quality, care and to increase patient access to health care while enhancing clinical and academic productivity and physician satisfaction. Key components of this system include annual targets, flexibility in meeting these targets, and ability to convert clinical productivity generated in excess of what was necessary to meet the target to support scholarly activities. This system led to increased faculty productivity, improved patient access, enhanced scholarly activity, and overall enhanced career satisfaction.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Lindor, KD (corresponding author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.							ATLAS RF, 1996, J COMPENSATION B JUL, P45; Averill R, 1999, Mod Healthc, V29, P66; AVERILL R, 1999, MOD HEALTHCARE, V29, P66; Blalock J, 1998, ACAD MED, V73, P1062, DOI 10.1097/00001888-199810000-00013; Cejka S, 1998, Healthc Exec, V13, P38; Donnelly J T, 1993, Healthc Financ Manage, V47, P44; DONNELLY JT, 1993, HEALTHC FINANC MANAG, V47, P48; DONNELLY JT, 1993, HEALTHC FINANC MANAG, V47, P50; Epstein D, 1996, Manag Care, V5, P26; EPSTEIN D, 1996, MANAG CARE, V5, P35; Garcia L B, 1998, Healthc Financ Manage, V52, P52; Grumbach K, 1998, NEW ENGL J MED, V339, P1516, DOI 10.1056/NEJM199811193392106; Guzzetta D, 1996, Healthc Financ Manage, V50, P54; GUZZETTA D, 1996, HEALTHC FINANC MANAG, V50, P52; GUZZETTA D, 1996, HEALTHC FINANC MANAG, V50, P54; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; Louiselle P P, 1998, Healthc Financ Manage, V52, P67; Maria B L, 1997, J Fla Med Assoc, V84, P510; RELMAN AS, 1988, NEW ENGL J MED, V319, P784, DOI 10.1056/NEJM198809223191209; Shea S, 1996, NEW ENGL J MED, V334, P162, DOI 10.1056/NEJM199601183340307; Smith R, 1997, Healthc Financ Manage, V51, P48; Terry K, 1998, Med Econ, V75, P114; Tkach D J, 1991, Med Group Manage J, V38, P32; TKACH DJ, 1991, MED GROUP MANAGE J, V38, P36; Woodson S B, 1999, Healthc Financ Manage, V53, P39; WOODSON SB, 1999, HEALTHC FINANC MANAG, V53, P44	26	19	19	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2002	137	9					738	743		10.7326/0003-4819-137-9-200211050-00009	http://dx.doi.org/10.7326/0003-4819-137-9-200211050-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612BA	12416947				2022-12-28	WOS:000179052400005
J	Dinsmore, AD; Hsu, MF; Nikolaides, MG; Marquez, M; Bausch, AR; Weitz, DA				Dinsmore, AD; Hsu, MF; Nikolaides, MG; Marquez, M; Bausch, AR; Weitz, DA			Colloidosomes: Selectively permeable capsules composed of colloidal particles	SCIENCE			English	Article							EMULSION DROPLETS; LATEX-PARTICLES; ENCAPSULATION; TEMPLATES; CELLS; MICROENCAPSULATION; ENDOSTATIN; INTERFACES	We present an approach to fabricate solid capsules with precise control of size, permeability, mechanical strength, and compatibility. The capsules are fabricated by the self-assembly of colloidal particles onto the interface of emulsion droplets. After the particles are locked together to form elastic shells, the emulsion droplets are transferred to a fresh continuous-phase fluid that is the same as that inside the droplets. The resultant structures, which we call "colloidosomes", are hollow, elastic shells whose permeability and elasticity can be precisely controlled. The generality and robustness of these structures and their potential for cellular immunoisolation are demonstrated by the use of a variety of solvents, particles, and contents.	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Harvard Univ, DEAS, Cambridge, MA 02138 USA; Los Alamos Natl Lab, Div Chem, Los Alamos, NM 87545 USA; Kraft Foods R&D, Nanotechnol Lab, Glenview, IL 60025 USA	Harvard University; Harvard University; United States Department of Energy (DOE); Los Alamos National Laboratory; Kraft Heinz	Dinsmore, AD (corresponding author), Univ Massachusetts, Dept Phys, Amherst, MA 01003 USA.	dinsmore@physics.umass.edu; abausch@ph.atum.de; weitz@deas.harvard.edu						BAUSCH AR, UNPUB; Berg, 2018, RANDOM WALKS BIOL; Binks BP, 2002, LANGMUIR, V18, P1270, DOI 10.1021/la011420k; Bowick MJ, 2000, PHYS REV B, V62, P8738, DOI 10.1103/PhysRevB.62.8738; Caruso F, 2000, LANGMUIR, V16, P8932, DOI 10.1021/la000401s; Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111; Chaikof EL, 1999, ANNU REV BIOMED ENG, V1, P103, DOI 10.1146/annurev.bioeng.1.1.103; Cohen I, 2001, SCIENCE, V292, P265, DOI 10.1126/science.1059175; Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232; Desai TA, 2000, BIOMOL ENG, V17, P23, DOI 10.1016/S1389-0344(00)00063-0; Ganan-Calvo AM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.274501; Gibbs BF, 1999, INT J FOOD SCI NUTR, V50, P213, DOI 10.1080/096374899101256; GORDON V, UNPUB; HURD AJ, 1985, J PHYS A-MATH GEN, V18, P1055; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; Kralchevsky PA, 2000, ADV COLLOID INTERFAC, V85, P145, DOI 10.1016/S0001-8686(99)00016-0; Lanza R.P., 2000, PRINCIPLES TISSUE EN; Leoni L, 2001, IEEE T BIO-MED ENG, V48, P1335, DOI 10.1109/10.959329; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Lin Y. P., UNPUB; Loscertales IG, 2002, SCIENCE, V295, P1695, DOI 10.1126/science.1067595; Lowe KC, 1999, ARTIF CELL BLOOD SUB, V27, P255, DOI 10.3109/10731199909117698; Marinakos SM, 1999, J AM CHEM SOC, V121, P8518, DOI 10.1021/ja990945k; NIKOLAIDES MG, IN PRESS NATURE; ONODA GY, 1985, PHYS REV LETT, V55, P226, DOI 10.1103/PhysRevLett.55.226; Park JK, 2000, BIOTECHNOL ADV, V18, P303, DOI 10.1016/S0734-9750(00)00040-9; PIERANSKI P, 1980, PHYS REV LETT, V45, P569, DOI 10.1103/PhysRevLett.45.569; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; Read TA, 2001, NAT BIOTECHNOL, V19, P29, DOI 10.1038/83471; RODRIGUEZ BE, 1994, MACROMOLECULES, V27, P6642, DOI 10.1021/ma00100a058; Sukhorukov GB, 1999, J PHYS CHEM B, V103, P6434, DOI 10.1021/jp990095v; Tiarks F, 2001, LANGMUIR, V17, P908, DOI 10.1021/la001276n; Umbanhowar PB, 2000, LANGMUIR, V16, P347, DOI 10.1021/la990101e; Velev OD, 2000, SCIENCE, V287, P2240, DOI 10.1126/science.287.5461.2240; Velev OD, 1996, LANGMUIR, V12, P2385, DOI 10.1021/la950679y; Velev OD, 1996, LANGMUIR, V12, P2374, DOI 10.1021/la9506786; Velev OD, 1997, LANGMUIR, V13, P1856, DOI 10.1021/la960652u; Willaert RG, 1996, REV CHEM ENG, V12, P5	38	1759	1864	22	912	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	2002	298	5595					1006	1009		10.1126/science.1074868	http://dx.doi.org/10.1126/science.1074868			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411700	Green Submitted			2022-12-28	WOS:000178932000050
J	Ganesan, S; Silver, DP; Greenberg, RA; Avni, D; Drapkin, R; Miron, A; Mok, SC; Randrianarison, V; Brodie, S; Salstrom, J; Rasmussen, TP; Klimke, A; Marrese, C; Marahrens, Y; Deng, CX; Feunteun, J; Livingston, DM				Ganesan, S; Silver, DP; Greenberg, RA; Avni, D; Drapkin, R; Miron, A; Mok, SC; Randrianarison, V; Brodie, S; Salstrom, J; Rasmussen, TP; Klimke, A; Marrese, C; Marahrens, Y; Deng, CX; Feunteun, J; Livingston, DM			BRCA1 supports XIST RNA concentration on the inactive X chromosome	CELL			English	Article							MEIOTIC CELLS; BREAST-CANCER; ESTROGEN-RECEPTOR; DNA-REPAIR; TRANSCRIPTION; MUTATION; ASSOCIATION; PROTEINS; COMPLEX; CHROMATIN	BRCA1, a breast and ovarian tumor suppressor, colocalizes with markers of the inactive X chromosome (Xi) on Xi in female somatic cells and associates with XIST RNA, as detected by chromatin immunoprecipitation. Breast and ovarian carcinoma cells lacking BRCA1 show evidence of defects in Xi chromatin structure. Reconstitution of BRCA1-deficient cells with wt BRCA1 led to the appearance of focal XIST RNA staining without altering XIST abundance. Inhibiting BRCA1 synthesis in a suitable reporter line led to increased expression of an otherwise silenced Xi-located GFP transgene. These observations suggest that loss of BRCA1 in female cells may lead to Xi perturbation and destabilization of its silenced state.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA; Inst Gustave Roussy, Lab Genet Oncol, Lab Vectorol & Transfert Genes, F-94805 Villejuif, France; NIDDKD, Genet Dev & Dis Branch 10 9N105, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Dept Human Genet, Gonda Ctr, Los Angeles, CA 90095 USA; Univ Connecticut, Ctr Regenerat Biol, Storrs, CT 06269 USA; Univ Connecticut, Dept Anim Sci, Storrs, CT 06269 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; UNICANCER; Gustave Roussy; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California Los Angeles; University of Connecticut; University of Connecticut	Livingston, DM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		Avni, Dror/GRE-8325-2022; deng, chuxia/N-6713-2016; Feunteun, Jean/AAZ-1267-2020; Silver, Daniel/P-3443-2019; Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Feunteun, Jean/0000-0003-1212-9189; Rasmussen, Theodore/0000-0001-9450-3394; Avni, Dror/0000-0002-8738-1840	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayoub N, 1997, CHROMOSOMA, V106, P1, DOI 10.1007/s004120050218; Bieche I, 1999, CLIN CHEM, V45, P1148; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Buller RE, 1999, JNCI-J NATL CANCER I, V91, P339, DOI 10.1093/jnci/91.4.339; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chadwick BP, 2002, J CELL BIOL, V157, P1113, DOI 10.1083/jcb.200112074; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; Csankovszki G, 1999, NAT GENET, V22, P323, DOI 10.1038/11887; Deng CX, 2000, BIOESSAYS, V22, P728; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gilbert SL, 2000, J BIOL CHEM, V275, P36491, DOI 10.1074/jbc.C000409200; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HANDEL MA, 1992, BIOESSAYS, V14, P817, DOI 10.1002/bies.950141205; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Huynh KD, 2001, CURR OPIN CELL BIOL, V13, P690, DOI 10.1016/S0955-0674(00)00272-6; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Kelley RL, 2000, CELL, V103, P9, DOI 10.1016/S0092-8674(00)00099-4; KIMMEL VM, 1957, CANCER, V10, P922; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; MOORE R, 1957, BRIT J CANCER, V11, P384; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; PERRY M, 1972, BRIT J SURG, V59, P731, DOI 10.1002/bjs.1800590912; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; RICHLER C, 1992, NAT GENET, V2, P192, DOI 10.1038/ng1192-192; Richler C, 2000, CYTOGENET CELL GENET, V89, P118, DOI 10.1159/000015589; SAVINO A, 1971, ACTA CYTOL, V15, P372; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Squire JA, 2000, GENOMICS, V65, P234, DOI 10.1006/geno.2000.6155; Tomlinson GE, 1998, CANCER RES, V58, P3237; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Y, 2000, GENE DEV, V14, P927; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	52	232	239	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 1	2002	111	3					393	405		10.1016/S0092-8674(02)01052-8	http://dx.doi.org/10.1016/S0092-8674(02)01052-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419249	Bronze			2022-12-28	WOS:000179010100011
J	Fitzgerald, DW; Marotte, C; Verdier, RI; Johnson, WD; Pape, JW				Fitzgerald, DW; Marotte, C; Verdier, RI; Johnson, WD; Pape, JW			Comprehension during informed consent in a less-developed country	LANCET			English	Article							TRIALS	Few practical guidelines exist on how to ensure that research participants in less-developed countries understand the consent form before enrolment. In a study of HIV-1 transmission in Haiti, participants were required to pass an oral examination on the contents of the consent form with a passing score of 12/15 (80%) before enrolment. 15 individuals were given information during a single meeting with a physician, and three (20%) passed. 30 subsequent volunteers were given information by a counsellor during three meetings, and 24 (80%) passed. Formal assessment of research participants' comprehension of the consent form should be considered as a routine step in the informed consent process in less-developed countries.	Cornell Univ, Coll Med, Div Int Med & Infect Dis, New York, NY 10021 USA; GHESKIO, Port Au Prince, Haiti	Cornell University	Johnson, WD (corresponding author), Cornell Univ, Coll Med, Div Int Med & Infect Dis, New York, NY 10021 USA.				FIC NIH HHS [TW00002, TW00018] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Benitez O, 2002, LANCET, V359, P1406, DOI 10.1016/S0140-6736(02)08361-7; Joffe S, 2001, LANCET, V358, P1772, DOI 10.1016/S0140-6736(01)06805-2; LEVINE RJ, 1986, ETHICS REGULATION CL, P95; Lynoe N, 2001, NEW ENGL J MED, V344, P460, DOI 10.1056/NEJM200102083440617; Mason SA, 2000, LANCET, V356, P2045, DOI 10.1016/S0140-6736(00)03401-2	5	126	132	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1301	1302		10.1016/S0140-6736(02)11338-9	http://dx.doi.org/10.1016/S0140-6736(02)11338-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414207				2022-12-28	WOS:000178827200014
J	Rettig, J; Neher, E				Rettig, J; Neher, E			Emerging roles of presynaptic proteins in Ca++-triggered exocytosis	SCIENCE			English	Review							READILY RELEASABLE POOL; INTRACELLULAR CALCIUM-DEPENDENCE; CORE VESICLE EXOCYTOSIS; SHORT-TERM PLASTICITY; TRANSMITTER RELEASE; CHROMAFFIN CELLS; C-TERMINUS; NEUROTRANSMITTER RELEASE; KINETIC COMPONENTS; GLUTAMATE RELEASE	Molecules involved in late steps of neurotransmitter release at the synapse can be examined by noting the two speeds of the components of the exocytotic burst that are triggered by an increase in free Ca++. From studies of Ca++-dependent exocytosis of large dense-core vesicles in chromaffin cells, it seems that initiation of the SNARE complex is the molecular event underlying the priming process and that Munc13 acts as a priming factor by opening syntaxin. If synaptic mechanisms are similar, much could be learned from the molecular and kinetic studies that can be performed in chromaffin cells. The twinning of techiques from biophysics and molecular biology has led to remarkable progress in understanding the molecular mechanisms of synaptic transmission. Here we review the current picture of Ca++-triggered exocytosis, which has emerged from studies of a simple cellular model, the adrenal chromaffin cell. We discuss the molecular players that have been assigned a specific role in a particular step of this process and give a brief outlook on what these insights might tell us about mechanisms of short-term plasticity at classical synapses.	Univ Saarland, Dept Physiol, D-66421 Homburg, Germany; Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	Saarland University; Max Planck Society	Rettig, J (corresponding author), Univ Saarland, Dept Physiol, D-66421 Homburg, Germany.	jrettig@uniklinik-saarland.de; eneher@gwdg.de	Neher, Erwin/A-2109-2013; Oka, Yoshitaka/C-9670-2010; Rettig, Jens/K-5103-2013	Oka, Yoshitaka/0000-0002-3482-3051; Rettig, Jens/0000-0001-6160-3954				Aravamudan B, 1999, NAT NEUROSCI, V2, P965, DOI 10.1038/14764; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Bertram R, 1996, J NEUROPHYSIOL, V75, P1919, DOI 10.1152/jn.1996.75.5.1919; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bollmann JH, 2000, SCIENCE, V289, P953, DOI 10.1126/science.289.5481.953; BRENNER S, 1974, GENETICS, V77, P71; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; Bruns D., COMMUNICATION; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; Criado M, 1999, P NATL ACAD SCI USA, V96, P7256, DOI 10.1073/pnas.96.13.7256; Dinkelacker V, 2000, J NEUROSCI, V20, P8377, DOI 10.1523/JNEUROSCI.20-22-08377.2000; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Dobrunz LE, 1997, P NATL ACAD SCI USA, V94, P14843, DOI 10.1073/pnas.94.26.14843; Elhamdani A, 1999, J NEUROSCI, V19, P7375, DOI 10.1523/JNEUROSCI.19-17-07375.1999; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; EllisDavies GCR, 1996, BIOPHYS J, V70, P1006, DOI 10.1016/S0006-3495(96)79644-3; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Harlow ML, 2001, NATURE, V409, P479, DOI 10.1038/35054000; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Hsu SF, 1996, NEURON, V17, P501, DOI 10.1016/S0896-6273(00)80182-8; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KAPLAN JH, 1989, TRENDS NEUROSCI, V12, P54, DOI 10.1016/0166-2236(89)90136-7; Kasai H, 1999, TRENDS NEUROSCI, V22, P88, DOI 10.1016/S0166-2236(98)01293-4; LANDO L, 1989, J GEN PHYSIOL, V93, P1017, DOI 10.1085/jgp.93.6.1017; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; Neher E, 2001, J NEUROSCI, V21, P444, DOI 10.1523/JNEUROSCI.21-02-00444.2001; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pelham HRB, 1995, COLD SPRING HARB SYM, V60, P105, DOI 10.1101/SQB.1995.060.01.013; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Renden R, 2001, NEURON, V31, P421, DOI 10.1016/S0896-6273(01)00382-8; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; Rosenmund C, 2002, NEURON, V33, P411, DOI 10.1016/S0896-6273(02)00568-8; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Rupnik M, 2000, P NATL ACAD SCI USA, V97, P5627, DOI 10.1073/pnas.090359097; Sakaba T, 2001, NEURON, V32, P1119, DOI 10.1016/S0896-6273(01)00543-8; Sakaba T, 2001, P NATL ACAD SCI USA, V98, P331, DOI 10.1073/pnas.021541098; Sakaba T, 2001, J NEUROSCI, V21, P462, DOI 10.1523/JNEUROSCI.21-02-00462.2001; Schneggenburger R, 2000, NATURE, V406, P889, DOI 10.1038/35022702; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; Sorensen JB, 2002, P NATL ACAD SCI USA, V99, P1627, DOI 10.1073/pnas.251673298; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; Voets T, 2000, NEURON, V28, P537, DOI 10.1016/S0896-6273(00)00131-8; Voets T, 2001, P NATL ACAD SCI USA, V98, P11680, DOI 10.1073/pnas.201398798; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; VOETS T, UNPUB; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wei SH, 2000, EMBO J, V19, P1279, DOI 10.1093/emboj/19.6.1279; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241; Wu LG, 1999, NEURON, V23, P821, DOI 10.1016/S0896-6273(01)80039-8; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; YAMADA WM, 1992, BIOPHYS J, V61, P671, DOI 10.1016/S0006-3495(92)81872-6	72	253	263	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					781	785		10.1126/science.1075375	http://dx.doi.org/10.1126/science.1075375			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399579				2022-12-28	WOS:000178791200046
J	Mushlin, SB; Shepard, JO; Drazen, JM; Samuels, MA; Mark, EJ; Kanarek, DJ				Mushlin, SB; Shepard, JO; Drazen, JM; Samuels, MA; Mark, EJ; Kanarek, DJ			A 28-year-old woman with ocular inflammation, fever, and headache - Sarcoidosis with hilar and cervical lymphadenopathy (Lofgren's syndrome)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAL PROGRESS; GRAVES-DISEASE		Brigham & Womens Hosp, Preliminary Med Residency Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Mushlin, SB (corresponding author), Brigham & Womens Hosp, Preliminary Med Residency Program, 75 Francis St, Boston, MA 02115 USA.		Drazen, Jeffrey M/E-5841-2012					APICELLA MA, 2000, MANDELL DOUGLAS BENN, V2, P2228; BAYER AS, 2000, MANDELL DOUGLAS BENN, V1, P857; CROSS JT, 2000, MANDELL DOUGLAS BENN, V2, P2393; FARRAR WE, 1995, MANDELL DOUGLAS BENN, V2, P2137; GELFAND JA, 2000, MANDELL DOUGLAS BENN, V2, P2899; GILMAN MJ, 1980, AM REV RESPIR DIS, V122, P721, DOI 10.1164/arrd.1980.122.5.721; GLADMAN DD, 1998, RHEUMATOLOGY, V2; GROVE DI, 2000, MANDELL DOUGLAS BENN, V2, P2943; HOFFMAN GS, 1998, RHEUMATOLOGY, V2; Huge W, 1976, Z Erkr Atmungsorgane, V146, P62; LHOTE F, 1998, RHEUMATOLOGY, V2; LIGHTFOOT RW, 1998, RHEUMATOLOGY, V2; LOEFGREN S, 1952, ACTA MED SCAND, V142, P265; LOFGREN S, 1955, BEITR KLIN ERFOVSCH, V144, P75; LORBER B, 2000, MANDELL DOUGLAS BENN, V2, P2208; Mana J, 1999, AM J MED, V107, P240, DOI 10.1016/S0002-9343(99)00223-5; MORALES CF, 1994, CHEST, V106, P709, DOI 10.1378/chest.106.3.709; Mundlein E, 1996, NEPHROL DIAL TRANSPL, V11, P860, DOI 10.1093/oxfordjournals.ndt.a027415; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Nikhar NK, 2000, NEUROLOGIST, V6, P126, DOI 10.1097/00127893-200006020-00005; SAAH AJ, 2000, MANDELL DOUGLAS BENN, V2, P2033; Steere AC, 2001, NEW ENGL J MED, V345, P115, DOI 10.1056/NEJM200107123450207; YOUNG EJ, 1995, MANDELL DOUGLAS BENN, V2, P2053; Zimmermann-Belsing T, 2000, THYROID, V10, P275, DOI 10.1089/thy.2000.10.275	24	3	3	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1350	1357		10.1056/NEJMcpc020018	http://dx.doi.org/10.1056/NEJMcpc020018			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397194				2022-12-28	WOS:000178781300008
J	Pinto, DS; Tu, TM				Pinto, DS; Tu, TM			Ventricular septal rupture after myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Pinto, DS (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.			Pinto, Duane/0000-0002-2309-8480					0	0	0	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1334	1334		10.1056/NEJMicm020204	http://dx.doi.org/10.1056/NEJMicm020204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397191				2022-12-28	WOS:000178781300005
J	Jerby, E; Dikhtyar, V; Aktushev, O; Grosglick, U				Jerby, E; Dikhtyar, V; Aktushev, O; Grosglick, U			The microwave drill	SCIENCE			English	Article							THERMAL RUNAWAY	We present a drilling method that is based on the phenomenon of local hot spot generation by near-field microwave radiation. The microwave drill is implemented by a coaxial near-field radiator fed by a conventional microwave source. The near-field radiator induces the microwave energy into a small volume in the drilled material under its surface, and a hot spot evolves in a rapid thermal-runaway process. The center electrode of the coaxial radiator itself is then inserted into the softened material to form the hole. The method is applicable for drilling a variety of nonconductive materials. It does not require fast rotating parts, and its operation makes no dust or noise.	Tel Aviv Univ, Fac Engn, IL-69978 Ramat Aviv, Israel	Tel Aviv University	Jerby, E (corresponding author), Tel Aviv Univ, Fac Engn, IL-69978 Ramat Aviv, Israel.		Jerby, Eli/T-8338-2019	Jerby, Eli/0000-0003-1752-6554				Alpert Y, 1999, IEEE T PLASMA SCI, V27, P555, DOI 10.1109/27.772285; [Anonymous], 1997, IND APPL LASERS; Birnboim A, 1998, J AM CERAM SOC, V81, P1493, DOI 10.1111/j.1151-2916.1998.tb02508.x; Evans NG, 1996, MATER RES SOC SYMP P, V430, P9, DOI 10.1557/PROC-430-9; HUTCHEON RM, 1992, MATER RES SOC SYMP P, V269, P541, DOI 10.1557/PROC-269-541; Jerby E, 2000, U.S. Patent, Patent No. [6,114,676, 6114676]; King R. W. P., 1969, ANTENNAS WAVES MODER; Krajick K, 1999, SCIENCE, V283, P781, DOI 10.1126/science.283.5403.781; Lindroth D. P., 1991, U.S. Patent, Patent No. 5003144; Metaxas A., 1996, FDN ELECT UNIFIED AP; Parris PE, 1997, PHYS STATUS SOLIDI B, V200, P39, DOI 10.1002/1521-3951(199703)200:1<39::AID-PSSB39>3.0.CO;2-R; THUERY J, 1992, MICROWAVE IND SCI ME; Vriezinga CA, 1998, J APPL PHYS, V83, P438, DOI 10.1063/1.366657	13	98	107	5	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					587	589		10.1126/science.1077062	http://dx.doi.org/10.1126/science.1077062			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386331				2022-12-28	WOS:000178634800037
J	Yifrach, O; MacKinnon, R				Yifrach, O; MacKinnon, R			Energetics of pore opening in a voltage-gated K+ channel	CELL			English	Article							SHAKER POTASSIUM CHANNELS; ION CHANNELS; GATING CHARGE; WILD-TYPE; ACTIVATION; MOVEMENT; S4; SELECTIVITY; TRANSITIONS; SENSOR	Voltage-dependent gating in K+ channels results from the mechanical coupling of voltage sensor movements to pore opening. We used single and double mutations in the pore of the Shaker K+ channel to analyze a late concerted pore opening transition and interpreted the results in the context of known K+ channel structures. Gating sensitive mutations are located at mechanistically informative regions of the pore and are coupled energetically across distances up to 15 Angstrom. We propose that the pore is intrinsically more stable when closed, and that to open the pore the voltage sensors must exert positive work by applying an outward lateral force near the inner helix bundle.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.		YIFRACH, Ofer/F-1480-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; Horn R, 2000, J GEN PHYSIOL, V116, P461, DOI 10.1085/jgp.116.3.461; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Ledwell JL, 1999, J GEN PHYSIOL, V113, P389, DOI 10.1085/jgp.113.3.389; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Schoppa NE, 1998, J GEN PHYSIOL, V111, P313, DOI 10.1085/jgp.111.2.313; Schoppa NE, 1998, J GEN PHYSIOL, V111, P271, DOI 10.1085/jgp.111.2.271; Schoppa NE, 1998, J GEN PHYSIOL, V111, P295, DOI 10.1085/jgp.111.2.295; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P279, DOI 10.1085/jgp.103.2.279; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	26	249	254	0	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 18	2002	111	2					231	239		10.1016/S0092-8674(02)01013-9	http://dx.doi.org/10.1016/S0092-8674(02)01013-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408867	Bronze			2022-12-28	WOS:000178753500012
J	Rafkin, SCR; Maria, MRVS; Michaels, TI				Rafkin, SCR; Maria, MRVS; Michaels, TI			Simulation of the atmospheric thermal circulation of a martian volcano using a mesoscale numerical model	NATURE			English	Article							SYSTEM	Mesoscale (< 100 km) atmospheric phenomena are ubiquitous on Mars, as revealed by Mars Orbiter Camera images(1-3). Numerical models provide an important means of investigating martian atmospheric dynamics, for which data availability is limited. But the resolution of general circulation models, which are traditionally used for such research, is not sufficient to resolve mesoscale phenomena(4-6). To provide better understanding of these relatively small-scale phenomena, mesoscale models have recently been introduced(7-9). Here we simulate the mesoscale spiral dust cloud observed over the caldera of the volcano Arsia Mons by using the Mars Regional Atmospheric Modelling System. Our simulation uses a hierarchy of nested models with grid sizes ranging from 240 km to 3 km, and reveals that the dust cloud is an indicator of a greater but optically thin thermal circulation that reaches heights of up to 30 km, and transports dust horizontally over thousands of kilometres.	San Jose State Univ, Dept Meteorol, San Jose, CA 95117 USA	California State University System; San Jose State University	Rafkin, SCR (corresponding author), San Jose State Univ, Dept Meteorol, 1 Washington Sq, San Jose, CA 95117 USA.	rafkin@metsun1.met.sjsu.edu						Cantor B, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001588; Cantor BA, 2001, J GEOPHYS RES-PLANET, V106, P23653, DOI 10.1029/2000JE001310; Forget F, 1999, J GEOPHYS RES-PLANET, V104, P24155, DOI 10.1029/1999JE001025; HUNT GE, 1980, NATURE, V286, P362, DOI 10.1038/286362a0; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; MURPHY JR, 1993, J GEOPHYS RES-PLANET, V98, P3197, DOI 10.1029/92JE02945; PIELKE RA, 1992, METEOROL ATMOS PHYS, V49, P69, DOI 10.1007/BF01025401; Rafkin SCR, 2001, ICARUS, V151, P228, DOI 10.1006/icar.2001.6605; Smith DE, 1999, J GEOPHYS RES-PLANET, V104, P1885, DOI 10.1029/1998JE900024; TOIGO AD, 2002, J GEOPHYS RES, V107, DOI DOI 10.1029/2001JE001489; Tyler D, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001618; Wilson RJ, 1996, J ATMOS SCI, V53, P1290, DOI 10.1175/1520-0469(1996)053<1290:CMSOTT>2.0.CO;2	12	72	72	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	2002	419	6908					697	699		10.1038/nature01114	http://dx.doi.org/10.1038/nature01114			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384691				2022-12-28	WOS:000178615200033
J	Neff, JM; Lane, JM; Fulginiti, VA; Henderson, DA				Neff, JM; Lane, JM; Fulginiti, VA; Henderson, DA			Contact vaccinia - Transmission of vaccinia from smallpox vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ATOPIC-DERMATITIS; PREVALENCE		Childrens Hosp & Med Ctr, Ctr Children Special Needs, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Smallpox Eradicat Progeam, Atlanta, GA USA; Univ Arizona, Sch Med, Tucson, AZ USA; Johns Hopkins Univ, Ctr Civilian Biodef Strategies, Baltimore, MD USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA; University of Arizona; Johns Hopkins University	Neff, JM (corresponding author), Childrens Hosp & Med Ctr, Ctr Children Special Needs, 4800 Sand Point Way NE,CM-09, Seattle, WA 98105 USA.							*ADV COMM IMM PRAC, 2002, US SMALLP VACC VACC; Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357; CONYBEARE E T, 1964, Mon Bull Minist Health Public Health Lab Serv, V23, P126; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; COPEMAN PWM, 1964, BRIT MED J, V2, P906, DOI 10.1136/bmj.2.5414.906; de Rugy V., 2002, POLICY ANAL, V434, P1; ELLIS EA, 1935, JAMA-J AM MED ASSOC, V104, P1891; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; Fauci AS, 2002, NEW ENGL J MED, V346, P1319, DOI 10.1056/NEJM200204253461711; FENNER F, 1988, SMALLPOX ITS ERADICA, P140; FULGINITI VA, 1966, BRENNEMANS PRACTICE, V2, P1; GREENBERG M, 1948, AM J DIS CHILD, V76, P492; Habbick BF, 1999, CAN MED ASSOC J, V160, P1824; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; KEMPE CH, 1960, PEDIATRICS, V26, P176; KEMPE CH, 1965, J PEDIATR-US, V67, P1017, DOI 10.1016/S0022-3476(65)82101-1; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; LANE JM, 1970, J AMER MED ASSOC, V212, P441, DOI 10.1001/jama.212.3.441; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; LUNDSTROM R, 1956, J PEDIATR-US, V49, P129, DOI 10.1016/S0022-3476(56)80028-0; NEFF JM, 1967, PEDIATRICS, V39, P916; NEFF JM, 1972, PEDIATRICS, V50, P481; NEFF JM, 1967, NEW ENGL J MED, V276, P1; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; Rudikoff D, 1998, LANCET, V351, P1715, DOI 10.1016/S0140-6736(97)12082-7; Safai Bijan, 1997, P393; Walensky RP, 2002, ARCH INTERN MED, V162, P887, DOI 10.1001/archinte.162.8.887; WEINSTEIN I, 1947, AM J PUBLIC HEALTH, V37, P1376; SURVEILLANCE HLTH CA	30	88	91	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	2002	288	15					1901	1905		10.1001/jama.288.15.1901	http://dx.doi.org/10.1001/jama.288.15.1901			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604EU	12377090				2022-12-28	WOS:000178604200030
J	Whelton, PK; He, J; Appel, LJ; Cutler, JA; Havas, S; Kotchen, TA; Roccella, EJ; Stout, R; Vallbona, C; Winston, MC; Karimbakas, J				Whelton, PK; He, J; Appel, LJ; Cutler, JA; Havas, S; Kotchen, TA; Roccella, EJ; Stout, R; Vallbona, C; Winston, MC; Karimbakas, J		Natl High Blood Pressure Educ Prog	Primary prevention of hypertension - Clinical and public health advisory from the National High Blood Pressure Education Program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REDUCED DIETARY-SODIUM; WEIGHT-LOSS; CARDIOVASCULAR-DISEASE; ADULT-POPULATION; UNITED-STATES; RISK-FACTOR; METAANALYSIS; REDUCTION; MORTALITY; MEN	The National High Blood Pressure Education Program Coordinating Committee published its first statement on the primary prevention of hypertension in 1993. This article updates the 1993 report, using new and further evidence from the scientific literature. Current recommendations for primary prevention of hypertension involve a population-based approach and an intensive targeted strategy focused on individuals at high risk for hypertension. These 2 strategies are complementary and emphasize 6 approaches with proven efficacy for prevention of hypertension: engage in moderate physical activity; maintain normal body weight; limit alcohol consumption; reduce sodium intake; maintain adequate intake of potassium; and consume a diet rich in fruits, vegetables, and low-fat dairy products and reduced in saturated and total fat. Applying these approaches to the general population as a component of public health and clinical practice can help prevent blood pressure from increasing and can help decrease elevated blood pressure levels for those with high normal blood pressure or hypertension.	NHLBI, Natl High Blood Pressure Educ Program, Off Prevent Educ & Control, NIH, Bethesda, MD 20892 USA; Tulane Univ, Hlth Sci Ctr, Dept Epidemiol & Med, New Orleans, LA 70118 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA; Johns Hopkins Med Inst, Dept Internal Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Int Hlth, Baltimore, MD 21205 USA; NHLBI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Med Coll Wisconsin, Dept Med, Div Endocrinol Metab & Clin Nutr, Milwaukee, WI 53226 USA; Procter & Gamble Co, Hlth Care Res Ctr, Mason, OH USA; Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA; Amer Heart Assoc, Dallas, TX USA; Amer Inst Res Hlth Program, Silver Spring, MD USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Tulane University; Tulane University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University System of Maryland; University of Maryland Baltimore; Medical College of Wisconsin; Procter & Gamble; Baylor College of Medicine; American Institutes for Research	Roccella, EJ (corresponding author), NHLBI, Natl High Blood Pressure Educ Program, Off Prevent Educ & Control, NIH, 31 Ctr Dr,MSC 2480, Bethesda, MD 20892 USA.	roccella@nih.gov	Appel, Larry/GLT-2608-2022					[Anonymous], 1997, ARCH INTERN MED, V157, P2413; APPEL LJ, 1993, ARCH INTERN MED, V153, P1429, DOI 10.1001/archinte.153.12.1429; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; DEHMER GJ, 1988, NEW ENGL J MED, V319, P733, DOI 10.1056/NEJM198809223191201; Falkner B, 1996, PEDIATRICS, V98, P649; FLACK JM, 1995, CIRCULATION, V92, P2437, DOI 10.1161/01.CIR.92.9.2437; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; Griffith LE, 1999, AM J HYPERTENS, V12, P84, DOI 10.1016/S0895-7061(98)00224-6; He J, 1999, J HYPERTENS, V17, pS7; He JA, 2000, HYPERTENSION, V35, P544, DOI 10.1161/01.HYP.35.2.544; He JA, 1999, JAMA-J AM MED ASSOC, V282, P2027, DOI 10.1001/jama.282.21.2027; *I MED, 1997, DIET REF INT CALC PH, P106; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; LAST JM, 1995, DICT EPIDEMIOLOGY; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; MATTES RD, 1991, J AM COLL NUTR, V10, P383; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; MORRIS MC, 1993, CIRCULATION, V88, P523, DOI 10.1161/01.CIR.88.2.523; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Pocock SJ, 2001, BMJ-BRIT MED J, V323, P75, DOI 10.1136/bmj.323.7304.75; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; STAMLER R, 1991, HYPERTENSION, V17, pI16, DOI 10.1161/01.HYP.17.1_Suppl.I16; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; Tuomilehto J, 2001, LANCET, V357, P848, DOI 10.1016/S0140-6736(00)04199-4; *US DEPT HHS, 1996, PHYS ACT HLTH REP SU, V28; *US DEPT HHS, 2002, HEARTS N PARKS; *US DEPT HHS, 2002, YOUR GUID LOW HIGH B; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417; Vollmer WM, 2001, ANN INTERN MED, V135, P1019, DOI 10.7326/0003-4819-135-12-200112180-00005; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; WHELTON PK, 1994, LANCET, V344, P101, DOI 10.1016/S0140-6736(94)91285-8; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006; Wolz M, 2000, AM J HYPERTENS, V13, P103, DOI 10.1016/S0895-7061(99)00241-1; Xin X, 2001, HYPERTENSION, V38, P1112, DOI 10.1161/hy1101.093424	45	1000	1042	2	88	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	2002	288	15					1882	1888		10.1001/jama.288.15.1882	http://dx.doi.org/10.1001/jama.288.15.1882			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604EU	12377087				2022-12-28	WOS:000178604200027
J	Schneider, RK; Levenson, JL				Schneider, RK; Levenson, JL			Update in psychiatry	ANNALS OF INTERNAL MEDICINE			English	Review							ST-JOHNS-WORT; POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; MINI-COG; DEPRESSION; RISK; PAROXETINE; SERTRALINE; ILLNESS		Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA	Virginia Commonwealth University	Schneider, RK (corresponding author), Virginia Commonwealth Univ, Dept Psychiat, Med Coll Virginia Campus,POB 980268, Richmond, VA 23298 USA.	rkschnei@mail2.vcu.edu						AKISKAL HS, 1983, J AFFECT DISORDERS, V5, P115, DOI 10.1016/0165-0327(83)90004-6; Barnes J, 2001, J PHARM PHARMACOL, V53, P583, DOI 10.1211/0022357011775910; Borson S, 2000, INT J GERIATR PSYCH, V15, P1021, DOI 10.1002/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Glassman AH, 2001, AM J PSYCHIAT, V158, P1774, DOI 10.1176/appi.ajp.158.11.1774; Goddard AW, 2001, ARCH GEN PSYCHIAT, V58, P681, DOI 10.1001/archpsyc.58.7.681; Goldberg JF, 2001, AM J PSYCHIAT, V158, P1265, DOI 10.1176/appi.ajp.158.8.1265; Goodwin PJ, 2001, NEW ENGL J MED, V345, P1719, DOI 10.1056/NEJMoa011871; Kroenke K, 2001, JAMA-J AM MED ASSOC, V286, P2947, DOI 10.1001/jama.286.23.2947; Musselman DL, 2001, NEW ENGL J MED, V344, P961, DOI 10.1056/NEJM200103293441303; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; North CS, 1999, JAMA-J AM MED ASSOC, V282, P755, DOI 10.1001/jama.282.8.755; Ray WA, 2001, ARCH GEN PSYCHIAT, V58, P1161, DOI 10.1001/archpsyc.58.12.1161; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Scanlan J, 2001, INT J GERIATR PSYCH, V16, P216, DOI 10.1002/1099-1166(200102)16:2<216::AID-GPS316>3.0.CO;2-B; Schneider RK, 2002, ANN INTERN MED, V136, P293, DOI 10.7326/0003-4819-136-4-200202190-00009; Schneider RK, 1999, ANN INTERN MED, V131, P514, DOI 10.7326/0003-4819-131-7-199910050-00007; Schneider RK, 2001, ANN INTERN MED, V134, P387, DOI 10.7326/0003-4819-134-5-200103060-00011; Seidman SN, 2001, AM J PSYCHIAT, V158, P1623, DOI 10.1176/appi.ajp.158.10.1623; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; Soares CD, 2001, ARCH GEN PSYCHIAT, V58, P529; Woelk H, 2000, BMJ-BRIT MED J, V321, P536, DOI 10.1136/bmj.321.7260.536; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55	24	3	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2002	137	8					671	677		10.7326/0003-4819-137-8-200210150-00012	http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604WL	12379068				2022-12-28	WOS:000178644000007
J	Teo, KK; Yusuf, S; Pfeffer, M; Kober, L; Hall, A; Pogue, J; Latini, R; Collins, R				Teo, KK; Yusuf, S; Pfeffer, M; Kober, L; Hall, A; Pogue, J; Latini, R; Collins, R		ACE Inhibitors Collaborative Grp	Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review	LANCET			English	Review							LEFT-VENTRICULAR DYSFUNCTION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACUTE MYOCARDIAL-INFARCTION; ENALAPRIL; CAPTOPRIL; MORTALITY; SURVIVAL; THERAPY	Background Results from a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) study suggest that angiotensin-converting-enzyme (ACE) inhibitors may be less effective in patients receiving aspirin. We aimed to confirm or refute this theory. Methods We used the Peto-Yusuf method to undertake a systematic overview of data for 22 060 patients from six long-term randomised trials of ACE inhibitors to assess whether aspirin altered the effects of ACE inhibitor therapy on major clinical outcomes (composite of death, myocardial infarction, stroke, hospital admission for congestive heart failure, or revascularisation). Findings Baseline characteristics, and prognosis in patients allocated placebo, differed strikingly between those who were and were not taking aspirin at baseline. Results from analyses of all trials, except SOLVD, did not suggest any significant differences between the proportional reductions in risk with ACE inhibitor therapy in the presence or absence of aspirin for the major clinical outcomes (p=0.15), or in any of its individual components, except myocardial infarction (interaction p=0.01). Overall, ACE inhibitor therapy significantly reduced the risk of the major clinical outcomes by 22% (p<0.0001), with clear reductions in risk both among those receiving aspirin at baseline (odds ratio 0.80, [99% CI 0.73-0-88]) and those who were not (0-71 [99% CI 0.62-0.81], interaction p=0.07). Interpretation Considering the totality of evidence on all major vascular outcomes in these trials, there is only weak evidence of any reduction in the benefit of ACE-inhibitor therapy when added to aspirin. However, there is definite evidence of clinically important benefits with respect to these major clinical outcomes with ACE-inhibitor therapy, irrespective of whether concomitant aspirin is used.	McMaster Univ, Med Ctr, Populat Hlth Res Inst, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Div Cardiol, Hamilton, ON L8N 3Z5, Canada; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark; Yorkshire Heart Ctr, Inst Cardiovasc Res, Leeds, W Yorkshire, England; Ist Ric Farmacol Mario Negri, Milan, Italy; Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England	McMaster University; Population Health Research Institute; McMaster University; Harvard University; Brigham & Women's Hospital; Rigshospitalet; University of Copenhagen; University of Leeds; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Radcliffe Infirmary; University of Oxford	Teo, KK (corresponding author), McMaster Univ, Med Ctr, Populat Hlth Res Inst, Room 3 U4,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	teok@mcmaster.ca	Hall, Alistair/K-1953-2019; Latini, Roberto/AAB-1410-2020	Latini, Roberto/0000-0002-3729-4650; Kober, Lars/0000-0002-6635-1466; Yusuf, Salim/0000-0003-4776-5601; Hall, Alistair/0000-0003-0306-7887				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BALL SG, 1993, LANCET, V342, P821; BAUR LHB, 1995, BRIT HEART J, V73, P227; Blais C, 1997, AM J PHYSIOL-HEART C, V273, pH2263, DOI 10.1152/ajpheart.1997.273.5.H2263; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; HALL D, 1992, J AM COLL CARDIOL, V20, P1549, DOI 10.1016/0735-1097(92)90449-W; Heesch CM, 1996, AM J PHYSIOL-REG I, V270, pR728, DOI 10.1152/ajpregu.1996.270.4.R728; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Latini R, 2000, J AM COLL CARDIOL, V35, P1801, DOI 10.1016/S0735-1097(00)00638-0; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; MANTEL N, 1959, J NATL CANCER I, V22, P719; Nguyen KN, 1997, AM J CARDIOL, V79, P115, DOI 10.1016/S0002-9149(96)00696-0; Oosterga M, 1998, AM J CARDIOL, V81, P1178, DOI 10.1016/S0002-9149(98)00153-2; PACKER M, 1988, CIRCULATION, V77, P64; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PITT B, 1992, Journal of the American College of Cardiology, V19, p215A; *SOLVD INV, 1991, NEW ENGL J MED, V327, P685; Spaulding C, 1998, CIRCULATION, V98, P757, DOI 10.1161/01.CIR.98.8.757; STURROCK NDC, 1993, BRIT J CLIN PHARMACO, V35, P343, DOI 10.1111/j.1365-2125.1993.tb04149.x; SWARTZ SL, 1980, J CLIN INVEST, V65, P1257, DOI 10.1172/JCI109788; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; Yusuf S, 2000, NEW ENGL J MED, V342, P145; ZUCKER IH, 1991, AM J PHYSIOL, V260, pH260, DOI 10.1152/ajpheart.1991.260.1.H260	27	156	164	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	2002	360	9339					1037	1043		10.1016/S0140-6736(02)11138-X	http://dx.doi.org/10.1016/S0140-6736(02)11138-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383982				2022-12-28	WOS:000178485200007
J	Horton, R				Horton, R			WHO's mandate: a damaging reinterpretation is taking place	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							The World Bank Group, MILL DEV GOALS	1	11	11	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 28	2002	360	9338					960	961		10.1016/S0140-6736(02)11117-2	http://dx.doi.org/10.1016/S0140-6736(02)11117-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383659				2022-12-28	WOS:000178249000002
J	O'Neill, WW; Grines, CL				O'Neill, WW; Grines, CL			Surgery or stent? The gap continues to narrow	LANCET			English	Editorial Material							CORONARY-BYPASS SURGERY; RANDOMIZED TRIAL; DISEASE ERACI; FOLLOW-UP; ANGIOPLASTY		William Beaumont Hosp, Dept Internal Med, Div Cardiol, Royal Oak, MI 48073 USA	Beaumont Health	O'Neill, WW (corresponding author), William Beaumont Hosp, Dept Internal Med, Div Cardiol, Royal Oak, MI 48073 USA.							Alderman EL, 1996, NEW ENGL J MED, V335, P217; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; RICKARDS AF, 1995, LANCET, V346, P1179; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; Rodriguez A, 2001, J AM COLL CARDIOL, V37, P51, DOI 10.1016/S0735-1097(00)01052-4; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502	9	9	9	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 28	2002	360	9338					961	962		10.1016/S0140-6736(02)11118-4	http://dx.doi.org/10.1016/S0140-6736(02)11118-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383660				2022-12-28	WOS:000178249000003
J	Doty, JR; Doty, DB				Doty, JR; Doty, DB			Floating left atrial thrombus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; LDS Hosp, Salt Lake City, UT 84103 USA	Johns Hopkins University; Johns Hopkins Medicine	Doty, JR (corresponding author), Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.								0	2	2	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2002	347	19					E5	E5		10.1056/ENEJMicm010908	http://dx.doi.org/10.1056/ENEJMicm010908			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611XG	12421907				2022-12-28	WOS:000179042700007
J	Gilden, DH; Lipton, HL; Wolf, JS; Akenbrandt, W; Smith, JE; Mahalingam, R; Forghani, B				Gilden, DH; Lipton, HL; Wolf, JS; Akenbrandt, W; Smith, JE; Mahalingam, R; Forghani, B			Brief report - Two patients with unusual forms of varicella-zoster virus vasculopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HERPES-ZOSTER; TRIGEMINAL GANGLIA; INFARCTION; VASCULITIS; BRAIN		Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Evanston Hosp Corp, Div Neurol, Evanston, IL USA; Evanston Hosp Corp, Dept Radiol, Evanston, IL USA; Northwestern Univ, Sch Med, Evanston, IL USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Calif Dept Hlth Serv, Viral & Rickettsial Dis Lab, Richmond, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; NorthShore University Health System; NorthShore University Health System; Northwestern University; Johns Hopkins University; California Department of Health Care Services	Gilden, DH (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, Mail Stop B-182,4200 E 9th Ave, Denver, CO 80262 USA.				NIA NIH HHS [AG06127] Funding Source: Medline; NINDS NIH HHS [NS32623] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS032623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006127, R37AG006127] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAEKEBEKE JFV, 1990, ARCH NEUROL-CHICAGO, V47, P1033, DOI 10.1001/archneur.1990.00530090115023; DUELAND AN, 1991, ANN NEUROL, V29, P569, DOI 10.1002/ana.410290520; Forghani B., 1986, METHOD ENZYMAT AN, V10, P267; GENY C, 1991, NEUROLOGY, V41, P1846, DOI 10.1212/WNL.41.11.1846; Gilden DH, 1996, NEUROLOGY, V47, P1441, DOI 10.1212/WNL.47.6.1441; Gilden DH, 2002, J NEUROL SCI, V195, P99, DOI 10.1016/S0022-510X(02)00021-7; Haanpaa M, 1998, NEUROLOGY, V51, P1405, DOI 10.1212/WNL.51.5.1405; HALL S, 1983, ANN NEUROL, V13, P217, DOI 10.1002/ana.410130226; HILT DC, 1983, ANN NEUROL, V14, P543, DOI 10.1002/ana.410140509; HORTEN B, 1981, ANN NEUROL, V9, P251, DOI 10.1002/ana.410090308; KleinschmidtDeMasters BK, 1996, HUM PATHOL, V27, P927, DOI 10.1016/S0046-8177(96)90220-8; MAYBERG M, 1981, SCIENCE, V213, P228, DOI 10.1126/science.6166046; Nau R, 1998, NEUROLOGY, V51, P914, DOI 10.1212/WNL.51.3.914; RAWLINSON WD, 1991, MED J AUSTRALIA, V155, P344, DOI 10.5694/j.1326-5377.1991.tb142297.x; REIBER H, 1991, CLIN CHEM, V37, P1153; ROSS MH, 1991, NEUROLOGY, V41, P1685, DOI 10.1212/WNL.41.10.1685; SAITO K, 1989, STROKE, V20, P524, DOI 10.1161/01.STR.20.4.524; SNOW BJ, 1988, NEUROLOGY, V38, P1331, DOI 10.1212/WNL.38.8.1331	18	68	76	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2002	347	19					1500	1503		10.1056/NEJMoa020841	http://dx.doi.org/10.1056/NEJMoa020841			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611XG	12421892				2022-12-28	WOS:000179042700005
J	Levey, AS				Levey, AS			Nondiabetic kidney disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIETARY-PROTEIN RESTRICTION; CHRONIC RENAL-DISEASE; BLOOD-PRESSURE CONTROL; SERUM CREATININE; ACE-INHIBITION; PROGRESSION; NEPHROPATHY; PREDICTION; SAFETY; RISK		Tufts Univ, New England Med Ctr, Div Nephrol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Levey, AS (corresponding author), Tufts Univ, New England Med Ctr, Div Nephrol, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053869] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-53869] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; American Diabetes Association, 2001, DIABETES CARE S1, V24, pS69; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Basta E, 2000, J CLIN PHARMACOL, V40, P978, DOI 10.1177/00912700022009701; Beto JA, 1998, AM J KIDNEY DIS, V32, pS172, DOI 10.1053/ajkd.1998.v32.pm9820474; BLANE GF, 1987, AM J MED, V83, P26, DOI 10.1016/0002-9343(87)90868-0; Broeders N, 2000, NEPHROL DIAL TRANSPL, V15, P1993, DOI 10.1093/ndt/15.12.1993; Buter H, 1998, NEPHROL DIAL TRANSPL, V13, P1682, DOI 10.1093/ndt/13.7.1682; Clinical practice guidelines for nutrition in chronic renal failure, 2000, AM J KIDNEY DIS, V35, pS1; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; DAVIES DF, 1950, J CLIN INVEST, V29, P496, DOI 10.1172/JCI102286; DOUGLAS J, 2001, AM HEART ASS SCI SES; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; Fouque D, 2000, NEPHROL DIAL TRANSPL, V15, P1986, DOI 10.1093/ndt/15.12.1986; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; Jafar TH, 2001, ANN INTERN MED, V135, P73, DOI 10.7326/0003-4819-135-2-200107170-00007; Kasiske BL, 1998, AM J KIDNEY DIS, V32, pS142, DOI 10.1053/ajkd.1998.v32.pm9820472; Keane WF, 1999, AM J KIDNEY DIS, V33, P1004, DOI 10.1016/S0272-6386(99)70442-7; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Koshy S, 2000, CARDIOVASC DRUG THER, V14, P295, DOI 10.1023/A:1007882624572; Lazarus JM, 1997, HYPERTENSION, V29, P641, DOI 10.1161/01.HYP.29.2.641; Levey AS, 1999, J AM SOC NEPHROL, V10, P2426; Levey AS, 1998, AM J KIDNEY DIS, V32, P853, DOI 10.1016/S0272-6386(98)70145-3; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Levey AS, 2000, J AM SOC NEPHROL, V11, pA0828; MAKI DD, 1995, ARCH INTERN MED, V155, P1073, DOI 10.1001/archinte.155.10.1073; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; *NAT CHOL ED PROGR, 2001, NIH PUBL; Orth SR, 1997, KIDNEY INT, V51, P1669, DOI 10.1038/ki.1997.232; Pedrini MT, 1996, ANN INTERN MED, V124, P627, DOI 10.7326/0003-4819-124-7-199604010-00002; PERRONE RD, 1992, CLIN CHEM, V38, P1933; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; *PREV SERV TASK FO, 1996, GUID CLIN PREV SERV, P597; Remuzzi G, 2002, NEW ENGL J MED, V346, P1145, DOI 10.1056/NEJMcp011773; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1999, LANCET, V354, P359, DOI 10.1016/S0140-6736(98)10363-X; Russo D, 2001, AM J KIDNEY DIS, V38, P18, DOI 10.1053/ajkd.2001.25176; SMITH HW, 1951, KIDNEY STRUCTURE FUN, P520; STRIKER G, 1995, J AM SOC NEPHROL, V5, P1537; Warram JH, 1996, J AM SOC NEPHROL, V7, P930; 2000, AM J KIDNEY DIS S2, V36	43	106	111	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2002	347	19					1505	1511		10.1056/NEJMcp013462	http://dx.doi.org/10.1056/NEJMcp013462			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611XG	12421894				2022-12-28	WOS:000179042700008
J	Lincoff, AM; Califf, RM; Van de Werf, F; Willerson, JT; White, HD; Armstrong, PW; Guetta, V; Gibler, WB; Hochman, JS; Bode, C; Vahanian, A; Steg, PG; Ardissino, D; Savonitto, S; Bar, F; Sadowski, Z; Betriu, A; Booth, JE; Wolski, K; Waller, M; Topol, EJ				Lincoff, AM; Califf, RM; Van de Werf, F; Willerson, JT; White, HD; Armstrong, PW; Guetta, V; Gibler, WB; Hochman, JS; Bode, C; Vahanian, A; Steg, PG; Ardissino, D; Savonitto, S; Bar, F; Sadowski, Z; Betriu, A; Booth, JE; Wolski, K; Waller, M; Topol, EJ		GUSTO V Investigators	Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction - GUSTO V randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; RECEPTOR BLOCKADE; REPERFUSION; ABCIXIMAB; ANGIOPLASTY	Context Among patients with acute myocardial infarction, combination reperfusion therapy with a platelet glycoprotein IIb/IIIa receptor inhibitor (abciximab) and a half dose of a plasminogen activator (reteplase) did not significantly reduce mortality at 30 days compared with a full dose of reteplase. Rates of nonfatal ischemic complications were significantly diminished. Objective To determine if the beneficial effects of abciximab and reteplase (combination therapy) on early nonfatal complications would translate into a reduction in the risk of death by 1 year. Design, Setting, and Patients One-year follow-up of a randomized controlled trial (Global Use of Strategies To Open Coronary Arteries [GUSTO] V). Of 16588 patients who had been treated in 820 community and referral hospitals in 20 countries between July 1999 and February 2001, mortality data were available for 16453 (99.2%). Intervention Patients were randomly assigned to receive (intravenously) a standard dose of reteplase (two 10-U boluses, 30 minutes apart) or the combination of a standard dose of abdximab (0.25 mg/kg bolus, 0.125 mug/kg per minute infusion [maximum 10 mug/min for 12 hours]) and a half dose of reteplase (two 5-U boluses, 30 minutes apart). Main Outcome Measure One-year all-cause mortality rates. Results All-cause mortality at 1 year occurred in 692 (8.38%) of 8260 patients in the reteplase group and 698 (8.38%) of the 8328 patients in the combination therapy group (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.90-1.11; P>.99). Reinfarction within the first 7 days occurred in 3.5% of patients in the reteplase group and 2.3% of patients in the combination therapy group, and was significantly associated with 1-year mortality (22.6% in patients with reinfarction vs 8.0% in patients without reinfarction; HR, 3.08; 95% CI, 2.53-3.75; P<.001). However, treatment assignment did not significantly influence time of mortality regardless of reinfarction status. Conclusion Combination therapy (abciximab and reteplase) did not reduce mortality over 1 year compared with fibrinolytic therapy with reteplase alone.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Dike Clin Res Inst, Durham, NC USA; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Houston Med Ctr, Houston, TX USA; Green Lane Hosp, Auckland 3, New Zealand; Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; Chaim Sheba Med Ctr, Ramat Gan, Israel; Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; St Lukes Hosp, New York, NY USA; Univ Freiburg, Med Klin, D-7800 Freiburg, Germany; Hop Bichat Claude Bernard, F-75877 Paris, France; Hop Tenon, F-75970 Paris, France; Azienda Osped Parma, Parma, Italy; Osped Niguarda Ca Granda, Milan, Italy; Acad Ziekenhuis Maastricht, Maastricht, Netherlands; Natl Inst Cardiol, Warsaw, Poland; Univ Barcelona Hosp Clin, Barcelona, Spain; Centocor Inc, Malvern, PA 19355 USA	Cleveland Clinic Foundation; KU Leuven; University Hospital Leuven; University of Alberta; Chaim Sheba Medical Center; University System of Ohio; University of Cincinnati; Mount Sinai St. Luke's; University of Freiburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Parma; University Hospital of Parma; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Maastricht University; Maastricht University Medical Centre (MUMC); Institute of Cardiology - Poland; University of Barcelona; Hospital Clinic de Barcelona; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Lincoff, AM (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	lincofa@ccf.org	Ardissino, Diego/AAC-4041-2022; STEG, Philippe Gabriel/Z-1567-2019	Hochman, Judith/0000-0002-5889-5981; STEG, Philippe Gabriel/0000-0001-6896-2941; solinas, emilia/0000-0003-3532-1317; Armstrong, Paul/0000-0002-0460-3445; Van de Werf, Frans/0000-0001-9479-7767; Topol, Eric/0000-0002-1478-4729				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; de Lemos JA, 2000, CIRCULATION, V101, P239, DOI 10.1161/01.CIR.101.3.239; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; *GUSTO 5 INV, 2000, LANCET, V357, P1905; Harrington RA, 1998, J AM COLL CARDIOL, V32, P2003; Hudson MP, 2001, CIRCULATION, V104, P1229, DOI 10.1161/hc3601.095717; KLEIMAN NS, 1991, CIRCULATION S2, V84, P522; LINCOFF AM, 1993, CIRCULATION, V88, P1361, DOI 10.1161/01.CIR.88.3.1361; LINCOFF AM, 1993, CIRCULATION, V87, P1792; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Neumann FJ, 2000, J AM COLL CARDIOL, V35, P915, DOI 10.1016/S0735-1097(99)00635-X; Ohman EM, 1997, CIRCULATION, V95, P846; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SAVONITTO S, IN PRESS EUR HEART J; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2000, CIRCULATION, V101, P2788; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2001, LANCET, V358, P605; White HD, 2001, LANCET, V358, P1855	25	90	93	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2130	2135		10.1001/jama.288.17.2130	http://dx.doi.org/10.1001/jama.288.17.2130			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413372				2022-12-28	WOS:000179048100023
J	Agalioti, T; Chen, GY; Thanos, D				Agalioti, T; Chen, GY; Thanos, D			Deciphering the transcriptional histone acetylation code for a human gene	CELL			English	Article							IFN-BETA ENHANCEOSOME; H3 PHOSPHORYLATION; IN-VITRO; COACTIVATORS; HETEROCHROMATIN; DEACETYLATION; REQUIREMENTS; RECRUITMENT; ACTIVATION; EXPRESSION	We report the results of experiments designed to test the histone code hypothesis. We found that only a small subset of lysines in histories H4 and H3 are acetylated in vivo by the GCN5 acetyltransferase during activation of the IFN-beta gene. Reconstitution of recombinant nucleosomes bearing mutations in these lysine residues revealed the cascade of gene activation via a point-by-point interpretation of the histone code through the ordered recruitment of bromodomain-containing transcription complexes. Acetylation of histone H4 K8 mediates recruitment of the SWI/SNF complex whereas acetylation of K9 and K14 in histone H3 is critical for the recruitment of TFIID. Thus, the information contained in the DNA address of the enhancer is transferred to the histone N termini by generating novel adhesive surfaces required for the recruitment of transcription complexes.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Biomed Sci Res Ctr Al Fleming, Inst Mol Biol & Genet, Athens 16672, Greece	Columbia University; Alexander Fleming Biomedical Sciences Research Center	Thanos, D (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	dt73@columbia.edu	Thanos, Dimitris/AAE-5720-2019	Agalioti, Theodora/0000-0002-5898-2751	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Featherstone M, 2002, CURR OPIN GENET DEV, V12, P149, DOI 10.1016/S0959-437X(02)00280-0; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Katan-Khaykovich Y, 2002, GENE DEV, V16, P743, DOI 10.1101/gad.967302; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; Loyola A, 2001, GENE DEV, V15, P2837; Luger K, 1999, METH MOL B, V119, P1; Marmorstein R, 2001, GENE, V272, P1, DOI 10.1016/S0378-1119(01)00519-4; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Peterson CL, 2002, CURR BIOL, V12, pR245, DOI 10.1016/S0960-9822(02)00782-0; PTASHNE M, 2002, GENES SIGNALS; Ren QH, 2001, MOL CELL, V7, P1329, DOI 10.1016/S1097-2765(01)00269-6; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108	40	500	516	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	2002	111	3					381	392		10.1016/S0092-8674(02)01077-2	http://dx.doi.org/10.1016/S0092-8674(02)01077-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419248	Bronze			2022-12-28	WOS:000179010100010
J	Heussler, VT; Rottenberg, S; Schwab, R; Kuenzi, P; Fernandez, PC; McKellar, S; Shiels, B; Chen, ZJJ; Orth, K; Wallach, D; Dobbelaere, DAE				Heussler, VT; Rottenberg, S; Schwab, R; Kuenzi, P; Fernandez, PC; McKellar, S; Shiels, B; Chen, ZJJ; Orth, K; Wallach, D; Dobbelaere, DAE			Hijacking of host cell IKK signalosomes by the transforming parasite Theileria	SCIENCE			English	Article							NF-KAPPA-B; BOVINE LYMPHOCYTES; SIGNALING PATHWAYS; PARVA INFECTION; KINASE IKK; T-CELLS; ACTIVATION; RIP; OLIGOMERIZATION; LEUKOCYTES	Parasites have evolved a plethora of mechanisms to ensure their propagation and evade antagonistic host responses. The intracellular protozoan parasite Theileria is the only eukaryote known to induce uncontrolled host cell proliferation. Survival of Theileria-transformed leukocytes depends strictly on constitutive nuclear factor kappa B (NF-kappaB) activity. We found that this was mediated by recruitment of the multisubunit IkappaB kinase (IKK) into large, activated foci on the parasite surface. IKK signalosome assembly was specific for the transforming schizont stage of the parasite and was down-regulated upon differentiation into the nontransforming merozoite stage. Our findings provide insights into IKK activation and how pathogens subvert host-cell signaling pathways.	Univ Bern, Inst Anim Pathol, Div Mol Pathol, CH-3012 Bern, Switzerland; Univ Glasgow, Dept Vet Parasitol, Glasgow G61 1QH, Lanark, Scotland; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	University of Bern; University of Glasgow; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Weizmann Institute of Science	Dobbelaere, DAE (corresponding author), Univ Bern, Inst Anim Pathol, Div Mol Pathol, CH-3012 Bern, Switzerland.		Orth, Kim/AAV-4421-2021; Heussler, Volker/H-9322-2019; Chen, Zhijian/C-6039-2012; Dobbelaere, Dirk/A-3885-2013	Orth, Kim/0000-0002-0678-7620; Heussler, Volker/0000-0001-8028-9825; Chen, Zhijian/0000-0002-8475-8251; Dobbelaere, Dirk/0000-0003-0672-8468; Shiels, Brian/0000-0001-7595-2514; Rottenberg, Sven/0000-0003-2044-9844; Fernandez, Paula Carolina/0000-0003-3237-6283	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063692] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63692] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Dobbelaere D, 1999, ANNU REV MICROBIOL, V53, P1, DOI 10.1146/annurev.micro.53.1.1; DOBBELAERE DAE, 1988, P NATL ACAD SCI USA, V85, P4730, DOI 10.1073/pnas.85.13.4730; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GIRARDIN SE, 2001, EMBO REP, V19, P19; Heussler VT, 2001, CELL MICROBIOL, V3, P537, DOI 10.1046/j.1462-5822.2001.00134.x; Heussler VT, 1999, P NATL ACAD SCI USA, V96, P7312, DOI 10.1073/pnas.96.13.7312; HUDSON AT, 1985, PARASITOLOGY, V90, P45, DOI 10.1017/S0031182000049003; Inohara N, 2000, J BIOL CHEM, V275, P27823; IVANOV V, 1989, MOL CELL BIOL, V9, P4677, DOI 10.1128/MCB.9.11.4677; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; KUENZI P, UNPUB; Machado J, 2000, MICROBES INFECT, V2, P1311, DOI 10.1016/S1286-4579(00)01284-3; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer GH, 1997, P NATL ACAD SCI USA, V94, P12527, DOI 10.1073/pnas.94.23.12527; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Shaw MK, 1997, INT J PARASITOL, V27, P457, DOI 10.1016/S0020-7519(97)00015-5; SHIELS B, 1992, J CELL SCI, V101, P99; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	28	106	116	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					1033	1036		10.1126/science.1075462	http://dx.doi.org/10.1126/science.1075462			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411708				2022-12-28	WOS:000178932000059
J	Packard, M; Koo, ES; Gorczyca, M; Sharpe, J; Cumberledge, S; Budnik, V				Packard, M; Koo, ES; Gorczyca, M; Sharpe, J; Cumberledge, S; Budnik, V			The drosophila wnt, wingless, provides an essential signal for pre- and postsynaptic differentiation	CELL			English	Article							TUMOR-SUPPRESSOR GENE; LARVAL NEUROMUSCULAR-JUNCTION; PRESYNAPTIC ACTIVE ZONES; SYNAPTIC GROWTH; PROTEIN; LOCALIZATION; TRANSDUCTION; PLASTICITY; SYNAPSES; DYNAMIN	At vertebrate neuromuscular junctions (NMJs), Agrin plays pivotal roles in synapse development, but molecules that activate synapse formation at central synapses are largely unknown. Members of the Wnt family are well established as morphogens, yet recently they have also been implicated in synapse maturation. Here we demonstrate that the Drosophila Wnt, Wingless (Wg), is essential for synapse development. We show that Wg and its receptor are expressed at glutamatergic NMJs, and that Wg is secreted by synaptic boutons. Loss of Wg leads to dramatic reductions in target-dependent synapse formation, and new boutons either fail to develop active zones and postsynaptic specializations or these are strikingly aberrant. We suggest that Wg signals the coordinated development of pre- and postsynaptic compartments.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Cell Mol & Dev Biol Program, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Budnik, V (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH070000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037061, R01NS042629] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 36000, R01 HD036000] Funding Source: Medline; NIMH NIH HHS [R01 MH070000] Funding Source: Medline; NINDS NIH HHS [R01 NS 42629, R01 NS 3700, R01 NS 37061] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aberle H, 2002, NEURON, V33, P545, DOI 10.1016/S0896-6273(02)00589-5; Binari RC, 1997, DEVELOPMENT, V124, P2623; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Burden SJ, 2000, CELL, V100, P495, DOI 10.1016/S0092-8674(00)80685-6; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Chen CM, 1999, DEVELOPMENT, V126, P5441; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Davis GW, 1998, CURR OPIN NEUROBIOL, V8, P149, DOI 10.1016/S0959-4388(98)80018-4; Davis GW, 2000, NEURON, V26, P551, DOI 10.1016/S0896-6273(00)81190-3; Day SJ, 2000, DEVELOPMENT, V127, P2977; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; Delgado R, 2000, NEURON, V28, P941, DOI 10.1016/S0896-6273(00)00165-3; Dent EW, 1999, J NEUROSCI, V19, P8894, DOI 10.1523/JNEUROSCI.19-20-08894.1999; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; Dubois L, 2001, CELL, V105, P613, DOI 10.1016/S0092-8674(01)00375-0; Estes PS, 1996, J NEUROSCI, V16, P5443; FRADKIN LG, 1995, DEV BIOL, V168, P202, DOI 10.1006/dbio.1995.1072; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; Goold RG, 1999, J CELL SCI, V112, P3373; GORCZYCA M, 1993, J NEUROSCI, V13, P3692; Gramates LS, 1999, INT REV NEUROBIOL, V43, P93, DOI 10.1016/S0074-7742(08)60542-5; Guan B, 1996, CURR BIOL, V6, P695, DOI 10.1016/S0960-9822(09)00451-5; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; JIA XX, 1993, J NEUROBIOL, V24, P1025, DOI 10.1002/neu.480240804; JOHANSEN J, 1989, J NEUROSCI, V9, P710; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; KAPHINGST K, 1994, CELL, V78, P437, DOI 10.1016/0092-8674(94)90422-7; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; Koh YH, 2002, J NEUROSCI, V22, P2496, DOI 10.1523/JNEUROSCI.22-07-02496.2002; Koh YH, 2000, MICROSC RES TECHNIQ, V49, P14, DOI 10.1002/(SICI)1097-0029(20000401)49:1<14::AID-JEMT3>3.3.CO;2-7; Kovalchuk Y, 2002, SCIENCE, V295, P1729, DOI 10.1126/science.1067766; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lnenicka GA, 2000, J NEUROBIOL, V43, P186, DOI 10.1002/(SICI)1097-4695(200005)43:2<186::AID-NEU8>3.3.CO;2-E; Lucas FR, 1998, J CELL SCI, V111, P1351; Marques G, 2002, NEURON, V33, P529, DOI 10.1016/S0896-6273(02)00595-0; Moline MM, 1999, DEVELOPMENT, V126, P4375; NUSSLEINVOLHARD C, 1985, COLD SPRING HARB SYM, V50, P145, DOI 10.1101/SQB.1985.050.01.020; Parnas D, 2001, NEURON, V32, P415, DOI 10.1016/S0896-6273(01)00485-8; Petersen SA, 1997, NEURON, V19, P1237, DOI 10.1016/S0896-6273(00)80415-8; Pfeiffer S, 2000, CURR BIOL, V10, P321, DOI 10.1016/S0960-9822(00)00381-X; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; Prokop A, 1996, NEURON, V17, P617, DOI 10.1016/S0896-6273(00)80195-6; Prokop A, 1998, J CELL BIOL, V143, P1283, DOI 10.1083/jcb.143.5.1283; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Roos J, 2000, NEURON, V26, P371, DOI 10.1016/S0896-6273(00)81170-8; Salinas P C, 1999, Bipolar Disord, V1, P87, DOI 10.1034/j.1399-5618.1999.010205.x; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SchultzEhrenburg U, 1996, PHLEBOLOGY, V11, P17; Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X; Torroja L, 1999, J NEUROSCI, V19, P7793; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X; Zito K, 1999, NEURON, V22, P719, DOI 10.1016/S0896-6273(00)80731-X	57	323	329	0	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 1	2002	111	3					319	330		10.1016/S0092-8674(02)01047-4	http://dx.doi.org/10.1016/S0092-8674(02)01047-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419243	Green Accepted, Bronze			2022-12-28	WOS:000179010100005
J	Jang, MS; Czoschke, NM; Lee, S; Kamens, RM				Jang, MS; Czoschke, NM; Lee, S; Kamens, RM			Heterogeneous atmospheric aerosol production by acid-catalyzed particle-phase reactions	SCIENCE			English	Article							CHEMICAL-COMPOSITION; ORGANIC-COMPOUNDS; ALPHA-PINENE; GAS-PHASE; PHOTOOXIDATION; EMISSION; VALLEY; MODEL	According to evidence from our laboratory, acidic surfaces on atmospheric aerosols lead to potentially multifold increases in secondary organic aerosol (SOA) mass. Experimental observations using a multichannel flow reactor, Teflon (polytetrauoroethylene) film bag batch reactors, and outdoor Teflon-film smog chambers strongly confirm that inorganic acids, such as sulfuric acid, catalyze particle-phase heterogeneous reactions of atmospheric organic carbonyl species. The net result is a large increase in SOA mass and stabilized organic layers as particles age. If acid-catalyzed heterogeneous reactions of SOA products are included in current models, the predicted SOA formation will be much greater and could have a much larger impact on climate forcing effects than we now predict.	Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Jang, MS (corresponding author), Univ N Carolina, Dept Environm Sci & Engn, CB 7431,Rosenau Hall, Chapel Hill, NC 27599 USA.							Adams J.M., 2001, CHEMOSPHERE GLOBAL C, V3, P73, DOI DOI 10.1016/S1465-9972(00)00023-4; ALTSHULLER AP, 1983, ATMOS ENVIRON, V17, P2131, DOI 10.1016/0004-6981(83)90211-1; BARTON D, 1979, COMPREHENSIVE ORGANI, P960; Blando JD, 1998, ENVIRON SCI TECHNOL, V32, P604, DOI 10.1021/es970405s; CAREY FA, 2000, ADV ORGANIC CHEM A, P4; Curtius J, 2001, J GEOPHYS RES-ATMOS, V106, P31975, DOI 10.1029/2001JD000605; FINLAYSONPITTS BJ, 2000, CHEM UPPER LOWER ATM, P207; Hansen JE, 2001, P NATL ACAD SCI USA, V98, P14778, DOI 10.1073/pnas.261553698; Hoffmann T, 1997, J ATMOS CHEM, V26, P189, DOI 10.1023/A:1005734301837; Jang M, 1997, ENVIRON SCI TECHNOL, V31, P2805, DOI 10.1021/es970014d; Jang MS, 2001, ENVIRON SCI TECHNOL, V35, P3626, DOI 10.1021/es010676+; Jeffries H. E., 1995, COMPOSITION CHEM CLI, P308; Kamens R, 1999, ENVIRON SCI TECHNOL, V33, P1430, DOI 10.1021/es980725r; KAMENS RM, 1982, INT J CHEM KINET, V14, P955, DOI 10.1002/kin.550140902; Kesselmeier J, 1999, J ATMOS CHEM, V33, P23, DOI 10.1023/A:1006127516791; Nguyen MT, 1997, J CHEM PHYS, V106, P8710, DOI 10.1063/1.473925; Noziere B, 1999, J GEOPHYS RES-ATMOS, V104, P23645, DOI 10.1029/1999JD900778; Odum JR, 1997, SCIENCE, V276, P96, DOI 10.1126/science.276.5309.96; Paerl HW, 2002, ENVIRON SCI TECHNOL, V36, p323A, DOI 10.1021/es022392a; PANKOW JF, 1994, ATMOS ENVIRON, V28, P2275; Reddy MS, 2002, ATMOS ENVIRON, V36, P699, DOI 10.1016/S1352-2310(01)00464-2; Reddy MS, 2002, ATMOS ENVIRON, V36, P677, DOI 10.1016/S1352-2310(01)00463-0; Tanner RL, 2000, J AIR WASTE MANAGE, V50, P1299, DOI 10.1080/10473289.2000.10464175; Tobias HJ, 2000, ENVIRON SCI TECHNOL, V34, P2116, DOI 10.1021/es991057s; Tobias HJ, 2001, ENVIRON SCI TECHNOL, V35, P2233, DOI 10.1021/es0016654; *US EPA, 1996, EPA600P95001CF; WINER AM, 1992, ATMOS ENVIRON A-GEN, V26, P2647, DOI 10.1016/0960-1686(92)90116-3; Yu JZ, 1997, ATMOS ENVIRON, V31, P2261, DOI 10.1016/S1352-2310(97)00011-3; [No title captured]	29	749	781	22	510	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					814	817		10.1126/science.1075798	http://dx.doi.org/10.1126/science.1075798			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399587				2022-12-28	WOS:000178791200055
J	Drescher, M; Hentschel, M; Kienberger, R; Uiberacker, M; Yakovlev, V; Scrinzi, A; Westerwalbesloh, T; Kleineberg, U; Heinzmann, U; Krausz, F				Drescher, M; Hentschel, M; Kienberger, R; Uiberacker, M; Yakovlev, V; Scrinzi, A; Westerwalbesloh, T; Kleineberg, U; Heinzmann, U; Krausz, F			Time-resolved atomic inner-shell spectroscopy	NATURE			English	Article							HARMONIC-GENERATION; PULSES; PHOTOIONIZATION; DECAY; XE	The characteristic time constants of the relaxation dynamics of core-excited atoms have hitherto been inferred from the linewidths of electronic transitions measured by continuous-wave extreme ultraviolet or X-ray spectroscopy. Here we demonstrate that a laser-based sampling system, consisting of a few-femtosecond visible light pulse and a synchronized sub-femtosecond soft X-ray pulse, allows us to trace these dynamics directly in the time domain with attosecond resolution. We have measured a lifetime of 7.9(-0.9)(+1.0) fs of M-shell vacancies of krypton in such a pump-probe experiment.	Vienna Univ Technol, Inst Photon, A-1040 Vienna, Austria; Univ Bielefeld, Fak Phys, D-33615 Bielefeld, Germany	Technische Universitat Wien; University of Bielefeld	Drescher, M (corresponding author), Vienna Univ Technol, Inst Photon, Gusshausstr 27, A-1040 Vienna, Austria.	drescher@physik.uni-bielefeld.de; ferenc.krausz@tuwien.ac.at	Yakovlev, Vladislav S/C-4091-2015; Heinzmann, Ulrich/A-6248-2012	Yakovlev, Vladislav S/0000-0002-0648-9375; Kienberger, Reinhard/0000-0001-8781-3685				AKSELA H, 1984, PHYS REV A, V30, P2456, DOI 10.1103/PhysRevA.30.2456; BECKER U, 1989, PHYS REV A, V39, P3902, DOI 10.1103/PhysRevA.39.3902; BORST M, 1986, PHYS REV A, V33, P4456, DOI 10.1103/PhysRevA.33.4456; Bouhal A, 1997, J OPT SOC AM B, V14, P950, DOI 10.1364/JOSAB.14.000950; Bromage J, 1999, PHYS REV LETT, V83, P4963, DOI 10.1103/PhysRevLett.83.4963; CARLSON TA, 1989, PHYS REV A, V39, P1170, DOI 10.1103/PhysRevA.39.1170; Drescher M, 2001, SCIENCE, V291, P1923, DOI 10.1126/science.1058561; FANO U, 1961, PHYS REV, V124, P1866, DOI 10.1103/PhysRev.124.1866; FREEMAN RR, 1991, J PHYS B-AT MOL OPT, V24, P325, DOI 10.1088/0953-4075/24/2/004; Glover TE, 1996, PHYS REV LETT, V76, P2468, DOI 10.1103/PhysRevLett.76.2468; Hentschel M, 2001, NATURE, V414, P509, DOI 10.1038/35107000; Itatani J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.173903; Jurvansuu M, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.012502; Kitzler M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.173904; KRAUSE MO, 1979, J PHYS CHEM REF DATA, V8, P307, DOI 10.1063/1.555594; Krausz F, 2002, OPT PHOTONICS NEWS, V13, P62, DOI 10.1364/OPN.13.5.000062; Papadogiannis NA, 1999, PHYS REV LETT, V83, P4289, DOI 10.1103/PhysRevLett.83.4289; Paul PM, 2001, SCIENCE, V292, P1689, DOI 10.1126/science.1059413; SCHINS JM, 1994, PHYS REV LETT, V73, P2180, DOI 10.1103/PhysRevLett.73.2180; Schmidtke B, 2001, J PHYS B-AT MOL OPT, V34, P4293, DOI 10.1088/0953-4075/34/22/302; TOPLER A, 1866, ANN PHYS CHEM, V128, P126; Zewail AH, 2000, J PHYS CHEM A, V104, P5660, DOI 10.1021/jp001460h	23	1222	1242	8	288	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					803	807		10.1038/nature01143	http://dx.doi.org/10.1038/nature01143			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397349				2022-12-28	WOS:000178769800037
J	Aiken, LH; Clarke, SP; Sloane, DM; Sochalski, J; Silber, JH				Aiken, LH; Clarke, SP; Sloane, DM; Sochalski, J; Silber, JH			Hospital nurse staffing and patient mortality, nurse burnout, and job dissatisfaction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; OUTCOMES; SURGERY; RATES; QUALITY	Context The worsening hospital nurse shortage and recent California legislation mandating minimum hospital patient-to-nurse ratios demand an understanding of how nurse staffing levels affect patient outcomes and nurse retention in hospital practice. Objective To determine the association between the patient-to-nurse ratio and patient mortality, failure-to-rescue (deaths following complications) among surgical patients, and factors related to nurse retention. Design, Setting, and Participants Cross-sectional analyses of linked data from 10184 staff nurses surveyed, 232342 general, orthopedic, and vascular surgery patients discharged from the hospital between April 1, 1998, and November 30, 1999 and administrative data from 168 nonfederal adult general hospitals in Pennsylvania. Main Outcome Measures Risk-adjusted patient mortality and failure-to-rescue within 30 days of admission, and nurse-reported job dissatisfaction and job-related burnout. Results After adjusting for patient and hospital characteristics (size, teaching status, and technology), each additional patient per nurse was associated with a 7% (odds ratio [OR], 1.07; 95% confidence interval [CI], 1.03-1.12) increase in the likelihood of dying within 30 days of admission and a 7% (OR, 1.07; 95% CI, 1.02-1.11) increase in the odds of failure-to-rescue. After adjusting for nurse and hospital characteristics, each additional patient per nurse was associated with a 23% (OR, 1.23; 95% CI, 1.13-1.34) increase in the odds of burnout and a 15% (OR, 1.15; 95% CI, 1.07-1.25) increase in the odds of job dissatisfaction. Conclusions In hospitals with high patient-to-nurse ratios, surgical patients experience higher risk-adjusted 30-day mortality and failure-to-rescue rates, and nurses, are more likely to experience burnout and job dissatisfaction.	Univ Penn, Sch Nursing, Ctr Hlth Outcomes & Policy Res, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Populat Studies, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Anesthesia, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Aiken, LH (corresponding author), Univ Penn, Sch Nursing, Ctr Hlth Outcomes & Policy Res, 420 Guardian Dr, Philadelphia, PA 19104 USA.				NINR NIH HHS [R01 NR04513] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR004513] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Aiken LH, 1999, MED CARE, V37, P760, DOI 10.1097/00005650-199908000-00006; Aiken LH, 2001, HEALTH AFFAIR, V20, P43, DOI 10.1377/hlthaff.20.3.43; *AM HOSP ASS, 1999, AHA ANN SURV DAT; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; *AUD COMM, 2001, AC HOSP PROTF REV NA, P3; Ayanian JZ, 1998, HEALTH AFFAIR, V17, P194, DOI 10.1377/hlthaff.17.6.194; Bishop YM., 2007, DISCRETE MULTIVARIAT; *COMM PENNS, HOSP QUEST REP PER 1; Commonwealth Fund, 2000, COMMONWEALTH FUND Q, V6, P1; FRIEDMAN L, 2002, SAN FRANCISCO C 0130, pA19; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; *HJ KAIS FAM FDN, 2002, SURV PHYS NURS; HOSMER DW, 1989, APPL LOGISTIC REGRES; Huber PJ, 1967, P 5 BERK S MATH STAT, P221; Institute of Medicine, 1996, NURS STAFF HOSP NURS; *JOINT COMM ACCR H, 2002, HLTH CAR CROSSR STRA; Lake ET, 1998, RES SOC H, V15, P147; Maslach C, 2016, MASLACH BURNOUT INVE; Maslach C, 1982, SOCIAL PSYCHOL HLTH, P227; Mitchell PH, 1997, MED CARE, V35, pNS19, DOI 10.1097/00005650-199711001-00003; MOSES LE, 1968, J AMER MED ASSOC, V203, P492, DOI 10.1001/jama.203.7.492; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; NEEDLEMAN J, 2002, NURSE STAFFING PATIE; *NURS EX COMM, 2000, REV FLIGHT TAL NURS; Parker-Pope T, 2001, WALL STREET J, pB1; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Seago JA, 2002, J NURS ADMIN, V32, P48, DOI 10.1097/00005110-200201000-00012; ShindulRothschild J, 1996, AM J NURS, V96, P25, DOI 10.1097/00000446-199611000-00034; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; SILBER JH, 1992, MED CARE, V30, P615, DOI 10.1097/00005650-199207000-00004; SILBER JH, 1995, J AM STAT ASSOC, V90, P7, DOI 10.2307/2291124; Silber JH, 2000, ANESTHESIOLOGY, V93, P152, DOI 10.1097/00000542-200007000-00026; Silber JH, 2002, ANESTHESIOLOGY, V96, P1044, DOI 10.1097/00000542-200205000-00004; SILBER JH, 1995, JAMA-J AM MED ASSOC, V274, P317, DOI 10.1001/jama.274.4.317; Silber JH, 2001, MED CARE, V39, P1048, DOI 10.1097/00005650-200110000-00003; Spetz J, 2001, J NURS ADMIN, V31, P132, DOI 10.1097/00005110-200103000-00009; Stolberg S G, 2002, N Y Times Web, pA18; TRAFFORD A, 2002, WASHINGTON POST 0820, pHE1; *US DEP HHS, 1996, REG NURS POP; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526	42	2822	2874	13	416	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	2002	288	16					1987	1993		10.1001/jama.288.16.1987	http://dx.doi.org/10.1001/jama.288.16.1987			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	606QW	12387650				2022-12-28	WOS:000178745500021
J	Chan, SK; Struhl, G				Chan, SK; Struhl, G			RETRACTED: Evidence that Armadillo transduces Wingless by mediating nuclear export or cytosolic activation of Pangolin (Retracted Article. See vol 116, pg 481, 2004)	CELL			English	Article; Retracted Publication							C-ELEGANS EMBRYOS; LONG-RANGE ACTION; BARR-VIRUS EBNA2; BETA-CATENIN; CUBITUS-INTERRUPTUS; SIGNALING ACTIVITY; IMPORTIN-ALPHA; CELL-NUCLEUS; DROSOPHILA; PROTEIN	Secreted proteins of the Wnt family have profound organizing roles during animal development and are transduced via the activities of the Frizzled (Fz) class of transmembrane receptors and the TCF/LEF/Pangolin class of transcription factors. beta-catenins, including Drosophila Armadillo (Arm), link activation of Fz at the cell surface to transcriptional regulation by TCF in the nucleus. The consensus view is that Wnt signaling induces beta-catenin to enter the nucleus and combine with TCF to form a transcription factor complex in which TCF binds DNA and the C-terminal domain of beta-catenin activates transcription. Here, we present findings, which challenge this view and suggest instead that R-catenin may transduce Wnt signals by exporting TCF from the nucleus or activating it in the cytoplasm.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Struhl, G (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Genet & Dev, New York, NY 10032 USA.	struhi@cuccfa.ccc.columbia.edu						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ARIAS AM, 1988, DEVELOPMENT, V103, P157; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Cox RT, 1999, DEVELOPMENT, V126, P1327; Cox RT, 1999, GENETICS, V153, P319; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Klymkowsky MW, 1999, MOL BIOL CELL, V10, P3151, DOI 10.1091/mbc.10.10.3151; Korswagen HC, 1999, COLD SPRING HARB SYM, V64, P141, DOI 10.1101/sqb.1999.64.141; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; LIN L, 1990, J BIOL CHEM, V265, P12596; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; Merriam JM, 1997, DEV BIOL, V185, P67, DOI 10.1006/dbio.1997.8550; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morel V, 2000, GENE DEV, V14, P377; Nelson RW, 1998, ANN NY ACAD SCI, V857, P86, DOI 10.1111/j.1749-6632.1998.tb10109.x; Neufeld KL, 2000, EMBO REP, V1, P519; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Pai LM, 1997, DEVELOPMENT, V124, P2255; Pandur P, 2001, BIOESSAYS, V23, P207, DOI 10.1002/1521-1878(200103)23:3<207::AID-BIES1029>3.0.CO;2-0; Parker DS, 2002, DEVELOPMENT, V129, P2565; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Tolwinski NS, 2001, DEVELOPMENT, V128, P2107; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	62	49	53	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	2002	111	2					265	280		10.1016/S0092-8674(02)01037-1	http://dx.doi.org/10.1016/S0092-8674(02)01037-1			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408870	Bronze			2022-12-28	WOS:000178753500015
J	Haritoglou, C; Dotse, SD; Rudolph, G; Stephan, CM; Thurau, SR; Klauss, V				Haritoglou, C; Dotse, SD; Rudolph, G; Stephan, CM; Thurau, SR; Klauss, V			A tourist with dengue fever and visual loss	LANCET			English	Article							VIRUS		Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany	University of Munich	Haritoglou, C (corresponding author), Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.	christos.haritoglou@ak-i.med.uni-muenchen.de						Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2; Haritoglou C, 2000, OPHTHALMOLOGE, V97, P433, DOI 10.1007/s003470070094; Jelinek T, 1997, ARCH INTERN MED, V157, P2367, DOI 10.1001/archinte.157.20.2367; SCHWARZ TF, 1995, ZBL BAKT-INT J MED M, V282, P533; SPITZNAS M, 1978, KLIN MONATSBL AUGENH, V172, P105	5	57	61	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	2002	360	9339					1070	1070		10.1016/S0140-6736(02)11145-7	http://dx.doi.org/10.1016/S0140-6736(02)11145-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383989				2022-12-28	WOS:000178485200014
J	Winer, S; Astsaturov, I; Cheung, R; Tsui, H; Song, AH; Gaedigk, R; Winer, D; Sampson, A; McKerlie, C; Bookman, A; Dosch, HM				Winer, S; Astsaturov, I; Cheung, R; Tsui, H; Song, AH; Gaedigk, R; Winer, D; Sampson, A; McKerlie, C; Bookman, A; Dosch, HM			Primary Sjogren's syndrome and deficiency of ICA69	LANCET			English	Article							NONOBESE DIABETIC MICE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ALPHA-FODRIN; ANIMAL-MODEL; NOD MOUSE; AUTOANTIGEN; AUTOANTIBODIES; LYMPHOCYTES; EXPRESSION; SECONDARY	Background Sjogren's syndrome is a common (about 1% of the population) autoimmune disease of salivary and lacrimal glands. Its cause and pathogenesis are poorly understood, and treatments are mostly for symptoms of the disease. ICA69 is a self-antigen expressed in brain, pancreas, salivary, and lacrimal glands. NOD-strain mice are an animal model of spontaneous Sjogren's syndrome. We aimed to assess the role of ICA69 in autoimmunity against Sjogren's syndrome. Methods We inactivated the genomic ICA69 locus, generated NOD congenic mice that were deficient in ICA69, and assessed development of Sjogren's syndrome. ICA69 autoimmunity was investigated in controls and in patients with primary Sjogren's syndrome or systemic lupus erythematosus, and in various NOD mice, some of which were given an ICA69-directed prototype peptide vaccine. Findings Disruption of the ICA69 locus prevented lacrimal gland disease and greatly reduced salivary gland disease in NOD mice. In healthy NOD mice, ICA69-specific T cells accumulated in lymph nodes that drain salivary tissue. T-cell and B-cell autoreactivity against ICA69 was much the same in patients with primary Sjogren's syndrome, but not in those with systemic lupus erythematosus or in healthy controls. Immunotherapy with a high-affinity mimicry peptide targeting ICA69-specific T-cells reduced established Sjogren's syndrome in wild-type NOD mice in the long term. Interpretation ICA69 is a new autoantigen in primary Sjogren's syndrome that has an important role in progression of disease and could be of diagnostic value. Immunotherapy of primary Sjogren's syndrome is promising, since autoimmunity in NOD mice with Sjogren's syndrome seems to be uniquely susceptible to such treatment even late in disease.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Immunol, Toronto, ON, Canada; Toronto Western Hosp, Res Inst, Toronto, ON M5T 2S8, Canada; Univ Toronto, Clin Studies Resource Ctr, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Dosch, HM (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hmdosch@sickkids.ca	ASTSATUROV, Igor/AAG-4099-2021	Astsaturov, Igor/0000-0002-8613-1890; McKerlie, Colin/0000-0002-2232-0967; Gaedigk, Roger/0000-0001-5942-1609				ANDONOPOULOS AP, 1990, BRIT J RHEUMATOL, V29, P21; Billaut-Mulot O, 2001, J CLIN INVEST, V108, P861, DOI 10.1172/JCI13469; Brayer JB, 2001, ARCH IMMUNOL THER EX, V49, P353; Chen W, 2001, J IMMUNOL, V167, P4926, DOI 10.4049/jimmunol.167.9.4926; CHUSED TM, 1977, NEW ENGL J MED, V296, P895, DOI 10.1056/NEJM197704212961602; Dosch HM, 1999, J IMMUNOL, V163, P6933; Dosch HM, 2000, DIABETOLOGIA, V43, P386; FOSTER H, 1993, ARTHRITIS RHEUM-US, V36, P473; Fox R I, 1999, Curr Opin Rheumatol, V11, P364, DOI 10.1097/00002281-199909000-00007; Fox RI, 2000, CURR OPIN RHEUMATOL, V12, P391, DOI 10.1097/00002281-200009000-00007; GOILLOT E, 1991, CLIN IMMUNOL IMMUNOP, V59, P462, DOI 10.1016/0090-1229(91)90041-8; Groom J, 2002, J CLIN INVEST, V109, P59, DOI 10.1172/JCI200214121; HANEJI N, 1994, J IMMUNOL, V153, P2769; Haneji N, 1997, SCIENCE, V276, P604, DOI 10.1126/science.276.5312.604; HARLEY JB, 1986, ARTHRITIS RHEUM, V29, P196, DOI 10.1002/art.1780290207; HOFFMAN RW, 1984, ARTHRITIS RHEUM, V27, P157, DOI 10.1002/art.1780270206; HUMPHREYSBEHER MG, 1994, ADV EXP MED BIOL, V350, P631; Hunger RE, 1998, J CLIN INVEST, V101, P1300, DOI 10.1172/JCI1230; James JA, 2001, CURR OPIN RHEUMATOL, V13, P370, DOI 10.1097/00002281-200109000-00005; Karges W, 1997, DIABETES, V46, P1548, DOI 10.2337/diabetes.46.10.1548; Karges W, 1996, DIABETES, V45, P513, DOI 10.2337/diabetes.45.4.513; Kuwana M, 2001, J IMMUNOL, V167, P5449, DOI 10.4049/jimmunol.167.9.5449; Lafitte C, 2001, J NEUROL, V248, P577, DOI 10.1007/s004150170135; MALINOW K, 1986, ANN NEUROL, V20, P535, DOI 10.1002/ana.410200416; Masago R, 2001, ARTHRITIS RHEUM, V44, P693, DOI 10.1002/1529-0131(200103)44:3<693::AID-ANR119>3.0.CO;2-7; Pilon M, 2000, MOL BIOL CELL, V11, P3277, DOI 10.1091/mbc.11.10.3277; Robinson CP, 1998, ARTHRITIS RHEUM, V41, P150, DOI 10.1002/1529-0131(199801)41:1<150::AID-ART18>3.3.CO;2-K; Robinson CP, 1998, P NATL ACAD SCI USA, V95, P7538, DOI 10.1073/pnas.95.13.7538; Robinson CP, 1996, CLIN IMMUNOL IMMUNOP, V79, P50, DOI 10.1006/clin.1996.0050; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; Winer S, 2001, J IMMUNOL, V166, P2831, DOI 10.4049/jimmunol.166.4.2831; Winer S, 2002, J IMMUNOL, V168, P475, DOI 10.4049/jimmunol.168.1.475; Winer S, 2000, J IMMUNOL, V165, P4086, DOI 10.4049/jimmunol.165.7.4086; Yanagi K, 1998, EUR J IMMUNOL, V28, P3336, DOI 10.1002/(SICI)1521-4141(199810)28:10<3336::AID-IMMU3336>3.3.CO;2-I	34	49	53	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	2002	360	9339					1063	1069		10.1016/S0140-6736(02)11144-5	http://dx.doi.org/10.1016/S0140-6736(02)11144-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383988				2022-12-28	WOS:000178485200013
J	Kanabar, D; Volans, G				Kanabar, D; Volans, G			Accidental superwarfarin poisoning in children - less treatment is better	LANCET			English	Editorial Material									Guys & St Thomas NHS Trust UK, Med Toxicol Unit, London SW1 9RT, England		Kanabar, D (corresponding author), Guys & St Thomas NHS Trust UK, Med Toxicol Unit, London SW1 9RT, England.	dkanabar@doctors.org.uk						*EUR ASS POIS CTR, 1997, CLIN TOXICOL, V35, P721; *EUR ASS POIS CTR, 1997, CLIN TOXICOL, V35, P711; *EUR ASS POIS CTR, 1997, CLIN TOXICOL, V35, P699; HENRY J, 1984, BRIT MED J, V289, P94, DOI 10.1136/bmj.289.6437.94; Ingels M, 2002, ANN EMERG MED, V40, P75, DOI 10.1067/mem.2002.125449; JONES EC, 1984, JAMA-J AM MED ASSOC, V252, P3005, DOI 10.1001/jama.252.21.3005; Mullins ME, 2000, PEDIATRICS, V105, P402, DOI 10.1542/peds.105.2.402; SMOLINSKE SC, 1989, PEDIATRICS, V84, P490	8	12	12	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	2002	360	9338					963	963		10.1016/S0140-6736(02)11120-2	http://dx.doi.org/10.1016/S0140-6736(02)11120-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383662				2022-12-28	WOS:000178249000005
J	La Bella, V; Collinge, J; Pocchiari, M; Piccoli, F				La Bella, V; Collinge, J; Pocchiari, M; Piccoli, F			Variant Creutzfeldt-Jakob disease in an Italian woman	LANCET			English	Article								As of May, 2002, 128 cases of variant Creutzfeldt-Jakob (vCJD) disease have been identified In the UK, France, and Ireland. We report the first case of vCJD in Italy. The patient was a young Italian woman who had never travelled to a country with bovine spongiform encephalopathy (BSE). She was diagnosed by cerebral MRI and western blot analysis of tonsil biopsy samples. The results of these analyses suggest that vCJD in continental Europe and the UK share genetic, clinical, and neuroimaging features, with similar western blot patterns. The identification of vCJD in Italy could have important implications for public-health policy decisions and clinical surveillance in Italy and other continental European countries where BSE has been identified.	Univ Palermo, Inst Neuropsychiat, I-90129 Palermo, Italy; UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, MRC, Prion Unit, London WC1N 3BG, England; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy	University of Palermo; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Istituto Superiore di Sanita (ISS)	La Bella, V (corresponding author), Univ Palermo, Inst Neuropsychiat, I-90129 Palermo, Italy.	labella@unipa.it	Pocchiari, Maurizio/J-8443-2018; La Bella, Vincenzo/H-4532-2012	Pocchiari, Maurizio/0000-0002-7269-2486; 				Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; *NAT CATTL BEEF AS, NEW VAR CJD NVCJD; Will RG, 2000, ANN NEUROL, V47, P575; Zeidler M, 2000, LANCET, V355, P1412, DOI 10.1016/S0140-6736(00)02140-1	5	16	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 28	2002	360	9338					997	998		10.1016/S0140-6736(02)11085-3	http://dx.doi.org/10.1016/S0140-6736(02)11085-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383671				2022-12-28	WOS:000178249000014
J	McClellan, MB				McClellan, MB			Request for grant applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2112	2112		10.1001/jama.288.17.2112	http://dx.doi.org/10.1001/jama.288.17.2112			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413360				2022-12-28	WOS:000179048100010
J	Sun, BL; Griffin, BM; Ayala-del-Rio, HL; Hashsham, SA; Tiedje, JM				Sun, BL; Griffin, BM; Ayala-del-Rio, HL; Hashsham, SA; Tiedje, JM			Microbial dehalorespiration with 1,1,1-trichloroethane	SCIENCE			English	Article							REDUCTIVELY DECHLORINATES TETRACHLOROETHENE; CHLORINATED ALIPHATIC-HYDROCARBONS; DESULFOMONILE-TIEDJEI; MIXED CULTURE; DEGRADATION; BACTERIUM; ACETATE; DEHALOGENATION; COMETABOLISM; MIXTURES	1,1,1-Trichloroethane (TCA) is a ubiquitous environmental pollutant because of its widespread use as an industrial solvent, its improper disposal, and its substantial emission to the atmosphere. We report the isolation of an anaerobic bacterium, strain TCA1, that reductively dechlorinates TCA to 1,1-dichloroethane and chloroethane. Strain TCA1 required H 2 as an electron donor and TCA as an electron acceptor for growth, indicating that dechlorination is a respiratory process. Phylogenetic analysis indicated that strain TCA1 is related to gram-positive bacteria with low DNA G + C content and that its closest relative is Dehalobacter restrictus, an obligate H-2-oxidizing, chloroethene-respiring bacterium.	Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Michigan State Univ, Dept Civil & Environm Engn, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Tiedje, JM (corresponding author), Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA.	tiedjej@msu.edu	Sun, Baolin/C-8354-2014	Sun, Baolin/0000-0002-2896-3015; Hashsham, Syed/0000-0003-2398-7453				Adamson DT, 1999, WATER RES, V33, P1482, DOI 10.1016/S0043-1354(98)00344-3; Adrian L, 2000, NATURE, V408, P580, DOI 10.1038/35046063; *AG TOX SUBST DIS, 1996, TAXF 1 1 1 TRICHL; Aziz CE, 1999, BIOTECHNOL BIOENG, V65, P100, DOI 10.1002/(SICI)1097-0290(19991005)65:1<100::AID-BIT12>3.0.CO;2-1; deBest JH, 1997, APPL MICROBIOL BIOT, V48, P417, DOI 10.1007/s002530051073; Holliger C, 1998, ARCH MICROBIOL, V169, P313, DOI 10.1007/s002030050577; Kim Y, 2000, J ENVIRON ENG-ASCE, V126, P934, DOI 10.1061/(ASCE)0733-9372(2000)126:10(934); Lee MD, 1998, ANNU REV MICROBIOL, V52, P423, DOI 10.1146/annurev.micro.52.1.423; Maidak BL, 2001, NUCLEIC ACIDS RES, V29, P173, DOI 10.1093/nar/29.1.173; MaymoGatell X, 1997, SCIENCE, V276, P1568, DOI 10.1126/science.276.5318.1568; MCNAB WW, 1994, ENVIRON SCI TECHNOL, V28, P769, DOI 10.1021/es00054a005; MOHN WW, 1991, ARCH MICROBIOL, V157, P1; Montzka SA, 2000, SCIENCE, V288, P500, DOI 10.1126/science.288.5465.500; OLDENHUIS R, 1989, APPL ENVIRON MICROB, V55, P2819, DOI 10.1128/AEM.55.11.2819-2826.1989; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; Schlotelburg C, 2000, INT J SYST EVOL MICR, V50, P1505, DOI 10.1099/00207713-50-4-1505; SCHOLTZ R, 1987, J GEN MICROBIOL, V133, P267; STRUNK O, 1998, SOFTWARE ENV SEQUENC; Sun BL, 2000, APPL ENVIRON MICROB, V66, P2408, DOI 10.1128/AEM.66.6.2408-2413.2000; Townsend GT, 1997, APPL ENVIRON MICROB, V63, P3594, DOI 10.1128/AEM.63.9.3594-3599.1997; U.S. EPA (Environmental Protection Agency), 1989, FED REG, V54, P22062; *UN ENV PROGR, 1999, PROD CONS OZ DEPL SU; VOGEL TM, 1987, ENVIRON SCI TECHNOL, V21, P722, DOI 10.1021/es00162a001; von Wintzingerode F, 1999, APPL ENVIRON MICROB, V65, P283; WESTRICK JJ, 1984, J AM WATER WORKS ASS, V76, P52; Wild A, 1997, BIODEGRADATION, V7, P507, DOI 10.1007/BF00115297	26	92	101	7	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	2002	298	5595					1023	1025		10.1126/science.1074675	http://dx.doi.org/10.1126/science.1074675			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411705				2022-12-28	WOS:000178932000056
J	Rost, K; Nutting, P; Smith, JL; Elliott, CE; Dickinson, M				Rost, K; Nutting, P; Smith, JL; Elliott, CE; Dickinson, M			Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROBLEM-SOLVING TREATMENT; DISSEMINATING QUALITY IMPROVEMENT; LONG-TERM OUTCOMES; MAJOR DEPRESSION; COLLABORATIVE MANAGEMENT; MINOR DEPRESSION; INTERVENTION; GUIDELINES; PHYSICIANS; EDUCATION	Objectives To evaluate the long term effect of ongoing intervention to improve treatment of depression in primary care. Design Randomised controlled trial. Setting Twelve primary care practices across the United States. Participants 211 adults beginning a new treatment episode for major depression; 94% of patients assigned to ongoing intervention participated. Intervention Practices assigned to ongoing intervention encouraged participating patients to engage in active treatment, using practice nurses to provide care management over 24 months. Main outcome measures Patients' report of remission and functioning. Results Ongoing intervention significantly improved both symptoms and functioning at 24 months, increasing remission by 33 percentage points (95% confidence interval 7% to 46%), improving emotional functioning by 24 points (11 to 38) and physical functioning by 17 points (6 to 28). By 24 months, 741% of patients in enhanced care reported remission, with emotional functioning exceeding 90% of population norms and physical functioning approaching 75% of population norms. Conclusions Ongoing intcrvention increased remission rates and improved indicators of emotional and physical functioning. Studies are needed to compare the cost effectiveness of ongoing depression management with other chronic disease treatment routinely undertaken by primary care.	Univ Colorado, Hlth Sci Ctr, UCHSC Fitzsimmons,Ctr Studies Family Med, Dept Family Med, Aurora, CO 80045 USA; Ctr Res Strategies, Denver, CO 80203 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Rost, K (corresponding author), Univ Colorado, Hlth Sci Ctr, UCHSC Fitzsimmons,Ctr Studies Family Med, Dept Family Med, POB 6508 Mail Stop F496, Aurora, CO 80045 USA.	Kathryn.Rost@UCHSC.edu			NIMH NIH HHS [K02 MH063651, R01 MH054444, MH54444, MH63651] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH063651, R01MH054444, U01MH054444] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andress G, 2001, BRIT MED J, V322, P419, DOI 10.1136/bmj.322.7283.419; ANGST J, 1988, DEPRESSIVE ILLNESS P, P1; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Bovasso GB, 1999, J CONSULT CLIN PSYCH, V67, P529, DOI 10.1037/0022-006X.67.4.529; Brown J B, 2000, Jt Comm J Qual Improv, V26, P39; Bryk A. S., 1992, HIERARCHICAL LINEAR; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P839, DOI 10.1111/j.1532-5415.1994.tb06555.x; Carr VJ, 1997, AUST NZ J PSYCHIAT, V31, P714; *DEPR GUID PAN, 1993, AHCPR PUBL; Fava M, 2001, J CLIN PSYCHIAT, V62, P4; Goldberg H I, 1998, Jt Comm J Qual Improv, V24, P130; HAYS RD, 1995, ARCH GEN PSYCHIAT, V52, P11; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; Judd LL, 1998, ARCH GEN PSYCHIAT, V55, P694, DOI 10.1001/archpsyc.55.8.694; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katzelnick DJ, 2000, ARCH FAM MED, V9, P345, DOI 10.1001/archfami.9.4.345; Lin EHB, 1998, ARCH FAM MED, V7, P443, DOI 10.1001/archfami.7.5.443; Lin EHB, 1997, MED CARE, V35, P831, DOI 10.1097/00005650-199708000-00008; Lin EHB, 1999, AM J PSYCHIAT, V156, P643; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; MIRANDA J, 1994, PSYCHOSOM MED, V56, P136, DOI 10.1097/00006842-199403000-00009; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; MynorsWallis L, 1997, BRIT J PSYCHIAT, V170, P113, DOI 10.1192/bjp.170.2.113; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rost K, 1998, GEN HOSP PSYCHIAT, V20, P12, DOI 10.1016/S0163-8343(97)00095-9; Rost K, 2000, GEN HOSP PSYCHIAT, V22, P66, DOI 10.1016/S0163-8343(00)00059-1; Rost K, 2001, J GEN INTERN MED, V16, P143, DOI 10.1111/j.1525-1497.2001.00537.x; Schulberg HC, 1996, ARCH GEN PSYCHIAT, V53, P913; Sharpe M, 1997, PSYCHOSOMATICS, V38, P356, DOI 10.1016/S0033-3182(97)71443-9; Sherbourne CD, 2001, ARCH GEN PSYCHIAT, V58, P696, DOI 10.1001/archpsyc.58.7.696; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; TEASDALE JD, 1984, BRIT J PSYCHIAT, V144, P400, DOI 10.1192/bjp.144.4.400; Thase ME, 2001, J CLIN PSYCHIAT, V62, P18; Thompson C, 2000, LANCET, V355, P185, DOI 10.1016/S0140-6736(99)03171-2; Tiemens BG, 1999, PSYCHOL MED, V29, P833, DOI 10.1017/S0033291799008545; Trivedi MH, 2001, J CLIN PSYCHIAT, V62, P25; Tutty S, 2000, Eff Clin Pract, V3, P170; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Von Korff M, 2001, J Fam Pract, V50, P530; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; Ware JE, 1993, SF36 HLTH SURVEY MAN; WARE JE, 1994, SF 36 PHYSICAL MENT; WELLS KB, 1992, ARCH GEN PSYCHIAT, V49, P788; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Williams JW, 2000, JAMA-J AM MED ASSOC, V284, P1519, DOI 10.1001/jama.284.12.1519; Worrall G, 1999, CAN MED ASSOC J, V161, P37	50	133	136	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 26	2002	325	7370					934	937		10.1136/bmj.325.7370.934	http://dx.doi.org/10.1136/bmj.325.7370.934			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399343	Bronze, Green Published			2022-12-28	WOS:000178986300016
J	Aarts, M; Liu, YT; Liu, LD; Besshoh, S; Arundine, M; Gurd, JW; Wang, YT; Salter, MW; Tymianski, M				Aarts, M; Liu, YT; Liu, LD; Besshoh, S; Arundine, M; Gurd, JW; Wang, YT; Salter, MW; Tymianski, M			Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions	SCIENCE			English	Article							CEREBRAL-ARTERY OCCLUSION; NITRIC-OXIDE; NEUROTOXICITY; ANTAGONIST; PSD-95; MODEL; RAT; SELFOTEL; STROKE	N-methyl-D-aspartate receptors (NMDARs) mediate ischemic brain damage but also mediate essential neuronal excitation. To treat stroke without blocking NMDARs, we transduced neurons with peptides that disrupted the interaction of NMDARs with the postsynaptic density protein PSD-95. This procedure dissociated NMDARs from downstream neurotoxic signaling without blocking synaptic activity or calcium influx. The peptides, when applied either before or 1 hour after an insult, protected cultured neurons from excitotoxicity, reduced focal ischemic brain damage in rats, and improved their neurological function. This approach circumvents the negative consequences associated with blocking NMDARs and may constitute a practical stroke therapy.	Hosp Sick Children, Programme Brain & Behav, Toronto, ON M5G 1X8, Canada; Toronto Western Hosp, Res Inst, Toronto, ON M5T 2S8, Canada; Hosp Sick Children, Div Lab Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Pathobiol, Toronto, ON M5G 1X8, Canada; Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Dept Med, Vancouver, BC V6T 1Z3, Canada; Univ Toronto Scarborough, Ctr Neurobiol Stress, Div Life Sci, Toronto, ON M1C 1A3, Canada; Univ Toronto, Dept Surg, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of British Columbia; University of British Columbia; University of Toronto; University Toronto Scarborough; University of Toronto; University of Toronto	Salter, MW (corresponding author), Hosp Sick Children, Programme Brain & Behav, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Wang, Yu Tian/J-8255-2015; Aarts, Michelle/C-5766-2008; Wang, Yu Tian/A-4729-2008	Aarts, Michelle/0000-0002-9171-0571; Liu, Lidong/0000-0002-7026-690X; Tymianski, Mike/0000-0002-6311-9565	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039060] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 39060] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Davis SM, 2000, STROKE, V31, P347, DOI 10.1161/01.STR.31.2.347; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 2000, J NEUROSCI, V20, P22, DOI 10.1523/JNEUROSCI.20-01-00022.2000; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256	20	770	865	4	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					846	850		10.1126/science.1072873	http://dx.doi.org/10.1126/science.1072873			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399596				2022-12-28	WOS:000178791200065
J	Dillin, A; Crawford, DK; Kenyon, C				Dillin, A; Crawford, DK; Kenyon, C			Timing requirements for insulin/IGF-1 signaling in C-elegans	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; LIFE-SPAN; LONGEVITY; REPRODUCTION; INTERFERENCE; EXTENSION; MUTANT; DAF-2; GENES	The insulin/IGF-1 (where IGF-1 is insulin-like growth factor 1) signaling pathway influences longevity, reproduction, and diapause in many organisms. Because of the fundamental importance of this system in animal physiology, we asked when during the animal's life it is required to regulate these different processes. We find that in Caenorhabditis elegans, the pathway acts during adulthood, to relatively advanced ages, to influence aging. In contrast, it regulates diapause during development. In addition, the pathway controls longevity and reproduction independently of one another. Together our findings show that life-span regulation can be dissociated temporally from phenotypes that might seem to decrease the quality of life.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.			Kenyon, Cynthia/0000-0003-3446-2636	NIA NIH HHS [5RO1AG11816] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011816] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bartke A, 2000, RES PRO CEL, V29, P181; BERMAN J, UNPUB; CHNG Q, UNPUB; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; DILLIN A, UNPUB; Garigan D, 2002, GENETICS, V161, P1101; Gems D, 2001, CURR OPIN GENET DEV, V11, P287, DOI 10.1016/S0959-437X(00)00192-1; Gems D, 1998, GENETICS, V150, P129; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; GOTTLIEB S, 1994, GENETICS, V137, P107; Johnson TE, 2001, EXP GERONTOL, V36, P1609, DOI 10.1016/S0531-5565(01)00144-9; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; LARSEN PL, 1995, GENETICS, V139, P1567; Lithgow GJ, 2000, RES PRO CEL, V29, P131; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; RIDDLE DL, 1977, STADLER GENET S, V9, P101; Sun JT, 2002, GENETICS, V161, P661; Sun JT, 1999, MOL CELL BIOL, V19, P216; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Tissenbaum HA, 1998, GENETICS, V148, P703; 5RO1AG11816 NIH; DRG1525 D RUNY FDN F	25	330	342	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					830	834		10.1126/science.1074240	http://dx.doi.org/10.1126/science.1074240			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399591				2022-12-28	WOS:000178791200060
J	Fodde, R; Smits, R				Fodde, R; Smits, R			A matter of dosage	SCIENCE			English	Editorial Material							HAPLO-INSUFFICIENT; TUMOR SUPPRESSION; CANCER; MICE; HAPLOINSUFFICIENCY; MUTATIONS; P53		Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Fodde, R (corresponding author), Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands.		Fodde, Riccardo/AAW-9394-2021	Fodde, Riccardo/0000-0001-9839-4324				Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Gruber SB, 2002, SCIENCE, V297, P2013, DOI 10.1126/science.1074399; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Miyoshi H, 2002, CANCER RES, V62, P2261; Smits R, 2000, GASTROENTEROLOGY, V119, P1045, DOI 10.1053/gast.2000.18162; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wetmore C, 2000, CANCER RES, V60, P2239; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	18	100	104	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					761	763		10.1126/science.1077707	http://dx.doi.org/10.1126/science.1077707			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399571				2022-12-28	WOS:000178791200039
J	Leach, RE; Romero, R; Kim, YM; Chaiworapongsa, T; Kilbum, B; Das, SK; Dey, SK; Johnson, A; Qureshi, F; Jacques, S; Armant, DR				Leach, RE; Romero, R; Kim, YM; Chaiworapongsa, T; Kilbum, B; Das, SK; Dey, SK; Johnson, A; Qureshi, F; Jacques, S; Armant, DR			Pre-eclampsia and expression of heparin-binding EGF-like growth factor	LANCET			English	Article							PREECLAMPSIA; APOPTOSIS; PLACENTATION; CYTOTROPHOBLASTS; IMPLANTATION; PREGNANCIES; INVASION; UTERINE	Background Pre-eclampsia is a disorder of pregnancy associated with poor extravillous cytotrophoblast invasion and above-normal rates of apoptosis in the trophoblast. Heparin-binding epidermal-growth-factor-like growth factor (HB-EGF) has strong cytoprotective activity and is an important signalling protein that regulates trophoblast invasion during early placentation. We aimed to establish whether HB-EGF expression is altered in placentae of pre-eclamptic women. Methods We assessed the expression of HB-EGF mRNA and protein by in-situ hybridisation and immunohistochemical techniques, respectively, in archived placental tissues from pregnancies terminated at around 20 weeks of gestation, and from women delivering between weeks 19 and 35 of gestation with preterm labour, small for gestational age infants, or pre-eclampsia. Findings HB-EGF mRNA and protein were expressed in villous and extravillous cytotrophoblast cells up to week 35 of gestation in placentae from women who delivered preterm. Similar levels of HB-EGF protein were found in the placentae of women who were not in labour. HB-EGF expression was reduced about five-fold (p=0.0001) in pre-eclamptic pregnancies. Fetal growth retardation, which has been linked with shallow trophoblast invasion and moderate apoptosis, was associated with placentae expressing intermediate levels of HB-EGF. Interpretation In pre-eclampsia, deficient HB-EGF signalling during placental development could impair trophoblast survival, differentiation, and invasion, leading to poor placental perfusion and hypertension.	Wayne State Univ, Sch Med, CS Mott Ctr Human Growth & Dev, Dept Obstet & Gynecol, Detroit, MI USA; Wayne State Univ, Sch Med, CS Mott Ctr Human Growth & Dev, Dept Anat & Cell Biol, Detroit, MI USA; Wayne State Univ, Sch Med, CS Mott Ctr Human Growth & Dev, Dept Pathol, Detroit, MI USA; NICHHD, Perinatol Res Branch, NIH, Bethesda, MD 20892 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, Nashville, TN 37232 USA	Wayne State University; Wayne State University; Wayne State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Vanderbilt University	Armant, DR (corresponding author), Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Mott Ctr, 275 E Hancock Ave, Detroit, MI 48201 USA.		Romero, Roberto/A-5268-2019	Romero, Roberto/0000-0002-4448-5121; Armant, D. Randall/0000-0001-5904-9325	NIAAA NIH HHS [AA12057] Funding Source: Medline; NICHD NIH HHS [HD37830, HD37500, HD36764, HD33994, HD12304, HD98004] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012304, R55HD036764, R01HD037830, R03HD036764, R37HD012304, R01HD037500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012057] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Allaire AD, 2000, OBSTET GYNECOL, V96, P271, DOI 10.1016/S0029-7844(00)00895-4; CHESLEY LC, 1985, OBSTET GYNECOL, V65, P423; DiFederico E, 1999, AM J PATHOL, V155, P293, DOI 10.1016/S0002-9440(10)65123-1; Furugori K, 1997, J CLIN ENDOCR METAB, V82, P2726, DOI 10.1210/jc.82.8.2726; Horikawa M, 1999, FEBS LETT, V459, P100, DOI 10.1016/S0014-5793(99)01213-2; Ishihara N, 2002, AM J OBSTET GYNECOL, V186, P158, DOI 10.1067/mob.2002.119176; Iwabu A, 2002, BASIC RES CARDIOL, V97, P214, DOI 10.1007/s003950200014; Kauma SW, 1999, J CLIN ENDOCR METAB, V84, P4092, DOI 10.1210/jc.84.11.4092; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Leach RE, 1999, J CLIN ENDOCR METAB, V84, P3355, DOI 10.1210/jc.84.9.3355; Lindqvist P, 1999, EARLY HUM DEV, V56, P143, DOI 10.1016/S0378-3782(99)00037-7; Martin KL, 1998, HUM REPROD, V13, P1645, DOI 10.1093/humrep/13.6.1645; Michalsky MP, 2001, J PEDIATR SURG, V36, P1130, DOI 10.1053/jpsu.2001.25730; Nguyen HT, 2000, AM J PATHOL, V156, P889, DOI 10.1016/S0002-9440(10)64958-9; Page NM, 2002, REPRODUCTION, V123, P487, DOI 10.1530/reprod/123.4.487; Paria BC, 2001, P NATL ACAD SCI USA, V98, P1047, DOI 10.1073/pnas.98.3.1047; Redman CWG, 2000, PLACENTA, V21, P597, DOI 10.1053/plac.2000.0560; Reis FM, 2002, ENDOCR REV, V23, P230, DOI 10.1210/er.23.2.230; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Roberts JM, 1998, SEMIN REPROD ENDOCR, V16, P5, DOI 10.1055/s-2007-1016248; Shiverick KT, 1999, PLACENTA, V20, P265, DOI 10.1053/plac.1998.0377; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Wang J, 2000, DEVELOPMENT, V127, P33; Xia GL, 2002, J PEDIATR SURG, V37, P1081, DOI 10.1053/jpsu.2002.33881; Yoo HJ, 1997, DEV GENET, V21, P102, DOI 10.1002/(SICI)1520-6408(1997)21:1<102::AID-DVG12>3.0.CO;2-C; Zhou Y, 1997, J CLIN INVEST, V99, P2152, DOI 10.1172/JCI119388; Zhou Y, 2002, AM J PATHOL, V160, P1405, DOI 10.1016/S0002-9440(10)62567-9	27	79	85	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1215	1219		10.1016/S0140-6736(02)11283-9	http://dx.doi.org/10.1016/S0140-6736(02)11283-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401248				2022-12-28	WOS:000178708100011
J	Damste, JSS; Strous, M; Rijpstra, WIC; Hopmans, EC; Geenevasen, JAJ; van Duin, ACT; van Niftrik, LA; Jetten, MSM				Damste, JSS; Strous, M; Rijpstra, WIC; Hopmans, EC; Geenevasen, JAJ; van Duin, ACT; van Niftrik, LA; Jetten, MSM			Linearly concatenated cyclobutane lipids form a dense bacterial membrane	NATURE			English	Article							ANAEROBIC AMMONIUM OXIDATION; GLYCEROL DIETHERS; NITRATE; GENUS	Lipid membranes are essential to the functioning of cells, enabling the existence of concentration gradients of ions and metabolites. Microbial membrane lipids can contain three-, five-, six- and even seven-membered aliphatic rings(1-3), but four-membered aliphatic cyclobutane rings have never been observed. Here we report the discovery of cyclobutane rings in the dominant membrane lipids of two anaerobic ammonium-oxidizing (anammox) bacteria. These lipids contain up to five linearly fused cyclobutane moieties with cis ring junctions. Such 'ladderane' molecules are unprecedented in nature but are known as promising building blocks in optoelectronics(4). The ladderane lipids occur in the membrane of the anammoxosome, the dedicated intracytoplasmic compartment where anammox catabolism takes place. They give rise to an exceptionally dense membrane, a tight barrier against diffusion. We propose that such a membrane is required to maintain concentration gradients during the exceptionally slow anammox metabolism and to protect the remainder of the cell from the toxic anammox intermediates. Our results further illustrate that microbial membrane lipid structures are far more diverse than previously recognized(5-7).	Royal Netherlands Sea Res, Dept Marine Biogeochem & Toxicol, NL-1790 AB Den Burg, Netherlands; Univ Nijmegen, Dept Microbiol, NL-6525 ED Nijmegen, Netherlands; Univ Amsterdam, Inst Mol Chem, NL-1018 WS Amsterdam, Netherlands; Newcastle Univ, Dept Fossil Fuels & Environm Geochem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Delft Univ Technol, Dept Biotechnol, NL-2628 BC Delft, Netherlands	Radboud University Nijmegen; University of Amsterdam; Newcastle University - UK; Delft University of Technology	Damste, JSS (corresponding author), Royal Netherlands Sea Res, Dept Marine Biogeochem & Toxicol, POB 59, NL-1790 AB Den Burg, Netherlands.	damste@nioz.nl	Strous, Marc/B-4064-2017; van Niftrik, Laura/AAQ-7724-2020; Damste, Jaap S Sinninghe/F-6128-2011; van Niftrik, Laura/C-3269-2011; Jetten, Mike/B-8834-2011	Strous, Marc/0000-0001-9600-3828; van Niftrik, Laura/0000-0002-7011-7234; Damste, Jaap S Sinninghe/0000-0002-8683-1854; Jetten, Mike/0000-0002-4691-7039				BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Damste JSS, 2000, CHEM COMMUN, P1683, DOI 10.1039/b004517i; DEROSA M, 1989, FEMS SYMP, V49, P167; DEROSA M, 1988, PROG LIPID RES, V27, P153, DOI 10.1016/0163-7827(88)90011-2; Egli K, 2001, ARCH MICROBIOL, V175, P198, DOI 10.1007/s002030100255; Grogan DW, 1997, MICROBIOL MOL BIOL R, V61, P429, DOI 10.1128/.61.4.429-441.1997; HUBER R, 1992, SYST APPL MICROBIOL, V15, P340, DOI 10.1016/S0723-2020(11)80206-7; Huber R, 1996, SYST APPL MICROBIOL, V19, P40, DOI 10.1016/S0723-2020(96)80007-5; LANGWORTHY TA, 1986, SYST APPL MICROBIOL, V7, P253; LANGWORTHY TA, 1983, SYST APPL MICROBIOL, V4, P1, DOI 10.1016/S0723-2020(83)80029-0; Li WJ, 1996, J AM CHEM SOC, V118, P11752, DOI 10.1021/ja961647f; Lindsay MR, 2001, ARCH MICROBIOL, V175, P413, DOI 10.1007/s002030100280; MEHTA G, 1992, ANGEW CHEM INT EDIT, V31, P1488, DOI 10.1002/anie.199214881; MILLER MA, 1988, J MOL STRUC-THEOCHEM, V40, P133, DOI 10.1016/0166-1280(88)80385-3; Olsen GJ, 1999, NATURE, V400, P403, DOI 10.1038/22643; Pancost RD, 2001, ORG GEOCHEM, V32, P695, DOI 10.1016/S0146-6380(01)00015-8; Rutters H, 2001, ARCH MICROBIOL, V176, P435, DOI 10.1007/s002030100343; Schalk J, 2000, BIOCHEMISTRY-US, V39, P5405, DOI 10.1021/bi992721k; Schmid M, 2000, SYST APPL MICROBIOL, V23, P93, DOI 10.1016/S0723-2020(00)80050-8; Schouten S, 2000, P NATL ACAD SCI USA, V97, P14421, DOI 10.1073/pnas.97.26.14421; SITTIG M, 1993, SYST APPL MICROBIOL, V16, P92; Strous M, 1999, NATURE, V400, P446, DOI 10.1038/22749; Strous M, 1998, APPL MICROBIOL BIOT, V50, P589, DOI 10.1007/s002530051340; Thamdrup B, 2002, APPL ENVIRON MICROB, V68, P1312, DOI 10.1128/AEM.68.3.1312-1318.2002; Van De Graaf Astrid A., 1996, Microbiology (Reading), V142, P2187; van de Vossenberg JLCM, 1998, EXTREMOPHILES, V2, P163, DOI 10.1007/s007920050056; vandeGraaf AA, 1997, MICROBIOL-SGM, V143, P2415, DOI 10.1099/00221287-143-7-2415; VANDUIN ACT, 2001, GEOCHEM T, V6; WISOTZKEY JD, 1992, INT J SYST BACTERIOL, V42, P263, DOI 10.1099/00207713-42-2-263	29	317	340	18	223	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	2002	419	6908					708	712		10.1038/nature01128	http://dx.doi.org/10.1038/nature01128			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	604JF	12384695				2022-12-28	WOS:000178615200037
J	Bozzetti, F				Bozzetti, F			Bitter lessons	LANCET			English	Editorial Material									Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Bozzetti, F (corresponding author), Ist Nazl Studio & Cura Tumori, Via Venezian 1, I-20133 Milan, Italy.		REDONDO, PEDRO/H-7989-2017	REDONDO, PEDRO/0000-0001-7899-2511					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1043	1043		10.1016/S0140-6736(02)11139-1	http://dx.doi.org/10.1016/S0140-6736(02)11139-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383987				2022-12-28	WOS:000178485200008
J	Danielewicz, P; Lacey, R; Lynch, WG				Danielewicz, P; Lacey, R; Lynch, WG			Determination of the equation of state of dense matter	SCIENCE			English	Article							OUT-OF-PLANE; NUCLEAR-EQUATION; COLLECTIVE FLOW; SIDEWARD FLOW; ELLIPTIC FLOW; FRAGMENT FLOW; ENERGY; DEPENDENCE; EMISSION; COLLISIONS	Nuclear collisions can compress nuclear matter to densities achieved within neutron stars and within core-collapse supernovae. These dense states of matter exist momentarily before expanding. We analyzed the flow of matter to extract pressures in excess of 10(34) pascals, the highest recorded under laboratory-controlled conditions. Using these analyses, we rule out strongly repulsive nuclear equations of state from relativistic mean field theory and weakly repulsive equations of state with phase transitions at densities less than three times that of stable nuclei, but not equations of state softened at higher densities because of a transformation to quark matter.	Michigan State Univ, Natl Superconducting Cyclotron Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA; Gesell Schwerionenforsch mbH, D-64291 Darmstadt, Germany; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	Michigan State University; Michigan State University; Helmholtz Association; GSI Helmholtz-Center for Heavy Ion Research; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lynch, WG (corresponding author), Michigan State Univ, Natl Superconducting Cyclotron Lab, E Lansing, MI 48824 USA.	lynch@nscl.msu.edu	Danielewicz, Pawel/AAM-6319-2020; Lynch, William G./I-1447-2013	Lynch, William G./0000-0003-4503-176X				AICHELIN J, 1987, PHYS REV LETT, V58, P1926, DOI 10.1103/PhysRevLett.58.1926; Akmal A, 1998, PHYS REV C, V58, P1804, DOI 10.1103/PhysRevC.58.1804; Badro J, 1999, PHYS REV LETT, V83, P4101, DOI 10.1103/PhysRevLett.83.4101; Barrette J, 1997, PHYS REV C, V56, P3254, DOI 10.1103/PhysRevC.56.3254; BERTSCH GF, 1988, PHYS REP, V160, P189, DOI 10.1016/0370-1573(88)90170-6; BETHE HA, 1990, REV MOD PHYS, V62, P801, DOI 10.1103/RevModPhys.62.801; BOGUTA J, 1982, PHYS LETT B, V109, P251, DOI 10.1016/0370-2693(82)90428-2; Braun-Munzinger P, 1998, NUCL PHYS A, V638, p3C, DOI 10.1016/S0375-9474(98)00342-X; Brill D, 1996, Z PHYS A-HADRON NUCL, V355, P61, DOI 10.1007/s002180050078; Colonna M, 1998, PHYS REV C, V57, P1410, DOI 10.1103/PhysRevC.57.1410; DANIELEWICZ P, 1995, PHYS REV C, V51, P716, DOI 10.1103/PhysRevC.51.716; Danielewicz P, 2000, NUCL PHYS A, V673, P375, DOI 10.1016/S0375-9474(00)00083-X; Danielewicz P, 2002, ACTA PHYS POL B, V33, P45; DANIELEWICZ P, 1985, PHYS LETT B, V157, P146, DOI 10.1016/0370-2693(85)91535-7; DOSS KGR, 1986, PHYS REV LETT, V57, P302, DOI 10.1103/PhysRevLett.57.302; Fuchs C, 2001, PHYS REV LETT, V86, P1974, DOI 10.1103/PhysRevLett.86.1974; GALE C, 1987, PHYS REV C, V35, P1666, DOI 10.1103/PhysRevC.35.1666; GLENDENNING NK, 1992, PHYS REV C, V45, P844, DOI 10.1103/PhysRevC.45.844; GUSTAFSSON HA, 1988, MOD PHYS LETT A, V3, P1323, DOI 10.1142/S0217732388001598; GUTBROD HH, 1989, PHYS LETT B, V216, P267, DOI 10.1016/0370-2693(89)91113-1; Lalazissis GA, 1997, PHYS REV C, V55, P540, DOI 10.1103/PhysRevC.55.540; Lattimer JM, 2001, ASTROPHYS J, V550, P426, DOI 10.1086/319702; Li BA, 2000, PHYS REV LETT, V85, P4221, DOI 10.1103/PhysRevLett.85.4221; Li BA, 1998, PHYS REV C, V58, pR1382, DOI 10.1103/PhysRevC.58.R1382; Liu H, 2000, PHYS REV LETT, V84, P5488, DOI 10.1103/PhysRevLett.84.5488; Muller H, 1996, NUCL PHYS A, V606, P508, DOI 10.1016/0375-9474(96)00187-X; OLLITRAULT JY, 1992, PHYS REV D, V46, P229, DOI 10.1103/PhysRevD.46.229; PAN QB, 1993, PHYS REV LETT, V70, P2062, DOI 10.1103/PhysRevLett.70.2062; PARTLAN MD, 1995, PHYS REV LETT, V75, P2100, DOI 10.1103/PhysRevLett.75.2100; Pinkenburg C, 1999, PHYS REV LETT, V83, P1295, DOI 10.1103/PhysRevLett.83.1295; PRAKASH M, 1988, PHYS REV LETT, V61, P2518, DOI 10.1103/PhysRevLett.61.2518; Reisdorf W, 1997, ANNU REV NUCL PART S, V47, P663, DOI 10.1146/annurev.nucl.47.1.663; Sahu PK, 2000, NUCL PHYS A, V672, P376, DOI 10.1016/S0375-9474(99)00854-4; Sorge H, 1997, PHYS REV LETT, V78, P2309, DOI 10.1103/PhysRevLett.78.2309; STOCKER H, 1986, PHYS REP, V137, P277, DOI 10.1016/0370-1573(86)90131-6; Tsang MB, 2001, PHYS REV LETT, V86, P5023, DOI 10.1103/PhysRevLett.86.5023; Typel S, 1999, NUCL PHYS A, V656, P331, DOI 10.1016/S0375-9474(99)00310-3; WESTFALL GD, 1993, PHYS REV LETT, V71, P1986, DOI 10.1103/PhysRevLett.71.1986; WIRINGA RB, 1988, PHYS REV C, V38, P1010, DOI 10.1103/PhysRevC.38.1010; ZHANG JM, 1994, PHYS REV C, V50, P1617, DOI 10.1103/PhysRevC.50.1617	40	1118	1147	1	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	2002	298	5598					1592	1596		10.1126/science.1078070	http://dx.doi.org/10.1126/science.1078070			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	617KV	12411575	Green Submitted			2022-12-28	WOS:000179361600041
J	Tattersfield, AE; Knox, AJ; Britton, JR; Hall, IP				Tattersfield, AE; Knox, AJ; Britton, JR; Hall, IP			Asthma	LANCET			English	Review							AIRWAY SMOOTH-MUSCLE; GENOME-WIDE SEARCH; LEUKOTRIENE RECEPTOR ANTAGONIST; CHURG-STRAUSS-SYNDROME; LONG-TERM TREATMENT; INHALED CORTICOSTEROIDS; CHILDHOOD ASTHMA; ALLERGIC SENSITIZATION; PERSISTENT ASTHMA; ATOPIC ASTHMA	Asthma is one of the commonest chronic diseases of affluent societies. The striking increase in prevalence of asthma over recent decades and the rarity of this disease in less affluent populations confirms the importance of environmental factors in the cause of asthma-although which environmental factors are responsible is still not clear. Family studies show that genetic factors are also important in determining individual susceptibility to asthma, with results of genetic studies suggesting that there are many genes with moderate effects rather than a few major genes. Asthmatic airways show inflammation and remodelling, with CD4+ helper cells, mast cells, and eosinophils characterising the inflammatory response. Inhaled corticosteroids remain the cornerstone of treatment with the addition of long-acting beta agonists as the next step if symptoms continue. Leukotriene antagonists, the only new drugs to reach the market in the past decade, have modest effects. However, a better understanding of the mechanisms underlying asthma and the genetic and environmental factors that predispose individuals to asthma should lead to better preventative strategies and new therapeutic approaches.	City Hosp, Div Resp Med, Nottingham NG5 1PB, England; Univ Hosp, Queens Med Ctr, Div Therapeut, Nottingham, England	University of Nottingham; Nottingham University Hospital NHS Trust; University of Nottingham	Tattersfield, AE (corresponding author), City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.	anne.tattersfield@nottingham.ac.uk		Hall, Ian/0000-0001-9933-3216; Knox, Alan/0000-0002-5906-4143				ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Ammit AJ, 1997, AM J RESP CRIT CARE, V155, P1123, DOI 10.1164/ajrccm.155.3.9116997; Asher MI, 1998, EUR RESPIR J, V12, P315; AYRES JG, 1983, BRIT J DIS CHEST, V77, P370, DOI 10.1016/0007-0971(83)90072-4; Barnes NC, 2000, THORAX, V55, P478, DOI 10.1136/thorax.55.6.478; BEASLEY R, 1995, CLIN SCI, V88, P14, DOI 10.1042/cs0880014; Belvisi MG, 2001, J IMMUNOL, V166, P1975, DOI 10.4049/jimmunol.166.3.1975; BEYNON HLC, 1988, LANCET, V2, P370; Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Campbell LA, 2001, AM J RESP CRIT CARE, V163, P1051, DOI 10.1164/ajrccm.163.5.16353; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; Conron M, 2000, THORAX, V55, P870, DOI 10.1136/thorax.55.10.870; CORRIGAN CJ, 1988, LANCET, V1, P1129; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dawson-Hughes B, 2001, NEW ENGL J MED, V345, P989, DOI 10.1056/NEJM200109273451310; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; Denzler KL, 2000, J IMMUNOL, V165, P5509, DOI 10.4049/jimmunol.165.10.5509; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Fenech A, 2002, BRIT J CLIN PHARMACO, V53, P3, DOI 10.1046/j.0306-5251.2001.01509.x; FJELLBIRKELAND L, 1994, RESP MED, V88, P599, DOI 10.1016/S0954-6111(05)80008-3; Fogarty A, 2000, CLIN EXP ALLERGY, V30, P615, DOI 10.1046/j.1365-2222.2000.00766.x; Folkerts G, 1998, TRENDS PHARMACOL SCI, V19, P334, DOI 10.1016/S0165-6147(98)01232-2; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; Hellewell PG, 1999, PULM PHARMACOL THER, V12, P137, DOI 10.1006/pupt.1999.0189; HILL JM, 1995, THORAX, V50, P577, DOI 10.1136/thx.50.5.577; HOGG JC, 1993, J ALLERGY CLIN IMMUN, V92, P1, DOI 10.1016/0091-6749(93)90029-F; Horwitz RJ, 1998, AM J RESP CRIT CARE, V157, P1363, DOI 10.1164/ajrccm.157.5.9706059; Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P144, DOI 10.1210/jc.83.1.144; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Johnson SR, 1997, TRENDS PHARMACOL SCI, V18, P288, DOI 10.1016/S0165-6147(97)01092-4; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; KNOX AJ, 1994, CLIN SCI, V86, P647, DOI 10.1042/cs0860647; Knox AJ, 2001, EUR RESPIR J, V17, P1059, DOI 10.1183/09031936.01.00092301; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; Lewith GT, 1998, THORAX, V53, P898, DOI 10.1136/thx.53.10.898; Linneberg A, 2001, ALLERGY, V56, P328, DOI 10.1034/j.1398-9995.2000.00509.x-i1; Lonjou C, 2000, P NATL ACAD SCI USA, V97, P10942, DOI 10.1073/pnas.97.20.10942; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; *LUNG ASTHM INF AG, 1994, LUNG AST INF AG; Lynch JP, 1997, AM J RESP CRIT CARE, V155, P395, DOI 10.1164/ajrccm.155.2.9032171; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; Marsh DG, 1997, NAT GENET, V15, P389; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Murray RD, 1999, EUR RESPIR J, V14, P966, DOI 10.1034/j.1399-3003.1999.14d39.x; Newton R, 2000, THORAX, V55, P603, DOI 10.1136/thorax.55.7.603; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pearson MG, 1997, THORAX, V52, pS1; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Priftanji A, 2001, LANCET, V358, P1426, DOI 10.1016/S0140-6736(01)06521-7; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; Reiss TF, 1997, THORAX, V52, P45, DOI 10.1136/thx.52.1.45; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; ROBINSON DS, 1993, CLIN EXP ALLERGY, V23, P1, DOI 10.1111/j.1365-2222.1993.tb02475.x; Rona RJ, 2000, THORAX, V55, P239, DOI 10.1136/thorax.55.3.239; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Spiegelberg HL, 1997, ALLERGY, V52, P964, DOI 10.1111/j.1398-9995.1997.tb02415.x; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Stirling RG, 1999, THORAX, V54, P865, DOI 10.1136/thx.54.10.865; Stirling RG, 2000, EUR RESPIR J, V16, P1158, DOI 10.1034/j.1399-3003.2000.16f24.x; STOLLEY PD, 1978, PREV MED, V7, P519, DOI 10.1016/0091-7435(78)90265-7; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; Sunyer J, 2000, ALLERGY, V55, P762, DOI 10.1034/j.1398-9995.2000.00657.x; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Tamaoki J, 2000, LANCET, V356, P273, DOI 10.1016/S0140-6736(00)02501-0; Tattersfield AE, 2001, LANCET, V357, P257, DOI 10.1016/S0140-6736(00)03611-4; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Tournoy KG, 2001, J IMMUNOL, V166, P6982, DOI 10.4049/jimmunol.166.11.6982; Tuggey JM, 2000, THORAX, V55, P805, DOI 10.1136/thorax.55.9.805; Turlej RK, 2001, THORAX, V56, P696, DOI 10.1136/thorax.56.9.696; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; *US NIH, 1995, NHLBI WHO WORKSH REP; *US NIH, 1997, 2 US NAT I HLTH NAT, P4051; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Walsh LJ, 1996, BRIT MED J, V313, P344, DOI 10.1136/bmj.313.7053.344; Weinberg EG, 2000, J ALLERGY CLIN IMMUN, V105, P224, DOI 10.1016/S0091-6749(00)90069-1; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; WILSON N, 1982, BRIT MED J, V284, P1226, DOI 10.1136/bmj.284.6324.1226; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	131	176	192	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 26	2002	360	9342					1313	1322		10.1016/S0140-6736(02)11312-2	http://dx.doi.org/10.1016/S0140-6736(02)11312-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414223				2022-12-28	WOS:000178827200029
J	Hirata, H; Yoshiura, S; Ohtsuka, T; Bessho, Y; Harada, T; Yoshikawa, K; Kageyama, R				Hirata, H; Yoshiura, S; Ohtsuka, T; Bessho, Y; Harada, T; Yoshikawa, K; Kageyama, R			Oscillatory expression of the bHLH factor Hes1 regulated by a negative feedback loop	SCIENCE			English	Article							SOMITE SEGMENTATION; PRESOMITIC MESODERM; NEURONAL DIFFERENTIATION; VERTEBRATE SEGMENTATION; DYNAMIC EXPRESSION; GENE-EXPRESSION; NOTCH; CLOCK; SOMITOGENESIS; HAIRY	Transcription of messenger RNAs (mRNAs) for Notch signaling molecules oscillates with 2-hour cycles, and this oscillation is important for coordinated somite segmentation. However, the molecular mechanism of such oscillation remains to be determined. Here, we show that serum treatment of cultured cells induces cyclic expression of both mRNA and protein of the Notch effector Hes1, a basic helix-loop-helix (bHLH) factor, with 2-hour periodicity. Cycling is cell-autonomous and depends on negative autoregulation of hes1 transcription and ubiquitin-proteasome mediated degradation of Hes1 protein. Because Hes1 oscillation can be seen in many cell types, this clock may regulate timing in many biological systems.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Sci, Kyoto 6068502, Japan; CREST, Kyoto 6068502, Japan	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST)	Kageyama, R (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan.	rkageyam@virus.kyoto-u.ac.jp	Yoshikawa, Kenichi/L-4774-2016; Yoshikawa, Kenichi/N-1867-2019	Yoshikawa, Kenichi/0000-0002-2751-7136; Hirata, Hiromi/0000-0002-3769-7441				Aulehla A, 1999, DEV BIOL, V207, P49, DOI 10.1006/dbio.1998.9164; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bessho Y, 2001, GENE DEV, V15, P2642, DOI 10.1101/gad.930601; Cole SE, 2002, DEV CELL, V3, P75, DOI 10.1016/S1534-5807(02)00212-5; DALE JK, IN PRESS NATURE; Davis RL, 2001, DEV CELL, V1, P553, DOI 10.1016/S1534-5807(01)00054-5; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Forsberg H, 1998, CURR BIOL, V8, P1027, DOI 10.1016/S0960-9822(07)00424-1; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holley SA, 2000, GENE DEV, V14, P1678; Holley SA, 2002, DEVELOPMENT, V129, P1175; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jiang YJ, 2000, NATURE, V408, P475, DOI 10.1038/35044091; Jouve C, 2000, DEVELOPMENT, V127, P1421; Leimeister C, 2000, DEV BIOL, V227, P91, DOI 10.1006/dbio.2000.9884; McGrew MJ, 1998, CURR BIOL, V8, P979, DOI 10.1016/S0960-9822(98)70401-4; Morales AV, 2002, DEV CELL, V3, P63, DOI 10.1016/S1534-5807(02)00211-3; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Pourquie O, 2001, ANNU REV CELL DEV BI, V17, P311, DOI 10.1146/annurev.cellbio.17.1.311; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Saga Y, 2001, NAT REV GENET, V2, P835, DOI 10.1038/35098552; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Sawada A, 2000, DEVELOPMENT, V127, P1691; Strom A, 1997, GENE DEV, V11, P3168, DOI 10.1101/gad.11.23.3168; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150	27	565	578	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					840	843		10.1126/science.1074560	http://dx.doi.org/10.1126/science.1074560			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399594				2022-12-28	WOS:000178791200063
J	Check, E				Check, E			Malta provides loophole for breast-cancer screen	NATURE			English	News Item																		Bessereau JL, 2001, NATURE, V413, P70, DOI 10.1038/35092567	1	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	2002	419	6909					767	767		10.1038/419767b	http://dx.doi.org/10.1038/419767b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397316	Bronze			2022-12-28	WOS:000178769800006
J	Kitabwalla, M; Ruprecht, RM				Kitabwalla, M; Ruprecht, RM			RNA interference - A new weapon against HIV and beyond	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMID DNA; RECEPTOR; GENE; HEPATOCYTES; INDIVIDUALS; RESISTANCE; INFECTION; CELLS		Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Kitabwalla, M (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014180] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR14180] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chang JH, 2001, J VIROL, V75, P3469, DOI 10.1128/JVI.75.7.3469-3473.2001; Dornburg R, 2000, Adv Pharmacol, V49, P229; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	25	52	84	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1364	1367		10.1056/NEJMcibr022294	http://dx.doi.org/10.1056/NEJMcibr022294			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397198				2022-12-28	WOS:000178781300012
J	Sharp, D				Sharp, D			From Demetrius to Serageldin	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							LAPORTE RE, 1995, BRIT MED J, V310, P1387, DOI 10.1136/bmj.310.6991.1387; EPIDEMIOLOGY INTERNE	2	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1188	1188		10.1016/S0140-6736(02)11293-1	http://dx.doi.org/10.1016/S0140-6736(02)11293-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401243				2022-12-28	WOS:000178708100006
J	Batlle, E; Henderson, JT; Beghtel, H; van den Born, MMW; Sancho, E; Huls, G; Meeldijk, J; Robertson, J; van de Wetering, M; Pawson, T; Clevers, H				Batlle, E; Henderson, JT; Beghtel, H; van den Born, MMW; Sancho, E; Huls, G; Meeldijk, J; Robertson, J; van de Wetering, M; Pawson, T; Clevers, H			beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/EphrinB	CELL			English	Article							RECEPTOR TYROSINE KINASE; FOCAL-ADHESION-KINASE; EPH RECEPTORS; COLORECTAL-CANCER; COMMISSURAL AXONS; EPHRINS; LIGANDS; MICE; MIGRATION; DYNAMICS	In the small intestine, the progeny of stem cells migrate in precise patterns. Absorptive, enteroendocrine, and goblet cells migrate toward the villus while Paneth cells occupy the bottom of the crypts. We show here that beta-catenin and TCF inversely control the expression of the EphB2/EphB3 receptors and their ligand ephrin-B1 in colorectal cancer and along the crypt-villus axis. Disruption of EphB2 and EphB3 genes reveals that their gene products restrict cell intermingling and allocate cell populations within the intestinal epithelium. In EphB2/EphB3 null mice, the proliferative and differentiated populations intermingle. In adult EphB3(-/-) mice, Paneth cells do not follow their downward migratory path, but scatter along crypt and villus. We conclude that in the intestinal epithelium beta-catenin and TCF couple proliferation and differentiation to the sorting of cell populations through the EphB/ephrin-B system.	Univ Med Ctr, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr, Ctr Biomed Genet, NL-3584 CX Utrecht, Netherlands; Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 262, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Clevers, H (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	h.clevers@azu.nl	Eckhardt, Erik/G-1567-2010; Sancho, Elena/ABH-4867-2020; Huls, G.A./L-4398-2015; Pawson, Tony J/E-4578-2013; Batlle, Eduard/K-8080-2014	Sancho, Elena/0000-0002-8182-513X; Batlle, Eduard/0000-0003-2422-0326				Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1996, MOL CELL NEUROSCI, V8, P199, DOI 10.1006/mcne.1996.0057; Durbin L, 1998, GENE DEV, V12, P3096, DOI 10.1101/gad.12.19.3096; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; FLANAGAN JG, 2001, NAT REV CANC, V1, P55; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Heath JP, 1996, CELL BIOL INT, V20, P139, DOI 10.1006/cbir.1996.0018; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holder N, 1999, DEVELOPMENT, V126, P2033; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lickert H, 2001, MECH DEVELOP, V105, P181, DOI 10.1016/S0925-4773(01)00390-2; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Oshima H, 1997, CANCER RES, V57, P1644; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Polakis P, 2000, GENE DEV, V14, P1837; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Robinson V, 1997, CELL TISSUE RES, V290, P265, DOI 10.1007/s004410050931; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092-8674(01)00391-9; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wilkinson DG, 2000, CURR BIOL, V10, pR447, DOI 10.1016/S0960-9822(00)00530-3; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Xu QL, 1995, DEVELOPMENT, V121, P4005	37	874	909	1	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	2002	111	2					251	263		10.1016/S0092-8674(02)01015-2	http://dx.doi.org/10.1016/S0092-8674(02)01015-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408869	Bronze			2022-12-28	WOS:000178753500014
J	Hurley, JH; Wendland, B				Hurley, JH; Wendland, B			Endocytosis: Driving membranes around the bend	CELL			English	Review							ENTH DOMAIN; CLATHRIN; BINDING; CURVATURE; AP180; EPSIN	When a nascent vesicle buds, the membrane must curve. Several mechanisms have been proposed for curvature creation or stabilization. Structural analysis of the ENTH domain of the endocytic protein epsin has suggested a new mechanism, in which the ENTH domain pushes its way into membranes, thus bending them into shape.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Johns Hopkins University	Hurley, JH (corresponding author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	james.hurley@nih.gov; bwendland@jhu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036118] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hristova K, 2001, BIOPHYS J, V80, P801, DOI 10.1016/S0006-3495(01)76059-6; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kay BK, 1999, PROTEIN SCI, V8, P435; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Mao YX, 2001, CELL, V104, P433, DOI 10.1016/S0092-8674(01)00230-6; NOSSAL R, 2002, IN PRESS CURR BIOL; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Stubbs CD, 1996, CHEM PHYS LIPIDS, V81, P185, DOI 10.1016/0009-3084(96)02581-9; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; WENDLAND B, 2002, IN PRESS NAT REV MOL	19	44	46	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	2002	111	2					143	146		10.1016/S0092-8674(02)01044-9	http://dx.doi.org/10.1016/S0092-8674(02)01044-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408856	Bronze			2022-12-28	WOS:000178753500001
J	Gaba, DM; Howard, SK				Gaba, DM; Howard, SK			Patient safety: Fatigue among clinicians and the safety of patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SLEEP-DEPRIVATION; WORK HOURS; PERFORMANCE; RESIDENTS; DECREMENTS; ALCOHOL; DOCTORS; RISK; NAPS; NEED		Vet Affairs Palo Alto Hlth Care Syst, Patient Safety Ctr Inquiry, Palo Alto, CA USA; Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Gaba, DM (corresponding author), Anesthesiol Serv, 112A,3801 Miranda Ave, Palo Alto, CA 94304 USA.	gaba@stanford.edu	Gaba, David M/D-5229-2009	Gaba, David M/0000-0002-0657-5396; Howard, Steven/0000-0001-6475-1792				*ACCR COUNC GRAD M, 2001, ACGME RESP PAT PHYS; *ACCR COUNC GRAD M, 2002, PROGR REQ IND SPEC R; *ACCR COUNC GRAD M, 2001, PERC PROGR CIT WORK; *ACCR COUNC GRAD M, 2002, ACGME APPR NEW PROP; Arnedt JT, 2001, ACCIDENT ANAL PREV, V33, P337, DOI 10.1016/S0001-4575(00)00047-6; ASKEN MJ, 1983, J MED EDUC, V58, P382; *ASS AM MED COLL, 2001, AAMC POL GUID GRAD M; *AUSTR MED ASS, 1998, OV EXP REG HOURS WOR; Batejat DM, 1999, AVIAT SPACE ENVIR MD, V70, P493; Clark PA, 2001, ACAD MED, V76, P419, DOI 10.1097/00001888-200105000-00008; Collier VU, 2002, ANN INTERN MED, V136, P384, DOI 10.7326/0003-4819-136-5-200203050-00011; Cooper J B, 1989, J Clin Anesth, V1, P228, DOI 10.1016/0952-8180(89)90047-0; Coulehan J, 2001, ACAD MED, V76, P598, DOI 10.1097/00001888-200106000-00008; Daugherty SR, 1998, JAMA-J AM MED ASSOC, V279, P1194, DOI 10.1001/jama.279.15.1194; Dawson D, 1997, NATURE, V388, P235, DOI 10.1038/40775; Dinges DF, 1997, SLEEP, V20, P267; DINGES DF, 1996, 110404 NASA AM RES C; DUNCAN D, 1996, RESIDENTS; FRIEDMAN FC, 1973, J MED EDUC, V48, P436; GABA DM, 1994, ANESTHESIOLOGY, V81, P488, DOI 10.1097/00000542-199408000-00028; GLICKMAN RM, 1988, NEW ENGL J MED, V318, P780, DOI 10.1056/NEJM198803243181212; Heins A, 2002, ANN EMERG MED, V39, P444, DOI 10.1067/mem.2002.122773; Holzman IR, 2000, MT SINAI J MED, V67, P136; Hopkins GE, 1971, AIRLINE PILOTS STUDY, P116; Howard SK, 2002, ACAD MED, V77, P1019, DOI 10.1097/00001888-200210000-00015; HOWARD SK, IN PRESS ANESTHESIOL; JHA AK, 2001, AHRQ PUBLICATION, P519; Kapur N, 1998, MED EDUC, V32, P432, DOI 10.1046/j.1365-2923.1998.00238.x; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Leach DC, 2000, ACAD MED, V75, P1156, DOI 10.1097/00001888-200012000-00005; LEUNG L, 1992, J OCCUP ENVIRON MED, V34, P1153; Marcus CL, 1996, SLEEP, V19, P763, DOI 10.1093/sleep/19.10.763; MCKEE M, 1993, J PUBLIC HEALTH MED, V15, P16, DOI 10.1093/oxfordjournals.pubmed.a042815; Mizrahi T., 1986, GETTING RID PATIENTS; *NY STAT DEP HLTH, 1998, ASS HOSP COMPL RES W; Office of Technology Assessment, 1991, OTABA463; Owens J A, 2001, Curr Opin Pulm Med, V7, P411, DOI 10.1097/00063198-200111000-00009; PANKRATZ H, 1995, DENVER POST     0915, pA1; Patton D V, 2001, J Health Law, V34, P377; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Pickersgill T, 2001, BRIT MED J, V323, P1266, DOI 10.1136/bmj.323.7324.1266; *PUBL CIT HLTH RES, 2002, HRG PUBL, V1570; Reid K, 2001, OCCUP ENVIRON MED, V58, P58, DOI 10.1136/oem.58.1.58; Robins NS, 1995, GIRL WHO DIED TWICE; Rosekind MR, 1995, J SLEEP RES, V4, P62, DOI 10.1111/j.1365-2869.1995.tb00229.x; Rosekind MR, 1996, BEHAV MED, V21, P166, DOI 10.1080/08964289.1996.9933754; ROSEKIND MR, 1994, NTSBAAR9404; SAMKOFF JS, 1991, ACAD MED, V66, P687, DOI 10.1097/00001888-199111000-00013; SCHWARTZ RJ, 1992, ARCH SURG-CHICAGO, V127, P778; Shine KI, 2002, ACAD MED, V77, P92, DOI 10.1097/00001888-200201000-00021; Steele MT, 1999, ACAD EMERG MED, V6, P1050, DOI 10.1111/j.1553-2712.1999.tb01191.x; STODDARD JJ, 1994, JAMA-J AM MED ASSOC, V272, P1256; STODDARD JJ, 1994, JAMA-J AM MED ASSOC, V272, P53, DOI 10.1001/jama.272.1.53; Stone MD, 2000, SURGERY, V128, P465, DOI 10.1067/msy.2000.108048; Taffinder N, 1999, J ROY SOC MED, V92, P329, DOI 10.1177/014107689909200701; Taffinder NJ, 1998, LANCET, V352, P1191, DOI 10.1016/S0140-6736(98)00034-8; Torkington J, 2000, ANN ROY COLL SURG, V82, P88; Van Dongen HP., 2000, PRINCIPLE PRACT SLEE, V20, P391; Wallack MK, 2001, ARCH SURG-CHICAGO, V136, P1426, DOI 10.1001/archsurg.136.12.1426; Weinger MB, 2002, JAMA-J AM MED ASSOC, V287, P955, DOI 10.1001/jama.287.8.955; 1999, NEW YORK POST   0207, P1; 2002, NY TIMES        0507, pA1; 2002, NY TIMES        0509, pB6	64	459	466	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1249	1255		10.1056/NEJMsa020846	http://dx.doi.org/10.1056/NEJMsa020846			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393823	Bronze			2022-12-28	WOS:000178598300007
J	Lunyak, VV; Burgess, R; Prefontaine, GG; Nelson, C; Sze, SH; Chenoweth, J; Schwartz, P; Pevzner, PA; Glass, C; Mandel, G; Rosenfeld, MG				Lunyak, VV; Burgess, R; Prefontaine, GG; Nelson, C; Sze, SH; Chenoweth, J; Schwartz, P; Pevzner, PA; Glass, C; Mandel, G; Rosenfeld, MG			Corepressor-dependent silencing of chromosomal regions encoding neuronal genes	SCIENCE			English	Article							ACETYLCHOLINE-RECEPTOR GENE; NEURAL-SPECIFIC EXPRESSION; HISTONE H3; DNA METHYLATION; LYSINE 9; PROTEIN; TRANSCRIPTION; COMPLEX; ELEMENT; COREST	The molecular mechanisms by which central nervous system-specific genes are expressed only in the nervous system and repressed in other tissues remain a central issue in developmental and regulatory biology. Here, we report that the zinc-finger gene-specific repressor element RE-1 silencing transcription factor/neuronal restricted silencing factor (REST/NRSF) can mediate extra-neuronal restriction by imposing either active repression via histone deacetylase recruitment or long-term gene silencing using a distinct functional complex. Silencing of neuronal-specific genes requires the recruitment of an associated corepressor, CoREST, that serves as a functional molecular beacon for the recruitment of molecular machinery that imposes silencing across a chromosomal interval, including transcriptional units that do not themselves contain REST/NRSF response elements.	Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Comp Sci & Engn, La Jolla, CA 92093 USA; SUNY Stony Brook, Dept Neurobiol, Howard Hughes Med Inst, Stony Brook, NY 11794 USA; Affin BioReagents Inc, Golden, CO 80401 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California San Diego	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, 9500 Gilman Dr,Room 345, La Jolla, CA 92093 USA.	mrosenfeld@ucsd.edu	lunyak, victoria/R-3765-2017	lunyak, victoria/0000-0001-9093-2714				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Gregory RI, 2001, MOL CELL BIOL, V21, P5426, DOI 10.1128/MCB.21.16.5426-5436.2001; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lorincz MC, 2001, MOL CELL BIOL, V21, P7913, DOI 10.1128/MCB.21.23.7913-7922.2001; LUNYAK VV, UNPUB; MECHTLER K, 2000, NATURE, V406, P593; Mieda M, 1997, J BIOL CHEM, V272, P5854, DOI 10.1074/jbc.272.9.5854; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Pevzner P A, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P269; RAZIN A, 1989, BIOCHIM BIOPHYS ACTA, V782, P331; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tweedie S, 1997, MOL CELL BIOL, V17, P1469, DOI 10.1128/MCB.17.3.1469; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454	40	377	392	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	2002	298	5599					1747	1752		10.1126/science.1076469	http://dx.doi.org/10.1126/science.1076469			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12399542				2022-12-28	WOS:000179494800033
J	McClellan, MB				McClellan, MB			New drug for hepatitis B	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2112	2112		10.1001/jama.288.17.2112	http://dx.doi.org/10.1001/jama.288.17.2112			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413360				2022-12-28	WOS:000179048100008
J	Montori, VM; Bistrian, BR; McMahon, MM				Montori, VM; Bistrian, BR; McMahon, MM			Hyperglycemia in acutely ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MYOCARDIAL-INFARCTION; DIABETIC-PATIENTS; GLUCOSE CONTROL; BLOOD-GLUCOSE; INFECTIOUS COMPLICATIONS; STRESS HYPERGLYCEMIA; INSULIN; MORTALITY; INFUSION; STROKE		Mayo Clin & Mayo Fdn, Div Endocrinol Metab & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Rochester, MN USA; Harvard Univ, Sch Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Clin Nutr, Boston, MA 02215 USA	Mayo Clinic; Mayo Clinic; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	McMahon, MM (corresponding author), Mayo Clin & Mayo Fdn, Div Endocrinol Metab & Internal Med, 200 1st St SW,W18, Rochester, MN 55905 USA.	mcmahon.molly@mayo.edu		Montori, Victor/0000-0003-0595-2898				Bistrian BR, 2001, JPEN-PARENTER ENTER, V25, P180, DOI 10.1177/0148607101025004180; Brown G, 2001, CRIT CARE MED, V29, P1714, DOI 10.1097/00003246-200109000-00010; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Ferrando AA, 1999, ANN SURG, V229, P11, DOI 10.1097/00000658-199901000-00002; Furnary AP, 1999, ANN THORAC SURG, V67, P352, DOI 10.1016/S0003-4975(99)00014-4; Golden SH, 1999, DIABETES CARE, V22, P1408, DOI 10.2337/diacare.22.9.1408; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kudsk KA, 2001, JPEN-PARENTER ENTER, V25, P174, DOI 10.1177/0148607101025004174; Latham R, 2001, INFECT CONT HOSP EP, V22, P607, DOI 10.1086/501830; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; MALMBERG KA, 1994, DIABETES CARE, V17, P1007, DOI 10.2337/diacare.17.9.1007; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; MCMAHON MM, 1995, INFECT DIS CLIN N AM, V9, P1; Montori VM, 2002, DIABETES CARE, V25, P583, DOI 10.2337/diacare.25.3.583; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; OLIVER MF, 1968, LANCET, V1, P710; Pomposelli JJ, 1998, JPEN-PARENTER ENTER, V22, P77, DOI 10.1177/014860719802200277; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Tenerz A, 2001, EUR HEART J, V22, P1102, DOI 10.1053/euhj.2000.2445; Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; *VET AFF TOT PAR N, 1993, NEW ENGL J MED, V325, P525; VONDAHL J, 1993, CIRCULATION, V88, P395	25	115	122	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2167	2169		10.1001/jama.288.17.2167	http://dx.doi.org/10.1001/jama.288.17.2167			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413377				2022-12-28	WOS:000179048100028
J	Rowland, D; DiGuiseppi, C; Roberts, I; Curtis, K; Roberts, H; Ginnelly, L; Sculpher, M; Wade, A				Rowland, D; DiGuiseppi, C; Roberts, I; Curtis, K; Roberts, H; Ginnelly, L; Sculpher, M; Wade, A			Prevalence of working smoke alarms in local authority inner city housing: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article								Objectives To identify which type of smoke alarm is most likely to remain working in local authority inner city housing, and to identify an alarm tolerated in households with smokers. Design Randomised controlled trial. Setting Two local authority housing estates in inner London. Participants 2145 households. Intervention Installation of one of five types of smoke alarm (ionisation sensor with a zinc battery; ionisation sensor with a zinc battery and pause button; ionisation sensor with a lithium battery and pause button; optical sensor with a lithium battery; or optical sensor with a zinc battery). Main outcome measure Percentage of homes with any working alarm and percentage in which the alarm installed for this study was working after 15 months. Results 54.4% (1166/2145) of all households and 45.9% (465/1012) of households occupied by smokers had a working smoke alarm. Ionisation sensor, lithium battery, and there being a smoker in the household were independently associated with whether an alarm was working (adjusted odds ratios 2.24 (95% confidence interval 1.75 to 2.87), 2.20 (1.77 to 2.75), and 0.62 (0.52 to 0.74)). The most common reasons for non-function were missing battery (19%), missing alarm (17%), and battery disconnected (4%). Conclusions Nearly half of the alarms installed were not working when tested 15 months later. Type of alarm and power source are important determinants of whether a household had a working alarm.	London Sch Hyg & Trop Med, Publ Hlth Intervent Res Unit, London WC1B 3DP, England; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; City Univ London, Inst Hlth Sci, London EC1A 7QN, England; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Inst Child Hlth, Ctr Paeidat Epidemiol & Biostat, London WC1N 3JH, England	University of London; London School of Hygiene & Tropical Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; City University London; University of York - UK; University of London; University College London	Roberts, I (corresponding author), London Sch Hyg & Trop Med, Publ Hlth Intervent Res Unit, London WC1B 3DP, England.		DiGuiseppi, Carolyn/AAU-1341-2020	DiGuiseppi, Carolyn/0000-0002-6440-7817; Sculpher, Mark/0000-0003-3746-9913; Roberts, Helen/0000-0002-6319-061X; Curtis Tyler, Katherine/0000-0002-8212-1134				BOSLEY K, 1997, 75 HOM OFF FIR RES D; Budd T., 1997, FIRES HOME 1995 RESU; DiGuiseppi C, 2002, BRIT MED J, V325, P995, DOI 10.1136/bmj.325.7371.995; DiGuiseppi C, 2000, Inj Prev, V6, P250, DOI 10.1136/ip.6.4.250; DiGuiseppi C, 1999, ARCH DIS CHILD, V81, P400, DOI 10.1136/adc.81.5.400; DIGUISEPPI C, 2001, COCHRANE LIB, V4; EVANS S, MINIMISATION PROGRAM; *HOM OFF, 1995, WAK UP GET SMOK AL; Kay R L Jr, 2000, Inj Prev, V6, P72, DOI 10.1136/ip.6.1.72; MARRIOTT MD, 1994, 58 HOM OFF FIR RES D; National Statistics, 2000, BRIT UPD NOV 2000; *OFF DEP PRIM MIN, 2002, HOUS HOUS POL SMOK A; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; WATSON L, 1999, FIRE STAT UK 1998	15	29	29	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					998	1001		10.1136/bmj.325.7371.998	http://dx.doi.org/10.1136/bmj.325.7371.998			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411356	Green Submitted, Green Accepted, Green Published, Bronze			2022-12-28	WOS:000179415600018
J	Tilzey, AJ; Banatvala, JE				Tilzey, AJ; Banatvala, JE			Protection from HIV on electives: questionnaire survey of UK medical schools	BRITISH MEDICAL JOURNAL			English	Article							STUDENTS; PROVISION; OVERSEAS		Guys Kings & St Thomass Sch Med & Dent, Dept Infect Virol, London SE1 7EH, England	University of London; King's College London	Tilzey, AJ (corresponding author), Guys Kings & St Thomass Sch Med & Dent, Dept Infect Virol, London SE1 7EH, England.							Franklin GF, 2001, J INFECTION, V43, P191, DOI 10.1053/jinf.2001.0903; Gamester CF, 1999, BRIT MED J, V318, P158, DOI 10.1136/bmj.318.7177.158; Karstaedt AS, 2001, S AFR MED J, V91, P57; Moss PJ, 1999, BRIT MED J, V318, P161, DOI 10.1136/bmj.318.7177.161; *UK HLTH DEP, 2000, HIV POST EXP PROPH G	5	12	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					1010	1011		10.1136/bmj.325.7371.1010	http://dx.doi.org/10.1136/bmj.325.7371.1010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411360	Green Published, Bronze			2022-12-28	WOS:000179415600022
J	Ahmad, K; Henikoff, S				Ahmad, K; Henikoff, S			Epigenetic consequences of nucleosome dynamics	CELL			English	Review							METHYLATION; CHROMATIN; MECHANISM; ALFALFA	Current models for epigenetic gene silencing envision a static relationship between histone modifications and transcription. However, evidence for nucleosome mobility and replacement favors a dynamic model that may explain phenomena ranging from variegation to the neural restriction of Rett syndrome.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Henikoff, S (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.			Henikoff, Steven/0000-0002-7621-8685				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Ahmad K, 2001, CELL, V104, P839, DOI 10.1016/S0092-8674(01)00281-1; Altheim BA, 1999, P NATL ACAD SCI USA, V96, P1345, DOI 10.1073/pnas.96.4.1345; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; Gottesfeld JM, 2002, J MOL BIOL, V321, P249, DOI 10.1016/S0022-2836(02)00598-3; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Kelly WG, 2002, DEVELOPMENT, V129, P479; Misteli T, 2001, J CELL BIOL, V155, P181, DOI 10.1083/jcb.200108110; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; WATERBORG JH, 1993, J BIOL CHEM, V268, P4918; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	18	97	99	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 1	2002	111	3					281	284		10.1016/S0092-8674(02)01081-4	http://dx.doi.org/10.1016/S0092-8674(02)01081-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419239	Bronze			2022-12-28	WOS:000179010100001
J	Hassan, AH; Prochasson, P; Neely, KE; Galasinski, SC; Chandy, M; Carrozza, MJ; Workman, JL				Hassan, AH; Prochasson, P; Neely, KE; Galasinski, SC; Chandy, M; Carrozza, MJ; Workman, JL			Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes	CELL			English	Article							HISTONE ACETYLTRANSFERASE COMPLEXES; TRANSCRIPTION IN-VIVO; SACCHAROMYCES-CEREVISIAE; REMODELING COMPLEX; ORDERED RECRUITMENT; ACTIVATION DOMAIN; GCN5 BROMODOMAIN; SWI/SNF COMPLEX; SAGA COMPLEX; YEAST	The functions of the SAGA and SWI/SNF complexes are interrelated and can form stable "epigenetic marks" on promoters in vivo. Here we show that stable promoter occupancy by SWI/SNF and SAGA in the absence of transcription activators requires the bromodomains of the Swi2/Snf2 and Gcn5 subunits, respectively, and nucleosome acetylation. This acetylation can be brought about by either the SAGA or NuA4 HAT complexes. The bromodomain in the Spt7 subunit of SAGA is dispensable for this activity but will anchor SAGA if it is swapped into Gcn5, indicating that specificity of bromodomain function is determined in part by the subunit it occupies. Thus, bromodomains within the catalytic subunits of SAGA and SWI/SNF anchor these complexes to acetylated promoter nucleosomes.	Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, Althouse Lab 306, University Pk, PA 16802 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Workman, JL (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, Althouse Lab 306, University Pk, PA 16802 USA.		Chandy, Mark Joseph Koonthanam/GLT-9682-2022; Hassan, Ahmed/AAB-7241-2019	Chandy, Mark Joseph Koonthanam/0000-0002-6741-2822; Al-Marzouqi, Ahmed/0000-0003-4586-5676				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Carrozza MJ, 2002, J BIOL CHEM, V277, P24648, DOI 10.1074/jbc.M201965200; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Elfring LK, 1998, GENETICS, V148, P251; GANSHEROFF LJ, 1995, GENETICS, V139, P523; Grewal SIS, 2002, CURR OPIN GENET DEV, V12, P178, DOI 10.1016/S0959-437X(02)00284-8; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jia MH, 2000, PHYSIOL GENOMICS, V3, P83, DOI 10.1152/physiolgenomics.2000.3.2.83; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Matangkasombut O, 2000, GENE DEV, V14, P951; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; NEIGEBORN L, 1984, GENETICS, V108, P845; Ornaghi P, 1999, J MOL BIOL, V287, P1, DOI 10.1006/jmbi.1999.2577; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Reinke H, 2001, MOL CELL, V7, P529, DOI 10.1016/S1097-2765(01)00200-3; Roberts SM, 1997, GENETICS, V147, P451; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369	49	397	406	1	18	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 1	2002	111	3					369	379		10.1016/S0092-8674(02)01005-X	http://dx.doi.org/10.1016/S0092-8674(02)01005-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419247	Bronze			2022-12-28	WOS:000179010100009
J	Kajikawa, M; Okada, N				Kajikawa, M; Okada, N			LINEs mobilize SINEs in the eel through a shared 3 ' sequence	CELL			English	Article							LTR RETROTRANSPOSABLE ELEMENTS; HIV-1 REVERSE-TRANSCRIPTASE; TRANSFER-RNA; L1 RETROTRANSPOSITION; SECONDARY STRUCTURE; MAMMALIAN-CELLS; TELOMERASE; ORIGIN; GENOME; ENDS	We characterized members of the LINE (UnaL2) and SINE (UnaSINE1) families from the eel genome and found that these LINE/SINE partners share similar 3' tails. A retrotransposition assay in HeLa cells demonstrated that the 3' conserved tail of UnaL2 is necessary for its retrotransposition. This 3' tail is recognized in trans by the UnaL2 reverse transcriptase at a surprisingly high rate, and that of UnaSINE1 can also be recognized, thus providing experimental evidence that a SINE can be mobilized by the retrotransposition machinery of a partner LINE. We also demonstrated that short repeats at the 3' end of UnaL2 are required for retrotransposition suggesting that UnaL2 retrotransposes in a manner reminiscent of the reverse transcriptase activity of telomerases.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Tokyo, Japan	Tokyo Institute of Technology	Okada, N (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Tokyo, Japan.	nokada@bio.titech.ac.jp		Okada, Norihiro/0000-0002-3655-8060				BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; Boeke JD, 1998, CELL, V93, P1087, DOI 10.1016/S0092-8674(00)81450-6; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Chaboissier MC, 2000, NUCLEIC ACIDS RES, V28, P2467, DOI 10.1093/nar/28.13.2467; DEININGER PL, 1993, EVOL BIOL, V27, P157; Eickbush TH, 1997, SCIENCE, V277, P911, DOI 10.1126/science.277.5328.911; EICKBUSH TH, 1992, NEW BIOL, V4, P430; ENDOH H, 1986, P NATL ACAD SCI USA, V83, P251, DOI 10.1073/pnas.83.2.251; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; FREEMAN JD, 1994, BIOTECHNIQUES, V17, P46; Gilbert N, 1999, P NATL ACAD SCI USA, V96, P2869, DOI 10.1073/pnas.96.6.2869; Goodier JL, 2000, HUM MOL GENET, V9, P653, DOI 10.1093/hmg/9.4.653; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; Hohjoh H, 1997, EMBO J, V16, P6034, DOI 10.1093/emboj/16.19.6034; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kajikawa M, 1997, MOL BIOL EVOL, V14, P1206, DOI 10.1093/oxfordjournals.molbev.a025730; Kazazian HH, 2000, SCIENCE, V289, P1152, DOI 10.1126/science.289.5482.1152; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LIU CT, 1993, HIGH TEMPERATURE ORD, V5, P3; Lovsin N, 2001, MOL BIOL EVOL, V18, P2213, DOI 10.1093/oxfordjournals.molbev.a003768; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; Malik HS, 1999, MOL BIOL EVOL, V16, P793, DOI 10.1093/oxfordjournals.molbev.a026164; Mathews DH, 1997, RNA, V3, P1; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Ogiwara I, 1999, MOL BIOL EVOL, V16, P1238, DOI 10.1093/oxfordjournals.molbev.a026214; Ogiwara I, 2002, GENOME RES, V12, P316, DOI 10.1101/gr.212302; Ohshima K, 1996, MOL CELL BIOL, V16, P3756; Okada N, 1997, J MOL EVOL, V44, pS52, DOI 10.1007/PL00000058; Okada N, 1997, GENE, V205, P229, DOI 10.1016/S0378-1119(97)00409-5; OKADA N, 1991, TRENDS ECOL EVOL, V6, P358, DOI 10.1016/0169-5347(91)90226-N; Okada N., 1995, IMPACT SHORT INTERSP, P61; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Peng Y, 2001, MOL CELL, V7, P1201, DOI 10.1016/S1097-2765(01)00268-4; Pickeral OK, 2000, GENOME RES, V10, P411, DOI 10.1101/gr.10.4.411; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; Shedlock AM, 2000, BIOESSAYS, V22, P148, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;148::AID-BIES6&gt;3.0.CO;2-Z; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Terai Y, 1998, MOL BIOL EVOL, V15, P1460, DOI 10.1093/oxfordjournals.molbev.a025873; Viguera E, 2001, EMBO J, V20, P2587, DOI 10.1093/emboj/20.10.2587; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; Weiner AM, 2000, NAT GENET, V24, P332, DOI 10.1038/74135; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	54	242	256	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 1	2002	111	3					433	444		10.1016/S0092-8674(02)01041-3	http://dx.doi.org/10.1016/S0092-8674(02)01041-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419252	Bronze			2022-12-28	WOS:000179010100014
J	Kulesa, PM; Fraser, SE				Kulesa, PM; Fraser, SE			Cell dynamics during somite boundary formation revealed by time-lapse analysis	SCIENCE			English	Article							SEGMENTATION CLOCK; LUNATIC FRINGE; CHICK-EMBRYO; SOMITOGENESIS; MODEL; MORPHOGENESIS; EXPRESSION; OSCILLATOR; ZEBRAFISH; MESODERM	We follow somite segmentation in living chick embryos and find that the shaping process is not simple periodic slicing of tissue blocks but much more carefully choreographed separation in which the somite pulls apart from the segmental plate. Cells move across the presumptive somite boundary and violate gene expression boundaries thought to correlate with the site of the somite boundary. Similarly, cells do not appear to be preassigned to given somite as they leave the node. The results offer detailed picture of somite shaping and provide spatiotemporal framework for linking gene expression with cell movements.	CALTECH, Beckman Inst, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Fraser, SE (corresponding author), CALTECH, Beckman Inst, Div Biol, Pasadena, CA 91125 USA.		Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223				Aulehla A, 1999, DEV BIOL, V207, P49, DOI 10.1006/dbio.1998.9164; Barrantes ID, 1999, CURR BIOL, V9, P470, DOI 10.1016/S0960-9822(99)80212-7; BELLAIRS R., 1980, B ZOOL, V47, P245; Buchberger A, 1998, DEV BIOL, V199, P201, DOI 10.1006/dbio.1998.8919; Collier JR, 2000, J THEOR BIOL, V207, P305, DOI 10.1006/jtbi.2000.2172; Cooke J, 1998, TRENDS GENET, V14, P85, DOI 10.1016/S0168-9525(98)01396-1; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; Dale KJ, 2000, BIOESSAYS, V22, P72, DOI 10.1002/(SICI)1521-1878(200001)22:1<72::AID-BIES12>3.0.CO;2-S; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Durbin L, 1998, GENE DEV, V12, P3096, DOI 10.1101/gad.12.19.3096; Henry CA, 2000, CURR BIOL, V10, P1063, DOI 10.1016/S0960-9822(00)00677-1; JACOBSON AG, 1986, SOMITES DEV EMBRYOS, P1; Jiang YJ, 2000, NATURE, V408, P475, DOI 10.1038/35044091; Keller R, 2000, CURR TOP DEV BIOL, V47, P183; Kerszberg M, 2000, J THEOR BIOL, V205, P505, DOI 10.1006/jtbi.2000.2085; MEINHARDT H, 1986, SOMITES DEV EMBRYOS, P179; Pourquie O, 2001, ANNU REV CELL DEV BI, V17, P311, DOI 10.1146/annurev.cellbio.17.1.311; PRIMMETT DRN, 1989, DEVELOPMENT, V105, P119; Saga Y, 2001, NAT REV GENET, V2, P835, DOI 10.1038/35098552; Sakamoto K, 1997, BIOCHEM BIOPH RES CO, V234, P754, DOI 10.1006/bbrc.1997.6652; Schmidt C, 2001, DEV DYNAM, V220, P377, DOI 10.1002/dvdy.1117; Schnell S, 2000, DEV DYNAM, V217, P415, DOI 10.1002/(SICI)1097-0177(200004)217:4<415::AID-DVDY8>3.0.CO;2-3; STERN CD, 1988, DEVELOPMENT, V104, P231; Stickney HL, 2000, DEV DYNAM, V219, P287; Stockdale FE, 2000, DEV DYNAM, V219, P304, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1057>3.0.CO;2-5; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; WOOD A, 1994, DEV DYNAM, V201, P151, DOI 10.1002/aja.1002010206; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452	28	100	104	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					991	995		10.1126/science.1075544	http://dx.doi.org/10.1126/science.1075544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411697				2022-12-28	WOS:000178932000046
J	Bishop, JKB; Davis, RE; Sherman, JT				Bishop, JKB; Davis, RE; Sherman, JT			Robotic observations of dust storm enhancement of carbon biomass in the North Pacific	SCIENCE			English	Article							SUB-ARCTIC PACIFIC; PHYTOPLANKTON DYNAMICS; TEMPORAL VARIABILITY; ATLANTIC OCEAN; IRON; SENSORS; BLOOM; FLUX	Two autonomous robotic pro ling oats deployed in the subarctic North Pacific on 10 April 2001 provided direct records of carbon biomass variability from surface to 1000 meters below surface at daily and diurnal time scales. Eight months of real-time data documented the marine biological response to natural events, including hydrographic changes, multiple storms, and the April 2001 dust event. High-frequency observations of upper ocean particulate organic carbon variability show a near doubling of biomass in the mixed layer over a 2-week period after the passage of a cloud of Gobi desert dust. The temporal evolution of particulate organic carbon enhancement and an increase in chlorophyll use efficiency after the dust storm suggest a biotic response to a natural iron fertilization by the dust.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Earth Sci, Berkeley, CA 94720 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Diego; Scripps Institution of Oceanography	Bishop, JKB (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Earth Sci, 1 Cyclotron Rd,MS 90-1116, Berkeley, CA 94720 USA.	JKBishop@lbl.gov		Bishop, James/0000-0002-8036-3017; Davis, Russ/0000-0003-1903-6313				Abbott MR, 2000, DEEP-SEA RES PT II, V47, P3285, DOI 10.1016/S0967-0645(00)00069-2; Behrenfeld MJ, 1999, SCIENCE, V283, P840, DOI 10.1126/science.283.5403.840; Bishop JKB, 1999, DEEP-SEA RES PT I, V46, P353, DOI 10.1016/S0967-0637(98)00069-7; BISHOP JKB, 1991, J GEOPHYS RES-OCEANS, V96, P16839, DOI 10.1029/91JC01754; Bishop JKB, 1999, DEEP-SEA RES PT II, V46, P2699; Boyd P, 1999, DEEP-SEA RES PT II, V46, P2405, DOI 10.1016/S0967-0645(99)00069-7; Boyd PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500; Boyd PW, 1999, DEEP-SEA RES PT II, V46, P2761, DOI 10.1016/S0967-0645(99)00083-1; Boyd PW, 1998, GLOBAL BIOGEOCHEM CY, V12, P429, DOI 10.1029/98GB00745; Davis RE, 1998, J GEOPHYS RES-OCEANS, V103, P24619, DOI 10.1029/98JC01913; Davis RE, 2001, J ATMOS OCEAN TECH, V18, P982, DOI 10.1175/1520-0426(2001)018<0982:PAAOAI>2.0.CO;2; DICKEY T, 1991, J GEOPHYS RES-OCEANS, V96, P8643, DOI 10.1029/91JC00413; DICKEY T, 1994, J GEOPHYS RES-OCEANS, V99, P22541, DOI 10.1029/94JC01221; DITULLIO GR, 1991, DEEP-SEA RES, V38, P1305, DOI 10.1016/0198-0149(91)90029-F; Falkowski P, 2000, SCIENCE, V290, P291, DOI 10.1126/science.290.5490.291; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; Foley DG, 1997, DEEP-SEA RES PT II, V44, P1801, DOI 10.1016/S0967-0645(97)00080-5; Fung IY, 2000, GLOBAL BIOGEOCHEM CY, V14, P281, DOI 10.1029/1999GB900059; Husar RB, 2001, J GEOPHYS RES-ATMOS, V106, P18317, DOI 10.1029/2000JD900788; *INT UND ASS LOND, 1999, 2 UK BOD INJ AW STUD, P1; Kinkade CS, 1999, DEEP-SEA RES PT II, V46, P1813, DOI 10.1016/S0967-0645(99)00045-4; Lenes JM, 2001, LIMNOL OCEANOGR, V46, P1261, DOI 10.4319/lo.2001.46.6.1261; LONGHURST AR, 1989, PROG OCEANOGR, V22, P47, DOI 10.1016/0079-6611(89)90010-4; MARRA J, 1992, J GEOPHYS RES-OCEANS, V97, P7399, DOI 10.1029/92JC00408; MARTIN JH, 1989, DEEP-SEA RES, V36, P649, DOI 10.1016/0198-0149(89)90144-1; MILLER CB, 1993, PROG OCEANOGR, V32, P1, DOI 10.1016/0079-6611(93)90007-Z; OREILLY JE, SEAWIFS POSTLAUNCH 3, P1; SIEGEL DA, 1989, DEEP-SEA RES, V36, P211, DOI 10.1016/0198-0149(89)90134-9; SMITH RC, 1978, LIMNOL OCEANOGR, V23, P247, DOI 10.4319/lo.1978.23.2.0247; STRAMSKA M, 1995, J GEOPHYS RES-OCEANS, V100, P6621, DOI 10.1029/94JC01447; Thibault D, 1999, DEEP-SEA RES PT II, V46, P2669, DOI 10.1016/S0967-0645(99)00080-6; Volk T., 1985, GEOPHYS MONOGR SER, V32, P99, DOI DOI 10.1029/GM032P0099; Whitney FA, 1999, DEEP-SEA RES PT II, V46, P2351, DOI 10.1016/S0967-0645(99)00067-3; Young RW, 1991, GLOBAL BIOGEOCHEM CY, V5, P119, DOI 10.1029/91GB00927	35	305	357	6	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					817	821		10.1126/science.1074961	http://dx.doi.org/10.1126/science.1074961			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399588	Green Published			2022-12-28	WOS:000178791200056
J	Miller, M; Iliff, P; Stoltzfus, RJ; Humphrey, J				Miller, M; Iliff, P; Stoltzfus, RJ; Humphrey, J			Breastmilk erythropoietin and mother-to-child HIV transmission through breastmilk	LANCET			English	Article							HUMAN-MILK; DEFICIENCY; INFANTS; ANEMIA	A third to a half the 1.5 million HIV-positive children in the world today acquired their infection via breastfeeding. However, what protects the 85% of breastfed babies of HIV-infected mothers who do not become infected? We postulate that erythropoietin (EPO), a hormone in human milk, has a role in the prevention of HIV transmission during breastfeeding. EPO might maintain mammary epithelium integrity, thereby reducing viral loads in milk, or maintain intestinal epithelial integrity in the breastfed neonate, and thus preventing ingested milk-borne virus being infective. This hypothesis could be tested by administration of recombinant human EPO parenterally to HIV-infected mothers or enterally to breastfed babies, or both, and assessment of the effect on mammary permeability, viral load in milk, and intestinal permeability in babies. If our hypothesis is correct, EPO treatment for mother or baby, or both might help prevent transmission of HIV.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Human Nutr, Baltimore, MD 21205 USA; ZVITAMBO Project, Harare, Zimbabwe; Univ Zimbabwe, Sch Med, Dept Paediat & Child Hlth, Harare, Zimbabwe	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Zimbabwe	Stoltzfus, RJ (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Human Nutr, Baltimore, MD 21205 USA.							Ballin A, 1999, LANCET, V353, P1849, DOI 10.1016/S0140-6736(99)01222-2; BOYD HK, 1991, EUR J HAEMATOL, V46, P198; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; Filteau SM, 1999, AM J CLIN NUTR, V69, P953; Goldman AS, 1996, J MAMMARY GLAND BIOL, V1, P251, DOI 10.1007/BF02018078; Henry DH, 1998, SEMIN ONCOL, V25, P64; Humphrey J, 2001, NUTR REV, V59, P119, DOI 10.1111/j.1753-4887.2001.tb06999.x; ITO K, 1991, RES GASTROINTEST BLO, V7, P57; Juul SE, 2000, PEDIATR RES, V48, P660, DOI 10.1203/00006450-200011000-00018; Juul SE, 1999, PEDIATR RES, V46, P263, DOI 10.1203/00006450-199909000-00003; Juul SE, 2001, GUT, V49, P182, DOI 10.1136/gut.49.2.182; Kling PJ, 1998, PEDIATR RES, V43, P216, DOI 10.1203/00006450-199802000-00010; Krafft A, 1999, LANCET, V354, P778, DOI 10.1016/S0140-6736(05)76022-0; Ledbetter DJ, 2000, J PEDIATR SURG, V35, P178, DOI 10.1016/S0022-3468(00)90006-X; MAHMOOD T, 1977, BLOOD, V50, P449; NEVILLE MC, 1984, AM J CLIN NUTR, V40, P635, DOI 10.1093/ajcn/40.3.635; Okada A, 1996, DIGESTION, V57, P328, DOI 10.1159/000201353; Semba R D, 1999, J Hum Lact, V15, P301, DOI 10.1177/089033449901500407; SPIVAK JL, 1989, JAMA-J AM MED ASSOC, V261, P3104, DOI 10.1001/jama.261.21.3104	19	12	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1246	1248		10.1016/S0140-6736(02)11277-3	http://dx.doi.org/10.1016/S0140-6736(02)11277-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401271				2022-12-28	WOS:000178708100033
J	Wolchik, SA; Sandler, IN; Millsap, RE; Plummer, BA; Greene, SM; Anderson, ER; Dawson-McClure, SR; Hipke, K; Haine, RA				Wolchik, SA; Sandler, IN; Millsap, RE; Plummer, BA; Greene, SM; Anderson, ER; Dawson-McClure, SR; Hipke, K; Haine, RA			Six-year follow-up of preventive interventions for children of divorce - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPRESSION; CHILDHOOD	Context Compared with their peers with nondivorced parents, adolescents with divorced parents are more likely to have mental health problems, drop out of school, and become pregnant. The long-term effects of intervention programs for this population are unknown. Objective To evaluate the long-term effectiveness of 2 programs designed to prevent mental health problems in children with divorced parents. Design and Setting Six-year follow-up of a randomized controlled trial of 2 intervention programs (mother program: 11 group and 2 individual sessions; mother plus child program: mother program and 11 group sessions for children) and a control condition (books on postdivorce adjustment), which was conducted in a large metropolitan US city from April 1998 through March 2000. Participants A total of 218 families (91% of the original sample) with adolescents aged between 15 and 19 years were reinterviewed. Main Outcome Measures Externalizing and internalizing problems, diagnosed mental disorders, drug and alcohol use, and number of sexual partners. Results Eleven percent of adolescents in the mother plus child program (95% confidence interval [CI], 3.8%-18.2%) had a 1-year prevalence of diagnosed mental disorder compared with 23.5% (95% Cl, 13.8%-33.2%) of adolescents in the control program (P=.007). Adolescents in the mother plus child program had fewer sexual partners (mean [SE], 0.68 [0.16]) compared with adolescents in the control program 0.65 [0.37]; P=.01). Adolescents with higher initial mental health problems whose families were in the mother plus child program had lower externalizing problems (P=.007) and fewer symptoms of mental disorder (P=.02) compared with those in the control program. Compared with controls, adolescents whose mothers participated in the mother program and who had higher initial mental health problems had lower levels of externalizing problems (P<.001); fewer symptoms of mental disorder (P=.005); and less alcohol (P=.005), marijuana (P=.02), and other drug use (P=.01). Conclusions In adolescents of divorced parents, the mother program and the mother plus child program reduced symptoms of mental disorder; rates of diagnoses of mental disorder; levels of externalizing problems; marijuana, alcohol, and other drug use; and number of sexual partners.	Arizona State Univ, Prevent Res Ctr, Dept Psychol, Prevent Res Program, Tempe, AZ 85287 USA; Univ Texas, Populat Res Ctr, Austin, TX 78712 USA	Arizona State University; Arizona State University-Tempe; University of Texas System; University of Texas Austin	Wolchik, SA (corresponding author), Arizona State Univ, Prevent Res Ctr, Dept Psychol, Prevent Res Program, POB 876005, Tempe, AZ 85287 USA.	sharlene.wolchjk@asu.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039346, R01MH057013] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Achenbach T.M., 1991, MANUAL CHILD BEHAV C, DOI DOI 10.1023/A; Amato PR, 2001, J FAM PSYCHOL, V15, P355, DOI 10.1037/0893-3200.15.3.355; Angold A, 1999, J AM ACAD CHILD PSY, V38, P129, DOI 10.1097/00004583-199902000-00011; BROOKSGUNN J, 1991, J YOUTH ADOLESCENCE, V20, P115, DOI 10.1007/BF01537603; BURBACH DJ, 1986, J ABNORM CHILD PSYCH, V14, P579, DOI 10.1007/BF01260525; CASPI A, 1995, DEV PSYCHOPATHOLOGY, V2; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; COLE JD, 1993, AM PSYCHOL, V10, P1013; EPSTEIN S, 1983, J PERS, V51, P360, DOI 10.1111/j.1467-6494.1983.tb00338.x; FLEWELLING RL, 1990, J MARRIAGE FAM, V52, P171, DOI 10.2307/352848; Forehand R., 1981, HELPING NONCOMPLIANT; GUERNEY LF, 1978, PARENTING SKILLS TRA; Hetherington EM, 1999, J CHILD PSYCHOL PSYC, V40, P129, DOI 10.1111/1469-7610.00427; Hetherington EM, 1998, AM PSYCHOL, V53, P167, DOI 10.1037/0003-066X.53.2.167; Hipke KN, 2002, FAM RELAT, V51, P121, DOI 10.1111/j.1741-3729.2002.00121.x; Hofstra MB, 2000, J AM ACAD CHILD PSY, V39, P850, DOI 10.1097/00004583-200007000-00013; HOSMER DW, 1989, APPL LOGISTIC REGRES; Huitema B., 1980, ANAL COVARIANCE ALTE; Johnston L D, 1985, NIDA Res Monogr, V57, P31; JOHNSTON LD, 1993, MONITORING FUTURE QU; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; KOVACS M, 1981, ACTA PAEDOPSYCHIATR, V46, P305; Little R. J. A., 1987, STAT ANAL MISSING DA; MCCORD J, 1990, THRESHOLD DEV ADOLES, P414; MEICHENBAUM D, 1986, STRESS INOCULATION T; *NAT CTR HLTH STAT, 1995, MONTHLY VITAL STAT R, V4, P1; PEDROCARROLL JL, 1985, J CONSULT CLIN PSYCH, V53, P603, DOI 10.1037/0022-006X.53.5.603; REED JB, 1999, AM J COMMUN PSYCHOL, V24, P483; REYNOLDS CR, 1978, J ABNORM CHILD PSYCH, V6, P271, DOI 10.1007/BF00919131; Rodgers B, 1997, J CHILD PSYCHOL PSYC, V38, P867, DOI 10.1111/j.1469-7610.1997.tb01605.x; SANDLER IN, 1997, ISSUES CLIN CHILD PS, P3; SCHWARTZ JE, 1995, AM J PUBLIC HEALTH, V85, P1237, DOI 10.2105/AJPH.85.9.1237; Shadish W. R., 2001, EXPT QUASIEXPERIMENT, V2nd; Shaffer D, 2000, J AM ACAD CHILD PSY, V39, P28, DOI 10.1097/00004583-200001000-00014; STOLBERG AL, 1994, J CONSULT CLIN PSYCH, V62, P147, DOI 10.1037/0022-006X.62.1.147; STOLBERG AL, 1985, AM J COMMUN PSYCHOL, V13, P111, DOI 10.1007/BF00905724; STOLBERG AL, 1991, CHILDREN DIVORCE LEA; WEISS L, 1998, HDB PARENT TRAINING, P445; Wolchik SA, 2000, J CONSULT CLIN PSYCH, V68, P843, DOI 10.1037/0022-006X.68.5.843; WOLCHIK SA, 1993, AM J COMMUN PSYCHOL, V21, P293, DOI 10.1007/BF00941505; Woodward LJ, 2001, J AM ACAD CHILD PSY, V40, P1086, DOI 10.1097/00004583-200109000-00018	42	166	171	1	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	2002	288	15					1874	1881		10.1001/jama.288.15.1874	http://dx.doi.org/10.1001/jama.288.15.1874			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	604EU	12377086				2022-12-28	WOS:000178604200026
J	Struzhkin, VV; Eremets, MI; Gan, W; Mao, HK; Hemley, RJ				Struzhkin, VV; Eremets, MI; Gan, W; Mao, HK; Hemley, RJ			Superconductivity in dense lithium	SCIENCE			English	Article							HIGH-PRESSURE; TEMPERATURE	Superconductivity in compressed lithium is observed by magnetic susceptibility and electrical resistivity measurements. A superconducting critical temperature (T-c) is found ranging from 9 to 16 kelvin at 23 to 80 gigapascals. The pressure dependence of c suggests multiple phase transitions, consistent with theoretical predictions and reported x-ray diffraction results. The observed values for T-c are much lower than those theoretically predicted, indicating that more sophisticated theoretical treatments similar to those proposed for metallic hydrogen may be required to understand superconductivity in dense phases of lithium.	Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Max Planck Inst Chem, D-55020 Mainz, Germany; Thomas S Wootton High Sch, Rockville, MD 20850 USA	Carnegie Institution for Science; Max Planck Society	Struzhkin, VV (corresponding author), Carnegie Inst Washington, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.		Struzhkin, Viktor V/J-9847-2013	Struzhkin, Viktor V/0000-0002-3468-0548				ASHCROFT NW, IN PRESS P INT SCH P, V147; Christensen NE, 2001, PHYS REV LETT, V86, P1861, DOI 10.1103/PhysRevLett.86.1861; Eremets MI, 2001, SCIENCE, V293, P272, DOI 10.1126/science.1062286; Gregoryanz E, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.064504; Hanfland M, 2000, NATURE, V408, P174, DOI 10.1038/35041515; Hinks DG, 2001, NATURE, V411, P457, DOI 10.1038/35078037; Lang KM, 1999, J LOW TEMP PHYS, V114, P445, DOI 10.1023/A:1021854204812; LIN TH, 1986, PHYS REV B, V33, P807, DOI 10.1103/PhysRevB.33.807; Moulopoulos K, 1999, PHYS REV B, V59, P12309, DOI 10.1103/PhysRevB.59.12309; Neaton JB, 1999, NATURE, V400, P141, DOI 10.1038/22067; Nelmes RJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.155503; OVERHAUSER AW, 1984, PHYS REV LETT, V53, P64, DOI 10.1103/PhysRevLett.53.64; Richardson CF, 1997, PHYS REV LETT, V78, P118, DOI 10.1103/PhysRevLett.78.118; Richardson CF, 1997, PHYS REV B, V55, P15130, DOI 10.1103/PhysRevB.55.15130; SHIMIZU K, COMMUNICATION; STRUZHKIN VV, 1999, B AM PHYS SOC, V44, P1489; Timofeev YA, 2002, REV SCI INSTRUM, V73, P371, DOI 10.1063/1.1431257	17	206	208	4	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1213	1215		10.1126/science.1078535	http://dx.doi.org/10.1126/science.1078535			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12386338				2022-12-28	WOS:000179080400043
J	Lauhon, LJ; Gudiksen, MS; Wang, CL; Lieber, CM				Lauhon, LJ; Gudiksen, MS; Wang, CL; Lieber, CM			Epitaxial core-shell and core-multishell nanowire heterostructures	NATURE			English	Article							BUILDING-BLOCKS; SEMICONDUCTOR NANOCRYSTALS; DEPENDENCE; TECHNOLOGY; DEVICES	Semiconductor heterostructures with modulated composition and/or doping enable passivation of interfaces and the generation of devices with diverse functions(1). In this regard, the control of interfaces in nanoscale building blocks with high surface area will be increasingly important in the assembly of electronic and photonic devices(2-10). Core-shell heterostructures formed by the growth of crystalline overlayers on nanocrystals offer enhanced emission efficiency 7, important for various applications(8-10). Axial heterostructures have also been formed by a one-dimensional modulation of nanowire composition(11-13) and doping(11). However, modulation of the radial composition and doping in nanowire structures has received much less attention than planar 1 and nanocrystal(7) systems. Here we synthesize silicon and germanium core-shell and multishell nanowire heterostructures using a chemical vapour deposition method applicable to a variety of nanoscale materials(14). Our investigations of the growth of boron-doped silicon shells on intrinsic silicon and silicon-silicon oxide core-shell nanowires indicate that homoepitaxy can be achieved at relatively low temperatures on clean silicon. We also demonstrate the possibility of heteroepitaxial growth of crystalline germanium-silicon and silicon-germanium core-shell structures, in which band-offsets drive hole injection into either germanium core or shell regions. Our synthesis of core-multi-shell structures, including a high-performance coaxially gated field-effect transistor, indicates the general potential of radial heterostructure growth for the development of nanowire-based devices.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.		Lauhon, Lincoln J/B-7526-2009; Lauhon, Lincoln/AAF-8269-2020; Chu, Yung-Ming/C-6318-2009; Lauhon, Lincoln/H-2976-2015	Lauhon, Lincoln/0000-0001-6046-3304; Lauhon, Lincoln/0000-0001-6046-3304				Bjork MT, 2002, APPL PHYS LETT, V80, P1058, DOI 10.1063/1.1447312; Briand D, 1999, SEMICOND SCI TECH, V14, P173, DOI 10.1088/0268-1242/14/2/012; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Cheng IC, 2002, APPL PHYS LETT, V80, P440, DOI 10.1063/1.1435798; Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; Cui Y, 2001, APPL PHYS LETT, V78, P2214, DOI 10.1063/1.1363692; Duan XF, 2000, ADV MATER, V12, P298, DOI 10.1002/(SICI)1521-4095(200002)12:4<298::AID-ADMA298>3.0.CO;2-Y; Duan XF, 2001, NATURE, V409, P66, DOI 10.1038/35051047; GIBSON JM, 1989, APPL PHYS LETT, V55, P1394, DOI 10.1063/1.102280; GRUTZMACHER DA, 1993, APPL PHYS LETT, V63, P2531, DOI 10.1063/1.110449; Gudiksen MS, 2002, NATURE, V415, P617, DOI 10.1038/415617a; Gudiksen MS, 2000, J AM CHEM SOC, V122, P8801, DOI 10.1021/ja002008e; Huang Y, 2001, SCIENCE, V294, P1313, DOI 10.1126/science.1066192; Hull R, 1999, GERMANIUM SILICON PH; JONES AC, 1997, CVD COMPOUND SEMICON; KLAASSEN DBM, 1992, SOLID STATE ELECTRON, V35, P953, DOI 10.1016/0038-1101(92)90325-7; Klimov VI, 2000, SCIENCE, V290, P314, DOI 10.1126/science.290.5490.314; Lieber CM, 2001, SCI AM, V285, P58, DOI 10.1038/scientificamerican0901-58; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; Mooney PM, 2000, ANNU REV MATER SCI, V30, P335, DOI 10.1146/annurev.matsci.30.1.335; Nirmal M, 1999, ACCOUNTS CHEM RES, V32, P407, DOI 10.1021/ar9700320; Solomon PM, 2000, ANNU REV MATER SCI, V30, P681, DOI 10.1146/annurev.matsci.30.1.681; SZE SM, 1981, PHYSICS SEMICONDUCTO; Wind SJ, 2002, APPL PHYS LETT, V80, P3817, DOI 10.1063/1.1480877; Wu YY, 2002, NANO LETT, V2, P83, DOI 10.1021/nl0156888	27	1817	1935	17	1087	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					57	61		10.1038/nature01141	http://dx.doi.org/10.1038/nature01141			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422212				2022-12-28	WOS:000179068100034
J	Toescu, V; Nuttall, SL; Kendall, MJ; Martin, U; Dunne, F				Toescu, V; Nuttall, SL; Kendall, MJ; Martin, U; Dunne, F			Women with gestational diabetes should be targeted to reduce cardiovascular risk	BRITISH MEDICAL JOURNAL			English	Letter									Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Toescu, V (corresponding author), Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.							MUSLINER TA, 1988, CLIN CHEM, V34, P78; Rajman I, 1996, ATHEROSCLEROSIS, V125, P231; Sattar N, 2002, BMJ-BRIT MED J, V325, P157, DOI 10.1136/bmj.325.7356.157; TOESCU V, 2002, IN PRESS CLIN ENDOCR	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					966	966		10.1136/bmj.325.7370.966	http://dx.doi.org/10.1136/bmj.325.7370.966			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399355	Green Published			2022-12-28	WOS:000178986300029
J	Dillehay, TD				Dillehay, TD			Climate and human migrations	SCIENCE			English	Editorial Material									Univ Kentucky, Dept Anthropol, Lexington, KY 40506 USA	University of Kentucky	Dillehay, TD (corresponding author), Univ Kentucky, Dept Anthropol, Lexington, KY 40506 USA.							Clapperton CM, 1993, QUATERNARY GEOLOGY G; Dillehay T. D., 1997, ARCHAEOLOGICAL CONTE, VII; DILLEHAY TD, IN PRESS QUAT INT; Houghton J. T., 2001, CLIMATE CHANGE 2001; KELLY RL, 1988, AM ANTIQUITY, V53, P231, DOI 10.2307/281017; Mann ME, 2002, SCIENCE, V297, P1481, DOI 10.1126/science.1074318; Martin P. S., 1967, Natural History New York, V76, P32; Nunez L, 2002, SCIENCE, V298, P821, DOI 10.1126/science.1076449; NUNEZ L, 1994, REV CHIL HIST NAT, V67, P503; O'Connor S, 1999, QUATERN INT, V59, P61, DOI 10.1016/S1040-6182(98)00072-X; Redman C.L., 1999, HUMAN IMPACT ANCIENT; Schiffer M.B., 1976, BEHAV ARCHEOLOGY; Steig EJ, 1999, SCIENCE, V286, P1485, DOI 10.1126/science.286.5444.1485; TOSI J, 1960, ZONAS VIDA NATURAL P	14	21	24	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					764	765		10.1126/science.1078163	http://dx.doi.org/10.1126/science.1078163			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399573				2022-12-28	WOS:000178791200041
J	Dustin, ML; Colman, DR				Dustin, ML; Colman, DR			Neural and immunological synaptic relations	SCIENCE			English	Article							T-CELL ACTIVATION; IMMUNE-SYSTEM; CUTTING EDGE; POSTSYNAPTIC DENSITY; EXCITATORY SYNAPSES; ANTIGEN RECOGNITION; ACTIN CYTOSKELETON; ADHESION MOLECULE; DENDRITIC CELLS; N-CADHERIN	A synapse is a stable adhesive junction between two cells across which information is relayed by directed secretion. The nervous system and immune system utilize these specialized cell surface contacts to directly convey and transduce highly controlled secretory signals between their constituent cell populations. Each of these synaptic types is built around a microdomain structure comprising central active zones of exocytosis and endocytosis encircled by adhesion domains. Surface molecules that may be incorporated into and around the active zones contribute to modulation of the functional state of the synapse.	NYU, Sch Med, Dept Pathol, Skirball Inst Biomol Med,Program Mol Pathogenesis, New York, NY 10016 USA; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	New York University; McGill University	Dustin, ML (corresponding author), NYU, Sch Med, Dept Pathol, Skirball Inst Biomol Med,Program Mol Pathogenesis, New York, NY 10016 USA.	dustin@saturn.med.nyu.edu; david.colman@mcgill.ca	Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Al-Alwan MM, 2001, J IMMUNOL, V166, P1452, DOI 10.4049/jimmunol.166.3.1452; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; [Anonymous], 2000, OXFORD ENGLISH DICT; Arndt K, 1998, MOL CELL NEUROSCI, V10, P211, DOI 10.1006/mcne.1998.0665; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; Benson DL, 1998, J NEUROSCI, V18, P6892; Benson DL, 2001, NAT REV NEUROSCI, V2, P899, DOI 10.1038/35104078; BOES M, 2002, NATURE, V48, P6901; BRAUN J, 1978, J CELL BIOL, V79, P409, DOI 10.1083/jcb.79.2.409; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; BURRY RW, 1986, NEUROCHEM PATHOL, V5, P345, DOI 10.1007/BF02842943; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006; Colicos MA, 2001, CELL, V107, P605, DOI 10.1016/S0092-8674(01)00579-7; Davis DM, 2002, TRENDS IMMUNOL, V23, P356, DOI 10.1016/S1471-4906(02)02243-3; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; EDELMAN GM, 1968, NEUROSCIENCE RES PRO, V6; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Fahmy TM, 2002, J IMMUNOL METHODS, V268, P93, DOI 10.1016/S0022-1759(02)00203-X; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hagler DJ, 1998, NEURON, V20, P1059, DOI 10.1016/S0896-6273(00)80486-9; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; Huntley GW, 1999, J COMP NEUROL, V407, P453; Klopfenstein DR, 2002, CELL, V109, P347, DOI 10.1016/S0092-8674(02)00708-0; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; Kuhn JR, 2002, IMMUNITY, V16, P111, DOI 10.1016/S1074-7613(02)00262-5; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; LEE SJ, IN PRESS TRENDS IMMU; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; Lujan R, 1997, J CHEM NEUROANAT, V13, P219, DOI 10.1016/S0891-0618(97)00051-3; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; NORCROSS MA, 1984, ANN INST PASTEUR IMM, VD135, P113, DOI 10.1016/S0769-2625(84)81105-8; Obst-Pernberg K, 1999, J NEUROSCI RES, V58, P130, DOI 10.1002/(SICI)1097-4547(19991001)58:1<130::AID-JNR13>3.0.CO;2-8; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; Peters A., 1991, FINE STRUCTURE NERVO; Peterson DA, 1999, J IMMUNOL, V162, P3117; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; POO WJ, 1988, NATURE, V332, P378, DOI 10.1038/332378a0; Qi SY, 2001, P NATL ACAD SCI USA, V98, P6548, DOI 10.1073/pnas.111536798; Reichert P, 2001, J IMMUNOL, V166, P4278, DOI 10.4049/jimmunol.166.7.4278; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Shapiro L, 1999, NEURON, V23, P427, DOI 10.1016/S0896-6273(00)80796-5; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Sherrington C, 1906, INTEGRATIVE ACTION N; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUBLI U, 1990, BEHAV NEURAL BIOL, V53, P1, DOI 10.1016/0163-1047(90)90712-F; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065; Tanaka H, 2000, NEURON, V25, P93, DOI 10.1016/S0896-6273(00)80874-0; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; Valtschanoff JG, 2001, J NEUROSCI, V21, P1211; van der Merwe PA, 2000, SEMIN IMMUNOL, V12, P5, DOI 10.1006/smim.2000.0203; Wild MK, 1999, J EXP MED, V190, P31, DOI 10.1084/jem.190.1.31; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	78	199	209	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					785	789		10.1126/science.1076386	http://dx.doi.org/10.1126/science.1076386			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399580				2022-12-28	WOS:000178791200047
J	Perry, SJ; Baillie, GS; Kohout, TA; McPhee, I; Magiera, MM; Ang, KL; Miller, WE; McLean, AJ; Conti, M; Houslay, MD; Lefkowitz, RJ				Perry, SJ; Baillie, GS; Kohout, TA; McPhee, I; Magiera, MM; Ang, KL; Miller, WE; McLean, AJ; Conti, M; Houslay, MD; Lefkowitz, RJ			Targeting of cyclic AMP degradation to beta(2)-adrenergic receptors by beta-arrestins	SCIENCE			English	Article							CAMP; PROTEIN; INTERACTS; KINASES	Catecholamines signal through the beta(2)-adrenergic receptor by promoting production of the second messenger adenosine 3'-5'-monophosphate (cAMP). The magnitude of this signal is restricted by desensitization of the receptors through their binding to beta-arrestins and by cAMP degradation by phosphodiesterase (PDE) enzymes. We show that arrestins coordinate both processes by recruiting PDEs to activated beta(2)-adrenergic receptors in the plasma membrane of mammalian cells. In doing so, the beta-arrestins limit activation of membrane-associated cAMP-activated protein kinase by simultaneously slowing the rate of cAMP production through receptor desensitization and increasing the rate of its degradation at the membrane.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; University of Glasgow; Stanford University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Magiera, Maria M./Y-8754-2019; Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011; Lefkowitz, Robert/AAW-2649-2021	Magiera, Maria M./0000-0003-4847-3053; Houslay, Miles/0000-0002-3826-8091; Baillie, George/0000-0003-2469-6316	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bolger GB, 1997, BIOCHEM J, V328, P539; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Houslay MD, 2001, PROG NUCLEIC ACID RE, V69, P249, DOI 10.1016/S0079-6603(01)69049-4; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Rich TC, 2001, J GEN PHYSIOL, V118, P63, DOI 10.1085/jgp.118.1.63; SETTE C, 1994, J BIOL CHEM, V269, P18271; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zaccolo M, 2002, CURR OPIN CELL BIOL, V14, P160, DOI 10.1016/S0955-0674(02)00316-2; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	18	381	407	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					834	836		10.1126/science.1074683	http://dx.doi.org/10.1126/science.1074683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399592				2022-12-28	WOS:000178791200061
J	Muller, J; Hart, CM; Francis, NJ; Vargas, ML; Sengupta, A; Wild, B; Miller, EL; O'Connor, MB; Kingston, RE; Simon, JA				Muller, J; Hart, CM; Francis, NJ; Vargas, ML; Sengupta, A; Wild, B; Miller, EL; O'Connor, MB; Kingston, RE; Simon, JA			Histone methyltransferase activity of a Drosophila polycomb group repressor complex	CELL			English	Article							GROUP GENE ENHANCER; GROUP PROTEIN; HOMEOTIC GENE; CAENORHABDITIS-ELEGANS; DEACETYLASE RPD3; CHROMATIN STRUCTURE; LYSINE 9; ZESTE; TRITHORAX; ARABIDOPSIS	Polycomb group (PcG) proteins maintain transcriptional repression during development, likely by creating repressive chromatin states. The Extra Sex Combs (ESC) and Enhancer of Zeste [E(Z)] proteins are partners in an essential PcG complex, but its full composition and biochemical activities are not known. A SET domain in E(Z) suggests this complex might methylate histones. We purified an ESC-E(Z) complex from Drosophila embryos and found four major subunits: ESC, E(Z), NURF-55, and the PcG repressor, SU(Z)12. A recombinant complex reconstituted from these four subunits methylates lysine-27 of histone H3. Mutations in the E(Z) SET domain disrupt methyltransferase activity in vitro and HOX gene repression in vivo. These results identify E(Z) as a PcG protein with enzymatic activity and implicate histone methylation in PcG-mediated silencing.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany; Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	European Molecular Biology Laboratory (EMBL); Max Planck Society; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Muller, J (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		O'Connor, Michael B/C-9977-2014; Hart, Craig/B-4832-2016	O'Connor, Michael B/0000-0002-3067-5506; Hart, Craig/0000-0002-9870-991X				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Beuchle D, 2001, DEVELOPMENT, V128, P993; Birve A, 2001, DEVELOPMENT, V128, P3371; Carrington EA, 1996, DEVELOPMENT, V122, P4073; Cavalli G, 1999, SCIENCE, V286, P955, DOI 10.1126/science.286.5441.955; Chang YL, 2001, P NATL ACAD SCI USA, V98, P9730, DOI 10.1073/pnas.171325498; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; DeRubertis F, 1996, NATURE, V384, P589; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Francis NJ, 2001, MOL CELL, V8, P545, DOI 10.1016/S1097-2765(01)00316-1; Gendall AR, 2001, CELL, V107, P525, DOI 10.1016/S0092-8674(01)00573-6; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; Holdeman R, 1998, DEVELOPMENT, V125, P2457; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; JONES RS, 1990, GENETICS, V126, P185; Kal AJ, 2000, GENE DEV, V14, P1058; Kelly WG, 1998, DEVELOPMENT, V125, P2451; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Levenstein ME, 2002, J BIOL CHEM, V277, P8749, DOI 10.1074/jbc.M111212200; Mak W, 2002, CURR BIOL, V12, P1016, DOI 10.1016/S0960-9822(02)00892-8; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng J, 2000, MOL CELL BIOL, V20, P3069, DOI 10.1128/MCB.20.9.3069-3078.2000; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Petruk S, 2001, SCIENCE, V294, P1331, DOI 10.1126/science.1065683; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Schumacher A, 1996, NATURE, V384, P648, DOI 10.1038/384648a0; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Spillane C, 2000, CURR BIOL, V10, P1535, DOI 10.1016/S0960-9822(00)00839-3; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tie F, 2001, DEVELOPMENT, V128, P275; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574; Xu L, 2001, P NATL ACAD SCI USA, V98, P5061, DOI 10.1073/pnas.081016198; Yoshida N, 2001, PLANT CELL, V13, P2471, DOI 10.1105/tpc.13.11.2471; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	61	1197	1242	2	49	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 18	2002	111	2					197	208		10.1016/S0092-8674(02)00976-5	http://dx.doi.org/10.1016/S0092-8674(02)00976-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408864	Green Published, Bronze			2022-12-28	WOS:000178753500009
J	Steinbrook, R				Steinbrook, R			The debate over residents' work hours.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LONG HOURS; SLEEP; PHYSICIANS; FATIGUE											*ACCR COUNC GRAD M, 2002, STAT JUST IMP FIN AP; *ACCR COUNC GRAD M, 2001, ACGME DUT HOUR REQ P; *ACCR COUNC GRAD M, 2001, ACGMES ROL PROT ED P; *ACCR COUNC GRAD M, 2002, ROL ACGME; *ACCR COUNC GRAD M, 2002, REP ACGME WORK GROUP; *ACGME, 2001, ACGME WORK GROUP CHA; *AM MED ASS, 2002, 9A02 CME AM MED ASS; *ASS AM MED COLL, 2001, AAMC POL GUID GRAD M; *ASS AM MED COLL D, 2001, 2001 AAMC SURV HOUS; BARNARD A, 2002, BOSTON GLOBE    0520, pA1; Brotherton SE, 2002, JAMA-J AM MED ASSOC, V288, P1073, DOI 10.1001/jama.288.9.1073; Defoe DM, 2001, OBSTET GYNECOL, V97, P1015, DOI 10.1016/S0029-7844(01)01363-1; Gaba DM, 2002, NEW ENGL J MED, V347, P1249, DOI 10.1056/NEJMsa020846; GURJALA A, 2001, PETITION OCCUPATIONA; HOFFMAN J, 1995, NY TIMES        0207, pB1; Kassirer JP, 2001, ANN INTERN MED, V134, P587, DOI 10.7326/0003-4819-134-7-200104030-00012; Kohn KT, 2000, ERR IS HUMAN BUILDIN; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; Lamberg L, 2002, JAMA-J AM MED ASSOC, V287, P303, DOI 10.1001/jama.287.3.303; LURIE P, 2002, COMMUNICATION   0801; *NY STAT DEP HLTH, 1998, RES ASS COMPL WORK H; *NY STAT DEP HLTH, 1987, REP NEW YORK STAT AD; *OFF PROF, 2002, NEW YORK STAT PROF N; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Philibert I, 2002, JAMA-J AM MED ASSOC, V288, P1112, DOI 10.1001/jama.288.9.1112; Veasey S, 2002, JAMA-J AM MED ASSOC, V288, P1116, DOI 10.1001/jama.288.9.1116; Wallack MK, 2001, ARCH SURG-CHICAGO, V136, P1426, DOI 10.1001/archsurg.136.12.1426; Weinger MB, 2002, JAMA-J AM MED ASSOC, V287, P955, DOI 10.1001/jama.287.8.955; Weinstein DF, 2002, NEW ENGL J MED, V347, P1275, DOI 10.1056/NEJMsb022065; 2002, JAMA, V288, P1151; 2002, NY TIMES        0614, pA34	31	137	141	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1296	1302		10.1056/NEJMhpr022383	http://dx.doi.org/10.1056/NEJMhpr022383			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393837				2022-12-28	WOS:000178598300035
J	Nebert, DW; Russell, DW				Nebert, DW; Russell, DW			Clinical importance of the cytochromes P450	LANCET			English	Review							BILE-ACID; VITAMIN-D; HYDROCARBON RECEPTOR; XENOBIOTIC RESPONSE; ACCESSION NUMBERS; NUCLEAR RECEPTORS; GENE; EXPRESSION; MICE; SUPERFAMILY	The human cytochrome P450 (CYP) superfamily comprises 57 genes. These genes code for enzymes that can have a role in: metabolism of drugs, foreign chemicals, arachidonic acid and eicosanoids; cholesterol metabolism and bile-acid biosynthesis; steroid synthesis and metabolism; vitamin D-3 synthesis and metabolism; retinoic acid hydroxylation; and those of still unknown function. Cytochrome P450 was once believed to be mainly a hepatic drug detoxication system, but is now understood to include a myriad of enzymic reactions implicated In important life processes. Mutations in many CYP genes cause inborn errors of metabolism and contribute to many clinically relevant diseases.	Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nebert, DW (corresponding author), Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA.	dan.nebert@uc.edu		Russell, David/0000-0002-0277-403X	NHLBI NIH HHS [P50 HL20948] Funding Source: Medline; NIEHS NIH HHS [P30 ES06096, R01 ES08147, R01 ES06321] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008147, R01ES006321, P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andreola F, 1997, CANCER RES, V57, P2835; Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; Barwick JL, 1996, MOL PHARMACOL, V50, P10; BJORKHEM I, 2001, METABOLIC MOL BASES, P2981; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Clapper M L, 2000, Curr Oncol Rep, V2, P251, DOI 10.1007/s11912-000-0075-z; Corchero J, 2001, MOL PHARMACOL, V60, P1260, DOI 10.1124/mol.60.6.1260; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V267, P184, DOI 10.1006/bbrc.1999.1913; Eggertsen G, 1996, J BIOL CHEM, V271, P32269, DOI 10.1074/jbc.271.50.32269; Evans WE, 2001, ANNU REV GENOM HUM G, V2, P9, DOI 10.1146/annurev.genom.2.1.9; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GONZALEZ FJ, 1984, GENE, V29, P281, DOI 10.1016/0378-1119(84)90057-X; Gonzalez FJ, 2001, MUTAT RES-FUND MOL M, V477, P79, DOI 10.1016/S0027-5107(01)00109-9; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; Goodwin B, 2002, ANNU REV PHARMACOL, V42, P1, DOI 10.1146/annurev.pharmtox.42.111901.111051; Guengerich FP, 1998, DRUG METAB DISPOS, V26, P1175; Hartter S, 2001, J CLIN PSYCHOPHARM, V21, P167, DOI 10.1097/00004714-200104000-00008; Hennan JK, 2001, CIRCULATION, V104, P820, DOI 10.1161/hc3301.092790; Honda A, 2001, J BIOL CHEM, V276, P34579, DOI 10.1074/jbc.M103025200; Ingelman-Sundberg M, 2001, MUTAT RES-FUND MOL M, V482, P11, DOI 10.1016/S0027-5107(01)00205-6; Kato S, 1999, MOL CELL ENDOCRINOL, V156, P7, DOI 10.1016/S0303-7207(99)00128-8; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lasker JM, 2000, J BIOL CHEM, V275, P4118, DOI 10.1074/jbc.275.6.4118; Liang HCL, 1996, P NATL ACAD SCI USA, V93, P1671, DOI 10.1073/pnas.93.4.1671; LU AYH, 1972, ARCH BIOCHEM BIOPHYS, V152, P457, DOI 10.1016/0003-9861(72)90239-1; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Meyer UA, 2000, LANCET, V356, P1667, DOI 10.1016/S0140-6736(00)03167-6; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Miller WL, 1998, ENDOCR RES, V24, P817, DOI 10.3109/07435809809032692; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Murray GI, 1997, CANCER RES, V57, P3026; Nebert D W, 1994, Prog Liver Dis, V12, P63; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Nebert DW, 2000, PHARMACOLOGY, V61, P124, DOI 10.1159/000028393; Nebert DW, 1999, CLIN GENET, V56, P247, DOI 10.1034/j.1399-0004.1999.560401.x; NEBERT DW, 1987, DNA-J MOLEC CELL BIO, V6, P1, DOI 10.1089/dna.1987.6.1; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; Nebert DW, 2000, PHARMACOGENETICS, V10, P279, DOI 10.1097/00008571-200006000-00001; NEBERT DW, 2002, EMERY RIMOINS PRINCI, P590; NEBERT DW, ENCY HUMAN GENOME; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NELSON DR, CYTOCHROME P450 GENE; Norman AW, 2001, J STEROID BIOCHEM, V76, P49, DOI 10.1016/S0960-0760(00)00145-X; OSCARSON M, HUMAN CYTOCHROME P45; Phillips KA, 2001, JAMA-J AM MED ASSOC, V286, P2270, DOI 10.1001/jama.286.18.2270; Plastaras JP, 2000, J BIOL CHEM, V275, P11784, DOI 10.1074/jbc.275.16.11784; Pullingr CR, 2002, J CLIN INVEST, V110, P109, DOI 10.1172/JCI200215387; RYNER LC, 1995, CELL, V81, P483, DOI 10.1016/0092-8674(95)90069-1; Schuetz EG, 2001, CURR DRUG METAB, V2, P139, DOI 10.2174/1389200013338595; SELYE H, 1971, J PHARM SCI, V60, P1, DOI 10.1002/jps.2600600102; Setchell KDR, 1998, J CLIN INVEST, V102, P1690, DOI 10.1172/JCI2962; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Simpson ER, 2000, J SOC GYNECOL INVEST, V7, pS18, DOI 10.1177/1071557600007001S07; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Smith AG, 2001, TOXICOL APPL PHARM, V173, P89, DOI 10.1006/taap.2001.9167; St-Arnaud R, 2000, ENDOCRINOLOGY, V141, P2658, DOI 10.1210/en.141.7.2658; Stoilov I, 2001, TRENDS GENET, V17, P629, DOI 10.1016/S0168-9525(01)02444-1; Stoilov I, 1997, HUM MOL GENET, V6, P641, DOI 10.1093/hmg/6.4.641; Stoilov I, 2001, DRUG METAB DRUG INTE, V18, P33, DOI DOI 10.1515/DMDI.2001.18.1.33); Tang W, 2001, CURR DRUG METAB, V2, P185, DOI 10.2174/1389200013338658; Tuder RM, 2001, CLIN CHEST MED, V22, P405, DOI 10.1016/S0272-5231(05)70280-X; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; WAXMAN DJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P160, DOI 10.1016/0003-9861(91)90602-F; White PC, 2001, BEST PRACT RES CL EN, V15, P17, DOI 10.1053/beem.2000.0117; Wikvall K, 2001, INT J MOL MED, V7, P201; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Yoshida Y, 2000, BIOCHEM BIOPH RES CO, V273, P799, DOI 10.1006/bbrc.2000.3030	72	971	1032	2	169	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	2002	360	9340					1155	1162		10.1016/S0140-6736(02)11203-7	http://dx.doi.org/10.1016/S0140-6736(02)11203-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387968				2022-12-28	WOS:000178632000020
J	Schafer, DF; Sorrell, MF				Schafer, DF; Sorrell, MF			Optimising immunosuppression	LANCET			English	Editorial Material							LIVER-TRANSPLANTATION; TACROLIMUS FK506; CYCLOSPORINE		Univ Nebraska, Liver Transplant Program, Omaha, NE USA	University of Nebraska System	Sorrell, MF (corresponding author), Univ Nebraska, Liver Transplant Program, Omaha, NE USA.							Berenguer M, 2000, HEPATOLOGY, V32, P852, DOI 10.1053/jhep.2000.17924; CALNE RY, 1979, LANCET, V2, P1033; Hemming AW, 1996, TRANSPLANTATION, V62, P1798, DOI 10.1097/00007890-199612270-00020; Pichlmayr R, 1997, TRANSPL P, V29, P2499, DOI 10.1016/S0041-1345(97)00464-8; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1981, NEW ENGL J MED, V305, P266, DOI 10.1056/NEJM198107303050507; Wiesner RH, 1998, TRANSPLANTATION, V66, P493, DOI 10.1097/00007890-199808270-00014	7	6	6	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1114	1115		10.1016/S0140-6736(02)11237-2	http://dx.doi.org/10.1016/S0140-6736(02)11237-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387953				2022-12-28	WOS:000178632000005
J	DeLuca, TH; Zackrisson, O; Nilsson, MC; Sellstedt, A				DeLuca, TH; Zackrisson, O; Nilsson, MC; Sellstedt, A			Quantifying nitrogen-fixation in feather moss carpets of boreal forests	NATURE			English	Article							COMMUNITIES; ECOSYSTEM; PATTERNS	Biological nitrogen (N) fixation is the primary source of N within natural ecosystems(1), yet the origin of boreal forest N has remained elusive. The boreal forests of Eurasia and North America lack any significant, widespread symbiotic N-fixing plants(1-6). With the exception of scattered stands of alder in early primary successional forests(7), N-fixation in boreal forests is considered to be extremely limited. Nitrogen-fixation in northern European boreal forests has been estimated(2) at only 0.5 kg Nha(-1) yr(-1); however, organic N is accumulated in these ecosystems at a rate of 3 kg N ha(-1) yr(-1) (ref. 8). Our limited understanding of the origin of boreal N is unacceptable given the extent of the boreal forest region, but predictable given our imperfect knowledge of N-fixation(1,9). Herein we report on a N-fixing symbiosis between a cyanobacterium (Nostoc sp.) and the ubiquitous feather moss, Pleurozium schreberi (Bird) Mitt. that alone fixes between 1.5 and 2.0 kg N ha(-1) yr(-1) in mid- to late-successional forests of northern Scandinavia and Finland. Previous efforts have probably underestimated N-fixation potential in boreal forests.	Univ Montana, Sch Forestry, Missoula, MT 59812 USA; Swedish Univ Agr Sci, Dept Forest Vegetat Ecol, SE-90183 Umea, Sweden; Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, SE-90187 Umea, Sweden	University of Montana System; University of Montana; Swedish University of Agricultural Sciences; Umea University	DeLuca, TH (corresponding author), Univ Montana, Sch Forestry, Missoula, MT 59812 USA.		Hegethorn, Marie-Charlotte Nilsson/B-1802-2017; DeLuca, Thomas/GYU-3468-2022; DeLuca, Thomas Henry/B-4547-2012	Hegethorn, Marie-Charlotte Nilsson/0000-0002-9254-2223; DeLuca, Thomas Henry/0000-0003-1561-9597; Sellstedt, Anita/0000-0002-0536-903X				Alexander V., 1986, FOREST ECOSYSETMS AL, P112; Binkley D, 2000, ECOSYSTEMS, V3, P321, DOI 10.1007/s100210000029; CHAPIN DM, 1991, CAN J BOT, V69, P2744, DOI 10.1139/b91-345; CHAPIN FS, 1986, AM NAT, V127, P48, DOI 10.1086/284466; CHRISTIE P, 1987, J ECOL, V75, P73, DOI 10.2307/2260537; Cleve K. Van, 1981, Ecological Bulletins, P375; Cleveland CC, 1999, GLOBAL BIOGEOCHEM CY, V13, P623, DOI 10.1029/1999GB900014; DELUCA TH, 2002, OECOLOGIA ADV O 0828; FOSTER DR, 1985, J ECOL, V73, P517, DOI 10.2307/2260491; GRANHALL U, 1973, OIKOS, V24, P8, DOI 10.2307/3543247; Hagglund B., 1977, Studia Forestalia Suecica; Kuc M, 1997, CAN FIELD NAT, V111, P630; Longton Royce E., 1992, P32; Mattsson U, 2000, CAN J MICROBIOL, V46, P1091, DOI 10.1139/cjm-46-12-1091; MELKONEN E, 1974, COMM I FOR FENN, V84, P1; Oechel W, 1986, FOREST ECOSYSTEMS AL, P121; PANDEY KD, 1992, ISRAEL J BOT, V41, P187; Rai AN, 2000, NEW PHYTOL, V147, P449, DOI 10.1046/j.1469-8137.2000.00720.x; Rastetter EB, 2001, ECOSYSTEMS, V4, P369, DOI 10.1007/s10021-001-0018-z; REDDY GB, 1981, SOIL BIOL BIOCHEM, V13, P537, DOI 10.1016/0038-0717(81)90047-X; ROSEN K, 1980, HOLARCTIC ECOL, V3, P137; SHUGART R, 1992, SYSTEM ANAL GLOBAL B, P565; Tamm C.O., 1991, NITROGEN TERRESTRIAL, P34, DOI DOI 10.1007/978-3-642-75168-4_3; Vitousek PM, 2000, ECOLOGY, V81, P2366, DOI 10.1890/0012-9658(2000)081[2366:HNFIDL]2.0.CO;2; Vogel JG, 1998, ECOSYSTEMS, V1, P386, DOI 10.1007/s100219900032; Walter H, 1989, ECOLOGICAL SYSTEMS G, DOI DOI 10.1007/978-3-642-70160-3; Wardle DA, 1997, SCIENCE, V277, P1296, DOI 10.1126/science.277.5330.1296; WEAVER RW, 1994, METHODS SOIL ANAL 2, P985; Whitehead D, 2001, TREE PHYSIOL, V21, P925, DOI 10.1093/treephys/21.12-13.925	29	389	405	5	228	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					917	920		10.1038/nature01051	http://dx.doi.org/10.1038/nature01051			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410308				2022-12-28	WOS:000178909700041
J	Turpie, AGG; Chin, BSP; Lip, GYH				Turpie, AGG; Chin, BSP; Lip, GYH			ABC of antithrombotic therapy - Venous thromboembolism: treatment strategies	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PULMONARY-EMBOLISM		McMaster Univ, Hamilton, ON, Canada; City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England	McMaster University; University of Birmingham	Turpie, AGG (corresponding author), McMaster Univ, Hamilton, ON, Canada.							Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Heit JA, 2002, ARCH INTERN MED, V162, P1245, DOI 10.1001/archinte.162.11.1245; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Walker ID, 2001, BRIT J HAEMATOL, V114, P512, DOI 10.1046/j.1365-2141.2001.02981.x	5	32	33	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 26	2002	325	7370					948	950		10.1136/bmj.325.7370.948	http://dx.doi.org/10.1136/bmj.325.7370.948			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399348	Green Published			2022-12-28	WOS:000178986300021
J	Cyranoski, D				Cyranoski, D			Marie Curie doesn't live here, Japanese women say	NATURE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					768	768		10.1038/419768b	http://dx.doi.org/10.1038/419768b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397318	Bronze			2022-12-28	WOS:000178769800008
J	Jiang, KL; Li, QQ; Fan, SS				Jiang, KL; Li, QQ; Fan, SS			Nanotechnology: Spinning continuous carbon nanotube yarns - Carbon nanotubes weave their way into a range of imaginative macroscopic applications.	NATURE			English	Article							ARRAYS		Tsing Hua Univ, Dept Phys, Beijing 100084, Peoples R China; Tsing Hua Univ, Tsinghua Foxconn Nanotechnol Res Ctr, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University	Jiang, KL (corresponding author), Tsing Hua Univ, Dept Phys, Beijing 100084, Peoples R China.		Li, Qunqing/O-2254-2014; Jiang, Kaili/G-8154-2018; Funde, Adinath M./D-8169-2012	Li, Qunqing/0000-0001-9565-0855; Jiang, Kaili/0000-0002-1547-5848; 				Ball P, 2001, NATURE, V414, P142, DOI 10.1038/35102721; DEHEER WA, 1995, SCIENCE, V268, P845, DOI 10.1126/science.268.5212.845; Fan SS, 1999, SCIENCE, V283, P512, DOI 10.1126/science.283.5401.512; Li WZ, 1996, SCIENCE, V274, P1701, DOI 10.1126/science.274.5293.1701; Li ZM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.127401; Ren ZF, 1998, SCIENCE, V282, P1105, DOI 10.1126/science.282.5391.1105; Vigolo B, 2000, SCIENCE, V290, P1331, DOI 10.1126/science.290.5495.1331; Wang JF, 2001, SCIENCE, V293, P1455, DOI 10.1126/science.1062340	8	924	1040	23	674	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					801	801		10.1038/419801a	http://dx.doi.org/10.1038/419801a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397346	Bronze			2022-12-28	WOS:000178769800034
J	Nathan, DG; Weatherall, DJ				Nathan, DG; Weatherall, DJ			Academic freedom in clinical research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IRON-CHELATION-THERAPY; ORAL DEFERIPRONE; THALASSEMIA; DEFEROXAMINE; TOXICITY; OVERLOAD		Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Oxford, Oxford OX3 9DS, England	Harvard University; Dana-Farber Cancer Institute; University of Oxford	Nathan, DG (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.				NHLBI NIH HHS [HL54785-07] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 2001, NATURE, V409, P119; BERDOUKAS V, 1993, LANCET, V341, P1088, DOI 10.1016/0140-6736(93)92443-W; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; CHOUDHURY R, 1995, DRUG METAB DISPOS, V23, P314; CRANTON J, 2001, COMMUNICATION   1219; Davidoff F, 1999, ANN INTERN MED, V130, P246; Davidoff F, 2001, NEW ENGL J MED, V345, P825, DOI 10.1056/NEJMed20010093; Del Vecchio GC, 2000, ACTA HAEMATOL-BASEL, V104, P99, DOI 10.1159/000039759; HIDER RC, 1990, ANN NY ACAD SCI, V612, P327; Hoffbrand AV, 1998, BLOOD, V91, P295, DOI 10.1182/blood.V91.1.295.295_295_300; Kern DG, 1999, ANN INTERN MED, V130, P246; KONTOGHIORGHES GJ, 1987, BRIT MED J, V295, P1509, DOI 10.1136/bmj.295.6612.1509; Kowdley KV, 1998, NEW ENGL J MED, V339, P468, DOI 10.1056/NEJM199808133390709; LETSKY EA, 1974, J CLIN PATHOL, V27, P652, DOI 10.1136/jcp.27.8.652; Mazza P, 1998, HAEMATOLOGICA, V83, P496; NAIMARK A, 1998, CLIN TRIAL L1 DEFERI; NATHAN DG, 1995, NEW ENGL J MED, V332, P1315; Naylor CD, 2002, CAN MED ASSOC J, V166, P452; Olivieri N. F., 1996, Blood, V88, p310A; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; Olivieri NF, 1998, NEW ENGL J MED, V339, P417, DOI 10.1056/NEJM199808133390701; OLIVIERI NF, 1995, NEW ENGL J MED, V332, P918, DOI 10.1056/NEJM199504063321404; Pippard MJ, 2000, BRIT J HAEMATOL, V111, P2, DOI 10.1046/j.1365-2141.2000.02406.x; Porter JB, 2001, BRIT J HAEMATOL, V115, P239, DOI 10.1046/j.1365-2141.2001.03195.x; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1762; SINGH S, 1992, DRUG METAB DISPOS, V20, P256; Somerville MA, 2002, NAT REV DRUG DISCOV, V1, P316, DOI 10.1038/nrd773; Thompson J., 2001, REPORT COMMITTEE INQ; Tondury P, 1998, BRIT J HAEMATOL, V101, P413, DOI 10.1046/j.1365-2141.1998.00725.x; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503	30	60	60	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1368	1371		10.1056/NEJMsb020394	http://dx.doi.org/10.1056/NEJMsb020394			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397199				2022-12-28	WOS:000178781300013
J	Shamim, W; Yousufuddin, M; Wang, D; Henein, M; Seggewiss, H; Flather, M; Coats, AJS; Sigwart, U				Shamim, W; Yousufuddin, M; Wang, D; Henein, M; Seggewiss, H; Flather, M; Coats, AJS; Sigwart, U			RETRACTED: Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy (Retracted article. See vol 348, pg 951, 2003)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Retracted Publication							ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR HYPERTROPHY; OBSTRUCTIVE CARDIOMYOPATHY; LONG-TERM; MAJOR DETERMINANT; HEART-FAILURE; DOUBLE-BLIND; FOLLOW-UP; ABLATION; THERAPY	Background: In patients with hypertrophic cardiomyopathy and obstruction of the left ventricular outflow tract, nonsurgical reduction of the septum is a treatment option when medical therapy has failed. We investigated the long-term effects of nonsurgical reduction of the septum on functional capacity and electrocardiographic and echocardiographic characteristics. Methods: Sixty-four consecutive patients with hypertrophic cardiomyopathy and a mean (+/-SD) age of 48.5+/-17.2 years underwent nonsurgical reduction of the septum by injection of ethanol into the septal perforator branch of the left anterior descending coronary artery. These patients were assessed by exercise testing, electrocardiography, and resting and dobutamine (stress-induced) echocardiography after a mean period of 3.0+/-1.3 years. Results: At follow-up, patients had significant improvements in New York Heart Association class, peak oxygen consumption (from 18.4+/-5.8 to 30.0+/-4.4 ml per kilogram of body weight per minute, P<0.001), and left ventricular outflow tract gradients (resting gradient, from 64+/-36 to 16+/-15 mm Hg; P<0.001; stress-induced gradient, from 132+/-34 to 45+/-19 mm Hg; P<0.001). Procedure-related complications included right bundle-branch block in all patients, complete heart block in 31 patients (48 percent), and significant increases in QRS and corrected QT intervals. Seventeen patients (27 percent) required permanent pacing. R-wave amplitude was significantly decreased (from 32+/-8 to 17+/-7 mV, P<0.001). The dimensions of the left ventricular cavity increased, and the interventricular septal thickness was reduced. Conclusions: Nonsurgical septal reduction leads to sustained improvements in both subjective and objective measures of exercise capacity in association with a persistent reduction in resting and stress-induced left ventricular outflow tract gradients. It is also associated with a high incidence of procedure-related complete heart block, however, often requiring permanent pacing.	Cleveland Clin Fdn, Dept Cardiovasc Med, Kaufman Ctr Heart Failure & Transplantat, Cleveland, OH 44195 USA; Univ London Imperial Coll Sci Technol & Med, Royal Brompton & Harefield Hosp, Natl Heart & Lung Inst, London, England; London Sch Hyg & Trop Med, London WC1, England; Ruhr Univ Bochum, Univ Hosp, Bad Oeynhausen, Germany	Cleveland Clinic Foundation; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton Hospital; University of London; London School of Hygiene & Tropical Medicine; Ruhr University Bochum	Yousufuddin, M (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, Kaufman Ctr Heart Failure & Transplantat, F-25,9500 Euclid Ave, Cleveland, OH 44195 USA.		Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				ASSMANN I, 1990, ACTA CARDIOL, V45, P501; BRAUNWALD E, 1991, AM J CARDIOL, V68, pD1; Brilakis ES, 2002, AM J CARDIOL, V89, P1013, DOI 10.1016/S0002-9149(02)02267-1; BROCKENBROUGH EC, 1960, AM J CARDIOL, V6, P1062, DOI 10.1016/0002-9149(60)90361-1; BRUCE R A, 1963, Pediatrics, V32, P742; CANNON RO, 1989, CIRCULATION, V79, P766, DOI 10.1161/01.CIR.79.4.766; DAVIES NJH, 1979, RESP PHYSIOL, V36, P261, DOI 10.1016/0034-5687(79)90029-X; Faber L, 1998, CIRCULATION, V98, P2415, DOI 10.1161/01.CIR.98.22.2415; FANANAPAZIR L, 1992, CIRCULATION, V85, P2149, DOI 10.1161/01.CIR.85.6.2149; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; GOODWIN JF, 1960, BRIT HEART J, V22, P403; HUTCHINS GM, 1978, AM J CARDIOL, V41, P1127, DOI 10.1016/0002-9149(78)90869-X; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; KATZ AM, 1990, NEW ENGL J MED, V322, P100; Knight C, 1997, CIRCULATION, V95, P2075, DOI 10.1161/01.CIR.95.8.2075; Kuhn H, 1999, EUR HEART J, V20, P1808, DOI 10.1053/euhj.1999.1692; LINDEEDELSTAM C, 1992, PACE, V15, P1467, DOI 10.1111/j.1540-8159.1992.tb02920.x; Mann C, 1999, PEDIATR CARDIOL, V20, P229, DOI 10.1007/s002469900450; Maron BJ, 1999, CIRCULATION, V99, P2927, DOI 10.1161/01.CIR.99.22.2927; Maron BJ, 2000, LANCET, V355, P425, DOI 10.1016/S0140-6736(00)82005-X; Mazur W, 2001, CIRCULATION, V103, P1492; MCDONALD K, 1988, EUR HEART J, V9, P893, DOI 10.1093/oxfordjournals.eurheartj.a062584; MORROW AG, 1959, CIRCULATION, V20, P181, DOI 10.1161/01.CIR.20.2.181; Nagueh SF, 2001, J AM COLL CARDIOL, V38, P1701, DOI 10.1016/S0735-1097(01)01614-X; NOLAN SE, 1988, J AM COLL CARDIOL, V12, P1318, DOI 10.1016/0735-1097(88)92616-2; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; PFEFFER MA, 1995, ANNU REV MED, V46, P455, DOI 10.1146/annurev.med.46.1.455; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SCHOENDUBE FA, 1995, CIRCULATION, V92, P122, DOI 10.1161/01.CIR.92.9.122; Seggewiss H, 1998, J AM COLL CARDIOL, V31, P252, DOI 10.1016/S0735-1097(97)00508-1; SHERRID M, 1988, AM J CARDIOL, V62, P1085, DOI 10.1016/0002-9149(88)90553-X; SIGWART U, 1995, LANCET, V346, P211, DOI 10.1016/S0140-6736(95)91267-3; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; VOLTERRANI M, 1994, EUR HEART J, V15, P801, DOI 10.1093/oxfordjournals.eurheartj.a060588; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WIGLE ED, 1969, AM J CARDIOL, V24, P698, DOI 10.1016/0002-9149(69)90457-3	36	33	38	0	14	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1326	1333		10.1056/NEJMoa012710	http://dx.doi.org/10.1056/NEJMoa012710			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397190	Bronze			2022-12-28	WOS:000178781300004
J	Goldacre, MJ; Roberts, SE; Yeates, D				Goldacre, MJ; Roberts, SE; Yeates, D			Mortality after admission to hospital with fractured neck of femur: database study	BRITISH MEDICAL JOURNAL			English	Article							HIP-FRACTURES		Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.							BOEREBOOM FTJ, 1992, NETH J MED, V41, P4; GOLDACRE MJ, 1993, J EPIDEMIOL COMMUN H, V47, P491, DOI 10.1136/jech.47.6.491; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; NHS Executive, 1999, QUAL PERF NHS CLIN I, P30; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904	5	133	134	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 19	2002	325	7369					868	869		10.1136/bmj.325.7369.868	http://dx.doi.org/10.1136/bmj.325.7369.868			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386038	Bronze, Green Published			2022-12-28	WOS:000178793000020
J	Gray, A; Clarke, P; Farmer, A; Holman, R				Gray, A; Clarke, P; Farmer, A; Holman, R		UKPDS Grp	Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63)	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; JOB STRAIN; DECISION LATITUDE; RISK-FACTORS; SWEDISH MEN; WORK STRESS; MELLITUS; HEALTH; WOMEN	Objective To estimate the incremental cost of implementing policies for more intensive control of blood glucose concentration and blood pressure for all patients with type 2 diabetes in England. Design Extrapolation of resource use and cost data derived from a randomised controlled trial. Setting General practice, outpatient care, and inpatient care. Population Trial population with diagnosed type 2 diabetes in England extrapolated to the population of England. Main outcome measures Total costs based on use of healthcare resources including costs of management, treatment, and hospitalisation. Results The incremental net annual cost of implementing more intensive control of blood glucose and blood pressure to all people with diagnosed type 2 diabetes in England is estimated to be pound100.5m ($156m; is not an element of159m), which is equivalent to less than 1% of the proposed additional annual expenditure on the NHS in 2001-5. This estimate varied in sensitivity analyses from pound67m to pound121m. Conclusions Policies to improve control of blood glucose and blood pressure of people with type 2 diabetes are effective in reducing complications associated with the disease and are also cost effective. The total cost represents a small fraction of the NHS's spending plans.	Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX1 2JD, England; Univ Oxford, Nuffield Dept Clin Med, Diabet Trials Unit, Oxford OX2 6HE, England; Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Hlth Econ Res Ctr, Oxford OX3 7LF, England	University of Oxford; University of Oxford; University of Oxford	Gray, A (corresponding author), Radcliffe Infirm, Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, UKPDS Grp, Oxford OX2 6HE, England.			Clarke, Philip/0000-0002-7555-5348	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTERMAN T, 1994, AM J EPIDEMIOL, V139, P620, DOI 10.1093/oxfordjournals.aje.a117051; Audit Commission, 2000, TEST TIM REV DIAB SE; BLACK DAK, 1975, BRIT J PREV SOC MED, V29, P222; Bosma H, 1998, AM J PUBLIC HEALTH, V88, P68, DOI 10.2105/AJPH.88.1.68; *BRIT MED ASS ROYA, 1999, BRIT NAT FORM; Cheng YW, 2000, BRIT MED J, V320, P1432, DOI 10.1136/bmj.320.7247.1432; Clarke P, 2001, DIABETOLOGIA, V44, P298, DOI 10.1007/s001250051617; Claxton K, 1996, HEALTH ECON, V5, P513, DOI 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Gray A, 1995, DIABETIC MED, V12, P1068, DOI 10.1111/j.1464-5491.1995.tb00423.x; Gray A, 2000, BMJ-BRIT MED J, V320, P1373, DOI 10.1136/bmj.320.7246.1373; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; Hemingway H, 1999, BMJ-BRIT MED J, V318, P1460, DOI 10.1136/bmj.318.7196.1460; *HER MAJ TREAS, 2002, STRENGTH MAK LONG TE; HIGGS ER, 1992, DIABETIC MED, V9, P550, DOI 10.1111/j.1464-5491.1992.tb01837.x; *HLTH SURV, 2000, HLTH SURV ENGL HLTH; *HLTH SURV, 1999, HLTH SURV ENGL CARD; Karasek R, 1990, STRESS PRODUCTIVITY; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; Khunti K, 2001, BRIT J GEN PRACT, V51, P356; Khunti K, 1999, BRIT J GEN PRACT, V49, P375; LEINO PI, 1993, SPINE, V18, P863, DOI 10.1097/00007632-199306000-00009; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Lynch J, 1997, AM J PUBLIC HEALTH, V87, P617, DOI 10.2105/AJPH.87.4.617; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; *METELI, 1975, 9 METELI RES I PHYS; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; National Institute for Clinical Excellence, 2001, TECHN GUID MAN SPONS; Netten A, 1999, UNIT COSTS HLTH SOCI; Peter R, 1998, J EPIDEMIOL COMMUN H, V52, P540, DOI 10.1136/jech.52.9.540; REED DM, 1989, AM J EPIDEMIOL, V129, P495, DOI 10.1093/oxfordjournals.aje.a115160; SCHNALL PL, 1994, ANNU REV PUBL HEALTH, V15, P381, DOI 10.1146/annurev.pu.15.050194.002121; Siegrist J, 1996, J Occup Health Psychol, V1, P27, DOI 10.1037/1076-8998.1.1.27; Sokejima S, 1998, BRIT MED J, V317, P775, DOI 10.1136/bmj.317.7161.775; Songer TJ, 1998, STUDIES COST DIABETE; Stearne MR, 1998, BMJ-BRIT MED J, V317, P720; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Steenland K, 1997, AM J IND MED, V31, P256, DOI 10.1002/(SICI)1097-0274(199702)31:2<256::AID-AJIM16>3.0.CO;2-0; SUADICANI P, 1993, ATHEROSCLEROSIS, V101, P165, DOI 10.1016/0021-9150(93)90113-9; *T2ARDIS STEER COM, 2000, T2ARDIS IMPL SEAML C; Theorell T, 1996, J Occup Health Psychol, V1, P9, DOI 10.1037/1076-8998.1.1.9; Theorell T, 1998, AM J PUBLIC HEALTH, V88, P382, DOI 10.2105/AJPH.88.3.382; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Unwin N, 1998, DIABETIC MED, V15, P554, DOI 10.1002/(SICI)1096-9136(199807)15:7<554::AID-DIA626>3.0.CO;2-E; Vrijkotte TGM, 1999, PSYCHOSOM MED, V61, P796, DOI 10.1097/00006842-199911000-00012; Vrijkotte TGM, 2000, HYPERTENSION, V35, P880, DOI 10.1161/01.HYP.35.4.880; WINOCOUR PH, 2001, SURVEY SECONDARY CAR	50	56	58	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 19	2002	325	7369					860	863		10.1136/bmj.325.7369.860	http://dx.doi.org/10.1136/bmj.325.7369.860			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386035	Green Published, Bronze			2022-12-28	WOS:000178793000017
J	Vermund, SH; Wilson, CM				Vermund, SH; Wilson, CM			Barriers to HIV testing - where next?	LANCET			English	Editorial Material							ADOLESCENTS; ACCESS; WOMEN; CARE; CITY		Univ Alabama, Div Geog Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama, Dept Epidemiol & Int Hlth, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wilson, CM (corresponding author), Univ Alabama, Div Geog Med, Birmingham, AL 35294 USA.		Vermund, Sten/AAD-3592-2020	Vermund, Sten/0000-0001-7289-8698; Wilson, Craig/0000-0001-6869-1053				Allen S., 1999, PREVENTING HIV DEV C, P87; Coovadia HM, 2000, ANN NY ACAD SCI, V918, P57; Futterman DC, 2001, J ADOLESCENT HEALTH, V29, P19, DOI 10.1016/S1054-139X(01)00290-7; Gupta GR, 2002, BRIT MED J, V324, P183, DOI 10.1136/bmj.324.7331.183; Inungu JN, 2002, AIDS PATIENT CARE ST, V16, P293, DOI 10.1089/10872910260066723; Jemmott JB, 1998, JAMA-J AM MED ASSOC, V279, P1529, DOI 10.1001/jama.279.19.1529; Kawichai S, 2002, J ACQ IMMUN DEF SYND, V30, P493, DOI 10.1097/00126334-200208150-00005; Kopelman LM, 2002, J MED PHILOS, V27, P231, DOI 10.1076/jmep.27.2.231.2987; Murphy DA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e36; NICHOLS SA, IN PRESS AM J MED SC; Royce RA, 2001, AM J PUBLIC HEALTH, V91, P727, DOI 10.2105/AJPH.91.5.727; SCHOENBAUM EE, 1993, AM J PUBLIC HEALTH, V83, P363, DOI 10.2105/AJPH.83.3.363; STOTO MA, 1998, REDUCING ODDS PREVEN; Stringer EM, 2001, OBSTET GYNECOL, V98, P1104, DOI 10.1016/S0029-7844(01)01631-3; Stringer JSA, 1999, J ACQ IMMUN DEF SYND, V21, P217, DOI 10.1097/00126334-199907010-00006; Webber MP, 2001, AM J PERINAT, V18, P49, DOI 10.1055/s-2001-12941	16	55	57	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1186	1187		10.1016/S0140-6736(02)11291-8	http://dx.doi.org/10.1016/S0140-6736(02)11291-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	605ZZ	12401241				2022-12-28	WOS:000178708100004
J	Walshe, K; Higgins, J				Walshe, K; Higgins, J			The use and impact of inquiries in the NHS	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Manchester Ctr Healthcare Management, Manchester M13 9PL, Lancs, England	University of Manchester	Walshe, K (corresponding author), Univ Manchester, Manchester Ctr Healthcare Management, Manchester M13 9PL, Lancs, England.			Walshe, Kieran/0000-0002-0696-480X				*CAB OFF CENTR SEC, 2001, GUID INQ; CLARKE LJ, 2000, THAMES SAFETY INQUIR; *COMM HLTH IMPR, 2000, INV N LAK NHS TRUST; *COUNC TRIB, 1997, CMND3744; *DEP HLTH, 1999, REP COMM INQ PERS DI; *DEP HLTH, 2001, ROYAL LIV CHILDR INQ; *DEP HLTH, 2000, INQ QUAL PRACT NAT H; *DEP HLTH, 2001, MOD REG HLTH PROF CO; *DEP HLTH, 1994, ALL INQ IND INQ REL; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; *DEP HTLH, 2001, LEARN BRIST REP PUBL; Department of Health, 2001, BUILD SAF NHS PAT; Department of Health, 1999, SUPP DOCT PROT PAT; Department of Health and Social Security, 1986, REP COMM INQ OUTBR F; Department of Health and Social Security, 1969, REP COMM INQ ALL ILL; GRANT H, 2001, PUBLIC LAW       SUM, P377; Higgins J., 2001, HLTH SERV J, V111, P22; Howe G, 1999, POLIT QUART, V70, P294, DOI 10.1111/1467-923X.00232; Maclean M, 2001, J LAW SOC, V28, P590, DOI 10.1111/1467-6478.00204; MARTIN J, 1984, HOSP TROUBLE; Miles M., 2013, QUALITATIVE DATA ANA; *NE THAM REG HLTH, 1994, REP INQ CAR TREATM C; *NHS EX, 2000, REP REV RES FRAM N S; NOYES P, 1991, CHILD ABUSE STUDY IN; Salmon C.B, 1966, ROYAL COMMISSION TRI; Scott Richard, 1995, LAW Q REV, V111, P596; Sedley S., 1989, MOD LAW REV, V52, P469; Smith R, 2000, BRIT MED J, V321, P715, DOI 10.1136/bmj.321.7263.715; WINETROBE BK, 1997, PUBLIC LAW, P18; Yin RK, 1999, HEALTH SERV RES, V34, P1209; YIN RK, 1993, CASE STUDY RES DESIG	31	51	51	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 19	2002	325	7369					895	900		10.1136/bmj.325.7369.895	http://dx.doi.org/10.1136/bmj.325.7369.895			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386046	Green Published			2022-12-28	WOS:000178793000029
J	Seidenberg, MS; MacDonald, MC; Saffran, JR				Seidenberg, MS; MacDonald, MC; Saffran, JR			Does grammar start where statistics stop?	SCIENCE			English	Editorial Material							LANGUAGE-ACQUISITION; CONSTRAINTS		Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Seidenberg, MS (corresponding author), Univ Wisconsin, Dept Psychol, 1202 W Johnson St, Madison, WI 53706 USA.	marks@lcnl.wisc.edu						Allen J, 1999, CARN S COGN, P115; Altmann G. T. M., 1999, SCIENCE, V284, P875, DOI DOI 10.1126/SCIENCE.284.5416.875A; Aslin RN, 1999, CARN S COGN, P359; Chomsky N., 2002, JANUA LINGUARUM; Christiansen MH, 1997, PROCEEDINGS OF THE NINETEENTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P113; CLEEREMANS A, 1991, J EXP PSYCHOL GEN, V120, P235, DOI 10.1037/0096-3445.120.3.235; Gomez R. L., 2001, LANGUAGE DEV; Hunt RH, 2001, J EXP PSYCHOL GEN, V130, P658, DOI 10.1037//0096-3445.130.4.658; Johnstone T, 1999, J EXP PSYCHOL LEARN, V25, P524, DOI 10.1037/0278-7393.25.2.524; Marcus GF, 1999, SCIENCE, V283, P77, DOI 10.1126/science.283.5398.77; Meulemans T, 1997, J EXP PSYCHOL LEARN, V23, P1007; MORGAN J, 1995, SIGNAL TO SYNTAX; Newport EL, 2000, PROC ANN BUCLD, P1; Pena M, 2002, SCIENCE, V298, P604, DOI 10.1126/science.1072901; Saffran JR, 2002, J MEM LANG, V47, P172, DOI 10.1006/jmla.2001.2839; Seidenberg MS, 1997, SCIENCE, V275, P1599, DOI 10.1126/science.275.5306.1599; Seidenberg MS, 1999, COGNITIVE SCI, V23, P569, DOI 10.1207/s15516709cog2304_8; Seidenberg MS, 1999, SCIENCE, V284, P434; Thornton, 1998, INVESTIGATIONS UNIVE	19	62	63	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	2002	298	5593					553	554		10.1126/science.1078094	http://dx.doi.org/10.1126/science.1078094			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	604RL	12386323				2022-12-28	WOS:000178634800028
J	Wetherbee, R				Wetherbee, R			The diatom glasshouse	SCIENCE			English	Editorial Material							CYLINDROTHECA-FUSIFORMIS; SILICA; PEPTIDES		Univ Melbourne, Sch Bot, Parkville, Vic 3010, Australia	University of Melbourne	Wetherbee, R (corresponding author), Univ Melbourne, Sch Bot, Parkville, Vic 3010, Australia.		Wetherbee, Richard/ABA-6881-2020					Crawford CG, 2001, J AM WATER RESOUR AS, V37, P1, DOI 10.1111/j.1752-1688.2001.tb05470.x; Kroger N, 1999, SCIENCE, V286, P1129, DOI 10.1126/science.286.5442.1129; Kroger N, 2000, P NATL ACAD SCI USA, V97, P14133, DOI 10.1073/pnas.260496497; Kroger N, 2002, SCIENCE, V298, P584, DOI 10.1126/science.1076221; Kroger N, 2000, PROTIST, V151, P263, DOI 10.1078/1434-4610-00024; Kroger N, 2001, J BIOL CHEM, V276, P26066, DOI 10.1074/jbc.M102093200; Pickett-Heaps J., 1990, PROGR PHYCOLOGICAL R, V7, P1; SCHMID AMM, 1979, PROTOPLASMA, V100, P267, DOI 10.1007/BF01279316; Sumper M, 2002, SCIENCE, V295, P2430, DOI 10.1126/science.1070026; van de Poll WH, 1999, J PHYCOL, V35, P1044	10	45	45	3	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					547	547		10.1126/science.1078222	http://dx.doi.org/10.1126/science.1078222			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386319				2022-12-28	WOS:000178634800024
J	Sawamura, M; Kawai, K; Matsuo, Y; Kanie, K; Kato, T; Nakamura, E				Sawamura, M; Kawai, K; Matsuo, Y; Kanie, K; Kato, T; Nakamura, E			Stacking of conical molecules with a fullerene apex into polar columns in crystals and liquid crystals	NATURE			English	Article							SUPRAMOLECULAR COMPLEX; CONE; ORGANIZATION; BEHAVIOR; C-60; BOWL; 1ST	Polar liquid crystalline materials can be used in optical and electronic applications, and recent interest has turned to formation strategies that exploit the shape of polar molecules and their interactions to direct molecular alignment(1,2). For example, banana-shaped molecules align their molecular bent within smectic layers(3), whereas conical molecules should form polar columnar assemblies(4-9). However, the flatness of the conical molecules used until now(4-6,9) and their ability to flip(7,8) have limited the success of this approach to making polar liquid crystalline materials. Here we show that the attachment of five aromatic groups to one pentagon of a C-60 fullerene molecule yields deeply conical molecules that stack into polar columnar assemblies. The stacking is driven by attractive interactions between the spherical fullerene moiety and the hollow cone formed by the five aromatic side groups of a neighbouring molecule in the same column. This packing pattern is maintained when we extend the aromatic groups by attaching flexible aliphatic chains, which yields compounds with thermotropic and lyotropic liquid crystalline properties. In contrast, the previously reported fullerene-containing liquid crystals(10-17) all exhibit thermotropic properties only, and none of them contains the fullerene moiety as a functional part of its mesogen units. Our design strategy should be applicable to other molecules and yield a range of new polar liquid crystalline materials.	Univ Tokyo, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo; University of Tokyo	Nakamura, E (corresponding author), Univ Tokyo, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan.	nakamura@chem.s.u-tokyo.ac.jp	KIYOSHI, KANIE/F-6660-2014; NAKAMURA, EIICHI/G-5041-2014; Kato, Takashi/Q-8050-2016; Matsuo, Yutaka/C-9897-2011; Sawamura, Masaya/G-1428-2012	KIYOSHI, KANIE/0000-0003-1477-6515; Kato, Takashi/0000-0002-0571-0883; Matsuo, Yutaka/0000-0001-9084-9670; 				Chuard T, 1999, CHEM COMMUN, P2103, DOI 10.1039/a905058b; Chuard T, 2002, J MATER CHEM, V12, P1944, DOI 10.1039/b201353n; Chuard T, 1996, HELV CHIM ACTA, V79, P736, DOI 10.1002/hlca.19960790316; COMETTI G, 1990, J CHEM SOC CHEM COMM, P163, DOI 10.1039/c39900000163; Dardel B, 2001, J MATER CHEM, V11, P2814, DOI 10.1039/b103798f; Felder D, 2000, CHEM-EUR J, V6, P3501, DOI 10.1002/1521-3765(20001002)6:19<3501::AID-CHEM3501>3.0.CO;2-0; Georgakilas V, 2002, P NATL ACAD SCI USA, V99, P5075, DOI 10.1073/pnas.072006599; Guillon D, 2000, ADV CHEM PHYS, V113, P1, DOI 10.1002/9780470141724.ch1; Iikura H, 1997, J ORG CHEM, V62, P7912, DOI 10.1021/jo971025s; Kang SH, 1999, CHEM COMMUN, P1661, DOI 10.1039/a904254g; Kato T, 2002, SCIENCE, V295, P2414, DOI 10.1126/science.1070967; Kimura M, 2002, J AM CHEM SOC, V124, P5274, DOI 10.1021/ja012614p; KOMORI T, 1993, CHEM LETT, P1455, DOI 10.1246/cl.1993.1455; MALTHETE J, 1985, NOUV J CHIM, V9, P151; MALTHETE J, 1987, J AM CHEM SOC, V109, P7544, DOI 10.1021/ja00258a057; Manners I, 2001, SCIENCE, V294, P1664, DOI 10.1126/science.1066321; Niori T, 1996, J MATER CHEM, V6, P1231, DOI 10.1039/jm9960601231; RUOFF RS, 1993, J PHYS CHEM-US, V97, P3379, DOI 10.1021/j100115a049; Sawamura M, 1996, J AM CHEM SOC, V118, P12850, DOI 10.1021/ja962681x; Sawamura M, 2000, J AM CHEM SOC, V122, P12407, DOI 10.1021/ja005564h; Sawamura M, 2002, J AM CHEM SOC, V124, P9354, DOI 10.1021/ja026069j; Suzuki M, 2001, MOL CRYST LIQ CRYST, V368, P3959; Tirelli N, 2000, J CHEM SOC PERK T 2, P193, DOI 10.1039/a907824j; Tschierske C, 1998, J MATER CHEM, V8, P1485, DOI 10.1039/a800946e; XU B, 1993, J AM CHEM SOC, V115, P1159, DOI 10.1021/ja00056a056	25	348	350	5	136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	2002	419	6908					702	705		10.1038/nature01110	http://dx.doi.org/10.1038/nature01110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	604JF	12384693				2022-12-28	WOS:000178615200035
J	McCarthy, M				McCarthy, M			A brief history of the World Health Organization	LANCET			English	Article																			0	12	13	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1111	1112		10.1016/S0140-6736(02)11244-X	http://dx.doi.org/10.1016/S0140-6736(02)11244-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387972				2022-12-28	WOS:000178632000003
J	Chintu, C; Mudenda, V; Lucas, S; Nunn, A; Lishimpi, K; Maswahu, D; Kasolo, F; Mwaba, P; Bhat, G; Terunuma, H; Zumla, A				Chintu, C; Mudenda, V; Lucas, S; Nunn, A; Lishimpi, K; Maswahu, D; Kasolo, F; Mwaba, P; Bhat, G; Terunuma, H; Zumla, A		UNZA-UCLMS Project Paediat Post-Mo	Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study	LANCET			English	Article							PNEUMOCYSTIS-CARINII-PNEUMONIA; IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-INFECTION; CLINICAL PRESENTATION; IMPACT; TUBERCULOSIS; ABIDJAN	Background Accurate information about specific causes of death in African children dying of respiratory illnesses is scarce, and can only be obtained by autopsy. We undertook a study of children who died from respiratory diseases at University Teaching Hospital, Lusaka, Zambia. Methods 137 boys (93 HIV-1-positive, 44 HIV-1-negative), and 127 girls (87 HIV-1-positive, 40 HIV-1-negative) aged between 1 month and younger than 16 years underwent autopsy restricted to the chest cavity. Outcome measures were specific lung diseases, stratified by age and HIV-1 status. Findings The presence of multiple diseases was common. Acute pyogenic pneumonia (population-adjusted prevalence 39.1%, 116/264), Pneumocystis carinii pneumonia (27.5%, 58/264), tuberculosis (18.8%, 54/264), and cytomegalovirus infection (CMV, 20.2%, 43/264) were the four most common findings overall. The three most frequent findings in the HIV-1-negative group were acute pyogenic pneumonia (50%), tuberculosis (26%), and interstitial pneumonitis (18%); and in the HIV-1-positive group were acute pyogenic pneumonia (41%), P carinii pneumonia (29%), and CMV (22%). HIV-1-positive children more frequently had P carinii pneumonia (odds ratio 5.28, 95% CI 2.12-15.68, p=0.0001), CMV (7.71, 2.33-40.0, p=0.0002), and shock lung (4-15, 1.20-22.10, p=0.03) than did HIV-1-negative children. 51/58 (88%) cases of P carinii pneumonia were in children younger than 12 months, and five in children aged over 24 months. Tuberculosis was common in all age groups, irrespective of HIV-1 status. Interpretation Most children dying from respiratory diseases have preventable or treatable infectious illnesses. The presence of multiple diseases might make diagnosis difficult. WHO recommendations should therefore be updated with mention of HIV-1-positive children. Improved diagnostic tests for bacterial pathogens, tuberculosis, and P carinii pneumonia are urgently needed.	Univ Zambia, Univ Coll London, Sch Med, Res & Training Project,Univ Teaching Hosp, Lusaka, Zambia; Univ Teaching Hosp, Dept Pathol, Lusaka, Zambia; Univ Teaching Hosp, Dept Paediat & Child Hlth, Lusaka, Zambia; Guys Kings & St Thomass Hosp, Sch Med, Dept Histopathol, London, England; Univ Teaching Hosp, JICA Project, Lusaka, Zambia; MRC, Clin Trials Unit, London, England; Royal Free & UCL, Sch Med, Ctr Infect Dis & Int Hlth, Dept Med, London W1T 4JF, England	University of Zambia; University of Zambia; University of Zambia; University of London; King's College London; University of Zambia; Medical Research Council Clinical Trials Unit; University of London; University College London; UCL Medical School	Zumla, A (corresponding author), UCL Windeyer Inst Med Sci, Ctr Infect Dis & Int Hlth, Room G41,46 Cleveland St, London W1T 4JF, England.	a.zumla@ucl.ac.uk	ZUMLA, Alimuddin/ABA-8208-2020; Mwaba, Peter/V-6017-2019	ZUMLA, Alimuddin/0000-0002-5111-5735; Nunn, Andrew/0000-0002-9158-4595				ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; Abrams EJ, 2001, PEDIATR INFECT DIS J, V20, P511, DOI 10.1097/00006454-200105000-00008; ANSARI NA, 1999, INT J TUBERC LUNG S1, V3, pS201; Beyers N, 1997, INT J TUBERC LUNG D, V1, P38; CARME B, 1991, T ROY SOC TROP MED H, V85, P80, DOI 10.1016/0035-9203(91)90167-W; Chintu C, 1995, J TROP PEDIATRICS, V41, P348, DOI 10.1093/tropej/41.6.348; CHINTU C, 1993, PEDIATR INFECT DIS J, V12, P499, DOI 10.1097/00006454-199306000-00008; CORNFIELD J, 1996, P 3 BERK S BERK, V4, P135; Dray-Spira R, 2000, AIDS, V14, P1091, DOI 10.1097/00002030-200006160-00005; Graham SM, 2000, LANCET, V355, P369, DOI 10.1016/S0140-6736(98)11074-7; Ikeogu MO, 1997, ARCH DIS CHILD, V76, P124, DOI 10.1136/adc.76.2.124; Jeena PM, 1996, ANN TROP PAEDIATR, V16, P361, DOI 10.1080/02724936.1996.11747852; Kamiya Y, 1997, ANN TROP PAEDIATR, V17, P121, DOI 10.1080/02724936.1997.11747874; Kiwanuka J, 2001, ANN TROP PAEDIATR, V21, P5, DOI 10.1080/02724930020028849; Lishimpi K, 2001, ARCH DIS CHILD, V84, P463, DOI 10.1136/adc.84.6.463; Lucas SB, 1996, BRIT MED J, V312, P335, DOI 10.1136/bmj.312.7027.335; Madhi SA, 2000, CLIN INFECT DIS, V31, P170, DOI 10.1086/313925; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MUGANGA N, 1991, PEDIATRIE, V46, P825; Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011; Nathoo KJ, 2001, T ROY SOC TROP MED H, V95, P37, DOI 10.1016/S0035-9203(01)90325-6; Pillay K, 2001, ARCH DIS CHILD, V85, P50, DOI 10.1136/adc.85.1.50; SASSANMOROKRO M, 1994, T ROY SOC TROP MED H, V88, P178, DOI 10.1016/0035-9203(94)90285-2; Smyth A, 1997, ARCH DIS CHILD, V77, P227, DOI 10.1136/adc.77.3.227; Taha T E, 2000, Pediatrics, V106, pE77, DOI 10.1542/peds.106.6.e77; THIJS A, 1963, Trop Geogr Med, V15, P158; *UNAIDS, US COTR PROPH AD CHI; *UNAIDS WHO, AIDS EP UPD 2001; Vetter KM, 1996, PEDIATR INFECT DIS J, V15, P438, DOI 10.1097/00006454-199605000-00011; *WHO UNICEF, 1999, WHOCHSCAH98IDREV1 WH; Zar HJ, 2000, PEDIATR INFECT DIS J, V19, P603, DOI 10.1097/00006454-200007000-00004; Zar HJ, 2001, ACTA PAEDIATR, V90, P119, DOI 10.1080/080352501300049163	32	240	247	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	2002	360	9338					985	990		10.1016/S0140-6736(02)11082-8	http://dx.doi.org/10.1016/S0140-6736(02)11082-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383668				2022-12-28	WOS:000178249000011
J	Nishtar, S				Nishtar, S			Prevention of coronary heart disease in south Asia	LANCET			English	Article							CARDIOVASCULAR RISK-FACTORS; INSULIN-RESISTANCE; CENTRAL OBESITY; ARTERY-DISEASE; PREVALENCE; POPULATIONS; TOBACCO; MALES; MEN	The great increase in rates of cardiovascular disease in developing countries will probably have grave implications for south Asia, which houses nearly a quarter of the world's population. Several factors might contribute to this effect, such as increased susceptibility of south Asian people to cardiovascular disease, unrecognised targets for preventive interventions, and restricted access to high-cost tertiary cardiovascular care for economically disadvantaged communities. Furthermore, prevention and control of cardiovascular disease does not feature prominently in the health care agendas of south Asian countries. To address these issues, therefore, a multifaceted approach is needed, which should include epidemiological studies to fill in the gaps in knowledge. Additionally, political, social, cultural, and economic issues need to be considered in prevention and control of these diseases, to identify and address key limitations and opportunities specific to the region. A set of recommendations outlining the approach is crucial.	Heartfile Pakistan, Islamabad, Pakistan		Nishtar, S (corresponding author), Heartfile Pakistan, 1 Pk Rd, Islamabad, Pakistan.	sania@heartfile.org						BHATNAGAR D, 1995, LANCET, V345, P405; Bhopal R, 2000, J PUBLIC HEALTH MED, V22, P375, DOI 10.1093/pubmed/22.3.375; Bhopal R, 1999, BRIT MED J, V319, P215, DOI 10.1136/bmj.319.7204.215; Chambers JC, 2001, CIRCULATION, V104, P145, DOI 10.1161/01.CIR.104.2.145; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; FERNANDES VL, 2001, CORONARY ARTERY DIS, P147; Gupta Rajeev, 2002, Indian Heart J, V54, P59; HAQ MU, 1999, HUM DEV S ASIA CRISI; Hoogeveen RC, 2001, J LIPID RES, V42, P631; KLATSKY AL, 1994, AM J PUBLIC HEALTH, V84, P1672, DOI 10.2105/AJPH.84.10.1672; KRISHNASWAMI S, 1989, INT J CARDIOL, V24, P337, DOI 10.1016/0167-5273(89)90013-2; Lee J, 2001, INT J EPIDEMIOL, V30, P983, DOI 10.1093/ije/30.5.983; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MENDIS S, 1994, INT J CARDIOL, V46, P135, DOI 10.1016/0167-5273(94)90034-5; Ministry of Health, 1994, PAK NAT PLAN PREV BL; Mohan V, 2001, J AM COLL CARDIOL, V38, P682, DOI 10.1016/S0735-1097(01)01415-2; NISHTAR S, PREVENTING CORONARY; PANDEY MR, 1988, INT J EPIDEMIOL, V17, P535, DOI 10.1093/ije/17.3.535; PUSKA P, 1995, N KARELIA PROJECT 20; Ramachandran A, 2001, AM J CARDIOL, V87, P267, DOI 10.1016/S0002-9149(00)01356-4; Reddy KB., 1996, APOPTOSIS, V1, P33, DOI [10.1007/BF00142076, DOI 10.1007/BF00142076]; Riste L, 2001, DIABETES CARE, V24, P1377, DOI 10.2337/diacare.24.8.1377; Seidell JC, 2000, BRIT J NUTR, V83, pS5, DOI 10.1017/S000711450000088X; Singh R B, 1996, J Cardiovasc Risk, V3, P489, DOI 10.1097/00043798-199612000-00002; Singh RB, 1997, EUR HEART J, V18, P1728; SQUIRES WG, 1984, PREV MED, V13, P195, DOI 10.1016/0091-7435(84)90051-3; Tinker H., 1974, NEW SYSTEM SLAVERY E; WHO, 2001, WORLD HLTH REPORT 20; *WORLD BANK, 2001, WORLD BANK REP 2001; Zaman MM, 2001, J CARDIOVASC RISK, V8, P103, DOI 10.1097/00043798-200104000-00007; Zoratti R, 2000, METABOLISM, V49, P245, DOI 10.1016/S0026-0495(00)91507-5	34	84	86	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	2002	360	9338					1015	1018		10.1016/S0140-6736(02)11088-9	http://dx.doi.org/10.1016/S0140-6736(02)11088-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383683				2022-12-28	WOS:000178249000026
J	Jinks, RN; Markley, TL; Taylor, EE; Perovich, G; Dittel, AI; Epifanio, CE; Cronin, TW				Jinks, RN; Markley, TL; Taylor, EE; Perovich, G; Dittel, AI; Epifanio, CE; Cronin, TW			Adaptive visual metamorphosis in a deep-sea hydrothermal vent crab	NATURE			English	Article							SHRIMPS; MORPHOLOGY; DISPERSAL; BEHAVIOR; SULFIDE; LARVAE; EYES	Hydrothermal vents along the mid-ocean ridges host ephemeral ecosystems of diverse endemic fauna including several crustacean species(1-4), some of which undergo planktonic development as larvae up to 1,000 m above and 100 km away from the vents(5,6). Little is known about the role of vision in the life history of vent fauna. Here we report that planktonic zoea larvae of the vent crab Bythograea thermydron possess image-forming compound eyes with a visual pigment sensitive to the blue light of mesopelagic waters. As they metamorphose and begin to descend to and settle at the vents, they lose their image-forming optics and develop high-sensitivity naked-retina eyes. The spectral absorbance of the visual pigment in these eyes shifts towards longer wavelengths from larva to postlarva to adult. This progressive visual metamorphosis trades imaging for increased sensitivity, and changes spectral sensitivity from the blue wavelengths of the larval environment towards the dim, longer wavelengths(7) produced in the deeper bathypelagic vent environment of the adults. As hydrothermal vents produce light(7), vision may supplement thermal and chemical senses to orient postlarval settlement at vent sites.	Franklin & Marshall Coll, Dept Biol, Lancaster, PA 17604 USA; Univ Delaware, Grad Coll Marine Studies, Lewes, DE 19958 USA; Univ Maryland Baltimore Cty, Dept Biol Sci, Baltimore, MD 21250 USA	Franklin & Marshall College; University of Delaware; University System of Maryland; University of Maryland Baltimore County	Jinks, RN (corresponding author), Franklin & Marshall Coll, Dept Biol, Lancaster, PA 17604 USA.	rjinks@fandm.edu			NATIONAL EYE INSTITUTE [R15EY013196] Funding Source: NIH RePORTER; NEI NIH HHS [R15 EY013196] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENNETT JT, 1984, LIMNOL OCEANOGR, V29, P1088, DOI 10.4319/lo.1984.29.5.1088; Cronin TW, 2001, AM ZOOL, V41, P1098, DOI 10.1668/0003-1569(2001)041[1098:OOVIMC]2.0.CO;2; Cronin TW, 1995, MAR FRESHW BEHAV PHY, V26, P219, DOI 10.1080/10236249509378941; Epifanio CE, 1999, MAR ECOL PROG SER, V185, P147, DOI 10.3354/meps185147; FRANK TM, 1988, BIOL BULL, V175, P261, DOI 10.2307/1541567; Gaten E, 1998, BIOL BULL, V194, P267, DOI 10.2307/1543097; GRASSLE JF, 1985, SCIENCE, V229, P713, DOI 10.1126/science.229.4715.713; Herring PJ, 1999, NATURE, V398, P116, DOI 10.1038/18142; Herring PJ, 1998, DEEP-SEA RES PT I, V45, P2105, DOI 10.1016/S0967-0637(98)00050-8; Jinks RN, 1998, CAH BIOL MAR, V39, P309; LAND MF, 1989, NATURE, V337, P404, DOI 10.1038/337404a0; ONEILL PJ, 1995, VISUAL NEUROSCI, V12, P861, DOI 10.1017/S0952523800009421; Pond D, 1997, MAR ECOL PROG SER, V146, P289, DOI 10.3354/meps146289; RENNINGER GH, 1995, BIOL BULL, V189, P69, DOI 10.2307/1542456; RONA PA, 1986, NATURE, V321, P33, DOI 10.1038/321033a0; STAVENGA DG, 1993, VISION RES, V33, P1011, DOI 10.1016/0042-6989(93)90237-Q; Tapley DW, 1999, BIOL BULL, V196, P52, DOI 10.2307/1543166; Van Dover CL, 2001, SCIENCE, V294, P818, DOI 10.1126/science.1064574; VanDover CL, 1996, GEOPHYS RES LETT, V23, P2049, DOI 10.1029/96GL02151; VANDOVER CL, 1989, NATURE, V337, P458, DOI 10.1038/337458a0; VANDOVER CL, 1995, SPECIAL PUBLICATION, V87, P257; White SN, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000015; WILLIAMS A B, 1980, Proceedings of the Biological Society of Washington, V93, P443	23	42	42	3	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	2002	420	6911					68	70		10.1038/nature01144	http://dx.doi.org/10.1038/nature01144			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422215				2022-12-28	WOS:000179068100037
J	Weston, W				Weston, W			Access to scientific literature - The Web can complement libraries, but not replace them.	NATURE			English	Editorial Material									Univ New Orleans, Earl K Long Lib, Reference Dept, New Orleans, LA 70148 USA	University of Louisiana System; University of New Orleans	Weston, W (corresponding author), Univ New Orleans, Earl K Long Lib, Reference Dept, New Orleans, LA 70148 USA.		Weston, Wil/A-4101-2011; Weston, Wil/AAT-6042-2021	Weston, Wil/0000-0003-1047-2493; Weston, Wil/0000-0003-1047-2493				Herring Mark, 2001, AM LIB, P76; Lawrence S, 1999, IEEE COMMUN MAG, V37, P116, DOI 10.1109/35.739314; Lawrence S., 2001, NATURE YB SCI TECHNO, P86; LAWRENCE S, 2001, ONLINE INVISIBLE; LEBEDEV A, 1996, BEST SEARCH ENG FIND	5	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	2002	420	6911					19	19		10.1038/420019a	http://dx.doi.org/10.1038/420019a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422186	Bronze			2022-12-28	WOS:000179068100019
J	McClellan, MB				McClellan, MB			Adjuvant breast cancer treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2112	2112		10.1001/jama.288.17.2112	http://dx.doi.org/10.1001/jama.288.17.2112			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413360				2022-12-28	WOS:000179048100009
J	Kessler, D; Bennewith, O; Lewis, G; Sharp, D				Kessler, D; Bennewith, O; Lewis, G; Sharp, D			Detection of depression and anxiety in primary care: follow up study	BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bristol, Div Psychiat, Bristol BS6 6JL, Avon, England	University of Bristol; University of Bristol; University of Bristol	Kessler, D (corresponding author), Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England.		Lewis, Glyn/E-9944-2012	Lewis, Glyn/0000-0001-5205-8245				Goldberg D, 1991, USERS GUIDE GEN HLTH; Goldberg DP., 1992, COMMON MENTAL DISORD; Jenkinson C, 1997, J Health Serv Res Policy, V2, P14; Kessler D, 1999, BRIT MED J, V318, P436, DOI 10.1136/bmj.318.7181.436; LEWIS G, 1988, PSYCHOL MED, V18, P737, DOI 10.1017/S0033291700008448	5	122	124	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					1016	1017		10.1136/bmj.325.7371.1016	http://dx.doi.org/10.1136/bmj.325.7371.1016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411363	Bronze, Green Published			2022-12-28	WOS:000179415600025
J	Smith, GCS; Pell, JP; Dobbie, R				Smith, GCS; Pell, JP; Dobbie, R			Birth order, gestational age, and risk of delivery related perinatal death in twins: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							INFANT-MORTALITY; NEONATAL DEATH; 2ND TWIN; RATES; MODE	Objective To determine whether twins born second are at increased risk of perinatal death because of complications during labour and delivery. Design Retrospective cohort study. Setting Scotland, 1992 and 1997. Participants All twin births at or after 24 weeks' gestation, excluding twin pairs in which either twin died before labour or delivery or died during or after labour and delivery because of congenital abnormality, non-immune hydrops, or twin to twin transfusion syndrome. Main outcome measure Delivery related perinatal deaths (deaths during labour or the neonatal period). Results Overall, delivery related perinatal deaths were recorded for 23 first twins only and 23 second twins only of 1438 twin pairs born before 36 weeks (preterm) by means other than planned caesarean section (P>0.99). No deaths of first twins and nine deaths of second twins (P=0.004) were recorded among the 2436 twin pairs born at or after 36 weeks (term). Discordance between first and second twins differed significantly in preterm and term births (P=0.007). Seven of nine deaths of second twins at term were due to anoxia during the birth (2.9 (95% confidence interval 1.2 to 5.9) per 1000); five of these deaths were associated with mechanical problems following vaginal delivery of the first twin. No deaths were recorded among 454 second twins delivered at term by planned caesarean section. Conclusions Second twins born at term are at higher risk than first twins of death due to complications of vaginal delivery. Previous studies may not have shown an increased risk because of inadequate categorisation of deaths, lack of statistical power, inappropriate analyses, and pooling of data about preterm births and term births.	Rosie Matern Hosp, Dept Obstet & Gynaecol, Cambridge CB2 2QQ, England; Greater Glasgow Hlth Board, Dept Publ Hlth, Glasgow G3 8YU, Lanark, Scotland; Common Serv Agcy, Informat & Stat Div, Edinburgh EH5 3SE, Midlothian, Scotland		Smith, GCS (corresponding author), Rosie Matern Hosp, Dept Obstet & Gynaecol, Cambridge CB2 2QQ, England.		Smith, Gordon/A-8070-2008	Smith, Gordon/0000-0003-2124-0997; Pell, Jill/0000-0002-8898-7035				ADAM C, 1991, AM J OBSTET GYNECOL, V165, P23, DOI 10.1016/0002-9378(91)90216-E; Boggess K A, 1997, Obstet Gynecol Surv, V52, P728, DOI 10.1097/00006254-199712000-00003; COLE SK, 1980, PERINATAL AUDIT SURV, P39; GREIG PC, 1992, AM J OBSTET GYNECOL, V167, P901, DOI 10.1016/S0002-9378(12)80009-3; Hartley RS, 2001, AM J OBSTET GYNECOL, V184, P451, DOI 10.1067/mob.2001.109399; HEY EN, 1986, BRIT J OBSTET GYNAEC, V93, P1213, DOI 10.1111/j.1471-0528.1986.tb07854.x; Imaizumi Y, 2001, PAEDIATR PERINAT EP, V15, P346, DOI 10.1046/j.1365-3016.2001.00378.x; *INF STAT DIV, 2001, SCOTT PER INF MORT M; MCCARTHY BJ, 1981, AM J OBSTET GYNECOL, V141, P252; MCILWAINE GM, 1985, BRIT J OBSTET GYNAEC, V92, P9, DOI 10.1111/j.1471-0528.1985.tb01041.x; Newman RB, 1999, AM J OBSTET GYNECOL, V180, P757, DOI 10.1016/S0002-9378(99)70284-X; SIMPSON LI, 1997, MANAGEMENT LABOR DEL, P395; Smith GCS, 2002, JAMA-J AM MED ASSOC, V287, P2684, DOI 10.1001/jama.287.20.2684; Smith GCS, 2001, BRIT MED J, V323, P476, DOI 10.1136/bmj.323.7311.476; WYSHAK G, 1963, JAMA-J AM MED ASSOC, V186, P869; Zhang J, 1996, OBSTET GYNECOL, V88, P593, DOI 10.1016/0029-7844(96)00269-4; Ziadeh SM, 2000, ARCH GYNECOL OBSTET, V264, P128, DOI 10.1007/s004040000096	17	90	95	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					1004	1006		10.1136/bmj.325.7371.1004	http://dx.doi.org/10.1136/bmj.325.7371.1004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411358	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000179415600020
J	Hayes, T; Haston, K; Tsui, M; Hoang, A; Haeffele, C; Vonk, A				Hayes, T; Haston, K; Tsui, M; Hoang, A; Haeffele, C; Vonk, A			Herbicides: Feminization of male frogs in the wild	NATURE			English	Article									Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Museum Vertebrate Zool, Lab Integrat Studies Amphibian Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Hayes, T (corresponding author), Univ Calif Berkeley, Museum Vertebrate Zool, Lab Integrat Studies Amphibian Biol, Berkeley, CA 94720 USA.	tyrone@socrates.berkeley.edu						Akingbemi BT, 2001, ANN MED, V33, P391, DOI 10.3109/07853890108995952; BATTAGLIN WA, 1995, 944176 US GEOL SURV; Conant R., 1991, FIELD GUIDE REPTILES; Crain DA, 1997, ENVIRON HEALTH PERSP, V105, P528, DOI 10.2307/3433582; Hayes TB, 2002, P NATL ACAD SCI USA, V99, P5476, DOI 10.1073/pnas.082121499; KIMBROUGH RA, 1995, PESTICIDES SURFACE W; Reeder AL, 1998, ENVIRON HEALTH PERSP, V106, P261, DOI 10.2307/3434013; Sanderson JT, 2000, TOXICOL SCI, V54, P121, DOI 10.1093/toxsci/54.1.121; Sanderson JT, 2001, ENVIRON HEALTH PERSP, V109, P1027, DOI 10.2307/3454957; Stebbins R.C., 1985, FIELD GUIDE W REPTIL, V2nd; Tavera-Mendoza L, 2002, ENVIRON TOXICOL CHEM, V21, P527, DOI 10.1897/1551-5028(2002)021&lt;0527:ROTATX&gt;2.0.CO;2; WAKE DB, 1991, SCIENCE, V253, P860, DOI 10.1126/science.253.5022.860; 1994, FEDERAL REGISTER, V59, P60412	13	293	341	12	203	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					895	896		10.1038/419895a	http://dx.doi.org/10.1038/419895a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410298				2022-12-28	WOS:000178909700030
J	Nathan, DM				Nathan, DM			Initial management of glycemia in type 2 diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; IMPAIRED GLUCOSE-TOLERANCE; MICROVASCULAR COMPLICATIONS; FASTING GLUCOSE; INSULIN; METFORMIN; EFFICACY; THERAPY; PREVENTION; ONSET		Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Nathan, DM (corresponding author), Massachusetts Gen Hosp, Ctr Diabet, 50 Staniford St,Suite 340, Boston, MA 02114 USA.							ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; American Diabetes Association, 2002, DIABETES CARE S1, V25, pS33, DOI DOI 10.2337/DIACARE.25.2007.S33; [Anonymous], 1995, Diabetes, V44, P1249; [Anonymous], 1995, DIABETES, V44, P968; Arauz-Pacheco C, 2002, DIABETES CARE, V25, P134, DOI 10.2337/diacare.25.1.134; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; Cefalu WT, 2001, ANN INTERN MED, V134, P203, DOI 10.7326/0003-4819-134-3-200102060-00011; CHIASSON JL, 1994, ANN INTERN MED, V121, P928, DOI 10.7326/0003-4819-121-12-199412150-00004; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233; CUSI K, 1995, DIABETES CARE, V18, P843, DOI 10.2337/diacare.18.6.843; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P978; Diabetes Prevention Program Research Group, 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]; Fonseca V, 2000, JAMA-J AM MED ASSOC, V283, P1695, DOI 10.1001/jama.283.13.1695; Gavin JR, 1997, DIABETES CARE, V20, P1183; GENUTH SM, 1987, CLIN DIABETES, V5, P74; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; GROOP LC, 1992, DIABETES CARE, V15, P737, DOI 10.2337/diacare.15.6.737; HADDEN DR, 1975, BMJ-BRIT MED J, V3, P276, DOI 10.1136/bmj.3.5978.276; Haffner SM, 1998, DIABETES CARE, V21, P160, DOI 10.2337/diacare.21.1.160; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Horton ES, 2000, DIABETES CARE, V23, P1660, DOI 10.2337/diacare.23.11.1660; Ilkova H, 1997, DIABETES CARE, V20, P1353, DOI 10.2337/diacare.20.9.1353; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; Lindgren CM, 2001, ENDOCRINOLOGIST, V11, P178, DOI 10.1097/00019616-200105000-00004; *NAT DIAB DAT GROU, 1995, NIH PUBL, P613; Nathan DM, 1996, AM J MED, V100, P157, DOI 10.1016/S0002-9343(97)89453-3; NATHAN DM, 1988, ANN INTERN MED, V108, P334, DOI 10.7326/0003-4819-108-3-334; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; NATHAN DM, 2002, ELLENBERG RIFKINS DI, P515; Nathan DM, 1997, LANCET S1, V350, pSI4, DOI DOI 10.1016/S0140-6736(97)90021-0; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PORIES WJ, 1995, ANN SURG, V222, P339, DOI 10.1097/00000658-199509000-00011; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Rosenstock J, 2001, DIABETES CARE, V24, P631, DOI 10.2337/diacare.24.4.631; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Saudek CD, 1996, JAMA-J AM MED ASSOC, V276, P1322, DOI 10.1001/jama.276.16.1322; Schwartz S, 1998, NEW ENGL J MED, V338, P861, DOI 10.1056/NEJM199803263381302; Sherwin RS, 2002, DIABETES CARE, V25, P742; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wright A, 2002, DIABETES CARE, V25, P330, DOI 10.2337/diacare.25.2.330; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1; Yki-Jarvinen H, 1999, ANN INTERN MED, V130, P389, DOI 10.7326/0003-4819-130-5-199903020-00002; 1997, ARCH INTERN MED, V157, P2413; 2002, DIABETES CARE S1, V25, pS74	59	244	285	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1342	1349		10.1056/NEJMcp021106	http://dx.doi.org/10.1056/NEJMcp021106			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397193				2022-12-28	WOS:000178781300007
J	Clancy, L; Goodman, P; Sinclair, H; Dockery, DW				Clancy, L; Goodman, P; Sinclair, H; Dockery, DW			Effect of air-pollution control on death rates in Dublin, Ireland: an intervention study	LANCET			English	Article							DAILY MORTALITY; CITIES; PROJECT	Background Particulate air pollution episodes have been associated with increased daily death. However, there is little direct evidence that diminished particulate air pollution concentrations would lead to reductions in death rates. We assessed the effect of air pollution controls-ie, the ban on coal sales-on particulate air pollution and death rates in Dublin. Methods Concentrations of air pollution and directly-standardised non-trauma, respiratory, and cardiovascular death rates were compared for 72 months before and after the ban of coal sales in Dublin. The effect of the ban on age-standardised death rates was estimated with an interrupted time-series analysis, adjusting for weather, respiratory epidemics, and death rates in the rest of Ireland. Findings Average black smoke concentrations in Dublin declined by 35.6 mug/ml(3) (70%) after the ban on coal sales. Adjusted non-trauma death rates decreased by 5.7% (95% CI 4.7, p<0.0001), respiratory deaths by 15.5% (12-19, p<0.0001), and cardiovascular deaths by 10.3% (8-13, p<0.0001). Respiratory and cardiovascular standardised death rates fell coincident with the ban on coal sales. About 116 fewer respiratory deaths and 243 fewer cardiovascular deaths were seen per year in Dublin after the ban. Interpretation Reductions in respiratory and cardiovascular death rates in Dublin suggest that control of particulate air pollution could substantially diminish daily death. The net benefit of the reduced death rate was greater than predicted from results of previous time-series studies.	Harvard Univ, Sch Publ Hlth, Environm Epidemiol Program, Boston, MA 02115 USA; St James Hosp, Dublin 8, Ireland; Dublin Inst Technol, Dept Phys, Dublin, Ireland; Trinity Coll Dublin, Dublin, Ireland	Harvard University; Harvard T.H. Chan School of Public Health; Trinity College Dublin; Technological University Dublin; Trinity College Dublin	Dockery, DW (corresponding author), Harvard Univ, Sch Publ Hlth, Environm Epidemiol Program, 665 Huntington Ave, Boston, MA 02115 USA.		Clancy, Luke/O-6597-2019; , dwdockery/AAO-7272-2021; clancy, luke/ABA-1826-2020	Clancy, Luke/0000-0003-2407-2263; Goodman, Patrick/0000-0001-9509-131X; Dockery, Douglas/0000-0002-6052-4880	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-00002] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DEAN G, 1982, IRISH MED J, V75, P338; DEAN G, 1984, IRISH MED J, V77, P98; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; ELLIS FP, 1972, ENVIRON RES, V5, P1, DOI 10.1016/0013-9351(72)90019-9; Eng H, 1998, J Cardiovasc Risk, V5, P89, DOI 10.1097/00043798-199804000-00004; Flanagan P. J., 1986, AIR QUALITY IRELAND; Fleming DM, 1999, EUR J EPIDEMIOL, V15, P467, DOI 10.1023/A:1007525402861; KALKSTEIN LS, 1993, LANCET, V342, P1397, DOI 10.1016/0140-6736(93)92757-K; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658, DOI 10.1136/bmj.314.7095.1658; KELLY I, 1984, IRISH MED J, V77, P322; La Vecchia C, 1998, EUR J EPIDEMIOL, V14, P1, DOI 10.1023/A:1007440201137; MCMAHON G, 1986, IRISH MED J, V79, P130; McMichael AJ, 1998, INT J EPIDEMIOL, V27, P450, DOI 10.1093/ije/27.3.450; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211, DOI 10.1080/00039896.1992.9938351; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SHELLEY E, 1991, IRISH J MED SCI, V160, P5, DOI 10.1007/BF02950435; SHELLEY E, 1995, EUR HEART J, V16, P752, DOI 10.1093/oxfordjournals.eurheartj.a060993; SHELLEY E, 1996, IRAN MED J, V89, P183; SINCLAIR H, 1995, IRISH J MED SCI, V164, P163; Webster DW, 2002, AM J EPIDEMIOL, V155, P406, DOI 10.1093/aje/155.5.406	20	439	458	4	70	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1210	1214		10.1016/S0140-6736(02)11281-5	http://dx.doi.org/10.1016/S0140-6736(02)11281-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401247				2022-12-28	WOS:000178708100010
J	Dernburg, AF; Karpen, GH				Dernburg, AF; Karpen, GH			A chromosome RNAissance	CELL			English	Review							PROTEIN	In RNA-mediated interference (RNAI), double-stranded RNAs (dsRNAs) target complementary mRNAs for degradation. New work demonstrates that essential chromosomal functions are mediated through RNAi protein components and short RNAs, which alter chromosome function at specific DNA loci via histone modification.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Salk Inst Biol Studies, MCBL, La Jolla, CA 92037 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Salk Institute	Dernburg, AF (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd, Berkeley, CA 94720 USA.			Dernburg, Abby/0000-0001-8037-1079	NIGMS NIH HHS [R01 GM054549-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054549] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Chalker DL, 2001, GENE DEV, V15, P1287, DOI 10.1101/gad.884601; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Huang Y, 2002, NUCLEIC ACIDS RES, V30, P1465, DOI 10.1093/nar/30.7.1465; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; MUCHARDT C, 2002, EMBO REP; Nakagawa H, 2002, GENE DEV, V16, P1766, DOI 10.1101/gad.997702; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Taverna SD, 2002, CELL, V110, P701, DOI 10.1016/S0092-8674(02)00941-8; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Yao MC, 2002, MOBILE DNA, P730; Zamore PD, 2002, SCIENCE, V296, P1265, DOI 10.1126/science.1072457	17	40	48	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 18	2002	111	2					159	162		10.1016/S0092-8674(02)01039-5	http://dx.doi.org/10.1016/S0092-8674(02)01039-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408860	Bronze			2022-12-28	WOS:000178753500005
J	Capelluto, DGS; Kutateladze, TG; Habas, R; Finkielstein, CV; He, X; Overduin, M				Capelluto, DGS; Kutateladze, TG; Habas, R; Finkielstein, CV; He, X; Overduin, M			The DIX domain targets dishevelled to actin stress fibres and vesicular membranes	NATURE			English	Article							PLANAR CELL POLARITY; INTRACELLULAR-LOCALIZATION; PROTEIN INTERACTIONS; CORTICAL ROTATION; WNT PATHWAY; XENOPUS; AXIN; PHOSPHORYLATION; EMBRYOGENESIS; GASTRULATION	Colorectal cancer results from mutations in components of the Wnt pathway that regulate beta-catenin levels(1). Dishevelled (Dvl or Dsh) signals downstream of Wnt receptors and stabilizes beta-catenin during cell proliferation(1) and embryonic axis formation(2). Moreover, Dvl contributes to cytoskeletal reorganization during gastrulation(3-5) and mitotic spindle orientation during asymmetric cell division(6). Dvl belongs to a family of eukaryotic signalling proteins that contain a conserved 85-residue module of unknown structure and biological function called the DIX domain(7). Here we show that the DIX domain mediates targeting to actin stress fibres and cytoplasmic vesicles in vivo. Neighbouring interaction sites for actin and phospholipid are identified between two helices by nuclear magnetic resonance spectroscopy (NMR). Mutation of the actin-binding motif abolishes the cytoskeletal localization of Dvl, but enhances Wnt/beta-catenin signalling and axis induction in Xenopus. By contrast, mutation of the phospholipid interaction site disrupts vesicular association of Dvl, Dvl phosphorylation, and Wnt/beta-catenin pathway activation. We propose that partitioning of Dvl into cytoskeletal and vesicular pools by the DIX domain represents a point of divergence in Wnt signalling.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol,Div Neurosci, Boston, MA 02115 USA; NICHHD, Genet Mol Lab, Bethesda, MD 20892 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Boston Children's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Overduin, M (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.		Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585; Kutateladze, Tatiana/0000-0001-7375-6990; finkielstein, carla/0000-0002-8417-4643				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Anderson T., 1973, Acta Informatica, V2, P12, DOI 10.1007/BF00571461; Axelrod JD, 2001, GENE DEV, V15, P1182; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dahmen RP, 2001, CANCER RES, V61, P7039; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; Kato Y, 1999, J NEUROSCI, V19, P9364; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Miller JR, 1999, J CELL BIOL, V146, P427, DOI 10.1083/jcb.146.2.427; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tada M, 2000, DEVELOPMENT, V127, P2227; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200	30	159	161	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					726	729		10.1038/nature01056	http://dx.doi.org/10.1038/nature01056			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384700				2022-12-28	WOS:000178615200042
J	Weinstein, DF				Weinstein, DF			Duty hours for resident physicians - Tough choices for teaching hospitals	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Weinstein, DF (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							*ACCR COUNC GRAD M, 2002, COMM DUT HOUR STAND; *ASS AM MED COLL, 1999, AAMC DAT BOOK STAT I; Brown MD, 1999, AM J MED, V106, P134; *HRG, 2001, HRG PUBL; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Winshall J., 1999, JGIM, V14, P127	7	87	88	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1275	1278		10.1056/NEJMsb022065	http://dx.doi.org/10.1056/NEJMsb022065			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393829				2022-12-28	WOS:000178598300013
J	Bates, DW; Black, DM; Cummings, SR				Bates, DW; Black, DM; Cummings, SR			Clinical use of bone densitometry - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							OSTEOPOROSIS; FRACTURE	Osteoporosis represents a difficult problem for physicians because, although many diagnostic tests are available, interpreting their results is not straightforward. As a result, many patients, even those with clear indications such as long-term steroid therapy or vertebral fractures on radiography, do not get screened or treated. Current evidence-based guidelines recommend screening for all white women older than 65 years and not already receiving an osteoporosis treatment and for many nonwhite women. For postmenopausal women who are younger than 65 years and have strong risk factors for osteoporosis, screening may also be beneficial. The optimal testing strategy depends on what is available locally. The best role for follow-up testing is still being defined, and interpretation of such testing is tricky. Reports of results can be hard to understand; a randomized controlled trial of clearer reports increased testing and decreased confusion about the meaning of test results. Densitometry might be more effectively used in practice if strategies such as having patients fill out a short questionnaire to assess for risk factors or creating a nurse-based system were used to identify patients. Clinicians need better approaches for identifying patients most likely to benefit from screening, systems that facilitate their application, and test results that are easy to interpret.	Brigham & Womens Hosp, Div Gen Med & Primary Care, Dept Med, Boston, MA 02115 USA; Partners Healthcare Syst, Ctr Appl Med Informat Syst Res, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, UCSF Coordinating Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	Harvard University; Brigham & Women's Hospital; Partners Healthcare System; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, Dept Med, 75 Francis St, Boston, MA 02115 USA.							*AG FDN, OST SCREEN FORM; Black DM, 2001, OSTEOPOROSIS INT, V12, P519, DOI 10.1007/s001980170072; Cummings SR, 2002, JAMA-J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889; Gallagher JC, 2002, MENOPAUSE, V9, P84; Gehlbach SH, 2000, OSTEOPOROSIS INT, V11, P577, DOI 10.1007/s001980070078; Mudano A, 2001, J RHEUMATOL, V28, P1298; *NAT OST FDN, 2000, PHYS GUID PREV TREAT; Papa LJ, 1997, J GEN INTERN MED, V12, P781, DOI 10.1046/j.1525-1497.1997.07165.x; RUBIN SM, 1992, ANN INTERN MED, V116, P990, DOI 10.7326/0003-4819-116-12-990; *SEN PHYS THER I, OST RISK ASS; Stock JL, 1998, ANN INTERN MED, V128, P996, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00006; *US PREV SERV TAST, 1996, GUID CLIN PREV SERV	12	59	62	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	2002	288	15					1898	1900		10.1001/jama.288.15.1898	http://dx.doi.org/10.1001/jama.288.15.1898			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604EU	12377089	Bronze			2022-12-28	WOS:000178604200029
J	Cottam, J; Paerels, F; Mendez, M				Cottam, J; Paerels, F; Mendez, M			Gravitationally redshifted absorption lines in the X-ray burst spectra of a neutron star	NATURE			English	Article							PHOTON IMAGING CAMERA; XMM-NEWTON; MILLISECOND PULSAR; MASS; SPECTROSCOPY; DISCOVERY	The fundamental properties of neutron stars provide a direct test of the equation of state of cold nuclear matter, a relationship between pressure and density that is determined by the physics of the strong interactions between the particles that constitute the star. The most straightforward method of determining these properties is by measuring the gravitational redshift of spectral lines produced in the neutron star photosphere(1). The equation of state implies a mass-radius relation, while a measurement of the gravitational redshift at the surface of a neutron star provides a direct constraint on the mass-to-radius ratio. Here we report the discovery of significant absorption lines in the spectra of 28 bursts of the low-mass X-ray binary EXO0748-676. We identify the most significant features with the Fe XXVI and XXV n = 2-3 and O VIII n = 1-2 transitions, all with a redshift of z = 0.35, identical within small uncertainties for the respective transitions. For an astrophysically plausible range of masses (M approximate to 1.3-2.0 solar masses; refs 2-5), this value is completely consistent with models of neutron stars composed of normal nuclear matter, while it excludes some models(6,7) in which the neutron stars are made of more exotic matter.	NASA, Goddard Space Flight Ctr, High Energy Astrophys Lab, Greenbelt, MD 20771 USA; Columbia Univ, Columbia Astrophys Lab, New York, NY 10027 USA; Columbia Univ, Dept Astron, New York, NY 10027 USA; SRON, Natl Inst Space Res, NL-3584 CA Utrecht, Netherlands	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Columbia University; Columbia University	Cottam, J (corresponding author), NASA, Goddard Space Flight Ctr, High Energy Astrophys Lab, Greenbelt, MD 20771 USA.	jcottam@milkyway.gsfc.nasa.gov	Mendez, Mariano/C-8011-2012	Mendez, Mariano/0000-0003-2187-2708				Barziv O, 2001, ASTRON ASTROPHYS, V377, P925, DOI 10.1051/0004-6361:20011122; Bethe H. A., 1977, QUANTUM MECH ONE 2 E; Cottam J, 2001, ASTRON ASTROPHYS, V365, pL277, DOI 10.1051/0004-6361:20000053; den Herder JW, 2001, ASTRON ASTROPHYS, V365, pL7, DOI 10.1051/0004-6361:20000058; Dey M, 1999, PHYS LETT B, V467, P303; Galloway DK, 2002, ASTROPHYS J, V576, pL137, DOI 10.1086/343841; Jaasen F, 2001, ASTRON ASTROPHYS, V365, pL1, DOI 10.1051/0004-6361:20000036; KALLMAN TR, 1982, ASTROPHYS J SUPPL S, V50, P263, DOI 10.1086/190828; KUDRITZKI RP, 1990, ANNU REV ASTRON ASTR, V28, P303; Lattimer JM, 2001, ASTROPHYS J, V550, P426, DOI 10.1086/319702; LEWIN WHG, 1992, SPACE SCI REV, V62, P223, DOI 10.1007/BF00196124; MAGNIER E, 1989, MON NOT R ASTRON SOC, V237, P729, DOI 10.1093/mnras/237.3.729; NAKAMURA N, 1988, PUBL ASTRON SOC JPN, V40, P209; Orosz JA, 1999, MON NOT R ASTRON SOC, V305, P132, DOI 10.1046/j.1365-8711.1999.t01-1-02420.x; Paerels F, 2001, ASTROPHYS J, V546, P338, DOI 10.1086/318251; PARMAR AN, 1986, ASTROPHYS J, V308, P199, DOI 10.1086/164490; Sako M, 2001, ASTRON ASTROPHYS, V365, pL168, DOI 10.1051/0004-6361:20000081; Sanwal D, 2002, ASTROPHYS J, V574, pL61, DOI 10.1086/342368; Struder L, 2001, ASTRON ASTROPHYS, V365, pL18, DOI 10.1051/0004-6361:20000066; SZTAJNO M, 1985, ASTROPHYS J, V299, P487, DOI 10.1086/163715; TARTER CB, 1969, ASTROPHYS J, V156, P943, DOI 10.1086/150026; Thorsett SE, 1999, ASTROPHYS J, V512, P288, DOI 10.1086/306742; Turner MJL, 2001, ASTRON ASTROPHYS, V365, pL27, DOI 10.1051/0004-6361:20000087; VANPARADIJS J, 1979, ASTROPHYS J, V234, P609, DOI 10.1086/157535; WAKI I, 1984, PUBL ASTRON SOC JPN, V36, P819; Wijnands R, 1998, NATURE, V394, P344, DOI 10.1038/28557; Zhang W, 1998, ASTROPHYS J, V500, pL171, DOI 10.1086/311418	28	339	344	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	2002	420	6911					51	54		10.1038/nature01159	http://dx.doi.org/10.1038/nature01159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422210				2022-12-28	WOS:000179068100032
J	Page, SE; Siegert, F; Rieley, JO; Boehm, HDV; Jaya, A; Limin, S				Page, SE; Siegert, F; Rieley, JO; Boehm, HDV; Jaya, A; Limin, S			The amount of carbon released from peat and forest fires in Indonesia during 1997	NATURE			English	Article								Tropical peatlands are one of the largest near-surface reserves of terrestrial organic carbon, and hence their stability has important implications for climate change(1-3). In their natural state, lowland tropical peatlands support a luxuriant growth of peat swamp forest overlying peat deposits up to 20 metres thick(4,5). Persistent environmental change-in particular, drainage and forest clearing-threatens their stability 2, and makes them susceptible to fire(6). This was demonstrated by the occurrence of widespread fires throughout the forested peatlands of Indonesia(7-10) during the 1997 El Nino event. Here, using satellite images of a 2.5 million hectare study area in Central Kalimantan, Borneo, from before and after the 1997 fires, we calculate that 32% (0.79 Mha) of the area had burned, of which peatland accounted for 91.5% (0.73 Mha). Using ground measurements of the burn depth of peat, we estimate that 0.19-0.23 gigatonnes (Gt) of carbon were released to the atmosphere through peat combustion, with a further 0.05 Gt released from burning of the overlying vegetation. Extrapolating these estimates to Indonesia as a whole, we estimate that between 0.81 and 2.57 Gt of carbon were released to the atmosphere in 1997 as a result of burning peat and vegetation in Indonesia. This is equivalent to 13-40% of the mean annual global carbon emissions from fossil fuels, and contributed greatly to the largest annual increase in atmospheric CO2 concentration detected since records began in 1957 (ref. 1).	Univ Leicester, Dept Geog, Leicester LE1 7RH, Leics, England; Univ Munich, Dept Biol 2, D-80333 Munich, Germany; Remote Sensing Solut GmbH, D-81667 Munich, Germany; Kalteng Consultants, D-81663 Munich, Germany; Univ Nottingham, Sch Geog, Nottingham NG7 2RD, England; Univ Palangka Raya, Fac Agr, Ctr Int Cooperat Management Trop Peatland, Palangka Raya 73112, Indonesia	University of Leicester; University of Munich; University of Nottingham; Universitas Palangka Raya (UPR)	Page, SE (corresponding author), Univ Leicester, Dept Geog, Leicester LE1 7RH, Leics, England.	sep5@le.ac.uk	Nahas, Alberth/C-8379-2013; Jaya, Adi/X-4840-2018	Jaya, Adi/0000-0002-5946-8631; Page, Susan/0000-0002-3392-9241				*ADB BAPPENAS, 1999, 2999INO TA FORT ADB; Barber C, 2000, TRIAL FIRE FOREST FI; BOMPARD JM, 1999, LAND MANAGEMENT S SU; BOWEN MR, 2000, FOREST FIRES REGIONA, P52; Fuller DO, 2001, INT J REMOTE SENS, V22, P691, DOI 10.1080/01431160010013504; Houghton JT, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P1; JORDAN CF, 1983, ECOSYSTEMS WORLD, V14, P117; LIEW SC, 1998, P 1998 INT GEOSC REM, P87; Neuzil S.G., 1997, BIODIVERSITY SUSTAIN, P55; Page S.E., 1999, PHILOS T R SOC B, V354, P1; Page S.E., 1998, INT PEAT J, V8, P95; Rieley j. O., 1996, Tropical lowland peatlands of Southeast Asia. Proceedings of a workshop on integrated planning and management of tropical lowland peatlands, Cisarua, Indonesia, 3-8 July 1992., P17; Siegert F, 2001, NATURE, V414, P437, DOI 10.1038/35106547; Siegert F, 2000, INT J REMOTE SENS, V21, P831, DOI 10.1080/014311600210632; SORENSEN KW, 1993, CHEMOSPHERE, V27, P1065, DOI 10.1016/0045-6535(93)90068-G; STIEBIG HJ, 2000, FOREST COVER CHANGE; ULABY FT, 1986, MICROWAVE REMOTE SEN, V3, P1811; Watson RT, 2000, LAND USE LAND USE CH	18	1128	1176	2	310	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 7	2002	420	6911					61	65		10.1038/nature01131	http://dx.doi.org/10.1038/nature01131			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422213				2022-12-28	WOS:000179068100035
J	Simon, P; Weiss, FU; Zimmer, KP; Rand, S; Brinkmann, B; Domschke, W; Lerch, MM				Simon, P; Weiss, FU; Zimmer, KP; Rand, S; Brinkmann, B; Domschke, W; Lerch, MM			Spontaneous and sporadic trypsinogen mutations in idiopathic pancreatitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HEREDITARY PANCREATITIS		Univ Munster, Dept Mol Gastroenterol, D-4400 Munster, Germany; Univ Munster, Dept Pediat, D-4400 Munster, Germany; Univ Klinikum Munster, Dept Forens Med, Munster, Germany; Univ Munster, Dept Med B, D-4400 Munster, Germany	University of Munster; University of Munster; University of Munster; University of Munster	Simon, P (corresponding author), Univ Munster, Dept Mol Gastroenterol, D-4400 Munster, Germany.		Weiss, Frank Ulrich/A-6386-2009; Zimmer, Klaus-Peter/AAY-9261-2020; Lerch, Markus M./E-2206-2016; Zimmer, Klaus-Peter/AAY-9351-2020	Weiss, Frank Ulrich/0000-0003-3369-6369; Lerch, Markus M./0000-0002-9643-8263; 				Brinkmann B, 2001, INT J LEGAL MED, V114, P173, DOI 10.1007/s004140000174; Ellis I, 2001, PANCREATOLOGY, V1, P405, DOI 10.1159/000055840; Lowenfels AB, 1997, J NATL CANCER I, V89, P442, DOI 10.1093/jnci/89.6.442; Simon P, 2002, J BIOL CHEM, V277, P5404, DOI 10.1074/jbc.M108073200; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Witt H, 2002, J PEDIATR GASTR NUTR, V34, P125, DOI 10.1097/00005176-200202000-00006	6	35	37	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2122	2122		10.1001/jama.288.17.2122	http://dx.doi.org/10.1001/jama.288.17.2122			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413370				2022-12-28	WOS:000179048100021
J	Steed, JW				Steed, JW			Molecular "ghosts"	SCIENCE			English	Editorial Material							CHEMISTRY		Kings Coll London, Dept Chem, London WC2R 2LS, England	University of London; King's College London	Steed, JW (corresponding author), Kings Coll London, Dept Chem, London WC2R 2LS, England.	jon.steed@kcl.ac.uk	Steed, Jonathan/A-7916-2008	Steed, Jonathan/0000-0002-7466-7794				Albrecht M, 2000, NATURE, V406, P970, DOI 10.1038/35023107; Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; Atwood JL, 2002, SCIENCE, V298, P1000, DOI 10.1126/science.1077591; ATWOOD JL, 1996, COMPREHENSIVE SUPRAM, V7; Brouwer EB, 2001, CHEM COMMUN, P565, DOI 10.1039/b009133m; CLEGG W, 1998, XRAY CRYSTALLOGRAPHY; Eddaoudi M, 2001, ACCOUNTS CHEM RES, V34, P319, DOI 10.1021/ar000034b; Gutsche C.D., 1989, MONOGRAPHS SUPRAMOLE, V1; GUTSCHE CD, 1997, MONOGRAPHS SUPRAMOLE, V6; Rosi NL, 2002, CRYSTENGCOMM, V4, P401, DOI 10.1039/b203193k	10	18	18	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	2002	298	5595					976	977		10.1126/science.1078604	http://dx.doi.org/10.1126/science.1078604			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411692				2022-12-28	WOS:000178932000041
J	Clarke, T				Clarke, T			Penicillin paper restores Fleming's healthy reputation	NATURE			English	News Item																			0	0	0	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					867	867		10.1038/419867b	http://dx.doi.org/10.1038/419867b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410270	Bronze			2022-12-28	WOS:000178909700006
J	Winkler, W; Nahvi, A; Breaker, RR				Winkler, W; Nahvi, A; Breaker, RR			Thiamine derivatives bind messenger RNAs directly to regulate bacterial gene expression	NATURE			English	Article							SALMONELLA-TYPHIMURIUM; SELECTION; SWITCHES; SELEX	Although proteins fulfil most of the requirements that biology has for structural and functional components such as enzymes and receptors, RNA can also serve in these capacities. For example, RNA has sufficient structural plasticity to form ribozyme(1,2) and receptor(3,4) elements that exhibit considerable enzymatic power and binding specificity. Moreover, these activities can be combined to create allosteric ribozymes(5,6) that are modulated by effector molecules. It has also been proposed(7-12) that certain messenger RNAs might use allosteric mechanisms to mediate regulatory responses depending on specific metabolites. We report here that mRNAs encoding enzymes involved in thiamine (vitamin B-1) biosynthesis in Escherichia coli can bind thiamine or its pyrophosphate derivative without the need for protein cofactors. The mRNA-effector complex adopts a distinct structure that sequesters the ribosome-binding site and leads to a reduction in gene expression. This metabolite-sensing regulatory system provides an example of a 'riboswitch' whose evolutionary origin might pre-date the emergence of proteins.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Yale University	Breaker, RR (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208103, New Haven, CT 06520 USA.		Breaker, Ronald/E-9679-2010	Breaker, Ronald/0000-0002-2165-536X				BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; Breaker RR, 1997, CHEM REV, V97, P371, DOI 10.1021/cr960008k; CECH TR, 1998, RNA WORLD, P321; Gelfand MS, 1999, TRENDS GENET, V15, P439, DOI 10.1016/S0168-9525(99)01856-9; Gold L, 1997, CURR OPIN GENET DEV, V7, P848, DOI 10.1016/S0959-437X(97)80050-0; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gold L, 1997, P NATL ACAD SCI USA, V94, P59, DOI 10.1073/pnas.94.1.59; Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820; Joyce GF, 2002, NATURE, V418, P214, DOI 10.1038/418214a; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MILLER JH, 1992, SHORT COURSE BACTERI, V72; Miranda-Rios J, 2001, P NATL ACAD SCI USA, V98, P9736, DOI 10.1073/pnas.161168098; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Nou XW, 2000, P NATL ACAD SCI USA, V97, P7190, DOI 10.1073/pnas.130013897; Osborne SE, 1997, CHEM REV, V97, P349, DOI 10.1021/cr960009c; Seetharaman S, 2001, NAT BIOTECHNOL, V19, P336, DOI 10.1038/86723; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Soukup GA, 1999, RNA, V5, P1308, DOI 10.1017/S1355838299990891; Soukup GA, 1999, P NATL ACAD SCI USA, V96, P3584, DOI 10.1073/pnas.96.7.3584; Soukup GA, 2001, RNA, V7, P524, DOI 10.1017/S1355838201002175; Stormo GD, 2001, P NATL ACAD SCI USA, V98, P9465, DOI 10.1073/pnas.181334498; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; Webb E, 1996, J BACTERIOL, V178, P2533, DOI 10.1128/jb.178.9.2533-2538.1996; Webb E, 1997, J BIOL CHEM, V272, P15702, DOI 10.1074/jbc.272.25.15702; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; WHITING MJ, 1982, SURG GASTROENTEROL, V1, P17; Zuker M., 1999, V70, P11	27	895	997	8	181	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					952	956		10.1038/nature01145	http://dx.doi.org/10.1038/nature01145			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410317				2022-12-28	WOS:000178909700050
J	Wu, L; Bauer, CS; Zhen, XG; Xie, C; Yang, J				Wu, L; Bauer, CS; Zhen, XG; Xie, C; Yang, J			Dual regulation of voltage-gated calcium channels by PtdIns(4,5)P-2	NATURE			English	Article							PHOSPHOLIPASE-C; ATP; MODULATION; INHIBITION; EXPRESSION; MECHANISM; CURRENTS; RECEPTOR; NEURONS; SYNAPSE	Voltage-gated calcium channels (VGCCs) conduct calcium into cells after membrane depolarization and are vital for diverse biological events(1). They are regulated by various signalling pathways, which has profound functional consequences(1,2). The activity of VGCCs decreases with time in whole-cell and inside-out patch-clamp recordings(3). This rundown reflects persistent intrinsic modulation of VGCCs in intact cells. Although several mechanisms have been reported to contribute to rundown of L-type channels(3-6), the mechanism of rundown of other types of VGCC is poorly understood. Here we show that phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P-2), an essential regulator of ion channels and transporters(7-14), is crucial for maintaining the activity of P/Q- and N-type channels. Activation of membrane receptors that stimulate hydrolysis of PtdIns(4,5)P-2 causes channel inhibition in oocytes and neurons. PtdIns(4,5)P-2 also inhibits P/Q- type channels by altering the voltage dependence of channel activation and making the channels more difficult to open. This inhibition is alleviated by phosphorylation by protein kinase A. The dual actions of PtdIns(4,5)P-2 and the crosstalk between PtdIns(4,5)P-2 and protein kinase A set up a dynamic mechanism through which the activity of VGCCs can be finely tuned by various neurotransmitters, hormones and trophic factors.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Yang, J (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jy160@columbia.edu	Tuluc, Petronel/C-2527-2011					ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BEAN BP, 1994, ION CHANNELS CARDIOV, P237; BOLAND LM, 1993, J NEUROSCI, V13, P516; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; Choi DY, 2001, MOL CELL BIOL, V21, P2695, DOI 10.1128/MCB.21.8.2695-2705.2001; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Cremona O, 2001, J CELL SCI, V114, P1041; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; Hao LY, 1999, J PHYSIOL-LONDON, V514, P687, DOI 10.1111/j.1469-7793.1999.687ad.x; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; HILGEMANN DW, 2001, SCIENCE STKE; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; Lu T, 1999, NEURON, V22, P571, DOI 10.1016/S0896-6273(00)80711-4; McArdle CA, 2002, J ENDOCRINOL, V173, P1, DOI 10.1677/joe.0.1730001; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; RUNNELS LW, 2000, NATURE CELL BIOL, V4, P329; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Womack KB, 2000, J NEUROSCI, V20, P2792; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B	30	179	185	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					947	952		10.1038/nature01118	http://dx.doi.org/10.1038/nature01118			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410316				2022-12-28	WOS:000178909700049
J	Martin, K; Franco-Paredes, C				Martin, K; Franco-Paredes, C			Herpes encephalitis	LANCET			English	Editorial Material									Emory Univ, Sch Med, Grady Mem Hosp, Atlanta, GA 30303 USA	Emory University	Martin, K (corresponding author), Emory Univ, Sch Med, Grady Mem Hosp, Atlanta, GA 30303 USA.		Franco-Paredes, Carlos Ernesto/GRR-3214-2022; Franco-Paredes, Carlos/R-4226-2019	Franco-Paredes, Carlos Ernesto/0000-0001-8757-643X; 					0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1286	1286		10.1016/S0140-6736(02)11317-1	http://dx.doi.org/10.1016/S0140-6736(02)11317-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414203				2022-12-28	WOS:000178827200010
J	Campbell, CT; Parker, SC; Starr, DE				Campbell, CT; Parker, SC; Starr, DE			The effect of size-dependent nanoparticle energetics on catalyst sintering	SCIENCE			English	Article							SUPPORTED METAL-CATALYSTS; SURFACE FREE-ENERGIES; GROWTH; ADSORPTION; GOLD; TRANSITION; MORPHOLOGY; KINETICS; OXYGEN; PB	Calorimetric measurements of metal adsorption energies directly provide the energies of metal atoms in supported metal nanoparticles. As the metal coverage increases, the particles grow, revealing the dependence of this energy on particle size, which is found to be much stronger than predicted with the usual Gibbs-Thompson relation. It is shown that this knowledge is crucial to accurately model long-term sintering rates of metal nanoparticles in catalysts.	Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Campbell, CT (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.							Bachels T, 2000, PHYS REV LETT, V84, P4890, DOI 10.1103/PhysRevLett.84.4890; Baletto F, 2002, J CHEM PHYS, V116, P3856, DOI 10.1063/1.1448484; Bartholomew CH, 1997, STUD SURF SCI CATAL, V111, P585; BARTHOLOMEW CH, 1994, STUD SURF SCI CATAL, V88, P1; Bombis C, 2002, SURF SCI, V511, P83, DOI 10.1016/S0039-6028(02)01554-6; Bondzie VA, 1999, CATAL LETT, V63, P143, DOI 10.1023/A:1019012903936; Campbell CT, 1997, SURF SCI REP, V27, P1, DOI 10.1016/S0167-5729(96)00011-8; Campbell CT, 2002, J AM CHEM SOC, V124, P9212, DOI 10.1021/ja020146t; Cosandey F, 2001, SURF REV LETT, V8, P73, DOI 10.1016/S0218-625X(01)00088-4; Fuentes GA, 1997, STUD SURF SCI CATAL, V111, P573; Galanakis I, 2002, SURF SCI, V511, P1, DOI 10.1016/S0039-6028(02)01547-9; Gillet M, 2000, THIN SOLID FILMS, V374, P134, DOI 10.1016/S0040-6090(00)01070-1; Graoui H, 2001, PHILOS MAG B, V81, P1649, DOI 10.1080/13642810110079908; Haruta M, 1997, CATAL TODAY, V36, P153, DOI 10.1016/S0920-5861(96)00208-8; Henry CR, 1996, MAT SCI ENG A-STRUCT, V217, P239, DOI 10.1016/S0921-5093(96)10289-6; Jak MJJ, 2000, SURF SCI, V457, P295, DOI 10.1016/S0039-6028(00)00431-3; Jak MJJ, 2001, SURF SCI, V474, P28, DOI 10.1016/S0039-6028(00)00982-1; Lai XF, 2000, J MOL CATAL A-CHEM, V162, P33, DOI 10.1016/S1381-1169(00)00320-4; LIDE DR, 1996, CRC HDB CHEM PHYSICS, P77; MCVICKER GB, 1978, J CATAL, V54, P129, DOI 10.1016/0021-9517(78)90036-2; METHFESSEL M, 1992, APPL PHYS A-MATER, V55, P442, DOI 10.1007/BF00348331; OVERBURY SH, 1975, CHEM REV, V75, P547, DOI 10.1021/cr60297a001; Parker SC, 1999, SURF SCI, V441, P10, DOI 10.1016/S0039-6028(99)00753-0; PARKER SC, 2000, THESIS U WASHINGTON; Ruckenstein E., 1983, REV CHEM ENG, V1, P251; Starr DE, 2001, J CHEM PHYS, V114, P3752, DOI 10.1063/1.1337097; Starr DE, 2001, J PHYS CHEM B, V105, P3776, DOI 10.1021/jp003411a; STASSINOS EC, 1995, CHEM ENG SCI, V50, P1337, DOI 10.1016/0009-2509(95)98845-6; TOLMAN RC, 1949, J CHEM PHYS, V17, P333, DOI 10.1063/1.1747247; TYSON WR, 1977, SURF SCI, V62, P267, DOI 10.1016/0039-6028(77)90442-3; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; WYNBLATT P, 1976, ACTA METALL MATER, V24, P1165, DOI 10.1016/0001-6160(76)90034-1; Wynblatt P., 1975, PROG SOLID STATE CH, V9, P21, DOI [10.1016/0079-6786(75)90013-8, DOI 10.1016/0079-6786(75)90013-8]; YANG LQ, 1994, J CATAL, V149, P223, DOI 10.1006/jcat.1994.1288; Zhang HZ, 1999, J PHYS CHEM B, V103, P4656, DOI 10.1021/jp984574q	35	808	812	18	595	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					811	814		10.1126/science.1075094	http://dx.doi.org/10.1126/science.1075094			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399586				2022-12-28	WOS:000178791200054
J	Zheng, HW; You, H; Zhou, XZ; Murray, SA; Uchida, T; Wulf, G; Gu, L; Tang, XR; Lu, KP; Xiao, ZXJ				Zheng, HW; You, H; Zhou, XZ; Murray, SA; Uchida, T; Wulf, G; Gu, L; Tang, XR; Lu, KP; Xiao, ZXJ			The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response	NATURE			English	Article							DEPENDENT PROLINE ISOMERIZATION; PHOSPHORYLATION; PROTEIN; APOPTOSIS; BINDING; JUN	p53 is activated in response to various genotoxic stresses resulting in cell cycle arrest or apoptosis(1,2). It is well documented that DNA damage leads to phosphorylation and activation of p53 (refs 1-3), yet how p53 is activated is still not fully understood. Here we report that DNA damage specifically induces p53 phosphorylation on Ser/Thr-Pro motifs, which facilitates its interaction with Pin1, a member of peptidyl-prolyl isomerase(4-9). Furthermore, the interaction of Pin1 with p53 is dependent on the phosphorylation that is induced by DNA damage. Consequently, Pin1 stimulates the DNA-binding activity and transactivation function of p53. The Pin1-mediated p53 activation requires the WW domain, a phosphorylated Ser/Thr-Pro motif interaction module, and the isomerase activity of Pin1. Moreover, Pin1-deficient cells are defective in p53 activation and timely accumulation of p53 protein, and exhibit an impaired checkpoint control in response to DNA damage. Together, these data suggest a mechanism for p53 regulation in cellular response to genotoxic stress.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA; Tohoku Univ, Inst Dev Aging & Canc, Dept Pathol, Sendai, Miyagi 980, Japan	Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tohoku University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.	jxiao@bu.edu	Wulf, Gerburg/AAS-6713-2021	Tang, Xiaoren/0000-0002-2402-3659; Uchida, Takafumi/0000-0003-3665-4906; Zheng, Hongwu/0000-0002-5823-4913				Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hsu T, 2001, NAT CELL BIOL, V3, P538, DOI 10.1038/35078508; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; You H, 2002, J CELL BIOCHEM, V84, P211, DOI 10.1002/jcb.10037	30	317	328	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	2002	419	6909					849	853		10.1038/nature01116	http://dx.doi.org/10.1038/nature01116			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397361				2022-12-28	WOS:000178769800049
J	Davi, G; Guagnano, MT; Ciabattoni, G; Basili, S; Falco, A; Marinopiccoli, M; Nutini, M; Sensi, S; Patrono, C				Davi, G; Guagnano, MT; Ciabattoni, G; Basili, S; Falco, A; Marinopiccoli, M; Nutini, M; Sensi, S; Patrono, C			Platelet activation in obese women - Role of inflammation and oxidant stress	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; IN-VIVO FORMATION; BODY-MASS INDEX; OXIDATIVE STRESS; THROMBOXANE BIOSYNTHESIS; ENDOTHELIAL DYSFUNCTION; INSULIN-RESISTANCE; PRIMARY PREVENTION; HEALTHY; INTERLEUKIN-6	Context Obesity, in particular abdominal adiposity, is associated with increased cardiovascular morbidity and mortality through mechanisms possibly linking the metabolic disorder to platelet and vascular abnormalities. Objective To investigate the clinical and biochemical determinants of lipid peroxidation and platelet activation in obese women. Design, Setting, and Participants Cross-sectional comparison, conducted between September 1999 and September 2001, of urinary 8-iso prostaglandin F-2alpha (8-iso PGF(2alpha)) and 11-dehydrothromboxane B-2 (11-dehyhdro-TxB(2)) excretion levels in 93 women: 44 with a body mass index (BMI) higher than 28 and a waist-to-hip ratio (WHR) of 0.86 or higher, android obesity; 25 with a BMI higher than 28 and a WHR lower than 0.86, gynoid obesity; and 24 nonobese women with a BMI lower than 25. An additional study was conducted to determine the short-term effects of weight loss in 20 of the 44 women with android obesity. Intervention During a 12-week period, 20 women with android obesity followed a weight loss program to reduce caloric intake to about 1200 kcal/d. Main Outcome Measures Plasma C-reactive protein, insulin and leptin levels, and urinary 8-iso PGF(2alpha) (marker of in vivo lipid peroxidation) and 11-dehyhdro-TxB(2) (marker of in vivo platelet activation) excretion. Weight loss was defined as successful when the initial body weight decreased by at least 5 kg after a 12-week period of caloric restriction. Results Women with android obesity had higher levels of 8-iso PGF(2alpha) (median [interquartile range {IQR}] 523 [393-685] vs 187 [140-225] pg/mg creatinine) and 11 dehyhdro-TxB(2) (median [IQR], 948 [729-1296] vs 215 [184-253] pg/mg creatinine) than nonobese women (P<.001). Both 8-iso PGF(2alpha) and 11-dehyhdro-TxB(2) were higher in women with android obesity than women with gynoid obesity (P<.001). Based on multiple regression analysis, C-reactive protein levels and WHRs of 0.86 or higher predicted the rate of 8-iso PGF(2alpha) excretion independently of insulin and leptin levels. Of 20 women with android obesity, 11 achieved successful weight loss, which was associated with statistically significant reductions in C-reactive protein (median change, 23%; P<.05), 8-iso PGF(2alpha) (median change, 32%; P=.04) and 11-dehydro-TxB(2) (median change, 54%; P=.005). Conclusions Android obesity is associated with enhanced lipid peroxidation and persistent platelet activation. These abnormalities are driven by inflammatory triggers related to the degree of abdominal adiposity and are, at least in part, reversible with a successful weight-loss program.	Univ G DAnnunzio, Ctr Excellence Aging, Sch Med, I-66013 Chieti, Italy; Univ G DAnnunzio, Sch Med, Dept Med, I-66013 Chieti, Italy; Univ G DAnnunzio, Sch Med, Dept Drug Sci, I-66013 Chieti, Italy; Univ G DAnnunzio, Sch Pharm, I-66013 Chieti, Italy; Univ Roma La Sapienza, Rome, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Sapienza University Rome	Patrono, C (corresponding author), Univ G DAnnunzio, Ctr Eccellenza Invecchiamento, Via Vestini 31, I-66013 Chieti, Italy.	cpatrono@unich.it	Sensi, Stefano L./O-1335-2019; Sensi, Stefano L./J-3164-2016; Basili, Stefania/K-4024-2016; Guagnano, Maria Teresa/AAT-1701-2021	Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574; Basili, Stefania/0000-0002-6987-1926; Patrono, Carlo/0000-0002-6447-2424				Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898; Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231; Brook RD, 2001, AM J CARDIOL, V88, P1264, DOI 10.1016/S0002-9149(01)02088-4; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Ceriello A, 2000, METABOLISM, V49, P27, DOI 10.1016/S0026-0495(00)80082-7; CIABATTONI G, 1989, BIOCHIM BIOPHYS ACTA, V992, P66, DOI 10.1016/0304-4165(89)90051-2; CIABATTONI G, 1987, BIOCHIM BIOPHYS ACTA, V918, P293, DOI 10.1016/0005-2760(87)90233-5; CREPALDI G, 1991, INT J OBESITY, V15, P781; DAVI G, 1992, CIRCULATION, V85, P1792, DOI 10.1161/01.CIR.85.5.1792; Davi G, 2001, CIRCULATION, V104, P1124, DOI 10.1161/hc3501.095287; DAVI G, 1990, NEW ENGL J MED, V322, P1769, DOI 10.1056/NEJM199006213222503; Davi G, 1999, CIRCULATION, V99, P224; Davi G, 1997, ARTERIOSCL THROM VAS, V17, P3230, DOI 10.1161/01.ATV.17.11.3230; Dobrian AD, 2001, HYPERTENSION, V37, P554, DOI 10.1161/01.HYP.37.2.554; FITZGERALD GA, 1983, CIRCULATION, V67, P1174, DOI 10.1161/01.CIR.67.6.1174; Gavin JR, 1997, DIABETES CARE, V20, P1183; Hak AE, 1999, ARTERIOSCL THROM VAS, V19, P1986, DOI 10.1161/01.ATV.19.8.1986; Heilbronn LK, 2001, ARTERIOSCL THROM VAS, V21, P968, DOI 10.1161/01.ATV.21.6.968; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Laight DW, 1999, EUR J PHARMACOL, V377, P89, DOI 10.1016/S0014-2999(99)00407-0; Lauer MS, 2002, NEW ENGL J MED, V346, P1468, DOI 10.1056/NEJMcp012672; Ledue TB, 1998, ANN CLIN BIOCHEM, V35, P745, DOI 10.1177/000456329803500607; Lemieux I, 2001, ARTERIOSCL THROM VAS, V21, P961, DOI 10.1161/01.ATV.21.6.961; Lindemann S, 2001, J CELL BIOL, V154, P485, DOI 10.1083/jcb.200105058; Maytin M, 1999, Curr Atheroscler Rep, V1, P156, DOI 10.1007/s11883-999-0012-z; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Nakao C, 2000, FREE RADICAL RES, V33, P229, DOI 10.1080/10715760000301401; NOWAK J, 1987, CIRCULATION, V76, P6, DOI 10.1161/01.CIR.76.1.6; Pasceri V, 2000, CIRCULATION, V102, P2165; Patrignani P, 2000, CIRCULATION, V102, P539, DOI 10.1161/01.CIR.102.5.539; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; Patrono C, 2001, CHEST, V119, p39S, DOI 10.1378/chest.119.1_suppl.39S; PATRONO C, 1986, J CLIN INVEST, V77, P590, DOI 10.1172/JCI112341; Perticone F, 2001, DIABETES, V50, P159, DOI 10.2337/diabetes.50.1.159; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; Ridker PM, 2001, CIRCULATION, V103, P1813, DOI 10.1161/01.CIR.103.13.1813; Solomon CG, 1997, AM J CLIN NUTR, V66, P1044, DOI 10.1093/ajcn/66.4.1044S; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94; Willett WC, 2001, NEW ENGL J MED, V345, P1819, DOI 10.1056/NEJMcp010710; World Health Organization, 1997, REP WHO CONS OB OB P; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972	47	438	453	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	2002	288	16					2008	2014		10.1001/jama.288.16.2008	http://dx.doi.org/10.1001/jama.288.16.2008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	606QW	12387653	Green Published			2022-12-28	WOS:000178745500024
J	Howard, SC; Gajjar, AJ; Cheng, C; Kritchevsky, SB; Somes, GW; Harrison, PL; Ribeiro, RC; Rivera, GK; Rubnitz, JE; Sandlund, JT; de Armendi, AJ; Razzouk, BI; Pui, CH				Howard, SC; Gajjar, AJ; Cheng, C; Kritchevsky, SB; Somes, GW; Harrison, PL; Ribeiro, RC; Rivera, GK; Rubnitz, JE; Sandlund, JT; de Armendi, AJ; Razzouk, BI; Pui, CH			Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBROSPINAL-FLUID ANALYSIS; BACTERIAL-MENINGITIS; PREDICTIVE VALUE; BACTEREMIA; TAP; THROMBOCYTOPENIA; DIAGNOSIS; NEEDLE	Context Traumatic or bloody lumbar puncture (LP) reduces the diagnostic value of the procedure and may worsen the outcome of patients with acute lymphoblastic leukemia (ALL). Little is known about the risk factors for traumatic and bloody LP. Objectives To determine the risk factors for traumatic and bloody LP. Design, Setting, and Patients Retrospective cohort study of 956 consecutive patients with newly diagnosed childhood ALL who were treated at a pediatric cancer center between February 1984 and July 1998. Interventions All patients underwent a diagnostic LP followed by a median of 4 LPs to instill intrathecal chemotherapy. Main Outcome Measure Traumatic LP was defined as an LP in which cerebrospinal fluid contained at least 10 red blood cells (RBCs) per microliter and bloody LP as one in which the cerebrospinal fluid contained at least 500 RBcs per microliter. Results Of the 5609 LPs evaluated, 1643 (29%) were traumatic and 581 (10%) were bloody. The estimated odds ratios (ORs) and 95% confidence intervals (CIS) for traumatic LP were 1.5 (95% CI, 1.2-1.8) for black vs white race, 2.3 (95% CI, 1.7-3.0) for age younger than 1 year vs 1 year or older, 1.4 (95% CI, 1.2-1.7) for early vs recent (dedicated procedure area-and general anesthesia) treatment era, 1.5 (95% CI, 1.2-1.8) for platelet count of 100 x 10(3)/muL or more vs less than 100 x 10(3)/muL, 10.8 (95% CI, 7.7-15.2) for short (1 day) vs longer (>1 5 days) interval since the previous LP, and 1.4 (95%-CI, 1.1-1.8) for the least vs the most experienced practitioners. Analyses for bloody LP yielded similar results. Conclusions The unmodifiable risk factors for traumatic and bloody LP include black race, age younger than 1 year, a traumatic or bloody previous LP performed within the past 2 weeks, and a previous LP performed when the platelet count was 50 x 10(3)/muL or less. Modifiable risk factors include procedural factors reflected in treatment era, platelet count of 100 x 10(3)/muL or less, an interval of 15 days or less between LPs, and a less experienced practitioner.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Anesthesia, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Howard, SC (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, Barry Longinotti Bldg,Room S2014C,332 N Lauderdal, Memphis, TN 38105 USA.	scott.howard@stjude.org	Rubnitz, Jeffrey E/N-2619-2018; Howard, Scott C/K-3401-2013; Gajjar, Amar/N-8059-2018; Pui, Ching-Hon/N-8076-2018; Cheng, Cheng/N-8075-2018	Rubnitz, Jeffrey E/0000-0001-9885-3527; Howard, Scott C/0000-0003-2244-1686; Pui, Ching-Hon/0000-0003-0303-5658; Kritchevsky, Stephen/0000-0003-3336-6781; Razzouk, Bassem/0000-0003-0536-6135	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANBAR RD, 1986, AM J DIS CHILD, V140, P737, DOI 10.1001/archpedi.1986.02140220019006; ANDREW M, 1987, J PEDIATR-US, V110, P457, DOI 10.1016/S0022-3476(87)80517-6; ANMBAR RD, 1988, CLIN PEDIAT PHILA, V27, P53; BAKER RC, 1989, PEDIATR INFECT DIS J, V8, P329; BOCKER H, 1987, DEUT MED WOCHENSCHR, V112, P120; BONADIO WA, 1990, J INFECT DIS, V162, P251, DOI 10.1093/infdis/162.1.251; BREUER AC, 1982, CANCER-AM CANCER SOC, V49, P2168, DOI 10.1002/1097-0142(19820515)49:10<2168::AID-CNCR2820491031>3.0.CO;2-O; CARRACCIO C, 1995, PEDIATRICS, V96, P48; Craig F, 1997, ARCH DIS CHILD, V77, P450, DOI 10.1136/adc.77.5.450; ENG RHK, 1981, JAMA-J AM MED ASSOC, V245, P1456, DOI 10.1001/jama.245.14.1456; FISHMAN RA, 1995, MERRITS TXB NEUROLOG, P93; Gajjar A, 2000, BLOOD, V96, P3381; Gaur AH, 2001, CLIN INFECT DIS, V32, P1456, DOI 10.1086/320154; Hanson P, 1998, ACTA ANAT, V162, P226; Hanson P, 1998, ARCH PHYS MED REHAB, V79, P1545, DOI 10.1016/S0003-9993(98)90417-8; HARKER LA, 1972, NEW ENGL J MED, V287, P155, DOI 10.1056/NEJM197207272870401; Heldrich F J, 1986, Pediatr Emerg Care, V2, P180, DOI 10.1097/00006565-198609000-00008; HELWIG H, 1986, DEUT MED WOCHENSCHR, V111, P1461; Howard SC, 2000, JAMA-J AM MED ASSOC, V284, P2222, DOI 10.1001/jama.284.17.2222; IZQUIERDO PF, 1980, AN ESP PEDIATR, V13, P733; JACOB J, 1977, AM J DIS CHILD, V131, P46, DOI 10.1001/archpedi.1977.02120140048007; KRUSKALL MS, 1983, NEW ENGL J MED, V308, P697, DOI 10.1056/NEJM198303243081206; LIANG KY, 1986, BIOMETRIKA, V78, P153; MAYEFSKY JH, 1987, AM J MED, V82, P1175, DOI 10.1016/0002-9343(87)90221-X; MEHL AL, 1986, CLIN PEDIATR, V25, P523, DOI 10.1177/000992288602501008; MEHL AL, 1986, CLIN PEDIATR, V25, P575, DOI 10.1177/000992288602501108; OSBORNE JP, 1981, ARCH DIS CHILD, V56, P400, DOI 10.1136/adc.56.5.400; Parzen E., 1962, STOCHASTIC PROCESSES; Pui CH, 2000, LEUKEMIA, V14, P2286, DOI 10.1038/sj.leu.2401938; Pui CH, 1998, BLOOD, V92, P411, DOI 10.1182/blood.V92.2.411.414k34_411_415; RIDER LG, 1995, PEDIATR EMERG CARE, V11, P226, DOI 10.1097/00006565-199508000-00009; RUBENSTEIN JS, 1985, J PEDIATR-US, V107, P249, DOI 10.1016/S0022-3476(85)80137-2; SCHREINER RL, 1979, DEV MED CHILD NEUROL, V21, P483; STANTON A, 1988, BRIT MED J, V296, P574, DOI 10.1136/bmj.296.6621.574-c; SWAIMAN KE, 1999, PEDIAT NEUROLOGY PRI, P115; TEELE DW, 1981, NEW ENGL J MED, V305, P1079, DOI 10.1056/NEJM198110293051810; WINTERGERST U, 1986, MONATSSCHR KINDERH, V134, P826; YURDAKOK M, 1992, PEDIATR NEUROSURG, V17, P199; 1982, N ENGL J MED, V306, P608	39	110	114	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	2002	288	16					2001	2007		10.1001/jama.288.16.2001	http://dx.doi.org/10.1001/jama.288.16.2001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	606QW	12387652	Bronze			2022-12-28	WOS:000178745500023
J	Benson, J; Britten, N				Benson, J; Britten, N			Patients' decisions about whether or not to take antihypertensive drugs: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							MEDICATION; HYPERTENSION; BELIEFS; MEDICINES; RESPONSES	Objective To describe the ways in which patients taking antihypertensive drugs balance reservations against reasons for taking them. Design Qualitative study using detailed interviews. Setting Two urban general practices in the United Kingdom. Participants Maximum variety sample of 38 interviewees receiving repeat perscriptions for antihypertensives. Main outcome measures Interviewees' reservations about drugs and reasons for taking antihypertensives. Results Patients had reservations about drugs generally and reservations about antihypertensives specifically. Reasons for taking antihypertensive drugs comprised positive experiences with doctors, perceived benefits of medication, and pragmatic considerations. Patients balanced their reservations against reasons for taking antihypertensives in a way that made sense for them personally. Some individual patients weighed different reservations against different reasons for taking antihypertensives. Conclusions Patients' ideas may derive from considerations unrelated to the drugs' pharmacology. Doctors who want their patients to make well informed choices about antihypertensives and to reach concordant decisions about prescribing should explore how individuals strike this balance, to personalise discussion of drug use.	Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England; Guys Kings & St Thomass Hosp, Dept Gen Practice & Primary Care, GKT Concordance Unit, London SE11 6SP, England	University of Cambridge; University of London; King's College London	Benson, J (corresponding author), Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England.	J.Benson.jab62@medschl.cam.ac.uk						Ajzen I, 2005, ATTITUDES PERSONALIT, V2nd, P1; BANDURA A, 1986, SOCIAL FDN THOUGHT A; BENSON J, 2001, THESIS U LONDON LOND; BRITTEN N, 1994, BRIT J GEN PRACT, V44, P465; Britten N, 1996, MODERN MED LAY PERSP, P48; CONRAD P, 1985, SOC SCI MED, V20, P29, DOI 10.1016/0277-9536(85)90308-9; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; DONOVAN JL, 1989, BRIT J RHEUMATOL, V28, P58; FALLSBERG M, 1991, REFLECTIONS MED MED; Guba E., 1989, 4 GENERATION EVALUAT; Horne R, 1999, PSYCHOL HEALTH, V14, P1, DOI 10.1080/08870449908407311; Kjellgren KI, 1998, INT J CARDIOL, V64, P161, DOI 10.1016/S0167-5273(98)00038-2; KJELLGREN KI, 1995, INT J CARDIOL, V47, P257, DOI 10.1016/0167-5273(94)02203-U; KUZEL AJ, 1992, RES METH PR, V3, P31; LUSCHER TF, 1985, J HYPERTENS, V3, P3; MCMURRAY J, 2000, MACLEODS CLIN EXAMIN, P87; Miles M., 2013, QUALITATIVE DATA ANA; Misselbrook D, 2001, BRIT J GEN PRACT, V51, P276; MORGAN M, 1988, SOCIOL HEALTH ILL, V10, P561, DOI 10.1111/1467-9566.ep10837256; MORGAN M, 1995, INT J EPIDEMIOL, V24, pS79, DOI 10.1093/ije/24.Supplement_1.S79; *ROYAL PHARM SOC G, 1996, PARTN MED TAK CONS D; Svensson S, 2000, INT J CARDIOL, V76, P157, DOI 10.1016/S0167-5273(00)00374-0; Trostle J, 1988, Epilepsy Res Suppl, V1, P57; VERBEEKHEIDA PM, 1993, FAM PRACT, V10, P326, DOI 10.1093/fampra/10.3.326	24	151	154	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 19	2002	325	7369					873	876A		10.1136/bmj.325.7369.873	http://dx.doi.org/10.1136/bmj.325.7369.873			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	607LL	12386041	Bronze, Green Published			2022-12-28	WOS:000178793000023
J	Kiessling, A; Henriksson, P				Kiessling, A; Henriksson, P			Efficacy of case method learning in general practice for secondary prevention in patients with coronary artery disease: randomised controlled study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTINUING MEDICAL-EDUCATION; PRACTICE GUIDELINES; CLINICAL-PRACTICE; PRACTITIONERS; PHYSICIANS	Objective To study the efficacy of case method learning, for general practitioners, on patients' lipid concentrations in the secondary prevention of coronary artery disease. Design Prospective controlled trial. Setting Sodertalje, Stockholm County, Sweden. Participants 255 consecutive patients with coronary artery disease. Intervention Guidelines were mailed to all general practitioners (n=54) and presented at a common lecture. General practitioners who were randomised to the intervention group participated in recurrent case method learning dialogues at their primary healthcare centres during a two year period. A locally well known cardiologist served as a facilitator. Main outcome measure Concentration of low density lipoprotein cholesterol at baseline and after two years. Analysis according to intention to treat (intervention and control groups (n=88)) was based on group affiliation at baseline. Results Low density lipoprotein cholesterol was reduced by 0.5 mmol/l (95% confidence interval 0.2 to 0.8 mmol/l) (9.3% (2.9% to 15.8%)) from baseline in patients in the intervention group and by 0.5 (0.1 to 0.9) mmol/l compared with controls (P < 0.05). No change occurred in the control group (0.0 (- 0.2 to 0.2) mmol/l). Low density lipoprotein cholesterol decreased by 0.6 (0.4 to 0.8) mmol/l in a group of patients who received specialist care. Conclusion Case method learning resulted in a lowering of low density lipoprotein cholesterol in the primary care patients with coronary artery disease comparable to that achieved at a specialist clinic. Conventional presentation of practice guidelines had no effect.	Danderyd Hosp, Karolinska Inst, Dept Med, SE-18288 Stockholm, Sweden; Danderyd Hosp, Ctr Clin Educ, SE-18288 Stockholm, Sweden; Karolinska Inst, SE-18288 Stockholm, Sweden	Danderyds Hospital; Karolinska Institutet; Danderyds Hospital; Karolinska Institutet	Henriksson, P (corresponding author), Danderyd Hosp, Karolinska Inst, Dept Med, SE-18288 Stockholm, Sweden.	Peter.Henriksson@med.ds.sll.se						Allery LA, 1997, BMJ-BRIT MED J, V314, P870; Antonovsky A., 1979, HLTH STRESS COPING; Cantillon P, 1999, BMJ-BRIT MED J, V318, P1276; Davis DA, 1997, CAN MED ASSOC J, V157, P408; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; Dowie J, 1996, HEALTH CARE ANAL, V4, P5, DOI 10.1007/BF02251141; Eagle KA, 1997, J AM COLL CARDIOL, V29, P1141; Fairhurst K, 1998, BMJ-BRIT MED J, V317, P1130; FEINSTEIN AR, 1994, ANN INTERN MED, V120, P799, DOI 10.7326/0003-4819-120-9-199405010-00012; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Kotseva K, 2001, LANCET, V357, P995, DOI 10.1016/S0140-6736(00)04235-5; Leenders M. R., 2001, WRITING CASES; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; Marshall MN, 1998, BRIT MED J, V316, P442, DOI 10.1136/bmj.316.7129.442; Mauffette-Leenders L. A., 1997, LEARNING CASES; OBRIEN T, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003030; OWEN PA, 1989, BRIT MED J, V299, P238, DOI 10.1136/bmj.299.6693.238; PEDERSEN TR, 1994, LANCET, V344, P1383; Roethlisberger F.J., 1939, MANAGEMENT WORKER AC; Shaughnessy AF, 1999, BMJ-BRIT MED J, V319, P1280, DOI 10.1136/bmj.319.7220.1280; Smits PBA, 2002, BMJ-BRIT MED J, V324, P153, DOI 10.1136/bmj.324.7330.153; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; Watkins C, 1999, BRIT J GEN PRACT, V49, P11	25	30	30	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 19	2002	325	7369					877	880		10.1136/bmj.325.7369.877	http://dx.doi.org/10.1136/bmj.325.7369.877			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386042	Green Published, Bronze			2022-12-28	WOS:000178793000024
J	Zasloff, M				Zasloff, M			Innate immunity, antimicrobial peptides, and protection of the oral cavity	LANCET			English	Editorial Material							CATHELICIDIN; ANTIBIOTICS; EXPRESSION; LL-37; CELLS		Georgetown Univ, Med Ctr, Washington, DC 20007 USA	Georgetown University	Zasloff, M (corresponding author), Georgetown Univ, Med Ctr, 3900 Reservoir Rd, Washington, DC 20007 USA.							Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Chertov O, 2000, IMMUNOL REV, V177, P68, DOI 10.1034/j.1600-065X.2000.17702.x; Dale BA, 2001, J PERIODONTAL RES, V36, P285, DOI 10.1034/j.1600-0765.2001.360503.x; Dunsche A, 2002, EUR J ORAL SCI, V110, P121, DOI 10.1034/j.1600-0722.2002.11186.x; Gennaro R, 2000, BIOPOLYMERS, V55, P31, DOI 10.1002/1097-0282(2000)55:1<31::AID-BIP40>3.3.CO;2-0; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Krisanaprakornkit S, 2000, INFECT IMMUN, V68, P2907, DOI 10.1128/IAI.68.5.2907-2915.2000; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; Matsunaga T, 1998, IMMUNOL REV, V166, P177, DOI 10.1111/j.1600-065X.1998.tb01262.x; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	14	66	73	1	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1116	1117		10.1016/S0140-6736(02)11239-6	http://dx.doi.org/10.1016/S0140-6736(02)11239-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387955				2022-12-28	WOS:000178632000007
J	Tsukadaira, A; Okubo, Y; Sato, E; Kubo, K				Tsukadaira, A; Okubo, Y; Sato, E; Kubo, K			Chronic coccidioidomycosis	LANCET			English	Editorial Material									Okaya Enrei Hosp, Dept Internal Med 1, Okaya, Japan; Shinshu Univ, Sch Med, Matsumoto, Nagano 3908621, Japan	Shinshu University	Tsukadaira, A (corresponding author), Okaya Enrei Hosp, Dept Internal Med 1, Okaya, Japan.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 28	2002	360	9338					977	977		10.1016/S0140-6736(02)11080-4	http://dx.doi.org/10.1016/S0140-6736(02)11080-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383666				2022-12-28	WOS:000178249000009
J	Kremer, JM; Genovese, MC; Cannon, GW; Caldwell, JR; Cush, JJ; Furst, DE; Luggen, ME; Keystone, E; Weisman, MH; Bensen, WM; Kaine, JL; Ruderman, EM; Coleman, P; Curtis, DL; Kopp, EJ; Kantor, SM; Waltuck, J; Lindsley, HB; Markenson, JA; Strand, V; Crawford, B; Fernando, I; Simpson, K; Bathon, JM				Kremer, JM; Genovese, MC; Cannon, GW; Caldwell, JR; Cush, JJ; Furst, DE; Luggen, ME; Keystone, E; Weisman, MH; Bensen, WM; Kaine, JL; Ruderman, EM; Coleman, P; Curtis, DL; Kopp, EJ; Kantor, SM; Waltuck, J; Lindsley, HB; Markenson, JA; Strand, V; Crawford, B; Fernando, I; Simpson, K; Bathon, JM			Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM OUTCOMES; WORK DISABILITY; CLINICAL-TRIALS; COMBINATION; EFFICACY; SULFASALAZINE; ETANERCEPT; MECHANISM; SAFETY; SF-36	Background: Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate. Objective: To evaluate the efficacy and safety of leflunomide versus placebo when added to ongoing, stable-dose methotrexate therapy in patients with persistently active rheumatoid arthritis. Design: 24-week, multicenter, randomized, double-blind, placebo-controlled trial. Setting: 20 centers in the United States and Canada. Patients: Patients with persistent rheumatoid arthritis, as defined by American College of Rheumatology (ACR) criteria, despite receiving methotrexate for at least 6 months. Intervention: Leflunomide or matching placebo added to existing methotrexate therapy, Measurements: The primary efficacy variable was the rate of achievement of 20% improvement in ACR criteria (ACR20) at the end of the study. The Health Assessment Questionnaire Disability Index was assessed at each visit and the Medical Outcomes Study 36-Item Short Form was completed as an end point analysis. Results: In the leflunomide and placebo groups, 46.2% and 19.5% of patients, respectively, met ACR20 criteria at 24 weeks (P < 0.001). Clinical improvement was demonstrated by statistically significant mean changes in individual components of the ACR20 response criteria. Discontinuation rates were similar in both treatment groups (23.1% in the leflunomide group and 24.8% in the placebo group), as were the overall incidences of adverse events (89.2% vs. 89.5%, respectively). Adverse events were predominantly mild or moderate. Conclusions: Combination therapy with leflunomide and methotrexate provides statistically significant clinical benefit in patients with active rheumatoid arthritis who are receiving methotrexate therapy, Leflunomide plus methotrexate is generally well tolerated and can be used safely with appropriate liver enzyme and hematologic monitoring.	LLP, Ctr Rheumatol, Albany, NY 12206 USA; Hosp Special Surg, New York, NY 10021 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Univ Calif Los Angeles, Hlth Sci Ctr, Los Angeles, CA USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Calif Pacific Med Ctr, San Francisco, CA USA; Univ Utah, Sch Med, Salt Lake City, UT USA; Radiant Res, Daytona Beach, FL USA; Sarasota Arthrit Ctr, Sarasota, FL USA; Presbyterian Med Ctr, Dallas, TX USA; Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Toronto, Toronto, ON, Canada; McMaster Univ, Hamilton, ON, Canada; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Good Clin Practice, E Lansing, MI USA; CARE Ctr, Raleigh, NC USA; Emory Clin, Atlanta, GA 30322 USA; Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; MAPI Values USA, Boston, MA USA; Quintiles Inc, Kansas City, MO USA; Aventin Pharmaceut, Bridgewater, NJ USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Stanford University; University of California System; University of California Los Angeles; University of California System; University of California San Diego; California Pacific Medical Center; Utah System of Higher Education; University of Utah; University System of Ohio; University of Cincinnati; University System of Ohio; Ohio State University; University of Toronto; McMaster University; Northwestern University; Feinberg School of Medicine; Emory University; University of Kansas; University of Kansas Medical Center; IQVIA; Johns Hopkins University	Kremer, JM (corresponding author), LLP, Ctr Rheumatol, 1367 Washington Ave,Suite 101, Albany, NY 12206 USA.	jkremer@joint-docs.com		Crawford, Bruce/0000-0001-9109-728X				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Cronstein BN, 1996, ARTHRITIS RHEUM-US, V39, P1951, DOI 10.1002/art.1780391203; Fairbanks LD, 1999, BIOCHEM J, V342, P143, DOI 10.1042/0264-6021:3420143; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; Fox RI, 1999, CLIN IMMUNOL, V93, P198, DOI 10.1006/clim.1999.4777; FRIES JF, 1982, J RHEUMATOL, V9, P789; Jantti J, 1999, RHEUMATOLOGY, V38, P1138, DOI 10.1093/rheumatology/38.11.1138; Kosinski M, 2000, ARTHRITIS RHEUM-US, V43, P1478, DOI 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M; KREMER JM, 1995, ARTHRITIS RHEUM, V38, P1194, DOI 10.1002/art.1780380904; KREMER JM, 1994, ARTHRITIS RHEUM-US, V37, P316, DOI 10.1002/art.1780370304; Kremer JM, 1995, BRIT J RHEUMATOL, V34, P26; Kwoh CK, 2002, ARTHRITIS RHEUM-US, V46, P328; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; Pugner KM, 2000, SEMIN ARTHRITIS RHEU, V29, P305, DOI 10.1016/S0049-0172(00)80017-7; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3; Sokka T, 1999, J RHEUMATOL, V26, P1681; Strand V, 1999, ARCH INTERN MED, V159, P2542, DOI 10.1001/archinte.159.21.2542; Thumboo J, 1999, J RHEUMATOL, V26, P97; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 2001, SF 36 PHYSICAL MENTA; Weinblatt ME, 1999, ARTHRITIS RHEUM-US, V42, P1322, DOI 10.1002/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Wolfe F, 1998, J RHEUMATOL, V25, P2108; Wolfe F, 1998, ARTHRITIS RHEUM, V41, P1072, DOI 10.1002/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G	26	250	278	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2002	137	9					726	733		10.7326/0003-4819-137-9-200211050-00007	http://dx.doi.org/10.7326/0003-4819-137-9-200211050-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612BA	12416946				2022-12-28	WOS:000179052400003
J	Heaney, DC; MacDonald, BK; Everitt, A; Stevenson, S; Leonardi, GS; Wilkinson, P; Sander, JW				Heaney, DC; MacDonald, BK; Everitt, A; Stevenson, S; Leonardi, GS; Wilkinson, P; Sander, JW			Socioeconomic variation in incidence of epilepsy: prospective community based study in south east England	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; POPULATION; DISORDERS	Objective To determine the incidence of epilepsy in a general practice population and its variation with socioeconomic deprivation. Design Prospective surveillance for new cases over an 18 or 24 month period. Participants All patients on practice registers categorised for deprivation with the Carstairs score of their postcodc. Setting 20 general practices in London and south cast England. Main outcome measure Confirmed diagnosis of epilepsy. Results 190 new cases of epilepsy were identified during 369 283 person years of observation (crude incidence 51.5 (95% confidence interval 44.4 to 59.3) per 100 000 per year). The incidence was 190 (138 to 262) per 100 000 in children aged 0-4 years, 30.8 (21.3 to 44.6) in those aged 45-64 years, and 58.7 (42.5 to 81.0) in those aged greater than or equal to65 years. There was no apparent difference in incidence between males and females. The incidence showed a strong association with socioeconomic deprivation, the age and sex adjusted incidence in the most deprived fifth of the study population being 2.33 (1.46 to 3.72) times that in the least deprived fifth (P=0.001 for trend across fifths). Adjustment for area (London v outside London) weakened the association with deprivation (rate ratio 1.62 (0.91 to 2.88), P=0.12 for trend). Conclusions The incidence of epilepsy seems to increase with socioeconomic deprivation, though the association may be confounded by other factors.	UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England; Univ London London Sch Hyg & Trop Med, Environm Epidemiol Unit, London WC1E 7HT, England	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Sander, JW (corresponding author), UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England.	l.sander@ion.ucl.ac.uk	Leonardi, Giovanni/AAS-7603-2020; Sander, Josemir W/C-1576-2008; Leonardi, Giovanni S/E-5700-2015	Sander, Josemir W/0000-0001-6041-9661; Leonardi, Giovanni S./0000-0001-7477-1762; Wilkinson, Paul/0000-0001-7456-259X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACHESON D, 1998, INDEPENDENT INQUIRY, P1; Carstairs V., 1991, DEPRIVATION HLTH SCO; Department of Health, 1997, NEW NHS MOD DEP; HAERER AF, 1986, EPILEPSIA, V27, P66, DOI 10.1111/j.1528-1157.1986.tb03503.x; HART YM, 1995, EPILEPSY RES, V21, P43, DOI 10.1016/0920-1211(95)00007-W; Jacoby A, 1998, EPILEPSIA, V39, P776, DOI 10.1111/j.1528-1157.1998.tb01164.x; Jacoby A, 1996, EPILEPSIA, V37, P148, DOI 10.1111/j.1528-1157.1996.tb00006.x; LISLE JR, 1986, BRIT MED J, V292, P305, DOI 10.1136/bmj.292.6516.305-a; MacDonald BK, 2000, BRAIN, V123, P665, DOI 10.1093/brain/123.4.665; Morgan CLI, 2000, J NEUROL NEUROSUR PS, V69, P13, DOI 10.1136/jnnp.69.1.13; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; Ottman R, 1996, ANN NEUROL, V39, P442, DOI 10.1002/ana.410390406; RODIN E, 1972, EPILEPSIA, V13, P149, DOI 10.1111/j.1528-1157.1972.tb04562.x; Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433; SHAMANSKY SL, 1979, EPILEPSIA, V20, P457, DOI 10.1111/j.1528-1157.1979.tb04828.x; *WHO, 1985, TARG ALL; Wright J, 2000, SEIZURE-EUR J EPILEP, V9, P309, DOI 10.1053/seiz.2000.0422	17	130	133	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	2002	325	7371					1013	1016		10.1136/bmj.325.7371.1013	http://dx.doi.org/10.1136/bmj.325.7371.1013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411362	Green Submitted, Bronze, Green Published, Green Accepted			2022-12-28	WOS:000179415600024
J	Alexander, JM; Nelson, CA; van Berkel, V; Lau, EK; Studts, JM; Brett, TJ; Speck, SH; Handel, TM; Virgin, HW; Fremont, DH				Alexander, JM; Nelson, CA; van Berkel, V; Lau, EK; Studts, JM; Brett, TJ; Speck, SH; Handel, TM; Virgin, HW; Fremont, DH			Structural basis of chemokine sequestration by a herpesvirus decoy receptor	CELL			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-1; BINDING-PROTEIN; CC-CHEMOKINE; CRYSTAL-STRUCTURE; HEPARIN-BINDING; MCP-1 RECEPTOR; IDENTIFICATION; COMPLEX; RESIDUES; FRAGMENT	The M3 protein encoded by murine gammaherpesvirus68 (gammaHV68) functions as an immune system saboteur by the engagement of chemoattractant cytokines, thereby altering host antiviral inflammatory responses. Here we report the crystal structures of M3 both alone and in complex with the CC chemokine MCP-1. M3 is a two-domain beta sandwich protein with a unique sequence and topology, forming a tightly packed antiparallel dimer. The stoichiometry of the MCP-1:M3 complex is 2:2, with two monomeric chemokines embedded at distal ends of the preassociated M3 dimer. Conformational flexibility and electrostatic complementation are both used by M3 to achieve high-affinity and broad-spectrum chemokine engagement. M3 also employs structural mimicry to promiscuously sequester chemokines, engaging conservative structural elements associated with both chemokine homodimerization and binding to G protein-coupled receptors.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Mol Biophys & Med Scientist Training Program, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA; Emory Univ, Div Microbiol & Immunol, Atlanta, GA 30329 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California Berkeley; Emory University	Fremont, DH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.	fremont@pathbox.wustl.edu	Speck, Samuel/L-5893-2019; Brett, Thomas/AAC-9147-2019	Brett, Thomas/0000-0002-6871-6676; Virgin, Herbert/0000-0001-8580-7628; Fremont, Daved/0000-0002-8544-2689	NATIONAL CANCER INSTITUTE [R01CA074730, R01CA086803, R55CA074730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NCI NIH HHS [CA74730, CA86803-04] Funding Source: Medline; NHLBI NIH HHS [HL60090] Funding Source: Medline; NIAID NIH HHS [AI051426-01] Funding Source: Medline; NIAMS NIH HHS [AR32788-18] Funding Source: Medline; NIGMS NIH HHS [GM62414] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcami A, 2000, IMMUNOL TODAY, V21, P447, DOI 10.1016/S0167-5699(00)01699-6; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BLASKOVIC D, 1980, ACTA VIROL, V24, P468; Bridgeman A, 2001, J EXP MED, V194, P301, DOI 10.1084/jem.194.3.301; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carfi A, 1999, P NATL ACAD SCI USA, V96, P12379, DOI 10.1073/pnas.96.22.12379; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Dabbagh K, 2000, J IMMUNOL, V165, P3418, DOI 10.4049/jimmunol.165.6.3418; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Fremont DH, 1998, IMMUNITY, V9, P385, DOI 10.1016/S1074-7613(00)80621-4; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Lalani AS, 1997, J VIROL, V71, P4356, DOI 10.1128/JVI.71.6.4356-4363.1997; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Leong SR, 1997, PROTEIN SCI, V6, P609; Liu LY, 2000, J CLIN INVEST, V105, P1613, DOI 10.1172/JCI8934; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Louie GV, 1997, MOL CELL, V1, P67, DOI 10.1016/S1097-2765(00)80008-8; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Mellado M, 2001, CELL MOL BIOL, V47, P575; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Parry CM, 2000, J EXP MED, V191, P573, DOI 10.1084/jem.191.3.573; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Seet BT, 2001, P NATL ACAD SCI USA, V98, P9008, DOI 10.1073/pnas.171069398; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Stebbins CE, 2001, NATURE, V412, P701, DOI 10.1038/35089000; Sundberg EJ, 2000, STRUCTURE, V8, pR137, DOI 10.1016/S0969-2126(00)00167-2; Van Berkel V, 2000, J VIROL, V74, P6741, DOI 10.1128/JVI.74.15.6741-6747.2000; van Berkel V, 2002, J CLIN INVEST, V109, P905, DOI 10.1172/JCI14358; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	48	99	103	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	2002	111	3					343	356		10.1016/S0092-8674(02)01007-3	http://dx.doi.org/10.1016/S0092-8674(02)01007-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419245	Bronze			2022-12-28	WOS:000179010100007
J	Brazil, DP; Park, J; Hemmings, BA				Brazil, DP; Park, J; Hemmings, BA			PKB binding proteins: Getting in on the akt	CELL			English	Review							PLECKSTRIN HOMOLOGY DOMAIN; SYNTHASE KINASE 3-BETA; BETA-GAMMA-SUBUNITS; HEAT-SHOCK; SUBSTRATE-SPECIFICITY; PHOSPHOINOSITIDE 3-KINASE; CELL-PROLIFERATION; 3T3-L1 ADIPOCYTES; MOLECULAR-CLONING; C-ZETA	Protein kinase B (PKB) has emerged as the focal point for many signal transduction pathways, regulating multiple cellular processes such as glucose metabolism, transcription, apoptosis, cell proliferation, angiogenesis, and cell motility. In addition to acting as a kinase toward many substrates involved in these processes, PKB forms complexes with other proteins that are not substrates, but rather act as modulators of PKB activity and function. In this review, we discuss the implications of these data in understanding the multitude of functions predicted for PKB in cells.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Brazil, DP (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Park, Jongsun/E-7465-2010	Park, Jongsun/0000-0002-4690-1854; Brazil, Derek/0000-0003-1375-1076				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barthel A, 1997, ENDOCRINOLOGY, V138, P3559, DOI 10.1210/en.138.8.3559; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Conus NM, 2002, J BIOL CHEM, V277, P38021, DOI 10.1074/jbc.M203387200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; French SW, 2002, BIOCHEMISTRY-US, V41, P6376, DOI 10.1021/bi016068o; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Galarneau A, 2002, NAT BIOTECHNOL, V20, P619, DOI 10.1038/nbt0602-619; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; Ingley E, 2000, FEBS LETT, V478, P253, DOI 10.1016/S0014-5793(00)01866-4; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Konishi H, 1999, J BIOCHEM-TOKYO, V126, P1136, DOI 10.1093/oxfordjournals.jbchem.a022559; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; LI Y, 2002, IN PRESS J BIOL CHEM; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lindvall J, 2002, BIOCHEM BIOPH RES CO, V293, P1319, DOI 10.1016/S0006-291X(02)00382-0; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Tanaka M, 1999, BIOCHEM BIOPH RES CO, V255, P169, DOI 10.1006/bbrc.1999.0162; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Weston CR, 2001, SCIENCE, V292, P2439, DOI 10.1126/science.1063279; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Wu KK, 2002, ANN NY ACAD SCI, V962, P122, DOI 10.1111/j.1749-6632.2002.tb04062.x; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; YANG J, 2002, IN PRESS NAT STRUCT; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	85	473	493	0	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 1	2002	111	3					293	303		10.1016/S0092-8674(02)01083-8	http://dx.doi.org/10.1016/S0092-8674(02)01083-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419241	Bronze			2022-12-28	WOS:000179010100003
J	Knox, AJ; Pang, LH				Knox, AJ; Pang, LH			Glucocorticoid and beta-adrenoceptor agonist interactions in asthma	LANCET			English	Editorial Material							SMOOTH-MUSCLE CELLS; BETA(2)-AGONISTS; CORTICOSTEROIDS; ACTIVATION; FORMOTEROL; BUDESONIDE; RELEASE		City Hosp Nottingham, Div Resp Med, Nottingham, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital	Knox, AJ (corresponding author), City Hosp Nottingham, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham, England.			Knox, Alan/0000-0002-5906-4143				Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Knox AJ, 2002, CURR PHARM DESIGN, V8, P1863, DOI 10.2174/1381612023393774; Korn SH, 2001, EUR RESPIR J, V17, P1070, DOI 10.1183/09031936.01.00073301; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117, DOI 10.1164/ajrccm.164.1.2006003; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Spoelstra FM, 2002, THORAX, V57, P237, DOI 10.1136/thorax.57.3.237; Ye RD, 2000, AM J PHYSIOL-LUNG C, V279, pL615, DOI 10.1152/ajplung.2000.279.4.L615	12	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1265	1266		10.1016/S0140-6736(02)11356-0	http://dx.doi.org/10.1016/S0140-6736(02)11356-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414198				2022-12-28	WOS:000178827200005
J	Krishnan, M; Ugaz, VM; Burns, MA				Krishnan, M; Ugaz, VM; Burns, MA			PCR in a Rayleigh-Benard convection cell	SCIENCE			English	Article									Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Krishnan, M (corresponding author), Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.		Krishnan, Madhavi/J-4217-2015	Krishnan, Madhavi/0000-0003-1274-7155	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG001984] Funding Source: NIH RePORTER; NHGRI NIH HHS [P01 HG01984-01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Chandrasekhar S, 2013, HYDRODYNAMIC HYDROMA; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; MULLER G, 1984, J CRYST GROWTH, V70, P78, DOI 10.1016/0022-0248(84)90250-1	3	209	238	1	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					793	793		10.1126/science.298.5594.793	http://dx.doi.org/10.1126/science.298.5594.793			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399582				2022-12-28	WOS:000178791200049
J	Ogata, S; Li, J; Yip, S				Ogata, S; Li, J; Yip, S			Ideal pure shear strength of aluminum and copper	SCIENCE			English	Article							GENERALIZED GRADIENT APPROXIMATION; PLANE-WAVE; STRUCTURAL-PROPERTIES; AB-INITIO; METALS; STABILITY; ENERGY; AL; PSEUDOPOTENTIALS; NITRIDES	Although aluminum has a smaller modulus in {111}[11 (2) over bar] shear than that of copper, we find by first-principles calculation that its ideal shear strength is larger because of a more extended deformation range before softening. This fundamental behavior, along with an abnormally high intrinsic stacking fault energy and a different orientation dependence on pressure hardening, are traced to the directional nature of its bonding. By a comparative analysis of ion relaxations and valence charge redistributions in aluminum and copper, we arrive at contrasting descriptions of bonding characteristics in these two metals that can explain their relative strength and deformation behavior.	MIT, Dept Nucl Engn, Cambridge, MA 02139 USA; Osaka Univ, Dept Mech Engn & Syst, Suita, Osaka 5650871, Japan; Osaka Univ, Handai Frontier Res Ctr, Suita, Osaka 5650871, Japan; Ohio State Univ, Dept Mat Sci & Engn, Columbus, OH 43210 USA	Massachusetts Institute of Technology (MIT); Osaka University; Osaka University; University System of Ohio; Ohio State University	Yip, S (corresponding author), MIT, Dept Nucl Engn, Cambridge, MA 02139 USA.		Ogata, Shigenobu/G-5497-2011; Li, Ju/A-2993-2008	Ogata, Shigenobu/0000-0002-9072-4496; Li, Ju/0000-0002-7841-8058				Blaha P., 2001, WIEN2K; FEIBELMAN PJ, 1990, PHYS REV LETT, V65, P729, DOI 10.1103/PhysRevLett.65.729; Gouldstone A, 2000, ACTA MATER, V48, P2277, DOI 10.1016/S1359-6454(00)00009-4; Grossman JC, 1999, PHYS REV B, V60, P6343, DOI 10.1103/PhysRevB.60.6343; Hartford J, 1998, PHYS REV B, V58, P2487, DOI 10.1103/PhysRevB.58.2487; HELLWEGE KH, 1988, LANDOLTBORNSTEIN 3 A, V14; Hirth J. P., 1972, THEORY DISLOCATIONS; Jona F, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094113; Kioussis N, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.125501; Krenn CR, 2001, MAT SCI ENG A-STRUCT, V317, P44, DOI 10.1016/S0921-5093(01)01178-9; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558; Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758; Li J, 2002, NATURE, V418, P307, DOI 10.1038/nature00865; Lu G, 2000, PHYS REV B, V62, P3099, DOI 10.1103/PhysRevB.62.3099; METHFESSEL M, 1989, PHYS REV B, V40, P3616, DOI 10.1103/PhysRevB.40.3616; Milman V, 2000, INT J QUANTUM CHEM, V77, P895, DOI 10.1002/(SICI)1097-461X(2000)77:5<895::AID-QUA10>3.0.CO;2-C; Mishin Y, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.224106; Morris JW, 2000, PHILOS MAG A, V80, P2827, DOI 10.1080/01418610008223897; NELSON DF, 1992, LANDOLTBORNSTEIN 3 A, V29; PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; RICE JR, 1994, J MECH PHYS SOLIDS, V42, P333, DOI 10.1016/0022-5096(94)90013-2; Roundy D, 1999, PHYS REV LETT, V82, P2713, DOI 10.1103/PhysRevLett.82.2713; Stampfl C, 1999, PHYS REV B, V59, P5521, DOI 10.1103/PhysRevB.59.5521; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993; Umeno Y, 2002, MAT SCI ENG B-SOLID, V88, P79, DOI 10.1016/S0921-5107(01)00907-2; WANG JH, 1995, PHYS REV B, V52, P12627, DOI 10.1103/PhysRevB.52.12627; Zimmerman JA, 2000, MODEL SIMUL MATER SC, V8, P103, DOI 10.1088/0965-0393/8/2/302	29	611	621	10	233	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					807	811		10.1126/science.1076652	http://dx.doi.org/10.1126/science.1076652			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399585				2022-12-28	WOS:000178791200053
J	Irvine, DJ; Purbhoo, MA; Krogsgaard, M; Davis, MM				Irvine, DJ; Purbhoo, MA; Krogsgaard, M; Davis, MM			Direct observation of ligand recognition by T cells	NATURE			English	Article							PEPTIDE COMPLEXES; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; MINIMAL NUMBER; LIVING CELLS; MHC; ACTIVATION; CD4; SURFACE; BINDING	The activation of T cells through interaction of their T-cell receptors with antigenic peptide bound to major histocompatibility complex (MHC) on the surface of antigen presenting cells (APCs) is a crucial step in adaptive immunity. Here we use three-dimensional fluorescence microscopy to visualize individual peptide-I-E-k class II MHC complexes labelled with the phycobiliprotein phycoerythrin in an effort to characterize T-cell sensitivity and the requirements for forming an immunological synapse(1-3) in single cells. We show that T cells expressing the CD4 antigen respond with transient calcium signalling to even a single agonist peptide-MHC ligand, and that the organization of molecules in the contact zone of the T cell and APC takes on the characteristics of an immunological synapse when only about ten agonists are present. This sensitivity is highly dependant on CD4, because blocking this molecule with antibodies renders T cells unable to detect less than about 30 ligands.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Davis, MM (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.			Davis, Mark/0000-0001-6868-657X				ANDERSON P, 1988, J IMMUNOL, V140, P1732; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BROWER RC, 1994, MOL IMMUNOL, V31, P1285, DOI 10.1016/0161-5890(94)90079-5; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hampl J, 1997, IMMUNITY, V7, P379, DOI 10.1016/S1074-7613(00)80359-3; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Kimachi K, 1997, EUR J IMMUNOL, V27, P3310, DOI 10.1002/eji.1830271230; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Triantafilou K, 2000, CYTOMETRY, V41, P226, DOI 10.1002/1097-0320(20001101)41:3<226::AID-CYTO11>3.0.CO;2-1; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; Vidal K, 1999, J IMMUNOL, V163, P4811; Wang JH, 2001, P NATL ACAD SCI USA, V98, P10799, DOI 10.1073/pnas.191124098; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xiong Y, 2001, J BIOL CHEM, V276, P5659, DOI 10.1074/jbc.M009580200	30	585	605	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					845	849		10.1038/nature01076	http://dx.doi.org/10.1038/nature01076			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397360				2022-12-28	WOS:000178769800048
J	Mainland, JD; Bremner, EA; Young, N; Johnson, BN; Khan, RM; Bensafi, M; Sobel, N				Mainland, JD; Bremner, EA; Young, N; Johnson, BN; Khan, RM; Bensafi, M; Sobel, N			Olfactory plasticity - One nostril knows what the other learns	NATURE			English	Article							CORTEX; MEMORY		Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Bioengn Program, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Mainland, JD (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.		Mainland, Joel/C-5171-2009; Bensafi, Moustafa/H-6618-2017	Mainland, Joel/0000-0002-5056-4598; Bensafi, Moustafa/0000-0002-2991-3036; Sobel, Noam/0000-0002-3232-9391				Brennan PA, 1997, PROG NEUROBIOL, V51, P457, DOI 10.1016/S0301-0082(96)00069-X; CAIN WS, 1977, NATURE, V268, P50, DOI 10.1038/268050a0; Dalton P, 2002, NAT NEUROSCI, V5, P199, DOI 10.1038/nn803; Gilbert A.N., 1987, NATL GEOGR, V172, P514; HABERLY LB, 1989, TRENDS NEUROSCI, V12, P258, DOI 10.1016/0166-2236(89)90025-8; NEVITT GA, 1994, P NATL ACAD SCI USA, V91, P4288, DOI 10.1073/pnas.91.10.4288; Sobel N, 1998, NATURE, V392, P282, DOI 10.1038/32654; SULLIVAN RM, 1989, J NEUROSCI, V9, P3998; WANG HW, 1993, SCIENCE, V260, P998, DOI 10.1126/science.8493539; Wilson DA, 1997, J NEUROPHYSIOL, V78, P160, DOI 10.1152/jn.1997.78.1.160; WYSOCKI CJ, 1989, P NATL ACAD SCI USA, V86, P7976, DOI 10.1073/pnas.86.20.7976; Yee KK, 2001, PHYSIOL BEHAV, V72, P705, DOI 10.1016/S0031-9384(01)00428-0	12	69	70	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					802	802		10.1038/419802a	http://dx.doi.org/10.1038/419802a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397347	Bronze			2022-12-28	WOS:000178769800035
J	Thakar, R; Ayers, S; Clarkson, P; Stanton, S; Manyonda, I				Thakar, R; Ayers, S; Clarkson, P; Stanton, S; Manyonda, I			Outcomes after total versus subtotal abdominal hysterectomy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPRAVAGINAL UTERINE AMPUTATION; IRRITABLE-BOWEL-SYNDROME; COMPARING ENDOMETRIAL RESECTION; URINARY-INCONTINENCE; RANDOMIZED TRIAL; WOMEN; SYMPTOMS; MENORRHAGIA	Background: It is uncertain whether subtotal abdominal hysterectomy results in better bladder, bowel, or sexual function than total abdominal hysterectomy. Methods: We conducted a randomized, double-blind trial comparing total and subtotal abdominal hysterectomy in 279 women referred for hysterectomy because of benign disease; most of the women were premenopausal. The main outcomes were measures of bladder, bowel, and sexual function at 12 months. We also evaluated postoperative complications. Results: The rates of urinary frequency (urination more than seven times during the day) were 33 percent in the subtotal-hysterectomy group and 31 percent in the total-hysterectomy group before surgery, and they fell to 24 percent and 20 percent, respectively, at 12 months (P=0.03 for the change over time within each group; P=0.84 for the interaction between the treatment assignment and time). The reduction in nocturia and stress incontinence and the improvement in bladder capacity were similar in the two groups. The frequency of bowel symptoms (as indicated by reported constipation and use of laxatives) and measures of sexual function (including the frequency of intercourse and orgasm and the rating of the sexual relationship with a partner) did not change significantly in either group after surgery. The women in the subtotal-hysterectomy group had a shorter hospital stay (5.2 days, vs. 6.0 in the total-hysterectomy group; P=0.04) and a lower rate of fever (6 percent vs. 19 percent, P<0.001). After subtotal abdominal hysterectomy, 7 percent of women had cyclical bleeding and 2 percent had cervical prolapse. Conclusions: Neither subtotal nor total abdominal hysterectomy adversely affects pelvic organ function at 12 months. Subtotal abdominal hysterectomy results in more rapid recovery and fewer short-term complications but infrequently causes cyclical bleeding or cervical prolapse.	Univ London St Georges Hosp, Dept Gynecol, London, England; Univ London St Georges Hosp, Sch Med, Dept Psychol, London SW17 0RE, England; Mayday Univ Hosp, Dept Obstet & Gynecol, Croydon, England	St Georges University London; St Georges University London; Croydon University Hospital	Manyonda, I (corresponding author), Univ London St Georges Hosp, Dept Obstet & Gynecol, Blackshaw Rd, London SW17 0QT, England.			Ayers, Susan/0000-0002-6153-2460				Abrams P, 1988, Scand J Urol Nephrol Suppl, V114, P5; Bhattacharya S, 1996, BRIT J OBSTET GYNAEC, V103, P1273; Brown JS, 2000, LANCET, V356, P535, DOI 10.1016/S0140-6736(00)02577-0; Butler-Manuel SA, 2000, CANCER, V89, P2144; BUTLERMANUEL SA, 1999, BRIT J OBSTET GYNAEC, V19, P180; COPPEN A, 1981, LANCET, V1, P126; DENNERSTEIN L, 1977, OBSTET GYNECOL, V49, P92; *DEP HLTH, 1998, HOSP EP STAT; DRIFE J, 1994, BRIT J OBSTET GYNAEC, V101, P563, DOI 10.1111/j.1471-0528.1994.tb13643.x; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; GANNON MJ, 1991, BRIT MED J, V303, P1362, DOI 10.1136/bmj.303.6814.1362; Goffeng AR, 1997, ANN CHIR GYNAECOL FE, V86, P298; GUTHRIE D, 1981, PSYCHOL BULL, V90, P189, DOI 10.1037/0033-2909.90.1.189; Hawkins J, 1977, SHAWS TXB OPERATIVE, P146; HEATON KW, 1993, GUT, V34, P1108, DOI 10.1136/gut.34.8.1108; HELSTROM L, 1993, OBSTET GYNECOL, V81, P357; HENDRY WF, 1985, PROGR OBSTET GYNAECO, V5, P362; Herbert A, 2000, CYTOPATHOLOGY, V11, P471, DOI 10.1046/j.1365-2303.2000.00272.x; HOGSTON P, 1987, BRIT MED J, V294, P934, DOI 10.1136/bmj.294.6577.934; IOSIF CS, 1988, INT J GYNECOL OBSTET, V26, P255, DOI 10.1016/0020-7292(88)90270-6; KILKKU P, 1983, ACTA OBSTET GYN SCAN, V62, P147, DOI 10.3109/00016348309155779; KILKKU P, 1983, ACTA OBSTET GYN SCAN, V62, P141, DOI 10.3109/00016348309155778; KILKKU P, 1985, ACTA OBSTET GYN SCAN, V64, P375, DOI 10.3109/00016348509155151; KILKKU P, 1981, MATURITAS, V3, P197, DOI 10.1016/0378-5122(81)90026-8; KILKKU P, 1982, ACTA OBSTET GYN SCAN, V61, P265, DOI 10.3109/00016348209156569; Kjerulff KH, 2000, OBSTET GYNECOL, V95, P319, DOI 10.1016/S0029-7844(99)00544-X; KUJANSUU E, 1989, GYNECOL OBSTET INVES, V27, P105, DOI 10.1159/000293631; LALOS O, 1986, EUR J OBSTET GYN R B, V21, P143, DOI 10.1016/0028-2243(86)90028-6; LANGER R, 1990, AM J OBSTET GYNECOL, V163, P1139, DOI 10.1016/0002-9378(90)90672-T; Lepine L A, 1997, MMWR CDC Surveill Summ, V46, P1; LONGSTRETH GF, 1990, DIGEST DIS SCI, V35, P1285, DOI 10.1007/BF01536421; MANYONDA IT, 1990, BRIT J OBSTET GYNAEC, V97, P608, DOI 10.1111/j.1471-0528.1990.tb02548.x; MUNRO MG, 1995, CLIN OBSTET GYNECOL, V38, P401; NATHORSTBOOS J, 1992, ACTA OBSTET GYN SCAN, V71, P230, DOI 10.3109/00016349209009925; PARYS BT, 1989, BRIT J UROL, V64, P594, DOI 10.1111/j.1464-410X.1989.tb05316.x; PINION SB, 1994, BRIT MED J, V309, P979, DOI 10.1136/bmj.309.6960.979; POAD D, 1994, AUST NZ J OBSTET GYN, V34, P471, DOI 10.1111/j.1479-828X.1994.tb01274.x; PRESTON DM, 1986, GUT, V27, P41, DOI 10.1136/gut.27.1.41; PRIOR A, 1989, GUT, V30, P996, DOI 10.1136/gut.30.7.996; PRIOR A, 1992, GUT, V33, P264, DOI 10.1136/gut.33.2.264; Rhodes JC, 1999, JAMA-J AM MED ASSOC, V282, P1934, DOI 10.1001/jama.282.20.1934; TAYLOR T, 1989, BRIT MED J, V299, P300, DOI 10.1136/bmj.299.6694.300; VIRTANEN H, 1993, BRIT J UROL, V72, P868, DOI 10.1111/j.1464-410X.1993.tb16288.x; Weber AM, 1999, AM J OBSTET GYNECOL, V181, P530, DOI 10.1016/S0002-9378(99)70488-6; WHITELAW JM, 1990, AM J OBSTET GYNECOL, V162, P1451, DOI 10.1016/0002-9378(90)90905-M	45	263	272	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1318	1325		10.1056/NEJMoa013336	http://dx.doi.org/10.1056/NEJMoa013336			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397189				2022-12-28	WOS:000178781300003
J	Gardner-Medwin, JMM; Dolezalova, P; Cummins, C; Southwood, TR				Gardner-Medwin, JMM; Dolezalova, P; Cummins, C; Southwood, TR			Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins	LANCET			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; RHEUMATOLOGY 1990 CRITERIA; PEDIATRIC-RHEUMATOLOGY; UNITED-KINGDOM; CLASSIFICATION; EPIDEMIOLOGY; POPULATION; DERMATOMYOSITIS; ASSOCIATION; PREVALENCE	Background The frequency and ethnic variation of Henoch-Schonlein purpura, Kawasaki disease, and rarer vasculitides during childhood are not well characterised. Our aim was to ascertain the incidence, and ethnic distribution of these conditions in children resident in a region of the UK with a diverse ethnic mix. Methods 1.1 million children younger than age 17 years live in the West Midlands. Between Sept 1, 1996, and Aug 31, 1999, we surveyed this population with monthly questionnaires sent to 321 consultants, a single questionnaire sent to 2860 family doctors, and review of 406 case notes with diagnostic codes for vasculitis. We included in the analyses children who fulfilled established criteria for vasculitis with disease onset during the study, and calculated incidence rates from population rates derived from the census of 1991. Findings We identified 586 new instances of vasculitis and connective tissue disease. The estimated annual incidence of Henoch-Schonlein purpura was 20.4 per 100 000, and was highest between the ages of 4 years and 6 years (70.3 per 100 000). The estimated annual incidence of Kawasaki disease was 5.5 per 100 000 in children younger than 5 years, and was highest in Indian subcontinent Asian children (14.6 per 100 000). Indian subcontinent Asian and black children had the highest incidence of systemic lupus erythematosus, juvenile dermatomyositis, and other primary systemic vasculitides. Interpretation Childhood Henoch-Schonlein purpura is more frequent in the West Midlands than previously reported, and Kawasaki disease has a higher incidence than previously indicated in the UK, with the highest incidence in Indian subcontinental Asian children. Other vasculitis is rare in childhood.	Univ Birmingham, Dept Rheumatol, Birmingham, W Midlands, England; Univ Birmingham, Inst Child Hlth, Birmingham, W Midlands, England; Charles Univ, Dept Paediat & Adolescent Med, Prague, Czech Republic	University of Birmingham; University of Birmingham; Charles University Prague	Gardner-Medwin, JMM (corresponding author), Royal Hosp Sick Children, Dept Child Hlth, Glasgow GL3 8SJ, Lanark, Scotland.		Dolezalova, Pavla/N-6408-2017; Gardner-Medwin, Janet/J-2512-2012	Dolezalova, Pavla/0000-0001-8375-661X; Cummins, Carole/0000-0001-5464-1944				*AM HEART ASS COMM, 1990, AM J DIS CHILD, V144, P1218; Bhopal R, 1998, AM J PUBLIC HEALTH, V88, P1303, DOI 10.2105/AJPH.88.9.1303; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; Bowyer S, 1996, J RHEUMATOL, V23, P1968; Bundey Sarah, 1993, European Journal of Human Genetics, V1, P206; DENARDO BA, 1994, J RHEUMATOL, V21, P1553; GALLA JH, 1984, LANCET, V2, P522; HALL SM, 1989, ARCH DIS CHILD, V64, P121; Hook EB, 1999, J CLIN EPIDEMIOL, V52, P917, DOI 10.1016/S0895-4356(99)00060-8; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Jimenez-Sanchez G, 2001, NATURE, V409, P853, DOI 10.1038/35057050; JOHNSON AE, 1995, ARTHRITIS RHEUM, V38, P551, DOI 10.1002/art.1780380415; KaipiainenSeppanen O, 1996, CLIN EXP RHEUMATOL, V14, P441; Knox E., 1964, APPL STATIST, V13, P25, DOI DOI 10.2307/2985220; Kumar Lata, 1996, Indian Journal of Pediatrics, V63, P323, DOI 10.1007/BF02751524; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; Malleson PN, 1996, J RHEUMATOL, V23, P1981; MILLS JA, 1990, ARTHRITIS RHEUM, V33, P1114; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; NAIUDET P, 1993, ADV NEPHROL NECKER H, V2, P121; NIELSEN HE, 1988, ACTA PAEDIATR SCAND, V77, P125, DOI 10.1111/j.1651-2227.1988.tb10610.x; NIELSEN HE, 1990, AM J DIS CHILD, V144, P620, DOI 10.1001/archpedi.1990.02150300014008; SCHILLER B, 1995, ACTA PAEDIATR, V84, P769, DOI 10.1111/j.1651-2227.1995.tb13753.x; Schrag SJ, 2000, PEDIATR INFECT DIS J, V19, P17, DOI 10.1097/00006454-200001000-00005; SHULMAN ST, 1987, AM J DIS CHILD, V141, P420, DOI 10.1001/archpedi.1987.04460040078020; SILMAN AJ, 1990, LANCET, V335, P1078; STEWART M, 1988, EUR J PEDIATR, V147, P113, DOI 10.1007/BF00442205; SYMMONS DPM, 1995, BRIT J RHEUMATOL, V34, P732; Symmons DPM, 1996, J RHEUMATOL, V23, P1975; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TAUBERT KA, 1994, PEDIATR INFECT DIS J, V13, P704, DOI 10.1097/00006454-199408000-00005; Watts RA, 2000, ARTHRITIS RHEUM, V43, P414, DOI 10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0; YANAGAWA H, 1986, LANCET, V2, P1138; 1997, OFFICE NATL STAT CEN	34	435	471	0	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1197	1202		10.1016/S0140-6736(02)11279-7	http://dx.doi.org/10.1016/S0140-6736(02)11279-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401245				2022-12-28	WOS:000178708100008
J	Lipton, SA; Bossy-Wetzel, E				Lipton, SA; Bossy-Wetzel, E			Dueling activities of AIF in cell death versus survival: DNA binding and redox activity	CELL			English	Review							APOPTOSIS-INDUCING FACTOR; MITOCHONDRIAL	Apoptosis-inducing factor (AIF) was originally discovered as a mitochondrial protein that, like cytochrome c, is released into the cytoplasm during cell death. New evidence suggests, however, that a redox-active enzymatic region of AIF may be antiapoptotic while a DNA binding region is proapoptotic.	Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Lipton, SA (corresponding author), Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA.			Lipton, Stuart/0000-0002-3490-1259				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; HE H, 2002, NAT STRUCT BIOL, V9, P680; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Suzuki H, 1998, BIOCHEM BIOPH RES CO, V249, P542, DOI 10.1006/bbrc.1998.9181; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; WU SW, 2002, SCIENCE, V297, P259; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	18	153	160	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 18	2002	111	2					147	150		10.1016/S0092-8674(02)01046-2	http://dx.doi.org/10.1016/S0092-8674(02)01046-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408857	Bronze			2022-12-28	WOS:000178753500002
J	Thompson, LG; Mosley-Thompson, E; Davis, ME; Henderson, KA; Brecher, HH; Zagorodnov, VS; Mashiotta, TA; Lin, PN; Mikhalenko, VN; Hardy, DR; Beer, J				Thompson, LG; Mosley-Thompson, E; Davis, ME; Henderson, KA; Brecher, HH; Zagorodnov, VS; Mashiotta, TA; Lin, PN; Mikhalenko, VN; Hardy, DR; Beer, J			Kilimanjaro ice core records: Evidence of Holocene climate change in tropical Africa	SCIENCE			English	Article							NORTH-AFRICA; EAST-AFRICA; FLUORIDE; WATERS; FLUCTUATIONS; MILANKOVITCH; EVENTS	Six ice cores from Kilimanjaro provide an similar to11.7-thousand-year record of Holocene climate and environmental variability for eastern equatorial Africa, including three periods of abrupt climate change: similar to8.3, similar to5.2 and similar to4 thousand years ago (ka). The latter is coincident with the "First Dark Age," the period of the greatest historically recorded drought in tropical Africa. Variable deposition of F- and Na+ during the African Humid Period suggests rapidly fluctuating lake levels between similar to11.7 and 4 ka. Over the 20th century, the areal extent of Kilimanjaro's ice fields has decreased similar to80%, and if current climatological conditions persist, the remaining ice fields are likely to disappear between 2015 and 2020.	Ohio State Univ, Byrd Polar Res Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Geol Sci, Columbus, OH 43210 USA; Ohio State Univ, Dept Geog, Columbus, OH 43210 USA; Inst Geog, Moscow, Russia; Univ Massachusetts, Dept Geosci, Amherst, MA 01003 USA; Swiss Fed Inst Environm Sci EAWAG, Dubendorf, Switzerland	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Institute of Geography, Russian Academy of Sciences; University of Massachusetts System; University of Massachusetts Amherst; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG)	Thompson, LG (corresponding author), Ohio State Univ, Byrd Polar Res Ctr, Columbus, OH 43210 USA.	thompson.3@osu.edu	Mosley-Thompson, Ellen S/Z-2100-2018; Mikhalenko, Vladimir N/A-4253-2014					Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; Bar-Matthews M, 1999, EARTH PLANET SC LETT, V166, P85, DOI 10.1016/S0012-821X(98)00275-1; BLUNIER T, 1995, NATURE, V374, P46, DOI 10.1038/374046a0; Brostrom A, 1998, GEOPHYS RES LETT, V25, P3615, DOI 10.1029/98GL02804; CARTER MW, 1977, HEALTH PHYS, V33, P55, DOI 10.1097/00004032-197707000-00006; Cullen HM, 2000, GEOLOGY, V28, P379, DOI 10.1130/0091-7613(2000)28<379:CCATCO>2.0.CO;2; DALFES HN, 1994, NATO ASI SERIES, V1; Dansgaard W., 1969, J GLACIOL, V8, P215, DOI [10.3189/S0022143000031208, DOI 10.3189/S0022143000031208, 10.3189/s0022143000031208]; GACIRI SJ, 1993, J HYDROL, V143, P395, DOI 10.1016/0022-1694(93)90201-J; GASSE F, 1994, EARTH PLANET SC LETT, V126, P435, DOI 10.1016/0012-821X(94)90123-6; GROVE AT, 1968, GEOGR J, V134, P194, DOI 10.2307/1792436; Hastenrath S, 1997, J GLACIOL, V43, P455, DOI 10.3189/S0022143000035048; HILLAIREMARCEL C, 1987, PALAEOGEOGR PALAEOCL, V58, P155, DOI 10.1016/0031-0182(87)90058-7; KILHAM P, 1973, LIMNOL OCEANOGR, V18, P932, DOI 10.4319/lo.1973.18.6.0932; KUTZBACH JE, 1985, NATURE, V317, P130, DOI 10.1038/317130a0; KUTZBACH JE, 1980, QUATERNARY RES, V14, P210, DOI 10.1016/0033-5894(80)90049-6; MESSERLI B, 1980, INT ASS HYDROLOGICAL, V126, P197; NANYARO JT, 1984, J AFR EARTH SCI, V2, P129, DOI 10.1016/S0731-7247(84)80007-5; Nicholson S.E., 1996, LIMNOLOGY CLIMATOLOG, V1st ed., P25, DOI [DOI 10.1201/9780203748978-2, 10.1201/9780203748978-2]; NICHOLSON SE, 1980, CLIMATIC CHANGE, V2, P313, DOI 10.1007/BF00137203; Nye J.F., 1963, J GLACIOL, V4, P785, DOI [10.3189/S0022143000028367, DOI 10.3189/S0022143000028367]; Pachur HJ, 2000, J AFR EARTH SCI, V30, P929, DOI 10.1016/S0899-5362(00)00061-0; PALLARD D, 1996, EOS, V77, P379; SABURI J, 2000, SURV REV, V35, P278; SIROCKO F, 1993, NATURE, V364, P322, DOI 10.1038/364322a0; STREET FA, 1976, QUATERNARY RES, V12, P83; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; STREETPERROTT FA, 1990, T ROY SOC EDIN-EARTH, V81, P407, DOI 10.1017/S0263593300020897; Stuiver M, 1998, RADIOCARBON, V40, P1127, DOI 10.1017/S0033822200019172; SWAIN AM, 1983, QUATERNARY RES, V19, P17; Thompson LG, 1998, SCIENCE, V282, P1858, DOI 10.1126/science.282.5395.1858; Thompson LG, 2000, J QUATERNARY SCI, V15, P377, DOI 10.1002/1099-1417(200005)15:4<377::AID-JQS542>3.0.CO;2-L; Verschuren D, 2000, NATURE, V403, P410, DOI 10.1038/35000179; WEISS H, 2001, ANTHROPOLOGICAL PAPE, V7, P75	34	480	511	1	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	2002	298	5593					589	593		10.1126/science.1073198	http://dx.doi.org/10.1126/science.1073198			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386332				2022-12-28	WOS:000178634800038
J	van de Wetering, M; Sancho, E; Verweij, C; de Lau, W; Oving, I; Hurlstone, A; van der Horn, K; Batlle, E; Coudreuse, D; Haramis, AP; Tion-Pon-Fong, M; Moerer, P; van den Born, M; Soete, G; Pals, S; Eilers, M; Medema, R; Clevers, H				van de Wetering, M; Sancho, E; Verweij, C; de Lau, W; Oving, I; Hurlstone, A; van der Horn, K; Batlle, E; Coudreuse, D; Haramis, AP; Tion-Pon-Fong, M; Moerer, P; van den Born, M; Soete, G; Pals, S; Eilers, M; Medema, R; Clevers, H			The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells	CELL			English	Article							BETA-CATENIN; GENE-EXPRESSION; COLON-CARCINOMA; MICE LACKING; C-MYC; CYCLIN D1; DIFFERENTIATION; APC; P27(KIP1); MUTATIONS	The transactivation of TCF target genes induced by Writ pathway mutations constitutes the primary transforming event in colorectal cancer (CRC). We show that disruption of beta-catenin/TCF-4 activity in CRC cells induces a rapid G1 arrest and blocks a genetic program that is physiologically active in the proliferative compartment of colon crypts. Coincidently, an intestinal differentiation program is induced. The TCF-4 target gene c-MYC plays a central role in this switch by direct repression of the p21(CIP1/WAF1) promoter. Following disruption of beta-catenin/TCF-4 activity, the decreased expression of c-MYC releases p21(CIP1/WAF1), transcription, which in turn mediates G1 arrest and differentiation. Thus, the beta-catenin/TCF-4 complex constitutes the master switch that controls proliferation versus differentiation in healthy and malignant intestinal epithelial cells.	Univ Med Ctr, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr, Ctr Biomed Genet, NL-3584 CX Utrecht, Netherlands; VU Med Ctr, Dept Mol Cellular Biol, NL-1081 BT Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany; Netherlands Canc Inst, Dept Mol Biol, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute	Clevers, H (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		Medema, Rene H/G-5415-2011; Eckhardt, Erik/G-1567-2010; Sancho, Elena/ABH-4867-2020; Batlle, Eduard/K-8080-2014; Medema, Rene H/E-2981-2013	Sancho, Elena/0000-0002-8182-513X; Batlle, Eduard/0000-0003-2422-0326; Coudreuse, Damien/0000-0003-2534-1621; Hurlstone, Adam/0000-0001-5260-9457; Medema, Rene/0000-0002-6754-0381; Pals, Steven/0000-0002-1419-0939; Eilers, Martin/0000-0002-0376-6533				Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; CASTROP J, 1995, BLOOD, V86, P3050, DOI 10.1182/blood.V86.8.3050.bloodjournal8683050; CICLITIRA PJ, 1987, J PATHOL, V151, P293, DOI 10.1002/path.1711510409; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fujita M, 2001, CANCER RES, V61, P7722; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HARPER JW, 1993, CELL, V75, P805; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Kim JS, 2002, CANCER RES, V62, P2744; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitahara O, 2001, CANCER RES, V61, P3544; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Korswagen HC, 2000, NATURE, V406, P527, DOI 10.1038/35020099; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Mariadason JM, 2001, CANCER RES, V61, P3465; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; MELHEM MF, 1992, CANCER RES, V52, P5853; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Oba SM, 2001, CANCER LETT, V164, P97, DOI 10.1016/S0304-3835(00)00716-3; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Quaroni A, 2000, AM J PHYSIOL-CELL PH, V279, pC1045, DOI 10.1152/ajpcell.2000.279.4.C1045; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yang WC, 2001, CANCER RES, V61, P6297; Yang WC, 2001, CANCER RES, V61, P565; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	51	1628	1692	3	76	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 18	2002	111	2					241	250		10.1016/S0092-8674(02)01014-0	http://dx.doi.org/10.1016/S0092-8674(02)01014-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408868	Green Published, Bronze			2022-12-28	WOS:000178753500013
J	Meibom, A; Sleep, NH; Chamberlain, CP; Coleman, RG; Frei, R; Hren, MT; Wooden, JL				Meibom, A; Sleep, NH; Chamberlain, CP; Coleman, RG; Frei, R; Hren, MT; Wooden, JL			Re-Os isotopic evidence for long-lived heterogeneity and equilibration processes in the Earth's upper mantle	NATURE			English	Article							PLATINUM-GROUP MINERALS; ABYSSAL PERIDOTITES; OSMIUM ISOTOPES; SYSTEMATICS; GEOCHEMISTRY; PERSPECTIVE; RESERVOIR; RHENIUM	The geochemical composition of the Earth's upper mantle(1-3) is thought to reflect 4.5 billion years of melt extraction, as well as the recycling of crustal materials. The fractionation of rhenium and osmium during partial melting in the upper mantle makes the Re-Os isotopic system well suited for tracing the extraction of melt and recycling of the resulting mid-ocean-ridge basalt(3). Here we report osmium isotope compositions of more than 700 osmium-rich platinum-group element alloys derived from the upper mantle. The osmium isotopic data form a wide, essentially gaussian distribution, demonstrating that, with respect to Re-Os isotope systematics, the upper mantle is extremely heterogeneous. As depleted and enriched domains can apparently remain unequilibrated on a timescale of billions of years, effective equilibration seems to require high degrees of partial melting, such as occur under mid-ocean ridges or in back-arc settings, where percolating melts enhance the mobility of both osmium and rhenium. We infer that the gaussian shape of the osmium isotope distribution is the signature of a random mixing process between depleted and enriched domains, resulting from a 'plum pudding' distribution in the upper mantle, rather than from individual melt depletion events.	Stanford Univ, Dept Geophys, Stanford, CA 94305 USA; Univ Copenhagen, Inst Geol, DK-1350 Copenhagen K, Denmark; US Geol Survey, Menlo Pk, CA 94025 USA	Stanford University; University of Copenhagen; United States Department of the Interior; United States Geological Survey	Meibom, A (corresponding author), Stanford Univ, Dept Geophys, 320 Lomita Mall, Stanford, CA 94305 USA.	meibom@pangea.stanford.edu	Frei, Robert/N-6798-2014	Frei, Robert/0000-0001-7708-9881; Meibom, Anders/0000-0002-4542-2819; Hren, Michael/0000-0002-2866-8892				ALLEGRE CJ, 1980, EARTH PLANET SC LETT, V48, P148, DOI 10.1016/0012-821X(80)90177-6; Anderson DL, 2001, EARTH PLANET SC LETT, V193, P77, DOI 10.1016/S0012-821X(01)00507-6; Anderson DL, 2000, GEOPHYS RES LETT, V27, P2401, DOI 10.1029/1999GL008476; Auge T., 1988, MINERAL DEPOSITS EUR, P267; Brandon AD, 2000, EARTH PLANET SC LETT, V177, P319, DOI 10.1016/S0012-821X(00)00044-3; Burton KW, 1999, EARTH PLANET SC LETT, V172, P311, DOI 10.1016/S0012-821X(99)00207-1; Burton KW, 2000, EARTH PLANET SC LETT, V183, P93, DOI 10.1016/S0012-821X(00)00259-4; CAPRI LJ, 1996, EXPLOR MIN GEOL, V5, P73; CLARK WB, 1970, SERV CALIFOR DIV MIN, V23, P115; Coleman RG, 2000, GEOL S AM S, P351; HATTORI K, 1991, EARTH PLANET SC LETT, V107, P499, DOI 10.1016/0012-821X(91)90096-Z; Hauri EH, 1997, CHEM GEOL, V139, P185, DOI 10.1016/S0009-2541(97)00035-1; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; KELEMEN PB, 1992, NATURE, V358, P635, DOI 10.1038/358635a0; LEBLANC M, 1991, PETR STRU G, P231; LEE CTA, UNPUB EARTH PLANET S; Meibom A, 2002, SCIENCE, V296, P516, DOI 10.1126/science.1069119; Meisel T, 2001, GEOCHIM COSMOCHIM AC, V65, P1311, DOI 10.1016/S0016-7037(00)00566-4; Niu YL, 1997, EARTH PLANET SC LETT, V152, P251, DOI 10.1016/S0012-821X(97)00119-2; PAGE NJ, 1975, OCCURRENCE PLATINUM; Parkinson IJ, 1998, SCIENCE, V281, P2011, DOI 10.1126/science.281.5385.2011; Shen JJ, 1996, GEOCHIM COSMOCHIM AC, V60, P2887, DOI 10.1016/0016-7037(96)00120-2; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; SLEEP NH, 1984, J GEOPHYS RES, V89, P29, DOI 10.1029/JB089iB12p10029; STANDISH JJ, 2002, GEOCHEM GEOPHYS GEOS, V3; STOCKMAN HW, 1984, ECON GEOL, V79, P491, DOI 10.2113/gsecongeo.79.3.491; Walker RJ, 2002, GEOCHIM COSMOCHIM AC, V66, P329, DOI 10.1016/S0016-7037(01)00767-0; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425; [No title captured]	29	103	107	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					705	708		10.1038/nature01067	http://dx.doi.org/10.1038/nature01067			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384694				2022-12-28	WOS:000178615200036
J	Mwinga, A; Nunn, A; Ngwira, B; Chintu, C; Warndorff, D; Fine, P; Darbyshire, J; Zumla, A				Mwinga, A; Nunn, A; Ngwira, B; Chintu, C; Warndorff, D; Fine, P; Darbyshire, J; Zumla, A		LUSKAR Collaboration	Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; IMMUNIZATION; HEALTHY	Background Mortality rates of HIV-infected patients treated for tuberculosis remain high. This study aimed to assess the effect on mortality of immunotherapy with single-dose SRL172 added to standard antituberculosis chemotherapy in such patients. Methods The double-blind trial enrolled 1229 patients aged 18-60 years, who had never received antiretroviral treatment and who presented with newly diagnosed, sputum-smear-positive pulmonary tuberculosis to referral centres in Lusaka, Zambia, and Karonga, Malawi. Both HIV-positive and HIV-negative patients were enrolled, to avoid stigmatisation. Participants were randomly assigned a single injection of SRL172 or matching placebo within 2 weeks of starting 8 months of antituberculosis chemotherapy and followed up for at least 12 months. The primary endpoint was time to death in the HIV-infected population. Analyses were based on 760 HIV-positive patients after exclusion of 84 patients with errors in storage of the injection, no bacteriological confirmation, or no HIV result. Findings Of 760 HIV-infected patients, 374 received SRL172 and 386 received placebo. SRL172 did not cause any serious adverse events. The follow-up rate was 88% at 12 months in both groups. Of the HIV-positive patients, 109 (19.5 per 100 person-years) of 372 assigned SRL172 and 107 (19.3 per 100 person-years) of 386 assigned placebo died. In the Cox's regression analysis, stratified by centre, the hazard ratio of deaths (SRL172/placebo) was 1.03 (95% CI 0.79-1.35). There was no evidence of benefit to the group assigned SRL172. Interpretation Immunotherapy with single-dose SRL172 as an adjunct to standard antituberculosis treatment in HIV-positive adults with pulmonary tuberculosis had no significant effect on survival or bacteriological outcome, though the treatment was safe and well tolerated.	Univ Zambia, Univ Coll London, TB HIV Res & Training Project, Lusaka, Zambia; Univ Teaching Hosp, Lusaka, Zambia; MRC, Clin Trials Unit, London, England; Karonga Prevent Study, Karonga, Malawi; London Sch Hyg & Trop Med, London WC1, England; Royal Free & UCL Med Sch, Ctr Infect Dis & Int Hlth, London, England; UCL Hosp NHS Trust, London, England	University of Zambia; University of Zambia; Medical Research Council Clinical Trials Unit; Malawi Epidemiology and Intervention Research Unit; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Zumla, A (corresponding author), UCL, Windeyer Inst Med Sci, Ctr Infect Dis & Int Hlth, Room G41,46 Cleveland St, London W1P 6DB, England.	a.zumla@ucl.ac.uk	ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735; Nunn, Andrew/0000-0002-9158-4595				AbouZeid C, 1997, INFECT IMMUN, V65, P1856, DOI 10.1128/IAI.65.5.1856-1862.1997; Ahmed Y, 1999, INT J TUBERC LUNG D, V3, P675; BAHR GM, 1990, TUBERCLE, V71, P259, DOI 10.1016/0041-3879(90)90038-A; Corlan E, 1997, RESP MED, V91, P13, DOI 10.1016/S0954-6111(97)90132-3; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Glynn JR, 1998, B WORLD HEALTH ORGAN, V76, P295; Johnson JL, 2000, J INFECT DIS, V181, P1304, DOI 10.1086/315393; LUO C, 1994, TUBERCLE LUNG DIS, V75, P110, DOI 10.1016/0962-8479(94)90039-6; Luo SJ, 2001, IEEE T COMPON PACK T, V24, P43, DOI 10.1109/6144.910801; LUO Y, 2000, CHUNG HUA CHIEH HO H, V23, P85; Marsh BJ, 1997, AM J MED SCI, V313, P377, DOI 10.1097/00000441-199706000-00011; ONYEBUJOH PC, 1995, RESP MED, V89, P199, DOI 10.1016/0954-6111(95)90248-1; Onyebujoh PC, 1999, LANCET, V354, P116, DOI 10.1016/S0140-6736(98)10448-8; Skinner MA, 1997, INFECT IMMUN, V65, P4525, DOI 10.1128/IAI.65.11.4525-4530.1997; Vacirca A., 1994, Tubercle and Lung Disease, V75, P47, DOI 10.1016/0962-8479(94)90857-5; von Reyn CF, 1998, CLIN INFECT DIS, V27, P1517, DOI 10.1086/515024; vonReyn CF, 1997, CLIN INFECT DIS, V24, P843, DOI 10.1093/clinids/24.5.843; Waddell RD, 2000, CLIN INFECT DIS, V30, pS309, DOI 10.1086/313880; Wang CC, 1998, IMMUNOLOGY, V93, P307; World Health Organization, 2002, WHOCDSTB2002295	21	62	64	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	2002	360	9339					1050	1055		10.1016/S0140-6736(02)11141-X	http://dx.doi.org/10.1016/S0140-6736(02)11141-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383985				2022-12-28	WOS:000178485200010
J	Gollub, MJ				Gollub, MJ			Virtual colonoscopy	LANCET			English	Editorial Material							CT COLONOGRAPHY; FEASIBILITY		Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Gollub, MJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA.							Callstrom MR, 2001, RADIOLOGY, V219, P693, DOI 10.1148/radiology.219.3.r01jn22693; Fidler JL, 2002, ABDOM IMAGING, V27, P292, DOI 10.1007/s00261-001-0171-z; Gluecker T, 2002, GUT, V51, P207, DOI 10.1136/gut.51.2.207; Lauenstein TC, 2002, RADIOLOGY, V223, P248, DOI 10.1148/radiol.2231010887; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; Macari M, 2002, RADIOLOGY, V224, P383, DOI 10.1148/radiol.2242011382; McMahon PM, 2002, ABDOM IMAGING, V27, P235, DOI 10.1007/s00261-001-0164-y; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; Summers RM, 2001, RADIOLOGY, V219, P51, DOI 10.1148/radiology.219.1.r01ap0751; Svensson MH, 2002, RADIOLOGY, V222, P337, DOI 10.1148/radiol.2222010669; VINING DJ, 1994, SYLLABUS; Yee J, 2001, RADIOLOGY, V219, P685, DOI 10.1148/radiology.219.3.r01jn40685	12	4	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 28	2002	360	9338					964	964		10.1016/S0140-6736(02)11121-4	http://dx.doi.org/10.1016/S0140-6736(02)11121-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383663				2022-12-28	WOS:000178249000006
J	Hohler, T; Reuss, E; Evers, N; Dietrich, E; Rittner, C; Freitag, CM; Vollmar, J; Schneider, PM; Fimmers, R				Hohler, T; Reuss, E; Evers, N; Dietrich, E; Rittner, C; Freitag, CM; Vollmar, J; Schneider, PM; Fimmers, R			Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins	LANCET			English	Article							VIRAL-HEPATITIS; INFECTION; ASSOCIATION; HLA; SUSCEPTIBILITY; TUBERCULOSIS; AFRICANS; MHC	Background The course of viral hepatitis is thought to be affected by genetic host variability and, in particular, by genes of the major histocompatibility locus. Hepatitis A and B vaccination is a useful model to. study the effect of host factors on the immune response to viral antigens. We aimed to assess the heritability of the HBsAg (anti-HBs) and anti-hepatitis A virus (anti-HAV) immune response and to estimate the effect of the HLA-DRB1 locus and other genetic loci unlinked to HLA. Methods We did an open prospective study and vaccinated 202 twin pairs with a combined recombinant HBsAg/inactivated hepatitis A vaccine. We measured antibodies to HBsAg and HAV and determined HLA-DRB1* alleles. Heritability was calculated based on variance of antibody response within pairs. Model-fitting analyses were done to analyse genetic and environmental components of vaccine responses. Findings Anti-HBs and anti-HAV showed heritabilities of 0.61 (95% CI 0.41 to 0.81) and 0.36 (-0.02 to 0.73), respectively. For the anti-HBs immune response, 60% of the phenotypic variance was explained by additive genetic and 40% by non-shared environmental effects. The heritability of the HBsAg vaccine response accounted for by the DRB1* locus was estimated to be 0.25, leaving the remaining heritability of 0.36 to other gene loci. Interpretation Genetic factors have a strong effect on the immune response to HBsAg. Although genes encoded within the MHC are important for this immune response, more than half the heritability is determined outside this complex. Identification of these genes will help us to understand regulation of immune responses to viral proteins.	Johannes Gutenberg Univ Mainz, Med Klin & Poliklin, Dept Internal Med, D-55101 Mainz, Germany; Univ Bonn, Inst Med Biometry Informat & Epidemiol, D-5300 Bonn, Germany; GlaxoSmithKline, Munich, Germany; Johannes Gutenberg Univ Mainz, Inst Legal Med, D-6500 Mainz, Germany	Johannes Gutenberg University of Mainz; University of Bonn; GlaxoSmithKline; Johannes Gutenberg University of Mainz	Hohler, T (corresponding author), Johannes Gutenberg Univ Mainz, Med Klin & Poliklin, Dept Internal Med, D-55101 Mainz, Germany.	hoehler@mail.uni-mainz.de	Schneider, Peter M./A-6661-2011	Schneider, Peter M./0000-0003-0744-2349; Freitag, Christine Margarete/0000-0001-9676-4782				Ahn SH, 2000, HEPATOLOGY, V31, P1371, DOI 10.1053/jhep.2000.7988; ALMARRI A, 1994, LANCET, V344, P1194, DOI 10.1016/S0140-6736(94)90510-X; ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103; BEIN G, 1992, TISSUE ANTIGENS, V39, P68, DOI 10.1111/j.1399-0039.1992.tb01909.x; Bellamy R, 1998, QJM-INT J MED, V91, P13, DOI 10.1093/qjmed/91.1.13; Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614; CRAVEN DE, 1986, ANN INTERN MED, V105, P356, DOI 10.7326/0003-4819-105-3-356; Desombere I, 1998, TISSUE ANTIGENS, V51, P593, DOI 10.1111/j.1399-0039.1998.tb03001.x; Hill AVS, 2001, ANNU REV GENOM HUM G, V2, P373, DOI 10.1146/annurev.genom.2.1.373; Hohler T, 1998, EXP CLIN IMMUNOGENET, V15, P130, DOI 10.1159/000019064; Hohler T, 1998, CLIN EXP IMMUNOL, V111, P579; Hohler T, 1997, J HEPATOL, V26, P503, DOI 10.1016/S0168-8278(97)80414-X; Hohler T, 1998, HUM IMMUNOL, V59, P212, DOI 10.1016/S0198-8859(98)00014-7; Jepson A, 1997, INFECT IMMUN, V65, P872, DOI 10.1128/IAI.65.3.872-876.1997; Karayiannis P, 1995, HEPATOLOGY, V22, P1628, DOI 10.1016/0270-9139(95)90183-3; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; Lemon SM, 1997, NEW ENGL J MED, V336, P196, DOI 10.1056/NEJM199701163360307; LIN TM, 1989, ANTICANCER RES, V9, P737; Martin MP, 1998, IMMUNOGENETICS, V47, P503, DOI 10.1007/s002510050392; Neale M. C., 1999, MX STAT MODELING; Neale MC, 1992, METHODOLOGY GENETIC; *SAS I INC, 1997, SAS ETS SOFTW CHANG; Thio CL, 2000, HEPATOLOGY, V31, P819, DOI 10.1053/he.2000.4316; Thoelen S, 1999, VACCINE, V17, P1657, DOI 10.1016/S0264-410X(98)00421-6; Thomas HC, 1996, LANCET, V348, P1417, DOI 10.1016/S0140-6736(96)05409-8; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; Vogel F., 1997, HUMAN GENETICS PROBL; Zhang L, 2000, HEPATOLOGY, V32, p392A	28	145	158	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	2002	360	9338					991	995		10.1016/S0140-6736(02)11083-X	http://dx.doi.org/10.1016/S0140-6736(02)11083-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383669				2022-12-28	WOS:000178249000012
J	Ma, JY; Wollmann, R; Lindquist, S				Ma, JY; Wollmann, R; Lindquist, S			Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol	SCIENCE			English	Article							STRAUSSLER-SCHEINKER-DISEASE; MUTANT PRION PROTEIN; TRANSGENIC MICE; THERMODYNAMIC STABILITY; ENDOPLASMIC-RETICULUM; INSERTIONAL MUTATION; SCRAPIE; CELLS; TRANSMISSION; EXPRESSION	Changes in prion protein (PrP) folding are associated with fatal neurodegenerative disorders, but the neurotoxic species is unknown. Like other proteins that traffic through the endoplasmic reticulum, misfolded PrP is retrograde transported to the cytosol for degradation by proteasomes. Accumulation of even small amounts of cytosolic PrP was strongly neurotoxic in cultured cells and transgenic mice. Mice developed normally but acquired severe ataxia, with cerebellar degeneration and gliosis. This establishes a mechanism for converting wild-type PrP to a highly neurotoxic species that is distinct from the self-propagating PrPSc isoform and suggests a potential common framework for seemingly diverse PrP neurodegenerative disorders.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute; University of Chicago; University of Chicago	Lindquist, S (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			Ma, Jiyan/0000-0001-7150-1898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; Aguzzi A, 2000, CELL DEATH DIFFER, V7, P889, DOI 10.1038/sj.cdd.4400737; Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; Doyle D, 1998, TRENDS GENET, V14, P171, DOI 10.1016/S0168-9525(98)01454-1; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Holscher C, 2001, J BIOL CHEM, V276, P13388, DOI 10.1074/jbc.M007331200; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V192, P525, DOI 10.1006/bbrc.1993.1447; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Piccardo P, 1998, J NEUROPATH EXP NEUR, V57, P979, DOI 10.1097/00005072-199810000-00010; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RUSSELAKISCARNE.M, 2002, J BIOL CHEM, V18, P18; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396	41	380	396	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 29	2002	298	5599					1781	1785		10.1126/science.1073725	http://dx.doi.org/10.1126/science.1073725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	619UA	12386337				2022-12-28	WOS:000179494800043
J	Guttmacher, AE; Collins, FS				Guttmacher, AE; Collins, FS			Genomic medicine - A primer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							APOLIPOPROTEIN-E; LINKAGE DISEQUILIBRIUM; MOLECULAR-GENETICS; DISEASE; RISK		NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Guttmacher, AE (corresponding author), NHGRI, NIH, Bldg 31,Rm 4B09, Bethesda, MD 20892 USA.	guttmach@mail.nih.gov						Adams FL, 1886, GENUINE WORKS HIPPOC, V2, P338; Armstrong K, 2000, NEW ENGL J MED, V342, P564, DOI 10.1056/NEJM200002243420807; Campion D, 1999, AM J HUM GENET, V65, P664, DOI 10.1086/302553; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; Dean M, 1996, SCIENCE, V274, P1069; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Froguel P, 1999, TRENDS ENDOCRIN MET, V10, P142, DOI 10.1016/S1043-2760(98)00134-9; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Goldstein DB, 2001, CURR BIOL, V11, pR576, DOI 10.1016/S0960-9822(01)00348-7; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Horikawa Y, 2000, NAT GENET, V26, P502; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LUZZATTO L, 2001, METABOLIC MOL BASES, V3, P4517; Lynch HT, 1999, CYTOGENET CELL GENET, V86, P130, DOI 10.1159/000015365; Major DA, 2000, AM HEART J, V140, P189, DOI 10.1067/mhj.2000.108241; McKusick V., 1987, GENOMICS, V1, P1; McKusick V.A., 1998, MENDELIAN INHERITANC; Michael NL, 1999, CURR OPIN IMMUNOL, V11, P466, DOI 10.1016/S0952-7915(99)80078-8; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; Nathanson KL, 2001, NAT MED, V7, P749; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Online Mendelian Inheritance in Man OMIM, 2000, ONL MEND INH MAN OMI; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Robinson WP, 2000, BIOESSAYS, V22, P452; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Roses AD, 1998, AM J MED GENET, V81, P49, DOI 10.1002/(SICI)1096-8628(19980207)81:1<49::AID-AJMG10>3.0.CO;2-W; Sinden RR, 1999, AM J HUM GENET, V64, P346, DOI 10.1086/302271; Small PM, 2001, NEW ENGL J MED, V345, P189, DOI 10.1056/NEJM200107193450307; St George-Hyslop PH, 1999, SEMIN NEUROL, V19, P371, DOI 10.1055/s-2008-1040852; Todd JA, 1999, BIOESSAYS, V21, P164, DOI 10.1002/(SICI)1521-1878(199902)21:2<164::AID-BIES10>3.3.CO;2-W; Venter JC, 2001, SCIENCE, V292, P1838; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	40	394	416	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2002	347	19					1512	1520		10.1056/NEJMra012240	http://dx.doi.org/10.1056/NEJMra012240			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611XG	12421895				2022-12-28	WOS:000179042700009
J	Washington, DL; Stevens, CD; Shekelle, PG; Henneman, PL; Brook, RH				Washington, DL; Stevens, CD; Shekelle, PG; Henneman, PL; Brook, RH			Next-day care for emergency department users with nonacute conditions - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							PUBLIC HOSPITAL EMERGENCY; QUALITY-OF-LIFE; DEPARTMENTS; CONSEQUENCES; PHYSICIAN; LEAVE	Background: Because of overcrowding and cost-control efforts, emergency departments are under pressure to refer patients with nonacute conditions to other settings. However, no validated systematic methods exist for safely performing such referrals. Objective: To determine the effects on health status and access to care of systematically referring patients with nonacute conditions to next-day primary care. Design: Randomized, controlled trial. Setting: An emergency department in a public hospital. Patients: 156 adults who used the emergency department on weekdays from 7:00 a.m. to 3:00 p.m. and met criteria for deferred care. The criteria applied to three symptom complexes that account for 33% of U.S. emergency department visits by adults. Intervention: Next-day care at the study site's primary care center or usual same-day care. Measurements: Self-reported health status and use of health services during 1-week follow-up. Results: Patients assigned to next-day care did not demonstrate clinically important disadvantages in health status or physician visits compared with usual care patients. In each group, more than 95% of patients were evaluated at least once by a physician, 4% sought health services after their initial evaluation, and no patients were hospitalized or died. At follow-up, both groups reported improved health status and fewer days in bed or with disability, although the deferred care group reported less improvement on all three measures. The 95% Cls were sufficiently narrow to exclude a clinically significant difference in self-reported health status. However, the possibility of 1 additional day in bed or with disability in the deferred care group could not be excluded. Conclusions: Clinically detailed standardized screening criteria can safely identify patients at public hospital emergency departments for referral to next-day care. However, larger studies are needed to assess the possibility of adverse effects.	Vet Affairs Greater Los Angeles Healthcare syst, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; RAND Hlth, Santa Monica, CA USA; Baystate Med Ctr, Springfield, MA USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; RAND Corporation; Baystate Medical Center; Tufts University	Washington, DL (corresponding author), Vet Affairs Greater Los Angeles Healthcare syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA.	donna.washington@med.va.gov	Washington, Donna/AAW-2191-2021					BAKER DW, 1994, JAMA-J AM MED ASSOC, V271, P1909, DOI 10.1001/jama.271.24.1909; BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; BERMAN DA, 1989, ANN EMERG MED, V18, P141, DOI 10.1016/S0196-0644(89)80102-7; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; Birnbaum A, 1994, Acad Emerg Med, V1, P213; *CYT, 2001, STAT SOFTW EX NONP I; Derlet RW, 2001, ACAD EMERG MED, V8, P151, DOI 10.1111/j.1553-2712.2001.tb01280.x; Derlet RW, 2000, ANN EMERG MED, V35, P63, DOI 10.1016/S0196-0644(00)70105-3; DERLET RW, 1990, ANN EMERG MED, V19, P262, DOI 10.1016/S0196-0644(05)82041-4; DERLET RW, 1995, ANN EMERG MED, V25, P215, DOI 10.1016/S0196-0644(95)70327-6; FIELDS W, 1999, DEFENDING AM SAFETY; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Hobbs D, 2000, AM J EMERG MED, V18, P767, DOI 10.1053/ajem.2000.18075; Kim MY, 2001, STAT MED, V20, P2065, DOI 10.1002/sim.847; Lambe S, 2002, ANN EMERG MED, V39, P389, DOI 10.1067/mem.2002.122433; Lowe GDO, 2001, AGE AGEING, V30, P101, DOI 10.1093/ageing/30.2.101; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; *SAS I, 1989, SAS LANG PROC US VER; Scharli AF, 1998, PEDIATR SURG INT, V13, P1; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STOCK LM, 1994, ANN EMERG MED, V23, P294, DOI 10.1016/S0196-0644(94)70043-5; *US EM DEP, 1993, HRD934 US EM DEP; VAUGHN PB, 1980, ANN EMERG MED, V9, P31, DOI 10.1016/S0196-0644(80)80438-0; Washington D L, 2001, Eff Clin Pract, V4, P65; Washington D L, 2000, Jt Comm J Qual Improv, V26, P87; Washington DL, 2000, ANN EMERG MED, V36, P15, DOI 10.1067/mem.2000.107003; Young GP, 1996, JAMA-J AM MED ASSOC, V276, P460, DOI 10.1001/jama.276.6.460; 1990, ANN EMERG MED, V19, P336; 2001, GAO01747	30	51	53	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2002	137	9					707	714		10.7326/0003-4819-137-9-200211050-00005	http://dx.doi.org/10.7326/0003-4819-137-9-200211050-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612BA	12416944				2022-12-28	WOS:000179052400001
J	Helmuth, B; Harley, CDG; Halpin, PM; O'Donnell, M; Hofmann, GE; Blanchette, CA				Helmuth, B; Harley, CDG; Halpin, PM; O'Donnell, M; Hofmann, GE; Blanchette, CA			Climate change and latitudinal patterns of intertidal thermal stress	SCIENCE			English	Article							COMMUNITY STRUCTURE; TEMPERATURE; LIMITS; ORGANISMS; ABUNDANCE; PREDATOR; MUSSELS	The interaction of climate and the timing of low tides along the West Coast of the United States creates a complex mosaic of thermal environments, in which northern sites can be more thermally stressful than southern sites. Thus, climate change may not lead to a poleward shift in the distribution of intertidal organisms, as has been proposed, but instead will likely cause localized extinctions at a series of "hot spots". Patterns of exposure to extreme climatic conditions are temporally variable, and tidal predictions suggest that in the next 3 to 5 years "hot spots" are likely to appear at several northern sites.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; Univ S Carolina, Marine Sci Program, Columbia, SC 29208 USA; Univ Washington, Dept Zool, Seattle, WA 98195 USA; Stanford Univ, Hopkins Marine Stn, Pacific Grove, CA 93950 USA; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Washington; University of Washington Seattle; Stanford University; Oregon State University; University of California System; University of California Santa Barbara	Helmuth, B (corresponding author), Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.		Harley, Christopher D. G./K-5593-2012; Helmuth, Brian/AAD-2664-2019	Harley, Christopher D. G./0000-0003-4099-943X; Helmuth, Brian/0000-0003-0180-3414; O'Donnell, Michael/0000-0001-7016-0614				BARRY JP, 1995, SCIENCE, V267, P672, DOI 10.1126/science.267.5198.672; BELL EC, 1995, J EXP MAR BIOL ECOL, V191, P29, DOI 10.1016/0022-0981(95)00037-R; BELL EC, 1992, THESIS STANFORD U; Bertness MD, 1999, OECOLOGIA, V120, P446, DOI 10.1007/s004420050877; Broitman BR, 2001, MAR ECOL PROG SER, V224, P21, DOI 10.3354/meps224021; Buckley BA, 2001, J EXP BIOL, V204, P3571; Dahlhoff EP, 2001, ECOLOGY, V82, P2816, DOI 10.2307/2679963; Denny MW, 1998, BIOL BULL, V194, P108, DOI 10.2307/1543040; DOTY MS, 1946, ECOLOGY, V27, P315, DOI 10.2307/1933542; FIELDS PA, 1993, TRENDS ECOL EVOL, V8, P361, DOI 10.1016/0169-5347(93)90220-J; FRANK PW, 1975, MAR BIOL, V31, P181, DOI 10.1007/BF00391630; Gaylord B, 2000, AM NAT, V155, P769, DOI 10.1086/303357; GILMAN SE, 2002, 35 ANN M W SOC MAL A; Helmuth B, 1999, ECOLOGY, V80, P15; HELMUTH B, IN PRESS INTEGR COMP; Helmuth BST, 2001, BIOL BULL-US, V201, P374, DOI 10.2307/1543615; Helmuth BST, 1998, ECOL MONOGR, V68, P51, DOI 10.1890/0012-9615(1998)068[0051:IMMPTB]2.0.CO;2; Hofmann GE, 1996, MOL MAR BIOL BIOTECH, V5, P175; HOFMANN GE, UNPUB; JOHNSON SE, 1975, PERSPECTIVES BIOPHYS, P559; Lubchenco Jane, 1993, P147; MENGE B, COMMUNICATION; Menge BA, 1997, P NATL ACAD SCI USA, V94, P14530, DOI 10.1073/pnas.94.26.14530; MENGE BA, 1990, TRENDS ECOL EVOL, V5, P52, DOI 10.1016/0169-5347(90)90048-I; ORTON J. H., 1929, JOUR MARINE BIOL ASSOC UNITED KINGDOM, V16, P289; PAINE R T, 1974, Oecologia (Berlin), V15, P93, DOI 10.1007/BF00345739; Paine R. T., 1994, MARINE ROCKY SHORES; Roberts DA, 1997, BIOL BULL, V192, P309, DOI 10.2307/1542724; Sagarin RD, 1999, ECOL MONOGR, V69, P465, DOI 10.1890/0012-9615(1999)069[0465:CRCIAI]2.0.CO;2; Sagarin RD, 2002, J BIOGEOGR, V29, P985, DOI 10.1046/j.1365-2699.2002.00705.x; Sagarin RD, 2002, ECOL LETT, V5, P137, DOI 10.1046/j.1461-0248.2002.00297.x; Sanford E, 1999, SCIENCE, V283, P2095, DOI 10.1126/science.283.5410.2095; SOUTHWARD AJ, 1958, J MAR BIOL ASSOC UK, V37, P49, DOI 10.1017/S0025315400014818; SOUTHWARD AJ, 1995, J THERM BIOL, V20, P127, DOI 10.1016/0306-4565(94)00043-I; Tomanek L, 1999, J EXP BIOL, V202, P2925; WETHEY DS, 1983, BIOL BULL-US, V165, P330, DOI 10.2307/1541373; Wootton JT, 1997, ECOL MONOGR, V67, P45, DOI 10.1890/0012-9615(1997)067[0045:EATOPC]2.0.CO;2; [No title captured]	38	530	536	1	181	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					1015	1017		10.1126/science.1076814	http://dx.doi.org/10.1126/science.1076814			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411702				2022-12-28	WOS:000178932000053
J	Bhimji, A; Harrison, D				Bhimji, A; Harrison, D			Male circumcision, penile human papillomavirus infection, and cervical cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Assoc Genital Integr, Vancouver, BC V5Z 4R3, Canada		Bhimji, A (corresponding author), Assoc Genital Integr, Vancouver, BC V5Z 4R3, Canada.							Taylor JR, 1996, BRIT J UROL, V77, P291, DOI 10.1046/j.1464-410X.1996.85023.x; WINKELMANN RK, 1959, P STAFF M MAYO CLIN, V34, P39	2	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1452	1452						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12418039				2022-12-28	WOS:000178888400024
J	Christlieb, N; Bessell, MS; Beers, TC; Gustafsson, B; Korn, A; Barklem, PS; Karlsson, T; Mizuno-Wiedmer, M; Rossi, S				Christlieb, N; Bessell, MS; Beers, TC; Gustafsson, B; Korn, A; Barklem, PS; Karlsson, T; Mizuno-Wiedmer, M; Rossi, S			A stellar relic from the early Milky Way	NATURE			English	Article							INITIAL MASS FUNCTION; METAL-POOR STARS; POST-AGB STARS; POPULATION-III; HAMBURG/ESO SURVEY; ATMOSPHERES; ORIGIN	The chemical composition of the most metal-deficient stars largely reflects the composition of the gas from which they formed. These old stars provide crucial clues to the star formation history and the synthesis of chemical elements in the early Universe. They are the local relics of epochs otherwise observable only at very high redshifts(1,2); if totally metal-free ('population III') stars could be found, this would allow the direct study of the pristine gas from the Big Bang. Earlier searches for such stars found none with an iron abundance less than 1/10,000 that of the Sun(3,4), leading to the suggestion 5,6 that low-mass stars could form from clouds above a critical iron abundance. Here we report the discovery of a low-mass star with an iron abundance as low as 1/200,000 of the solar value. This discovery suggests that population III stars could still exist-that is, that the first generation of stars also contained long-lived low-mass objects. The previous failure to find them may be an observational selection effect.	Hamburger Sternwarte, D-21029 Hamburg, Germany; Uppsala Univ, Dept Space Phys & Astron, SE-75120 Uppsala, Sweden; Mt Stromlo & Siding Spring Observ, Res Sch Astron & Astrophys, Weston, ACT 2611, Australia; Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA; Univ Sternwarte Munchen, D-81679 Munich, Germany; Univ Sao Paulo, Dept Astron, Inst Astron Geofis & Ciencias Atmosfer, BR-05508900 Sao Paulo, Brazil	University of Hamburg; Uppsala University; Australian National University; Michigan State University; University of Munich; Universidade de Sao Paulo	Christlieb, N (corresponding author), Hamburger Sternwarte, Gojenbergsweg 112, D-21029 Hamburg, Germany.		ROSSI, SILVIA C F/M-8647-2019; Beers, Timothy/D-1193-2019; Rossi, Silvia C F/E-9157-2012	ROSSI, SILVIA C F/0000-0001-7479-5756; Rossi, Silvia C F/0000-0001-7479-5756; Christlieb, Norbert/0000-0002-4043-2727; Bessell, Michael/0000-0001-7801-1410; Korn, Andreas/0000-0002-3881-6756				Aoki W, 2002, ASTROPHYS J, V567, P1166, DOI 10.1086/338756; Bakker EJ, 1996, ASTRON ASTROPHYS, V306, P924; Beers TC, 1999, ASTR SOC P, V165, P202; BOND HE, 1981, ASTROPHYS J, V248, P606, DOI 10.1086/159186; Bromm V, 2001, MON NOT R ASTRON SOC, V328, P969, DOI 10.1046/j.1365-8711.2001.04915.x; Cayrel R, 2001, NATURE, V409, P691, DOI 10.1038/35055507; Christlieb N, 2001, ASTRON ASTROPHYS, V366, P898, DOI 10.1051/0004-6361:20000269; Cohen JG, 2002, ASTRON J, V124, P470, DOI 10.1086/340954; Fujimoto MY, 2000, ASTROPHYS J, V529, pL25, DOI 10.1086/312453; GASS H, 1988, ASTRON ASTROPHYS, V189, P194; MATHIS JS, 1992, ASTRON ASTROPHYS, V259, pL39; MCCLURE RD, 1990, ASTROPHYS J, V352, P709, DOI 10.1086/168573; Norris JE, 2001, ASTROPHYS J, V561, P1034, DOI 10.1086/323429; Norris JE, 1997, ASTROPHYS J, V489, pL169, DOI 10.1086/316787; Ostriker JP, 1996, ASTROPHYS J, V472, pL63, DOI 10.1086/310375; PALLA F, 1983, ASTROPHYS J, V271, P632, DOI 10.1086/161231; Ryan SG, 1999, ASTROPHYS J, V523, P654, DOI 10.1086/307769; SCHLATTL H, 2002, IN PRESS ASTRON ASTR; Schneider R, 2002, ASTROPHYS J, V571, P30, DOI 10.1086/339917; Siess L, 2002, ASTROPHYS J, V570, P329, DOI 10.1086/339733; VANWINCKEL H, 1995, ASTRON ASTROPHYS, V293, pL25; WATERS LBFM, 1992, ASTRON ASTROPHYS, V262, pL37; Wisotzki L, 2000, ASTRON ASTROPHYS, V358, P77; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; Yi S, 2001, ASTROPHYS J SUPPL S, V136, P417, DOI 10.1086/321795; YOSHII Y, 1981, ASTRON ASTROPHYS, V97, P280; YOSHII Y, 1979, PUBL ASTRON SOC JPN, V31, P505; YOSHII Y, 1986, ASTROPHYS J, V301, P587, DOI 10.1086/163925	29	468	470	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					904	906		10.1038/nature01142	http://dx.doi.org/10.1038/nature01142			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410304				2022-12-28	WOS:000178909700036
J	Dyment, DA; Ebers, GC				Dyment, DA; Ebers, GC			An array of sunshine in multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Oxford, Oxford OX2 6HE, England	University of Oxford	Dyment, DA (corresponding author), Univ Oxford, Oxford OX2 6HE, England.			Ebers, George/0000-0003-4771-4177				Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Whitney LW, 1999, ANN NEUROL, V46, P425	2	20	21	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1445	1447		10.1056/NEJMcibr021828	http://dx.doi.org/10.1056/NEJMcibr021828			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12409550				2022-12-28	WOS:000178888400011
J	Nunez, L; Grosjean, M; Cartajena, I				Nunez, L; Grosjean, M; Cartajena, I			Human occupations and climate change in the Puna de Atacama, Chile	SCIENCE			English	Article							NORTHERN; DESERT; RECORD; PRECIPITATION; CULTURE; HISTORY	Widespread evidence for human occupation of the Atacama Desert, 20degrees to 25degreesS in northern Chile, has been found from 13,000 calibrated 14 C years before the present (cal yr B. P.) to 9500 cal yr B. P., and again after 4500 cal yr B. P. Initial human occupation coincided with a change from very dry environments to humid environments. More than 39 open early Archaic campsites at elevations above 3600 meters show that hunters lived around late glacial/early Holocene paleolakes on the Altiplano. Cessation of the use of the sites between 9500 and 4500 cal yr B. P. is associated with drying of the lakes. The mid-Holocene collapse of human occupation is also recorded in cave deposits. One cave contained Pleistocene fauna associated with human artifacts. Faunal diversity was highest during the humid early Holocene.	Univ Bern, Natl Ctr Competence Res Climate, CH-3012 Bern, Switzerland; Univ Catolica Norte, Inst Invest Arqueol & Museo, San Pedro, Atacama, Chile; Univ Chile, Dept Antropol, Santiago, Chile	University of Bern; Universidad Catolica del Norte; Universidad de Chile	Grosjean, M (corresponding author), Univ Bern, Natl Ctr Competence Res Climate, 9A Erlachstr, CH-3012 Bern, Switzerland.	grosjean@giub.unibe.ch	Cartajena, Isabel/AAO-8406-2021	Cartajena, Isabel/0000-0003-4048-5359				ALBERDI MT, COMMUNICATION; ALDENDERFER M, 1988, SCIENCE, V241, P1828, DOI 10.1126/science.241.4874.1828; Baker PA, 2001, SCIENCE, V291, P640, DOI 10.1126/science.291.5504.640; Betancourt JL, 2000, SCIENCE, V289, P1542, DOI 10.1126/science.289.5484.1542; DILLEHAY TD, 1989, SCIENCE, V245, P1436; Fernandez J., 1991, Geoarchaeology, V6, P251, DOI 10.1002/gea.3340060303; *FOND NAC DES CIEN, 1930022 FOND NAC DES; Geyh MA, 1999, QUATERNARY RES, V52, P143, DOI 10.1006/qres.1999.2060; Grosjean M, 2001, SCIENCE, V292; Grosjean M, 1997, QUATERNARY RES, V48, P239, DOI 10.1006/qres.1997.1917; Grosjean M, 2001, GLOBAL PLANET CHANGE, V28, P35, DOI 10.1016/S0921-8181(00)00063-1; Latorre C, 2002, GEOL SOC AM BULL, V114, P349, DOI 10.1130/0016-7606(2002)114<0349:VIIADA>2.0.CO;2; LYNCH TF, 1992, QUATERNARY RES, V37, P117, DOI 10.1016/0033-5894(92)90010-G; Meltzer DJ, 1997, AM ANTIQUITY, V62, P659, DOI 10.2307/281884; N??ez AL., 1999, ESTUD ATACAMENOS, V17, P125; N??ez L., 2001, INTERHEMISPHERIC CLI, P105; *NAT GEOGR SOC, 583696 NAT GEOGR SOC; Sandweiss DH, 1999, SCIENCE, V283, P499, DOI 10.1126/science.283.5401.499; Sandweiss DH, 1998, SCIENCE, V281, P1830, DOI 10.1126/science.281.5384.1830; Seltzer GO, 1998, GEOLOGY, V26, P167, DOI 10.1130/0091-7613(1998)026<0167:HRSRPF>2.3.CO;2; *SWISS NAT SCI FDN, 2157073 SWISS NAT SC; Thompson LG, 1998, SCIENCE, V282, P1858, DOI 10.1126/science.282.5395.1858; TONNI EP, COMMUNICATION	23	197	213	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					821	824		10.1126/science.1076449	http://dx.doi.org/10.1126/science.1076449			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399589				2022-12-28	WOS:000178791200057
J	Chen, JH; Weidner, DJ; Vaughan, MT				Chen, JH; Weidner, DJ; Vaughan, MT			The strength of Mg(0.9)Fe(0.1)SiO(3) perovskite at high pressure and temperature	NATURE			English	Article							MGSIO3 PEROVSKITE; SUBDUCTED SLABS; LOWER MANTLE; CREEP; CATIO3; EARTHQUAKES; PLASTICITY; VISCOSITY; RHEOLOGY; ANALOG	The Earth's lower mantle consists mainly of (Mg,Fe)SiO(3) perovskite and (Mg,Fe)O magnesiowustite, with the perovskite taking up at least 70 per cent of the total volume(1). Although the rheology of olivine, the dominant upper-mantle mineral, has been extensively studied, knowledge about the rheological behaviour of perovskite is limited. Seismological studies indicate that slabs of subducting oceanic lithosphere are often deflected horizontally at the perovskite-forming depth, and changes in the Earth's shape and gravity field during glacial rebound indicate that viscosity increases in the lower part of the mantle. The rheological properties of the perovskite may be important in governing these phenomena. But (Mg,Fe)SiO(3) perovskite is not stable at high temperatures under ambient pressure, and therefore mechanical tests on (Mg,Fe)SiO(3) perovskite are difficult. Most rheological studies of perovskite have been performed on analogous materials(2-7), and the experimental data on (Mg,Fe)SiO(3) perovskite are limited to strength measurements at room temperature in a diamond-anvil cell(8) and microhardness tests at ambient conditions(9). Here we report results of strength and stress relaxation measurements of (Mg(0.9)Fe(0.1))SiO(3) perovskite at high pressure and temperature. Compared with the transition-zone mineral ringwoodite(10) at the same pressure and temperature, we found that perovskite is weaker at room temperature, which is consistent with a previous diamond-anvil-cell experiment(8), but that perovskite is stronger than ringwoodite at high temperature.	SUNY Stony Brook, Inst Mineral Phys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Chen, JH (corresponding author), SUNY Stony Brook, Inst Mineral Phys, Stony Brook, NY 11794 USA.	jiuhua.chen@sunysb.edu						ANDERSON DL, 1986, NATURE, V320, P321, DOI 10.1038/320321a0; Chen JH, 1998, GEOPHYS RES LETT, V25, P575, DOI 10.1029/98GL00043; Chen JH, 1998, GEOPHYS RES LETT, V25, P1103, DOI 10.1029/98GL00733; DECKER DL, 1971, J APPL PHYS, V42, P3239, DOI 10.1063/1.1660714; DERBY B, 1990, DEFORMATION PROCESSE, P354; DOUKHAN N, 1986, PHYS CHEM MINER, V13, P403; Frost H.J., 1982, DEFORMATION MECH MAP; GERWARD L, 1976, J APPL PHYS, V47, P822, DOI 10.1063/1.322714; GRIGGS DT, 1969, PROPERTIES MATTER UN, P23; GURNIS M, 1988, NATURE, V335, P317, DOI 10.1038/335317a0; KARATO S, 1989, PHYS EARTH PLANET IN, V55, P234, DOI 10.1016/0031-9201(89)90071-X; KARATO S, 1992, SCIENCE, V255, P1238, DOI 10.1126/science.255.5049.1238; KARATO S, 1990, GEOPHYS RES LETT, V17, P13, DOI 10.1029/GL017i001p00013; Karato S, 2001, PHYS EARTH PLANET IN, V127, P83, DOI 10.1016/S0031-9201(01)00223-0; LALLEMANT HGA, 1978, TECTONOPHYSICS, V48, P1, DOI DOI 10.1016/0040-1951(78)90083-5; Li P, 1996, PHYS EARTH PLANET IN, V95, P19, DOI 10.1016/0031-9201(95)03107-3; MEADE C, 1990, NATURE, V348, P533, DOI 10.1038/348533a0; OGAWA M, 1987, J GEOPHYS RES-SOLID, V92, P13801, DOI 10.1029/JB092iB13p13801; POIRIER JP, 1983, PHYS EARTH PLANET IN, V32, P273, DOI 10.1016/0031-9201(83)90131-0; SAPRIEL J, 1975, PHYS REV B, V12, P5128, DOI 10.1103/PhysRevB.12.5128; Shimizu I, 1998, GEOPHYS RES LETT, V25, P4237, DOI 10.1029/1998GL900136; TOLEDANO JC, 1980, PHYS REV B, V21, P1139, DOI 10.1103/PhysRevB.21.1139; WANG YB, 1990, SCIENCE, V248, P468, DOI 10.1126/science.248.4954.468; Weidner D.J., 1992, HIGH PRESSURE RES AP, V67, P13; Weidner DJ, 1998, GEOPH MONOG SERIES, V101, P473; WEIDNER DJ, 1994, GEOPHYS RES LETT, V21, P753, DOI 10.1029/93GL03549; Weidner DJ, 2001, PHYS EARTH PLANET IN, V127, P67, DOI 10.1016/S0031-9201(01)00222-9; WRIGHT K, 1992, PHYS EARTH PLANET IN, V74, P9, DOI 10.1016/0031-9201(92)90064-3; ZHAO YS, 1994, AM MINERAL, V79, P615	29	71	74	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					824	826		10.1038/nature01130	http://dx.doi.org/10.1038/nature01130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397354				2022-12-28	WOS:000178769800042
J	Herndon, LA; Schmeissner, PJ; Dudaronek, JM; Brown, PA; Listner, KM; Sakano, Y; Paupard, MC; Hall, DH; Driscoll, M				Herndon, LA; Schmeissner, PJ; Dudaronek, JM; Brown, PA; Listner, KM; Sakano, Y; Paupard, MC; Hall, DH; Driscoll, M			Stochastic and genetic factors influence tissue-specific decline in ageing C-elegans	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; LIFE-SPAN; STRESS RESISTANCE; QUANTITATIVE MEASURES; CELL-DEATH; GERM-LINE; EXPRESSION; MECHANISMS; MUTATIONS; LONGEVITY	The nematode Caenorhabditis elegans is an important model for studying the genetics of ageing, with over 50 life-extension mutations known so far. However, little is known about the pathobiology of ageing in this species, limiting attempts to connect genotype with senescent phenotype. Using ultrastructural analysis and visualization of specific cell types with green fluorescent protein, we examined cell integrity in different tissues as the animal ages. We report remarkable preservation of the nervous system, even in advanced old age, in contrast to a gradual, progressive deterioration of muscle, resembling human sarcopenia. The age-1 (hx546) mutation, which extends lifespan by 60-100%, delayed some, but not all, cellular biomarkers of ageing. Strikingly, we found strong evidence that stochastic as well as genetic factors are significant in C. elegans ageing, with extensive variability both among same-age animals and between cells of the same type within individuals.	Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Biol Labs A232, Piscataway, NJ 08854 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Rutgers State University New Brunswick; Yeshiva University; Albert Einstein College of Medicine	Driscoll, M (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Biol Labs A232, 604 Allison Rd, Piscataway, NJ 08854 USA.	hall@aecom.yu.edu; driscoll@mbcl.rutgers.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR012596] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [R24OD010943] Funding Source: NIH RePORTER; NCRR NIH HHS [R24 RR012596] Funding Source: Medline; NIH HHS [R24 OD010943] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Arantes-Oliveira N, 2002, SCIENCE, V295, P502, DOI 10.1126/science.1065768; BOLANOWSKI MA, 1983, MECH AGEING DEV, V21, P295, DOI 10.1016/0047-6374(83)90048-9; BOLANOWSKI MA, 1981, MECH AGEING DEV, V15, P279, DOI 10.1016/0047-6374(81)90136-6; Braeckman BP, 2001, MECH AGEING DEV, V122, P673, DOI 10.1016/S0047-6374(01)00222-6; Campagnola PJ, 2002, BIOPHYS J, V82, P493, DOI 10.1016/S0006-3495(02)75414-3; Colavita A, 1998, SCIENCE, V281, P706, DOI 10.1126/science.281.5377.706; Driscoll M, 1996, BRAIN PATHOL, V6, P411, DOI 10.1111/j.1750-3639.1996.tb00873.x; DUHON SA, 1995, J GERONTOL A-BIOL, V50, pB254, DOI 10.1093/gerona/50A.5.B254; Epstein J, 1972, MECH AGEING DEV, V1, P245, DOI 10.1016/0047-6374(72)90091-7; Finch C, 2000, CHANCE DEV AGING; FRIEDMAN DB, 1988, GENETICS, V118, P75; FUJISAWA K, 1975, J NEUROL SCI, V24, P447, DOI 10.1016/0022-510X(75)90170-7; Garigan D, 2002, GENETICS, V161, P1101; Hall DH, 1999, DEV BIOL, V212, P101, DOI 10.1006/dbio.1999.9356; Hall DH, 1997, J NEUROSCI, V17, P1033; Hall DH, 1995, METHOD CELL BIOL, V48, P395; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Helfand SL, 1996, MECH DEVELOP, V55, P45, DOI 10.1016/0925-4773(95)00489-0; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hughes SM, 1999, ACTA PHYSIOL SCAND, V167, P307; Johnson TE, 2001, EXP GERONTOL, V36, P1609, DOI 10.1016/S0531-5565(01)00144-9; JOHNSON TE, 1987, P NATL ACAD SCI USA, V84, P3777, DOI 10.1073/pnas.84.11.3777; JOHNSON TE, 1985, MECH AGEING DEV, V30, P285, DOI 10.1016/0047-6374(85)90118-6; Jucker M, 2000, EXP GERONTOL, V35, P1383, DOI 10.1016/S0531-5565(00)00190-X; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kirkwood TBL, 1996, BIOESSAYS, V18, P1009, DOI 10.1002/bies.950181211; Kirkwood TBL, 2002, MECH AGEING DEV, V123, P737, DOI 10.1016/S0047-6374(01)00419-5; Kirkwood TBL, 2002, NEUROBIOL AGING, V23, P21, DOI 10.1016/S0197-4580(01)00260-3; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; LEONARD DS, 1992, J NEUROBIOL, V23, P605, DOI 10.1002/neu.480230602; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; Lithgow GJ, 2002, MECH AGEING DEV, V123, P765, DOI 10.1016/S0047-6374(01)00422-5; Lund J, 2002, CURR BIOL, V12, P1566, DOI 10.1016/S0960-9822(02)01146-6; MADURO M, 1995, GENETICS, V141, P977; MITANI S, 1993, DEVELOPMENT, V119, P773; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Paupard MC, 2001, J HISTOCHEM CYTOCHEM, V49, P949, DOI 10.1177/002215540104900803; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Rogina B, 1998, CURR BIOL, V8, P475, DOI 10.1016/S0960-9822(98)70184-8; Sozou PD, 2001, J THEOR BIOL, V213, P573, DOI 10.1006/jtbi.2001.2432; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TAKAHASHI A, 1970, J GERONTOL, V25, P222, DOI 10.1093/geronj/25.3.222; Vanfleteren JR, 1999, NEUROBIOL AGING, V20, P487, DOI 10.1016/S0197-4580(99)00087-1; Waterston R., 1988, NEMATODE C ELEGANS, P281; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147	48	777	800	2	108	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 24	2002	419	6909					808	814		10.1038/nature01135	http://dx.doi.org/10.1038/nature01135			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397350				2022-12-28	WOS:000178769800038
J	Czermin, B; Melfi, R; McCabe, D; Seitz, V; Imhof, A; Pirrotta, V				Czermin, B; Melfi, R; McCabe, D; Seitz, V; Imhof, A; Pirrotta, V			Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites	CELL			English	Article							GROUP GENE; HETEROCHROMATIN PROTEIN-1; EPIGENETIC INHERITANCE; TRANSCRIPTION FACTORS; CORE PARTICLES; LYSINE 9; HP1; METHYLATION; CHROMATIN; CONTAINS	Enhancer of Zeste is a Polycomb Group protein essential for the establishment and maintenance of repression of homeotic and other genes. In the early embryo it is found in a complex that includes ESC and is recruited to Polycomb Response Elements. We show that this complex contains a methyltransferase activity that methylates lysine 9 and lysine 27 of histone H3, but the activity is lost when the E(Z) SET domain is mutated. The lysine 9 position is trimethylated and this mark is closely associated with Polycomb binding sites on polytene chromosomes but is also found in centric heterochromatin, chromosome 4, and telomeric sites. Histone H3 methylated in vitro by the E(Z)/ ESC complex binds specifically to Polycomb protein.	Univ Geneva, Dept Zool, CH-1011 Lausanne, Switzerland; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Geneva; University of Munich	Pirrotta, V (corresponding author), Univ Geneva, Dept Zool, 30 Quai Ernest Ansermet, CH-1011 Lausanne, Switzerland.	pirrotta@zoo.unige.ch	Imhof, Axel/AAU-5313-2021; jia, xu/A-8386-2016	Imhof, Axel/0000-0003-2993-8249; MELFI, Raffaella/0000-0003-4463-8156				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Birve A, 2001, DEVELOPMENT, V128, P3371; Breiling A, 1999, MOL CELL BIOL, V19, P8451; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; BROWN KL, 1998, RRD INORG CHEM, V1, P1; Carrington EA, 1996, DEVELOPMENT, V122, P4073; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Cavalli G, 1999, SCIENCE, V286, P955, DOI 10.1126/science.286.5441.955; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; Fanti L, 1998, MOL CELL, V2, P527, DOI 10.1016/S1097-2765(00)80152-5; FAUVARQUE MO, 1995, MECH DEVELOP, V52, P343, DOI 10.1016/0925-4773(95)00412-T; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Guenther MG, 2000, GENE DEV, V14, P1048; Hwang KK, 2001, P NATL ACAD SCI USA, V98, P11423, DOI 10.1073/pnas.211303598; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; JONES RS, 1990, GENETICS, V126, P185; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; MARTIN EC, 1993, DEVELOPMENT, V117, P641; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng J, 2000, MOL CELL BIOL, V20, P3069, DOI 10.1128/MCB.20.9.3069-3078.2000; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; PHILLIPS MD, 1990, GENETICS, V125, P91; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Platero JS, 1996, CHROMOSOMA, V104, P393, DOI 10.1007/BF00352263; Poux S, 2002, DEVELOPMENT, V129, P2483; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; Poux S, 2001, DEVELOPMENT, V128, P75; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; SATHE SS, 1995, MECH DEVELOP, V52, P77, DOI 10.1016/0925-4773(95)00392-E; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; Tie F, 2001, DEVELOPMENT, V128, P275; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5	42	1210	1253	1	55	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	2002	111	2					185	196		10.1016/S0092-8674(02)00975-3	http://dx.doi.org/10.1016/S0092-8674(02)00975-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408863	Bronze			2022-12-28	WOS:000178753500008
J	Iyer, R; Iverson, TM; Accardi, A; Miller, C				Iyer, R; Iverson, TM; Accardi, A; Miller, C			A biological role for prokaryotic ClC chloride channels	NATURE			English	Article							ESCHERICHIA-COLI; ACID RESISTANCE; POTASSIUM CHANNEL; LIGAND-BINDING; MECHANISMS; EXPRESSION; GLUTAMATE; DISRUPTION; PROTEINS; HOMOLOG	An unexpected finding emerging from large-scale genome analyses is that prokaryotesexpress ion channels belonging to molecular families long studied in neurons. Bacteria and archaea are now known to carry genes for potassium channels of the voltage-gated, inward rectifier and calcium-activated classes(1-3), ClC-type chloride channels(4), an ionotropic glutamate receptor(5) and a sodium channel(6). For two potassium channels and a chloride channel, these homologues have provided a means to direct structure determination(3,7-9). And yet the purposes of these ion channels in bacteria are unknown. Strong conservation of functionally important sequences from bacteria to vertebrates, and of structure itself(10), suggests that prokaryotes use ion channels in roles more adaptive than providing high-quality protein to structural biologists. Here we show that Escherichia coli uses chloride channels of the widespread ClC family in the extreme acid resistance response. We propose that the channels function as an electrical shunt for an outwardly directed virtual proton pump that is linked to amino acid decarboxylation.	Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA	Brandeis University; Howard Hughes Medical Institute	Miller, C (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA.		Iyer, Ram/AAQ-1329-2020	Iyer, Ram/0000-0002-3638-2421; Accardi, Alessio/0000-0002-6584-0102				Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Castanie-Cornet MP, 1999, J BACTERIOL, V181, P3525, DOI 10.1128/JB.181.11.3525-3535.1999; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; De Biase D, 1999, MOL MICROBIOL, V32, P1198, DOI 10.1046/j.1365-2958.1999.01430.x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Foster JW, 1999, NOVART FDN SYMP, V221, P55; GUTKNECHT J, 1981, BIOCHIM BIOPHYS ACTA, V641, P183, DOI 10.1016/0005-2736(81)90582-4; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; Hersh BM, 1996, J BACTERIOL, V178, P3978, DOI 10.1128/jb.178.13.3978-3981.1996; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Lin JS, 1996, APPL ENVIRON MICROB, V62, P3094, DOI 10.1128/AEM.62.9.3094-3100.1996; LIN JS, 1995, J BACTERIOL, V177, P4097, DOI 10.1128/jb.177.14.4097-4104.1995; Maduke M, 2000, ANNU REV BIOPH BIOM, V29, P411, DOI 10.1146/annurev.biophys.29.1.411; Maduke M, 1999, J GEN PHYSIOL, V114, P713, DOI 10.1085/jgp.114.5.713; Mayer ML, 2001, J MOL BIOL, V311, P815, DOI 10.1006/jmbi.2001.4884; Merrell DS, 2002, CURR OPIN MICROBIOL, V5, P51, DOI 10.1016/S1369-5274(02)00285-0; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MINDELL JA, 2001, GENOME BIOL, V2; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Purdy MD, 2000, FEBS LETT, V466, P26, DOI 10.1016/S0014-5793(99)01740-8; Ren DJ, 2001, SCIENCE, V294, P2372, DOI 10.1126/science.1065635; Rychkov GY, 1998, J GEN PHYSIOL, V111, P653, DOI 10.1085/jgp.111.5.653; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Small PLC, 1998, TRENDS MICROBIOL, V6, P214, DOI 10.1016/S0966-842X(98)01285-2; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J	30	161	172	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					715	718		10.1038/nature01000	http://dx.doi.org/10.1038/nature01000			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384697				2022-12-28	WOS:000178615200039
J	Whitmire, E; Khan, B; Coue, M				Whitmire, E; Khan, B; Coue, M			Cdc6 synthesis regulates replication competence in Xenopus oocytes	NATURE			English	Article							DNA-REPLICATION; NUCLEAR EXPORT; PROTEIN; KINASE; CHROMATIN; EXTRACTS; COMPLEX; MCM; LOCALIZATION; INITIATION	The early division cycles of an embryo rely on the oocyte's ability to replicate DNA. During meiosis, oocytes temporarily lose this ability. After a single round of pre-meiotic S-phase, oocytes enter meiosis and rapidly arrest at prophase of meiosis I (G2)(1). Upon hormonal stimulation, arrested oocytes resume meiosis, reestablish DNA replication competence in meiosis I shortly after germinal vesicle breakdown (GVBD), but repress replication until fertilization(2,3). How oocytes lose and regain replication competence during meiosis are important questions underlying the production of functional gametes. Here we show that the inability of immature Xenopus oocytes to replicate is linked to the absence of the Cdc6 protein and the cytoplasmic localization of other initiation proteins. Injection of Cdc6 protein into immature oocytes does not induce DNA replication. However, injection of Cdc6 into oocytes undergoing GVBD is sufficient to induce DNA replication in the absence of protein synthesis. Our results show that GVBD and Cdc6 synthesis are the only events that limit the establishment of the oocyte's replication competence during meiosis.	Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Coue, M (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, 3601 4th St, Lubbock, TX 79430 USA.	martine.coue@ttmc.ttuhsc.edu						Blow JJ, 2001, EMBO J, V20, P3293, DOI 10.1093/emboj/20.13.3293; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; COX LS, 1990, J CELL SCI, V97, P177; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Findeisen M, 1999, EUR J BIOCHEM, V264, P415, DOI 10.1046/j.1432-1327.1999.00613.x; Fisher D, 1998, BIOL CELL, V90, P497; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GURDON JB, 1967, P NATL ACAD SCI USA, V58, P545, DOI 10.1073/pnas.58.2.545; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; LASKEY RA, 1983, CIBA F SYMP, V98, P25; Lemaitre JM, 2002, NATURE, V419, P718, DOI 10.1038/nature01046; LENO GH, 1991, METHOD CELL BIOL, V36, P561; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Pereverzeva I, 2000, MOL CELL BIOL, V20, P3667, DOI 10.1128/MCB.20.10.3667-3676.2000; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	29	35	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	2002	419	6908					722	725		10.1038/nature01032	http://dx.doi.org/10.1038/nature01032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384699				2022-12-28	WOS:000178615200041
J	Marinella, MA				Marinella, MA			Necrobiosis lipoidica diabeticorum	LANCET			English	Editorial Material									Wright State Univ, Sch Med, Dayton, OH 45429 USA	University System of Ohio; Wright State University Dayton	Marinella, MA (corresponding author), Wright State Univ, Sch Med, Dayton, OH 45429 USA.								0	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1143	1143		10.1016/S0140-6736(02)11200-1	http://dx.doi.org/10.1016/S0140-6736(02)11200-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387963	Bronze			2022-12-28	WOS:000178632000015
J	Wei, WI				Wei, WI			Commentary: Head and neck carcinomas in the developing world	BRITISH MEDICAL JOURNAL			English	Editorial Material							MOUTH CANCER		Univ Hong Kong, Med Ctr, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Wei, WI (corresponding author), Univ Hong Kong, Med Ctr, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China.		Wei, William Ignace/C-4435-2009	wei, william/0000-0002-6281-7126				Moore SR, 2000, ORAL DIS, V6, P65; Qu JNY, 2000, LASER SURG MED, V26, P432, DOI 10.1002/1096-9101(2000)26:5<432::AID-LSM2>3.0.CO;2-1; WEI W, 2000, ENTOMOL NEWS, V9, P18; Wunsch V, 2001, SEMIN ONCOL, V28, P158, DOI [10.1016/S0093-7754(01)90087-9, 10.1053/sonc.2001.21958]	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 12	2002	325	7368					827	827						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12378727				2022-12-28	WOS:000178648700024
J	Wilkinson, D				Wilkinson, D			Nonoxynol-9 fails to prevents STDs, but microbicide research continues	LANCET			English	Editorial Material									Univ S Australia, Div Hlth Sci, Adelaide, SA 5000, Australia	University of South Australia	Wilkinson, D (corresponding author), Univ S Australia, Div Hlth Sci, Adelaide, SA 5000, Australia.		Wilkinson, David/A-6207-2008	Wilkinson, David/0000-0002-7265-9846				Cook RL, 1998, SEX TRANSM DIS, V25, P144, DOI 10.1097/00007435-199803000-00007; Elias CJ, 1996, AIDS, V10, pS43; *UNAIDS, 2001, AIDS EP UPD DEC 2001; *WHO, 1995, WHO IN HIV AIDS SEX; Wilkinson D, 2002, LANCET INFECT DIS, V2, P613, DOI 10.1016/S1473-3099(02)00396-1; World Health Organization (WHO), 2001, WHO CONRAD TECHN CON	6	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 28	2002	360	9338					962	963		10.1016/S0140-6736(02)11119-6	http://dx.doi.org/10.1016/S0140-6736(02)11119-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383661				2022-12-28	WOS:000178249000004
J	Kraus, WE; Houmard, JA; Duscha, BD; Knetzger, KJ; Wharton, MB; McCartney, JS; Bales, CW; Henes, S; Samsa, GP; Otvos, JD; Kulkarni, KR; Slentz, CA				Kraus, WE; Houmard, JA; Duscha, BD; Knetzger, KJ; Wharton, MB; McCartney, JS; Bales, CW; Henes, S; Samsa, GP; Otvos, JD; Kulkarni, KR; Slentz, CA			Effects of the amount and intensity of exercise on plasma lipoproteins	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALL-CAUSE MORTALITY; PARTICLE-SIZE DISTRIBUTION; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; INDUCED WEIGHT-LOSS; PHYSICAL-ACTIVITY; HEALTHY-MEN; DENSITY-LIPOPROTEINS; COLLEGE ALUMNI; OVERWEIGHT MEN	Background: Increased physical activity is related to reduced risk of cardiovascular disease, possibly because it leads to improvement in the lipoprotein profile. However, the amount of exercise training required for optimal benefit is unknown. In a prospective, randomized study, we investigated the effects of the amount and intensity of exercise on lipoproteins. Methods: A total of 111 sedentary, overweight men and women with mild-to-moderate dyslipidemia were randomly assigned to participate for six months in a control group or for approximately eight months in one of three exercise groups: high-amount-high-intensity exercise, the caloric equivalent of jogging 20 mi (32.0 km) per week at 65 to 80 percent of peak oxygen consumption; low-amount-high-intensity exercise, the equivalent of jogging 12 mi (19.2 km) per week at 65 to 80 percent of peak oxygen consumption; or low-amount-moderate-intensity exercise, the equivalent of walking 12 mi per week at 40 to 55 percent of peak oxygen consumption. Subjects were encouraged to maintain their base-line body weight. The 84 subjects who complied with these guidelines served as the basis for the main analysis. Detailed lipoprotein profiling was performed by nuclear magnetic resonance spectroscopy with verification by measurement of cholesterol in lipoprotein subfractions. Results: There was a beneficial effect of exercise on a variety of lipid and lipoprotein variables, seen most clearly with the high amount of high-intensity exercise. The high amount of exercise resulted in greater improvements than did the lower amounts of exercise (in 10 of 11 lipoprotein variables) and was always superior to the control condition (11 of 11 variables). Both lower-amount exercise groups always had better responses than the control group (22 of 22 comparisons). Conclusions: The highest amount of weekly exercise, with minimal weight change, had widespread beneficial effects on the lipoprotein profile. The improvements were related to the amount of activity and not to the intensity of exercise or improvement in fitness.	Duke Univ, Med Ctr, Dept Med,Duke Ctr Living, Div Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Geriatr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Hlth Policy Res, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA; Durham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC USA; E Carolina Univ, Dept Exercise & Sport Sci, Greenville, NC USA; E Carolina Univ, Human Performance Lab, Greenville, NC 27858 USA; LipoSci, Cary, NC USA; Atherotech, Birmingham, AL USA	Duke University; Duke University; Duke University; Duke University; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Kraus, WE (corresponding author), Duke Univ, Med Ctr, Dept Med,Duke Ctr Living, Div Cardiol, POB 3327, Durham, NC 27710 USA.			Kraus, William E/0000-0003-1930-9684	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057354] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-57354] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CHEUNG MC, 1991, J LIPID RES, V32, P383; Crouse SF, 1997, J APPL PHYSIOL, V82, P270, DOI 10.1063/1.365807; DUNCAN JJ, 1991, JAMA-J AM MED ASSOC, V266, P3295, DOI 10.1001/jama.266.23.3295; Durstine J L, 1994, Exerc Sport Sci Rev, V22, P477; Halle M, 1999, INT J SPORTS MED, V20, P464; Kamigaki AS, 2001, AM J EPIDEMIOL, V153, P939, DOI 10.1093/aje/153.10.939; KING AC, 1995, CIRCULATION, V91, P2596, DOI 10.1161/01.CIR.91.10.2596; Kraus WE, 2001, MED SCI SPORT EXER, V33, P1774, DOI 10.1097/00005768-200110000-00025; KULKARNI KR, 1994, J LIPID RES, V35, P159; KWITEROVICH PO, 1993, AM J CARDIOL, V71, P631, DOI 10.1016/0002-9149(93)91002-Y; KWITEROVICH PO, 1988, CLIN CHEM, V34, pB71; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; LAMARCHE B, 1995, AM J CARDIOL, V75, P1189, DOI 10.1016/S0002-9149(99)80760-7; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; Leon AS, 2001, MED SCI SPORT EXER, V33, pS502, DOI 10.1097/00005768-200106001-00021; OTVOS JD, 1991, CLIN CHEM, V37, P377; OTVOS JD, 1992, CLIN CHEM, V38, P1632; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Pascot A, 2001, J LIPID RES, V42, P2007; PASSMORE R, 1955, PHYSIOL REV, V35, P801, DOI 10.1152/physrev.1955.35.4.801; Sniderman AD, 1997, AM J CARDIOL, V79, P64; Sunami Y, 1999, METABOLISM, V48, P984, DOI 10.1016/S0026-0495(99)90194-4; Vakkilainen J, 2000, CIRCULATION, V102, P716, DOI 10.1161/01.CIR.102.7.716; WILLIAMS PT, 1982, JAMA-J AM MED ASSOC, V247, P2674, DOI 10.1001/jama.247.19.2674; WILLIAMS PT, 1989, ARTERIOSCLEROSIS, V9, P623, DOI 10.1161/01.ATV.9.5.623; WILLIAMS PT, 1992, METABOLISM, V41, P441, DOI 10.1016/0026-0495(92)90082-L; WILLIAMS PT, 1990, CIRCULATION, V81, P1293, DOI 10.1161/01.CIR.81.4.1293; WILLIAMS PT, 1986, METABOLISM, V35, P45, DOI 10.1016/0026-0495(86)90094-6; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; ZILVERSMIT DB, 1995, CLIN CHEM, V41, P153	34	632	651	2	98	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2002	347	19					1483	1492		10.1056/NEJMoa020194	http://dx.doi.org/10.1056/NEJMoa020194			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611XG	12421890				2022-12-28	WOS:000179042700003
J	Tahirov, TH; Temiakov, D; Anikin, M; Patlan, V; McAllister, WT; Vassylyev, DG; Yokoyama, S				Tahirov, TH; Temiakov, D; Anikin, M; Patlan, V; McAllister, WT; Vassylyev, DG; Yokoyama, S			Structure of a T7 RNA polymerase elongation complex at 2.9 angstrom resolution	NATURE			English	Article							CRYSTAL-STRUCTURE; TRANSCRIPTION INITIATION; PROMOTER; BACTERIOPHAGE-T7; HOLOENZYME; MOLSCRIPT; INSIGHTS; BINDING; BUBBLE	The single-subunit bacteriophage T7 RNA polymerase carries out the transcription cycle in an identical manner to that of bacterial and eukaryotic multisubunit enzymes. Here we report the crystal structure of a T7 RNA polymerase elongation complex, which shows that incorporation of an 8-base-pair RNA-DNA hybrid into the active site of the enzyme induces a marked rearrangement of the amino-terminal domain. This rearrangement involves alternative folding of about 130 residues and a marked reorientation (about 130degrees rotation) of a stable core subdomain, resulting in a structure that provides elements required for stable transcription elongation. A wide opening on the enzyme surface that is probably an RNA exit pathway is formed, and the RNA-DNA hybrid is completely buried in a newly formed, deep protein cavity. Binding of 10 base pairs of downstream DNA is stabilized mostly by long-distance electrostatic interactions. The structure implies plausible mechanisms for the various phases of the transcription cycle, and reveals important structural similarities with the multisubunit RNA polymerases.	RIKEN, Harima Inst SPring 8, Structurome Res Grp, Sayo, Hyogo 6795148, Japan; RIKEN, Harima Inst SPring 8, High Throughput Factory, Sayo, Hyogo 6795148, Japan; RIKEN, Harima Inst SPring 8, Cellular Signaling Lab, Sayo, Hyogo 6795148, Japan; SUNY Hlth Sci Ctr, Dept Microbiol, Morse Inst Mol Genet, Brooklyn, NY 11203 USA; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; RIKEN; RIKEN; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; RIKEN; University of Tokyo	Vassylyev, DG (corresponding author), RIKEN, Harima Inst SPring 8, Structurome Res Grp, 1-1-1 Kouto,Mikazuki Cho, Sayo, Hyogo 6795148, Japan.	dmitry@yumiyoshi.harima.riken.go.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Vassylyev, Dmitry/A-9005-2008; Patlan, Vsevolod/K-1825-2013	Yokoyama, Shigeyuki/0000-0003-3133-7338; Tahirov, Tahir/0000-0002-1238-0069	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038147] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038147, R01 GM038147-14S1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BONNER G, 1994, J BIOL CHEM, V269, P25120; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; Brieba LG, 2001, J BIOL CHEM, V276, P10306, DOI 10.1074/jbc.M009866200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 2000, CURR OPIN STRUC BIOL, V10, P117, DOI 10.1016/S0959-440X(99)00058-5; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gopal V, 1999, J MOL BIOL, V290, P411, DOI 10.1006/jmbi.1999.2836; GUNDERSON SI, 1987, BIOCHEMISTRY-US, V26, P1539, DOI 10.1021/bi00380a007; He B, 1997, J MOL BIOL, V265, P275, DOI 10.1006/jmbi.1996.0741; Huang JB, 2000, BIOCHEMISTRY-US, V39, P11571, DOI 10.1021/bi000579d; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Imburgio D, 2000, BIOCHEMISTRY-US, V39, P10419, DOI 10.1021/bi000365w; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jiang ML, 2001, J MOL BIOL, V310, P509, DOI 10.1006/jmbi.2001.4793; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; Lyakhov DL, 1997, J MOL BIOL, V269, P28, DOI 10.1006/jmbi.1997.1015; MA K, IN PRESS J BIOL CHEM; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCALLISTER WT, 1993, MOL MICROBIOL, V10, P1, DOI 10.1111/j.1365-2958.1993.tb00897.x; MCALLISTER WT, 1997, NUCL ACIDS MOL BIOL, V11, P15; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mukherjee S, 2002, CELL, V110, P81, DOI 10.1016/S0092-8674(02)00815-2; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; RASKIN CA, 1993, P NATL ACAD SCI USA, V90, P3147, DOI 10.1073/pnas.90.8.3147; Rong MQ, 1998, P NATL ACAD SCI USA, V95, P515, DOI 10.1073/pnas.95.2.515; Severinov K, 2001, P NATL ACAD SCI USA, V98, P5, DOI 10.1073/pnas.021535298; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; TEMIAKOV D, UNPUB ACTA CRYSTALLO; TEMIAKOV D, IN PRESS J BIOL CHEM; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Woody AYM, 1998, BIOCHEMISTRY-US, V37, P15958, DOI 10.1021/bi9805801; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	50	188	202	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	2002	420	6911					43	50		10.1038/nature01129	http://dx.doi.org/10.1038/nature01129			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422209				2022-12-28	WOS:000179068100031
J	de Bono, M; Tobin, DM; Davis, MW; Avery, L; Bargmann, CI				de Bono, M; Tobin, DM; Davis, MW; Avery, L; Bargmann, CI			Social feeding in Caenorhabditis elegans is induced by neurons that detect aversive stimuli	NATURE			English	Article							NEUROPEPTIDE-Y RECEPTOR; C-ELEGANS; VANILLOID RECEPTOR; NATURAL VARIATION; PATHWAY; PROTEIN; GENE; ENVIRONMENT; EXPRESSION; RESPONSES	Natural Caenorhabditis elegans isolates exhibit either social or solitary feeding on bacteria. We show here that social feeding is induced by nociceptive neurons that detect adverse or stressful conditions. Ablation of the nociceptive neurons ASH and ADL transforms social animals into solitary feeders. Social feeding is probably due to the sensation of noxious chemicals by ASH and ADL neurons; it requires the genes ocr-2 and osm-9, which encode TRP-related transduction channels, and odr-4 and odr-8, which are required to localize sensory chemoreceptors to cilia. Other sensory neurons may suppress social feeding, as social feeding in ocr-2 and odr-4 mutants is restored by mutations in osm-3, a gene required for the development of 26 ciliated sensory neurons. Our data suggest a model for regulation of social feeding by opposing sensory inputs: aversive inputs to nociceptive neurons promote social feeding, whereas antagonistic inputs from neurons that express osm-3 inhibit aggregation.	Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Program Neurosci, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Genet Program, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Genet Program, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Program Neurosci, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, Dept Biochem & Biophys, San Francisco, CA 94143 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; MRC Laboratory Molecular Biology; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	de Bono, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, Dept Anat, San Francisco, CA 94143 USA.	debono@mrc-lmb.cam.ac.uk		de Bono, Mario/0000-0001-8347-0443; Tobin, David/0000-0003-3465-5518; Bargmann, Cornelia/0000-0002-8484-0618; Davis, Mikel/0000-0003-1867-1593	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046154] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL046154] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bargmann C. I., 1997, C ELEGANS, P717; BARGMANN CI, 1990, COLD SPRING HARB SYM, V55, P529; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Choe JC, 1997, EVOLUTION SOCIAL BEH; CLARK SG, 1994, GENETICS, V137, P987; Colbert HA, 1997, J NEUROSCI, V17, P8259; CROLL NA, 1970, BEHAV NEMATODES, P18; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; DRISCOLL M, 1997, NEMATODE C ELEGANS, V2, P645; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Garsin DA, 2001, P NATL ACAD SCI USA, V98, P10892, DOI 10.1073/pnas.191378698; GREWAL PS, 1991, NEMATOLOGICA, V37, P72, DOI 10.1163/187529291X00079; HASSELL MP, 1973, J ANIM ECOL, V42, P693, DOI 10.2307/3133; Hodgkin J, 1997, GENETICS, V146, P149; Hodgkin J, 1997, C ELEGANS, P881; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Marroquin LD, 2000, GENETICS, V155, P1693; MCBRIDE JM, 1966, NATURE, V211, P545, DOI 10.1038/211545b0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Naveilhan P, 2001, NATURE, V409, P513, DOI 10.1038/35054063; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle DL, 1997, C ELEGANS, P739; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Sagasti A, 1999, GENE DEV, V13, P1794, DOI 10.1101/gad.13.14.1794; Sambongi Y, 1999, NEUROREPORT, V10, P753, DOI 10.1097/00001756-199903170-00017; Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SHORROCKS B, 1995, P ROY SOC B-BIOL SCI, V260, P305, DOI 10.1098/rspb.1995.0096; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TABISH M, 1995, J MOL BIOL, V247, P377, DOI 10.1006/jmbi.1994.0146; THOMAS JH, 1993, GENETICS, V134, P1105; Tobin DM, 2002, NEURON, V35, P307, DOI 10.1016/S0896-6273(02)00757-2; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Wilson E.O., 1975, P1	40	188	221	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					899	903		10.1038/nature01169	http://dx.doi.org/10.1038/nature01169			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410303	Green Accepted			2022-12-28	WOS:000178909700035
J	Schiermeier, Q				Schiermeier, Q			Low stocks prompt calls for North Atlantic fishing ban	NATURE			English	News Item																		2002, NATURE, V419, P664	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					866	866		10.1038/419866b	http://dx.doi.org/10.1038/419866b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410268	Bronze			2022-12-28	WOS:000178909700004
J	Sherman, G; Visscher, PK				Sherman, G; Visscher, PK			Honeybee colonies achieve fitness through dancing	NATURE			English	Article							COMMUNICATION; BEHAVIOR; DANCES	The honeybee dance language, in which foragers perform dances containing information about the distance and direction to food sources, is the quintessential example of symbolic communication in non-primates(1,2). The dance language has been the subject of controversy(3,4), and of extensive research into the mechanisms of acquiring(1,5,6), decoding(7,8) and evaluating(9) the information in the dance. The dance language has been hypothesized, but not shown, to increase colony food collection(1,9,10). Here we show that colonies with disoriented dances (lacking direction information) recruit less effectively to syrup feeders than do colonies with oriented dances. For colonies foraging at natural sources, the direction information sometimes increases food collected, but at other times it makes no difference. The food-location information in the dance is presumably important when food sources are hard to find, variable in richness and ephemeral. Recruitment based simply on arousal of foragers and communication of floral odour, as occurs in honeybees(1), bumble bees(11) and some stingless bees(12), can be equally effective under other circumstances. Clarifying the condition-dependent payoffs of the dance language provides new insight into its function in honeybee ecology.	Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA	University of California System; University of California Riverside	Visscher, PK (corresponding author), Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA.							Batschelet E., 1981, CIRCULAR STAT BIOL; BRINES ML, 1979, SCIENCE, V206, P571, DOI 10.1126/science.206.4418.571; Dornhaus A, 1999, NATURE, V401, P38, DOI 10.1038/43372; DYER FC, 1985, J COMP PHYSIOL A, V157, P183, DOI 10.1007/BF01350026; Dyer FC, 2002, ANNU REV ENTOMOL, V47, P917, DOI 10.1146/annurev.ento.47.091201.145306; Esch HE, 1996, J EXP BIOL, V199, P155; GOULD JL, 1976, Q REV BIOL, V51, P211, DOI 10.1086/409309; KIRCHNER WH, 1993, APIDOLOGIE, V24, P297, DOI 10.1051/apido:19930309; Kirchner WH, 1998, J INSECT BEHAV, V11, P169, DOI 10.1023/A:1021098405564; LINDAUER M, 1971, COMMUNICATION SOCIAL; MICHELSEN A, 1992, BEHAV ECOL SOCIOBIOL, V30, P143, DOI 10.1007/BF00166696; SEELEY TD, 1985, ECOL ENTOMOL, V10, P81, DOI 10.1111/j.1365-2311.1985.tb00537.x; SEELEY TD, 1995, WISDOM HIVE SOCIAL P, P69; SHERMAN G, 2002, THESIS U CALIFORNIA; VISSCHER PK, 1982, ECOLOGY, V63, P1790, DOI 10.2307/1940121; VISSCHER PK, 1994, 12 C INT UN STUD SOC; von Frisch K., 1967, DANCE LANGUAGE ORIEN; WADDINGTON KD, 1994, BEHAV ECOL SOCIOBIOL, V35, P423, DOI 10.1007/BF00165845; WEHNER R, 1985, EXPT BEHAV ECOLOGY S, P11; WENNER AM, 1990, ANATOMY CONTROVERSY, P57	20	121	122	3	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					920	922		10.1038/nature01127	http://dx.doi.org/10.1038/nature01127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410309				2022-12-28	WOS:000178909700042
J	Matthews, BN; Mirza, SA; Durrani, M				Matthews, BN; Mirza, SA; Durrani, M			A blinding combination	LANCET			English	Editorial Material							ANTIPHOSPHOLIPID SYNDROME		Univ Birmingham, City Hosp, Birmingham & Midland Eye Ctr, Div Immun & Infect, Birmingham B18 7QH, W Midlands, England; Univ Birmingham, Div Immun & Infect, Acad Unit Ophthalmol, Birmingham B18 7QH, W Midlands, England	University of Birmingham; University of Birmingham	Mirza, SA (corresponding author), Univ Birmingham, City Hosp, Birmingham & Midland Eye Ctr, Div Immun & Infect, Birmingham B18 7QH, W Midlands, England.	sammirza@hotmail.com						Bick RL, 1999, SEMIN THROMB HEMOST, V25, P333, DOI 10.1055/s-2007-994935; Durrani OM, 2002, SURV OPHTHALMOL, V47, P215, DOI 10.1016/S0039-6257(02)00289-8; HUGHES GRV, 1983, BRIT MED J, V287, P1088, DOI 10.1136/bmj.287.6399.1088; Smith JR, 2001, JPN J OPHTHALMOL, V45, P105, DOI 10.1016/S0021-5155(00)00300-2; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	2002	360	9341					1220	1220		10.1016/S0140-6736(02)11282-7	http://dx.doi.org/10.1016/S0140-6736(02)11282-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401249				2022-12-28	WOS:000178708100012
J	Patsalis, PC; Sismani, C; Quintana-Murci, L; Taleb-Bekkouche, F; Krausz, C; McElreavey, K				Patsalis, PC; Sismani, C; Quintana-Murci, L; Taleb-Bekkouche, F; Krausz, C; McElreavey, K			Effects of transmission of Y chromosome AZFc deletions	LANCET			English	Article							MICRODELETIONS; MOSAICISM	Deletions of specific regions on the Y chromosome cause male infertility. Recent advances in infertility treatment allow Y chromosome deletions to be transmitted to male offspring with the assumption that there will be no clinical consequences other than infertility in adult life. We screened 12 patients, who had a 45X/46XY karyotype and presented with Turner stigmata or sexual ambiguities, or both, for Y chromosome microdeletions with PCR. A third of these patients had Y chromosome microdeletions of distal Yq, the most common microdeletion seen in infertile men with azoospermia or severe oligozoospermia. Transmission of Y chromosome microdeletions could potentially have severe clinical consequences other than male infertility, such as the development of sexual ambiguities and Turner stigmata.	Inst Pasteur, Dept Dev Biol, F-75724 Paris, France; Cyprus Inst Neurol & Genet, Nicosia, Cyprus; Univ Florence, Androl Unit, Florence, Italy	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Florence	McElreavey, K (corresponding author), Inst Pasteur, Dept Dev Biol, F-75724 Paris, France.		Quintana-Murci, Lluis/AAB-7468-2022	Krausz, Csilla Gabriella/0000-0001-6748-8918; Quintana-Murci, Lluis/0000-0003-2429-6320				CHANG HJ, 1990, AM J HUM GENET, V46, P156; McElreavey K, 2000, Results Probl Cell Differ, V28, P211; Papadimas J, 2001, FERTIL STERIL, V76, P1261, DOI 10.1016/S0015-0282(01)02877-1; Siffroi JP, 2000, HUM REPROD, V15, P2559, DOI 10.1093/humrep/15.12.2559; van Golde RJT, 2001, HUM REPROD, V16, P289, DOI 10.1093/humrep/16.2.289	5	67	72	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1222	1224		10.1016/S0140-6736(02)11248-7	http://dx.doi.org/10.1016/S0140-6736(02)11248-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401251				2022-12-28	WOS:000178708100014
J	Labrador, M; Corces, VG				Labrador, M; Corces, VG			Setting the boundaries of chromatin domains and nuclear organization	CELL			English	Review							CHROMOSOMAL DOMAINS; HISTONE ACETYLATION; METHYLATION; TRANSITIONS; EXPRESSION; LOCUS; GENE	The nuclear architecture of the interphase nucleus is established by laying down an intricate three-dimensional framework of higher-order chromatin structure. This arrangement is essential for the integration of complex biological processes such as DNA replication, RNA processing, and transcription. Boundary or insulator elements are emerging as key players in the establishment and maintenance of this organization.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Corces, VG (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.			Labrador-San Jose, Mariano/0000-0002-8075-2717; Corces, Victor/0000-0001-5140-4337				Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Chao W, 2002, SCIENCE, V295, P345, DOI 10.1126/science.1065982; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; Farrell CM, 2002, MOL CELL BIOL, V22, P3820, DOI 10.1128/MCB.22.11.3820-3831.2002; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Ishii K, 2002, CELL, V109, P551, DOI 10.1016/S0092-8674(02)00756-0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702	17	176	183	0	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 18	2002	111	2					151	154		10.1016/S0092-8674(02)01004-8	http://dx.doi.org/10.1016/S0092-8674(02)01004-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408858	Bronze			2022-12-28	WOS:000178753500003
J	Peters, JW				Peters, JW			A trio of transition metals in anaerobic CO2 fixation	SCIENCE			English	Editorial Material							CARBON-MONOXIDE DEHYDROGENASE; CRYSTAL-STRUCTURE; LIFE		Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA	Montana State University System; Montana State University Bozeman	Peters, JW (corresponding author), Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA.			Peters, John/0000-0001-9117-9568				Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Dobbek H, 2001, SCIENCE, V293, P1281, DOI 10.1126/science.1061500; Doukov TI, 2002, SCIENCE, V298, P567, DOI 10.1126/science.1075843; Drennan CL, 2001, P NATL ACAD SCI USA, V98, P11973, DOI 10.1073/pnas.211429998; Ermler U, 1997, SCIENCE, V278, P1457, DOI 10.1126/science.278.5342.1457; FERRY JG, 1995, ANNU REV MICROBIOL, V49, P305, DOI 10.1146/annurev.mi.49.100195.001513; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; Lindahl PA, 2002, BIOCHEMISTRY-US, V41, P2097, DOI 10.1021/bi015932+; Ragsdale SW, 1996, CHEM REV, V96, P2515, DOI 10.1021/cr950058+; Rees DC, 2002, ANNU REV BIOCHEM, V71, P221, DOI 10.1146/annurev.biochem.71.110601.135406; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; WOOD HG, 1991, FASEB J, V5, P156, DOI 10.1096/fasebj.5.2.1900793	13	6	6	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					552	553		10.1126/science.1077335	http://dx.doi.org/10.1126/science.1077335			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386322				2022-12-28	WOS:000178634800027
J	Veronesi, U; Cascinelli, N; Mariani, L; Greco, M; Saccozzi, R; Luini, A; Aguilar, M; Marubini, E				Veronesi, U; Cascinelli, N; Mariani, L; Greco, M; Saccozzi, R; Luini, A; Aguilar, M; Marubini, E			Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIOTHERAPY; RADIATION; THERAPY	Background: We conducted 20 years of follow-up of women enrolled in a randomized trial to compare the efficacy of radical (Halsted) mastectomy with that of breast-conserving surgery. Methods: From 1973 to 1980, 701 women with breast cancers measuring no more than 2 cm in diameter were randomly assigned to undergo radical mastectomy (349 patients) or breast-conserving surgery (quadrantectomy) followed by radiotherapy to the ipsilateral mammary tissue (352 patients). After 1976, patients in both groups who had positive axillary nodes also received adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil. Results: Thirty women in the group that underwent breast-conserving therapy had a recurrence of tumor in the same breast, whereas eight women in the radical-mastectomy group had local recurrences (P<0.001). The crude cumulative incidence of these events was 8.8 percent and 2.3 percent, respectively, after 20 years. In contrast, there was no significant difference between the two groups in the rates of contralateral-breast carcinomas, distant metastases, or second primary cancers. After a median follow-up of 20 years, the rate of death from all causes was 41.7 percent in the group that underwent breast-conserving surgery and 41.2 percent in the radical-mastectomy group (P=1.0). The respective rates of death from breast cancer were 26.1 percent and 24.3 percent (P=0.8). Conclusions: The long-term survival rate among women who undergo breast-conserving surgery is the same as that among women who undergo radical mastectomy. Breast-conserving surgery is therefore the treatment of choice for women with relatively small breast cancers.	European Oncol Inst, Dept Senol, I-20141 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Senol, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Biometr, I-20133 Milan, Italy; Univ Milan, Inst Med Stat & Biometry, Milan, Italy	IRCCS European Institute of Oncology (IEO); Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan	Veronesi, U (corresponding author), European Oncol Inst, Dept Senol, 435 Via G Ripamonti, I-20141 Milan, Italy.	umberto.veronesi@ico.it	Mariani, Luigi/AAB-9464-2019; Mariani, Luigi/C-2580-2017	Mariani, Luigi/0000-0001-6208-4084				Cronin KA, 2000, STAT MED, V19, P1729, DOI 10.1002/1097-0258(20000715)19:13<1729::AID-SIM484>3.0.CO;2-9; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Halsted W S, 1898, Ann Surg, V28, P557; Hirsch J, 1927, DEUT MED WOCHENSCHR, V53, P1419, DOI 10.1055/s-0028-1126769; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keynes G, 1937, BRIT MED J, V1937, P643, DOI 10.1136/bmj.2.4004.643; Marubini E, 1995, ANAL SURVIVAL DATA C, P331; Sarrazin D, 1983, CONSERVATIVE MANAGEM, P101; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754; van Dongen JA, 2000, JNCI-J NATL CANCER I, V92, P1143, DOI 10.1093/jnci/92.14.1143; VERONESI U, 1977, CANCER, V39, P2822, DOI 10.1002/1097-0142(197706)39:6<2822::AID-CNCR2820390670>3.0.CO;2-#; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; *WHO, 1969, M INV EV METH DIAGN; ZUCALI R, 1987, EUR J SURG ONCOL, V13, P413	17	2877	3070	4	115	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1227	1232		10.1056/NEJMoa020989	http://dx.doi.org/10.1056/NEJMoa020989			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393819				2022-12-28	WOS:000178598300003
J	Barbour, V				Barbour, V			Celebrating death - the 2002 Nobel prize in physiology or medicine	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Barbour, V (corresponding author), The Lancet, London NW1 7BY, England.			Barbour, Virginia/0000-0002-2358-2440					0	2	2	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1117	1117		10.1016/S0140-6736(02)11240-2	http://dx.doi.org/10.1016/S0140-6736(02)11240-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387956				2022-12-28	WOS:000178632000008
J	Band, PR; Le, ND; Fang, R; Deschamps, M				Band, PR; Le, ND; Fang, R; Deschamps, M			Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer	LANCET			English	Article							POSTMENOPAUSAL WOMEN; UNITED-STATES; MENOPAUSE; EXPOSURE; DISEASE; DIET	Background Results of epidemiological studies, assessing the relation between smoking and breast cancer, have been inconclusive. Our aim was to assess the carcinogenic and possibly antioestrogenic effects of cigarette smoke on risk of breast cancer. Methods We sent a questionnaire to 1431 women younger than age 75 years who had breast cancer and were listed on the population-based British Columbia cancer registry between June 1, 1988, and June 30, 1989. We also sent questionnaires to 1502 age-matched controls, randomly selected from the 1989 provincial voters list. We obtained information on all known and suspected risk factors for breast cancer, and on lifetime smoking, alcohol consumption, and occupational history. We assessed the effect of smoking separately for premenopausal and postmenopausal women, adjusting for confounding variables. Findings 318 premenopausal women and 340 controls replied. Risk of breast cancer was significantly increased (adjusted odds ratio 1.69, 95% CI 1.13-2.51) in women who had been pregnant and who started to smoke within 5 years of menarche, and in nulliparous women who smoked 20 cigarettes daily or more (7.08, 1.63-30.8) and had smoked for 20 cumulative pack-years or more (7.48, 1.59-35.2). Postmenopausal women (700 breast cancer and 685 controls) whose body-mass index increased from age 18 to current and who started to smoke after a first fullterm pregnancy had a significantly reduced risk of breast cancer (0.49, 0.27-0.89). Interpretation Our results suggest that cigarette smoke exerts a dual action on the breast, with different effects in premenopausal and postmenopausal women. Our observations reinforce the importance of smoking prevention, especially in early adolescence, and draw attention to the timing of exposure in relation to susceptibility and refractory windows in the design of studies to investigate associations between environmental carcinogens or putative endocrine disruptors and risk of breast cancer.	Hlth Canada, Longueuil, PQ J4K 1C7, Canada; Univ Ottawa, Inst Populat Hlth, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON K1N 6N5, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Sociaux Montreal Ctr, Regie Reg Sante & Serv, Direct Sante Publ, Montreal, PQ, Canada	Health Canada; University of Ottawa; British Columbia Cancer Agency	Band, PR (corresponding author), Hlth Canada, 1001 St Laurent O, Longueuil, PQ J4K 1C7, Canada.							Band PR, 2000, J OCCUP ENVIRON MED, V42, P284, DOI 10.1097/00043764-200003000-00010; Baron JA, 1996, CANCER EPIDEM BIOMAR, V5, P399; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75; ClavelChapelon F, 1997, CANCER DETECT PREV, V21, P426; EWERTZ M, 1990, CANCER CAUSE CONTROL, V1, P31, DOI 10.1007/BF00053181; Gammon MD, 1998, CANCER CAUSE CONTROL, V9, P583, DOI 10.1023/A:1008868922799; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; HANKINSON SE, 1995, J NATL CANCER I, V87, P1297, DOI 10.1093/jnci/87.17.1297; HIATT RA, 1986, JNCI-J NATL CANCER I, V76, P833; Ishibe N, 1998, CANCER RES, V58, P667; Jefcoate C R, 2000, J Natl Cancer Inst Monogr, P95; JOHN EM, 1993, EPIDEMIOL REV, V15, P157, DOI 10.1093/oxfordjournals.epirev.a036099; Johnson KC, 2000, CANCER CAUSE CONTROL, V11, P211, DOI 10.1023/A:1008906105790; KADOHAMA N, 1993, CANCER LETT, V75, P175, DOI 10.1016/0304-3835(93)90060-M; KAUFMAN DW, 1980, AM J PUBLIC HEALTH, V70, P420, DOI 10.2105/AJPH.70.4.420; Li DH, 1999, CANCER DETECT PREV, V23, P454, DOI 10.1046/j.1525-1500.1999.99059.x; MACMAHON B, 1982, NEW ENGL J MED, V307, P1062, DOI 10.1056/NEJM198210213071707; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835; PALMER JR, 1993, EPIDEMIOL REV, V15, P145, DOI 10.1093/oxfordjournals.epirev.a036098; PETRAKIS NL, 1993, EPIDEMIOL REV, V15, P188, DOI 10.1093/oxfordjournals.epirev.a036104; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; RUSSO J, 1995, CANCER LETT, V90, P81, DOI 10.1016/0304-3835(94)03681-8; Russo J, 1993, Eur J Cancer Prev, V2 Suppl 3, P85; Trentham-Dietz A, 2000, CANCER CAUSE CONTROL, V11, P533, DOI 10.1023/A:1008961931534; Wartenberg D, 2000, J NATL CANCER I, V92, P1666, DOI 10.1093/jnci/92.20.1666; Willett WC, 2001, CANCER EPIDEM BIOMAR, V10, P3	28	146	149	0	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1044	1049		10.1016/S0140-6736(02)11140-8	http://dx.doi.org/10.1016/S0140-6736(02)11140-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383984				2022-12-28	WOS:000178485200009
J	Hall, W				Hall, W			The prospects for immunotherapy in smoking cessation	LANCET			English	Review							NICOTINE DISTRIBUTION; ACTIVE IMMUNIZATION; TOBACCO DEPENDENCE; VACCINE; RATS	Context Smoking is a major preventable cause of death and disability that is maintained by dependence on nicotine. Smoking cessation reduces mortality and morbidity. Although existing pharmacological aids to smoking cessation and relapse prevention (nicotine replacement therapy and bupropion) improve on unassisted quitting and behavioural, methods, they are only modestly effective. More effective pharmacological methods are required that improve compliance, reduce side-effects, and can be used in combination with existing cessation methods.	Univ Queensland, Inst Mol Biosci, Off Publ Policy & Eth, St Lucia, Qld 4067, Australia	University of Queensland	Hall, W (corresponding author), Univ Queensland, Inst Mol Biosci, Off Publ Policy & Eth, St Lucia, Qld 4067, Australia.	W.Hall@imb.uq.edu.au	Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				Balfour DJK, 2002, RESPIRATION, V69, P7, DOI 10.1159/000049362; Balfour DJK, 2001, INT J CLIN PRACT, V55, P53; Benowitz NL, 2001, SMOKING: RISK, PERCEPTION, & POLICY, P159; Bondurant, 2001, CLEARING SMOKE ASSES; Carrera MRA, 2001, P NATL ACAD SCI USA, V98, P1988, DOI 10.1073/pnas.041610998; Cohen PJ, 1997, DRUG ALCOHOL DEPEN, V48, P167, DOI 10.1016/S0376-8716(97)00075-6; de Villiers SHL, 2002, RESPIRATION, V69, P247, DOI 10.1159/000063628; Degenhardt L, 2001, Nicotine Tob Res, V3, P225; FAGERSTROM KO, 2000, NICOTINE PUBLIC HLTH, P199; Hieda Y, 2000, INT J IMMUNOPHARMACO, V22, P809, DOI 10.1016/S0192-0561(00)00042-4; Hughes J, 2002, COCHRANE LIB; Kosten T. R., 2000, Drug and Alcohol Dependence, V60, pS250, DOI 10.1016/S0376-8716(00)90007-3; Kosten TR, 2002, VACCINE, V20, P1196, DOI 10.1016/S0264-410X(01)00425-X; Lindblom N, 2002, RESPIRATION, V69, P254, DOI 10.1159/000063629; Malin DH, 2001, PHARMACOL BIOCHEM BE, V68, P87, DOI 10.1016/S0091-3057(00)00436-6; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Pentel P, 2002, RESPIRATION, V69, P193, DOI 10.1159/000063617; Pentel PR, 2000, PHARMACOL BIOCHEM BE, V65, P191, DOI 10.1016/S0091-3057(99)00206-3; Picciotto MR, 1998, DRUG ALCOHOL DEPEN, V51, P165, DOI 10.1016/S0376-8716(98)00074-X; Picciotto MR, 2002, J NEUROSCI, V22, P3338; SILAGY C, 2002, COCHRANE LIB; Tuncok Y, 2001, EXP CLIN PSYCHOPHARM, V9, P228; US Surgeon General, 1988, HLTH CONS SMOK NIC A; Vocci FJ, 2001, CNS DRUGS, V15, P505, DOI 10.2165/00023210-200115070-00001	24	27	27	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	2002	360	9339					1089	1091		10.1016/S0140-6736(02)11134-2	http://dx.doi.org/10.1016/S0140-6736(02)11134-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12384004				2022-12-28	WOS:000178485200029
J	Russo, IH				Russo, IH			Cigarette smoking and risk of breast cancer in women	LANCET			English	Editorial Material							TRENDS		Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Russo, IH (corresponding author), Fox Chase Canc Ctr, Breast Canc Res Lab, 7701 Burholme Ave, Philadelphia, PA 19111 USA.							BARON JA, 2001, J WOMENS CANC, V3, P23; Forbes John F., 1997, Seminars in Oncology, V24, P20; GARFINKEL L, 1991, CA-CANCER J CLIN, V41, P137, DOI 10.3322/canjclin.41.3.137; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HARRIS CC, 2001, J WOMENS CANC, V3, P1; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; MORABIA A, 2001, J WOMENS CANC, V3, P5; Russo I.H., 2001, J WOMENS CANC, V3, P29; SATCHER D, 2001, WOMEN HLTH REPORT SU, P1; SINGH KG, 2002, J NATL CANCER I, V94, P916; Tryggvadottir L, 2002, INT J CANCER, V98, P604, DOI 10.1002/ijc.10217	12	10	11	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1033	1034		10.1016/S0140-6736(02)11174-3	http://dx.doi.org/10.1016/S0140-6736(02)11174-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383978				2022-12-28	WOS:000178485200003
J	Pitman, NCA; Jorgensen, PM				Pitman, NCA; Jorgensen, PM			Estimating the size of the world's threatened flora	SCIENCE			English	Article									Duke Univ, Ctr Trop Conservat, Durham, NC 27706 USA; Missouri Bot Garden, St Louis, MO 63166 USA	Duke University; Missouri Botanical Gardens	Pitman, NCA (corresponding author), Duke Univ, Ctr Trop Conservat, Box 90381, Durham, NC 27706 USA.	ncp@duke.edu	Pitman, Nigel C A/A-7681-2008	Pitman, Nigel C A/0000-0002-9211-2880				Bramwell D., 2002, PLANT TALK, V28, P32; Davis S.D., 1997, CTR PLANT DIVERSITY, VVolume 3; Govaerts R, 2001, TAXON, V50, P1085, DOI 10.2307/1224723; Jorgensen P. M., 1999, CATALOGUE VASCULAR P; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Prance GT, 2000, ANN MO BOT GARD, V87, P67, DOI 10.2307/2666209; Valencia R., 2000, LIBRO ROJO PLANTAS E; Walter KS, 1998, 1997 IUCN RED LIST T	8	146	163	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	2002	298	5595					989	989		10.1126/science.298.5595.989	http://dx.doi.org/10.1126/science.298.5595.989			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411696				2022-12-28	WOS:000178932000045
J	Steinbrook, R				Steinbrook, R			Testing medications in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LABEL DRUG-USE											Blumer JL, 1999, PEDIATRICS, V104, P598; Bucheler R, 2002, BRIT MED J, V324, P1311, DOI 10.1136/bmj.324.7349.1311; CONNOLLY C, 2002, WASHINGTON POST 0728, pA10; Conroy S, 2000, BRIT MED J, V320, P79, DOI 10.1136/bmj.320.7227.79; Cote CJ, 1996, PEDIATRICS, V98, P118; DEMBNER A, 2001, BOSTON GLOBE    0218, pA1; *DEP HLTH HUM SERV, 1994, FED REGISTER, V59, P64240; *FDA, 2002, CDER 2001 REP NAT IM; Federal Register, 1998, FED REGISTER, V63, P66632; *FOOD DRUG ADM, 2001, PED EXCL PROV JAN 20; Geiling EMK., 1938, J AM MED ASS, V111, P919, DOI [10.1001/jama.1938.72790360005007, DOI 10.1001/JAMA.1938.72790360005007]; *IMS HLTH, 2002, US TOP 10 PROD PRESC; Kaiser J, 2002, SCIENCE, V297, P1461; KAUFFMAN RE, 1995, PEDIATRICS, V95, P286; KAUFFMAN RE, 1998, CHILD LEGAL RIGHTS J, V18, P27; KAUFMAN M, 2002, WASHINGTON POST 0420, pA3; KOHRMAN A, 1995, PEDIATRICS, V95, P314; *MEDC HLTH SOL, 2002, DRUG TREND REP; Nahata MC, 1999, PEDIATRICS, V104, P607; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1977, DHEW PUBL; PINA LM, 1997, CTR IDS TOP 10 DRUGS, P6; Rosato J, 2000, J LAW MED ETHICS, V28, P362, DOI 10.1111/j.1748-720X.2000.tb00687.x; Schirm E, 2002, BRIT MED J, V324, P1312, DOI 10.1136/bmj.324.7349.1312; Steinbrook R, 2002, NEW ENGL J MED, V346, P1842, DOI 10.1056/NEJMp020046; Steinbrook R, 2002, NEW ENGL J MED, V346, P1425, DOI 10.1056/NEJM200205023461828; Stolberg S G, 2001, N Y Times Web, P24; 'T Jong GW, 2000, NEW ENGL J MED, V343, P1125, DOI 10.1056/NEJM200010123431515; 't Jong GW, 2002, BRIT MED J, V324, P1313, DOI 10.1136/bmj.324.7349.1313; Tejeda HA, 1996, J NATL CANCER I, V88, P812, DOI 10.1093/jnci/88.12.812; WARD R, 2001, WALL STREET J   0216, pA11; Wilson JT, 1999, PEDIATRICS, V104, P585; ZIMMERMAN R, 2001, WALL ST J       0205, pA1; Zimmerman Rachel, 2002, Wall St J (East Ed), pD6; 2002, FED REG, V67, P51283; 2001, FED REG, V66, P20589; 1978, FED REG, V43, P31786; 1937, JAMA, V109, P1531; 2002, PEDIAT EXCLUSIVITY L; 2002, NY TIMES        0407, P14; 2002, FED REG, V67, P20070	40	148	156	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1462	1470		10.1056/NEJMhpr021646	http://dx.doi.org/10.1056/NEJMhpr021646			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12409558				2022-12-28	WOS:000178888400035
J	Jankowski, J; Jones, R; Delaney, B; Dent, J				Jankowski, J; Jones, R; Delaney, B; Dent, J			10-minute consultation - Gastro-oesophageal reflux disease	BRITISH MEDICAL JOURNAL			English	Article									Leicester Royal Infirm, Ctr Digest Dis, Leicester LE1 5WW, Leics, England; Leicester Royal Infirm, Epithelial Off, Dept Med, Leicester LE1 5WW, Leics, England; Leicester Royal Infirm, Epithelial Off, Dept Oncol, Leicester LE1 5WW, Leics, England; Univ London Kings Coll, Guys Kings & St Thomass Sch Med, London WC2R 2LS, England; Univ Birmingham, Birmingham, W Midlands, England; Royal Adelaide Hosp, Adelaide, SA 5000, Australia	University of Leicester; University of Leicester; University of Leicester; University of London; King's College London; University of Birmingham; Royal Adelaide Hospital	Jankowski, J (corresponding author), Leicester Royal Infirm, Ctr Digest Dis, Leicester LE1 5WW, Leics, England.		Jankowski, Janusz/H-2706-2012; Delaney, Brendan C/C-5578-2008	Jankowski, Janusz/0000-0003-2130-9181; Delaney, Brendan/0000-0002-3518-0131				de Caestecker J, 2001, BRIT MED J, V323, P736, DOI 10.1136/bmj.323.7315.736; Jankowski JA, 2000, LANCET, V356, P2079, DOI 10.1016/S0140-6736(00)03411-5	2	2	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					945	945		10.1136/bmj.325.7370.945	http://dx.doi.org/10.1136/bmj.325.7370.945			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399346	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000178986300019
J	Mallet, L; Mesnage, V; Houeto, JL; Pelissolo, A; Yelnik, J; Behar, C; Gargiulo, M; Welter, ML; Bonnet, AM; Pillon, B; Cornu, P; Dormont, D; Pidoux, B; Allilaire, JF; Agid, Y				Mallet, L; Mesnage, V; Houeto, JL; Pelissolo, A; Yelnik, J; Behar, C; Gargiulo, M; Welter, ML; Bonnet, AM; Pillon, B; Cornu, P; Dormont, D; Pidoux, B; Allilaire, JF; Agid, Y			Compulsions, Parkinson's disease, and stimulation	LANCET			English	Article								Pathophysiological models suggest that obsessive compulsive disorder (OCD) might be associated with dysfunctions in cortico-striato-pallido-thalamo-corticaI neuronal circuits. We implanted subthalamic electrodes to alleviate parkinsonian symptoms in two patients who had Parkinson's disease and a history of severe OCD. Parkinsonian disability improved postoperatively in both patients, and 2 weeks after the procedure, their compulsions had disappeared and obsessive symptoms improved (58% improvement for patient I on the Yale-Brown obsessive compulsive scale, 64% for patient 2). The improvements in these two patients suggest that high-frequency stimulation could improve function in the subcortical-limbic circuitry in patients with severe OCD.	Hop La Pitie Salpetriere, Assistance Publ Hop Paris, CNRS, UMR 7593, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, GH Pitie Salpetriere, F-75651 Paris, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Ctr Invest Clin, Federat Neurol, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, INSERM, U289, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, EPI 007, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Serv Neurochirurg, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Serv Neuroradiol, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Serv Neurophysiol, F-75651 Paris 13, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite	Mallet, L (corresponding author), Hop La Pitie Salpetriere, Assistance Publ Hop Paris, CNRS, UMR 7593, F-75651 Paris 13, France.		Mallet, Luc/F-7156-2013; Yelnik, Jérôme/F-7153-2013; Dormont, Didier/F-5492-2012; dormont, didier/B-2175-2012	Mallet, Luc/0000-0001-8061-1167; YELNIK, Jerome/0000-0003-4814-708X; Gargiulo, Marcela/0000-0003-1056-0653; PELISSOLO, Antoine/0000-0003-0465-5648				Alegret M, 2001, ARCH NEUROL-CHICAGO, V58, P1223, DOI 10.1001/archneur.58.8.1223; Benabid AL, 1998, MOVEMENT DISORD, V13, P119; Houeto JL, 2002, J NEUROL NEUROSUR PS, V72, P701, DOI 10.1136/jnnp.72.6.701; RAUCH SL, 2001, TOURETTE SYNDROME, P207; Yelnik J, 2000, NEUROSCIENCE, V101, P77, DOI 10.1016/S0306-4522(00)00364-X	5	250	254	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1302	1304		10.1016/S0140-6736(02)11339-0	http://dx.doi.org/10.1016/S0140-6736(02)11339-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414208				2022-12-28	WOS:000178827200015
J	Lelieveld, J; Berresheim, H; Borrmann, S; Crutzen, PJ; Dentener, FJ; Fischer, H; Feichter, J; Flatau, PJ; Heland, J; Holzinger, R; Korrmann, R; Lawrence, MG; Levin, Z; Markowicz, KM; Mihalopoulos, N; Minikin, A; Ramanathan, V; de Reus, M; Roelofs, GJ; Scheeren, HA; Sciare, J; Schlager, H; Schultz, M; Siegmund, P; Steil, B; Stephanou, EG; Stier, P; Traub, M; Warneke, C; Williams, J; Ziereis, H				Lelieveld, J; Berresheim, H; Borrmann, S; Crutzen, PJ; Dentener, FJ; Fischer, H; Feichter, J; Flatau, PJ; Heland, J; Holzinger, R; Korrmann, R; Lawrence, MG; Levin, Z; Markowicz, KM; Mihalopoulos, N; Minikin, A; Ramanathan, V; de Reus, M; Roelofs, GJ; Scheeren, HA; Sciare, J; Schlager, H; Schultz, M; Siegmund, P; Steil, B; Stephanou, EG; Stier, P; Traub, M; Warneke, C; Williams, J; Ziereis, H			Global air pollution crossroads over the Mediterranean	SCIENCE			English	Article							INDIAN-OCEAN EXPERIMENT; TROPOSPHERIC OZONE; BACKGROUND OZONE; AEROSOL; TRANSPORT; RAINFALL; CLIMATE; SULFUR; ISLAND; DISTRIBUTIONS	The Mediterranean Intensive Oxidant Study, performed in the summer of 2001, uncovered air pollution layers from the surface to an altitude of 15 kilometers. In the boundary layer, air pollution standards are exceeded throughout the region, caused by West and East European pollution from the north. Aerosol particles also reduce solar radiation penetration to the surface, which can suppress precipitation. In the middle troposphere, Asian and to a lesser extent North American pollution is transported from the west. Additional Asian pollution from the east, transported from the monsoon in the upper troposphere, crosses the Mediterranean tropopause, which pollutes the lower stratosphere at middle latitudes.	Max Planck Inst Chem, D-55020 Mainz, Germany; German Weather Serv, Meteorol Observ, D-82383 Hohenpeissenberg, Germany; Johannes Gutenberg Univ Mainz, Inst Atmospher Phys, D-55099 Mainz, Germany; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Joint Res Ctr, Inst Environm, I-21020 Ispra, Va, Italy; Max Planck Inst Meteorol, D-20146 Hamburg, Germany; USN, Res Lab, Monterey, CA 93943 USA; German Aerosp Ctr DLR, Inst Atmospher Phys, D-82230 Wessling, Germany; Tel Aviv Univ, Dept Geophys & Planetary Sci, IL-69978 Tel Aviv, Israel; Warsaw Univ, Inst Geophys, PL-02093 Warsaw, Poland; Univ Crete, Environm Chem Proc Lab, Iraklion 71409, Greece; Univ Utrecht, Inst Marine & Atmospher Res, NL-3584 CC Utrecht, Netherlands; Lab Environm & Climate Sci, F-91191 Gif Sur Yvette, France; Royal Netherlands Meteorol Inst, NL-3730 AE De Bilt, Netherlands; NOAA, Aeron Lab, Boulder, CO 80305 USA	Max Planck Society; Deutscher Wetterdienst; Johannes Gutenberg University of Mainz; University of California System; University of California San Diego; Scripps Institution of Oceanography; European Commission Joint Research Centre; EC JRC ISPRA Site; Italian Institute for Environmental Protection & Research (ISPRA); Max Planck Society; United States Department of Defense; United States Navy; Naval Research Laboratory; Helmholtz Association; German Aerospace Centre (DLR); Tel Aviv University; University of Warsaw; University of Crete; Utrecht University; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Royal Netherlands Meteorological Institute; National Oceanic Atmospheric Admin (NOAA) - USA	Lelieveld, J (corresponding author), Max Planck Inst Chem, POB 3060, D-55020 Mainz, Germany.	lelieveld@mpch-mainz.mpg.de	Warneke, Carsten/E-7174-2010; Borrmann, Stephan/E-3868-2010; Mihalopoulos, Nikolaos/ABF-2255-2020; Flatau, Piotr/E-2219-2011; Stier, Philip/B-2258-2008; Holzinger, Rupert/C-9160-2009; Lelieveld, Jos/A-1986-2013; Mihalopoulos, Nikolaos/H-5327-2016; Minikin, Andreas/A-3904-2011; Berresheim, Harald/F-9670-2011; Schultz, Martin G/I-9512-2012; sciare, jean/A-9529-2008; Crutzen, Paul J/F-6044-2012; Williams, Jonathan/K-7686-2017	Borrmann, Stephan/0000-0002-4774-9380; Stier, Philip/0000-0002-1191-0128; Holzinger, Rupert/0000-0003-1902-1824; Lelieveld, Jos/0000-0001-6307-3846; Mihalopoulos, Nikolaos/0000-0002-1282-0896; Minikin, Andreas/0000-0003-0999-4657; Schultz, Martin G/0000-0003-3455-774X; Williams, Jonathan/0000-0001-9421-1703; Scheeren, Bert/0000-0001-6333-8402; sciare, jean/0000-0002-9908-6718; Markowicz, Krzysztof/0000-0003-4190-0243; Lawrence, Mark/0000-0002-2178-4903				Andreae TW, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD900252; [Anonymous], 2002, MEDITERRANEAN CLIMAT; Avila A, 2002, ATMOS ENVIRON, V36, P2881, DOI 10.1016/S1352-2310(02)00098-5; Board AS, 1999, J GEOPHYS RES-ATMOS, V104, P16181, DOI 10.1029/1999JD900021; Browell EV, 2001, J GEOPHYS RES-ATMOS, V106, P32481, DOI 10.1029/2001JD900001; CHEN P, 1995, J GEOPHYS RES-ATMOS, V100, P16661, DOI 10.1029/95JD01264; Clarke AD, 2001, J GEOPHYS RES-ATMOS, V106, P32555, DOI 10.1029/2000JD900842; Dethof A, 2000, J GEOPHYS RES-ATMOS, V105, P12279, DOI 10.1029/2000JD900127; Formenti P, 2001, J GEOPHYS RES-ATMOS, V106, P9807, DOI 10.1029/2000JD900609; GANGIOTI G, 2001, ATMOS ENV, V35; Ganor E, 2000, ATMOS ENVIRON, V34, P3453, DOI 10.1016/S1352-2310(00)00077-7; Gros V., 1999, CHEMOSPHERE GLOBAL C, V1, P163, DOI DOI 10.1016/S1465-9972(99)00009-4; Hauglustaine DA, 2001, J GEOPHYS RES-ATMOS, V106, P32337, DOI 10.1029/2001JD900175; Haywood J, 2000, REV GEOPHYS, V38, P513, DOI 10.1029/1999RG000078; Hoor P, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000289; Kouvarakis G, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000081; Kouvarakis G, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000291; Kouvarakis G, 2000, J GEOPHYS RES-ATMOS, V105, P4399, DOI 10.1029/1999JD900984; Lawrence MG, 1999, J GEOPHYS RES-ATMOS, V104, P26245, DOI 10.1029/1999JD900425; Lelieveld J, 2000, J GEOPHYS RES-ATMOS, V105, P3531, DOI 10.1029/1999JD901011; Lelieveld J, 2001, SCIENCE, V291, P1031, DOI 10.1126/science.1057103; Luria M, 1996, J GEOPHYS RES-ATMOS, V101, P25917, DOI 10.1029/96JD01579; Maheras P, 1999, THEOR APPL CLIMATOL, V64, P189, DOI 10.1007/s007040050122; MARACCHI G, 2000, 3 EUR C APPL CLIM PI; Markowicz KM, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015767; Mihalopoulos N, 1997, TELLUS B, V49, P314, DOI 10.1034/j.1600-0889.49.issue3.7.x; Millan MM, 1997, J GEOPHYS RES-ATMOS, V102, P8811, DOI 10.1029/96JD03610; Millan MM, 2000, J APPL METEOROL, V39, P487, DOI 10.1175/1520-0450(2000)039<0487:OCITWM>2.0.CO;2; Mylona S, 1996, TELLUS B, V48, P662, DOI 10.1034/j.1600-0889.1996.t01-2-00005.x; Nicholson SE, 2000, J CLIMATE, V13, P2628, DOI 10.1175/1520-0442(2000)013<2628:AAORRC>2.0.CO;2; Nolle M, 2002, ATMOS ENVIRON, V36, P1391, DOI 10.1016/S1352-2310(01)00505-2; Novelli PC, 1998, J GEOPHYS RES-ATMOS, V103, P19015, DOI 10.1029/98JD01366; OZSOY T, 2000, GLOBAL ATMOS OCEAN S, V7, P185; Palutikof JP., 1996, MEDITERRANEAN DESERT, P43; Ramanathan V, 2001, J GEOPHYS RES-ATMOS, V106, P28371, DOI 10.1029/2001JD900133; Ramanathan V, 2001, SCIENCE, V294, P2119, DOI 10.1126/science.1064034; RAYNER NA, 1996, 74 HADL CTR; Roeckner E, 1999, J CLIMATE, V12, P3004, DOI 10.1175/1520-0442(1999)012<3004:TCCSWA>2.0.CO;2; Roelofs GJ, 2000, J GEOPHYS RES-ATMOS, V105, P22697, DOI 10.1029/2000JD900316; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; Rotstayn LD, 2002, J CLIMATE, V15, P2103, DOI 10.1175/1520-0442(2002)015&lt;2103:TRTATI&gt;2.0.CO;2; ROWELL DP, 1995, Q J ROY METEOR SOC, V121, P669, DOI 10.1256/smsqj.52310; Schultz MG, 1999, J GEOPHYS RES-ATMOS, V104, P5829, DOI 10.1029/98JD02309; Sciare J, 2001, J ATMOS CHEM, V39, P281, DOI 10.1023/A:1010631305307; Singh H, 2001, NATURE, V410, P1078, DOI 10.1038/35074067; TRAGOU E, IN PRESS J GEOPHYS R; van Aardenne JA, 2001, GLOBAL BIOGEOCHEM CY, V15, P909, DOI 10.1029/2000GB001265; [No title captured]	48	744	755	1	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					794	799		10.1126/science.1075457	http://dx.doi.org/10.1126/science.1075457			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399583				2022-12-28	WOS:000178791200050
J	Beisel, C; Imhof, A; Greene, J; Kremmer, E; Sauer, F				Beisel, C; Imhof, A; Greene, J; Kremmer, E; Sauer, F			RETRACTED: Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1 (Retracted article. See vol. 521, pg. 110, 2015)	NATURE			English	Article; Retracted Publication							GENETIC-ANALYSIS; LYSINE 9; CHROMATIN; H3; PROTEIN; TRITHORAX; POLYCOMB; METHYLTRANSFERASE; INHERITANCE; ACTIVATION	The establishment and maintenance of mitotic and meiotic stable (epigenetic) transcription patterns is fundamental for cell determination and function(1). Epigenetic regulation of transcription is mediated by epigenetic activators and repressors, and may require the establishment, 'spreading' and maintenance of epigenetic signals(2). Although these signals remain unclear, it has been proposed that chromatin structure and consequently post-translational modification of histones may have an important role in epigenetic gene expression(3,4). Here we show that the epigenetic activator Ash1 (ref. 5) is a multi-catalytic histone methyl-transferase (HMTase) that methylates lysine residues 4 and 9 in H3 and 20 in H4. Transcriptional activation by Ash1 coincides with methylation of these three lysine residues at the promoter of Ash1 target genes. The methylation pattern placed by Ash1 may serve as a binding surface for a chromatin remodelling complex containing the epigenetic activator Brahma (Brm)(6), an ATPase, and inhibits the interaction of epigenetic repressors with chromatin. Chromatin immunoprecipitation indicates that epigenetic activation of Ultrabithorax transcription in Drosophila coincides with trivalent methylation by Ash1 and recruitment of Brm. Thus, histone methylation by Ash1 may provide a specific signal for the establishment of epigenetic, active transcription patterns.	Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; GSF Munich, Forschungszentrum, Inst Mol Immunol, D-81377 Munich, Germany	Ruprecht Karls University Heidelberg; University of Munich; University of California System; University of California Riverside; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Sauer, F (corresponding author), Heidelberg Univ, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	f.sauer@mail.zmbh.uni-heidelberg.de	Imhof, Axel/AAU-5313-2021	Imhof, Axel/0000-0003-2993-8249				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Cavalli G, 1999, SCIENCE, V286, P955, DOI 10.1126/science.286.5441.955; Elfring LK, 1998, GENETICS, V148, P251; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LAJEUNESSE D, 1995, MECH DEVELOP, V53, P123, DOI 10.1016/0925-4773(95)00430-0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Ridgway P, 2000, J CELL SCI, V113, P2647; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; TRIPOULAS NA, 1994, GENETICS, V137, P1027; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Urnov FD, 2001, J MAMMARY GLAND BIOL, V6, P153, DOI 10.1023/A:1011304606604; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	28	238	250	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	2002	419	6909					857	862		10.1038/nature01126	http://dx.doi.org/10.1038/nature01126			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397363				2022-12-28	WOS:000178769800051
J	Buchanan, M				Buchanan, M			A game of chance	NATURE			English	Editorial Material																		Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; CALDARELLI G, CONDMAT0107228; Parisi G, 1999, PHYSICA A, V263, P557, DOI 10.1016/S0378-4371(98)00524-X; Rodriguez-lturbe I., 1999, FRACTAL RIVER BASINS	4	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					787	787		10.1038/419787a	http://dx.doi.org/10.1038/419787a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397334	Bronze			2022-12-28	WOS:000178769800023
J	Adams, DL; Horton, JC				Adams, DL; Horton, JC			Shadows cast by retinal blood vessels mapped in primary visual cortex	SCIENCE			English	Article							OCULAR-DOMINANCE COLUMNS; MACAQUE STRIATE CORTEX; MONOCULAR DEPRIVATION; MONKEY; CATS; ORGANIZATION; PERIODICITY; VARIABILITY; PLASTICITY; PATTERN	The mammalian eye is a remarkable optical device, but its design is not perfect. The blood vessels that supply the inner retina are located in front of the photoreceptor layer, blocking access to light. Their shadows create a pattern of blindness in the field of vision that corresponds precisely to the location of the largest vessels in the eye. We show here that in squirrel monkeys, focal deprivation by blood vessels leads to rewiring of the eye's geniculocortical projections, imprinting an image of the retinal vascular tree onto the primary visual cortex. This process illustrates vividly that local imbalances in neuronal activity can influence column formation during normal development.	Univ Calif San Francisco, Beckman Vis Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Adams, DL (corresponding author), Univ Calif San Francisco, Beckman Vis Ctr, 10 Kirkham St, San Francisco, CA 94143 USA.		Adams, Daniel L/A-5229-2009	Adams, Daniel L/0000-0003-0376-4949; Horton, Jonathan/0000-0002-3952-435X	NCRR NIH HHS [RR00169, P51 RR000169] Funding Source: Medline; NEI NIH HHS [R01 EY010217, R01 EY010217-19, R01 EY10217, EY02162, P30 EY002162] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000169] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY010217, P30EY002162] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEGATE RA, 1990, INVEST OPHTH VIS SCI, V31, P2088; BLASDEL GG, 1984, J NEUROSCI, V4, P880; COWEY A, 1964, J NEUROPHYSIOL, V27, P366, DOI 10.1152/jn.1964.27.3.366; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; Crowley JC, 1999, NAT NEUROSCI, V2, P1125, DOI 10.1038/16051; EVANS JN, 1926, AM J OPHTHALMOL, V9, P489; GOODHILL GJ, 1993, BIOL CYBERN, V69, P109, DOI 10.1007/BF00226194; Goodhill GJ, 1998, NETWORK-COMP NEURAL, V9, P419, DOI 10.1088/0954-898X/9/3/009; HENDRICKSON AE, 1978, J COMP NEUROL, V182, P123, DOI 10.1002/cne.901820108; Horton JC, 1997, J NEUROSCI, V17, P3684; Horton JC, 1996, J NEUROSCI, V16, P5510; Horton JC, 1996, J NEUROSCI, V16, P7228; Horton JC, 1996, J NEUROSCI, V16, P1791; HORTON JC, 1984, PHILOS T ROY SOC B, V304, P199, DOI 10.1098/rstb.1984.0021; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; HUBEL DH, 1969, NATURE, V221, P747, DOI 10.1038/221747a0; JONES DG, 1991, J NEUROSCI, V11, P3794; Kaschube M, 2002, J NEUROSCI, V22, P7206; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Livingstone MS, 1996, J NEUROSCI, V16, P2086; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; Mooney R, 1996, NEURON, V17, P863, DOI 10.1016/S0896-6273(00)80218-4; Schiefer U, 1999, VISION RES, V39, P1897, DOI 10.1016/S0042-6989(98)00295-8; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SWINDALE NV, 1981, PROC R SOC SER B-BIO, V213, P435, DOI 10.1098/rspb.1981.0074; SWINDALE NV, 1980, PROC R SOC SER B-BIO, V208, P243, DOI 10.1098/rspb.1980.0051; VANESSEN DC, 1984, VISION RES, V24, P429, DOI 10.1016/0042-6989(84)90041-5; von der Malsburg C., 1976, EXP BRAIN RES, V(Suppl 1), P463; VONHELMHOLTZ H, 1924, HDB PHYSL OPTICS, V2, P28; WIESEL TN, 1974, BRAIN RES, V79, P273, DOI 10.1016/0006-8993(74)90416-8; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5	33	47	47	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					572	576		10.1126/science.1074887	http://dx.doi.org/10.1126/science.1074887			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386328	Green Accepted, Green Submitted			2022-12-28	WOS:000178634800033
J	Wachowiak, A; Wiebe, J; Bode, M; Pietzsch, O; Morgenstern, M; Wiesendanger, R				Wachowiak, A; Wiebe, J; Bode, M; Pietzsch, O; Morgenstern, M; Wiesendanger, R			Direct observation of internal spin structure of magnetic vortex cores	SCIENCE			English	Article							ATOMIC-SCALE; ANTIFERROMAGNETISM; FE(110)	Thin film nanoscale elements with a curling magnetic structure (vortex) are a promising candidate for future nonvolatile data storage devices. Their properties are strongly influenced by the spin structure in the vortex core. We have used spin-polarized scanning tunneling microscopy on nanoscale iron islands to probe for the first time the internal spin structure of magnetic vortex cores. Using tips coated with a layer of antiferromagnetic chromium, we obtained images of the curling in-plane magnetization around and of the out-of-plane magnetization inside the core region. The experimental data are compared with micromagnetic simulations. The results confirm theoretical predictions that the size and the shape of the vortex core as well as its magnetic field dependence are governed by only two material parameters, the exchange stiffness and the saturation magnetization that determines the stray field energy.	Univ Hamburg, Inst Appl Phys, D-20355 Hamburg, Germany; Univ Hamburg, Microstruct Res Ctr, D-20355 Hamburg, Germany	University of Hamburg; University of Hamburg	Bode, M (corresponding author), Univ Hamburg, Inst Appl Phys, Jungiusstr 11, D-20355 Hamburg, Germany.		Bode, Matthias/S-3249-2016; Wiesendanger, Roland/P-9726-2016; Morgenstern, Markus/K-7785-2013; Wiebe, Jens/C-7580-2018	Bode, Matthias/0000-0001-7514-5560; Wiesendanger, Roland/0000-0002-0472-4183; Morgenstern, Markus/0000-0002-3993-6880; Wiebe, Jens/0000-0003-1668-6142				Bode M, 1998, PHYS REV LETT, V81, P4256, DOI 10.1103/PhysRevLett.81.4256; Bussmann K, 1999, APPL PHYS LETT, V75, P2476, DOI 10.1063/1.125053; FELDTKELLER E, 1965, PHYS KONDENS MATER, V4, P8, DOI 10.1007/BF02423256; GRADMANN U, 1990, HYPERFINE INTERACT, V57, P1845, DOI 10.1007/BF02405732; GRADMANN U, 1986, APPL PHYS A-MATER, V39, P101, DOI 10.1007/BF00616826; Heinze S, 2000, SCIENCE, V288, P1805, DOI 10.1126/science.288.5472.1805; Hubert A, 1998, MAGNETIC DOMAINS; Kubetzka A, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.057201; Pietzsch O, 2000, REV SCI INSTRUM, V71, P424, DOI 10.1063/1.1150218; Pietzsch O, 2000, PHYS REV LETT, V84, P5212, DOI 10.1103/PhysRevLett.84.5212; Pratzer M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.127201; Raabe J, 2000, J APPL PHYS, V88, P4437, DOI 10.1063/1.1289216; Shinjo T, 2000, SCIENCE, V289, P930, DOI 10.1126/science.289.5481.930; Wortmann D, 2001, PHYS REV LETT, V86, P4132, DOI 10.1103/PhysRevLett.86.4132	14	730	738	8	228	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					577	580		10.1126/science.1075302	http://dx.doi.org/10.1126/science.1075302			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386329				2022-12-28	WOS:000178634800034
J	Lemaitre, JM; Bocquet, S; Mechali, M				Lemaitre, JM; Bocquet, S; Mechali, M			Competence to replicate in the unfertilized egg is conferred by Cdc6 during meiotic maturation	NATURE			English	Article							CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; CELL-CYCLE; XENOPUS-LAEVIS; CHROMOSOME-REPLICATION; CHROMATIN ASSOCIATION; OOCYTE MATURATION; CYTOSTATIC FACTOR; PROTO-ONCOGENE; MCM COMPLEX	Meiotic maturation, the final step of oogenesis, is a crucial stage of development in which an immature oocyte becomes a fertilizable egg(1). In Xenopus, the ability to replicate DNA is acquired during maturation at breakdown of the nuclear envelope 2 by translation of a DNA synthesis inducer that is not present in the oocyte(2,3). Here we identify Cdc6, which is essential for recruiting the minichromosome maintenance (MCM) helicase to the prereplication complex, as this inducer of DNA synthesis. We show that maternal cdc6 mRNA but not protein is stored in the oocyte. Cdc6 protein is synthesized during maturation, but this process can be blocked by degrading the maternal cdc6 mRNA by oligonucleotide antisense injections or by translation inhibition. Rescue experiments using recombinant Cdc6 protein show that Cdc6 is the only missing replication factor whose translation is necessary and sufficient to confer DNA replication competence to the egg before fertilization. The licence to replicate is given by Cdc6 at the end of meiosis I, but the cytostatic factor (CSF) pathway, which maintains large amounts of active Cdc2/Cyclin B2, prevents the entry into S phase until fertilization.	CNRS, Inst Human Genet, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mechali, M (corresponding author), CNRS, Inst Human Genet, 141 Rue Cardonille, F-34396 Montpellier 5, France.		LEMAITRE, Jean-Marc/I-4989-2016	LEMAITRE, Jean-Marc/0000-0002-6492-5219				Abrieu A, 2001, J CELL SCI, V114, P257; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Calzada A, 2001, NATURE, V412, P355, DOI 10.1038/35085610; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GURDON JB, 1967, P NATL ACAD SCI USA, V58, P545, DOI 10.1073/pnas.58.2.545; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; Hochegger H, 2001, DEVELOPMENT, V128, P3795; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Lei M, 2001, J CELL SCI, V114, P1447; Lemaitre JM, 1998, J CELL BIOL, V142, P1159, DOI 10.1083/jcb.142.5.1159; Madine MA, 2000, J STRUCT BIOL, V129, P198, DOI 10.1006/jsbi.2000.4218; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Masui Y, 2000, NAT REV MOL CELL BIO, V1, P228, DOI 10.1038/35043096; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Menut S, 1999, ADV MOLEC BIOL, P196; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Pereverzeva I, 2000, MOL CELL BIOL, V20, P3667, DOI 10.1128/MCB.20.10.3667-3676.2000; Reimann JDR, 2002, NATURE, V416, P850, DOI 10.1038/416850a; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; Tian JD, 1997, P NATL ACAD SCI USA, V94, P10729, DOI 10.1073/pnas.94.20.10729; Weinreich M, 2001, P NATL ACAD SCI USA, V98, P11211, DOI 10.1073/pnas.201387198; Whitmire E, 2002, NATURE, V419, P722, DOI 10.1038/nature01032; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	30	45	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					718	722		10.1038/nature01046	http://dx.doi.org/10.1038/nature01046			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384698				2022-12-28	WOS:000178615200040
J	Eddleston, M; Karalliedde, L; Buckley, N; Fernando, R; Hutchinson, G; Isbister, G; Konradsen, F; Murray, D; Piola, JC; Senanyake, N; Sheriff, R; Singh, S; Siwach, SB; Smit, L				Eddleston, M; Karalliedde, L; Buckley, N; Fernando, R; Hutchinson, G; Isbister, G; Konradsen, F; Murray, D; Piola, JC; Senanyake, N; Sheriff, R; Singh, S; Siwach, SB; Smit, L			Pesticide poisoning in the developing world - a minimum pesticides list	LANCET			English	Article							EPIDEMIC; PATTERN	In parts of the developing world, pesticide poisoning causes more deaths than infectious diseases. Use of pesticides is poorly regulated and often dangerous; their easy availability also makes them a popular method of self-harm. In 1985, the UN Food and Agriculture Organisation (FAO) produced a voluntary code of conduct for the pesticide industry in an attempt to limit the harmful effects of pesticides. Unfortunately, a lack of adequate government resources in the developing world makes this code ineffective, and thousands of deaths continue today. WHO has recommended that access to highly toxic pesticides be restricted-where this has been done, suicide rates have fallen. Since an Essential Drugs List was established in 1977, use of a few essential drugs has rationalised drug use in many regions. An analogous Minimum Pesticides List would identify a restricted number of less dangerous pesticides to do specific tasks within an Integrated pest management system. Use of safer pesticides should result in fewer deaths, just as the change from barbiturates to benzodiazepines has reduced the number of deaths from pharmaceutical self-poisoning.	Univ Oxford, Ctr Trop Med, Oxford OX1 2JD, England; Univ Colombo, Fac Med, Dept Clin Med, Oxford Colombo Collaborat, Colombo 08, Sri Lanka; Guys & St Thomas Hosp, Med Toxicol Unit, London SE1 9RT, England; Canberra Hosp, Dept Clin Pharmacol & Toxicol, Canberra, ACT, Australia; Natl Hosp Sri Lanka, Natl Poisons Informat Ctr, Colombo, Sri Lanka; Univ Colombo, Dept Forens Med & Toxicol, Colombo, Sri Lanka; Univ W Indies, Dept Med, St Augustine, Trinidad Tobago; Univ W Indies, Dept Pathol, St Augustine, Trinidad Tobago; Mater Hosp, Dept Clin Pharmacol & Toxicol, Newcastle, NSW, Australia; Univ Copenhagen, Dept Int Hlth, Copenhagen, Denmark; Colorado State Univ, Dept Sociol, Ft Collins, CO 80523 USA; Sanatorio de Ninos, Serv Toxicol, Rosario, Argentina; Univ Peradeniya, Dept Med, Peradeniya, Sri Lanka; Postgrad Inst Med Educ & Res, Dept Internal Med, Chandigarh 160012, India; Postgrad Inst Med Sci, Dept Med, Rohtak, Haryana, India; Int Water Management Inst, Colombo, Sri Lanka	University of Oxford; University of Colombo; Guy's & St Thomas' NHS Foundation Trust; Australian National University; Canberra Hospital; University of Colombo; University West Indies Mona Jamaica; University West Indies Saint Augustine; University West Indies Mona Jamaica; University West Indies Saint Augustine; University of Copenhagen; Colorado State University; University of Peradeniya; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; CGIAR; International Water Management Institute (IWMI)	Eddleston, M (corresponding author), Univ Colombo, Fac Med, Dept Clin Med, Oxford Colombo Collaborat, POB 271,25 Kynsey Rd, Colombo 08, Sri Lanka.	edlestonm@eureka.lk	Buckley, Nicholas A/D-4030-2012; Isbister, Geoffrey K/G-8052-2015; Smit, Lidwien AM/AFC-8689-2022	Buckley, Nicholas A/0000-0002-6326-4711; Isbister, Geoffrey K/0000-0003-1519-7419; Smit, Lidwien AM/0000-0003-0292-0946; Konradsen, Flemming/0000-0003-1036-6949	Wellcome Trust [063560] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*AD HOC COMM HLTH, 1996, WHOTDRGEN961 AD HOC; ALRAGHEB SYA, 1989, AM J FOREN MED PATH, V10, P221, DOI 10.1097/00000433-198909000-00010; Bowles J. R., 1995, PREVENTIVE STRATEGIE, P173; Bull D, 1982, GROWING PROBLEM PEST; CHUGH SN, 1991, INDIAN J MED RES-B, V94, P232; *CROPL INT, 2001, INT PEST MAN; *CROPL INT, 2001, WORLD FOOD SEC; Daisley H, 1998, LANCET, V352, P1393, DOI 10.1016/S0140-6736(05)60796-9; Dinham Barbara, 1993, PESTICIDE HAZARD GLO; Eddleston M, 2000, QJM-INT J MED, V93, P715, DOI 10.1093/qjmed/93.11.715; Eddleston M, 1999, TROP MED INT HEALTH, V4, P266, DOI 10.1046/j.1365-3156.1999.00397.x; Eddleston M, 1998, BRIT MED J, V317, P133, DOI 10.1136/bmj.317.7151.133; HETTIARACHCHI J, 1989, INT J EPIDEMIOL, V18, P418, DOI 10.1093/ije/18.2.418; HOGERZEIL HV, 1989, LANCET, V1, P141; MCCONNELL R, 1993, AM J PUBLIC HEALTH, V83, P1559, DOI 10.2105/AJPH.83.11.1559; MCKENZIE W, 2001, ANN REV CROP PROTECT; Meister R T., 1999, FARM CHEM HDB 99; Murray CJL, 1996, GLOBAL BURDEN DIS IN, V1; Murray Douglas L., 1994, CULTIVATING CRISIS H; Piola J. C., 2001, REV MED ROSARIO REV MED ROSARIO, V67, P19; *PRES SECR, 1999, SUIC RED OPP IMPR TR; PROUDFOOT AT, 1978, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.6105.90; Singh D, 1999, AM J FOREN MED PATH, V20, P203, DOI 10.1097/00000433-199906000-00019; Singh S., 1997, J ASSOC PHYSICIAN I, V45, P194; Siwach S B, 1995, J Assoc Physicians India, V43, P756; *SRI LANK MIN HLTH, 1997, ANN HLTH B; STONE R, 1992, SCIENCE, V256, P1272, DOI 10.1126/science.1598564; *UN FOOD AGR ORG, 1990, 25 SESS FAO C NOV 19; Van der Hoek W, 1998, SOC SCI MED, V46, P495, DOI 10.1016/S0277-9536(97)00193-7; Wesseling C, 1997, INT J HEALTH SERV, V27, P273, DOI 10.2190/E259-N3AH-TA1Y-H591; WHO, 2001, WORLD HLTH REPORT 20; *WHO COLL UNEP, 1990, PUBL HLTH IMP PEST U; *WHO EXP COMM US E, 1995, WHO TECHN REP SER, V850; World Health Organization, 2000, WHO REC CLASS PEST H	34	305	318	1	43	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	2002	360	9340					1163	1167		10.1016/S0140-6736(02)11204-9	http://dx.doi.org/10.1016/S0140-6736(02)11204-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387969				2022-12-28	WOS:000178632000021
J	Chiu, RWK; Lau, TK; Leung, TN; Chow, KCK; Chui, DHK; Lo, YMD				Chiu, RWK; Lau, TK; Leung, TN; Chow, KCK; Chui, DHK; Lo, YMD			Prenatal exclusion of beta thalassaemia major by examination of maternal plasma	LANCET			English	Article								The discovery of the presence of fetal DNA in maternal plasma has provided a new approach for non-Invasive prenatal diagnosis. At present, the prenatal diagnosis of beta thalassaemia relies on invasive methods. We designed allele-specific primers and a fluorescent probe for detection of the codon 41/42 (-CTTT) mutation in the beta globin gene from maternal plasma by real-time PCR. The specificity and sensitivity of the allele-specific assay was confirmed by subjecting plasma, buffy coat, and amniotic fluid samples from 100 pregnancies to screening for the mutation. Subsequently, the assay was applied to the prenatal testing of eight fetuses at risk of beta thalassaemia major, the aim being to exclude fetal inheritance of paternally transmitted codon 41/42 mutation. The fetal genotype was completely concordant with conventional analysis and beta thalassaemia major was excluded in two of the pregnancies non-invasively.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China; McMaster Univ, Fac Hlth Sci, Dept Pathol & Mol Med, Hamilton, ON, Canada	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; McMaster University	Lo, YMD (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Room 38023,1-F Clin Sci Bldg,30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China.		Lo, Yuk Ming Dennis/D-4468-2011	Lo, Yuk Ming Dennis/0000-0001-8746-0293; Lau, Tze Kin/0000-0002-0242-1410; Chui, David/0000-0002-1475-7309				Costa JM, 2002, NEW ENGL J MED, V346, P1502, DOI 10.1056/NEJM200205093461918; Lau YL, 1997, NEW ENGL J MED, V336, P1298, DOI 10.1056/NEJM199705013361805; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Lo YMD, 1998, NEW ENGL J MED, V339, P1734, DOI 10.1056/NEJM199812103392402; Weatherall DJ, 1997, BRIT MED J, V314, P1675, DOI 10.1136/bmj.314.7095.1675	5	204	250	0	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 28	2002	360	9338					998	1000		10.1016/S0140-6736(02)11086-5	http://dx.doi.org/10.1016/S0140-6736(02)11086-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383672				2022-12-28	WOS:000178249000015
J	Koepsell, T; McCloskey, L; Wolf, M; Moudon, AV; Buchner, D; Kraus, J; Patterson, M				Koepsell, T; McCloskey, L; Wolf, M; Moudon, AV; Buchner, D; Kraus, J; Patterson, M			Crosswalk markings and the risk of pedestrian-motor vehicle collisions in older pedestrians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INJURIES	Context Motor vehicles struck and killed 4739 pedestrians in the United States in the year 2000. Older pedestrians are at especially high risk. Objective To determine whether crosswalk markings at urban intersections influence the risk of injury to older pedestrians. Design Case-control study in which the units of study were crossing locations. Setting Six cities in Washington and California, with case accrual from February 1995 through January 1999. Participants A total of 282 case sites were street-crossing locations at an intersection where a pedestrian aged 65 years or older had been struck by a motor vehicle while crossing the street; 564 control sites were other nearby crossings that were matched to case sites based on street classification. Trained observers recorded environmental characteristics, vehicular traffic flow and speed, and pedestrian use at each site on the same day of the week and time of day as when the case event had occurred. Main Outcome Measure Risk of pedestrian-motor vehicle collision involving an older pedestrian. Results After adjusting for pedestrian flow, vehicle flow, crossing length, and signalization, risk of a pedestrian-motor vehicle collision was 2.1-fold greater (95% confidence interval, 1.1-4.0) at sites with a marked crosswalk. Almost all of the excess risk was due to 3.6-fold (95% confidence interval, 1.7-7.9) higher risk associated with marked crosswalks at sites with no traffic signal or stop sign. Conclusions Crosswalk markings appear associated with increased risk of pedestrian-motor vehicle collision to older pedestrians at sites where no signal or stop sign is present to halt traffic.	Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Coll Architecture & Urban Planning, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Phys Act Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA; Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, Los Angeles, CA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA; University of California System; University of California Los Angeles	Koepsell, T (corresponding author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA.	koepsell@u.washington.edu			NATIONAL INSTITUTE ON AGING [R01AG010147] Funding Source: NIH RePORTER; NIA NIH HHS [AG10147] Funding Source: Medline; ODCDC CDC HHS [CCR002570] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); ODCDC CDC HHS		Armstrong B.K., 1992, PRINCIPLES EXPOSURE; ARMSTRONG BG, 1989, STAT MED, V8, P1151, DOI 10.1002/sim.4780080916; Aronson S C, 1984, R I Med J, V67, P485; BAKER SP, 1974, AM J PUBLIC HEALTH, V64, P318, DOI 10.2105/AJPH.64.4.318; Britt J.W., 1995, TRANSPORT RES REC, V1485, P160; CHAPMAN AJ, 1982, PEDESTRIAN ACCIDENTS; Duperrex O, 2002, BRIT MED J, V324, P1129, DOI 10.1136/bmj.324.7346.1129; Greenland S, 1996, INT J EPIDEMIOL, V25, P1107, DOI 10.1093/ije/25.6.1107-a; Harruff RC, 1998, ACCIDENT ANAL PREV, V30, P11, DOI 10.1016/S0001-4575(97)00057-2; Herms BF, 1972, HIGHWAY RES REC, V406, P1; HOXIE RE, 1994, J AM GERIATR SOC, V42, P241, DOI 10.1111/j.1532-5415.1994.tb01745.x; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; KEALL MD, 1995, ACCIDENT ANAL PREV, V27, P729, DOI 10.1016/0001-4575(95)00019-V; KNOBLAUCH RL, 1986, FED HIGHWAY ADM PUBL; Knoblauch RL, 1984, TRANSPORT RES REC, V959, P35; *NAT COMM INJ PREV, 1989, AM J PREV MED S, V5, P115; *NAT HIGHW TRAFF S, 2000, B09091 DOT HS NAT HI; *NAT HIGHW TRAFF S, 1999, 808983 DOT HS NAT HI; *NAT HIGHW TRAFF S, 1998, 808983 DOT HS NAT HI; *NAT HIGHW TRAFF S, 2001, 809331 DOT HS; Oxley J, 1997, ACCIDENT ANAL PREV, V29, P839, DOI 10.1016/S0001-4575(97)00053-5; RETTING RA, 1996, INFLUENCE SIGNS PAVE; RIVARA FP, 1989, PUBLIC HEALTH REP, V104, P293; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; SAIBEL C, 1995, OBSERVATIONAL SURVEY; SAVITZ DA, 1989, AM J EPIDEMIOL, V129, P1062, DOI 10.1093/oxfordjournals.aje.a115210; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Smith S.A., 1987, TRANSP RES REC, V1141, P15; Tidwell JE, 1995, TRANSPORT RES REC, V1502, P119; TOBEY HN, 1983, PEDESTRIAN TRIP MAKI; WALLER JA, 1985, INJURY CONTROL, P1129; Zegeer CV, 2001, TRANSPORT RES REC, P56, DOI 10.3141/1773-07; ZEGEER CV, 1988, PEDESTRIANS TRAFFIC; 1899, NY TIMES        0914, P1	35	91	92	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2136	2143		10.1001/jama.288.17.2136	http://dx.doi.org/10.1001/jama.288.17.2136			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	611ZJ	12413373	Bronze			2022-12-28	WOS:000179048100024
J	Bjornstad, ON; Peltonen, M; Liebhold, AM; Baltensweiler, W				Bjornstad, ON; Peltonen, M; Liebhold, AM; Baltensweiler, W			Waves of larch budmoth outbreaks in the European Alps	SCIENCE			English	Article							POPULATION-DYNAMICS; TRAVELING WAVES; TIME; SYNCHRONY; PATTERNS; MODELS	Spatially extended population models predict complex spatiotemporal patterns, such as spiral waves and spatial chaos, as a result of the reaction-diffusion dynamics that arise from trophic interactions. However, examples of such patterns in ecological systems are scarce. We develop a quantitative technique to demonstrate the existence of waves in Central European larch budmoth (Zeiraphera diniana Gn.) outbreaks. We show that these waves travel toward the northeast-east at 210 kilometers per year. A theoretical model involving a moth-enemy interaction predicts directional waves, but only if dispersal is directionally biased or habitat productivity varies across the landscape. Our study confirms that nonlinear ecological interactions can lead to complex spatial dynamics at a regional scale.	Penn State Univ, Dept Entomol, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; US Forest Serv, USDA, Morgantown, WV 26505 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; United States Department of Agriculture (USDA); United States Forest Service	Bjornstad, ON (corresponding author), Penn State Univ, Dept Entomol, 501 ASI Bldg, University Pk, PA 16802 USA.		Villsen, Kurt/C-7965-2015; Bjornstad, Ottar N/I-4518-2012; Liebhold, Andrew M./C-1423-2008	Liebhold, Andrew M./0000-0001-7427-6534				BALTENSWEILER W, 1993, OECOLOGIA, V94, P62, DOI 10.1007/BF00317302; Baltensweiler Werner, 1999, Forest Snow and Landscape Research, V74, P1; Bjornstad ON, 2001, J ANIM ECOL, V70, P924, DOI 10.1046/j.0021-8790.2001.00560.x; Bjornstad ON, 1999, TRENDS ECOL EVOL, V14, P427, DOI 10.1016/S0169-5347(99)01677-8; Bjornstad ON, 2001, ENVIRON ECOL STAT, V8, P53, DOI 10.1023/A:1009601932481; Bjornstad ON, 2001, SCIENCE, V293, P638, DOI 10.1126/science.1062226; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; Gurney WSC, 1998, ECOLOGY, V79, P2516; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; Hastings A, 1997, P ROY SOC B-BIOL SCI, V264, P1837, DOI 10.1098/rspb.1997.0253; Haydon DT, 2000, THEOR POPUL BIOL, V58, P239, DOI 10.1006/tpbi.2000.1489; Lambin X, 1998, P ROY SOC B-BIOL SCI, V265, P1491, DOI 10.1098/rspb.1998.0462; Maron JL, 1997, SCIENCE, V278, P1619, DOI 10.1126/science.278.5343.1619; MAY RM, 1986, PROC R SOC SER B-BIO, V228, P241, DOI 10.1098/rspb.1986.0054; Ranta E, 1997, ECOGRAPHY, V20, P454, DOI 10.1111/j.1600-0587.1997.tb00412.x; Wilson WG, 1999, J ANIM ECOL, V68, P94, DOI 10.1046/j.1365-2656.1999.00265.x; [No title captured]; [No title captured]	18	138	142	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					1020	1023		10.1126/science.1075182	http://dx.doi.org/10.1126/science.1075182			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411704				2022-12-28	WOS:000178932000055
J	Ganz, T				Ganz, T			Versatile defensins	SCIENCE			English	Editorial Material							DENDRITIC CELLS		Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Ganz, T (corresponding author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA.	tganz@mednet.ucla.edu	Ganz, Tomas/AAN-3308-2020; Ganz, Tomas/D-4567-2009	Ganz, Tomas/0000-0002-2830-5469				Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Barker E, 1998, BLOOD, V92, P3105, DOI 10.1182/blood.V92.9.3105.421k46_3105_3114; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Castelli JC, 2002, BLOOD, V99, P4225, DOI 10.1182/blood-2001-11-0078; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; Perez-Canadillas JM, 2001, J BIOL CHEM, V276, P28372, DOI 10.1074/jbc.M103121200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zhang LQ, 2002, SCIENCE, V298, P995, DOI 10.1126/science.1076185	12	62	72	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	2002	298	5595					977	+		10.1126/science.1078708	http://dx.doi.org/10.1126/science.1078708			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411693				2022-12-28	WOS:000178932000042
J	Patel, P; Topilow, A				Patel, P; Topilow, A			Atypical pyoderma gangrenosum in a splenectomy incision	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Jersey Shore Med Ctr, Neptune, NJ 07754 USA	Jersey Shore University Medical Center	Patel, P (corresponding author), Jersey Shore Med Ctr, Neptune, NJ 07754 USA.								0	9	10	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1419	1419		10.1056/NEJMicm010244	http://dx.doi.org/10.1056/NEJMicm010244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12409544				2022-12-28	WOS:000178888400005
J	Miller, FG; Rosenstein, DL				Miller, FG; Rosenstein, DL			Reporting of ethical issues in publications of medical research	LANCET			English	Article							PLACEBO-CONTROLLED TRIALS; PSYCHIATRIC RESEARCH; INFORMED CONSENT	Clinical investigators rarely describe the rationale for ethically controversial features of study design or procedures instituted to enhance the protection of patients taking part in research, or how they ensured informed consent. We recommend a policy of extensive reporting of pertinent ethical issues to promote public accountability for clinical research. Guidelines are presented, and possible objections to this recommended policy are addressed.	NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA; NIH, Psychiat Consultat Liaison Serv, Bethesda, MD USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Miller, FG (corresponding author), NIH, Dept Clin Bioeth, Bldg 10,Room 1c118, Bethesda, MD 20892 USA.							Angell M., 1992, NAZI DOCTORS NUREMBE, P276; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; BOR J, 2001, BALTIMORE SUN B 0720; Charney DS, 1999, BIOL PSYCHIAT, V46, P1007; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; Emanuel EJ, 2001, NEW ENGL J MED, V345, P915, DOI 10.1056/NEJM200109203451211; Levine RJ, 1986, ETHICS REGULATION CL, P27; Miller FG, 1999, ARCH GEN PSYCHIAT, V56, P763, DOI 10.1001/archpsyc.56.8.763; Miller FG, 1998, JAMA-J AM MED ASSOC, V280, P1449, DOI 10.1001/jama.280.16.1449; Miller FG, 2000, BIOL PSYCHIAT, V47, P707, DOI 10.1016/S0006-3223(00)00833-7; Miller FG, 2001, CLIN INFECT DIS, V33, P1028, DOI 10.1086/322664; Miller FG, 1997, BIOL PSYCHIAT, V42, P403, DOI 10.1016/S0006-3223(97)00189-3; Moreno JD, 2001, HASTINGS CENT REP, V31, P9, DOI 10.2307/3527549; *NAT BIOETH ADV CO, 1998, RES INV PERS MENT DI; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P922, DOI 10.1001/jama.277.11.922; Rosenstein DL, 2001, BIOL PSYCHIAT, V50, P802, DOI 10.1016/S0006-3223(01)01236-7; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SILVERMA.WA, 1966, NEW ENGL J MED, V275, P790; Stephenson J, 2000, JAMA-J AM MED ASSOC, V284, P2043, DOI 10.1001/jama.284.16.2043; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Wendler D, 1996, MILBANK Q, V74, P87, DOI 10.2307/3350434	21	35	35	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1326	1328		10.1016/S0140-6736(02)11346-8	http://dx.doi.org/10.1016/S0140-6736(02)11346-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414226				2022-12-28	WOS:000178827200032
J	Selkoe, DJ				Selkoe, DJ			Alzheimer's disease is a synaptic failure	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; LONG-TERM POTENTIATION; TRANSGENIC MICE; A-BETA; COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E; MOUSE MODEL; BRAIN; TRANSMISSION; DEPOSITION	In its earliest clinical phase, Alzheimer's disease characteristically produces a remarkably pure impairment of memory. Mounting evidence suggests that this syndrome begins with subtle alterations of hippocampal synaptic efficacy prior to frank neuronal degeneration, and that the synaptic dysfunction is caused by diffusible oligomeric assemblies of the amyloid beta protein.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Ctr Neurodegenerat & Repair, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University	Selkoe, DJ (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, 75 Francis St, Boston, MA 02115 USA.	selkoe@cnd.bwh.harvard.edu	Sancheti, Harsh/H-3538-2012					Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; DAVIES CA, 1987, J NEUROL SCI, V78, P151, DOI 10.1016/0022-510X(87)90057-8; DAVIES P, 1976, LANCET, V2, P1403; Dewachter I, 2002, J NEUROSCI, V22, P3445; DICKSON DW, 1995, NEUROBIOL AGING, V16, P285, DOI 10.1016/0197-4580(95)00013-5; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Fitzjohn SM, 2001, J NEUROSCI, V21, P4691, DOI 10.1523/JNEUROSCI.21-13-04691.2001; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Larson J, 1999, BRAIN RES, V840, P23, DOI 10.1016/S0006-8993(99)01698-4; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Masliah E, 2001, NEUROLOGY, V56, P127, DOI 10.1212/WNL.56.1.127; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Morris JC, 1996, NEUROLOGY, V46, P707, DOI 10.1212/WNL.46.3.707; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Stephan A, 2001, J NEUROSCI, V21, P5703, DOI 10.1523/JNEUROSCI.21-15-05703.2001; Sze CI, 1997, J NEUROPATH EXP NEUR, V56, P933, DOI 10.1097/00005072-199708000-00011; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341	34	3150	3320	5	485	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					789	791		10.1126/science.1074069	http://dx.doi.org/10.1126/science.1074069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399581				2022-12-28	WOS:000178791200048
J	Check, E				Check, E			National academies slam Bush proposal for data security	NATURE			English	News Item																		2002, NATURE, V418, P906	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					769	769		10.1038/419769b	http://dx.doi.org/10.1038/419769b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397320	Bronze			2022-12-28	WOS:000178769800010
J	De Martini, F; Buzek, V; Sciarrino, F; Sias, C				De Martini, F; Buzek, V; Sciarrino, F; Sias, C			Experimental realization of the quantum universal NOT gate	NATURE			English	Article							CLONING; STATES	In classical computation, a 'bit' of information can be flipped (that is, changed in value from zero to one and vice versa) using a logical NOT gate; but the quantum analogue of this process is much more complicated. A quantum bit (qubit) can exist simultaneously in a superposition of two logical states with complex amplitudes, and it is impossible(1-3) to find a universal transformation that would flip the original superposed state into a perpendicular state for all values of the amplitudes. But although perfect flipping of a qubit prepared in an arbitrary state (a universal NOT operation) is prohibited by the rules of quantum mechanics, there exists an optimal approximation(2) to this procedure. Here we report the experimental realization of a universal quantum machine(4) that performs the best possible approximation to the universal NOT transformation. The system adopted was an optical parametric amplifier of entangled photon states, which also enabled us to investigate universal quantum cloning.	Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy; Univ Roma La Sapienza, Ist Nazl Fis Mat, I-00185 Rome, Italy; Slovak Acad Sci, Inst Phys, Res Ctr Quantum Informat, Bratislava 84228, Slovakia; Natl Univ Ireland, Dept Math Phys, Maynooth, Kildare, Ireland	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Sapienza University Rome; Slovak Academy of Sciences; Institute of Physics, SAS; Maynooth University	De Martini, F (corresponding author), Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy.	francesco.demartini@uniroma1.it	Sias, Carlo/D-1317-2014; Buzek, Vladimir/AAD-9646-2019	Sias, Carlo/0000-0002-5390-8288; Buzek, Vladimir/0000-0002-4339-0745; Sciarrino, Fabio/0000-0003-1715-245X				Alber G, 2001, SPRINGER TRAC MOD PH, V173, P1; Bechmann-Pasquinucci H, 1999, PHYS REV A, V59, P4238, DOI 10.1103/PhysRevA.59.4238; Buzek V, 1999, PHYS REV A, V60, pR2626, DOI 10.1103/PhysRevA.60.R2626; De Martini F, 1998, PHYS REV LETT, V81, P2842, DOI 10.1103/PhysRevLett.81.2842; De Martini F, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.150401; De Martini F, 2000, OPT COMMUN, V179, P581, DOI 10.1016/S0030-4018(00)00611-8; Derka R, 1998, PHYS REV LETT, V80, P1571, DOI 10.1103/PhysRevLett.80.1571; Gisin N, 1999, PHYS REV LETT, V83, P432, DOI 10.1103/PhysRevLett.83.432; Lamas-Linares A, 2002, SCIENCE, V296, P712, DOI 10.1126/science.1068972; Simon C, 2000, PHYS REV LETT, V84, P2993, DOI 10.1103/PhysRevLett.84.2993	10	141	143	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	2002	419	6909					815	818		10.1038/nature01093	http://dx.doi.org/10.1038/nature01093			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397351				2022-12-28	WOS:000178769800039
J	Klerk, M; Verhoef, P; Clarke, R; Blom, HJ; Kok, FJ; Schouten, EG				Klerk, M; Verhoef, P; Clarke, R; Blom, HJ; Kok, FJ; Schouten, EG		MTHFR Studies Collaboration Grp	MTHFR 677C -> T polymorphism and risk of coronary heart disease - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							METHYLENETETRAHYDROFOLATE REDUCTASE GENE; METHYLENE-TETRAHYDROFOLATE REDUCTASE; PLASMA TOTAL HOMOCYSTEINE; MYOCARDIAL-INFARCTION; COMMON MUTATION; ARTERY-DISEASE; 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE; CARDIOVASCULAR-DISEASE; VASCULAR-DISEASE; THERMOLABILE VARIANT	Context In observational studies, individuals with elevated levels of plasma homocysteine tend to have moderately increased risk of coronary heart disease (CHD). The MTHFR 677C-->T polymorphism is a genetic alteration in an enzyme involved in folate metabolism that causes elevated homocysteine concentrations, but its relevance to risk of CHD is uncertain. Objective To assess the relation of MTHFR 677C-->T polymorph ism and risk of CHD by conducting a meta-analysis of individual participant data from all case-control observational studies with data on this polymorphism and risk of CHD. Data Sources Studies were identified by searches of the electronic literature (MEDLINE and Current Contents) for relevant reports published before June 2001 (using the search terms MTHFR and coronary heart disease), hand searches of reference lists of original studies and review articles (including meta-analyses) on this topic, and contact with investigators in the field. Study Selection Studies were included if they had data on the MTHFR 677C-->T genotype and a case-control design (retrospective or nested case-control) and involved CHD as an end point. Data were obtained from 40 (34 published and 6 unpublished) observational studies involving a total of 11162 cases and 12758 controls. Data Extraction Data were collected on MTHFR 677C-->T genotype, case-control status, and plasma levels of homocysteine, folate, and other cardiovascular risk factors. Data were checked for consistency with the published article or with information provided by the investigators and converted into a standard format for incorporation into a central database. Combined odds ratios (ORs) for the association between the MTHFR 677C-->T polymorphism and CHD were assessed by logistic regression. Data Synthesis Individuals with the MTHFR 677 TT genotype had a 16% (OR, 1.16; 95% confidence interval [CI], 1.05-1.28) higher odds of CHD compared with individuals with the CC genotype. There was significant heterogeneity between the results obtained in European populations (OR, 1.14; 95% CI, 1.01-1.28) compared with North American populations (OR, 0.87; 95% CI, 0.73-1.05), which might largely be explained by interaction between the MTHFR 677C-->T polymorphism and folate status. Conclusions Individuals with the MTHFR 677 TT genotype had a significantly higher risk of CHD, particularly in the setting of low folate status. These results support the hypothesis that impaired folate metabolism, resulting in high homocysteine levels, is causally related to increased risk of CHD.	Univ Wageningen & Res Ctr, Wageningen Ctr Food Sci, NL-6700 EV Wageningen, Netherlands; Univ Wageningen & Res Ctr, Div Human Nutr & Epidemiol, NL-6700 EV Wageningen, Netherlands; Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Univ Med Ctr Nijmegen, Lab Pediat & Neurol, Nijmegen, Netherlands	Wageningen University & Research; Wageningen University & Research; Radcliffe Infirmary; University of Oxford; Radboud University Nijmegen	Verhoef, P (corresponding author), Univ Wageningen & Res Ctr, Wageningen Ctr Food Sci, POB 8129, NL-6700 EV Wageningen, Netherlands.	petra.verhoef@staff.nutepi.wau.nl	Kozich, Viktor/A-7672-2008	Kozich, Viktor/0000-0001-5820-5277; Blom, Henk/0000-0001-5202-9241; solinas, emilia/0000-0003-3532-1317; Gulec, Sadi/0000-0002-2685-2522; Marcucci, Rossella/0000-0001-9549-7176; Verhoef, Petra/0000-0002-6927-6182; GIRELLI, Domenico/0000-0001-9684-1899				Abbate R, 1998, THROMB HAEMOSTASIS, V79, P727; Adams M, 1996, QJM-MON J ASSOC PHYS, V89, P437; Amorim Cruz J. A., 1996, European Journal of Clinical Nutrition, V50, pS77; Anderson JL, 1997, J AM COLL CARDIOL, V30, P1206, DOI 10.1016/S0735-1097(97)00310-0; Anderson JL, 2000, CIRCULATION, V102, P1227, DOI 10.1161/01.CIR.102.11.1227; Araujo F, 2000, THROMB HAEMOSTASIS, V83, P517; Ardissino D, 1999, BLOOD, V94, P46; Bladbjerg EM, 1999, THROMB HAEMOSTASIS, V82, P1100; Blom HJ, 2000, CIRCULATION, V101, pE171; Botto LD, 2000, AM J EPIDEMIOL, V151, P862; Brattstrom L, 2000, AM J CLIN NUTR, V72, P315; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Brattstrom L, 1998, ATHEROSCLEROSIS, V141, P315, DOI 10.1016/S0021-9150(98)00154-3; Brugada R, 1997, ATHEROSCLEROSIS, V128, P107, DOI 10.1016/S0021-9150(96)05977-1; Chambers JC, 2000, ARTERIOSCL THROM VAS, V20, P2448, DOI 10.1161/01.ATV.20.11.2448; Chao CL, 1999, ATHEROSCLEROSIS, V147, P379, DOI 10.1016/S0021-9150(99)00208-7; Chen TY, 2000, HAEMATOLOGICA, V85, P445; Christensen B, 1997, ARTERIOSCL THROM VAS, V17, P569, DOI 10.1161/01.ATV.17.3.569; Clark ZE, 1998, CLIN CHEM, V44, P2360; Clarke R, 1998, J Cardiovasc Risk, V5, P249, DOI 10.1097/00043798-199808000-00007; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Danesh J, 1998, J Cardiovasc Risk, V5, P229, DOI 10.1097/00043798-199808000-00004; Deloughery TG, 1996, CIRCULATION, V94, P3074, DOI 10.1161/01.CIR.94.12.3074; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; Fernandez-Arcas N, 1999, ATHEROSCLEROSIS, V145, P293, DOI 10.1016/S0021-9150(99)00080-5; Ferrer-Antunes C, 1998, THROMB HAEMOSTASIS, V80, P521; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; Fowkes FGR, 2000, ATHEROSCLEROSIS, V150, P179, DOI 10.1016/S0021-9150(99)00366-4; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Gardemann A, 1999, EUR HEART J, V20, P584, DOI 10.1053/euhj.1998.1340; Gemmati D, 1999, HAEMATOLOGICA, V84, P824; Girelli D, 1998, BLOOD, V91, P4158, DOI 10.1182/blood.V91.11.4158.411k23_4158_4163; Goracy I, 1999, Pol Arch Med Wewn, V102, P849; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Gulec S, 2001, CLIN CARDIOL, V24, P281; Harmon DL, 1996, QJM-MON J ASSOC PHYS, V89, P571; Heijmans BT, 1999, EUR J HUM GENET, V7, P197, DOI 10.1038/sj.ejhg.5200283; Hessner MJ, 2001, CLIN CHEM, V47, P1879; Hsu LA, 2000, HUM HERED, V51, P41; Inbal A, 1999, BLOOD, V93, P2186, DOI 10.1182/blood.V93.7.2186.407k28_2186_2190; Izumi M, 1996, ATHEROSCLEROSIS, V121, P293, DOI 10.1016/0021-9150(95)05764-1; Jacques PF, 2001, AM J CLIN NUTR, V73, P613; Jacques PF, 1996, CIRCULATION, V93, P7, DOI 10.1161/01.CIR.93.1.7; Jee SH, 2000, ATHEROSCLEROSIS, V153, P161, DOI 10.1016/S0021-9150(00)00389-0; Kim CH, 2001, INT J CARDIOL, V78, P13, DOI 10.1016/S0167-5273(00)00431-9; Kluijtmans LAJ, 1997, CIRCULATION, V96, P2573, DOI 10.1161/01.CIR.96.8.2573; Kostulas K, 1998, EUR J CLIN INVEST, V28, P285; KOZICH V, 2002, CORONARY ARTERY DIS; Lievers KJA, 2001, J MOL MED-JMM, V79, P522, DOI 10.1007/s001090100253; Ma J, 1997, CANCER RES, V57, P1098; Ma J, 1996, CIRCULATION, V94, P2410, DOI 10.1161/01.CIR.94.10.2410; Mager A, 1999, CIRCULATION, V100, P2406, DOI 10.1161/01.CIR.100.24.2406; Malik NM, 1998, CLIN SCI, V95, P311, DOI 10.1042/CS19970193; Malinow MR, 1997, ARTERIOSCL THROM VAS, V17, P1157, DOI 10.1161/01.ATV.17.6.1157; MCDOWELL IF, 1998, NETH J MED, V52, pS1; McQuillan BM, 1999, CIRCULATION, V99, P2383, DOI 10.1161/01.CIR.99.18.2383; Meisel C, 2001, ATHEROSCLEROSIS, V154, P651, DOI 10.1016/S0021-9150(00)00679-1; Morita H, 1997, CIRCULATION, V95, P2032, DOI 10.1161/01.CIR.95.8.2032; Nakai K, 2000, CORONARY ARTERY DIS, V11, P47, DOI 10.1097/00019501-200002000-00009; Narang R, 1996, CIRCULATION, V94, P2322; Ou T, 1998, ATHEROSCLEROSIS, V137, P23, DOI 10.1016/S0021-9150(97)00244-X; Pinto X, 2001, EUR J CLIN INVEST, V31, P24, DOI 10.1046/j.1365-2362.2001.00760.x; RAPAPORT E, 1979, CIRCULATION, V59, P607; Raslova K, 2001, METABOLISM, V50, P24, DOI 10.1053/meta.2001.19499; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reinhardt D, 1998, EUR J CLIN INVEST, V28, P20; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Roest M, 2001, AM J EPIDEMIOL, V153, P673, DOI 10.1093/aje/153.7.673; Schmitz C, 1996, CIRCULATION, V94, P1812, DOI 10.1161/01.CIR.94.8.1812; Schwartz SM, 1997, CIRCULATION, V96, P412; Silberberg JS, 2001, AM J CARDIOL, V87, P1003, DOI 10.1016/S0002-9149(01)01438-2; Szczeklik A, 2001, AM J MED GENET, V101, P36, DOI 10.1002/ajmg.1315; Tanis BC, 2001, NEW ENGL J MED, V345, P1787, DOI 10.1056/NEJMoa003216; Thogersen AM, 2001, CORONARY ARTERY DIS, V12, P85, DOI 10.1097/00019501-200103000-00001; Thuillier L, 1998, J INHERIT METAB DIS, V21, P812, DOI 10.1023/A:1005414617390; Todesco L, 1999, EUR J CLIN INVEST, V29, P1003; Tokgozoglu S, 1999, HEART, V81, P518, DOI 10.1136/hrt.81.5.518; Tsai MY, 1999, ATHEROSCLEROSIS, V143, P163, DOI 10.1016/S0021-9150(98)00271-8; Tucker KL, 1996, J NUTR, V126, P3025, DOI 10.1093/jn/126.12.3025; Ueland PM, 2000, AM J CLIN NUTR, V72, P324; Usui M, 1999, CLIN SCI, V96, P235, DOI 10.1042/CS19980382; vanBockxmeer FM, 1997, CIRCULATION, V95, P21, DOI 10.1161/01.CIR.95.1.21; VANDERPUT NMJ, 1995, LANCET, V346, P1070, DOI 10.1016/S0140-6736(95)91743-8; Verhoef P, 1998, J AM COLL CARDIOL, V32, P353, DOI 10.1016/S0735-1097(98)00244-7; Verhoef P, 1998, CURR OPIN LIPIDOL, V9, P17, DOI 10.1097/00041433-199802000-00005; Verhoef P, 1997, ATHEROSCLEROSIS, V132, P105, DOI 10.1016/S0021-9150(97)00084-1; Verhoeff BJ, 1998, ATHEROSCLEROSIS, V141, P161, DOI 10.1016/S0021-9150(98)00156-7; Voutilainen S, 2001, CIRCULATION, V103, P2674, DOI 10.1161/01.CIR.103.22.2674; Voutilainen S, 2000, EUR J CLIN NUTR, V54, P424, DOI 10.1038/sj.ejcn.1600991; Wacholder S, 2000, J NATL CANCER I, V92, P1151, DOI 10.1093/jnci/92.14.1151; Wilcken DEL, 1996, ARTERIOSCL THROM VAS, V16, P878, DOI 10.1161/01.ATV.16.7.878; WU LL, 1994, CLIN CHEM, V40, P552; Zheng YZ, 2000, BRIT J HAEMATOL, V109, P870, DOI 10.1046/j.1365-2141.2000.02112.x	93	718	763	3	62	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	2002	288	16					2023	2031		10.1001/jama.288.16.2023	http://dx.doi.org/10.1001/jama.288.16.2023			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	606QW	12387655	Green Published			2022-12-28	WOS:000178745500026
J	Kapur, N; House, A; Dodgson, K; May, C; Creed, F				Kapur, N; House, A; Dodgson, K; May, C; Creed, F			Effect of general hospital management on repeat episodes of deliberate self poisoning: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ERYSIPELAS; CELLULITIS; ADULTS; PRISTINAMYCIN; PENICILLIN; INFECTIONS; THERAPY		Manchester Royal Infirm, Dept Psychiat & Behav Sci, Manchester M13 9WL, Lancs, England; Univ Leeds, Acad Univ Psychiat & Behav Sci, Leeds LS2 9JT, W Yorkshire, England	University of Manchester; University of Leeds	Kapur, N (corresponding author), Univ Manchester, 7th Floor,Williamson Bldg, Manchester M13 9PL, Lancs, England.	nav.kapur@man.ac.uk		House, Allan/0000-0001-8721-8026				[Anonymous], 2000, Ann Dermatol Venereol, V127, P1118; Bergkvist PI, 1997, SCAND J INFECT DIS, V29, P377, DOI 10.3109/00365549709011834; BERNARD P, 1989, ARCH DERMATOL, V125, P779, DOI 10.1001/archderm.125.6.779; Bernard P, 1997, ANN DERMATOL VENER, V124, P384; BERNARD P, 1992, BRIT J DERMATOL, V127, P155, DOI 10.1111/j.1365-2133.1992.tb08048.x; Bernard P, 1996, ANN DERMATOL VENER, V123, P16; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; CHARTIER C, 1990, INT J DERMATOL, V29, P459, DOI 10.1111/j.1365-4362.1990.tb04833.x; Chartier C, 1996, INT J DERMATOL, V35, P779, DOI 10.1111/j.1365-4362.1996.tb02971.x; Committee for Proprietary Medicinal Products, 2000, POINTS CONS SWITCH S; Dupuy A, 1999, BRIT MED J, V318, P1591, DOI 10.1136/bmj.318.7198.1591; DUVANEL T, 1989, ARCH INTERN MED, V149, P293, DOI 10.1001/archinte.149.2.293; Eriksson B, 1996, CLIN INFECT DIS, V23, P1091, DOI 10.1093/clinids/23.5.1091; Gilbody S, 1997, J ROY COLL PHYS LOND, V31, P171; HAWTON K, 2001, COCHRANE DATABASE SY, P1764; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; JORUPRONSTROM C, 1986, SCAND J INFECT DIS, V18, P519, DOI 10.3109/00365548609021656; JORUPRONSTROM C, 1984, INFECTION, V12, P390, DOI 10.1007/BF01645222; JORUPRONSTROM C, 1982, SCAND J INFECT DIS S, V36, pS150; Kapur N, 1998, BRIT MED J, V316, P831, DOI 10.1136/bmj.316.7134.831; Kopp M, 2001, ANN DERMATOL VENER, V128, P338; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; REVERDY ME, 1994, MED MALADIES INFECT, V24, P898, DOI 10.1016/S0399-077X(05)80580-3; RONNEN M, 1985, INT J DERMATOL, V24, P169, DOI 10.1111/j.1365-4362.1985.tb05415.x; Royal College of Psychiatrists, 1994, GEN HOSP MAN AD DEL; Schmit JL, 2001, ANN DERMATOL VENER, V128, P334; Siegel JP, 2000, AM HEART J, V139, pS166, DOI 10.1016/S0002-8703(00)90066-8; [No title captured]; 1998, EFFECTIVE HLTH CARE, V4, P1	29	48	48	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 19	2002	325	7369					866	867		10.1136/bmj.325.7369.866	http://dx.doi.org/10.1136/bmj.325.7369.866			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386037	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000178793000019
J	Berger, PJ; Skuza, EM; Brodecky, V; Wilkinson, MH				Berger, PJ; Skuza, EM; Brodecky, V; Wilkinson, MH			Physiology - The ventilatory response to hypoxia	NATURE			English	Article							SUSTAINED HYPOXIA; S-NITROSOTHIOLS		Monash Med Ctr, Monash Inst Reprod & Dev, Ritchie Ctr Baby Hlth Res, Clayton, Vic 3168, Australia	Monash University	Berger, PJ (corresponding author), Monash Med Ctr, Monash Inst Reprod & Dev, Ritchie Ctr Baby Hlth Res, Clayton, Vic 3168, Australia.	philip.berger@med.monash.edu.au						BADR MS, 1992, J APPL PHYSIOL, V73, P1958, DOI 10.1152/jappl.1992.73.5.1958; BUREAU MA, 1986, J APPL PHYSIOL, V61, P836, DOI 10.1152/jappl.1986.61.3.836; Butcher J, 2001, LANCET, V358, P897, DOI 10.1016/S0140-6736(01)06085-8; EASTON PA, 1986, J APPL PHYSIOL, V61, P906, DOI 10.1152/jappl.1986.61.3.906; Heymans C., 1958, REFLEXOGENIC AREAS C; HONDA Y, 1992, J APPL PHYSIOL, V73, P1; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; Lipton SA, 2001, NATURE, V413, P118, DOI 10.1038/35093186; Mato JM, 2001, NAT MED, V7, P1107, DOI 10.1038/nm1001-1107; Maxova H, 2001, PHYSIOL RES, V50, P327; Robinson DM, 2000, J APPL PHYSIOL, V88, P1907, DOI 10.1152/jappl.2000.88.5.1907	11	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	2002	419	6908					686	686		10.1038/419686a	http://dx.doi.org/10.1038/419686a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384687				2022-12-28	WOS:000178615200029
J	Cummings, SR; Bates, D; Black, DM				Cummings, SR; Bates, D; Black, DM			Clinical use of bone densitometry - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUANTITATIVE COMPUTED-TOMOGRAPHY; BAND ULTRASOUND ATTENUATION; VERTEBRAL FRACTURE RISK; PREDICT HIP FRACTURE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; ELDERLY-WOMEN; RANDOMIZED-TRIAL; BACK-PAIN; MASS	Context Osteoporosis causes substantial morbidity and costs $13.8 billion annually in the United States. Measurement of bone mass by densitometry is a primary part of diagnosing osteoporosis and deciding a preventive treatment course. Bone mineral densitometry has become more widely available and commonly used in practice. Objective To review evidence about the value of various clinical applications of bone densitometry. Data Sources A MEDLINE search was performed to update previous meta-analyses of the relationship between various measurements of bone density and risk of vertebral and hip fracture. We used data from the prospective Study of Osteoporotic Fractures to estimate risk of fracture from bone density and age in postmenopausal women. Study Selection and Data Extraction When available, meta-analyses and systematic reviews are emphasized in the review. Data Synthesis Bone mineral density (BMb) predicts fracture and can be used in combination with age to estimate absolute risk of fractures in postmenopausal white women. Hip BMD predicts hip fracture more strongly than other, measurements of BMD. There are insufficient data to translate BMD results into risk of fracture for men and nonwhite women. The benefits of treatments to prevent fractures depend on BMD: women with osteoporosis have a greater risk of fractures and greater benefit from treatments than women without osteoporosis. Conclusions Guidelines based on systematic reviews and a cost-effectiveness analysis have suggested that it is worthwhile to measure BMD in white women older than 65 years and perhaps to use risk factors to select younger postmenopausal women for densitometry. Other potential clinical applications of BMD that have not yet been adequately studied include screening men or nonwhite women, monitoring BMD in patients receiving treatment, and using BMD to identify patients who should be evaluated for secondary causes of osteoporosis.	Univ Calif San Francisco, UCSF Coordinating Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Cummings, SR (corresponding author), Suite 600,74 New Montgomery St, San Francisco, CA 94105 USA.	scummings@psg.ucsf.edu						BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; Bauer DC, 1997, ARCH INTERN MED, V157, P629, DOI 10.1001/archinte.157.6.629; Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003-4819-137-6-200209170-00014; BLACK D, 2002, OSTEOPOROSIS EVIDENC, P29; BLACK DM, 1992, J BONE MINER RES, V7, P633; Black DM, 2001, OSTEOPOROSIS INT, V12, P519, DOI 10.1007/s001980170072; Black DM, 1999, J BONE MINER RES, V14, P821, DOI 10.1359/jbmr.1999.14.5.821; BLACK DM, 1992, J BONE MINER RES, V7, P639; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bouxsein ML, 2002, OSTEOPOROSIS INT, V13, P358, DOI 10.1007/s001980200040; Burger H, 1999, BONE, V25, P369, DOI 10.1016/S8756-3282(99)00173-8; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHAPURLAT R, IN PRESS J BONE MINE; Chesnut CH, 2000, AM J MED, V109, P267, DOI 10.1016/S0002-9343(00)00490-3; Clowes JA, 2002, OSTEOPOROSIS EVIDENC, P59; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; COURTNEY AC, 1995, J BONE JOINT SURG AM, V77A, P387, DOI 10.2106/00004623-199503000-00008; Cummings SR, 2000, JAMA-J AM MED ASSOC, V283, P1318, DOI 10.1001/jama.283.10.1318; Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; Dargent-Molina P, 1999, OSTEOPOROSIS INT, V9, P188, DOI 10.1007/s001980050134; Eddy D. M., 1998, OSTEOPOROS INT S4, V8, pS7; ENSRUD KE, 1995, J BONE MINER RES, V10, P1778; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Faulkner KG, 1999, J CLIN DENSITOM, V2, P343, DOI 10.1385/JCD:2:3:343; Faulkner KG, 2001, RHEUM DIS CLIN N AM, V27, P81, DOI 10.1016/S0889-857X(05)70188-5; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; Garnero P, 1996, J BONE MINER RES, V11, P1531; GLUER CC, 1992, J BONE MINER RES, V7, P1071; Gluer CC, 1999, J BONE MINER RES, V14, P1952, DOI 10.1359/jbmr.1999.14.11.1952; GLUER CC, 1994, J BONE MINER RES, V9, P671; Grampp S, 1997, J BONE MINER RES, V12, P697, DOI 10.1359/jbmr.1997.12.5.697; Gregg EW, 1997, OSTEOPOROSIS INT, V7, P89, DOI 10.1007/BF01623682; HABERG L, 1977, GERIATRICS       APR, P55; Hans D, 1996, LANCET, V348, P511, DOI 10.1016/S0140-6736(95)11456-4; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; Ismail AA, 1999, OSTEOPOROSIS INT, V9, P206, DOI 10.1007/s001980050138; Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KAUFMAN JJ, 1993, J BONE MINER RES, V8, P517; Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721; Lang TF, 1997, BONE, V21, P101, DOI 10.1016/S8756-3282(97)00072-0; Lang TF, 1999, J COMPUT ASSIST TOMO, V23, P130, DOI 10.1097/00004728-199901000-00027; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; LOTZ JC, 1990, J BONE JOINT SURG AM, V72A, P689, DOI 10.2106/00004623-199072050-00008; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; Melton LJ, 1997, J BONE MINER RES, V12, P1769, DOI 10.1359/jbmr.1997.12.11.1769; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; NELSON HD, IN PRESS J BONE MINE; Nevitt MC, 1998, ANN INTERN MED, V128, P793, DOI 10.7326/0003-4819-128-10-199805150-00001; NEVITT MC, 1994, OSTEOPOROSIS INT, V4, P325, DOI 10.1007/BF01622192; Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902; Orwoll ES, 1996, ANN INTERN MED, V124, P187, DOI 10.7326/0003-4819-124-2-199601150-00001; PECK WA, 1993, AM J MED, V94, P646; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; RUSSELLAULET M, 1993, J BONE MINER RES, V8, P575; RUSSELLAULET M, 1991, J BONE MINER RES, V6, P1109; SINGH M, 1970, J BONE JOINT SURG AM, VA 52, P457, DOI 10.2106/00004623-197052030-00005; Siris ES, 2001, JAMA-J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; STEIGER P, 1992, J BONE MINER RES, V7, P625; van Staa TP, 2001, J BONE MINER RES, V16, P581, DOI 10.1359/jbmr.2001.16.3.581; WASNICH RD, 1989, J NUCL MED, V30, P1166; Woodhouse A, 2000, J BONE MINER RES, V15, pS145; YANG SO, 1994, RADIOLOGY, V192, P857, DOI 10.1148/radiology.192.3.8058960	72	547	586	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	2002	288	15					1889	1897		10.1001/jama.288.15.1889	http://dx.doi.org/10.1001/jama.288.15.1889			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604EU	12377088				2022-12-28	WOS:000178604200028
J	Van Damme, L; Ramjee, G; Alary, M; Vuylsteke, B; Chandeying, V; Rees, H; Sirivongrangson, P; Mukenge-Tshibaka, L; Ettiegne-Traore, V; Uaheowitchai, C; Karim, SSA; Masse, B; Perriens, J; Laga, M				Van Damme, L; Ramjee, G; Alary, M; Vuylsteke, B; Chandeying, V; Rees, H; Sirivongrangson, P; Mukenge-Tshibaka, L; Ettiegne-Traore, V; Uaheowitchai, C; Karim, SSA; Masse, B; Perriens, J; Laga, M		COL-1492 Study Grp	Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial	LANCET			English	Article							CHLAMYDIA-TRACHOMATIS; CONTRACEPTIVE SPONGE; INVITRO; INFECTION; INACTIVATION; EFFICACY; SAFETY; WOMEN; RISK	Background Nonoxynol-9 (rINN, nonoxinol-9) is an over-the-counter spermicide that has in-vitro anti-HIV-1 activity. Results of studies of its effectiveness in prevention of HIV-1 infection in women have been inconclusive. We aimed to assess effectiveness of this vaginal gel. Methods We did a randomised, placebo-controlled, triple-blinded, phase 2/3 trial with COL-1492, a nonoxynol-9 vaginal gel, in 892 female sex workers in four countries: Benin, Cote d'lvoire, South Africa, and Thailand. 449 women were randomly allocated nonoxynol-9 and 443 placebo. Primary endpoint was incident HIV-1 infection. Secondary endpoints included Neisseria gonorrhoeae and Chlamydia trachomatis infections. Analysis was by intention to treat. Findings 765 women were included in the primary analysis. HIV-1 frequency in nonoxynol-9 users was 59 (16%) of 376 compared with 104 (27%) of 389 in placebo users (402.5 vs 435.0 woman-years; hazard ratio adjusted for centre 1.5; 95% CI 1.0-2.2; p=0.047). 239 (32%) women reported use of a mean of more than 3.5 applicators per working day, and in these women, risk of HIV-1 infection in nonoxynol-9 users was almost twice that in placebo users (hazard ratio 1.8; 95% CI 1.0-3.2). 516 (68%) women used the gel less frequently tan 3.5 times a day, and in these, risk did not differ between he two treatments. No significant effect of nonoxynol-9 on N gonorrhoeae (1.2; 0.9-1.6) or C trachomatis (1.2; 0.8-1.6) infections was reported. Interpretation This study did not show a protective effect of COL-1492 on HIV-1 transmission in high-risk women. Multiple use of nonoxynol-9 could cause toxic effects enhancing HIV-1 infection. This drug can no longer be deemed a potential HIV-1-prevention method. Assessment of other microbicides should continue.	Inst Trop Med, B-2000 Antwerp, Belgium; MRC, Durban, South Africa; Ctr Hosp Affilie Univ Quebec & Univ Laval, Grp Rech Epidemiol, Quebec City, PQ, Canada; Projet SIDA 2, Cotonou, Benin; Projet RETROCI, Abidjan, Cote Ivoire; Prince Songkla Univ, Hat Yai, Thailand; Univ Witwatersrand, Dept Obstet & Gynaecol, Reprod Hlth Res Unit, Johannesburg, South Africa; Minist Hlth, Venereal Dis Div, Bangkok, Thailand; Ctr Sante Circonscript Urbaine Cotonou 1, Dispensaire Malad Sexuellement Transmissibles, Cotonou, Benin; Veneral Dis Ctr Reg 12, Songkhla, Thailand; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; UNAIDS, Geneva, Switzerland	Institute of Tropical Medicine (ITM); Laval University; Prince of Songkla University; University of Witwatersrand; Ministry of Public Health - Thailand; Fred Hutchinson Cancer Center; UNAIDS	Van Damme, L (corresponding author), CONRAD, 1611 N Kent St,Suite 806, Arlington, VA 22209 USA.	lvandamme@conrad.org	Karim, Salim Safurdeen Abdool/N-5947-2013; Karim, Salim Abdool/AAE-7118-2019; Karim, Salim Abdool/P-3117-2019	Karim, Salim Safurdeen Abdool/0000-0002-4986-2133; Karim, Salim Abdool/0000-0002-4986-2133; Masse, Benoit/0000-0002-4944-8098; Rees, Helen/0000-0003-1442-6734				BENES S, 1985, ANTIMICROB AGENTS CH, V27, P724, DOI 10.1128/AAC.27.5.724; Bourinbaiar AS, 1996, AIDS, V10, P558, DOI 10.1097/00002030-199605000-00024; Ghys PD, 2001, AIDS, V15, P1421, DOI 10.1097/00002030-200107270-00012; HICKS DR, 1985, LANCET, V2, P1422; KELLY JP, 1985, ANTIMICROB AGENTS CH, V27, P760, DOI 10.1128/AAC.27.5.760; KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477; LOUV WC, 1988, J INFECT DIS, V158, P518, DOI 10.1093/infdis/158.3.518; MILLER CJ, 1992, FERTIL STERIL, V57, P1126; NIRUTHISARD S, 1992, LANCET, V339, P1371, DOI 10.1016/0140-6736(92)91195-E; POLSKY B, 1988, LANCET, V1, P1456; Roddy RE, 1998, SEX TRANSM DIS, V25, P151, DOI 10.1097/00007435-199803000-00008; Roddy RE, 2002, JAMA-J AM MED ASSOC, V287, P1117, DOI 10.1001/jama.287.9.1117; RODDY RE, 1993, INT J STD AIDS, V4, P165, DOI 10.1177/095646249300400308; Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803; ROSENBERG MJ, 1987, JAMA-J AM MED ASSOC, V257, P2308, DOI 10.1001/jama.257.17.2308; Van Damme L, 2000, AIDS, V14, P85, DOI 10.1097/00002030-200001070-00010; Van Damme L, 1998, AIDS, V12, P433, DOI 10.1097/00002030-199804000-00013; Williams B, 2001, STAT MED, V20, P2003, DOI 10.1002/sim.840; ZEKENG L, 1993, AIDS, V7, P725, DOI 10.1097/00002030-199305000-00018	19	648	661	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	2002	360	9338					971	977		10.1016/S0140-6736(02)11079-8	http://dx.doi.org/10.1016/S0140-6736(02)11079-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383665				2022-12-28	WOS:000178249000008
J	Searle, IR; Men, AE; Laniya, TS; Buzas, DM; Iturbe-Ormaetxe, I; Carroll, BJ; Gresshoff, PM				Searle, IR; Men, AE; Laniya, TS; Buzas, DM; Iturbe-Ormaetxe, I; Carroll, BJ; Gresshoff, PM			Long-distance signaling in nodulation directed by a CLAVATA1-like receptor kinase	SCIENCE			English	Article							GENETIC-ANALYSIS; MUTANTS; SHOOT; ARABIDOPSIS	Proliferation of legume nodule primordia is controlled by shoot-root signaling known as autoregulation of nodulation (AON). Mutants defective in AON show supernodulation and increased numbers of lateral roots. Here, we demonstrate that AON in soybean is controlled by the receptor-like protein kinase GmNARK (Glycine max nodule autoregulation receptor kinase), similar to Arabidopsis CLAVATA1 (CLV1). Whereas CLV1 functions in a protein complex controlling stem cell proliferation by short-distance signaling in shoot apices, GmNARK expression in the leaf has a major role in long-distance communication with nodule and lateral root primordia.	Univ Queensland, Sch Mol & Microbial Sci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Land & Food Sci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Life Sci, St Lucia, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Carroll, BJ (corresponding author), Univ Queensland, Sch Mol & Microbial Sci, St Lucia, Qld 4072, Australia.		Searle, Iain/AAE-8869-2019; Carroll, Bernard/C-7690-2009; Han, Liqi/K-6127-2013; Buzas, Diana Mihaela/AAA-1431-2020; Buzas, Diana M/J-3826-2014	Buzas, Diana Mihaela/0000-0002-8625-7872; Carroll, Bernard/0000-0002-1976-8269				AKAO S, 1992, SOIL SCI PLANT NUTR, V38, P183, DOI 10.1080/00380768.1992.10416966; Becraft PW, 2002, ANNU REV CELL DEV BI, V18, P163, DOI 10.1146/annurev.cellbio.18.012502.083431; CARROLL BJ, 1985, P NATL ACAD SCI USA, V82, P4162, DOI 10.1073/pnas.82.12.4162; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; DELVES AC, 1988, J GENET, V67, P1, DOI 10.1007/BF02927732; DELVES AC, 1992, PLANT CELL ENVIRON, V15, P249, DOI 10.1111/j.1365-3040.1992.tb01479.x; DELVES AC, 1986, PLANT PHYSIOL, V82, P588, DOI 10.1104/pp.82.2.588; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; Fletcher JC, 2002, ANNU REV PLANT BIOL, V53, P45, DOI 10.1146/annurev.arplant.53.092701.143332; FRANCISCO PB, 1995, PLANT SCI, V107, P167, DOI 10.1016/0168-9452(95)04107-6; GREMAUD MF, 1989, PLANT PHYSIOL, V89, P169, DOI 10.1104/pp.89.1.169; Gresshoff P. M., 1986, A genetic approach to plant biochemistry, P159; Kolchinsky A, 1997, MOL GEN GENET, V254, P29, DOI 10.1007/s004380050387; LANDAUELLIS D, 1991, MOL GEN GENET, V228, P221, DOI 10.1007/BF00282469; MEN AE, IN PRESS GENOME LETT; PARK SJ, 1988, CAN J PLANT SCI, V68, P199, DOI 10.4141/cjps88-019; PIERCE M, 1983, PLANT PHYSIOL, V73, P286, DOI 10.1104/pp.73.2.286; POSTMA JG, 1988, J PLANT PHYSIOL, V132, P424, DOI 10.1016/S0176-1617(88)80056-7; SEARLE IR, UNPUB; SEARLE IR, 2002, THESIS U QUEENSLAND; Spaink HP, 2000, ANNU REV MICROBIOL, V54, P257, DOI 10.1146/annurev.micro.54.1.257; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841; Takayama S, 2002, CURR OPIN PLANT BIOL, V5, P382, DOI 10.1016/S1369-5266(02)00284-4; TOMPKINS JP, 1999, PLANT MOL BIOL, V41, P25; Trotochaud AE, 2000, SCIENCE, V289, P613, DOI 10.1126/science.289.5479.613; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wopereis J, 2000, PLANT J, V23, P97, DOI 10.1046/j.1365-313x.2000.00799.x; Yamamoto E, 2000, BBA-GENE STRUCT EXPR, V1491, P333, DOI 10.1016/S0167-4781(00)00061-0	28	388	420	4	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 3	2003	299	5603					109	112		10.1126/science.1077937	http://dx.doi.org/10.1126/science.1077937			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	631JZ	12411574				2022-12-28	WOS:000180165800045
J	Shafran, SD; Mashinter, LD; Phillips, P; Lalonde, RG; Gill, MJ; Walmsley, SL; Toma, E; Conway, B; Fong, IW; Rachlis, AR; Williams, KE; Garber, GE; Schlech, WF; Smaill, F				Shafran, SD; Mashinter, LD; Phillips, P; Lalonde, RG; Gill, MJ; Walmsley, SL; Toma, E; Conway, B; Fong, IW; Rachlis, AR; Williams, KE; Garber, GE; Schlech, WF; Smaill, F			Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; SECONDARY PROPHYLAXIS; AIDS; RESOLUTION; BACTEREMIA; PATIENT; TRIAL	Background: Highly active antiretroviral therapy (HAART) is associated with improvement or resolution of several HIV-associated opportunistic infections. Although prophylaxis against disseminated Mycobacterium avium, complex infection may be successfully discontinued after a favorable response to HAART, the 1999 guidelines from the U.S. Public Health Service/infectious Diseases Society of America recommend continuing therapy for disseminated M. avium complex infection, regardless of the response to HAART. Objective: To examine the outcome among patients with disseminated M. avium complex infection whose antimycobacterial therapy was discontinued after a favorable response to HAART. Design: Retrospective chart review between May 2000 and May 2001. Setting: 13 Canadian HIV clinics. Patients: 52 HIV-infected adults (43 men; mean age, 37.3 years) in whom successful anti mycobacterial therapy for disseminated M. avium, complex infection was discontinued after a favorable virologic response to HAART. Measurements: Survival, survival free of disseminated M. avium complex infection, and CD4(+) cell count responses. Results: At the time of diagnosis of disseminated M. avium, complex infection, the median CD4(+) cell count was 0.016 x 109 cells/L, and the median plasma HIV RNA level was 90 000 copies/mL (plasma HIV RNA levels were available for only 21 patients). The patients received a median of 32 months of antimycobacterial therapy that included ethambutol plus either clarithromycin or azithromycin. When anti mycobacterial therapy was discontinued, the median CD4(+) cell count was 0.23 x 10(9) cells/L and the median plasma HIV RNA level was less than 50 copies/mL. A median of 20 months after discontinuation of antimycobacterial therapy, only 1 patient had developed recurrent M. avium complex disease (37 months after stopping antimycobacterial therapy). This patient had stopped HAART 2 months earlier because of uncontrolled HIV viremia. Twenty months after stopping anti mycobacterial therapy, the other 51 patients had a median CD4(+) cell count of 0.288 x 10(9) cells/L; 34 (67%) had undetectable plasma HIV RNA levels, and 8 (15%) had plasma HIV RNA levels of 50 to 1000 copies/mL. Conclusions: Discontinuation of successful disseminated M. avium complex therapy after a successful response to HAART is safe and reduces patients' pill burdens, potential drug adverse effects, drug interactions, and costs of therapy.	Univ Alberta, Edmonton, AB, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; McGill Univ, Montreal, PQ, Canada; Univ Montreal, Montreal, PQ, Canada; Univ Calgary, Calgary, AB, Canada; Univ Toronto, Toronto, ON, Canada; Univ Saskatchewan, Saskatoon, SK, Canada; Univ Ottawa, Ottawa, ON, Canada; Dalhousie Univ, Halifax, NS, Canada; McMaster Univ, Hamilton, ON, Canada	University of Alberta; University of British Columbia; McGill University; Universite de Montreal; University of Calgary; University of Toronto; University of Saskatchewan; University of Ottawa; Dalhousie University; McMaster University	Shafran, SD (corresponding author), Univ Alberta Hosp, Div Infect Dis, 8440 112 St,WMC 2E4-16, Edmonton, AB T6G 2B7, Canada.	shafran@uah.ualberta.ca	Dodsley, Maria/G-7083-2016; Gill, Michael John/G-7083-2016	Dodsley, Maria/0000-0001-7587-558X; Walmsley, Sharon/0000-0002-3959-5692; Gill, Michael John/0000-0002-8546-8790				Aberg JA, 1998, J INFECT DIS, V178, P1446, DOI 10.1086/314469; Carr A, 1998, LANCET, V351, P256, DOI 10.1016/S0140-6736(97)07529-6; Cinti SK, 2000, CLIN INFECT DIS, V30, P511, DOI 10.1086/313705; Currier JS, 2000, ANN INTERN MED, V133, P493, DOI 10.7326/0003-4819-133-7-200010030-00008; de Quiros JCLB, 2001, NEW ENGL J MED, V344, P159, DOI 10.1056/NEJM200101183440301; El-Sadr WM, 2000, NEW ENGL J MED, V342, P1085, DOI 10.1056/NEJM200004133421503; Guex AC, 2000, CLIN INFECT DIS, V30, P602, DOI 10.1086/313733; Hadad DJ, 1998, CLIN INFECT DIS, V26, P758, DOI 10.1086/514577; Hicks CB, 1997, CLIN INFECT DIS, V24, P1023, DOI 10.1093/clinids/24.5.1023; KAPLAN JE, 1995, CLIN INFECT DIS    S, V1, pS1; KEMPER CA, 1994, J INFECT DIS, V170, P488, DOI 10.1093/infdis/170.2.488; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; Martinez E, 1999, AIDS, V13, P147; Masur H, 1999, ANN INTERN MED, V131, P873, DOI 10.7326/0003-4819-131-11-199912070-00022; Miralles P, 1998, AIDS, V12, P2467, DOI 10.1097/00002030-199818000-00016; Murray R, 2001, EUR J CLIN MICROBIOL, V20, P199, DOI 10.1007/PL00011252; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Soriano V, 2000, AIDS, V14, P383, DOI 10.1097/00002030-200003100-00011; *USPHS IDSA PREV O, 2002, 2001 USPHS IDSA GUID; Zingman BS, 1996, NEW ENGL J MED, V334, P1674, DOI 10.1056/NEJM199606203342516	20	28	28	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2002	137	9					734	737		10.7326/0003-4819-137-9-200211050-00008	http://dx.doi.org/10.7326/0003-4819-137-9-200211050-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612BA	12416943				2022-12-28	WOS:000179052400004
J	Munro, PT; Smith, RD; Parke, TRJ				Munro, PT; Smith, RD; Parke, TRJ			Effect of patients' age on management of acute intracranial haematoma: prospective national study	BRITISH MEDICAL JOURNAL			English	Article							HEAD-INJURY; HEMATOMAS	Objective To determine whether the management of head injuries differs between patients aged greater than or equal to65 years and those < 65. Design Prospective observational national study over four years. Setting 25 Scottish hospitals that admit trauma patients. Participants 527 trauma patients with extradural or acute subdural haematomas. Main outcome measures Time to cranial computed tomography in the first hospital attended, rates of transfer to neurosurgical care, rates of neurosurgical intervention, length of time to operation, and mortality in inpatients in the three months after admission. Results Patients aged &GE; 65 years had lower survival rates than patients < 65 years. Rates were 15/18 (83%) v 165/167 (99%) for Extradural haematoma. (P=0.007) and 61/93 (66%) v 229/249 (92%) for acute subdural haematoma (P <0.001). Older patients were less likely to be transferred to specialist neurosurgical care (10 (56%) v 142 (85%) for extradural haematoma (P=0.005) and 56 (60%) v 192 (77%) for subdural haematoma (P=0.004)). There was no significant difference between age groups in the incidence of neurosurgical interventions in patients who were transferred. Logistic regression analysis showed that age had a significant independent effect on transfer and on survival. Older patients had higher rates of coexisting medical conditions than younger patients but when severity of injury, initial physiological status at presentation, or previous health were controlled for in a log linear analysis, transfer rates were still lower in older patients than in younger patients (P<0.001). Conclusions Compared with those aged under 65 years, people aged 65 and over have a worse prognosis after head injury complicated by intracranial haematoma. The decision to transfer such patients to neurosurgical care seems to be biased against older patients.	So Gen Hosp, Dept Accid & Emergency, Glasgow G51 4TF, Lanark, Scotland; Royal Infirm Edinburgh NHS Trust, Scottish Trauma Audit Grp, Edinburgh EH3 9YW, Midlothian, Scotland	University of Glasgow; Royal Infirmary of Edinburgh; University of Edinburgh	Munro, PT (corresponding author), So Gen Hosp, Dept Accid & Emergency, Glasgow G51 4TF, Lanark, Scotland.							AMACHER AL, 1987, NEUROSURGERY, V20, P954; American Association for Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Beard D, 2000, Health Bull (Edinb), V58, P118; BROWN G, 1993, AGE AGEING, V22, P240, DOI 10.1093/ageing/22.4.240; BULLOCK R, 1996, ABC MAJOR TRAUMA, P25; DAVIS CS, 1988, J AM GERIATR SOC, V36, P225, DOI 10.1111/j.1532-5415.1988.tb01805.x; FENELLI FC, 1989, J TRAUMA, V29, P541; GENTLEMAN D, 1992, INJURY, V23, P471, DOI 10.1016/0020-1383(92)90066-2; Grant PT, 2000, INJURY, V31, P519, DOI 10.1016/S0020-1383(00)00038-3; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P27, DOI 10.3109/02688699209002898; JARNJOOM A, 1992, BRIT J NEUROSURG, V6, P27; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Maurice-Williams RS, 1999, BRIT J NEUROSURG, V13, P5, DOI 10.1080/02688699944104; MENDELOW AD, 1993, BRAINS DIS NERVOUS S, P192; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Rozelle CJ, 1995, J AM GERIATR SOC, V43, P240; SAYWELL RM, 1989, J AM GERIATR SOC, V37, P625, DOI 10.1111/j.1532-5415.1989.tb01253.x; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; VANAALST JA, 1991, J TRAUMA, V31, P1096; Wood R., 2001, HLTH WELL BEING OLDE	21	49	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					1001	1003		10.1136/bmj.325.7371.1001	http://dx.doi.org/10.1136/bmj.325.7371.1001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411357	Bronze, Green Published			2022-12-28	WOS:000179415600019
J	Netz, R				Netz, R			Proof, amazement, and the unexpected	SCIENCE			English	Editorial Material									Stanford Univ, Dept Classics, Stanford, CA 94305 USA	Stanford University	Netz, R (corresponding author), Stanford Univ, Dept Classics, Bldg 20, Stanford, CA 94305 USA.							FRIEDLANDER M, 1904, GRIECHISCHE PHILOS A, P151; NETZ R, 2002, EXACT SCI 2, V3, P109; NETZ R, 2001, EXACT SCI 1, V2, P9; NETZ R, 2002, SCI MATH GREEK CULTU, pCH11; VITRUVIUS, 1934, ARCHITECTURE, P202	5	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					967	968		10.1126/science.1078527	http://dx.doi.org/10.1126/science.1078527			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411688				2022-12-28	WOS:000178932000033
J	Wu, JW; Krawitz, AR; Chai, JJ; Li, WY; Zhang, FJ; Luo, KX; Shi, YG				Wu, JW; Krawitz, AR; Chai, JJ; Li, WY; Zhang, FJ; Luo, KX; Shi, YG			Structural mechanism of Smad4 recognition by the nuclear oncoprotein ski: Insights on Ski-mediated repression of TGF-beta signaling	CELL			English	Article							CRYSTAL-STRUCTURE; CO-REPRESSOR; DNA-BINDING; PROTEIN; DOMAIN; ACTIVATION; ONCOGENE; SNON; COACTIVATORS; ACTS	The Ski family of nuclear oncoproteins represses TGF-beta signaling through interactions with the Smad proteins. The crystal structure of the Smad4 binding domain of human c-Ski in complex with the MH2 domain of Smad4 reveals specific recognition of the Smad4 L3 loop region by a highly conserved interaction loop (I loop) from Ski. The Ski binding surface on Smad4 significantly overlaps with that required for binding of the R-Smads. Indeed, Ski disrupts the formation of a functional complex between the Co- and R-Smads, explaining how it could lead to repression of TGF-beta, activin, and BMP responses. Intriguingly, the structure of the Ski fragment, stabilized by a bound zinc atom, resembles the SAND domain, in which the corresponding I loop is responsible for DNA binding.	Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	Princeton University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Luo, KX (corresponding author), Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA.	kluo@uclink.berkeley.edu; yshi@molbio.princeton.edu		Shi, Yigong/0000-0003-2030-168X; Krakowski, Ari/0000-0003-0554-1669; Chai, Jijie/0000-0001-7591-3873	NATIONAL CANCER INSTITUTE [R01CA082171, R01CA087940] Funding Source: NIH RePORTER; NCI NIH HHS [CA82171, CA87940] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bottomley MJ, 2001, NAT STRUCT BIOL, V8, P626, DOI 10.1038/89675; BOYER PL, 1993, ONCOGENE, V8, P457; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Colmenares C, 1990, Semin Cancer Biol, V1, P383; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Sakashita E, 1996, J BIOCHEM, V120, P1028; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	46	162	178	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	2002	111	3					357	367		10.1016/S0092-8674(02)01006-1	http://dx.doi.org/10.1016/S0092-8674(02)01006-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419246	Bronze			2022-12-28	WOS:000179010100008
J	Cyranoski, D				Cyranoski, D			Japan plans web of English journals	NATURE			English	News Item																		1999, NATURE, V398, P272	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					868	868		10.1038/419868b	http://dx.doi.org/10.1038/419868b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410272	Bronze			2022-12-28	WOS:000178909700008
J	Kelber, A; Balkenius, A; Warrant, EJ				Kelber, A; Balkenius, A; Warrant, EJ			Scotopic colour vision in nocturnal hawkmoths	NATURE			English	Article							WAVELENGTH DISCRIMINATION; LIGHT; SENSITIVITY	Humans are colour-blind at night, and it has been assumed that this is true of all animals. But colour vision is as useful for discriminating objects(1) at night as it is during the day. Here we show, through behavioural experiments, that the nocturnal hawkmoth Deilephila elpenor uses colour vision to discriminate coloured stimuli at intensities corresponding to dim starlight (0.0001 cd m(-2)). It can do this even if the illumination colour changes, thereby showing colour constancy-a property of true colour vision systems(2). In identical conditions humans are completely colour-blind. Our calculations show that the possession of three photoreceptor classes reduces the absolute sensitivity of the eye, which indicates that colour vision has a high ecological relevance in nocturnal moths. In addition, the photoreceptors of a single ommatidium absorb too few photons for reliable discrimination, indicating that spatial and/or temporal summation must occur for colour vision to be possible. Taken together, our results show that colour vision occurs at nocturnal intensities in a biologically relevant context.	Lund Univ, Dept Cell Organism Biol, Vis Grp, S-22362 Lund, Sweden	Lund University	Kelber, A (corresponding author), Lund Univ, Dept Cell Organism Biol, Vis Grp, Helgonavagen 3, S-22362 Lund, Sweden.	almut.kelber@zool.lu.se	Kelber, Almut/H-6216-2014	Kelber, Almut/0000-0003-3937-2808; Warrant, Eric/0000-0001-7480-7016				De Vries H, 1943, PHYSICA, V10, P553, DOI 10.1016/S0031-8914(43)90575-0; Frisch K. von, 1914, Zool Jahrb Allg Jena, V35; HOGLUND G, 1973, J COMP PHYSIOL, V86, P265, DOI 10.1007/BF00696344; Kelber A, 1999, J COMP PHYSIOL A, V184, P535, DOI 10.1007/s003590050353; KELBER A, IN PRESS BIOL REV; Knoll F, 1926, Z VERGL PHYSIOL, V2, P328; Land M.F., 1981, HDB SENSORY PHYSL, P471, DOI DOI 10.1007/978-3-642-66907-14; MENZEL R, 1981, J COMP PHYSIOL, V141, P389, DOI 10.1007/BF00609941; Minnaert M., 1993, LIGHT COLOR OUTDOORS, DOI 10.1007/978-1-4612-2722-9; Neumeyer C., 1998, PERCEPTUAL CONSTANCY, P323; Pittaway A. R., 1993, HAWKMOTHS W PALAEARC; POWERS MK, 1978, VISION RES, V18, P1149, DOI 10.1016/0042-6989(78)90098-6; RAGUSO RA, IN PRESS P 3 INT S B; Rose A., 1942, PROC I RADIO ENG NEW, V30, P293, DOI [10.1109/jrproc.1942.230998, DOI 10.1109/JRPROC.1942.230998]; SCHLECHT P, 1979, J COMP PHYSIOL, V129, P257, DOI 10.1007/BF00657662; SCHWEMER J, 1973, J COMP PHYSIOL, V86, P215, DOI 10.1007/BF00696341; STAVENGA DG, 1993, VISION RES, V33, P1011, DOI 10.1016/0042-6989(93)90237-Q; Vogel S, 1954, BLUTENBIOLOGISCHE TY; Warrant E, 1996, P ROY SOC B-BIOL SCI, V263, P1521, DOI 10.1098/rspb.1996.0222; WARRANT EJ, 1990, J COMP PHYSIOL A, V167, P805; Warrant EJ, 1998, VISION RES, V38, P195, DOI 10.1016/S0042-6989(97)00151-X; Warrant EJ, 1999, VISION RES, V39, P1611, DOI 10.1016/S0042-6989(98)00262-4; WELSCH B, 1977, CYTOBIOLOGIE, V14, P378; WHITE RH, 1994, BIOTROPICA, V26, P427, DOI 10.2307/2389237	24	170	174	2	99	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					922	925		10.1038/nature01065	http://dx.doi.org/10.1038/nature01065			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410310				2022-12-28	WOS:000178909700043
J	Petersen, PH; Zou, KY; Hwang, JK; Jan, YN; Zhong, WM				Petersen, PH; Zou, KY; Hwang, JK; Jan, YN; Zhong, WM			Progenitor cell maintenance requires numb and numblike during mouse neurogenesis	NATURE			English	Article							CORTICAL NEUROGENESIS; NERVOUS-SYSTEM; NEURONAL DIFFERENTIATION; ASYMMETRIC LOCALIZATION; PATTERN-FORMATION; MAMMALIAN NUMB; GLIAL-CELLS; STEM-CELLS; EXPRESSION; GENE	Neurons in most regions of the mammalian nervous system are generated over an extended period of time during development. Maintaining sufficient numbers of progenitors over the course of neurogenesis is essential to ensure that neural cells are produced in correct numbers and diverse types(1-3). The underlying molecular mechanisms, like those governing stem-cell self-renewal in general, remain poorly understood. We report here that mouse numb and numblike (Nbl)(4-6), two highly conserved homologues of Drosophila numb(7,8), play redundant but critical roles in maintaining neural progenitor cells during embryogenesis, by allowing their progenies to choose progenitor over neuronal fates. In Nbl mutant embryos also conditionally mutant for mouse numb in the nervous system, early neurons emerge in the expected spatial and temporal pattern, but at the expense of progenitor cells, leading to a nearly complete depletion of dividing cells shortly after the onset of neurogenesis. Our findings show that a shared molecular mechanism, with mouse Numb and Nbl as key components, governs the self-renewal of all neural progenitor cells, regardless of their lineage or regional identities.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA	Yale University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Zhong, WM (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.		, PeturHenry/H-1506-2011	Jan, Yuh Nung/0000-0003-1367-6299	NINDS NIH HHS [R01 NS042048] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson DJ, 2001, NEURON, V30, P19, DOI 10.1016/S0896-6273(01)00260-4; Campos LS, 2001, J NEUROSCI RES, V64, P590, DOI 10.1002/jnr.1111.abs; Cayouette M, 2001, J NEUROSCI, V21, P5643, DOI 10.1523/JNEUROSCI.21-15-05643.2001; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; GU M, 1994, SCIENCE, V265, P103; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; Mizuguchi R, 2001, NEURON, V31, P757, DOI 10.1016/S0896-6273(01)00413-5; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Qian XM, 1998, DEVELOPMENT, V125, P3143; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Takebayashi H, 2000, MECH DEVELOP, V99, P143, DOI 10.1016/S0925-4773(00)00466-4; VERDI JM, 1996, CURR BIOL, V6, P113; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Zhong WM, 1997, DEVELOPMENT, V124, P1887; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; Zhong WM, 2000, P NATL ACAD SCI USA, V97, P6844, DOI 10.1073/pnas.97.12.6844; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3; Zilian O, 2001, CURR BIOL, V11, P494, DOI 10.1016/S0960-9822(01)00149-X; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	29	262	273	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					929	934		10.1038/nature01124	http://dx.doi.org/10.1038/nature01124			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410312				2022-12-28	WOS:000178909700045
J	Schulman, KA; Seils, DM; Timbie, JW; Sugarman, J; Dame, LA; Weinfurt, KP; Mark, DB; Califf, RM				Schulman, KA; Seils, DM; Timbie, JW; Sugarman, J; Dame, LA; Weinfurt, KP; Mark, DB; Califf, RM			A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONFLICTS-OF-INTEREST; BIOMEDICAL-RESEARCH; INVESTIGATORS; POLICIES; FACULTY; TRUST; BIAS	Background: Concerned about threats to the integrity of clinical trials in a research environment increasingly controlled by private interests, the International Committee of Medical Journal Editors (ICMJE) has issued revised guidelines for investigators' participation in the study design, access to data, and control over publication. It is unclear whether research conducted at academic institutions adheres to these new standards. Methods: From November 2001 through January 2002, we interviewed officials at U.S. medical schools about provisions in their institutions' agreements with industry sponsors of multicenter clinical trials. A subgroup of the respondents were also asked about coordinating-center agreements for such trials. Results: Of the 122 medical schools that are members of the Association of American Medical Colleges, 108 participated in the survey. The median number of site-level agreements executed per institution in the previous year was 103 (interquartile range, 50 to 210). Scores for compliance with a wide range of provisions - from ensuring that authors of reports on multicenter trials have access to all trial data (1 percent [interquartile range, 0 to 21]) to addressing the plan for data collection and monitoring (10 percent [interquartile range, 1 to 50]) - demonstrated limited adherence to the standards embodied in the new ICMJE guidelines. Scores for coordinating-center agreements were somewhat higher for most survey items. Conclusions: Academic institutions routinely engage in industry-sponsored research that fails to adhere to ICMJE guidelines regarding trial design, access to data, and publication rights. Our findings suggest that a reevaluation of the process of contracting for clinical research is urgently needed.	Duke Univ, Med Ctr, Duke Clin Res Inst, Ctr Clin & Genet Econ, Durham, NC 27715 USA; Duke Univ, Med Ctr, Outcomes Res & Assessment Grp, Durham, NC 27715 USA; Duke Univ, Med Ctr, Ctr Study Med Eth & Humanities, Durham, NC 27715 USA; Duke Univ, Sch Law, Durham, NC 27706 USA	Duke University; Duke University; Duke University; Duke University	Schulman, KA (corresponding author), Duke Univ, Med Ctr, Duke Clin Res Inst, Ctr Clin & Genet Econ, POB 17969, Durham, NC 27715 USA.			Seils, Damon/0000-0001-8257-745X; Sugarman, Jeremy/0000-0001-7022-8332; Mark, Daniel/0000-0001-6340-8087				*ADV COMM HUM RAD, 1996, FIN REP ADV COMM HUM, P459; *ASS AM MED COLL, 2002, MED SCH US CAN; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Boyd EA, 2000, JAMA-J AM MED ASSOC, V284, P2209, DOI 10.1001/jama.284.17.2209; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; Cho MK, 2000, JAMA-J AM MED ASSOC, V284, P2203, DOI 10.1001/jama.284.17.2203; Davidoff F, 2001, NEW ENGL J MED, V345, P825, DOI 10.1056/NEJMed20010093; DeAngelis CD, 2000, JAMA-J AM MED ASSOC, V284, P2237, DOI 10.1001/jama.284.17.2237; DeAngelis CD, 2001, JAMA-J AM MED ASSOC, V286, P89, DOI 10.1001/jama.286.1.89; DeMets DL, 1999, LANCET, V354, P1983, DOI 10.1016/S0140-6736(99)03464-9; Department of Agriculture Department of Energy National Aeronautics and Space Administration Department of Commerce Consumer Product Safety Commission International Development Cooperation Agency Agency for International Development Department of Housing and Urban Development Department of Justice Department of Defense Department of Education Department of Veterans Affairs Environmental Protection Agency Department of Health and Human Services National Science Foundation and Department of Transportation, 1991, FED REGISTER, V56, P28003; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; HILLMAN AL, 1991, NEW ENGL J MED, V324, P1362, DOI 10.1056/NEJM199105093241911; Hrachovec JB, 2001, JAMA-J AM MED ASSOC, V286, P2398, DOI 10.1001/jama.286.19.2398; *INT COMM MED J ED, 2002, NEW ENGL J MED, V346, P291; *INT COMM MED J ED, 2001, UN REQ MAN SUBM BIOM; Kass NE, 1996, HASTINGS CENT REP, V26, P25, DOI 10.2307/3528467; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; Lo B, 2000, NEW ENGL J MED, V343, P1616, DOI 10.1056/NEJM200011303432206; McCrary SV, 2000, NEW ENGL J MED, V343, P1621, DOI 10.1056/NEJM200011303432207; Morse MA, 2001, JAMA-J AM MED ASSOC, V285, P1201, DOI 10.1001/jama.285.9.1201; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1978, BELM REP ETH PRINC G; Naylor CD, 2002, CAN MED ASSOC J, V166, P453; *OFF EXTR RES, 2002, AW DAT; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1762; Rivara FP, 2002, ARCH PEDIAT ADOL MED, V156, P424, DOI 10.1001/archpedi.156.5.424; Rosenberg SA, 1996, NEW ENGL J MED, V334, P392, DOI 10.1056/NEJM199602083340610; Sade RM, 2002, ARCH INTERN MED, V162, P1439, DOI 10.1001/archinte.162.13.1439; SCHULMAN KA, 1995, PHARMACOECONOMICS, V7, P206, DOI 10.2165/00019053-199507030-00004; Sugarman J, 2001, J AM GERIATR SOC, V49, P1110, DOI 10.1046/j.1532-5415.2001.49218.x; *TASK FORC FIN CON, 2001, PROT SUBJ PRES TRUST	32	120	122	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1335	1341		10.1056/NEJMsa020349	http://dx.doi.org/10.1056/NEJMsa020349			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397192				2022-12-28	WOS:000178781300006
J	Kuna, ST; Burns				Kuna, ST; Burns			A 54-year-old man with obstructive sleep apnea	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							POSITIVE AIRWAY PRESSURE; CONTROLLED CROSSOVER TRIAL; TO-NIGHT VARIABILITY; MIDDLE-AGED MEN; 1ST 3 MONTHS; DAYTIME SLEEPINESS; CARDIOVASCULAR-DISEASE; NASAL OBSTRUCTION; CPAP THERAPY; WEIGHT-LOSS		Univ Penn, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Univ Penn, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA; Philadelphia VAMC, Pulm Crit Care Sleep Sect, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Kuna, ST (corresponding author), Philadelphia VAMC, Pulm Crit Care Sleep Sect, 111P,Univ & Woodland Ave, Philadelphia, PA 19104 USA.	skuna@mail.med.upenn.edu						[Anonymous], 1989, AM REV RESPIR DIS, V139, P559; Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; Barbe F, 2001, ANN INTERN MED, V134, P1015, DOI 10.7326/0003-4819-134-11-200106050-00007; Barnes M, 2002, AM J RESP CRIT CARE, V165, P773, DOI 10.1164/ajrccm.165.6.2003166; Barvaux VA, 2000, SLEEP MED REV, V4, P435, DOI 10.1053/smrv.2000.0114; BEARPARK H, 1995, AM J RESP CRIT CARE, V151, P1459, DOI 10.1164/ajrccm.151.5.7735600; Bennett LS, 1998, AM J RESP CRIT CARE, V158, P778, DOI 10.1164/ajrccm.158.3.9711033; Berry RB, 2002, SLEEP, V25, P148; Bixler EO, 1998, AM J RESP CRIT CARE, V157, P144, DOI 10.1164/ajrccm.157.1.9706079; BLIWISE DL, 1987, J AM GERIATR SOC, V35, P132; BLIWISE DL, 1991, CHEST, V100, P973, DOI 10.1378/chest.100.4.973; Bloch KE, 2000, AM J RESP CRIT CARE, V162, P246, DOI 10.1164/ajrccm.162.1.9908112; BONORA M, 1985, AM REV RESPIR DIS, V131, P41; BONORA M, 1984, AM REV RESPIR DIS, V130, P156; Boot H, 2000, LARYNGOSCOPE, V110, P469, DOI 10.1097/00005537-200003000-00027; Chasens ER, 2002, SLEEP, V25, pA1; Chesson AL, 1997, SLEEP, V20, P406; *CTR MED, 2001, COV DEC MEM CPAP; Davies RJO, 1996, THORAX, V51, pS65, DOI 10.1136/thx.51.Suppl_2.S65; DAVIES RJO, 1992, THORAX, V47, P101, DOI 10.1136/thx.47.2.101; Douglas NJ, 1998, THORAX, V53, P414, DOI 10.1136/thx.53.5.414; Engleman HM, 1997, THORAX, V52, P114, DOI 10.1136/thx.52.2.114; Engleman HM, 1999, AM J RESP CRIT CARE, V159, P461, DOI 10.1164/ajrccm.159.2.9803121; Engleman HM, 2002, AM J RESP CRIT CARE, V165, P743, DOI 10.1164/ajrccm.165.6.2202007c; Faccenda JF, 2001, AM J RESP CRIT CARE, V163, P344, DOI 10.1164/ajrccm.163.2.2005037; Farre R, 1999, LANCET, V353, P1154, DOI 10.1016/S0140-6736(99)01056-9; Ferguson KA, 1996, CHEST, V109, P1269, DOI 10.1378/chest.109.5.1269; FLEMONS WW, 1993, AM REV RESPIR DIS, V148, P618, DOI 10.1164/ajrccm/148.3.618; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; FLEMONS WW, 1994, AM J RESP CRIT CARE, V150, P1279, DOI 10.1164/ajrccm.150.5.7952553; Friedman M, 2000, OTOLARYNG HEAD NECK, V122, P71, DOI 10.1016/S0194-5998(00)70147-1; GASTAUT H, 1965, BRAIN RES, V2, P167; George CFP, 1999, SLEEP, V22, P790; GLEADHILL IC, 1991, AM REV RESPIR DIS, V143, P1300, DOI 10.1164/ajrccm/143.6.1300; Goldberg AN, 1998, OTOLARYNG CLIN N AM, V31, P919, DOI 10.1016/S0030-6665(05)70099-2; Gottlieb DJ, 1999, AM J RESP CRIT CARE, V159, P502, DOI 10.1164/ajrccm.159.2.9804051; Gurubhagavatula I, 2001, AM J RESP CRIT CARE, V164, P1904, DOI 10.1164/ajrccm.164.10.2103039; Hack M, 2000, THORAX, V55, P224, DOI 10.1136/thorax.55.3.224; Hedner J, 2001, AM J RESP CRIT CARE, V163, P5, DOI 10.1164/ajrccm.163.1.ed1400d; Henke KG, 2001, AM J RESP CRIT CARE, V163, P911, DOI 10.1164/ajrccm.163.4.9910025; Hoy CJ, 1999, AM J RESP CRIT CARE, V159, P1096, DOI 10.1164/ajrccm.159.4.9808008; Ip MSM, 2001, CHEST, V119, P62, DOI 10.1378/chest.119.1.62; Ip MSM, 2002, AM J RESP CRIT CARE, V165, P670, DOI 10.1164/ajrccm.165.5.2103001; Isono S, 1997, J APPL PHYSIOL, V82, P1319, DOI 10.1152/jappl.1997.82.4.1319; Jenkinson C, 1999, LANCET, V353, P2100, DOI 10.1016/S0140-6736(98)10532-9; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kingshott RN, 2000, AM J RESP CRIT CARE, V161, P866, DOI 10.1164/ajrccm.161.3.9905053; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; Kripke DF, 1997, SLEEP, V20, P65, DOI 10.1093/sleep/20.1.65; KUNA ST, 1991, JAMA-J AM MED ASSOC, V266, P1384, DOI 10.1001/jama.266.10.1384; LORD S, 1991, SLEEP, V14, P252; Loredo JS, 1999, CHEST, V116, P1545, DOI 10.1378/chest.116.6.1545; Loube DI, 1999, CHEST, V116, P1426, DOI 10.1378/chest.116.5.1426; LOWE AA, 1995, AM J ORTHOD DENTOFAC, V107, P589, DOI 10.1016/S0889-5406(95)70101-X; MAISLIN G, 1995, SLEEP, V18, P158, DOI 10.1093/sleep/18.3.158; Marcus C L, 1997, Curr Opin Pulm Med, V3, P464, DOI 10.1097/00063198-199711000-00014; Massie CA, 1999, CHEST, V116, P403, DOI 10.1378/chest.116.2.403; McArdle N, 1999, AM J RESP CRIT CARE, V159, P1108, DOI 10.1164/ajrccm.159.4.9807111; Meurice JC, 1996, AM J RESP CRIT CARE, V153, P794, DOI 10.1164/ajrccm.153.2.8564134; Miyazaki S, 1998, ACTA OTO-LARYNGOL, P43; Monasterio C, 2001, AM J RESP CRIT CARE, V164, P939, DOI 10.1164/ajrccm.164.6.2008010; MONSERRAT JM, 1997, AM J RESP CRIT CARE, V155, P211; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; OLSON LG, 1995, AM J RESP CRIT CARE, V152, P717, DOI 10.1164/ajrccm.152.2.7633732; Peker Y, 2002, AM J RESP CRIT CARE, V166, P159, DOI 10.1164/rccm.2105124; Pepin JL, 1999, AM J RESP CRIT CARE, V160, P1124, DOI 10.1164/ajrccm.160.4.9802027; Peppard PE, 2000, JAMA-J AM MED ASSOC, V284, P3015, DOI 10.1001/jama.284.23.3015; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; Punjabi NM, 2002, AM J RESP CRIT CARE, V165, P677, DOI 10.1164/ajrccm.165.5.2104087; REDLINE S, 1995, AM J RESP CRIT CARE, V151, P682; Redline S, 1998, AM J RESP CRIT CARE, V157, P858, DOI 10.1164/ajrccm.157.3.9709042; Redline S, 2000, AM J RESP CRIT CARE, V161, P369, DOI 10.1164/ajrccm.161.2.9904031; REEVESHOCHE MK, 1995, AM J RESP CRIT CARE, V151, P443, DOI 10.1164/ajrccm.151.2.7842204; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; Riley RW, 2000, PRINCIPLES PRACTICE, P913; SANDERS MH, 1986, CHEST, V90, P330, DOI 10.1378/chest.90.3.330; Sauter C, 2000, J SLEEP RES, V9, P293; Schechter GL, 1998, OTOLARYNG HEAD NECK, V118, P643, DOI 10.1177/019459989811800513; SCHMIDTNOWARA W, 1995, SLEEP, V18, P501, DOI 10.1093/sleep/18.6.501; SCHWAB RJ, 1995, AM J RESP CRIT CARE, V152, P1673, DOI 10.1164/ajrccm.152.5.7582313; Senior BA, 2000, OTOLARYNG HEAD NECK, V123, P179, DOI 10.1067/mhn.2000.106707; SERIES F, 1993, THORAX, V48, P360, DOI 10.1136/thx.48.4.360; SERIES F, 1992, AM REV RESPIR DIS, V146, P1261, DOI 10.1164/ajrccm/146.5_Pt_1.1261; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; SMITH PL, 1988, J APPL PHYSIOL, V64, P789, DOI 10.1152/jappl.1988.64.2.789; SMITH PL, 1985, ANN INTERN MED, V103, P850, DOI 10.7326/0003-4819-103-6-850; Strobel RJ, 1996, SLEEP, V19, P104, DOI 10.1093/sleep/19.2.104; Strohl KP, 1996, AM J RESP CRIT CARE, V154, P279, DOI 10.1164/ajrccm.154.2.8756795; SULLIVAN CE, 1981, LANCET, V1, P862; TAASAN VC, 1981, AM J MED, V71, P240; TANGEL DJ, 1991, J APPL PHYSIOL, V70, P2574, DOI 10.1152/jappl.1991.70.6.2574; Tegelberg A, 1999, SWED DENT J, V23, P117; Teschler H, 1996, AM J RESP CRIT CARE, V154, P734, DOI 10.1164/ajrccm.154.3.8810613; Thurnheer R, 2001, AM J RESP CRIT CARE, V164, P1914, DOI 10.1164/ajrccm.164.10.2102104; Tiihonen M, 1998, ELECTROEN CLIN NEURO, V107, P383, DOI 10.1016/S0013-4694(98)00079-0; Van DOngen H, 2001, SLEEP, V24, pA245; VANDONGEN HPA, 2001, SLEEP RES SOC B, V7, P69; Virkkula P, 1997, ACTA OTO-LARYNGOL, P195; Walker-Engstrom ML, 2002, CHEST, V121, P739, DOI 10.1378/chest.121.3.739; Weaver TE, 1997, SLEEP, V20, P278, DOI 10.1093/sleep/20.4.278; WEAVER TE, 2002, SLEEP APNEA PATHOGEN, P253; Wilhelmsson B, 1999, ACTA OTO-LARYNGOL, V119, P503; WILHOIT SC, 1987, CHEST, V91, P654, DOI 10.1378/chest.91.5.654; WITTIG RM, 1984, AM REV RESPIR DIS, V129, P244; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1997, J ALLERGY CLIN IMMUN, V99, pS757, DOI 10.1016/S0091-6749(97)70124-6; Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705; 2000, AM J RESP CRIT CARE, V161, P420	113	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	2002	288	16					2032	2039		10.1001/jama.288.16.2032	http://dx.doi.org/10.1001/jama.288.16.2032			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	606QW	12387656				2022-12-28	WOS:000178745500027
J	Brunekreef, B; Holgate, ST				Brunekreef, B; Holgate, ST			Air pollution and health	LANCET			English	Review							LONG-TERM EXPOSURE; INDUCED LUNG INFLAMMATION; DIESEL EXHAUST PARTICLES; FINE PARTICULATE MATTER; DAILY TIME-SERIES; DAILY MORTALITY; NITROGEN-DIOXIDE; RESPIRATORY SYMPTOMS; HOSPITAL ADMISSIONS; COARSE PARTICLES	The health effects of air pollution have been subject to intense study in recent years. Exposure to pollutants such as airborne particulate matter and ozone has been associated with increases in mortality and hospital admissions due to respiratory and cardiovascular disease. These effects have been found in short-term studies, which relate day-to-day variations in air pollution and health, and long-term studies, which have followed cohorts of exposed individuals over time. Effects have been seen at very low levels of exposure, and it is unclear whether a threshold concentration exists for particulate matter and ozone below which no effects on health are likely. In this review, we discuss the evidence for adverse effects on health of selected air pollutants.	Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Southampton Gen Hosp, Sch Med, RCMB Div, Southampton SO9 4XY, Hants, England	Utrecht University; University of Southampton	Brunekreef, B (corresponding author), Univ Utrecht, Inst Risk Assessment Sci, POB 80176, NL-3508 TD Utrecht, Netherlands.	B.Brunekreef@iras.uu.nl		brunekreef, bert/0000-0001-9908-0060				Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373, DOI 10.1164/ajrccm.159.2.9806020; AckermannLiebrich U, 1997, AM J RESP CRIT CARE, V155, P122, DOI 10.1164/ajrccm.155.1.9001300; Anderson HR, 2001, OCCUP ENVIRON MED, V58, P504, DOI 10.1136/oem.58.8.504; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860, DOI 10.1164/ajrccm.164.10.2010138; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067, DOI 10.1164/ajrccm.164.11.2102005; Bassett D, 2001, J TOXICOL ENV HEAL A, V64, P547, DOI 10.1080/15287390152627237; Bayram H, 2001, J ALLERGY CLIN IMMUN, V107, P287, DOI 10.1067/mai.2001.111141; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beck-Speier I, 2001, ENVIRON HEALTH PERSP, V109, P613, DOI 10.2307/3454679; Bell ML, 2001, ENVIRON HEALTH PERSP, V109, P389, DOI 10.2307/3434786; Bergamaschi E, 2001, AM J RESP CRIT CARE, V163, P1426, DOI 10.1164/ajrccm.163.6.2006056; Blomberg A, 1997, AM J RESP CRIT CARE, V156, P418, DOI 10.1164/ajrccm.156.2.9612042; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042, DOI 10.1164/ajrccm.155.3.9116984; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; Brunekreef B, 1999, AM J RESP CRIT CARE, V159, P354, DOI 10.1164/ajrccm.159.2.15922; BRUNEKREEF B, 1995, ENVIRON HEALTH PERSP, V103, P3, DOI 10.2307/3432443; Brunekreef B, 1997, OCCUP ENVIRON MED, V54, P781, DOI 10.1136/oem.54.11.781; Burnett R, 2001, ENVIRON HEALTH PERSP, V109, P375, DOI 10.2307/3434784; Cakmak S, 1999, RISK ANAL, V19, P487, DOI 10.1111/j.1539-6924.1999.tb00423.x; Chauhan A. J., 1998, Reviews on Environmental Health, V13, P73; Cho HY, 2001, AM J PHYSIOL-LUNG C, V280, pL537, DOI 10.1152/ajplung.2001.280.3.L537; Daniels MJ, 2000, AM J EPIDEMIOL, V152, P397, DOI 10.1093/aje/152.5.397; DASSEN W, 1986, JAPCA J AIR WASTE MA, V36, P1223, DOI 10.1080/00022470.1986.10466168; de Hollander AEM, 1999, EPIDEMIOLOGY, V10, P606, DOI 10.1097/00001648-199909000-00030; Dellinger B, 2001, CHEM RES TOXICOL, V14, P1371, DOI 10.1021/tx010050x; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; Dockery DW, 2001, ENVIRON HEALTH PERSP, V109, P483, DOI 10.2307/3454657; Donaldson K, 2001, ENVIRON HEALTH PERSP, V109, P523, DOI 10.2307/3454663; Donaldson K, 2000, Respir Res, V1, P12, DOI 10.1186/rr5; Ezzati M, 2001, LANCET, V358, P619, DOI 10.1016/S0140-6736(01)05777-4; Firket J, 1936, T FARADAY SOC, V32, P1192, DOI 10.1039/tf9363201192; FRAMPTON MW, 1989, ENVIRON RES, V48, P179, DOI 10.1016/S0013-9351(89)80033-7; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507, DOI 10.1165/ajrcmb.19.3.3143; Fujii T, 2001, AM J RESP CELL MOL, V25, P265, DOI 10.1165/ajrcmb.25.3.4445; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Ghio AJ, 2001, AM J RESP CRIT CARE, V164, P704, DOI 10.1164/ajrccm.164.4.2011089; Gilmour MI, 2001, ENVIRON HEALTH PERSP, V109, P619, DOI 10.2307/3454680; Goldsmith Carroll-Ann W., 1999, Reviews on Environmental Health, V14, P121; Gordon T, 2000, TOXICOL SCI, V56, P2, DOI 10.1093/toxsci/56.1.2; Greenbaum Daniel S., 2001, American Journal of Epidemiology, V154, pS78, DOI 10.1093/aje/154.12.S78; Hashimoto KI, 2001, AM J RESP CRIT CARE, V164, P1957, DOI 10.1164/ajrccm.164.10.2011070; Heinrich J, 2000, AM J RESP CRIT CARE, V161, P1930, DOI 10.1164/ajrccm.161.6.9906105; Hoek G, 2001, J EXPO ANAL ENV EPID, V11, P459, DOI 10.1038/sj.jea.7500189; HOEK G, IN PRESS LANCET; HOLLAND WW, 1979, AM J EPIDEMIOL, V110, P525, DOI 10.1093/oxfordjournals.aje.a112836; Holz O, 1999, AM J RESP CRIT CARE, V159, P776, DOI 10.1164/ajrccm.159.3.9806098; Janssen NAH, 2002, ENVIRON HEALTH PERSP, V110, P43, DOI 10.1289/ehp.0211043; Janssen NAH, 2000, J AIR WASTE MANAGE, V50, P1133, DOI 10.1080/10473289.2000.10464159; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; Jorres RA, 2000, AM J RESP CRIT CARE, V161, P1855; Katsouyanni K, 2001, EPIDEMIOLOGY, V12, P521, DOI 10.1097/00001648-200109000-00011; KATSOUYANNI K, 1995, EUR RESPIR J, V8, P1030; Kaur B, 1998, BRIT MED J, V316, P118; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; Kleeberger SR, 1997, NAT GENET, V17, P475, DOI 10.1038/ng1297-475; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717, DOI 10.1016/S0091-6749(99)70280-0; Krewski D., 2000, REANALYSIS HARVARD 6; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; LETERTRE A, IN PRESS J EPIDEMIOL; Lundborg M, 2001, ENVIRON RES, V86, P244, DOI 10.1006/enrs.2001.4269; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; McDonnell WF, 2000, J EXPO ANAL ENV EPID, V10, P427, DOI 10.1038/sj.jea.7500095; McMichael AJ, 1999, EPIDEMIOLOGY, V10, P1; McMichael AJ, 1998, INT J EPIDEMIOL, V27, P450, DOI 10.1093/ije/27.3.450; *MIN HLTH, 1954, REP PUBL HLTH MED SU, V95; Mochitate K, 2001, J HEALTH SCI, V47, P302, DOI 10.1248/jhs.47.302; Mudway IS, 1999, OCCUP ENVIRON MED, V56, P473, DOI 10.1136/oem.56.7.473; Mukae H, 2001, AM J RESP CRIT CARE, V163, P201, DOI 10.1164/ajrccm.163.1.2002039; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nemery B, 2001, LANCET, V357, P704, DOI 10.1016/S0140-6736(00)04135-0; Nichols BG, 2001, TOXICOL SCI, V60, P356, DOI 10.1093/toxsci/60.2.356; Nicolai T, 1999, PEDIATR PULM, P9; Nyberg F, 2000, EPIDEMIOLOGY, V11, P487, DOI 10.1097/00001648-200009000-00002; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; Oglesby L, 2000, J AIR WASTE MANAGE, V50, P1251, DOI 10.1080/10473289.2000.10464156; OSTRO B, 1984, ENVIRON HEALTH PERSP, V58, P397, DOI 10.2307/3429861; Ostro B, 1999, J AIR WASTE MANAGE, V49, P100, DOI 10.1080/10473289.1999.10463875; Peden DB, 2001, ANN ALLERG ASTHMA IM, V87, P12, DOI 10.1016/S1081-1206(10)62334-4; Penttinen P, 2001, ENVIRON HEALTH PERSP, V109, P319, DOI 10.2307/3454889; Peters A, 1999, AM J EPIDEMIOL, V150, P1094, DOI 10.1093/oxfordjournals.aje.a009934; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; Peters A, 2001, EUR HEART J, V22, P1198, DOI 10.1053/euhj.2000.2483; Peters A, 2001, CIRCULATION, V103, P2810; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; POPE CA, 1991, AM REV RESPIR DIS, V144, P668, DOI 10.1164/ajrccm/144.3_Pt_1.668; Pope CA, 2000, ENVIRON HEALTH PERSP, V108, P713, DOI 10.2307/3454408; Pope CA, 1996, ENVIRON HEALTH PERSP, V104, P414, DOI 10.2307/3432686; Pope CA, 1999, ENVIRON HEALTH PERSP, V107, P613, DOI 10.2307/3434450; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Pope CA, 1996, J EXPO ANAL ENV EPID, V6, P23; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123, DOI 10.1164/ajrccm/145.5.1123; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Puddicombe SM, 2000, CLIN EXP ALLERGY, V30, P7; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Raizenne M, 1996, ENVIRON HEALTH PERSP, V104, P506, DOI 10.2307/3432991; Renwick LC, 2001, TOXICOL APPL PHARM, V172, P119, DOI 10.1006/taap.2001.9128; Rijnders E, 2001, ENVIRON HEALTH PERSP, V109, P411, DOI 10.2307/3434789; Roemer W, 1998, EUR RESPIR J, V12, P1354, DOI 10.1183/09031936.98.12061354; Roemer W, 2000, CLIN EXP ALLERGY, V30, P1067; Roemer WH, 2001, EPIDEMIOLOGY, V12, P649, DOI 10.1097/00001648-200111000-00012; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702, DOI 10.1164/ajrccm.159.3.9709083; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550, DOI 10.1164/ajrccm.161.2.9905052; Samet J, 1998, ENVIRON RES, V77, P9, DOI 10.1006/enrs.1997.3821; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Samet JM, 2001, AM J RESP CRIT CARE, V164, P819, DOI 10.1164/ajrccm.164.5.2008003; Samet JM, 2000, RES REPORT HLTH EFFE, V75, P5; SANDSTROM T, 1992, EUR RESPIR J, V5, P1092; Sarnat JA, 2001, ENVIRON HEALTH PERSP, V109, P1053, DOI 10.2307/3454961; Schelegle ES, 2001, AM J RESP CRIT CARE, V163, P1121, DOI 10.1164/ajrccm.163.5.2003103; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 2000, AM J EPIDEMIOL, V151, P440, DOI 10.1093/oxfordjournals.aje.a010228; Schwartz J, 2001, EPIDEMIOLOGY, V12, P55, DOI 10.1097/00001648-200101000-00010; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185, DOI 10.1093/oxfordjournals.aje.a115473; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600, DOI 10.1164/ajrccm/145.3.600; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Seaton A, 1999, THORAX, V54, P1027, DOI 10.1136/thx.54.11.1027; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; Smith RL, 2000, J AIR WASTE MANAGE, V50, P1367, DOI 10.1080/10473289.2000.10464172; Spengler JD, 1996, ENVIRON HEALTH PERSP, V104, P492, DOI 10.2307/3432989; Stearns RC, 2001, AM J RESP CELL MOL, V24, P108, DOI 10.1165/ajrcmb.24.2.4081; Sun GB, 2001, AM J PHYSIOL-LUNG C, V281, pL807, DOI 10.1152/ajplung.2001.281.4.L807; Sunyer J, 2001, EUR RESPIR J, V17, P1024, DOI 10.1183/09031936.01.17510240; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; Takafuji S, 2000, J INVEST ALLERG CLIN, V10, P5; Thurston GD, 2001, J EXPO ANAL ENV EPID, V11, P286, DOI 10.1038/sj.jea.7500169; Touloumi G, 1997, AM J EPIDEMIOL, V146, P177, DOI 10.1093/oxfordjournals.aje.a009249; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; van Eeden SF, 2001, AM J RESP CRIT CARE, V164, P826, DOI 10.1164/ajrccm.164.5.2010160; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Vichit-Vadakan N, 2001, ENVIRON HEALTH PERSP, V109, P381, DOI 10.2307/3434785; WICHMANN HE, 1989, ENVIRON HEALTH PERSP, V79, P89, DOI 10.2307/3430534; World Health Organization, 2000, WHO EUR SER, V91; Wu WD, 2001, AM J PHYSIOL-LUNG C, V281, pL483, DOI 10.1152/ajplung.2001.281.2.L483; Zanobetti A, 2002, EPIDEMIOLOGY, V13, P87, DOI 10.1097/00001648-200201000-00014; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P1071, DOI 10.2307/3434961; Zeger SL, 1999, EPIDEMIOLOGY, V10, P171, DOI 10.1097/00001648-199903000-00015; Zemp E, 1999, AM J RESP CRIT CARE, V159, P1257, DOI 10.1164/ajrccm.159.4.9807052; 1955, BMJ, V231, P1135; [No title captured]	147	2706	2831	40	1325	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	2002	360	9341					1233	1242		10.1016/S0140-6736(02)11274-8	http://dx.doi.org/10.1016/S0140-6736(02)11274-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401268				2022-12-28	WOS:000178708100030
J	Buckley, RH				Buckley, RH			Gene therapy for SCID - a complication after remarkable progress	LANCET			English	Editorial Material							SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW TRANSPLANTATION		Duke Univ, Med Ctr, Durham, NC 27710 USA	Duke University	Buckley, RH (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.		Buckley, Rebecca/AAB-1578-2019					Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Haddad E, 1999, BLOOD, V94, P2923, DOI 10.1182/blood.V94.8.2923.420k44_2923_2930; Haddad E, 1998, BLOOD, V91, P3646; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Smogorzewska Elzbieta M., 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P111	9	58	59	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1185	1186		10.1016/S0140-6736(02)11290-6	http://dx.doi.org/10.1016/S0140-6736(02)11290-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401240				2022-12-28	WOS:000178708100003
J	Turpie, AGG; Chin, BSP; Lip, GYH				Turpie, AGG; Chin, BSP; Lip, GYH			ABC of antithrombotic therapy - Venous thromboembolism: pathophysiology, clinical features, and prevention	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MANAGEMENT		McMaster Univ, Hamilton, ON, Canada; Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B15 2TT, W Midlands, England	McMaster University; University of Birmingham	Turpie, AGG (corresponding author), McMaster Univ, Hamilton, ON, Canada.							*BRIT COMM STAND H, 1998, BRIT J HAEMATOL, V101, P374; Hyers TM, 2001, CHEST, V119, p176S, DOI 10.1378/chest.119.1_suppl.176S; Kearon C, 1997, NEW ENGL J MED, V336, P1506, DOI 10.1056/NEJM199705223362107; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; Turpie AGG, 2002, ARCH INTERN MED, V162, P1833, DOI 10.1001/archinte.162.16.1833; Walker ID, 2001, BRIT J HAEMATOL, V114, P512, DOI 10.1046/j.1365-2141.2001.02981.x	6	84	88	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 19	2002	325	7369					887	890		10.1136/bmj.325.7369.887	http://dx.doi.org/10.1136/bmj.325.7369.887			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386044	Green Published			2022-12-28	WOS:000178793000027
J	Adams, KE; Cohen, MH; Eisenberg, D; Jonsen, AR				Adams, KE; Cohen, MH; Eisenberg, D; Jonsen, AR			Ethical considerations of complementary and alternative medical therapies in conventional medical settings	ANNALS OF INTERNAL MEDICINE			English	Article							ST JOHNS WORT; PHYSICIANS	Increasing use of complementary and alternative medical (CAM) therapies by patients, health care providers, and institutions has made it imperative that physicians consider their ethical obligations when recommending, tolerating, or proscribing these therapies. The authors present a risk-benefit framework that can be applied to determine the appropriateness of using CAM therapies in various clinical scenarios. The major relevant issues are the severity and acuteness of illness; the curability of the illness by conventional forms of treatment; the degree of invasiveness, associated toxicities, and side effects of the conventional treatment; the availability and quality of evidence of utility and safety of the desired CAM treatment; the level of understanding of risks and benefits of the CAM treatment combined with the patient's knowing and voluntary acceptance of those risks; and the patient's persistence of intention to use CAM therapies. Even in the absence of scientific evidence for CAM therapies, by considering these relevant issues, providers can formulate a plan that is clinically sound, ethically appropriate, and targeted to the unique circumstances of individual patients. Physicians are encouraged to remain engaged in problem-solving with their patients and to attempt to elucidate and clarify the patient's core values and beliefs when counseling about CAM therapies.	Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, UHNSO, Portland, OR 97239 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Med Ctr, Seattle, WA 98195 USA	Oregon Health & Science University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle	Adams, KE (corresponding author), Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, UHNSO, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	adamsk@ohsu.edu						Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; COHEN M, 2000, COMPLEMENTARY MED LE; Cohen MH, 2002, ANN INTERN MED, V136, P596, DOI 10.7326/0003-4819-136-8-200204160-00009; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; EISENBERG DM, IN PRESS ANN INTERN; EISENBERG DM, 1996, HARVARD MED ALUMNI B, V70, P20; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; FUGHBERMAN A, 1997, ALTERNATIVE MED WHAT; Jonsen A. R., 1992, CLIN ETHICS; JONSEN AR, 1995, KENNEDY INST ETHIC J, V5, P237; JONSEN AR, 1997, INTRO HIST METHODS P, P158; KOTTOW MH, 1992, J MED ETHICS, V18, P18, DOI 10.1136/jme.18.1.18; Kramer N, 1999, RHEUM DIS CLIN N AM, V25, P833, DOI 10.1016/S0889-857X(05)70104-6; Long L, 2001, COMPLEMENT THER MED, V9, P178, DOI 10.1054/ctim.2001.0453; MAY WF, 1983, PHYSICIANS COVENANT; National Institutes of Health, 1995, INT BEH REL APPR TRE, P1; ORNISH D, 1983, JAMA-J AM MED ASSOC, V249, P54, DOI 10.1001/jama.249.1.54; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Ramsey P., 1970, PATIENT PERSON EXPLO; Spencer JW, 1999, COMPLEMENTARY ALTERN, P3; SPIEGEL D, 1989, LANCET, V2, P888; Studdert DM, 1998, JAMA-J AM MED ASSOC, V280, P1610, DOI 10.1001/jama.280.18.1610	30	75	77	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2002	137	8					660	664		10.7326/0003-4819-137-8-200210150-00010	http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604WL	12379066				2022-12-28	WOS:000178644000005
J	O'Grady, JG; Burroughs, A; Hardy, P; Elbourne, D; Truesdale, A				O'Grady, JG; Burroughs, A; Hardy, P; Elbourne, D; Truesdale, A		UK Republic Ireland Liver Transpla	Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial	LANCET			English	Article							ALLOGRAFT-REJECTION; IMMUNOSUPPRESSION; FK506; RISK	Background Calcineurin inhibitors are the most commonly used immunosuppressive drugs in liver transplantation, but the optimum initial immunosuppression regimen is not known. The aim of our study was to compare tacrolimus with microemulsified ciclosporin, in a regimen with standardised concomitant immunosuppressive therapy. Methods In all liver transplant centres in the UK and Republic of Ireland, 606 patients undergoing a first orthotopic liver transplantation were randomly assigned open-label tacrolimus or microemulsified ciclosporin. Primary outcome was the combined frequency (whichever occurred first) of death, retransplantation, or treatment failure for immunological reasons, analysed by intention to treat. Findings 96% of patients received the treatment allocated to them. The primary outcome was reached in 62 (21%) of 301 patients in the tacrolimus group versus 99 (32%) of 305 allocated microemulsified ciclosporin (relative risk 0.63 [95% CI 0.48-0.84], p=0.001; time-to-event analysis log-rank test p=0.002): deaths (50 [17%] vs 72 [24%]); retransplantations (11 [4%] vs 31 [10%]) treatment failure for immunological reasons (6 [2%] vs 12 [4%]). The relative risk for the composite outcome was in favour of tacrolimus. The main causes of death in both trial groups were sepsis and multiple organ failure (31 [10%] vs 30 [10%]), and the main cause for retransplantation was hepatic artery thrombosis (6 [2%] vs.17 [6%]). Renal dysfunction and the need for antihypertensive therapy were much the same in both groups. Tacrolimus was more diabetogenic. Interpretation Clinical outcome at 1 year was better with tacrolimus-based immunosuppression than with microemulsified ciclosporin during the first year after liver transplantation. Tacrolimus should be the first choice of calcineurin inhibitor for patients receiving their first liver graft.	Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England; Royal Free Hosp, London NW3 2QG, England; London Sch Hyg & Trop Med, Med Stat Unit, Data Coordinating Ctr, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; London School of Hygiene & Tropical Medicine	O'Grady, JG (corresponding author), Kings Coll Hosp London, Inst Liver Studies, Denmark Hill, London SE5 9RS, England.	john.o'grady@kcl.ac.uk	Burroughs, Andrew K/C-5645-2009	Burroughs, Andrew K/0000-0001-6527-457X				BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110; DAGHER H, 1999, EVIDENCE BASED GASTR, P491; Devlin J, 1998, HEPATOLOGY, V27, P926, DOI 10.1002/hep.510270406; Fung JJ, 1996, J AM COLL SURGEONS, V183, P117; Jain A, 2001, LIVER TRANSPLANT, V7, P623, DOI 10.1053/jlts.2001.25364; Klein IHHT, 2002, TRANSPLANTATION, V73, P732, DOI 10.1097/00007890-200203150-00012; LARUSSO A, 1997, BRIT J PHARMACOL, V121, P248; Levy GA, 2001, BIODRUGS, V15, P279, DOI 10.2165/00063030-200115050-00001; NEUHAUS P, 1994, LANCET, V344, P423; Otto MG, 1998, TRANSPLANTATION, V66, P1632, DOI 10.1097/00007890-199812270-00011; STARZL TE, 1995, LANCET, V346, P1346, DOI 10.1016/S0140-6736(95)92349-7; Wiesner RH, 1998, TRANSPLANTATION, V66, P493, DOI 10.1097/00007890-199808270-00014; Wiesner RH, 1998, HEPATOLOGY, V28, P638, DOI 10.1002/hep.510280306; Williams R, 1996, Transpl Int, V9 Suppl 1, pS144, DOI 10.1111/j.1432-2277.1996.tb01592.x	14	177	179	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1119	1125		10.1016/S0140-6736(02)11196-2	http://dx.doi.org/10.1016/S0140-6736(02)11196-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387959				2022-12-28	WOS:000178632000011
J	Daughton, CG				Daughton, CG			Environmental stewardship and drugs as pollutants	LANCET			English	Editorial Material									US EPA, ORD, Las Vegas, NV 89119 USA	United States Environmental Protection Agency	Daughton, CG (corresponding author), US EPA, ORD, Las Vegas, NV 89119 USA.		Daughton, Christian/AAK-2299-2021	Daughton, Christian/0000-0002-0302-7730				Daughton C.G., 2001, J AM CHEM SOC, V791, P2, DOI DOI 10.1021/BK-2001-0791.CH001; Daughton CG, 1999, ENVIRON HEALTH PERSP, V107, P907, DOI 10.2307/3434573; Daughton CG., 2002, PHARM PERSONAL CARE; DAUGHTON CG, 2001, S SERIES AM CHEM SOC, V791; Halling-Sorensen B, 1998, CHEMOSPHERE, V36, P357, DOI 10.1016/S0045-6535(97)00354-8; Kfimmerer K., 2001, PHARM ENV SOURCES FA; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Rajapakse N, 2002, ENVIRON HEALTH PERSP, V110, P917, DOI 10.1289/ehp.02110917; Ternes TA, 2002, ENVIRON SCI TECHNOL, V36, P3855, DOI 10.1021/es015757k; Zuccato E, 2000, LANCET, V355, P1789, DOI 10.1016/S0140-6736(00)02270-4	10	112	113	0	35	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1035	1036		10.1016/S0140-6736(02)11176-7	http://dx.doi.org/10.1016/S0140-6736(02)11176-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383980				2022-12-28	WOS:000178485200005
J	Brown, JA				Brown, JA			End-stage autosomal dominant polycystic kidney disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Med Coll Georgia, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Brown, JA (corresponding author), Med Coll Georgia, Augusta, GA 30912 USA.			Brown, James/0000-0002-6065-1716					0	3	5	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2002	347	19					1504	1504		10.1056/NEJMicm020402	http://dx.doi.org/10.1056/NEJMicm020402			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611XG	12421893				2022-12-28	WOS:000179042700006
J	Wolpert, AJ				Wolpert, AJ			The future of electronic data - Will the universities' own electronic repositories affect traditional publishing?	NATURE			English	Editorial Material									MIT, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Wolpert, AJ (corresponding author), MIT, 77 Massachusetts Ave,14S-216, Cambridge, MA 02139 USA.							2002, NATURE, V419, P869	1	4	4	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					17	18		10.1038/420017a	http://dx.doi.org/10.1038/420017a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422185				2022-12-28	WOS:000179068100018
J	Grinberg, I; Cooper, VR; Rappe, AM				Grinberg, I; Cooper, VR; Rappe, AM			Relationship between local structure and phase transitions of a disordered solid solution	NATURE			English	Article							PBTIO3	The Pb(Zr,Ti)O-3 (PZT) disordered solid solution is widely used in piezoelectric applications owing to its excellent electromechanical properties. Six different structural phases have been observed for PZT at ambient pressure, each with different lattice parameters and average electric polarization. It is of significant interest to understand the microscopic origin of the complicated phase diagram and local structure of PZT(1-8). Here, using density functional theory calculations, we show(t)hat the distortions of the material away from the parent perovskite structure can be predicted from the local arrangement of the Zr and Ti cations. We use the chemical rules obtained from density functional theory to create a phenomenological model to simulate PZT structures. We demonstrate how changes in the Zr/Ti composition give rise to phase transitions in PZT through changes in the populations of various local Pb atom environments.	Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Penn, Res Struct Matter Lab, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Rappe, AM (corresponding author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.	rappe@sas.upenn.edu	Rappe, Andrew Marshall/HFZ-8855-2022; Cooper, Valentino R/A-2070-2012	Cooper, Valentino R/0000-0001-6714-4410				Bellaiche L, 2000, PHYS REV LETT, V84, P5427, DOI 10.1103/PhysRevLett.84.5427; BRESE NE, 1991, ACTA CRYSTALLOGR B, V47, P192, DOI 10.1107/S0108768190011041; Brown I. D., 1981, STRUCTURE BONDING CR, P1; COHEN RE, 1992, NATURE, V358, P136, DOI 10.1038/358136a0; Dmowski W, 2001, AIP CONF PROC, V582, P33, DOI 10.1063/1.1399687; Egami T, 1998, AIP CONF PROC, P1, DOI 10.1063/1.56286; Fornai F, 2001, NEUROREPORT, V12, P63, DOI 10.1097/00001756-200101220-00021; Fu HX, 2000, NATURE, V403, P281, DOI 10.1038/35002022; Ghosez P, 1999, PHYS REV B, V60, P836, DOI 10.1103/PhysRevB.60.836; Noheda B, 1999, APPL PHYS LETT, V74, P2059, DOI 10.1063/1.123756; Saghi-Szabo G, 1999, PHYS REV B, V59, P12771, DOI 10.1103/PhysRevB.59.12771	11	204	204	3	137	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					909	911		10.1038/nature01115	http://dx.doi.org/10.1038/nature01115			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410319				2022-12-28	WOS:000178909700038
J	Neff, JC; Townsend, AR; Gleixner, G; Lehman, SJ; Turnbull, J; Bowman, WD				Neff, JC; Townsend, AR; Gleixner, G; Lehman, SJ; Turnbull, J; Bowman, WD			Variable effects of nitrogen additions on the stability and turnover of soil carbon	NATURE			English	Article							LEAF-LITTER DECOMPOSITION; FOREST ECOSYSTEMS; TEMPERATE FOREST; STORAGE; AVAILABILITY; DEPOSITION; DYNAMICS; LIGNIN; CYCLE	Soils contain the largest near-surface reservoir of terrestrial carbon(1) and so knowledge of the factors controlling soil carbon storage and turnover is essential for understanding the changing global carbon cycle. The influence of climate on decomposition of soil carbon has been well documented(2,3), but there remains considerable uncertainty in the potential response of soil carbon dynamics to the rapid global increase in reactive nitrogen (coming largely from agricultural fertilizers and fossil fuel combustion). Here, using C-14, C-13 and compound-specific analyses of soil carbon from long-term nitrogen fertilization plots, we show that nitrogen additions significantly accelerate decomposition of light soil carbon fractions (with decadal turnover times) while further stabilizing soil carbon compounds in heavier, mineral-associated fractions (with multidecadal to century lifetimes). Despite these changes in the dynamics of different soil pools, we observed no significant changes in bulk soil carbon, highlighting a limitation inherent to the still widely used single-pool approach to investigating soil carbon responses to changing environmental conditions. It remains to be seen if the effects observed here-caused by relatively high, short-term fertilizer additions-are similar to those arising from lower, long-term additions of nitrogen to natural ecosystems from atmospheric deposition, but our results suggest nonetheless that current models of terrestrial carbon cycling do not contain the mechanisms needed to capture the complex relationship between nitrogen availability and soil carbon storage.	US Geol Survey, Denver Fed Ctr, Geol Div, Earth Surface Proc Team, Denver, CO 80225 USA; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Max Planck Inst Biogeochem, Jena, Germany	United States Department of the Interior; United States Geological Survey; University of Colorado System; University of Colorado Boulder; Max Planck Society	Neff, JC (corresponding author), US Geol Survey, Denver Fed Ctr, Geol Div, Earth Surface Proc Team, MS 980, Denver, CO 80225 USA.		Turnbull, Jocelyn C/E-1426-2016; Neff, Jason/A-1211-2012; Gleixner, Gerd/O-4215-2019; Townsend, Alan/AAE-9602-2019; Gleixner, Gerd/M-8519-2017	Turnbull, Jocelyn C/0000-0002-0306-9658; Gleixner, Gerd/0000-0002-4616-0953; Gleixner, Gerd/0000-0002-4616-0953; NEFF, JASON/0000-0002-8290-1472				Aber J, 1998, BIOSCIENCE, V48, P921, DOI 10.2307/1313296; Berg Bjorn, 1997, Environmental Reviews, V5, P1, DOI 10.1139/er-5-1-1; BOWMAN WD, 1993, ECOLOGY, V74, P2085, DOI 10.2307/1940854; Burns SF, 1980, ALPINE SOIL DISTRIBU; Epstein HE, 2002, ECOLOGY, V83, P320, DOI 10.1890/0012-9658(2002)083[0320:RPODAP]2.0.CO;2; Gaudinski JB, 2000, BIOGEOCHEMISTRY, V51, P33, DOI 10.1023/A:1006301010014; Gleixner G, 2002, ORG GEOCHEM, V33, P357, DOI 10.1016/S0146-6380(01)00166-8; Hobbie SE, 2000, ECOSYSTEMS, V3, P484, DOI 10.1007/s100210000042; Kuder T, 1998, ORG GEOCHEM, V29, P1355, DOI 10.1016/S0146-6380(98)00092-8; LEVIN I, 1997, TRENDS COMPENDIUM DA; Magill AH, 1997, ECOL APPL, V7, P402, DOI 10.1890/1051-0761(1997)007[0402:BROFET]2.0.CO;2; MELILLO JM, 1982, ECOLOGY, V63, P621, DOI 10.2307/1936780; Nierop KGJ, 2001, SOIL BIOL BIOCHEM, V33, P755, DOI 10.1016/S0038-0717(00)00223-6; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; Resh SC, 2002, ECOSYSTEMS, V5, P217, DOI 10.1007/s10021-001-0067-3; SCHIMEL DS, 1994, GLOBAL BIOGEOCHEM CY, V8, P279, DOI 10.1029/94GB00993; Schlesinger WH, 2001, NATURE, V411, P466, DOI 10.1038/35078060; Schmidt H, 1998, STABLE ISOTOPES INTE, P13; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; Townsend AR, 1996, ECOL APPL, V6, P806, DOI 10.2307/2269486; Trumbore SE, 1996, SCIENCE, V272, P393, DOI 10.1126/science.272.5260.393; TRUMBORE SE, 1993, GLOBAL BIOGEOCHEM CY, V7, P275, DOI 10.1029/93GB00468; VITOUSEK P, 1982, AM NAT, V119, P553, DOI 10.1086/283931; Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431; Williams MW, 2001, WATER RESOUR RES, V37, P2569, DOI 10.1029/2001WR000485	25	559	691	48	529	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					915	917		10.1038/nature01136	http://dx.doi.org/10.1038/nature01136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410307				2022-12-28	WOS:000178909700040
J	Wang, YM; Chen, MW; Zhou, FH; Ma, E				Wang, YM; Chen, MW; Zhou, FH; Ma, E			High tensile ductility in a nanostructured metal	NATURE			English	Article							LOW-TEMPERATURE SUPERPLASTICITY; DEFORMATION-BEHAVIOR; NANOCRYSTALLINE COPPER; STRAIN; EVOLUTION; STRENGTH	Nanocrystalline metals-with grain sizes of less than 100 nm-have strengths exceeding those of coarse-grained and even alloyed metals(1,2), and are thus expected to have many applications. For example, pure nanocrystalline Cu (refs 1-7) has a yield strength in excess of 400 MPa, which is six times higher than that of coarse-grained Cu. But nanocrystalline materials often exhibit low tensile ductility at room temperature, which limits their practical utility. The elongation to failure is typically less than a few per cent; the regime of uniform deformation is even smaller(1-7). Here we describe a thermomechanical treatment of Cu that results in a bimodal grain size distribution, with micrometre-sized grains embedded inside a matrix of nanocrystalline and ultrafine (<300 nm) grains. The matrix grains impart high strength, as expected from an extrapolation of the Hall-Petch relationship. Meanwhile, the inhomogeneous microstructure induces strain hardening mechanisms(8-11) that stabilize the tensile deformation, leading to a high tensile ductility-65% elongation to failure, and 30% uniform elongation. We expect that these results will have implications in the development of tough nanostructured metals for forming operations and high-performance structural applications including microelectromechanical and biomedical systems.	Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Ma, E (corresponding author), Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA.	ema@jhu.edu	CHEN, Mingwei/A-4855-2010; Ma, En/A-3232-2010; Chen, Ming/GVU-8412-2022; Wang, Yinmin (Morris)/F-2249-2010; Chen, Mingwei/A-4855-2010	CHEN, Mingwei/0000-0002-8274-3099; Wang, Yinmin (Morris)/0000-0002-7161-2034; Wang, Yinmin (MORRIS)/0000-0003-0393-5154; Chen, Mingwei/0000-0002-2850-8872				ANDRADE U, 1994, ACTA METALL MATER, V42, P3183, DOI 10.1016/0956-7151(94)90417-0; Asgari S, 1997, METALL MATER TRANS A, V28, P1781, DOI 10.1007/s11661-997-0109-3; BLEWITT TH, 1957, J APPL PHYS, V28, P651, DOI 10.1063/1.1722824; CALLISTER WD, 1994, MATER SCI ENG, P167; Dieter G.E., 1986, MECH METALLURGY, pP290; Gao H, 1999, J MECH PHYS SOLIDS, V47, P1239, DOI 10.1016/S0022-5096(98)00103-3; Gertsman VY, 1996, MATER SCI FORUM, V225, P739, DOI 10.4028/www.scientific.net/MSF.225-227.739; HART EW, 1967, ACTA METALL MATER, V15, P351, DOI 10.1016/0001-6160(67)90211-8; HERTZBERG RW, 1989, DEFORMATION FRACTURE, P392; Hibbard GD, 2002, SCRIPTA MATER, V47, P83, DOI 10.1016/S1359-6462(02)00098-2; Huang JY, 1996, ACTA MATER, V44, P1211, DOI 10.1016/1359-6454(95)00231-6; Hughes DA, 1997, ACTA MATER, V45, P3871, DOI 10.1016/S1359-6454(97)00027-X; HUMPHREYS FJ, 1995, RECRYSTALLIZATION RE, P314; Jia D, 2001, APPL PHYS LETT, V79, P611, DOI 10.1063/1.1384000; Koch CC, 1999, MRS BULL, V24, P54, DOI 10.1557/S0883769400051551; Legros M, 2000, PHILOS MAG A, V80, P1017, DOI 10.1080/01418610008212096; Lu L, 2000, J MATER RES, V15, P270, DOI 10.1557/JMR.2000.0043; Lu L, 2000, SCIENCE, V287, P1463, DOI 10.1126/science.287.5457.1463; McFadden SX, 1999, NATURE, V398, P684, DOI 10.1038/19486; McFadden SX, 2000, MATER LETT, V45, P345, DOI 10.1016/S0167-577X(00)00131-2; Sanders PG, 1997, MAT SCI ENG A-STRUCT, V234, P77, DOI 10.1016/S0921-5093(97)00185-8; Sanders PG, 1997, ACTA MATER, V45, P4019, DOI 10.1016/S1359-6454(97)00092-X; Valiev RZ, 2002, J MATER RES, V17, P5, DOI 10.1557/JMR.2002.0002; Valiev RZ, 2000, PROG MATER SCI, V45, P103, DOI 10.1016/S0079-6425(99)00007-9; Wang YM, 2002, APPL PHYS LETT, V80, P2395, DOI 10.1063/1.1465528; WANG YM, IN PRESS MAT SCI E A; Weertman JR, 1999, MRS BULL, V24, P44, DOI 10.1557/S088376940005154X; Wei Q, 2002, APPL PHYS LETT, V81, P1240, DOI 10.1063/1.1501158; Youngdahl CJ, 2001, SCRIPTA MATER, V44, P1475, DOI 10.1016/S1359-6462(01)00712-6	29	2348	2452	48	1043	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					912	915		10.1038/nature01133	http://dx.doi.org/10.1038/nature01133			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410306				2022-12-28	WOS:000178909700039
J	Hannah, ME				Hannah, ME			Series of errors	LANCET			English	Editorial Material									Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M5G 1N8, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Hannah, ME (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M5G 1N8, Canada.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1322	1322		10.1016/S0140-6736(02)11313-4	http://dx.doi.org/10.1016/S0140-6736(02)11313-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414224				2022-12-28	WOS:000178827200030
J	Brundtland, GH				Brundtland, GH			Reducing risks to health, promoting healthy life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									WHO, CH-1211 Geneva, Switzerland	World Health Organization	Brundtland, GH (corresponding author), WHO, CH-1211 Geneva, Switzerland.								0	83	89	5	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	2002	288	16					1974	1974		10.1001/jama.288.16.1974	http://dx.doi.org/10.1001/jama.288.16.1974			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	606QW	12387638				2022-12-28	WOS:000178745500005
J	Antman, E; Cooper, H; Domanski, M; Feinstein, S; Gersh, B; Gibler, WB; Haigney, M; Hochman, J; McKinlay, S; Norman, J; Opie, L; Rogers, W; Rosenberg, Y; Woods, K; Mills, P; Rosenberg, Y; Assmann, S; Woods, K; Nannicelli, J; Scott, J; Oakleaf, K; Singh, S; Davis, B; Hallstrom, A; Levine, R; Robertson, R; Norman, J; Gretton, V; Scott, K; Dolan, S; Brown, M; Ewart, A; Hendriks, R; Jeffrey, I; Newman, R; Quinn, W; Rankin, J; Russell, A; Singh, B; Waites, J; Ziffer, R; Smetana, R; Col, J; Bruno, P; Evrard, P; Massart, PE; Vrabevski, M; Andreev, N; Benov, H; Boichev, B; Daskalov, T; Dzhurdzhev, A; Elenkova, A; Gateva, S; Genov, S; Georgiev, S; Hergeldzhieva, V; Kaloyanova, A; Karaassenoy, M; Kozhuharov, C; Krastev, A; Lovdzhicva, S; Margaritov, V; Mateeva, D; Mihov, A; Milanov, S; Nachev, C; Naidenova, L; Ninova, M; Penkoy, N; Perchev, I; Popov, A; Raev, D; Staykov, I; Tanev, T; Taneva, I; Toneva, L; Todorov, T; Vassileva, T; Lazarenko, G; Lubelsky, B; Senaratne, MPJ; Garber, P; Ringuette, G; Auersberg, E; Noseworthy, R; Corbalan, R; Betancourt, R; Potthoff, S; Kobulia, B; Tsintsadze, G; Khabeishvilli, G; Paposhvili, K; Chapidze, G; Khintibidze, I; Melia, A; Mamatsashvilli, M; Keltai, M; Toth, K; Janosi, A; Papp, A; Tarjan, J; Konya, L; Katona, A; Zoltan, L; Poor, F; Varadi, A; Soltesz, P; Mohacsi, A; Lupkovics, G; Bartal, G; Szaboki, F; Tahy, A; Fenyvesi, T; Shechter, M; Hod, H; Lotan, C; Weiss, AT; van der Heijden, MY; van Hessen, MWJ; van de Moer, WMM; van der Heijden, R; Jochemsen, GM; White, H; Rankin, R; Hedley, JM; Hamer, A; Abdul-Gaffar, N; Hills, M; Sebastian, C; Varshavsky, S; Zavolozin, S; Kosouhov, A; Timofeev, A; Kalinina, S; Gordienko, T; Ermoshkina, L; Tarasov, N; Sitnikova, V; Shulman, V; Nechepurenko, G; Sumin, A; Vertkin, A; Lyusoy, V; Emelyanov, I; Baranov, E; Strekalovsky, A; Fotianov, S; Goryachkin, I; Barbarich, V; Rifel, A; Belenky, D; Lapin, O; Pavlov, A; Yakovlev, O; Kharkov, A; Petrov, D; Bzhelyanskaya, V; Repin, M; Stefanenko, M; Vishnevsky, A; Klenina, I; Khankoeva, A; Yakusheva, S; Shlyakhto, E; Goloshchekin, B; Sorokin, L; Vorochnina, S; Zverev, D; Deryugin, M; Belekhov, G; Shwarts, Y; Orlikova, O; Novoghenina, A; Maximov, I; Stefanenko, M; Shalaev, S; Pomogalova, O; Yakusevish, V; Hrustalev, O; Sergeeva, M; Boyarkin, M; Mogilevsky, A; Grinshtein, Y; Mogilevsky, A; Moiseev, V; Saiganov, S; Striouck, R; Kots, Y; Antonova, T; Demko, A; Susharin, L; Ishmurzin, G; Khramov, V; Miller, MS; Battle, RW; Akosah, K; Grossman, D; Lader, E; Pollack, ML; Mezei, LE; Hull, W; Jenny, D; Ghahramani, AR; Linz, PE; Kutscher, AH; Cannon, JD; Keedy, D; O'Gara, PT; Scaggs, TR; Basu, D; Kmetzo, JJ; Rubin, A; Rubinstein, R; Rivera, E; Schachter, DT; DiBlasi, SL; Meyers, D; Heltne, CE; Hanovich, G; Arouni, A; Slater, J; Malik, S; Harchelroad, F; Genovely, HC; Alpert, M; Reese, S; Holland, S; McClure, JM; Priest, M; Dixon, D; Herzog, W; Ford, JK; Rave, M; Mahrer, P; Eisenberg, S; Ringham, J; Mattern, A; Hall, DM; Ramalanjaona, G; Walter, G; Bhalla, R; Hosny, A; Baber, Z; Wadhwani, J; Mikhail, M; Paul, TO; Lopez, F; Watkins, JW; Soloff, L; Tri, TB; Aliabadi, DG; Tice, P; Denny, DM; Bertolet, BD; Oschwald, CJ; Silverman, R; Varriale, P; Wilson, J; Ramamurti, S; Jenny, D; Pappas, JD; Beattie, JR; Rosenblatt, A; Courtade, D; Pond, MS; Fritz, RM; Siegel, RM; Tran, TP; Wright, RS; Hodsden, JE; Teichholz, L; Cox, JM; Munyak, J; Kippperman, RM; Vergne, R; Ghali, JK; Hudson, J; Rabbani, LE; Greenberg, R; McKendall, G; Mohan, K; Forker, AD; Hanley, HG; Brodsky, MA; Kluger, J; Blanda, M; Longo, J; Samadi, RR; Ziady, G; Young, SP; Liu, CY; Shapiro, M; Mamuya, W; Bowling, LS; Carrillo, E; Morr, I; Briceno, E				Antman, E; Cooper, H; Domanski, M; Feinstein, S; Gersh, B; Gibler, WB; Haigney, M; Hochman, J; McKinlay, S; Norman, J; Opie, L; Rogers, W; Rosenberg, Y; Woods, K; Mills, P; Rosenberg, Y; Assmann, S; Woods, K; Nannicelli, J; Scott, J; Oakleaf, K; Singh, S; Davis, B; Hallstrom, A; Levine, R; Robertson, R; Norman, J; Gretton, V; Scott, K; Dolan, S; Brown, M; Ewart, A; Hendriks, R; Jeffrey, I; Newman, R; Quinn, W; Rankin, J; Russell, A; Singh, B; Waites, J; Ziffer, R; Smetana, R; Col, J; Bruno, P; Evrard, P; Massart, PE; Vrabevski, M; Andreev, N; Benov, H; Boichev, B; Daskalov, T; Dzhurdzhev, A; Elenkova, A; Gateva, S; Genov, S; Georgiev, S; Hergeldzhieva, V; Kaloyanova, A; Karaassenoy, M; Kozhuharov, C; Krastev, A; Lovdzhicva, S; Margaritov, V; Mateeva, D; Mihov, A; Milanov, S; Nachev, C; Naidenova, L; Ninova, M; Penkoy, N; Perchev, I; Popov, A; Raev, D; Staykov, I; Tanev, T; Taneva, I; Toneva, L; Todorov, T; Vassileva, T; Lazarenko, G; Lubelsky, B; Senaratne, MPJ; Garber, P; Ringuette, G; Auersberg, E; Noseworthy, R; Corbalan, R; Betancourt, R; Potthoff, S; Kobulia, B; Tsintsadze, G; Khabeishvilli, G; Paposhvili, K; Chapidze, G; Khintibidze, I; Melia, A; Mamatsashvilli, M; Keltai, M; Toth, K; Janosi, A; Papp, A; Tarjan, J; Konya, L; Katona, A; Zoltan, L; Poor, F; Varadi, A; Soltesz, P; Mohacsi, A; Lupkovics, G; Bartal, G; Szaboki, F; Tahy, A; Fenyvesi, T; Shechter, M; Hod, H; Lotan, C; Weiss, AT; van der Heijden, MY; van Hessen, MWJ; van de Moer, WMM; van der Heijden, R; Jochemsen, GM; White, H; Rankin, R; Hedley, JM; Hamer, A; Abdul-Gaffar, N; Hills, M; Sebastian, C; Varshavsky, S; Zavolozin, S; Kosouhov, A; Timofeev, A; Kalinina, S; Gordienko, T; Ermoshkina, L; Tarasov, N; Sitnikova, V; Shulman, V; Nechepurenko, G; Sumin, A; Vertkin, A; Lyusoy, V; Emelyanov, I; Baranov, E; Strekalovsky, A; Fotianov, S; Goryachkin, I; Barbarich, V; Rifel, A; Belenky, D; Lapin, O; Pavlov, A; Yakovlev, O; Kharkov, A; Petrov, D; Bzhelyanskaya, V; Repin, M; Stefanenko, M; Vishnevsky, A; Klenina, I; Khankoeva, A; Yakusheva, S; Shlyakhto, E; Goloshchekin, B; Sorokin, L; Vorochnina, S; Zverev, D; Deryugin, M; Belekhov, G; Shwarts, Y; Orlikova, O; Novoghenina, A; Maximov, I; Stefanenko, M; Shalaev, S; Pomogalova, O; Yakusevish, V; Hrustalev, O; Sergeeva, M; Boyarkin, M; Mogilevsky, A; Grinshtein, Y; Mogilevsky, A; Moiseev, V; Saiganov, S; Striouck, R; Kots, Y; Antonova, T; Demko, A; Susharin, L; Ishmurzin, G; Khramov, V; Miller, MS; Battle, RW; Akosah, K; Grossman, D; Lader, E; Pollack, ML; Mezei, LE; Hull, W; Jenny, D; Ghahramani, AR; Linz, PE; Kutscher, AH; Cannon, JD; Keedy, D; O'Gara, PT; Scaggs, TR; Basu, D; Kmetzo, JJ; Rubin, A; Rubinstein, R; Rivera, E; Schachter, DT; DiBlasi, SL; Meyers, D; Heltne, CE; Hanovich, G; Arouni, A; Slater, J; Malik, S; Harchelroad, F; Genovely, HC; Alpert, M; Reese, S; Holland, S; McClure, JM; Priest, M; Dixon, D; Herzog, W; Ford, JK; Rave, M; Mahrer, P; Eisenberg, S; Ringham, J; Mattern, A; Hall, DM; Ramalanjaona, G; Walter, G; Bhalla, R; Hosny, A; Baber, Z; Wadhwani, J; Mikhail, M; Paul, TO; Lopez, F; Watkins, JW; Soloff, L; Tri, TB; Aliabadi, DG; Tice, P; Denny, DM; Bertolet, BD; Oschwald, CJ; Silverman, R; Varriale, P; Wilson, J; Ramamurti, S; Jenny, D; Pappas, JD; Beattie, JR; Rosenblatt, A; Courtade, D; Pond, MS; Fritz, RM; Siegel, RM; Tran, TP; Wright, RS; Hodsden, JE; Teichholz, L; Cox, JM; Munyak, J; Kippperman, RM; Vergne, R; Ghali, JK; Hudson, J; Rabbani, LE; Greenberg, R; McKendall, G; Mohan, K; Forker, AD; Hanley, HG; Brodsky, MA; Kluger, J; Blanda, M; Longo, J; Samadi, RR; Ziady, G; Young, SP; Liu, CY; Shapiro, M; Mamuya, W; Bowling, LS; Carrillo, E; Morr, I; Briceno, E		MAGIC Trial Investigators	Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial	LANCET			English	Article							NATIONAL REGISTRY; ARRHYTHMIAS; SULFATE; INFUSION; DESIGN; SCORE; SIZE; MI	Background The benefits of supplemental administration of intravenous magnesium in patients with ST-elevation myocardial infarction (STEMI) are controversial. Despite promising results from work in animals and the ready availability of this simple, inexpensive treatment, conflicting results have been reported in clinical trials. Our aim was to compare short-term mortality in patients with STEMI who received either intravenous magnesium sulphate or placebo. Methods We did a randomised, double-blind trial in 6213 patients with acute STEMI who were assigned a 2 g intravenous bolus of magnesium sulphate administered over 15 min, followed by a 17 g infusion of magnesium sulphate over 24 h (n=3113), or matching placebo (n=3100). Our primary endpoint was 30-day all-cause mortality. At randomisation, patients were stratified by their eligibility for reperfusion therapy. The first stratum included patients who were aged 65 years or older and eligible for reperfusion therapy, and the second stratum included patients of any age who were not eligible for reperfusion therapy. Analysis was by intention-to-treat. Findings At 30 days, 475 (15.3%) patients in the magnesium group and 472 (15.2%) in the placebo group had died (odds ratio 1.0, 95% CI 0.9-1.2, p=0.96). No benefit or harm of magnesium was observed in eight prespecified subgroup analyses of patients and in 15 additional exploratory subgroup analyses. After adjustment for factors shown to effect mortality risk in a multivariate regression model, no benefit of magnesium was observed (1.0, 0.8-1.1, p=0.53). Interpretation Early administration of magnesium in high-risk patients with STEMI has no effect on 30-day mortality. In view of the totality of the available evidence, in current coronary care practice there is no indication for the routine administration of intravenous magnesium in patients with STEMI.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; NHLBI, Bethesda, MD 20892 USA	Harvard University; Brigham & Women's Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Antman, E (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	eantman@rics.bwh.harvard.edu	Maximov, Ivan V/A-5552-2014; Camargo, Carlos A./C-2145-2008; Taneva, Ivanka/GXG-3789-2022; Ishmurzin, Gennady/W-7549-2019; Sumin, Alexey N/P-8897-2016; Grinshtein, Yury/M-4091-2014	Maximov, Ivan V/0000-0003-0367-1654; Camargo, Carlos A./0000-0002-5071-7654; Ishmurzin, Gennady/0000-0002-0962-5790; Grinshtein, Yury/0000-0001-8847-235X	PHS HHS [N01-8C-85155] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAM AS, 1987, ARCH INTERN MED, V147, P753, DOI 10.1001/archinte.147.4.753; Antman E, 2000, AM HEART J, V139, P10; ANTMAN EM, 1995, CIRCULATION, V92, P2367, DOI 10.1161/01.CIR.92.9.2367; Antman EM, 1996, AM HEART J, V132, P487, DOI 10.1016/S0002-8703(96)90341-5; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Baxter GF, 1996, LANCET, V348, P1424, DOI 10.1016/S0140-6736(96)07281-9; CEREMUZYNSKI L, 1989, AM HEART J, V118, P1333, DOI 10.1016/0002-8703(89)90027-6; CHANG C, 1985, J AM COLL CARDIOL, V5, P280, DOI 10.1016/S0735-1097(85)80048-6; COLLINS R, 1995, LANCET, V345, P669; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; FELDSTEDT M, 1991, EUR HEART J, V12, P1215, DOI 10.1093/eurheartj/12.11.1215; Gyamlani G, 2000, Am Heart J, V139, P703, DOI 10.1016/S0002-8703(00)90051-6; Kizer JR, 1999, AM HEART J, V137, P79, DOI 10.1016/S0002-8703(99)70462-X; KRAIKITPANITCH S, 1976, AM HEART J, V92, P615, DOI 10.1016/S0002-8703(76)80081-6; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LANDMARK K, 1993, ANGIOLOGY, V44, P347, DOI 10.1177/000331979304400502; Morrow DA, 2000, CIRCULATION, V102, P2031, DOI 10.1161/01.CIR.102.17.2031; Morrow DA, 2001, JAMA-J AM MED ASSOC, V286, P1356, DOI 10.1001/jama.286.11.1356; Morton B C, 1984, Magnesium, V3, P346; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Raghu C, 1999, INT J CARDIOL, V71, P209, DOI 10.1016/S0167-5273(99)00125-4; RASMUSSEN HS, 1986, LANCET, V1, P234; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; SEELIG M, 1989, AM J CARDIOL, V63, pG4, DOI 10.1016/0002-9149(89)90213-0; SHECHTER M, 1995, AM J CARDIOL, V75, P321, DOI 10.1016/S0002-9149(99)80546-3; SHECHTER M, 1990, AM J CARDIOL, V66, P271, DOI 10.1016/0002-9149(90)90834-N; SMITH LF, 1986, INT J CARDIOL, V12, P175, DOI 10.1016/0167-5273(86)90239-1; STEVENSON RN, 1991, BRIT HEART J, V66, P19; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; THOGERSEN AM, 1993, INT J CARDIOL, V39, P13, DOI 10.1016/0167-5273(93)90292-O; Topol EJ, 2001, LANCET, V357, P1905; Van de Werf F, 2001, LANCET, V358, P605; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; Woods KL, 2002, PROG CARDIOVASC DIS, V44, P267, DOI 10.1053/pcad.2002.31595; WOODS KL, 1991, BRIT J CLIN PHARMACO, V32, P3, DOI 10.1111/j.1365-2125.1991.tb05605.x	35	148	151	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	2002	360	9341					1189	1196		10.1016/S0140-6736(02)11278-5	http://dx.doi.org/10.1016/S0140-6736(02)11278-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401244				2022-12-28	WOS:000178708100007
J	Caffrey, SL; Willoughby, PJ; Pepe, PE; Becker, LB				Caffrey, SL; Willoughby, PJ; Pepe, PE; Becker, LB			Public use of automated external defibrillators	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; ACCESS DEFIBRILLATION; VENTRICULAR-FIBRILLATION; UNITED-STATES; SURVIVAL; OUTCOMES; DEATH; AIRLINE	Background: Automated external defibrillators save lives when they are used by designated personnel in certain public settings. We performed a two-year prospective study at three Chicago airports to assess whether random bystanders witnessing out-of-hospital cardiac arrests would retrieve and successfully use automated external defibrillators. Methods: Defibrillators were installed a brisk 60-to-90-second walk apart throughout passenger terminals at O'Hare, Midway, and Meigs Field airports, which together serve more than 100 million passengers per year. The use of defibrillators was promoted by public-service videos in waiting areas, pamphlets, and reports in the media. We assessed the time from notification of the dispatchers to defibrillation, survival rate at 72 hours and at one year among persons with cardiac arrest, their neurologic status, and the characteristics of rescuers. Results: Over a two-year period, 21 persons had nontraumatic cardiac arrest, 18 of whom had ventricular fibrillation. With two exceptions, defibrillator operators were good Samaritans, acting voluntarily. In the case of four patients with ventricular fibrillation, defibrillators were neither nearby nor used within five minutes, and none of these patients survived. Three others remained in fibrillation and eventually died, despite the rapid use of a defibrillator (within five minutes). Eleven patients with ventricular fibrillation were successfully resuscitated, including eight who regained consciousness before hospital admission. No shock was delivered in four cases of suspected cardiac arrest, and the device correctly indicated that the problem was not due to ventricular fibrillation. The rescuers of 6 of the 11 successfully resuscitated patients had no training or experience in the use of automated defibrillators, although 3 had medical degrees. Ten of the 18 patients with ventricular fibrillation were alive and neurologically intact at one year. Conclusions: Automated external defibrillators deployed in readily accessible, well-marked public areas in Chicago airports were used effectively to assist patients with cardiac arrest. In the cases of survivors, most of the users had no duty to act and no prior training in the use of these devices.	City Chicago Dept Aviat, Chicago, IL USA; Chicago Fire Dept, Chicago, IL USA; Univ Texas, SW Med Ctr, Sch Publ Hlth, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA; Univ Chicago, Div Emergency Med, Chicago, IL 60637 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Chicago	Caffrey, SL (corresponding author), OHare Int Airport, Dept Aviat, POB 66142, Chicago, IL 60666 USA.	sherord@aol.com						*AM HEART ASS, 2002, 2002 HEART STROK STA; Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; Becker L, 1996, CARDIAC ARREST SCI P, P28; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BECKER LB, 1993, ANN EMERG MED, V22, P354, DOI 10.1016/S0196-0644(05)80465-2; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P123; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; Cummins RO, 1997, ACAD EMERG MED, V4, P603; Domanovits H, 1998, RESUSCITATION, V39, P47, DOI 10.1016/S0300-9572(98)00114-2; Eisenberg MS, 2000, JAMA-J AM MED ASSOC, V284, P1435, DOI 10.1001/jama.284.11.1435; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; GREENE HL, 1990, AM J CARDIOL, V65, pB4; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; Hallstrom AP, 1996, CIRCULATION, V93, P2019, DOI 10.1161/01.CIR.93.11.2019; Hossack KF, 1982, J CARDIAC REHABIL, V2, P402; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; KERBER RE, 1981, CIRCULATION, V63, P676, DOI 10.1161/01.CIR.63.3.676; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; MacDonald Russell D, 2002, Prehosp Emerg Care, V6, P1; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Safar P, 1983, Am J Emerg Med, V1, P198, DOI 10.1016/0735-6757(83)90089-X; SoRelle R, 1999, CIRCULATION, V99, P2606, DOI 10.1161/01.CIR.99.20.2606; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Wassertheil J, 2000, RESUSCITATION, V44, P97, DOI 10.1016/S0300-9572(99)00168-9; White RD, 1998, RESUSCITATION, V39, P145, DOI 10.1016/S0300-9572(98)00135-X; White RD, 2001, RESUSCITATION, V49, P9, DOI 10.1016/S0300-9572(00)00338-5; Zheng ZJ, 2001, CIRCULATION, V104, P2158, DOI 10.1161/hc4301.098254; 2000, CIRCULATION S1, V102, P60	36	551	566	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1242	1247		10.1056/NEJMoa020932	http://dx.doi.org/10.1056/NEJMoa020932			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393821				2022-12-28	WOS:000178598300005
J	Putsep, K; Carlsson, G; Boman, HG; Andersson, M				Putsep, K; Carlsson, G; Boman, HG; Andersson, M			Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study	LANCET			English	Article							INFANTILE GENETIC AGRANULOCYTOSIS; ANTIMICROBIAL PEPTIDES; HUMAN NEUTROPHILS; LL-37; CATHELICIDIN; EXPRESSION; DEFENSINS; HCAP-18; FAMILY; ELISA	Background Antibacterial peptices, such as defensins and LL-37, are natural bactericidal components similar in potency to classic antibiotics. These peptices are produced at mucosal linings in the body and the skin, and by leucocytes such as neutrophils and natural killer cells. Patients with morbus Kostmann-a severe congenital neutropenia-are treated by recombinant granulocyte-colony stimulating factor, which restores their levels of neutrophils. Despite this treatment, patients still have recurrent infections and periodontal disease. Our aim was to investigate if defensins and LL-37 are deficient in patients with morbus Kostmann. Methods We studied samples of neutrophils, plasma, and saliva from six patients with congenital neutropenia and 22 healthy controls for presence of antibacterial peptides. Neutrophils were analysed by high-performance liquid chromatography and mass spectrometry for alpha-defensins. All samples were analysed by western blot for cathelin-LL-37 (precursor of LL-37) and LL-37. Neutrophils were also tested for lactoferrin and ability to produce oxidative burst. Findings Neutrophils from patients with morbus Kostmann were deficient in cathelin-LL-37 and had reduced concentrations of alpha-defensins HNP1-3. No cathelin-LL-37 could be detected in plasma and saliva from patients. One patient with morbus Kostmann who had had bone-marrow transplantation had almost normal concentrations of LL-37. Lactoferrin concentrations and oxidative burst were normal in all patients. All patients with morbus Kostmann had severe periodontal disease, apart from the individual who had had a bone-marrow transplant, whose dental status was normal. Interpretation Antibacterial peptides are a vital part of the first line of antibacterial immune defence. Deficiency in saliva LL-37 accords with occurrence of periodontal disease in patients with morbus Kostmann.	Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden; Sunderby Hosp, Lulea, Sweden	Karolinska Institutet; Sunderby Hospital	Andersson, M (corresponding author), Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden.	mats.andersson@mtc.ki.se	Andersson, Mats L/M-9124-2014; Andersson, Mats/A-2903-2008	Andersson, Mats L/0000-0001-7582-8791; 				Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Aprikyan AAG, 2001, CURR OPIN IMMUNOL, V13, P535, DOI 10.1016/S0952-7915(00)00254-5; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Borregaard N, 1997, ANN NY ACAD SCI, V832, P62, DOI 10.1111/j.1749-6632.1997.tb46237.x; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Carlsson G, 2001, ACTA PAEDIATR, V90, P757, DOI 10.1080/080352501750315663; Dale BA, 2001, J PERIODONTAL RES, V36, P285, DOI 10.1034/j.1600-0765.2001.360503.x; Defraia E, 2001, J Clin Pediatr Dent, V26, P99; Ellwood R, 1997, J CLIN PERIODONTOL, V24, P141, DOI 10.1111/j.1600-051X.1997.tb00482.x; Figueredo CMS, 2000, J CLIN PERIODONTOL, V27, P313, DOI 10.1034/j.1600-051x.2000.027005313.x; GANZ T, 1988, J CLIN INVEST, V82, P552, DOI 10.1172/JCI113631; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; GUDMUNDSSON GH, 1995, P NATL ACAD SCI USA, V92, P7085, DOI 10.1073/pnas.92.15.7085; Huttner KM, 1999, PEDIATR RES, V45, P785, DOI 10.1203/00006450-199906000-00001; KOSTMANN R, 1975, ACTA PAEDIATR SCAND, V64, P362, DOI 10.1111/j.1651-2227.1975.tb03847.x; KOSTMANN R, 1956, Acta Paediatr Suppl, V45, P1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LOLLIKE K, 1995, LEUKEMIA, V9, P159; Nagaoka I, 1998, J LEUKOCYTE BIOL, V64, P845, DOI 10.1002/jlb.64.6.845; Nagaoka I, 2000, INFLAMM RES, V49, P73, DOI 10.1007/s000110050561; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Raj PA, 2000, BIOCHEM J, V347, P633, DOI 10.1042/0264-6021:3470633; ROESLER J, 1991, EUR J HAEMATOL, V46, P112; Slots J, 2000, PERIODONTOL 2000, V22, P7; Sorensen O, 1997, J IMMUNOL METHODS, V206, P53, DOI 10.1016/S0022-1759(97)00084-7; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; Tanaka D, 2000, ORAL MICROBIOL IMMUN, V15, P226, DOI 10.1034/j.1399-302x.2000.150403.x; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	28	395	417	3	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	2002	360	9340					1144	1149		10.1016/S0140-6736(02)11201-3	http://dx.doi.org/10.1016/S0140-6736(02)11201-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387964				2022-12-28	WOS:000178632000016
J	Lloret, P; Redondo, P; Molano, E				Lloret, P; Redondo, P; Molano, E			Klebsiella pneumoniae and leukocytoclastic vasculitis	LANCET			English	Editorial Material									Univ Navarra Clin, Dept Dermatol, Pamplona, Spain; Univ Navarra Clin, Dept Internal Med, Pamplona, Spain	University of Navarra; University of Navarra	Lloret, P (corresponding author), Univ Navarra Clin, Dept Dermatol, Pamplona, Spain.		REDONDO, PEDRO/H-7989-2017	REDONDO, PEDRO/0000-0001-7899-2511					0	6	6	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1062	1062		10.1016/S0140-6736(02)11143-3	http://dx.doi.org/10.1016/S0140-6736(02)11143-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383983	Bronze			2022-12-28	WOS:000178485200012
J	De Jonghe, B; Janier, V; Abderrahim, N; Hillion, D; Lacherade, JC; Outin, H				De Jonghe, B; Janier, V; Abderrahim, N; Hillion, D; Lacherade, JC; Outin, H			Urinary tract infection and coma	LANCET			English	Editorial Material							HYPERAMMONEMIC ENCEPHALOPATHY; DIVERSION		Ctr Hosp Poissy St Germain, Serv Reanimat Med, F-78300 Poissy, France; Ctr Hosp Poissy St Germain, Biochim Lab, F-78300 Poissy, France; Ctr Hosp Poissy St Germain, Serv Med Interne Nephrol, F-78300 Poissy, France	Hospital Chi of Poissy Saint Germain; Hospital Chi of Poissy Saint Germain; Hospital Chi of Poissy Saint Germain	De Jonghe, B (corresponding author), Ctr Hosp Poissy St Germain, Serv Reanimat Med, F-78300 Poissy, France.							DRAYNA CJ, 1981, NEW ENGL J MED, V304, P766, DOI 10.1056/NEJM198103263041307; KAVEGGIA FF, 1990, ARCH INTERN MED, V150, P2389, DOI 10.1001/archinte.150.11.2389; OLIVER RM, 1989, POSTGRAD MED J, V65, P502, DOI 10.1136/pgmj.65.765.502; SAMTOY B, 1980, PEDIATRICS, V65, P294, DOI 10.1542/peds.65.2.294; Young GB., 1998, METABOLIC ENCEPHALOP, P307	5	23	25	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 28	2002	360	9338					996	996		10.1016/S0140-6736(02)11084-1	http://dx.doi.org/10.1016/S0140-6736(02)11084-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383670				2022-12-28	WOS:000178249000013
J	Campion, EW				Campion, EW			Perspective - Suspicions about the safety of vaccines.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	10	10	1	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2002	347	19					1474	1475		10.1056/NEJMp020125	http://dx.doi.org/10.1056/NEJMp020125			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611XG	12421888				2022-12-28	WOS:000179042700001
J	Mirebeau, I; Goncharenko, IN; Cadavez-Pares, P; Bramwell, ST; Gingras, MJP; Gardner, JS				Mirebeau, I; Goncharenko, IN; Cadavez-Pares, P; Bramwell, ST; Gingras, MJP; Gardner, JS			Pressure-induced crystallization of a spin liquid	NATURE			English	Article							PYROCHLORE ANTIFERROMAGNET TB2TI2O7; GADOLINIUM GALLIUM GARNET; FRUSTRATED MAGNET; DIPOLAR INTERACTIONS; NEUTRON-DIFFRACTION; TRANSITION; SCATTERING; TB2MO2O7; STATE; PHASE	Liquids are expected to crystallize at low temperature. The only exception is helium, which can remain liquid at 0 K, owing to quantum fluctuations(1,2). Similarly, the atomic magnetic moments (spins) in a magnet are expected to order at a temperature scale set by the Curie-Weiss temperature theta(CW) (ref. 3). Geometrically frustrated magnets represent an exception. In these systems, the pairwise spin interactions cannot be simultaneously minimized because of the lattice symmetry(4). This can stabilize a liquid-like state of short-range-ordered fluctuating moments well below theta(CW) (refs 5-7). Here we use neutron scattering to observe the spin liquid state in a geometrically frustrated system, Tb(2)Ti(2)O(7), under conditions of high pressure (similar to9 GPa) and low temperature (, 1 K). This compound is a three-dimensional magnet with theta(CW) = -19 K, where the negative value indicates antiferromagnetic interactions. At ambient pressure Tb(2)Ti(2)O(7) remains in a spin liquid state down to at least 70 mK (ref. 8). But we find that, under high pressure, the spins start to order or 'crystallize' below 2.1 K, with antiferromagnetic order coexisting with liquid-like fluctuations. These results indicate that a spin liquid/solid mixture can be induced by pressure in geometrically frustrated systems.	CE Saclay, CEA, CNRS, Lab Leon Brillouin, F-91191 Gif Sur Yvette, France; UCL, Dept Chem, London WC1H OAJ, England; Univ Waterloo, Dept Phys, Waterloo, ON N2L 3G1, Canada; Canadian Inst Adv Res, Toronto, ON M5G 1Z8, Canada; Natl Res Council Canada, Neutron Program Mat Res, Chalk River, ON KOJ 1J0, Canada	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of London; University College London; University of Waterloo; Canadian Institute for Advanced Research (CIFAR); National Research Council Canada	Mirebeau, I (corresponding author), CE Saclay, CEA, CNRS, Lab Leon Brillouin, F-91191 Gif Sur Yvette, France.	mirebea@llb.saclay.cea.fr	Gardner, Jason S/GON-6881-2022; Gardner, Jason S/A-1532-2013	Gardner, Jason S/0000-0002-7823-4072; Gardner, Jason S/0000-0002-7823-4072				Bramwell ST, 2001, SCIENCE, V294, P1495, DOI 10.1126/science.1064761; Canals B, 2001, CAN J PHYS, V79, P1323, DOI 10.1139/cjp-79-11/12-1323; Champion JDM, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.140407; CHAMPION JDM, 2001, UNPUB PHYS REV LETT; CHAMPIONJDM, CONDMAT0112007; den Hertog BC, 2000, PHYS REV LETT, V84, P3430, DOI 10.1103/PhysRevLett.84.3430; FEREY G, 1986, REV CHIM MINER, V23, P474; Gardner JS, 1999, PHYS REV LETT, V82, P1012, DOI 10.1103/PhysRevLett.82.1012; GAULIN BD, 1992, PHYS REV LETT, V69, P3244, DOI 10.1103/PhysRevLett.69.3244; Gingras MJP, 2000, PHYS REV B, V62, P6496, DOI 10.1103/PhysRevB.62.6496; GONCHARENKO IN, 1992, J ALLOY COMPD, V179, P253, DOI 10.1016/0925-8388(92)90226-Y; GONCHARENKO IN, 1998, REV HIGH PRESSURE SC, V7, P475; GREEDAN JE, 1991, PHYS REV B, V43, P5682, DOI 10.1103/PhysRevB.43.5682; KAO YJ, 2002, CONDMAT0207270; KEESON WM, 1942, HELIUM; Lee SH, 1996, PHYS REV LETT, V76, P4424, DOI 10.1103/PhysRevLett.76.4424; Luo G, 2001, PHYS LETT A, V291, P306, DOI 10.1016/S0375-9601(01)00734-4; MORRISH AH, 1965, PHYSICAL PRINCIPLES; Palmer SE, 2000, PHYS REV B, V62, P488, DOI 10.1103/PhysRevB.62.488; Petrenko OA, 1998, PHYS REV LETT, V80, P4570, DOI 10.1103/PhysRevLett.80.4570; REIMERS JN, 1991, PHYS REV B, V43, P865, DOI 10.1103/PhysRevB.43.865; REIMERS JN, 1992, PHYS REV B, V46, P193, DOI 10.1103/PhysRevB.46.193; RODRIGUEZCARVAJAL J, 1993, PHYSICA B, V192, P55, DOI 10.1016/0921-4526(93)90108-I; SCHIFFER P, 1994, PHYS REV LETT, V73, P2500, DOI 10.1103/PhysRevLett.73.2500; SIMON FE, 1950, NATURE, V165, P829, DOI 10.1038/165829a0; Tsui YK, 2001, CAN J PHYS, V79, P1439, DOI 10.1139/cjp-79-11/12-1439; Yasui Y, 2002, J PHYS SOC JPN, V71, P599, DOI 10.1143/JPSJ.71.599	27	149	151	1	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					54	57		10.1038/nature01157	http://dx.doi.org/10.1038/nature01157			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422211				2022-12-28	WOS:000179068100033
J	Mackenbach, JP; Stronks, K				Mackenbach, JP; Stronks, K			A strategy for tackling health inequalities in the Netherlands	BRITISH MEDICAL JOURNAL			English	Article							SOCIOECONOMIC INEQUALITIES; MORTALITY		Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Social Med, NL-1012 WX Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam	Mackenbach, JP (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.							Acheson D., 1998, INDEPENDENT INQUIRY; Benach J., 2002, REDUCING INEQUALITIE, P262; BOS V, 2001, SOCIAAL EC GEZONDHEI, P7; DALSTRA JAA, 2001, SOCIAAL EC GEZONDHEI, V2, P7; Mackenbach JP, 1997, J EPIDEMIOL COMMUN H, V51, P359, DOI 10.1136/jech.51.4.359; MACKENBACH JP, 1994, BRIT MED J, V309, P1487, DOI 10.1136/bmj.309.6967.1487; Mackenbach JP, 1997, LANCET, V349, P1655, DOI 10.1016/S0140-6736(96)07226-1; MACLNTYRE S, 2001, BMJ-BRIT MED J, V322, P222; OOYENDIJK WTM, 1991, SOCIAAL EC STATUS GE; OSTLIN P, 2000, POLICY LEARNING CURV, V1; *PROGR COMM SOC EC, 2001, RED SOC IN HLTH; Schrijvers CTM, 1999, AM J PUBLIC HEALTH, V89, P535, DOI 10.2105/AJPH.89.4.535; SCHRIJVERS CTM, 2001, VOORTGANGSVERSLAG 20; Smith GD, 2001, BRIT MED J, V322, P184, DOI 10.1136/bmj.322.7280.184; Stronks K, 1996, SOCIOL HEALTH ILL, V18, P653, DOI 10.1111/1467-9566.ep10934524; STRONKS K, 1999, REEKS SOCIAAL EC GEZ, V2; STRONKS K, 2001, REEKS SOC EC GEZONDH, V2; STRONKS K, 2001, REEKS SOCIAAL EC GEZ, V2; STRONKS K, 2001, KLOOF VERKLEINEN THE; VANDEWATER HPA, 1996, EUROPEAN J PUBLIC HL, V6, P21; *WHO, 1999, HLTH 21 HLTH POL FRA; 2001, KABINETSSTANDPUNT EI	22	62	64	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					1029	1032		10.1136/bmj.325.7371.1029	http://dx.doi.org/10.1136/bmj.325.7371.1029			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411368	Green Submitted, Green Published			2022-12-28	WOS:000179415600030
J	Merrison, AFA; Chidley, KE; Dunnett, J; Sieradzan, KA				Merrison, AFA; Chidley, KE; Dunnett, J; Sieradzan, KA			Lesson of the week - Wound botulism associated with subcutaneous drug use	BRITISH MEDICAL JOURNAL			English	Review							HEROIN		Frenchay Hosp, Dept Neurol, Bristol BS16 1LE, Avon, England; Frenchay Hosp, Dept Anaesthet, Bristol, Avon, England		Merrison, AFA (corresponding author), Frenchay Hosp, Dept Neurol, Bristol BS16 1LE, Avon, England.							Athwal BS, 2000, LANCET, V356, P2011, DOI 10.1016/S0140-6736(05)72984-6; CRITCHLEY EMR, 1989, LANCET, V2, P849, DOI 10.1016/S0140-6736(89)93010-9; Jensenius M, 2000, LANCET, V356, P1160, DOI 10.1016/S0140-6736(00)02759-8; Maselli RA, 2000, MUSCLE NERVE, V23, P1137, DOI 10.1002/1097-4598(200007)23:7<1137::AID-MUS21>3.0.CO;2-7; MCDONALD K, 1985, ANN INTERN MED, V102, P616; Mulleague L, 2001, ANAESTHESIA, V56, P120, DOI 10.1046/j.1365-2044.2001.01833.x; Passaro DJ, 1998, JAMA-J AM MED ASSOC, V279, P859, DOI 10.1001/jama.279.11.859; TACKET CO, 1984, AM J MED, V76, P794, DOI 10.1016/0002-9343(84)90988-4; Werner SB, 2000, CLIN INFECT DIS, V31, P1018, DOI 10.1086/318134	9	17	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					1020	1021		10.1136/bmj.325.7371.1020	http://dx.doi.org/10.1136/bmj.325.7371.1020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411365	Green Published			2022-12-28	WOS:000179415600027
J	Kuwana, T; Mackey, MR; Perkins, G; Ellisman, MH; Latterich, M; Schneiter, R; Green, DR; Newmeyer, DD				Kuwana, T; Mackey, MR; Perkins, G; Ellisman, MH; Latterich, M; Schneiter, R; Green, DR; Newmeyer, DD			Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane	CELL			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; RAT-LIVER MITOCHONDRIA; BCL-2 FAMILY MEMBER; CELL-FREE APOPTOSIS; CASPASE ACTIVATION; EGG EXTRACTS; CONTACT SITES; ION-CHANNEL; BH3 DOMAIN	Bcl-2 family proteins regulate the release of proteins like cytochrome c from mitochondria during apoptosis. We used cell-free systems and ultimately a vesicular reconstitution from defined molecules to show that outer membrane permeabilization by Bcl-2 family proteins requires neither the mitochondrial matrix, the inner membrane, nor other proteins. Bid, or its BH3-domain peptide, activated monomeric Bax to produce membrane openings that allowed the passage of very large (2 megadalton) dextran molecules, explaining the translocation of large mitochondrial proteins during apoptosis. This process required cardiolipin and was inhibited by antiapoptotic Bcl-x(L). We conclude that mitochondrial protein release in apoptosis can be mediated by supramolecular openings in the outer mitochondrial membrane, promoted by BH3/Bax/lipid interaction and directly inhibited by Bcl-x(L).	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA; Diversa Corp, San Diego, CA 92121 USA; Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	La Jolla Institute for Immunology; University of California System; University of California San Diego; Graz University of Technology	Newmeyer, DD (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417; Perkins, Guy/0000-0002-1834-6646; Schneiter, Roger/0000-0002-9102-8396	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062289] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline; NIAID NIH HHS [AI40646] Funding Source: Medline; NIGMS NIH HHS [GM62289, GM50284] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; de Kroon AIPM, 1999, MOL MEMBR BIOL, V16, P205; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; GHOSHROY S, 1995, J MEMBRANE BIOL, V146, P15; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HOVIUS R, 1993, FEBS LETT, V330, P71, DOI 10.1016/0014-5793(93)80922-H; HUI SW, 1983, CHEM PHYS LIPIDS, V33, P113, DOI 10.1016/0009-3084(83)90015-4; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KAN FWK, 1993, J HISTOCHEM CYTOCHEM, V41, P649, DOI 10.1177/41.5.8468446; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Mayer A, 1995, METHOD ENZYMOL, V260, P252, DOI 10.1016/0076-6879(95)60143-0; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Polster BM, 2001, J BIOL CHEM, V276, P37887; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1996, ONCOGENE, V13, P21; SIEGEL DP, 1984, BIOPHYS J, V45, P399, DOI 10.1016/S0006-3495(84)84164-8; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SMAAL EB, 1987, BIOCHIM BIOPHYS ACTA, V897, P191, DOI 10.1016/0005-2736(87)90327-0; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; von Ahsen O, 2000, METHOD ENZYMOL, V322, P183; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhai DY, 2001, EUR J BIOCHEM, V268, P48, DOI 10.1046/j.1432-1327.2001.01841.x; Zhai DY, 2000, FEBS LETT, V472, P293, DOI 10.1016/S0014-5793(00)01471-X; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	63	1173	1242	4	69	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 1	2002	111	3					331	342		10.1016/S0092-8674(02)01036-X	http://dx.doi.org/10.1016/S0092-8674(02)01036-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419244	Green Published, Bronze			2022-12-28	WOS:000179010100006
J	Faili, A; Aoufouchi, S; Flatter, E; Gueranger, Q; Reynaud, CA; Weill, JC				Faili, A; Aoufouchi, S; Flatter, E; Gueranger, Q; Reynaud, CA; Weill, JC			Induction of somatic hypermutation in immunoglobulin genes is dependent on DNA polymerase iota	NATURE			English	Article							CYTIDINE DEAMINASE AID; POL-IOTA; IG; ETA; DEFICIENCY; MUTATION; RNA	Somatic hypermutation of immunoglobulin genes is a unique, targeted, adaptive process. While B cells are engaged in germinal centres in T-dependent responses, single base substitutions are introduced in the expressed V-H/V-L genes to allow the selection of mutants with a higher affinity for the immunizing antigen. Almost every possible DNA transaction has been proposed to explain this process, but each of these models includes an error-prone DNA synthesis step that introduces the mutations(1,2). The Y family of DNA polymerases(3)-pol eta, pol iota, pol kappa and rev1-are specialized for copying DNA lesions and have high rates of error when copying a normal DNA template(4,5). By performing gene inactivation in a Burkitt's lymphoma cell line inducible for hypermutation, we show here that somatic hypermutation is dependent on DNA polymerase iota.	Hop Necker Enfants Malad, INSERM, U373, F-75730 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Weill, JC (corresponding author), Hop Necker Enfants Malad, INSERM, U373, 156 Rue Vaugirard, F-75730 Paris 15, France.	weill@necker.fr	Aoufouchi, Said/I-2985-2016; AOUFOUCHI, Said/P-9926-2019	AOUFOUCHI, Said/0000-0001-6547-2664; Gueranger, Quentin/0000-0002-9507-8315; Flatter, Eric/0000-0001-6812-5887				Bachl J, 1996, P NATL ACAD SCI USA, V93, P851, DOI 10.1073/pnas.93.2.851; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Denepoux S, 1997, IMMUNITY, V6, P35, DOI 10.1016/S1074-7613(00)80240-X; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Diaz M, 2001, J IMMUNOL, V167, P327, DOI 10.4049/jimmunol.167.1.327; Dorner T, 1998, IMMUNOL REV, V162, P161, DOI 10.1111/j.1600-065X.1998.tb01439.x; Faili A, 2002, NAT IMMUNOL, V3, P815, DOI 10.1038/ni826; Frank EG, 2001, EMBO J, V20, P2914, DOI 10.1093/emboj/20.11.2914; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Gearhart PJ, 2001, NAT REV IMMUNOL, V1, P187, DOI 10.1038/35105009; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; MITTRUCKER HW, 1993, INT IMMUNOL, V5, P985, DOI 10.1093/intimm/5.8.985; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Papavasiliou FN, 2002, J EXP MED, V195, P1193, DOI 10.1084/jem.20011858; Pavlov YI, 2002, P NATL ACAD SCI USA, V99, P9954, DOI 10.1073/pnas.152126799; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Poltoratsky V, 2001, P NATL ACAD SCI USA, V98, P7976, DOI 10.1073/pnas.141222198; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Tissier A, 2000, GENE DEV, V14, P1642; Weill JC, 2002, ADV IMMUNOL, V80, P183, DOI 10.1016/S0065-2776(02)80015-3; Zan H, 1999, J IMMUNOL, V162, P3437; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740; Zhang T, 2001, INT IMMUNOL, V13, P975, DOI 10.1093/intimm/13.8.975	29	165	173	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					944	947		10.1038/nature01117	http://dx.doi.org/10.1038/nature01117			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410315				2022-12-28	WOS:000178909700048
J	Rathore, SS; Wang, YF; Krumholz, HM				Rathore, SS; Wang, YF; Krumholz, HM			Sex-based differences in the effect of digoxin for the treatment of heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENDER-RELATED DIFFERENCES; LEFT-VENTRICULAR FUNCTION; CLINICAL-TRIALS; SUBGROUP ANALYSES; UNITED-STATES; SURVIVAL; PROGRESSION; GUIDELINES; EXPRESSION; MORTALITY	Background: The Digitalis Investigation Group trial reported that treatment with digoxin did not decrease overall mortality among patients with heart failure and depressed left ventricular systolic function, although it did reduce hospitalizations slightly. Even though the epidemiologic features, causes, and prognosis of heart failure vary between men and women, sex-based differences in the effect of digoxin were not evaluated. Methods: We conducted a post hoc subgroup analysis to assess whether there were sex-based differences in the effect of digoxin therapy among the 6800 patients in the Digitalis Investigation Group study. The presence of an interaction between sex and digoxin therapy with respect to the primary end point of death from any cause was evaluated with the use of Mantel-Haenszel tests of heterogeneity and a multivariable Cox proportional-hazards model, adjusted for demographic and clinical variables. Results: There was an absolute difference of 5.8 percent (95 percent confidence interval, 0.5 to 11.1) between men and women in the effect of digoxin on the rate of death from any cause (P=0.034 for the interaction). Specifically, women who were randomly assigned to digoxin had a higher rate of death than women who were randomly assigned to placebo (33.1 percent vs. 28.9 percent; absolute difference, 4.2 percent, 95 percent confidence interval, -0.5 to 8.8). In contrast, the rate of death was similar among men randomly assigned to digoxin and men randomly assigned to placebo (35.2 percent vs. 36.9 percent; absolute difference, -1.6 percent; 95 percent confidence interval, -4.2 to 1.0). In the multivariable analysis, digoxin was associated with a significantly higher risk of death among women (adjusted hazard ratio for the comparison with placebo, 1.23; 95 percent confidence interval, 1.02 to 1.47), but it had no significant effect among men (adjusted hazard ratio, 0.93; 95 percent confidence interval, 0.85 to 1.02; P=0.014 for the interaction). Conclusions: The effect of digoxin therapy differs between men and women. Digoxin therapy is associated with an increased risk of death from any cause among women, but not men, with heart failure and depressed left ventricular systolic function.	Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA	Yale University; Yale University; Yale University	Rathore, SS (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA.		, Harlan/AAI-2875-2020					Abernathy GT, 1996, CONTROL CLIN TRIALS, V17, P77; Adams KF, 1999, J CARD FAIL, V5, P357; Adams KF, 1996, J AM COLL CARDIOL, V28, P1781, DOI 10.1016/S0735-1097(96)00380-4; Aebi S, 1999, CANCER CHEMOTH PHARM, V44, P259, DOI 10.1007/s002800050976; *AM HEART ASS, 2001, 2002 HEART STROK STA; Aronson D, 2000, J CARDIOVASC ELECTR, V11, P1071, DOI 10.1111/j.1540-8167.2000.tb01750.x; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Brookes S T, 2001, Health Technol Assess, V5, P1; BUYSE ME, 1989, CONTROL CLIN TRIALS, V10, pS187; CARROLL JD, 1992, CIRCULATION, V86, P1099, DOI 10.1161/01.CIR.86.4.1099; Croft JB, 1999, ARCH INTERN MED, V159, P505, DOI 10.1001/archinte.159.5.505; Dash R, 2001, J MOL CELL CARDIOL, V33, P1345, DOI 10.1006/jmcc.2001.1394; Duscha BD, 2001, J APPL PHYSIOL, V90, P280, DOI 10.1152/jappl.2001.90.1.280; Freemantle N, 2001, BRIT MED J, V322, P989, DOI 10.1136/bmj.322.7292.989; Furberg CD, 2002, CIRCULATION, V105, P917, DOI 10.1161/hc0802.104280; Griffin M, 2000, MOL CELL BIOCHEM, V215, P21, DOI 10.1023/A:1026585420021; Heiat A, 2002, ARCH INTERN MED, V162, P1682, DOI 10.1001/archinte.162.15.1682; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; JELLIFFE RW, 1974, AM J MED, V57, P63, DOI 10.1016/0002-9343(74)90769-4; Kadokami T, 2000, J CLIN INVEST, V106, P589, DOI 10.1172/JCI9307; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Lindenfeld J, 1997, J AM COLL CARDIOL, V30, P1417; Matthews JNS, 1996, BRIT MED J, V313, P862; Moye LA, 2001, CIRCULATION, V103, P3150, DOI 10.1161/hc2501.090955; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Perry G, 1997, NEW ENGL J MED, V336, P525; Petrie MC, 1999, CIRCULATION, V99, P2334, DOI 10.1161/01.CIR.99.17.2334; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Rich MW, 2001, J AM COLL CARDIOL, V38, P806, DOI 10.1016/S0735-1097(01)01442-5; RIEMER RK, 1988, MOL PHARMACOL, V33, P389; SCHAIBLE TF, 1984, CIRC RES, V54, P38, DOI 10.1161/01.RES.54.1.38; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SIMON R, 1982, BRIT J CLIN PHARMACO, V14, P473, DOI 10.1111/j.1365-2125.1982.tb02015.x; Song M, 2001, J BIOL CHEM, V276, P31883, DOI 10.1074/jbc.M101058200; Tamura T, 1999, HYPERTENSION, V33, P676, DOI 10.1161/01.HYP.33.2.676; Wenger NK, 2002, CIRCULATION, V105, P1526, DOI 10.1161/01.CIR.0000014121.94868.81; Wizemann T. M., 2001, EXPLORING BIOL CONTR; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	42	413	428	1	14	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1403	1411		10.1056/NEJMoa021266	http://dx.doi.org/10.1056/NEJMoa021266			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12409542				2022-12-28	WOS:000178888400003
J	Ravin, P; Hedley-Whyte, ET; Houtchens, A; Cole, AJ				Ravin, P; Hedley-Whyte, ET; Houtchens, A; Cole, AJ			A 55-year-old man with cognitive and sensorimotor findings and intracranial lesions - Acute disseminated encephalomyelitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NEUROLOGIC COMPLICATIONS; ADEM		UMass Mem Med Ctr, Headache Clin, Worcester, MA 01655 USA; UMass Mem Med Ctr, Movement Disorders Clin, Worcester, MA USA; Univ Massachusetts, Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ravin, P (corresponding author), UMass Mem Med Ctr, Headache Clin, Worcester, MA 01655 USA.		Hedley-Whyte, E Tessa/AAJ-9975-2021	Hedley-Whyte, E Tessa/0000-0002-1687-8905				Dagher AP, 1996, NEURORADIOLOGY, V38, P560; DAVIS LE, 1993, NEUROLOGY, V43, P1775, DOI 10.1212/WNL.43.9.1775; Feasby TE, 2001, NEUROLOGY, V57, P753, DOI 10.1212/WNL.57.5.753; Garcia HH, 2000, INFECT DIS CLIN N AM, V14, P97, DOI 10.1016/S0891-5520(05)70220-8; Hartung HP, 2001, NEUROLOGY, V56, P1257, DOI 10.1212/WNL.56.10.1257; KELLY JJ, 1985, MUSCLE NERVE, V8, P138, DOI 10.1002/mus.880080210; Markell E. K., 1984, Hunter's tropical medicine. 6th edition., P740; Nasr JT, 2000, PEDIATR NEUROL, V22, P8, DOI 10.1016/S0887-8994(99)00116-2; Orrell RW, 1996, BRIT MED J, V313, P802; PATCHELL RA, 1991, NEUROL CLIN, V9, P817, DOI 10.1016/S0733-8619(18)30250-0; PRINEAS JW, 1997, GREENFIELDS NEUROPAT, V1, P813; RECHT LD, 1991, NEUROL CLIN, V9, P1001, DOI 10.1016/S0733-8619(18)30262-7; SALGADO AV, 1989, NEUROLOGY, V39, P173, DOI 10.1212/WNL.39.2.173; Schwarz S, 2001, NEUROLOGY, V56, P1313, DOI 10.1212/WNL.56.10.1313; Sepkowitz K., 1991, Infections of the central nervous system., P741; Stuve O, 1999, CURR OPIN NEUROL, V12, P395, DOI 10.1097/00019052-199908000-00005; Tunaci M, 1999, NEURORADIOLOGY, V41, P844, DOI 10.1007/s002340050854	17	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2002	347	18					1433	1440		10.1056/NEJMcpc020024	http://dx.doi.org/10.1056/NEJMcpc020024			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609DM	12409547				2022-12-28	WOS:000178888400008
J	Smit, RHM; Noat, Y; Untiedt, C; Lang, ND; van Hemert, MC; van Ruitenbeek, JM				Smit, RHM; Noat, Y; Untiedt, C; Lang, ND; van Hemert, MC; van Ruitenbeek, JM			Measurement of the conductance of a hydrogen molecule	NATURE			English	Article							SIZE METALLIC CONTACTS; ELECTRON-TRANSPORT; JUNCTION; SPECTROSCOPY; RESISTANCE; TRANSITION; WIRES	Recent years have shown steady progress towards molecular electronics(1,2), in which molecules form basic components such as switches(3-5), diodes(6) and electronic mixers(7). Often, a scanning tunnelling microscope is used to address an individual molecule, although this arrangement does not provide long-term stability. Therefore, metal-molecule-metal links using break-junction devices(8-10) have also been explored; however, it is difficult to establish unambiguously that a single molecule forms the contact(11). Here we show that a single hydrogen molecule can form a stable bridge between platinum electrodes. In contrast to results for organic molecules, the bridge has a nearly perfect conductance of one quantum unit, carried by a single channel. The hydrogen bridge represents a simple test system in which to understand fundamental transport properties of single-molecule devices.	Leiden Univ, Kamerlingh Onnes Lab, NL-2300 RA Leiden, Netherlands; IBM Corp, Div Res, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA; Leiden Univ, Gorlaeus Labs, Leids Inst Chem Onderzoek, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; International Business Machines (IBM); Leiden University; Leiden University - Excl LUMC	van Ruitenbeek, JM (corresponding author), Leiden Univ, Kamerlingh Onnes Lab, POB 9504, NL-2300 RA Leiden, Netherlands.	ruitenbe@phys.leidenuniv.nl	van Ruitenbeek, Jan M/B-3783-2008; Untiedt, Carlos/C-6269-2011; van hemert, marc/GPF-9085-2022; Lang, Norton D/ABD-3060-2021	van Ruitenbeek, Jan M/0000-0003-0381-0132; Untiedt, Carlos/0000-0003-4800-082X; Smit, Roel/0000-0002-4400-0585				Agrait N, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.216803; AGRAT N, 2002, CONDMAT0208239; ANDRAE D, 1990, THEOR CHIM ACTA, V77, P123, DOI 10.1007/BF01114537; Aviram A., 1998, MOL ELECT SCI TECHNO; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; BONCA J, 1995, PHYS REV LETT, V75, P2566, DOI 10.1103/PhysRevLett.75.2566; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Emberly EG, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.269701; Emberly EG, 2000, PHYS REV B, V61, P5740, DOI 10.1103/PhysRevB.61.5740; Frisch M.J., 2016, GAUSSIAN 16 REVISION; Gao HJ, 2000, PHYS REV LETT, V84, P1780, DOI 10.1103/PhysRevLett.84.1780; JANSEN AGM, 1980, J PHYS C SOLID STATE, V13, P6073, DOI 10.1088/0022-3719/13/33/009; Kergueris C, 1999, PHYS REV B, V59, P12505, DOI 10.1103/PhysRevB.59.12505; Khotkevich A.V., 1995, ATLAS POINT CONTACT, DOI [10.1007/978-1-4615-2265-2, DOI 10.1007/978-1-4615-2265-2]; Lang ND, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.125323; LANG ND, 1995, PHYS REV B, V52, P5335, DOI 10.1103/PhysRevB.52.5335; Langlais VJ, 1999, PHYS REV LETT, V83, P2809, DOI 10.1103/PhysRevLett.83.2809; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; Ludoph B, 2000, PHYS REV B, V61, P2273, DOI 10.1103/PhysRevB.61.2273; Metzger RM, 1998, ANN NY ACAD SCI, V852, P95, DOI 10.1111/j.1749-6632.1998.tb09866.x; MULLER CJ, 1992, PHYSICA C, V191, P485, DOI 10.1016/0921-4534(92)90947-B; Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Reed MA, 2001, APPL PHYS LETT, V78, P3735, DOI 10.1063/1.1377042; Reichert J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.176804; Rubio G, 1996, PHYS REV LETT, V76, P2302, DOI 10.1103/PhysRevLett.76.2302; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; Untiedt C, 2000, PHYS REV B, V62, P9962, DOI 10.1103/PhysRevB.62.9962; van den Brom HE, 1999, PHYS REV LETT, V82, P1526, DOI 10.1103/PhysRevLett.82.1526; van Ruitenbeek JM, 1997, NATO ADV SCI I E-APP, V345, P549; YANSON IK, 1974, ZH EKSP TEOR FIZ, V39, P506	32	846	857	3	166	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					906	909		10.1038/nature01103	http://dx.doi.org/10.1038/nature01103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410305	Green Submitted			2022-12-28	WOS:000178909700037
J	Syntichaki, P; Xu, KL; Driscoll, M; Tavernarakis, N				Syntichaki, P; Xu, KL; Driscoll, M; Tavernarakis, N			Specific aspartyl and calpain proteases are required for neurodegeneration in C-elegans	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DOUBLE-STRANDED-RNA; CELL-DEATH; GENETIC INTERFERENCE; FAMILY; IDENTIFICATION; CATHEPSIN; SUBUNIT; ENCODES; MEMBER	Necrotic cell death underlies the pathology of numerous human neurodegenerative conditions(1). In the nematode Caenorhabditis elegans, gain-of-function mutations in specific ion channel genes such as the degenerin genes deg-1 and mec-4, the acetylcholine receptor channel subunit gene deg-3 and the G(s) protein alpha-subunit gene gsa-1 evoke an analogous pattern of degenerative (necrotic-like) cell death in neurons that express the mutant proteins(2-6). An increase in concentrations of cytoplasmic calcium in dying cells, elicited either by extracellular calcium influx or by release of endoplasmic reticulum stores, is thought to comprise a major death-signalling event(7,8). But the biochemical mechanisms by which calcium triggers cellular demise remain largely unknown. Here we report that neuronal degeneration inflicted by various genetic lesions in C. elegans requires the activity of the calcium-regulated CLP-1 and TRA-3 calpain proteases and aspartyl proteases ASP-3 and ASP-4. Our findings show that two distinct classes of proteases are involved in necrotic cell death and suggest that perturbation of intracellular concentrations of calcium may initiate neuronal degeneration by deregulating proteolysis. Similar proteases may mediate necrotic cell death in humans.	Fdn Res & Technol, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA	Rutgers State University New Brunswick	Tavernarakis, N (corresponding author), Fdn Res & Technol, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece.	tavernarakis@imbb.forth.gr	Tavernarakis, Nektarios/B-9684-2013; Syntichaki, Popi/ABA-7218-2020	Tavernarakis, Nektarios/0000-0002-5253-1466; Syntichaki, Popi/0000-0001-9536-8905				Adamec E, 2000, NEUROSCIENCE, V100, P663, DOI 10.1016/S0306-4522(00)00281-5; Barger AJ, 1998, J NEUROSCI, V18, P2871; BARNES W, 1996, AUSTR J EMERGENCY CA, V3, P15; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; Chung SB, 2000, NAT CELL BIOL, V2, P931, DOI 10.1038/35046585; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; Ferrier DEK, 2001, EVOL DEV, V3, P263, DOI 10.1046/j.1525-142x.2001.003004263.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hall DH, 1997, J NEUROSCI, V17, P1033; HAWDON JM, 1989, BIOCHEM J, V264, P161, DOI 10.1042/bj2640161; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; JACOBSON LA, 1988, GENETICS, V119, P355; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Korswagen HC, 1997, GENE DEV, V11, P1493, DOI 10.1101/gad.11.12.1493; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Rogalski TM, 2001, BIOCHEM SOC T, V29, P171, DOI 10.1042/BST0290171; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; Sokol SB, 2000, GENE DEV, V14, P901; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Stracher A, 1999, ANN NY ACAD SCI, V884, P52, DOI 10.1111/j.1749-6632.1999.tb08635.x; Syntichaki P, 2002, EMBO REP, V3, P604, DOI 10.1093/embo-reports/kvf138; Tavernarakis N, 1997, NEURON, V18, P107, DOI 10.1016/S0896-6273(01)80050-7; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Tcherepanova I, 2000, J BIOL CHEM, V275, P26359, DOI 10.1074/jbc.M000956200; TREININ M, 1995, NEURON, V14, P871, DOI 10.1016/0896-6273(95)90231-7; Xu KL, 2001, NEURON, V31, P957, DOI 10.1016/S0896-6273(01)00432-9; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X	30	228	258	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	2002	419	6910					939	944		10.1038/nature01108	http://dx.doi.org/10.1038/nature01108			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410314				2022-12-28	WOS:000178909700047
J	Hermiz, O; Comino, E; Marks, G; Daffurn, K; Wilson, S; Harris, M				Hermiz, O; Comino, E; Marks, G; Daffurn, K; Wilson, S; Harris, M			Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease	BRITISH MEDICAL JOURNAL			English	Article							AIR-FLOW LIMITATION; RESPIRATORY QUESTIONNAIRE; COPD; EXACERBATIONS; PROGRAM; ASTHMA	Objectives To evaluate usefulness of limited community based care for patients with chronic obstructive pulmonary disease after discharge from hospital. Design Randomised controlled trial. Setting Liverpool Health Service and Macarthur Health Service in outer metropolitan Sydney between September 1999 and July 2000. Participants 177 patients randomised into an intervention group (84 patients) and a control group (93 patients) which received current usual care. Interventions Home visits by community nurse at one and four weeks after discharge and preventive general practitioner care. Main outcome measures Frequency of patients' presentation and admission to hospital; changes in patients' disease-specific quality of life, measured with St George's respiratory questionnaire, over three months after discharge; patients' knowledge of illness, self management, and satisfaction with care at discharge and three months later; frequency of general practitioner and nurse visits and their satisfaction with care. Results Intervention and control groups showed no differences in presentation or admission to hospital or in overall functional status. However, the intervention group improved their activity scores and the control group worsened their symptom scores. While intervention group patients received more visits from community nurses and were more satisfied with their care, involvement of general practitioners was much less (with only 31% (22) remembering receiving a care plan). Patients in the intervention group had higher knowledge scores and were more satisfied. There were no differences in general practitioner visits or management. Conclusions This brief intervention after acute care improved patients' knowledge and some aspects of quality of life. However, it failed to prevent presentation and readmission to hospital.	Univ New S Wales, Sch Community Med, Sydney, NSW 2052, Australia; Liverpool Hlth Serv, Div Crit Care, Sydney, NSW, Australia; SW Sydney Area Hlth Serv, Macarthur Hlth Serv, Sydney, NSW, Australia	University of New South Wales Sydney	Harris, M (corresponding author), Univ New S Wales, Sch Community Med, Sydney, NSW 2052, Australia.		Marks, Guy B./F-5058-2013	Marks, Guy B./0000-0002-8976-8053				Blakeman T, 2001, Aust Fam Physician, V30, P75; Crockett AJ, 1996, QUAL LIFE RES, V5, P330, DOI 10.1007/BF00433917; Crockett AJ, 2000, INT J QUAL HEALTH C, V12, P41, DOI 10.1093/intqhc/12.1.41; Farrero E, 2001, CHEST, V119, P364, DOI 10.1378/chest.119.2.364; Fried TR, 1998, J GEN INTERN MED, V13, P522, DOI 10.1046/j.1525-1497.1998.00162.x; Gallefoss F, 1999, AM J RESP CRIT CARE, V159, P812, DOI 10.1164/ajrccm.159.3.9804047; Gibson P G, 1998, J Qual Clin Pract, V18, P125; GIBSON PG, 1988, J QUAL CLIN PRACT, V18, P125; Gravil JH, 1998, LANCET, V351, P1853, DOI 10.1016/S0140-6736(97)11048-0; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; Keenan SP, 2000, CRIT CARE MED, V28, P2094, DOI 10.1097/00003246-200006000-00072; Ketelaars CAJ, 1998, HEART LUNG, V27, P109, DOI 10.1016/S0147-9563(98)90018-8; Madison JM, 1998, LANCET, V352, P467, DOI 10.1016/S0140-6736(97)11081-9; Rutten-van Molken M, 1999, THORAX, V54, P995; *S W SYDN AR HLTH, 1998, EP UN REP COPD ASTHM; Skwarska E, 2000, THORAX, V55, P907, DOI 10.1136/thorax.55.11.907; SMITH B, 2000, COCHRANE DATABASE SY, DOI UNSP CD000994; Smith BJ, 1999, AUST NZ J MED, V29, P718, DOI 10.1111/j.1445-5994.1999.tb01621.x; Strijbos JH, 1996, CHEST, V109, P366, DOI 10.1378/chest.109.2.366; Tirimanna PRS, 1996, BRIT J GEN PRACT, V46, P277; TRAVER GA, 1988, HEART LUNG, V17, P689; 1987, AM REV RESP DIS, V136, P225	22	110	111	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					938	940C		10.1136/bmj.325.7370.938	http://dx.doi.org/10.1136/bmj.325.7370.938			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399344	Green Published, Bronze			2022-12-28	WOS:000178986300017
J	Krishnan, STM; Philipose, Z; Rayman, G				Krishnan, STM; Philipose, Z; Rayman, G			Lesson of the week - Hypothyroidism mimicking intra-abdominal malignancy	BRITISH MEDICAL JOURNAL			English	Review							EVIDENCE-BASED GUIDELINE; PRIMARY-CARE MANAGEMENT; QUALITY-OF-LIFE; DECISION-SUPPORT; GENERAL-PRACTICE; ASTHMA; IMPLEMENTATION; ASCITES; DESIGN		Ipswich Hosp NHS Trust, Ctr Diabet, Ipswich IP4 5PD, Suffolk, England	Ipswich Hospital NHS Trust; Ipswich Hospital	Rayman, G (corresponding author), Ipswich Hosp NHS Trust, Ctr Diabet, Ipswich IP4 5PD, Suffolk, England.							BAKER R, 1992, BRIT J GEN PRACT, V42, P415; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Campbell M, 2000, J Health Serv Res Policy, V5, P12; Campbell M, 1999, CHANGING PROFESSIONA, P57; DECASTRO F, 1991, J CLIN GASTROENTEROL, V13, P411, DOI 10.1097/00004836-199108000-00010; Depczynski B, 1996, J CLIN ENDOCR METAB, V81, P4175, DOI 10.1210/jcem.81.11.8923881; Donner A, 1998, J R STAT SOC C-APPL, V47, P95, DOI 10.1111/1467-9876.00100; Eccles M, 2001, FAM PRACT, V18, P223, DOI 10.1093/fampra/18.2.223; Eccles M, 2001, FAM PRACT, V18, P217, DOI 10.1093/fampra/18.2.217; Eccles M, 2000, FAM PRACT, V17, P180, DOI 10.1093/fampra/17.2.180; ECCLES M, 2002, EVALUATION COMPUTERI; Foy R, 2001, FAM PRACT, V18, P353, DOI 10.1093/fampra/18.4.353; Friedman C.P., 1997, EVALUATION METHODS M, P41; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; HASHIMOTO T, 1989, ENDOCRINOL JAPON, V36, P873; Hetlevik I, 2000, INT J TECHNOL ASSESS, V16, P210, DOI 10.1017/S0266462300161185; Hetlevik Irene, 1998, Blood Pressure, V7, P270; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; James BC, 2001, NEW ENGL J MED, V345, P991, DOI 10.1056/NEJM200109273451311; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Purves IN, 1998, BRIT J GEN PRACT, V48, P1552; Sevinc A, 2000, J R SOC PROMO HEALTH, V120, P268; SPERTUS JA, 1995, J AM COLL CARDIOL, V25, P333, DOI 10.1016/0735-1097(94)00397-9; STEEN N, 1994, BRIT MED J, V309, P1065, DOI 10.1136/bmj.309.6961.1065; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	27	21	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					946	947		10.1136/bmj.325.7370.946	http://dx.doi.org/10.1136/bmj.325.7370.946			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399347	Green Published			2022-12-28	WOS:000178986300020
J	Cheeseman, LM; Anderson, S; Jwa, M; Green, EM; Kang, JS; Yates, JR; Chan, CSM; Drubin, DG; Barnes, G				Cheeseman, LM; Anderson, S; Jwa, M; Green, EM; Kang, JS; Yates, JR; Chan, CSM; Drubin, DG; Barnes, G			Phospho-regulation of kinetochore-microtubule attachments by the aurora kinase Ipl1p	CELL			English	Article							YEAST CHROMOSOME SEGREGATION; TYPE-1 PROTEIN PHOSPHATASE; MITOTIC SPINDLE INTEGRITY; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; DUO1P/DAM1P COMPLEX; OUTER KINETOCHORE; MITOSIS; CENTROMERE; DAM1P	The Aurora kinase lpL1p plays a crucial role in regulating kinetochore-microtubule attachments in budding yeast, but the underlying basis for this regulation is not known. To identify IpI1p targets, we first purified 28 kinetochore proteins from yeast protein extracts. These studies identified five previously uncharacterized kinetochore proteins and defined two additional kinetochore subcomplexes. We then used mass spectrometry to identify 18 phosphorylation sites in 7 of these 28 proteins. Ten of these phosphorylation sites are targeted directly by lpL1p, allowing us to identify a consensus phosphorylation site for an Aurora kinase. Our systematic mutational analysis of the IpI1p phosphorylation sites demonstrated that the essential microtubule binding protein Dam1p is a key IpI1p target for regulating kinetochore-microtubule attachments in vivo.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	University of California System; University of California Berkeley; Scripps Research Institute; University of Texas System; University of Texas Austin	Barnes, G (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	gbarnes@socrates.berkeley.edu	Green, Erin/J-6098-2019	Cheeseman, Iain/0000-0002-3829-5612; Green, Erin/0000-0003-3923-6726	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047842, R01GM045185, R55GM047842] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR11823] Funding Source: Medline; NIGMS NIH HHS [GM-45185, GM-47842] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews PD, 2000, J CELL SCI, V113, P507; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Blandin G, 2000, FEBS LETT, V487, P31, DOI 10.1016/S0014-5793(00)02275-4; CHAN CSM, 1993, GENETICS, V135, P677; Cheeseman IM, 2001, J CELL BIOL, V155, P1137, DOI 10.1083/jcb.200109063; Cheeseman IM, 2002, J CELL BIOL, V157, P199, DOI 10.1083/jcb.200201052; Cheeseman IM, 2001, J CELL BIOL, V152, P197, DOI 10.1083/jcb.152.1.197; Enquist-Newman M, 2001, MOL BIOL CELL, V12, P2601, DOI 10.1091/mbc.12.9.2601; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Ghosh SK, 2001, MOL GENET GENOMICS, V265, P249, DOI 10.1007/s004380000408; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; Hofmann C, 1998, J CELL BIOL, V143, P1029, DOI 10.1083/jcb.143.4.1029; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Janke C, 2002, EMBO J, V21, P181, DOI 10.1093/emboj/21.1.181; Janke C, 2001, EMBO J, V20, P777, DOI 10.1093/emboj/20.4.777; Jones MH, 2001, P NATL ACAD SCI USA, V98, P13675, DOI 10.1073/pnas.241417098; Jones MH, 1999, MOL BIOL CELL, V10, P2377, DOI 10.1091/mbc.10.7.2377; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; Li YM, 2002, GENE DEV, V16, P183, DOI 10.1101/gad.959402; Loidl J, 1998, METHOD CELL BIOL, V53, P257; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Measday V, 2002, GENE DEV, V16, P101, DOI 10.1101/gad.949302; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; Ortiz J, 1999, GENE DEV, V13, P1140, DOI 10.1101/gad.13.9.1140; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349; Yoon HJ, 1999, P NATL ACAD SCI USA, V96, P13208, DOI 10.1073/pnas.96.23.13208	39	497	529	1	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	2002	111	2					163	172		10.1016/S0092-8674(02)00973-X	http://dx.doi.org/10.1016/S0092-8674(02)00973-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408861	Bronze			2022-12-28	WOS:000178753500006
J	Li, XC; Schuler, MA; Berenbaum, MR				Li, XC; Schuler, MA; Berenbaum, MR			Jasmonate and salicylate induce expression of herbivore cytochrome P450 genes	NATURE			English	Article							LYCOPERSICON-ESCULENTUM; INDUCED RESISTANCE; MOLECULAR-CLONING; INDUCED INCREASES; HELICOVERPA-ZEA; PLANTS; ACID; DEFENSE; SIGNAL; BIOSYNTHESIS	Jasmonate and salicylate are plant-produced signals that activate plant defence genes after herbivory(1-3) or pathogen(4) attack. Amplification of these signals, evoked by either enemy attack or experimental manipulation, leads to an increase in the synthesis of toxic compounds (allelochemicals)(5-8) and defence proteins(6,9,10) in the plants. Although the jasmonate and salicylate signal cascades activate different sets of plant defence genes(10),or even act antagonistically(11,12), there is substantial communication between the pathways(2,3,13). Jasmonate and salicylate also contribute to protecting plants against herbivores by causing plants that experience insect damage to increase their production of volatile molecules that attract natural enemies of herbivorous insects(14). In response to plant defences, herbivores increase their production of enzymes that detoxify allelochemicals, including cytochrome P450s (refs 15, 16). But herbivores are potentially vulnerable to toxic allelochemicals in the duration between ingesting toxins and induction of detoxification systems. Here we show that the corn earworm Helicoverpa zea uses jasmonate and salicylate to activate four of its cytochrome P450 genes that are associated with detoxification either before or concomitantly with the biosynthesis of allelochemicals. This ability to 'eavesdrop' on plant defence signals protects H. zea against toxins produced by host plants.	Univ Illinois, Dept Entomol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Nanjing Agr Univ, Dept Plant Protect, Nanjing, Peoples R China	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Nanjing Agricultural University	Berenbaum, MR (corresponding author), Univ Illinois, Dept Entomol, 320 Morrill Hall, Urbana, IL 61801 USA.							Agrawal AA, 2001, SCIENCE, V294, P321, DOI 10.1126/science.1060701; BERENBAUM MR, 1999, MOL BIOL TOXIC RESPO, P553; Bi JL, 1997, J CHEM ECOL, V23, P1805, DOI 10.1023/B:JOEC.0000006452.81324.b8; Danielson PB, 1997, P NATL ACAD SCI USA, V94, P10797, DOI 10.1073/pnas.94.20.10797; Felton GW, 1999, CURR BIOL, V9, P317, DOI 10.1016/S0960-9822(99)80140-7; Keinanen M, 2001, J AGR FOOD CHEM, V49, P3553, DOI 10.1021/jf010200+; KIDDLE GA, 1994, J EXP BOT, V45, P1343, DOI 10.1093/jxb/45.9.1343; Li XC, 2002, INSECT BIOCHEM MOLEC, V32, P311, DOI 10.1016/S0965-1748(01)00092-3; Li XC, 2002, INSECT MOL BIOL, V11, P343, DOI 10.1046/j.1365-2583.2002.00341.x; Li XC, 2000, INSECT BIOCHEM MOLEC, V30, P75, DOI 10.1016/S0965-1748(99)00102-2; McCloud ES, 1997, PLANTA, V203, P430, DOI 10.1007/s004250050210; Miksch M, 1996, EXPERIENTIA, V52, P739, DOI 10.1007/BF01925585; Moran PJ, 2001, PLANT PHYSIOL, V125, P1074, DOI 10.1104/pp.125.2.1074; Preston CA, 1999, PLANTA, V209, P87, DOI 10.1007/s004250050609; Royo J, 1999, P NATL ACAD SCI USA, V96, P1146, DOI 10.1073/pnas.96.3.1146; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P26; Schuler MA, 1996, PLANT PHYSIOL, V112, P1411, DOI 10.1104/pp.112.4.1411; Seskar M, 1998, PLANT PHYSIOL, V116, P387, DOI 10.1104/pp.116.1.387; SNYDER MJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P13, DOI 10.1006/abbi.1995.1362; Stout MJ, 1999, PHYSIOL MOL PLANT P, V54, P115, DOI 10.1006/pmpp.1998.0193; Thaler JS, 1999, NATURE, V399, P686, DOI 10.1038/21420; Thaler JS, 1996, J CHEM ECOL, V22, P1767, DOI 10.1007/BF02028503; Thomma BPHJ, 1998, P NATL ACAD SCI USA, V95, P15107, DOI 10.1073/pnas.95.25.15107; TIETZ HM, 1972, INDEX DESCRIBED LIFE, V1; Tscharntke T, 2001, BIOCHEM SYST ECOL, V29, P1025, DOI 10.1016/S0305-1978(01)00048-5; VOLKER S, 1999, PHYTOCHEMISTRY, V50, P1141; WALDBAUER GP, 1984, GREAT LAKES ENTOMOL, V17, P113; Zangerl AR, 1997, OECOLOGIA, V109, P433, DOI 10.1007/s004420050103; [No title captured]	29	176	215	5	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					712	715		10.1038/nature01003	http://dx.doi.org/10.1038/nature01003			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384696				2022-12-28	WOS:000178615200038
J	Kleinert, S				Kleinert, S			What are the world's priorities?	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Kleinert, S (corresponding author), The Lancet, London NW1 7BY, England.							Kleinert S, 2000, LANCET, V356, P1869, DOI 10.1016/S0140-6736(00)03255-4; WHO, 2001, MACR HLTH INV HLTH D	2	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1118	1118		10.1016/S0140-6736(02)11241-4	http://dx.doi.org/10.1016/S0140-6736(02)11241-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387957				2022-12-28	WOS:000178632000009
J	Pol, S; Lebray, P				Pol, S; Lebray, P			N-acetylcysteine for paracetamol poisoning: effect on prothrombin	LANCET			English	Editorial Material							FULMINANT HEPATIC-FAILURE		Hop Necker Enfants Malad, Unite Hepatol, F-75015 Paris, France; Hop Necker Enfants Malad, INSERM, U370, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Pol, S (corresponding author), Hop Necker Enfants Malad, Unite Hepatol, F-75015 Paris, France.							BERNUAU J, 1986, HEPATOLOGY, V6, P648, DOI 10.1002/hep.1840060417; DEVLIN J, 1995, HEPATOLOGY, V21, P1018; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; Izumi S, 1996, HEPATOLOGY, V23, P1507; JEPSEN S, 1994, SCAND J CLIN LAB INV, V54, P543, DOI 10.3109/00365519409088566; JEPSEN S, 1992, CRIT CARE MED, V20, P918, DOI 10.1097/00003246-199207000-00004; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; OGRADY JG, 1991, GASTROENTEROLOGY, V100, P1480; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; VALE JA, 1995, LANCET, V346, P547, DOI 10.1016/S0140-6736(95)91385-8	11	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1115	1115		10.1016/S0140-6736(02)11238-4	http://dx.doi.org/10.1016/S0140-6736(02)11238-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387954				2022-12-28	WOS:000178632000006
J	Fourie, PB; Ellner, JJ; Johnson, JL				Fourie, PB; Ellner, JJ; Johnson, JL			Whither Mycobacterium vaccae - encore	LANCET			English	Editorial Material							IMMUNOTHERAPY; TUBERCULOSIS		MRC, Pretoria, South Africa; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Case Western Reserve Univ, Sch Med, Cleveland, OH USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Case Western Reserve University	Fourie, PB (corresponding author), MRC, Pretoria, South Africa.		FOURIE, Bernard/AAX-3457-2020	FOURIE, Bernard/0000-0002-1630-3554; Ellner, Jerrold/0000-0001-6150-0082				AbouZeid C, 1997, INFECT IMMUN, V65, P1856, DOI 10.1128/IAI.65.5.1856-1862.1997; Assersohn L, 2002, CLIN ONCOL-UK, V14, P23, DOI 10.1053/clon.2001.0030; Dalgleish AG, 1999, LANCET, V354, P1388, DOI 10.1016/S0140-6736(05)76243-7; DEBRUYN G, 2001, COCHRANE DATABASE SY, V1, DOI UNSP CD001166; Eaton JD, 2002, BJU INT, V89, P19, DOI 10.1046/j.1464-410X.2002.02572.x; Johnson JL, 2000, J INFECT DIS, V181, P1304, DOI 10.1086/315393; Luo SJ, 2001, IEEE T COMPON PACK T, V24, P43, DOI 10.1109/6144.910801; Luo Y, 2000, Zhonghua Jie He He Hu Xi Za Zhi, V23, P85; Mendes R, 2002, BRIT J CANCER, V86, P336, DOI 10.1038/sj.bjc.6600063; Onyebujoh PC, 1999, LANCET, V354, P1388, DOI 10.1016/S0140-6736(05)76244-9; Onyebujoh PC, 1999, LANCET, V354, P116, DOI 10.1016/S0140-6736(98)10448-8; Reichman LB, 1999, LANCET, V354, P90, DOI 10.1016/S0140-6736(99)90049-1; WU XQ, 2002, 4 WORLD C TUB MARR W	13	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1032	1033		10.1016/S0140-6736(02)11173-1	http://dx.doi.org/10.1016/S0140-6736(02)11173-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383977				2022-12-28	WOS:000178485200002
J	Hoffert, MI; Caldeira, K; Benford, G; Criswell, DR; Green, C; Herzog, H; Jain, AK; Kheshgi, HS; Lackner, KS; Lewis, JS; Lightfoot, HD; Manheimer, W; Mankins, JC; Mauel, ME; Perkins, LJ; Schlesinger, ME; Volk, T; Wigley, TML				Hoffert, MI; Caldeira, K; Benford, G; Criswell, DR; Green, C; Herzog, H; Jain, AK; Kheshgi, HS; Lackner, KS; Lewis, JS; Lightfoot, HD; Manheimer, W; Mankins, JC; Mauel, ME; Perkins, LJ; Schlesinger, ME; Volk, T; Wigley, TML			Advanced technology paths to global climate stability: Energy for a greenhouse planet	SCIENCE			English	Review							SPACE SOLAR POWER; CARBON-DIOXIDE; DISPOSAL; FUTURE; FUSION; STABILIZATION; EMISSIONS; SYSTEMS; FUELS	Stabilizing the carbon dioxide induced component of climate change is an energy problem. Establishment of a course toward such stabilization will require the development within the coming decades of primary energy sources that do not emit carbon dioxide to the atmosphere, in addition to efforts to reduce end-use energy demand. Mid-century primary power requirements that are free of carbon dioxide emissions could be several times what we now derive from fossil fuels (similar to10(13) watts), even with improvements in energy efficiency. Here we survey possible future energy sources, evaluated for their capability to supply massive amounts of carbon emission free energy and for their potential for large-scale commercialization. Possible candidates for primary energy sources include terrestrial solar and wind energy, solar power satellites, biomass, nuclear fission, nuclear fusion, fission-fusion hybrids, and fossil fuels from which carbon has been sequestered. Non primary power technologies that could contribute to climate stabilization include efficiency improvements, hydrogen production, storage and transport, superconducting global electric grids, and geoengineering. All of these approaches currently have severe deficiencies that limit their ability to stabilize global climate. We conclude that a broad range of intensive research and development is urgently needed to produce technological options that can allow both climate stabilization and economic development.	NYU, Dept Phys, New York, NY 10003 USA; NYU, Dept Biol, New York, NY 10003 USA; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA; Univ Houston, Inst Space Syst Operat, Houston, TX 77204 USA; McGill Univ, Dept Econ, Montreal, PQ H3A 2T7, Canada; MIT, Lab Energy & Environm, Cambridge, MA 02139 USA; Univ Illinois, Dept Atmospher Sci, Urbana, IL 61801 USA; Exxon Mobil Res & Engn Co, Annandale, NJ 08801 USA; Columbia Univ, Dept Earth & Environm Engn, New York, NY 10027 USA; Columbia Univ, Dept Appl Phys & Appl Math, New York, NY 10027 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; McGill Univ, Ctr Climate & Global Change Res, Montreal, PQ H3A 2K6, Canada; USN, Res Lab, Div Plasma Phys, Washington, DC 20375 USA; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; NASA Headquarters, Washington, DC 20546 USA	New York University; New York University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Irvine; University of Houston System; University of Houston; McGill University; Massachusetts Institute of Technology (MIT); University of Illinois System; University of Illinois Urbana-Champaign; Exxon Mobil Corporation; Columbia University; Columbia University; University of Arizona; McGill University; United States Department of Defense; United States Navy; Naval Research Laboratory; National Center Atmospheric Research (NCAR) - USA; National Aeronautics & Space Administration (NASA)	Hoffert, MI (corresponding author), NYU, Dept Phys, 4 Washington Pl, New York, NY 10003 USA.		Jain, Atul/D-2851-2016; Caldeira, Ken/E-7914-2011; Wigley, Tom M.L./B-4705-2008	Jain, Atul/0000-0002-4051-3228; Caldeira, Ken/0000-0002-4591-643X; Kheshgi, Haroon/0000-0002-4456-3601; Mauel, Michael/0000-0003-2490-7478				ADELMAN MA, 1983, ENERGY RESOURCES UNC, P334; [Anonymous], PHYS CLIMATE; Arrhenius S., 1896, LOND EDINB DUBLIN PH, V41, P237, DOI [10.1080/14786449608620846, DOI 10.1080/14786449608620846]; Ausubel JH, 1996, DAEDALUS, V125, P139; BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; BETHE H, 1979, PHYS TODAY, V32, P45; Bolin B, 2001, P NATL ACAD SCI USA, V98, P4850, DOI 10.1073/pnas.081078998; Budyko M. I., 1977, CLIMATE CHANGES; Caldeira K, 2000, GEOPHYS RES LETT, V27, P225, DOI 10.1029/1999GL002364; CHENEY R, 2001, NATL ENERGY POLICY R; Collins P., 1999, Space Energy & Transportation, V4, P47; Committee for the Assessment of NASA's Space Solar Power Investment Strategy Aeronautics and Space Engineering Board National Research Council Washington DC USA, 2001, LAYING FDN SPAC SOL; Committee on Separations Technology and Transmutation Systems, 1996, NUCL WAST TECHN SEP; Cox PM, 2000, NATURE, V408, P184, DOI 10.1038/35041539; Criswell, 2002, IND PHYS, V8, P12; CRISWELL DR, 2002, INNOVATIVE SOLUTIONS, P345; DYSON FJ, 1977, WORKSH GLOB EFF CARB, P111; Early JT., 1989, J BRIT INTER SOC, V42, P567; Fogg M.J., 1995, TERRAFORMING ENG PLA; Fowler T. Kenneth, 1997, FUSION QUEST; Fuller RB., 1981, CRITICAL PATH; Garwin RL., 2002, PHYS TODAY, V55, P80, DOI [10.1063/1.1480789, DOI 10.1063/1.1480789]; GLASER P, 1997, SOLAR POWER SATELLIT; GLASER PE, 1968, SCIENCE, V162, P857, DOI 10.1126/science.162.3856.857; Govindasamy B, 2000, GEOPHYS RES LETT, V27, P2141, DOI 10.1029/1999GL006086; Graetzer H., 1964, AM J PHYS, V32, P10; Hahn O, 1939, NATURWISSENSCHAFTEN, V27, P11, DOI 10.1007/BF01488241; Hansen J, 2000, P NATL ACAD SCI USA, V97, P9875, DOI 10.1073/pnas.170278997; HAYDEN HC, 2001, SOLAR FRAUD SOLAR EN, P161; Hellman K. H., 2001, EPA420R01008 EPA420R01008; HENDERSON P, 1982, INORGANIC GEOCHEMIST, P282; Herzog H, 2000, SCI AM, V282, P72, DOI 10.1038/scientificamerican0200-72; HOFFERT MI, 1992, NATURE, V360, P573, DOI 10.1038/360573a0; Hoffert MI, 1998, NATURE, V395, P881, DOI 10.1038/27638; HOFFERT MI, 1997, ENG RESPONSE GLOBAL, P205; HOFFERT MI, 1997, SOLAR POWER SATELLIT, P231; Holdren J. P., 1997, FEDERAL ENERGY RES D; Houghton J. T., 2001, CLIMATE CHANGE 2001; Johansson TB, 1993, RENEWABLE ENERGY; Keith DW, 2001, NATURE, V409, P420, DOI 10.1038/35053208; KESNER J, 1998, DIPOLE FUSION CONFIN; KHESHGI HS, 1994, ENERGY, V19, P967, DOI 10.1016/0360-5442(94)90082-5; Kheshgi HS, 2000, ANNU REV ENERG ENV, V25, P199, DOI 10.1146/annurev.energy.25.1.199; Kulcinski GL, 1998, NATURE, V396, P724, DOI 10.1038/25456; Lackner K.S., 1999, LAUR99583; LACKNER KS, 1995, ENERGY, V20, P1153, DOI 10.1016/0360-5442(95)00071-N; LANDIS GA, 1997, P SOL POW SAT 97 C 2, P327; LAWSON JD, 1957, P PHYS SOC LOND B, V70, P6, DOI 10.1088/0370-1301/70/1/303; LEWIS JS, 1991, SPACE POWER, V10, P363; LIDSKY LM, 1977, ENERGY TECHNOLOGY HD, P5; Manheimer W, 1999, FUSION TECHNOL, V36, P1; Mankins JC, 1997, AEROSPACE AM, V35, P30; MARCHETTI C, 1985, NUCL SCI ENG, V90, P521, DOI 10.13182/NSE85-A18502; Martin JH, 1990, GLOBAL BIOGEOCHEM CY, V4, P5, DOI 10.1029/GB004i001p00005; McNeill John R, 2000, FACE NATURAL HIST; METZ B, 2001, CLIMATE CHANGE 2001, P8; Metzger RA, 2001, CLIMATIC CHANGE, V49, P11, DOI 10.1023/A:1010765013104; Miley G. H., 1976, FUSION ENERGY CONVER; Nagatomo M, 1996, SOL ENERGY, V56, P111, DOI 10.1016/0038-092X(95)00098-C; Nakamura S, 1995, J CHEM ENG JPN, V28, P660, DOI 10.1252/jcej.28.660; NAKICENOVIC N, 1998, GLOBAL ENERGY PERSPE, P52; *NAT LAB DIR, 1997, TECHN OPP RED US GRE; O'Neill BC, 2002, SCIENCE, V296, P1971, DOI 10.1126/science.1071238; *PAN POL IMPL GREE, 1992, POL IMPL GREENH WARM, P433; Reichle D., 1999, CARBON SEQUESTRATION; Rosenfeld AH, 2000, PHYS TODAY, V53, P29, DOI 10.1063/1.1333283; Sailor WC, 2000, SCIENCE, V288, P1177, DOI 10.1126/science.288.5469.1177; Schneider SH, 2001, NATURE, V409, P417, DOI 10.1038/35053203; Smil V, 1999, ENERGIES; SMITH SJ, 2001, SPACE SOLAR ELECT PO; Steele BCH, 2001, NATURE, V414, P345, DOI 10.1038/35104620; Strickland JK, 1996, SOL ENERGY, V56, P23, DOI 10.1016/0038-092X(95)00087-8; TELLER E, 1997, UCRL231636 LAWR LIV; Turner JA, 1999, SCIENCE, V285, P687, DOI 10.1126/science.285.5428.687; *UN ENV PROGR WORL, 1992, UN NAT FRAM CONV CLI; WEINBERG AM, 1992, TECHNOLOGIES FOR A GREENHOUSE-CONSTRAINED SOCIETY, P227; Weiss MA, 2000, ROAD 2020 LIFE CYCLE; Wigley TML, 1996, NATURE, V379, P240, DOI 10.1038/379240a0; Winter C.-J., 1988, HYDROGEN ENERGY CARR; WITTENBERG LJ, 1986, FUSION TECHNOL, V10, P167, DOI 10.13182/FST86-A24972	80	941	969	22	719	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					981	987		10.1126/science.1072357	http://dx.doi.org/10.1126/science.1072357			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411695	Green Submitted			2022-12-28	WOS:000178932000044
J	Turner, BM				Turner, BM			Cellular memory and the histone code	CELL			English	Review							NUCLEOSOME; H3	The histone tails on the nucleosome surface are subject to enzyme-catalyzed modifications that may, singly or in combination, form a code specifying patterns of gene expression. Recent papers provide insights into how a combinatorial code might be set and read. They show how modification of one residue can influence that of another, even when they are located on different histories, and how modifications at specific genomic locations might be perpetuated on newly assembled chromatin.	Univ Birmingham, Sch Med, Dept Anat, Chromat & Gene Express Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Turner, BM (corresponding author), Univ Birmingham, Sch Med, Dept Anat, Chromat & Gene Express Grp, Birmingham B15 2TT, W Midlands, England.							Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; CZERMIN B, 2002, EMBO REP, V419, P407; DAUJAT S, 2002, IN PRESS CURR BIOL; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; SELKER EU, 2002, IN PRESS P NATL ACAD; Spotswood HT, 2002, J CLIN INVEST, V110, P577, DOI 10.1172/JCI200216547; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Vandel L, 2001, EMBO REP, V2, P21, DOI 10.1093/embo-reports/kve002; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	38	857	906	1	66	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 1	2002	111	3					285	291		10.1016/S0092-8674(02)01080-2	http://dx.doi.org/10.1016/S0092-8674(02)01080-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419240	Bronze			2022-12-28	WOS:000179010100002
J	Hermanson, O; Jepsen, K; Rosenfeld, MG				Hermanson, O; Jepsen, K; Rosenfeld, MG			N-CoR controls differentiation of neural stem cells into astrocytes	NATURE			English	Article							FIBRILLARY ACIDIC PROTEIN; NUCLEAR RECEPTOR-COREPRESSOR; CENTRAL-NERVOUS-SYSTEM; TRANSCRIPTION; KINASE; ROLES; GENE	Understanding the gene programmes that regulate maintenance and differentiation of neural stem cells is a central question in stem cell biology. Virtually all neural stem cells maintain an undifferentiated state and the capacity to self-renew in response to fibroblast growth factor-2 (FGF2)(1-5). Here we report that a repressor of transcription, the nuclear receptor co-repressor (NCoR), is a principal regulator in neural stem cells, as FGF2-treated embryonic cortical progenitors from N-CoR gene-disrupted mice display impaired self-renewal and spontaneous differentiation into astroglia-like cells. Stimulation of wild-type neural stem cells with ciliary neurotrophic factor (CNTF), a differentiation-inducing cytokine(3), results in phosphatidylinositol-3-OH kinase/Akt1 kinase-dependent phosphorylation of N-CoR, and causes a temporally correlated redistribution of N-CoR to the cytoplasm. We find that this is a critical strategy for cytokine-induced astroglia differentiation and lineage-characteristic gene expression. Recruitment of protein phosphatase-1 to a specific binding site on N-CoR exerts a reciprocal effect on the cellular localization of N-CoR. We propose that repression by NCoR, modulated by opposing enzymatic activities, is a critical mechanism in neural stem cells that underlies the inhibition of glial differentiation.	Univ Calif San Diego, Sch Med, Dept Mol Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Sch Med, Dept Mol Med, Howard Hughes Med Inst, 9500 Gilman Dr,Room 345, La Jolla, CA 92093 USA.		, Ola/AAF-5126-2021	Hermanson, Ola/0000-0001-9320-7921				Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BESNARD F, 1991, J BIOL CHEM, V266, P18877; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CHOI BH, 1988, GLIA, V1, P308, DOI 10.1002/glia.440010503; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Faux CH, 2001, J NEUROSCI, V21, P5587, DOI 10.1523/JNEUROSCI.21-15-05587.2001; Frisen J, 2001, BIOESSAYS, V23, P3, DOI 10.1002/1521-1878(200101)23:1<3::AID-BIES1001>3.0.CO;2-F; Ghosh MM, 1995, BIOREMED SER, V3, P15; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kahn MA, 1997, J NEUROCHEM, V68, P1413; KANEKO R, 1994, P NATL ACAD SCI USA, V91, P4529, DOI 10.1073/pnas.91.10.4529; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Molne M, 2000, J NEUROSCI RES, V59, P301, DOI 10.1002/(SICI)1097-4547(20000201)59:3<301::AID-JNR3>3.0.CO;2-H; Morrison SJ, 2002, NAT MED, V8, P16, DOI 10.1038/nm0102-16; Palmer TD, 1999, J NEUROSCI, V19, P8487; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Raballo R, 2000, J NEUROSCI, V20, P5012; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; Rhee Y, 2000, NAT BIOTECHNOL, V18, P433, DOI 10.1038/74500; Sauvageot CM, 2002, CURR OPIN NEUROBIOL, V12, P244, DOI 10.1016/S0959-4388(02)00322-7; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	28	242	265	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					934	939		10.1038/nature01156	http://dx.doi.org/10.1038/nature01156			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410313				2022-12-28	WOS:000178909700046
J	Zachos, JC; Arthur, MA; Bralower, TJ; Spero, HJ				Zachos, JC; Arthur, MA; Bralower, TJ; Spero, HJ			Palaeoclimatology - Tropical temperatures in greenhouse episodes	NATURE			English	Article							PALEOCENE THERMAL MAXIMUM; SEA-SURFACE TEMPERATURES		Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Univ N Carolina, Dept Geol Sci, Chapel Hill, NC 27599 USA; Univ Calif Davis, Dept Geol, Davis, CA 95616 USA	University of California System; University of California Santa Cruz; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Davis	Zachos, JC (corresponding author), Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA.		Arthur, Michael A/E-2872-2014; Zachos, James C/A-7674-2008	Arthur, Michael A/0000-0002-3028-6279; Zachos, James C/0000-0001-8439-1886; Spero, Howard/0000-0001-5465-8607				Kelly DC, 1998, PALAEOGEOGR PALAEOCL, V141, P139, DOI 10.1016/S0031-0182(98)00017-0; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; Pearson PN, 2001, NATURE, V413, P481, DOI 10.1038/35097000; SCHRAG DP, 1995, GEOCHIM COSMOCHIM AC, V59, P2265, DOI 10.1016/0016-7037(95)00105-9; Thomas DJ, 1999, PALEOCEANOGRAPHY, V14, P561, DOI 10.1029/1999PA900031; Wilson PA, 1996, GEOLOGY, V24, P555, DOI 10.1130/0091-7613(1996)024<0555:ESSTFT>2.3.CO;2; Wu GP, 1990, PALEOCEANOGRAPHY, V5, P581, DOI 10.1029/PA005i004p00581	7	23	23	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 31	2002	419	6910					897	898		10.1038/419897b	http://dx.doi.org/10.1038/419897b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609MN	12410301				2022-12-28	WOS:000178909700033
J	Kitahata, MM; Tegger, MK; Wagner, EH; Holmes, KK				Kitahata, MM; Tegger, MK; Wagner, EH; Holmes, KK			Comprehensive health care for people infected with HIV in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EXPERIENCE; SURVIVAL		Univ Washington, Harborview Med Ctr, Ctr AIDS & STD, Seattle, WA 98104 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, MacColl Inst Hlth Care Innovat, Seattle, WA 98101 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Group Health Cooperative	Kitahata, MM (corresponding author), Univ Washington, Harborview Med Ctr, Ctr AIDS & STD, Box 359931,325 9th Ave, Seattle, WA 98104 USA.	kitahata@u.washington.edu	, Holmes/K-6215-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757, K23AI001789] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-01789, AI-27757, P30 AI027757] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BADRI M, 2002, 14 INT AIDS C BARC S; COATES T, 2000, VOLUNTARY HIV 1 COUN; COLEBUNDERS R, 1993, LANCET, V342, P601, DOI 10.1016/0140-6736(93)91417-K; Cunningham CK, 2002, J INFECT DIS, V186, P181, DOI 10.1086/341300; DAKOURY C, 2002, 14 INT AIDS C BARC S; DALRYMPLE T, 1998, MASS LISTERIA MEANIN; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Epping-Jordan J, 2001, BMJ-BRIT MED J, V323, P947, DOI 10.1136/bmj.323.7319.947; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; JACK C, 2002, 14 INT AIDS C BARC S; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Kitahata MM, 1998, AM J MED, V104, P511; Kitahata MM, 2000, J ACQ IMMUN DEF SYND, V24, P106; MEKONNEN Y, 2002, 14 INT AIDS C BARC S; *PAHO WHO UNAIDS I, 2000, PAHO WORK GROUP SUMM, P1; POOLE C, 2002, 14 INT AIDS C BARC S; SANTOS B, 1994, INT J STD AIDS, V5, P279, DOI 10.1177/095646249400500410; *UN GEN ASS SPEC S, 2001, GLOB CRIS GLOB ACT; *UNAIDS, 2002, REP GLOB HIV AIDS EP; *UNAIDS USAID POL, 2000, MEAS LEV EFF NAT INT; VANLEEUWEN R, 2002, 14 INT AIDS C BARC S; WHO, 2002, INNOVATIVE CARE CHRO; *WHO WORK GROUP, 2002, DRAFT SCAL ANT THER	23	51	54	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 26	2002	325	7370					954	957		10.1136/bmj.325.7370.954	http://dx.doi.org/10.1136/bmj.325.7370.954			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399350	Green Published			2022-12-28	WOS:000178986300023
J	Rice, TM				Rice, TM			To condense or not to condense	SCIENCE			English	Editorial Material							MAGNETIZATION PLATEAUS; FIELD; GAP		Swiss Fed Inst Technol, Inst Theoret Phys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Rice, TM (corresponding author), Swiss Fed Inst Technol, Inst Theoret Phys, CH-8093 Zurich, Switzerland.							Cornell EA, 2002, REV MOD PHYS, V74, P875, DOI 10.1142/S0217979202014681; Giamarchi T, 1999, PHYS REV B, V59, P11398, DOI 10.1103/PhysRevB.59.11398; Kato T, 1998, J PHYS SOC JPN, V67, P752, DOI 10.1143/JPSJ.67.752; Kodama K, 2002, SCIENCE, V298, P395, DOI 10.1126/science.1075045; Matsumoto M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.077203; Miyahara S, 2000, PHYS REV B, V61, P3417, DOI 10.1103/PhysRevB.61.3417; Narumi Y, 1998, PHYSICA B, V246, P509, DOI 10.1016/S0921-4526(97)00974-5; Oshikawa M, 1997, PHYS REV LETT, V78, P1984, DOI 10.1103/PhysRevLett.78.1984; RUEGG C, IN PRESS APL PHYS A; SHASTRY BS, 1981, PHYSICA B & C, V108, P1069, DOI 10.1016/0378-4363(81)90838-X; Shiramura W, 1998, J PHYS SOC JPN, V67, P1548, DOI 10.1143/JPSJ.67.1548; Tanaka H, 2001, J PHYS SOC JPN, V70, P939, DOI 10.1143/JPSJ.70.939	12	134	135	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					760	761		10.1126/science.1078819	http://dx.doi.org/10.1126/science.1078819			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399570				2022-12-28	WOS:000178791200038
J	Clarke, R; Collins, R; Lewington, S; Donald, A; Alfthan, G; Tuomilehto, J; Arnesen, E; Bonaa, K; Blacher, J; Boers, GHJ; Bostom, A; Bots, ML; Grobee, DE; Brattstrom, L; Breteler, MMB; Hofman, A; Chambers, JC; Kooner, JS; Coull, BM; Evans, RW; Kuller, LH; Evers, S; Folsom, AR; Freyburger, G; Parrot, F; Genst, J; Dalery, K; Graham, IM; Daly, L; Hoogeveen, EK; Kostense, PJ; Stehouwer, CDA; Hopknis, PN; Jacques, P; Selhub, J; Luft, FC; Jungers, P; Lindgren, A; Lolin, YI; Loehrer, F; Fowler, B; Mansoor, MA; Malinow, MR; Ducimetiere, P; Nygard, O; Refsum, H; Vollset, SE; Ueland, PM; Omenn, GS; Beresford, SAA; Roseman, JM; Parving, HH; Gall, MA; Perry, IJ; Ebraham, SB; Shaper, AG; Robinson, K; Jacobsen, DW; Schwartz, SM; Siscovick, DS; Stampfer, MJ; Henekens, CH; Feskens, EJM; Kromhout, D; Ubbink, J; Elwood, P; Pickering, J; Verhoef, P; von Eckardstein, A; Schulte, H; Assmann, G; Wald, N; Law, MR; Whincup, PH; Wilcken, DEL; Sherliker, P; Linksted, P; Smith, GD; Witteman, JCM; Israelsson, B; Sexton, G; Wu, LL; Joubran, R; Norrving, B; Hultberg, B; Andersson, A; Johansson, BB; Bergmark, C; Svardal, AM; Evans, AE; Pancharuniti, N; Lewis, CA; Holman, R; Stratton, I; Johnston, C; Morris, J				Clarke, R; Collins, R; Lewington, S; Donald, A; Alfthan, G; Tuomilehto, J; Arnesen, E; Bonaa, K; Blacher, J; Boers, GHJ; Bostom, A; Bots, ML; Grobee, DE; Brattstrom, L; Breteler, MMB; Hofman, A; Chambers, JC; Kooner, JS; Coull, BM; Evans, RW; Kuller, LH; Evers, S; Folsom, AR; Freyburger, G; Parrot, F; Genst, J; Dalery, K; Graham, IM; Daly, L; Hoogeveen, EK; Kostense, PJ; Stehouwer, CDA; Hopknis, PN; Jacques, P; Selhub, J; Luft, FC; Jungers, P; Lindgren, A; Lolin, YI; Loehrer, F; Fowler, B; Mansoor, MA; Malinow, MR; Ducimetiere, P; Nygard, O; Refsum, H; Vollset, SE; Ueland, PM; Omenn, GS; Beresford, SAA; Roseman, JM; Parving, HH; Gall, MA; Perry, IJ; Ebraham, SB; Shaper, AG; Robinson, K; Jacobsen, DW; Schwartz, SM; Siscovick, DS; Stampfer, MJ; Henekens, CH; Feskens, EJM; Kromhout, D; Ubbink, J; Elwood, P; Pickering, J; Verhoef, P; von Eckardstein, A; Schulte, H; Assmann, G; Wald, N; Law, MR; Whincup, PH; Wilcken, DEL; Sherliker, P; Linksted, P; Smith, GD; Witteman, JCM; Israelsson, B; Sexton, G; Wu, LL; Joubran, R; Norrving, B; Hultberg, B; Andersson, A; Johansson, BB; Bergmark, C; Svardal, AM; Evans, AE; Pancharuniti, N; Lewis, CA; Holman, R; Stratton, I; Johnston, C; Morris, J		Homocysteine Studies Collaboration	Homocysteine and risk of ischemic heart disease and stroke - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-ARTERY DISEASE; PLASMA TOTAL HOMOCYSTEINE; SERUM TOTAL HOMOCYSTEINE; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; CARDIOVASCULAR-DISEASE; METHYLENETETRAHYDROFOLATE REDUCTASE; CEREBROVASCULAR-DISEASE; QUANTITATIVE ASSESSMENT; HORDALAND-HOMOCYSTEINE	Context it has been suggested that total blood homocysteine concentrations are associated with the risk of ischemic heart disease (IHD) and stroke. Objective To assess the relationship of homocysteine concentrations with vascular disease risk. Data Sources MEDLINE was searched for articles published from January 1966 to January 1999. Relevant studies were identified by systematic searches of the literature for all reported observational studies of associations between IHD or stroke risk and homocysteine concentrations. Additional studies were identified by a hand search of references of original articles or review articles and by personal communication with relevant investigators. Study Selection Studies were included if, they had data available by January 1999 on total blood homocysteine concentrations, sex, and age at event. Studies were excluded if they measured only blood concentrations of free homocysteine or of homocysteine after a methionine-loading test or if relevant clinical data were unavailable or incomplete. Data Extraction Data from 30 prospective or retrospective studies involving a total of 5073 IHD events and 1113 stroke events were included in a meta-analysis of individual participant data, with allowance made for differences between studies, for confounding by known cardiovascular risk factors, and for regression dilution bias. Combined odds ratios (ORs) for the association of IHD and stroke with blood homocysteine concentrations were obtained by using conditional logistic regression. Data Synthesis Stronger associations were observed in retrospective studies of homocysteine measured in blood collected after the onset of disease than in prospective studies among individuals who had no history of cardiovascular disease when blood was collected. After adjustment for known cardiovascular risk factors and regression dilution bias in the prospective studies, a 25% lower usual (corrected for regression. dilution bias) homocysteine level (about 3 mumol/L [0.41 mg/L]) was associated with an 11% (OR, 0.89; 95% confidence interval [CI], 0.83-0.96) lower IHD risk and 19% (OR, 0.81; 95% CI, 0.69-0.95) lower stroke risk. Conclusions This meta-analysis of observational studies suggests that elevated homocysteine is at most a modest independent predictor of IHD and stroke risk in healthy populations. Studies of the impact on disease risk of genetic variants that affect blood homocysteine concentrations will help determine whether homocysteine is causally related to vascular disease, as may large randomized trials of the effects on IHD and stroke of vitamin supplementation to lower blood homocysteine concentrations.	Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Clarke, R (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.		Feskens, Edith JM/A-3757-2012; stratton, irene/AAZ-3627-2020; Davey Smith, George/A-7407-2013; Wald, Nicholas/AAY-8924-2021; Feskens, Edith/ABI-1446-2020; Stehouwer, Coen/AAB-3435-2021; Blacher, Jacques/F-2685-2017; Refsum, Helga/A-4073-2010; Kromhout, Daan/A-8566-2014; Ueland, Per M/C-7340-2013; Wald, Nicholas/AAY-2814-2021; Breteler, Monique M.B./J-5058-2014	stratton, irene/0000-0003-1172-7865; Davey Smith, George/0000-0002-1407-8314; Feskens, Edith/0000-0001-5819-2488; Blacher, Jacques/0000-0003-4860-4279; Breteler, Monique M.B./0000-0002-0626-9305; Luft, Friedrich/0000-0002-8635-1199; Lewington, Sarah/0000-0002-4496-4771; Hoogeveen, Ellen/0000-0002-5482-2013; Ueland, Per Magne/0000-0002-1903-0571; Omenn, Gilbert S./0000-0002-8976-6074; Verhoef, Petra/0000-0002-6927-6182; Whincup, Peter/0000-0002-5589-4107				ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ANDERSSON A, 1991, ATHEROSCLEROSIS, V88, P143, DOI 10.1016/0021-9150(91)90076-F; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; Blacher J, 1996, ARCH MAL COEUR VAISS, V89, P1241; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; Bostom AG, 1999, ARCH INTERN MED, V159, P1077, DOI 10.1001/archinte.159.10.1077; Bots ML, 1999, ARCH INTERN MED, V159, P38, DOI 10.1001/archinte.159.1.38; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 2000, AM J CLIN NUTR, V72, P315; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; Chacko K A, 1998, Indian Heart J, V50, P295; Chambers JC, 2000, LANCET, V355, P523, DOI 10.1016/S0140-6736(99)93019-2; Clarke R, 1999, AM J EPIDEMIOL, V150, P341; Clarke R, 2001, J CARDIOVASC RISK, V8, P363, DOI 10.1097/00043798-200112000-00005; Clarke R, 1998, J Cardiovasc Risk, V5, P249, DOI 10.1097/00043798-199808000-00007; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; COULL BM, 1990, STROKE, V21, P572, DOI 10.1161/01.STR.21.4.572; DALERY K, 1995, AM J CARDIOL, V75, P1107, DOI 10.1016/S0002-9149(99)80739-5; Danesh J, 1998, J Cardiovasc Risk, V5, P229, DOI 10.1097/00043798-199808000-00004; de Groot JC, 2000, ANN NEUROL, V47, P145; Dierkes J, 1998, CLIN CHEM LAB MED, V36, P453, DOI 10.1515/CCLM.1998.076; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P1253, DOI 10.1161/01.ATV.13.9.1253; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Evers S, 1997, ARCH NEUROL-CHICAGO, V54, P1276, DOI 10.1001/archneur.1997.00550220074017; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; Freyburger G, 1997, THROMB HAEMOSTASIS, V77, P466; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Hoogeveen EK, 1998, ARTERIOSCL THROM VAS, V18, P133, DOI 10.1161/01.ATV.18.1.133; HOPKINS PN, 1995, ARTERIOSCL THROM VAS, V15, P1314, DOI 10.1161/01.ATV.15.9.1314; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; Joubran R, 1998, J Cardiovasc Risk, V5, P257, DOI 10.1097/00043798-199808000-00008; Kark JD, 1999, ANN INTERN MED, V131, P321, DOI 10.7326/0003-4819-131-5-199909070-00002; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Knekt P, 2001, ARCH INTERN MED, V161, P1589, DOI 10.1001/archinte.161.13.1589; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; Loehrer FMT, 1996, ARTERIOSCL THROM VAS, V16, P727, DOI 10.1161/01.ATV.16.6.727; Lolin YI, 1996, HEART, V76, P117, DOI 10.1136/hrt.76.2.117; Malinow MR, 1996, ATHEROSCLEROSIS, V126, P27, DOI 10.1016/0021-9150(96)05890-X; MCCULLY KS, 1969, AM J PATHOL, V56, P111; Mendis S, 1997, INT J CARDIOL, V62, P221, DOI 10.1016/S0167-5273(97)00225-8; Montalescot G, 1997, INT J CARDIOL, V60, P295, DOI 10.1016/S0167-5273(97)00099-5; Moustapha A, 1998, CIRCULATION, V97, P138, DOI 10.1161/01.CIR.97.2.138; Nygard O, 1997, AM J CLIN NUTR, V65, P136, DOI 10.1093/ajcn/65.1.136; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Petri M, 1996, LANCET, V348, P1120, DOI 10.1016/S0140-6736(96)03032-2; Ridker PM, 1999, JAMA-J AM MED ASSOC, V281, P1817, DOI 10.1001/jama.281.19.1817; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; Schwartz SM, 1997, CIRCULATION, V96, P412; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Silberberg J, 1997, ATHEROSCLEROSIS, V133, P105, DOI 10.1016/S0021-9150(97)00122-6; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Stehouwer CDA, 1999, KIDNEY INT, V55, P308, DOI 10.1046/j.1523-1755.1999.00256.x; Stehouwer CDA, 1998, ARTERIOSCL THROM VAS, V18, P1895, DOI 10.1161/01.ATV.18.12.1895; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Ubbink JB, 1998, ATHEROSCLEROSIS, V140, P349, DOI 10.1016/S0021-9150(98)00139-7; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Verhoef P, 1997, ARTERIOSCL THROM VAS, V17, P989, DOI 10.1161/01.ATV.17.5.989; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; Vollset SE, 2001, AM J CLIN NUTR, V74, P130; VONECKARDSTEIN A, 1994, ARTERIOSCLER THROMB, V14, P460, DOI 10.1161/01.ATV.14.3.460; Voutilainen S, 2000, J INTERN MED, V248, P217, DOI 10.1046/j.1365-2796.2000.00741.x; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; Whincup PH, 1999, HEART, V82, P448, DOI 10.1136/hrt.82.4.448; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350	73	1649	1730	3	135	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	2002	288	16					2015	2022		10.1001/jama.288.16.2015	http://dx.doi.org/10.1001/jama.288.16.2015			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	606QW	12387654	Green Accepted			2022-12-28	WOS:000178745500025
J	Hoek, G; Brunekreef, B; Goldbohm, S; Fischer, P; van den Brandt, PA				Hoek, G; Brunekreef, B; Goldbohm, S; Fischer, P; van den Brandt, PA			Association between mortality and indicators of traffic-related air pollution in the Netherlands: a cohort study	LANCET			English	Article							PARTICLES; OUTDOOR; HEALTH; CHILDREN; POLLUTANTS; EXHAUST; CANCER	Background Long-term exposure to particulate matter air pollution has been associated with increased cardiopulmonary mortality in the USA. We aimed to assess the relation between traffic-related air pollution and mortality in participants of the Netherlands Cohort study on Diet and Cancer (NLCS), an ongoing study. Methods We investigated a random sample of 5000 people from the full cohort of the NLCS study (age 55-69 years) from 1986 to 1994. Long-term exposure to traffic-related air pollutants (black smoke and nitrogen dioxide) was estimated for the 1986 home address. Exposure was characterised with the measured regional and urban background concentration and an indicator variable for living near major roads. The association between exposure to air pollution and (cause specific) mortality was assessed with Cox's proportional hazards models, with adjustment for potential confounders. Findings 489 (11%) of 4492 people with data died during the follow-up period. Cardiopulmonary mortality was associated with living near a major road (relative risk 1.95, 95% CI 1.09-3.52) and, less consistently, with the estimated ambient background concentration (1.34, 0.68-2.64). The relative risk for living near a major road was 1.41 (0.94-2.12) for total deaths. Non-cardiopulmonary, non-lung cancer deaths were unrelated to air pollution (1.03, 0.54-1.96 for living near a major road). Interpretation Long-term exposure to traffic-related air pollution may shorten life expectancy.	Univ Utrecht, Inst Risk Assessment Sci, Environm & Occupat Hlth Grp, NL-3508 TD Utrecht, Netherlands; Netherlands Org Appl Sci Res Nutr & Food Res, Dept Nutr Epidemiol, Zeist, Netherlands; Natl Inst Publ Hlth & Environm, Lab Exposure Assessment & Environm Epidemiol, NL-3720 BA Bilthoven, Netherlands; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands	Utrecht University; Netherlands Organization Applied Science Research; Netherlands National Institute for Public Health & the Environment; Maastricht University	Hoek, G (corresponding author), Univ Utrecht, Inst Risk Assessment Sci, Environm & Occupat Hlth Grp, POB 80176, NL-3508 TD Utrecht, Netherlands.	g.hoek@iras.uu.nl		brunekreef, bert/0000-0001-9908-0060; van den Brandt, Piet/0000-0001-8781-8099				Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373, DOI 10.1164/ajrccm.159.2.9806020; Babisch W, 1999, ARCH ENVIRON HEALTH, V54, P210, DOI 10.1080/00039899909602261; BLOEMEN HJT, 1998, 650010006 NAT I PUBL; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Brunekreef B, 1997, OCCUP ENVIRON MED, V54, P781, DOI 10.1136/oem.54.11.781; Burnett R, 2001, ENVIRON HEALTH PERSP, V109, P375, DOI 10.2307/3434784; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223, DOI 10.1080/00039896.1994.9937471; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Hoek G, 1996, ATMOS ENVIRON, V30, P3141, DOI 10.1016/1352-2310(96)00032-5; Hoek G, 1997, ATMOS ENVIRON, V31, P3609, DOI 10.1016/S1352-2310(97)00158-1; Hoek G, 2001, J EXPO ANAL ENV EPID, V11, P459, DOI 10.1038/sj.jea.7500189; Krewski D., 2000, REANALYSIS HARVARD 6; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Kunzli N, 2001, AM J EPIDEMIOL, V153, P1050, DOI 10.1093/aje/153.11.1050; Lebret E, 2000, ATMOS ENVIRON, V34, P177, DOI 10.1016/S1352-2310(99)00292-7; Nyberg F, 2000, EPIDEMIOLOGY, V11, P487, DOI 10.1097/00001648-200009000-00002; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; POPE CA, 1995, INHAL TOXICOL, V7, P1, DOI 10.3109/08958379509014267; Rijnders E, 2001, ENVIRON HEALTH PERSP, V109, P411, DOI 10.2307/3434789; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; van der Wal JT, 2000, ATMOS ENVIRON, V34, P3675, DOI 10.1016/S1352-2310(00)00085-6; van Wijnen J. H., 1998, Reviews on Environmental Health, V13, P1; VANDENBRANDT PA, 1990, J CLIN EPIDEMIOL, V43, P285, DOI 10.1016/0895-4356(90)90009-E; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Wallace L, 1996, J AIR WASTE MANAGE, V46, P98, DOI 10.1080/10473289.1996.10467451; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; *WHO, 2000, EUR SER WHO, V91; WJST M, 1993, BRIT MED J, V307, P596, DOI 10.1136/bmj.307.6904.596	33	1095	1128	3	273	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	2002	360	9341					1203	1209		10.1016/S0140-6736(02)11280-3	http://dx.doi.org/10.1016/S0140-6736(02)11280-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401246	Green Submitted			2022-12-28	WOS:000178708100009
J	Lyons, RA; Djahanbakhch, O; Saridogan, E; Naftalin, AA; Mahmood, T; Weekes, A; Chenoy, R				Lyons, RA; Djahanbakhch, O; Saridogan, E; Naftalin, AA; Mahmood, T; Weekes, A; Chenoy, R			Peritoneal fluid, endometriosis, and ciliary beat frequency in the human fallopian tube	LANCET			English	Article								Endometriosis and infertility are known to be associated, but it is unclear whether endometriosis causes infertility. We used contrast analogue enhancement to study the effect of peritoneal fluid from women with early stage endometriosis on the ciliary beat frequency of human fallopian tube epithelium. We obtained peritoneal fluid from six women with early stage endometriosis and from six fertile women with no evidence of endometriosis to use as controls. Fallopian tubes from hysterectomy specimens were collected from 17 women. The difference in ciliary beat frequency between fallopian tubes exposed to peritoneal fluids of women with and without endometriosis increased with the duration of incubation (mean difference at 24 h 1.35 Hz, 95% CI 0.94-1.75, p=0.01). At 24 h, ciliary beat frequency was significantly lower in the incubations with peritonal fluid from women with endometriosis than controls (4.29 [0.15] vs 5.64 Hz [0.15], respectively, p=0.001). Impairment of ciliary action in women with endometriosis might reduce fertility.	St Bartholomews Hosp, Acad Dept Obstet & Gynaecol, London, England; London Sch Med & Dent, London, England; Newham Dist Gen Hosp, Dept Obstet & Gynaecol, London, England; Harold Wood Hosp, Dept Obstet & Gynaecol, Romford, Essex, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Djahanbakhch, O (corresponding author), Royal London Hosp, Dept Obstet & Gynaecol, 4th Floor,Holland Wing, London E1 2BB, England.		yang, xiao-jun/B-1927-2009					Lyons RA, 2002, HUM REPROD, V17, P584, DOI 10.1093/humrep/17.3.584; Mahmood T, 1998, HUM REPROD, V13, P2991, DOI 10.1093/humrep/13.11.2991; Saridogan E, 1996, J CLIN ENDOCR METAB, V81, P2719, DOI 10.1210/jc.81.7.2719; STEINLEITNER A, 1990, FERTIL STERIL, V53, P926; SUGINAMI H, 1988, FERTIL STERIL, V50, P648	5	40	46	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1221	1222		10.1016/S0140-6736(02)11247-5	http://dx.doi.org/10.1016/S0140-6736(02)11247-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401250				2022-12-28	WOS:000178708100013
J	Ware, LB; Matthay, MA				Ware, LB; Matthay, MA			Measuring microvascular blood flow in sepsis - a continuing challenge	LANCET			English	Editorial Material									Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Vanderbilt Univ, Sch Med, Div Pulm & Crit Care Med, Dept Med, Nashville, TN 37212 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Vanderbilt University	Matthay, MA (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA.		Ware, Lorraine/AAJ-9307-2021	Ware, Lorraine/0000-0002-9429-4702				De Backer D, 2002, AM J RESP CRIT CARE, V166, P98, DOI 10.1164/rccm.200109-016OC; De Backer D, 2001, Curr Opin Crit Care, V7, P200, DOI 10.1097/00075198-200106000-00010; Fisher CJ, 2000, CRIT CARE MED, V28, pS49, DOI 10.1097/00003246-200009001-00011; GREENE R, 1981, AM REV RESPIR DIS, V124, P593; Groner W, 1999, NAT MED, V5, P1209, DOI 10.1038/13529; Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835; Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307	9	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 19	2002	360	9341					1187	1188		10.1016/S0140-6736(02)11292-X	http://dx.doi.org/10.1016/S0140-6736(02)11292-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401242				2022-12-28	WOS:000178708100005
J	Liu, YC; Fallon, L; Lashuel, HA; Liu, ZH; Lansbury, PT				Liu, YC; Fallon, L; Lashuel, HA; Liu, ZH; Lansbury, PT			The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility	CELL			English	Article							UBIQUITIN-PROTEASOME SYSTEM; C-TERMINAL HYDROLASES; GAD MUTANT MOUSE; CRYSTAL-STRUCTURE; NERVE-TERMINALS; DEUBIQUITINATING ENZYMES; POLYUBIQUITIN CHAINS; INHIBITION; NEURODEGENERATION; IDENTIFICATION	The assumption that each enzyme expresses a single enzymatic activity in vivo is challenged by the linkage of the neuronal enzyme ubiquitin C-terminal hydrolase-L1 (UCH-L1) to Parkinson's disease (PD). UCH-L1, especially those variants linked to higher susceptibility to PD, causes the accumulation of alpha-synuclein in cultured cells, an effect that cannot be explained by its recognized hydrolase activity. UCH-L1 is shown here to exhibit a second, dimerization-dependent, ubiquityl ligase activity. A polymorphic variant of UCH-L1 that is associated with decreased PD risk (S18Y) has reduced ligase activity but comparable hydrolase activity as the wild-type enzyme. Thus, the ligase activity as well as the hydrolase activity of UCH-L1 may play a role in proteasomal protein degradation, a critical process for neuronal health.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis,Dept Neurol, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital	Lansbury, PT (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis,Dept Neurol, 65 Landsdowne St, Cambridge, MA 02139 USA.		Lashuel, Hilal/M-3500-2017; Longo, Kenneth A/A-5631-2010		NINDS NIH HHS [NS38375] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038375] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; CHAIN DG, 1995, J NEUROSCI, V15, P7592; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Cole RN, 2001, J NEUROCHEM, V79, P1080, DOI 10.1046/j.1471-4159.2001.00655.x; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Hell JW, 1998, METHOD ENZYMOL, V296, P116; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kurihara LJ, 2001, HUM MOL GENET, V10, P1963, DOI 10.1093/hmg/10.18.1963; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lansbury PT, 2002, CURR OPIN GENET DEV, V12, P299, DOI 10.1016/S0959-437X(02)00302-7; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Layfield R, 2001, NEUROPATH APPL NEURO, V27, P171, DOI 10.1046/j.1365-2990.2001.00335.x; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Levecque C, 2001, J NEURAL TRANSM, V108, P979, DOI 10.1007/s007020170017; Maraganore DM, 1999, NEUROLOGY, V53, P1858, DOI 10.1212/WNL.53.8.1858; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; MIURA H, 1993, NEUROPATH APPL NEURO, V19, P41, DOI 10.1111/j.1365-2990.1993.tb00403.x; Momose Y, 2002, ANN NEUROL, V51, P133, DOI 10.1002/ana.10079; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; MUKOYAMA M, 1989, ACTA NEUROPATHOL, V79, P294, DOI 10.1007/BF00294664; Naze P, 2002, NEUROSCI LETT, V328, P1, DOI 10.1016/S0304-3940(02)00231-8; ODA K, 1992, NEUROPATH APPL NEURO, V18, P265, DOI 10.1111/j.1365-2990.1992.tb00789.x; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Satoh J, 2001, J NEUROL SCI, V189, P113, DOI 10.1016/S0022-510X(01)00555-X; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wang J, 2002, MOVEMENT DISORD, V17, P767, DOI 10.1002/mds.10179; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Wu J, 1995, No To Shinkei, V47, P881	47	637	677	0	32	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 18	2002	111	2					209	218		10.1016/S0092-8674(02)01012-7	http://dx.doi.org/10.1016/S0092-8674(02)01012-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408865	Green Published, Bronze			2022-12-28	WOS:000178753500010
J	Imai, S; Tsuge, N; Tomotake, M; Nagatome, Y; Sawada, H; Nagata, T; Kumagai, H				Imai, S; Tsuge, N; Tomotake, M; Nagatome, Y; Sawada, H; Nagata, T; Kumagai, H			An onion enzyme that makes the eyes water - A flavoursome, user-friendly bulb would give no cause for tears when chopped up.	NATURE			English	Article							LACHRYMATORY FACTOR; S-OXIDE		House Foods Corp, Somatech Ctr, Chiba 2840033, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan	House Foods Corporation; University of Tokyo; Kyoto University	Imai, S (corresponding author), House Foods Corp, Somatech Ctr, Chiba 2840033, Japan.							ADAMU I, 1982, EXPERIENTIA, V38, P899, DOI 10.1007/BF01953641; ARIGA T, 1981, LANCET, V1, P150; BLOCK E, 1992, ANGEW CHEM INT EDIT, V31, P1135, DOI 10.1002/anie.199211351; BLOCK E, 1979, J AM CHEM SOC, V101, P2200, DOI 10.1021/ja00502a044; BRODNITZ MH, 1971, J AGR FOOD CHEM, V19, P269, DOI 10.1021/jf60174a009; MAKHEJA AN, 1990, AGENTS ACTIONS, V29, P360, DOI 10.1007/BF01966468; Shen CX, 2000, J AGR FOOD CHEM, V48, P6254, DOI 10.1021/jf000711g	7	121	138	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					685	685		10.1038/419685a	http://dx.doi.org/10.1038/419685a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384686	Bronze			2022-12-28	WOS:000178615200028
J	Fiellin, DA; O'Connor, PG				Fiellin, DA; O'Connor, PG			New federal initiatives to enhance the medical treatment of opioid dependence	ANNALS OF INTERNAL MEDICINE			English	Review							METHADONE TREATMENT PRACTICES; RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; NARCOTIC ADDICTION; DRUG-ABUSE; FOLLOW-UP; MAINTENANCE; BUPRENORPHINE; DEPRESSION; OUTCOMES	Opioid dependence is a chronic relapsing medical condition with substantial health and societal complications. Recent federal initiatives are designed to enhance the medical treatment of patients with opioid dependence and will expand the role of internists in the care of these patients. These initiatives include a process for federal exemptions to allow for pharmacologic treatment in office settings, waivers for the use of new medications, and new rules governing the oversight and distribution of opioid agonist medications for maintenance treatment. This perspective describes these initiatives and their implications for internists.	Yale Univ, Sch Med, New Haven, CT 06520 USA	Yale University	Fiellin, DA (corresponding author), Yale Univ, Sch Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	david.fiellin@yale.edu		Fiellin, David/0000-0002-4006-010X	NATIONAL INSTITUTE ON DRUG ABUSE [K12DA000167] Funding Source: NIH RePORTER; NIDA NIH HHS [K12 DA00167] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		*AM PSYCH ASS, ONL CME PROGR BUPR T; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 1995, FEDERAL REGULATION M; COOPER JR, 1995, JAMA-J AM MED ASSOC, V273, P1619, DOI 10.1001/jama.273.20.1619; DAUNNO T, 1992, JAMA-J AM MED ASSOC, V267, P253, DOI 10.1001/jama.267.2.253; DOLE VP, 1995, JAMA-J AM MED ASSOC, V274, P1307; DOLE VP, 1966, ARCH INTERN MED, V118, P304, DOI 10.1001/archinte.118.4.304; DOLE VP, 1988, JAMA-J AM MED ASSOC, V260, P3025, DOI 10.1001/jama.260.20.3025; DOLE VP, 1965, J AMER MED ASSOC, V193, P646, DOI 10.1001/jama.1965.03090080008002; Fiellin DA, 2001, JAMA-J AM MED ASSOC, V286, P1724, DOI 10.1001/jama.286.14.1724; FIELLIN DA, 2002, NATL I DRUG ABUSE RE, P24; FLEMING M, 1995, TRAINING ALCOHOL SUB; Gossop M, 1999, BRIT J GEN PRACT, V49, P31; Hecht FM, 1999, ANN INTERN MED, V131, P136, DOI 10.7326/0003-4819-131-2-199907200-00011; Henney JE, 2000, JAMA-J AM MED ASSOC, V284, P2178, DOI 10.1001/jama.284.17.2178; Judd LL, 1998, JAMA-J AM MED ASSOC, V280, P1936; KAMEROW DB, 1986, JAMA-J AM MED ASSOC, V255, P2054, DOI 10.1001/jama.255.15.2054; LEPAY D, 2000, DEAR COLLEAGUE  0330; Lewis DC, 1997, MED CLIN N AM, V81, P831, DOI 10.1016/S0025-7125(05)70551-4; LOPEZ F, 1994, CONFIDENTIALITY PATI, V13; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Moatti JP, 1998, ADDICTION, V93, P1567, DOI 10.1046/j.1360-0443.1998.9310156714.x; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1997, NEW TREATMENTS OPIAT, P286; NEWMAN RG, 1987, NEW ENGL J MED, V317, P447, DOI 10.1056/NEJM198708133170710; NOVICK DM, 1994, J GEN INTERN MED, V9, P127, DOI 10.1007/BF02600025; O'Connor PG, 2000, ANN INTERN MED, V133, P40, DOI 10.7326/0003-4819-133-1-200007040-00008; *OFF NAT DRUG CONT, 1999, POL PAP OP AG TR MAR; Rounsaville BJ, 2000, JAMA-J AM MED ASSOC, V283, P1337, DOI 10.1001/jama.283.10.1337; Schulberg HC, 1998, ARCH GEN PSYCHIAT, V55, P1121, DOI 10.1001/archpsyc.55.12.1121; Schwartz RP, 1999, AM J ADDICTION, V8, P293; Senay Edward C., 1993, Journal of Addictive Diseases, V12, P59, DOI 10.1300/J069v12n04_05; Weinrich M, 2000, JAMA-J AM MED ASSOC, V283, P1343, DOI 10.1001/jama.283.10.1343; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Woods J, 2001, MT SINAI J MED, V68, P75; 1999, FED REG, V64, P39810; WEB BASED BUPRENORPH; 2000, H R, V4365, P122; 2001, FED REG, V66, P4076	39	63	64	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2002	137	8					688	692		10.7326/0003-4819-137-8-200210150-00014	http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00014			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604WL	12379070				2022-12-28	WOS:000178644000009
J	Qin, P; Agerbo, E; Mortensen, PB				Qin, P; Agerbo, E; Mortensen, PB			Suicide risk in relation to family history of completed suicide and psychiatric disorders: a nested case-control study based on longitudinal registers	LANCET			English	Article							ADOLESCENT SUICIDE; PSYCHOLOGICAL AUTOPSY; BEHAVIOR; CHILDREN; ILLNESS; DENMARK	Background Familial clustering of suicidal behaviour has been well documented. We aimed to assess whether family history of completed suicide and mental illness that results in admission to hospital are risk factors for suicide, and whether these factors interact. Methods We did a nested case-control study using data from Danisn longitudinal registers. We included 4262 people who had committed suicide aged 9-45 years during 1981-97 (cases), and 80 238 population-based controls matched for age, sex, and date of suicide. Suicide and psychiatric history of parents and siblings and socioeconomic, demographic, and psychiatric data for every case were retrieved and merged. Data were analysed with conditional logistic regression. Findings A family history of completed suicide and psychiatric illness significantly and independently increased suicide risk (odds ratio 2.58 [95% CI 1.84-3.61] and 1.31 [1.19-1.45], respectively). These effects were not accounted for by the socioeconomic status and psychiatric history of cases. A history of family psychiatric illness significantly raised suicide risk only in people without a history of psychiatric illness (1.55 [1.38-1.75]), whereas a family history of suicide increased suicide risk irrespective of psychiatric illness (2.7 [1.11-5.09] and 2.66 [1.82-3.88]) for people with and without a psychiatric history, respectively, Interpretation Completed suicide and psychiatric illness in relatives are risk factors for suicide, and the effect of family suicide history is independent of the familial cluster of mental disorders. Family history of suicide should be established in the assessment of suicide risk.	Aarhus Univ, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark	Aarhus University	Qin, P (corresponding author), Aarhus Univ, Natl Ctr Register Based Res, Taasingegade 1, DK-8000 Aarhus C, Denmark.		Agerbo, Esben/A-2645-2012; Mortensen, Preben B/D-2358-2015; farjad, farshad/AGC-9105-2022	Agerbo, Esben/0000-0002-2849-524X; Mortensen, Preben B/0000-0002-5230-9865; 				BRENT DA, 1994, ACTA PSYCHIAT SCAND, V89, P52, DOI 10.1111/j.1600-0447.1994.tb01485.x; Brent DA, 1996, ARCH GEN PSYCHIAT, V53, P1145; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CHENG ATA, 1995, ARCH GEN PSYCHIAT, V52, P594; Cheng ATA, 2000, BRIT J PSYCHIAT, V177, P360, DOI 10.1192/bjp.177.4.360; *DAN NAT BOARD, 1993, CAUS DEATH DENM 1991; *DANM STAT, 1991, IDA INT DAT ARB; Glowinski AL, 2001, J AM ACAD CHILD PSY, V40, P1300, DOI 10.1097/00004583-200111000-00010; Gould MS, 1996, ARCH GEN PSYCHIAT, V53, P1155; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hills, 1993, STAT MODELS EPIDEMIO; Johnson BA, 1998, ACTA PSYCHIAT SCAND, V97, P18, DOI 10.1111/j.1600-0447.1998.tb09957.x; Kendler KS, 1997, BRIT J PSYCHIAT, V170, P541, DOI 10.1192/bjp.170.6.541; MALIG C, 1996, 66 VRS INT I VIT REG; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Mortensen PB, 2000, LANCET, V355, P9, DOI 10.1016/S0140-6736(99)06376-X; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; MURPHY GE, 1982, J NERV MENT DIS, V170, P86, DOI 10.1097/00005053-198202000-00004; Pfeffer CR, 1998, J NERV MENT DIS, V186, P269, DOI 10.1097/00005053-199805000-00002; Powell J, 2000, BRIT J PSYCHIAT, V176, P266, DOI 10.1192/bjp.176.3.266; Qin P, 2000, BRIT J PSYCHIAT, V177, P546, DOI 10.1192/bjp.177.6.546; ROY A, 1991, ARCH GEN PSYCHIAT, V48, P29; Roy A., 2000, INT HDB SUICIDE ATTE, P209; Runeson BS, 1998, ACTA PSYCHIAT SCAND, V98, P497, DOI 10.1111/j.1600-0447.1998.tb10126.x; SHAFII M, 1985, AM J PSYCHIAT, V142, P1061; Statham DJ, 1998, PSYCHOL MED, V28, P839, DOI 10.1017/S0033291798006916; Wagner BM, 1997, PSYCHOL BULL, V121, P246, DOI 10.1037/0033-2909.121.2.246; WENDER PH, 1986, ARCH GEN PSYCHIAT, V43, P923; *WHO, 1967, MAN INT CLASS DIS IC; World Health Organisation, 1993, ICD 10 CLASSIFICATIO	30	227	230	0	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1126	1130		10.1016/S0140-6736(02)11197-4	http://dx.doi.org/10.1016/S0140-6736(02)11197-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387960				2022-12-28	WOS:000178632000012
J	Wallis, JP; Haynes, S; Stark, G; Green, FA; Lucas, GF; Chapman, CE				Wallis, JP; Haynes, S; Stark, G; Green, FA; Lucas, GF; Chapman, CE			Transfusion-related alloimmune neutropenia: an undescribed complication of blood transfusion	LANCET			English	Article							ANTIBODIES	Alloimmune neutropenia in neonates is rare. We describe severe and persistent neutropenia in a 4-week-old neonate, which arose within 2 h of a transfusion of blood that contained about 28 mL of plasma and in which strong antibodies against human neutrophil antigen 1b (HNA-1b) were subsequently identified. The infant was positive for HNA-1b. No other likely cause of neutropenia was discovered. We believe this complication of blood transfusion to be a previously unrecognised one, and have called the condition transfusion-related alloimmune neutropenia (TRAIN).	Freeman Rd Hosp, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Natl Blood Serv, Newcastle Upon Tyne, Tyne & Wear, England; Int Blood Grp Reference Lab, Bristol, Avon, England	Newcastle Freeman Hospital; Newcastle University - UK	Wallis, JP (corresponding author), Freeman Rd Hosp, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.							BUX J, 1992, TRANSFUSION MED, V2, P143, DOI 10.1111/j.1365-3148.1992.tb00148.x; Densmore TL, 1999, TRANSFUSION, V39, P103, DOI 10.1046/j.1537-2995.1999.39199116901.x; Dooren MC, 1998, LANCET, V352, P1601, DOI 10.1016/S0140-6736(05)61049-5; Popovsky MA, 2001, TRANSFUSION, V41, P312, DOI 10.1046/j.1537-2995.2001.41030312.x; YOMTOVIAN R, 1984, LANCET, V1, P244	5	30	30	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 5	2002	360	9339					1073	1074		10.1016/S0140-6736(02)11132-9	http://dx.doi.org/10.1016/S0140-6736(02)11132-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BN	12383991				2022-12-28	WOS:000178485200016
J	Makarov, EM; Makarova, OV; Urlaub, H; Gentzel, M; Will, CL; Wilm, M; Luhrmann, R				Makarov, EM; Makarova, OV; Urlaub, H; Gentzel, M; Will, CL; Wilm, M; Luhrmann, R			Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome	SCIENCE			English	Article							EXON JUNCTION COMPLEX; PROTEIN-COMPOSITION; MASS-SPECTROMETRY; COMPONENTS	Major structural changes occur in the spliceosome during its activation just before catalyzing the splicing of pre-messenger RNAs (pre-mRNAs). Whereas changes in small nuclear RNA ( snRNA) conformation are well documented, little is known about remodeling of small nuclear ribonucleoprotein ( snRNP) structures during spliceosome activation. Here, human 45S activated spliceosomes and a previously unknown 35S U5 snRNP were isolated by immunoaffinity selection and were characterized by mass spectrometry. Comparison of their protein components with those of other snRNP and spliceosomal complexes revealed a major change in protein composition during spliceosome activation. Our data also suggest that the U5 snRNP is dramatically remodeled at this stage, with the Prp19 complex and other factors tightly associating, possibly in exchange for other U5 proteins, and suggest that after catalysis the remodeled U5 is eventually released from the postsplicing complex as a 35S snRNP particle.	Max Planck Inst Biophys Chem, Dept Cellular Biochem, D-37077 Gottingen, Germany; European Mol Biol Lab, Bioanalyt Res Grp, D-69117 Heidelberg, Germany	Max Planck Society; European Molecular Biology Laboratory (EMBL)	Luhrmann, R (corresponding author), Max Planck Inst Biophys Chem, Dept Cellular Biochem, D-37077 Gottingen, Germany.			Wilm, Matthias/0000-0002-5461-6834; Gentzel, Marc/0000-0002-4482-6010; Makarov, Evgeny/0000-0003-2543-9637				Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; Burge CB, 1999, RNA WORLD, P525; Chen CH, 2002, NUCLEIC ACIDS RES, V30, P1029, DOI 10.1093/nar/30.4.1029; Gottschalk A, 2001, RNA, V7, P1554; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; HARTMUTH K, UNPUB; Jurica MS, 2002, RNA, V8, P426, DOI 10.1017/S1355838202021088; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Ohi MD, 2002, MOL CELL BIOL, V22, P2011, DOI 10.1128/MCB.22.7.2011-2024.2002; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; Will CL, 2002, EMBO J, V21, P4978, DOI 10.1093/emboj/cdf480; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	17	292	297	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 13	2002	298	5601					2205	2208		10.1126/science.1077783	http://dx.doi.org/10.1126/science.1077783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	624RA	12411573	Green Submitted			2022-12-28	WOS:000179773700052
J	Sousa, AR; Parikh, A; Scadding, G; Corrigan, CJ; Lee, TH				Sousa, AR; Parikh, A; Scadding, G; Corrigan, CJ; Lee, TH			Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYSINE-ASPIRIN; URINARY LEUKOTRIENE-E4; BRONCHIAL BIOPSIES; PROVOCATION TEST; ASTHMA; HISTAMINE; POPULATIONS; SECRETIONS; EXCRETION; RELEASE	Background: Patients with asthma who have aspirin sensitivity have greater cysteinyl leukotriene production and greater airway hyperresponsiveness to the effects of inhaled cysteinyl leukotrienes than their aspirin-tolerant counterparts. We hypothesized that the latter effect reflects elevated expression of the cysteinyl leukotriene receptor CysLT(sub 1) on inflammatory cells in the target organ and that its expression is down-regulated by aspirin desensitization. Methods: We obtained nasal-biopsy specimens from 22 aspirin-sensitive and 12 non-aspirin-sensitive patients with chronic rhinosinusitis and nasal polyps. Additional specimens were then obtained from subgroups of the aspirin-sensitive patients after intranasal application of lysine aspirin or placebo for two weeks (five and four patients, respectively) or for six months (five and four patients, respectively). The numbers of leukocytes expressing the CysLT(sub 1) and leukotriene B(sub 4) (LTB(sub 4)) receptors per unit area of sections of the nasal submucosa were determined by immunohistochemistry. Results: The absolute number of cells expressing the CysLT(sub 1) receptor was significantly higher in the aspirin-sensitive patients than in the non-aspirin-sensitive patients (median, 542 cells per square millimeter [range, 148 to 1390] vs. 116 cells per square millimeter [range, 40 to 259]; P<0.001). The percentage of CD45+ leukocytes expressing the CysLT(sub 1) receptor was also higher in the aspirin-sensitive subjects (25 percent of CD45+ leukocytes [range, 4 to 50] vs. 5 percent of CD45+ leukocytes [range, 2 to 11]; P<0.001); the percentage of CD45+ leukocytes expressing the LTB(sub 4) receptor did not differ significantly between these two groups. Desensitization was associated with a decrease in the numbers of inflammatory cells expressing CysLT(sub 1). Conclusions: The elevated numbers of nasal inflammatory leukocytes expressing the CysLT(sub 1) receptor in aspirin-sensitive patients with chronic rhinosinusitis as compared with their non-aspirin-sensitive counterparts and the down-regulation of receptor expression after desensitization to aspirin are probably fundamental in the pathogenesis of aspirin sensitivity and in the mechanism of aspirin desensitization.	Guys Kings & St Thomas Sch Med, London, England; Royal Natl Throat Nose & Ear Hosp, London WC1X 8DA, England	University of London; King's College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Lee, TH (corresponding author), Guys Hosp, Dept Asthma Allergy & Resp Sci, London SE1 9RT, England.	tak.lee@kcl.ac.uk	Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Corrigan, Chris/0000-0002-0706-6534				ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1531, DOI 10.1164/ajrccm/146.6.1531; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; Drazen JM, 1999, NEW ENGL J MED, V340, P663; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Leff AR, 2001, ANNU REV MED, V52, P1; Lynch KR, 1999, NATURE, V399, P789; Milewski M, 1998, J ALLERGY CLIN IMMUN, V101, P581, DOI 10.1016/S0091-6749(98)70163-0; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; Nicosia S, 2001, PULM PHARMACOL THER, V14, P3, DOI 10.1006/pupt.2000.0262; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; PATRIARCA G, 1991, LANCET, V337, P1488, DOI 10.1016/0140-6736(91)93185-C; PATRIARCA G, 1991, ANN ALLERGY, V67, P60; PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Scadding GK, 1995, CLIN OTOLARYNGOL, V20, P561, DOI 10.1111/j.1365-2273.1995.tb01603.x; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; Thivierge M, 2000, J IMMUNOL, V165, P5221, DOI 10.4049/jimmunol.165.9.5221; Varga EM, 1999, EUR RESPIR J, V14, P610, DOI 10.1034/j.1399-3003.1999.14c21.x	31	258	267	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2002	347	19					1493	1499		10.1056/NEJMoa013508	http://dx.doi.org/10.1056/NEJMoa013508			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611XG	12421891	Bronze			2022-12-28	WOS:000179042700004
J	Newberg, A; Alavi, A; van Rhijn, S; Cotter, A; Reilly, P				Newberg, A; Alavi, A; van Rhijn, S; Cotter, A; Reilly, P			Radiologic diagnosis of brain death	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SCINTIGRAPHY		Hosp Univ Penn, Dept Med, Div Nucl Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Newberg, A (corresponding author), Hosp Univ Penn, Dept Med, Div Nucl Med, Philadelphia, PA 19104 USA.			Newberg, Andrew/0000-0001-8230-1752				Jenkins D. H., 1997, Journal of Nuclear Medicine, V38, p275P; LARAR GN, 1992, J NUCL MED, V33, P2209; ROSENBERG JH, 1995, NEUROLOGY, V45, P1012; WIELER H, 1993, CLIN NUCL MED, V18, P104, DOI 10.1097/00003072-199302000-00002; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606	5	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2121	2122		10.1001/jama.288.17.2121	http://dx.doi.org/10.1001/jama.288.17.2121			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413369				2022-12-28	WOS:000179048100020
J	Scannell, K				Scannell, K			Writing for our lives: Physician narratives and medical practice - The continuous thread of revelation	ANNALS OF INTERNAL MEDICINE			English	Article									Permanente Med Grp Inc, Oakland, CA 94612 USA	Permanente Medical Groups	Scannell, K (corresponding author), Permanente Med Grp Inc, 1800 Harrison St,Suite 410, Oakland, CA 94612 USA.	Kate.Scannell@kp.org						LEE P, 1969, IS ALL THERE IS WORD; OLIVER M, 1992, NEW SELECTED POEMS, P10; RUKEYSAR M, 1998, POEMS MILLENNIUM U C, P70; Scannell K., 1999, DEATH GOOD DOCTOR LE; Verghese A, 2001, ANN INTERN MED, V135, P1012, DOI 10.7326/0003-4819-135-11-200112040-00028; WELTY E, 1984, ELCT HIST AM CIVILIZ, P68; WILLIAMS WC, 1967, EXCERPTED ASPHODEL T, P153; WINNICOTT DW, 1982, PLAYING REALITY, P95	8	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2002	137	9					779	781		10.7326/0003-4819-137-9-200211050-00034	http://dx.doi.org/10.7326/0003-4819-137-9-200211050-00034			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	612BA	12416971				2022-12-28	WOS:000179052400024
J	Rundall, TG; Shortell, SM; Wang, MC; Casalino, L; Bodenheimer, T; Gillies, RR; Schmittdiel, JA; Oswald, N; Robinson, JC				Rundall, TG; Shortell, SM; Wang, MC; Casalino, L; Bodenheimer, T; Gillies, RR; Schmittdiel, JA; Oswald, N; Robinson, JC			As good as it gets? Chronic care management in nine leading US physician organisations	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHRONIC ILLNESS; ASTHMA		Univ Calif Berkeley, Sch Publ Hlth, Div Hlth Policy & Management, Berkeley, CA 94720 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94110 USA; Healthcare Consulting, Berkeley, CA 94708 USA	University of California System; University of California Berkeley; University of Chicago; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Rundall, TG (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Hlth Policy & Management, 140 Warren Hall, Berkeley, CA 94720 USA.	trundall@uclink.berkeley.edu	Casalino, Lawrence/ABE-1245-2020	Casalino, Lawrence/0000-0002-7927-7859				Bates DW, 2000, BRIT MED J, V320, P788, DOI 10.1136/bmj.320.7237.788; Berg B.L., 2001, QUALITATIVE RES METH; BUNTINX F, 1993, FAM PRACT, V10, P219, DOI 10.1093/fampra/10.2.219; *CDC, 1998, DIAB FACT SHEET; Clark CM, 2000, JAMA-J AM MED ASSOC, V284, P363, DOI 10.1001/jama.284.3.363; DEGELING P, 1998, PROFESSIONAL SUBCULT; HOYERT DL, 2001, NATL VITAL STAT REP, P49; *I MED, 2001, CROSS QUAL CHASM, P28; Jessup M, 2001, NEW ENGL J MED, V345, P1490, DOI 10.1056/NEJMed010109; *JOHNS HOPK U R WO, 2002, PARTN SOL BETT LIV P; Legorreta AP, 2000, AM J MANAG CARE, V6, P445; Miles M., 2013, QUALITATIVE DATA ANA; *NAT CTR HLTH STAT, 2001, NEW ASTHM EST TRACK; *NAT HEART LUNG BL, 1996, CONG HEART FAIL DAT; National Institute of Mental Health, 2001, MENT DIS AM; Songer TJ, 1998, STUDIES COST DIABETE; Wagner E H, 1996, Manag Care Q, V4, P12; Wagner E H, 1999, Manag Care Q, V7, P56; Wagner E H, 2001, Jt Comm J Qual Improv, V27, P63; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55	23	106	108	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 26	2002	325	7370					958	961		10.1136/bmj.325.7370.958	http://dx.doi.org/10.1136/bmj.325.7370.958			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399351	Green Published, Green Submitted			2022-12-28	WOS:000178986300024
J	Kousteni, S; Chen, JR; Bellido, T; Han, L; Ali, AA; O'Brien, CA; Plotkin, L; Fu, Q; Mancino, AT; Wen, Y; Vertino, AM; Powers, CC; Stewart, SA; Ebert, R; Parfitt, AM; Weinstein, RS; Jilka, RL; Manolagas, SC				Kousteni, S; Chen, JR; Bellido, T; Han, L; Ali, AA; O'Brien, CA; Plotkin, L; Fu, Q; Mancino, AT; Wen, Y; Vertino, AM; Powers, CC; Stewart, SA; Ebert, R; Parfitt, AM; Weinstein, RS; Jilka, RL; Manolagas, SC			Reversal of bone loss in mice by nongenotropic signaling of sex steroids	SCIENCE			English	Article							ESTROGEN; RECEPTOR; ACTIVATION; MECHANISMS; HORMONES	We show that sex steroids protect the adult murine skeleton through a mechanism that is distinct from that used to preserve the mass and function of reproductive organs. The classical genotropic actions of sex steroid receptors are dispensable for their bone protective effects, but essential for their effects on reproductive tissues. A synthetic ligand (4-estren-3alpha, 17beta-diol) that reproduces the nongenotropic effects of sex steroids, without affecting classical transcription, increases bone mass and strength in ovariectomized females above the level of the estrogen-replete state and is at least as effective as dihydrotestosterone in orchidectomized males, without affecting reproductive organs. Such ligands merit investigation as potential therapeutic alternatives to hormone replacement for osteoporosis of bone mass in both women and men.	Univ Arkansas Med Sci, Dept Internal Med, Div Endocrinol & Metab, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Surg, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Div Biometry, Little Rock, AR 72205 USA; Cent Arkansas Vet Hlth Care Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Manolagas, SC (corresponding author), Univ Arkansas Med Sci, Dept Internal Med, Div Endocrinol & Metab, Little Rock, AR 72205 USA.		O'Brien, Charles A./AAL-5078-2020; Plotkin, Lilian/H-7188-2019	Plotkin, Lilian/0000-0002-9537-4544	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER; NIAMS NIH HHS [KO2-AR02127] Funding Source: Medline; NIA NIH HHS [P01-AG13918] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; de Jager T, 2001, J BIOL CHEM, V276, P27873, DOI 10.1074/jbc.M010984200; Doran PM, 2001, J BONE MINER RES, V16, P2118, DOI 10.1359/jbmr.2001.16.11.2118; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Fitzpatrick JL, 2002, J NEUROCHEM, V82, P674, DOI 10.1046/j.1471-4159.2002.01000.x; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kousteni S, 2002, J BONE MINER RES, V17, pS169; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; Ott SM, 2002, J BONE MINER RES, V17, P341, DOI 10.1359/jbmr.2002.17.2.341; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Samuels A, 1999, J BONE MINER RES, V14, P178, DOI 10.1359/jbmr.1999.14.2.178	21	345	371	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					843	846		10.1126/science.1074935	http://dx.doi.org/10.1126/science.1074935			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399595				2022-12-28	WOS:000178791200064
J	Mangano, DT; Saidman, L; Levin, J; Barash, P; Dietzel, C; Herskowitz, A; Ley, C; Hsu, P; Kardatzke, D; Wang, S; Tudor, IC; Beatty, D; Xavier, B; Kerkela, S; Aronson, S; Comunale, M; D'Ambra, M; Eaton, M; Engelman, R; Fitch, J; Grichnik, K; Hantler, CB; Hillel, Z; Kanchuger, M; Ostrowski, J; Mangano, CM; Mathew, J; Fontes, M; Barash, P; McSweeney, M; Wolman, R; Napolitano, CA; Nesbitt, LA; Nijhawan, N; Nussmeier, N; Pivalizza, EG; Polson, S; Ramsay, J; Roach, G; Schwann, N; Shenaq, S; Shevde, K; Shore-Lesserson, L; Bronheim, D; Wahr, J; Spiess, B; Wallace, A; Metzler, H; Ansley, D; O'Connor, JP; Cheng, D; Cote, D; Duke, P; Dupuis, JY; Hynes, M; Finnegan, B; Martineau, R; Couture, P; Mazer, D; Villalba, JC; Colmenares, ME; Girard, C; Isetta, C; Greim, CA; Roewer, N; Hoeft, A; Loeb, R; Radke, J; Mollhoff, T; Motsch, J; Martin, E; Ott, E; Ueberfuhr, P; Scholz, J; Tonner, P; Sonntag, H; Szekely, A; Juneja, R; Mani, G; Siregar, E; Drenger, B; Gozal, Y; Elami, E; Tommasino, C; Luna, P; Roekaerts, P; DeLange, S; Pfitzner, R; Filipescu, D; Prakanrattana, U; Duthie, DJR; Feneck, RO; Fox, MA; Park, JD; Smith, D; Vohra, A; Vuylsteke, A; Latimer, RD				Mangano, DT; Saidman, L; Levin, J; Barash, P; Dietzel, C; Herskowitz, A; Ley, C; Hsu, P; Kardatzke, D; Wang, S; Tudor, IC; Beatty, D; Xavier, B; Kerkela, S; Aronson, S; Comunale, M; D'Ambra, M; Eaton, M; Engelman, R; Fitch, J; Grichnik, K; Hantler, CB; Hillel, Z; Kanchuger, M; Ostrowski, J; Mangano, CM; Mathew, J; Fontes, M; Barash, P; McSweeney, M; Wolman, R; Napolitano, CA; Nesbitt, LA; Nijhawan, N; Nussmeier, N; Pivalizza, EG; Polson, S; Ramsay, J; Roach, G; Schwann, N; Shenaq, S; Shevde, K; Shore-Lesserson, L; Bronheim, D; Wahr, J; Spiess, B; Wallace, A; Metzler, H; Ansley, D; O'Connor, JP; Cheng, D; Cote, D; Duke, P; Dupuis, JY; Hynes, M; Finnegan, B; Martineau, R; Couture, P; Mazer, D; Villalba, JC; Colmenares, ME; Girard, C; Isetta, C; Greim, CA; Roewer, N; Hoeft, A; Loeb, R; Radke, J; Mollhoff, T; Motsch, J; Martin, E; Ott, E; Ueberfuhr, P; Scholz, J; Tonner, P; Sonntag, H; Szekely, A; Juneja, R; Mani, G; Siregar, E; Drenger, B; Gozal, Y; Elami, E; Tommasino, C; Luna, P; Roekaerts, P; DeLange, S; Pfitzner, R; Filipescu, D; Prakanrattana, U; Duthie, DJR; Feneck, RO; Fox, MA; Park, JD; Smith, D; Vohra, A; Vuylsteke, A; Latimer, RD		Multicenter Study Perioperative Is	Aspirin and mortality from coronary bypass surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VEIN-GRAFT PATENCY; MYOCARDIAL-ISCHEMIA; CARDIOVASCULAR MORBIDITY; PLATELET; REVASCULARIZATION; ASSOCIATION; DYSFUNCTION; TRANSFUSION; REPERFUSION; APROTININ	Background: There is no therapy known to reduce the risk of complications or death after coronary bypass surgery. Because platelet activation constitutes a pivotal mechanism for injury in patients with atherosclerosis, we assessed whether early treatment with aspirin could improve survival after coronary bypass surgery. Methods: At 70 centers in 17 countries, we prospectively studied 5065 patients undergoing coronary bypass surgery, of whom 5022 survived the first 48 hours after surgery. We gathered data on 7500 variables per patient and adjudicated outcomes centrally. The primary focus was to discern the relation between early aspirin use and fatal and nonfatal outcomes. Results: During hospitalization, 164 patients died (3.2 percent), and 812 others (16.0 percent) had nonfatal cardiac, cerebral, renal, or gastrointestinal ischemic complications. Among patients who received aspirin (up to 650 mg) within 48 hours after revascularization, subsequent mortality was 1.3 percent (40 of 2999 patients), as compared with 4.0 percent among those who did not receive aspirin during this period (81 of 2023, P<0.001). Aspirin therapy was associated with a 48 percent reduction in the incidence of myocardial infarction (2.8 percent vs. 5.4 percent, P<0.001), a 50 percent reduction in the incidence of stroke (1.3 percent vs. 2.6 percent, P=0.01), a 74 percent reduction in the incidence of renal failure (0.9 percent vs. 3.4 percent, P<0.001), and a 62 percent reduction in the incidence of bowel infarction (0.3 percent vs. 0.8 percent, P=0.01). Multivariate analysis showed that no other factor or medication was independently associated with reduced rates of these outcomes and that the risk of hemorrhage, gastritis, infection, or impaired wound healing was not increased with aspirin use (odds ratio for these adverse events, 0.63; 95 percent confidence interval, 0.54 to 0.74). Conclusions: Early use of aspirin after coronary bypass surgery is safe and is associated with a reduced risk of death and ischemic complications involving the heart, brain, kidneys, and gastrointestinal tract.	Ischemia Res & Educ Fdn, Editorial Off, San Francisco, CA 94134 USA		Mangano, DT (corresponding author), Ischemia Res & Educ Fdn, Editorial Off, 250 Execut Pk Blvd,Ste 3400, San Francisco, CA 94134 USA.	dtb@iref.org	Filipescu, Daniela/AAP-6967-2020; Napolitano, Carla/GXE-9727-2022; Vuylsteke, Alain/AAF-2108-2020; Székely, Andrea/AAD-9724-2020; Fuster, Valentin/H-4319-2015; Vohra, Akbar/G-5960-2015	Napolitano, Carla/0000-0002-9459-7957; Székely, Andrea/0000-0002-1382-7897; Fuster, Valentin/0000-0002-9043-9986; Vohra, Akbar/0000-0001-8148-8607; Cheng, Dongxu/0000-0002-4426-6316; Wang, Sheng/0000-0003-4429-3346; O'Connor, Joseph/0000-0002-3709-8123				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSEN LW, 1993, CRIT CARE MED, V21, P210, DOI 10.1097/00003246-199302000-00011; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; Antithrombotic Trialists' Collaboration, 2002, BMJ-BRIT MED J, V324, P141, DOI DOI 10.1136/BMJ.324.7330.141; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BAUMGARTNER WA, 1994, J HOPKINS MANUAL CAR; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; BREISBLATT WM, 1990, J AM COLL CARDIOL, V15, P1261, DOI 10.1016/S0735-1097(10)80011-7; CHESEBRO JH, 1984, NEW ENGL J MED, V310, P209, DOI 10.1056/NEJM198401263100401; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; COSGROVE DM, 1992, ANN THORAC SURG, V54, P1031, DOI 10.1016/0003-4975(92)90066-D; Eagle KA, 1999, J AM COLL CARDIOL, V34, P1262, DOI 10.1016/S0735-1097(99)00389-7; Fitzgerald T, 2000, AM SURGEON, V66, P623; GOLDMAN S, 1988, CIRCULATION, V77, P1324, DOI 10.1161/01.CIR.77.6.1324; HENNEIN HA, 1994, J THORAC CARDIOV SUR, V108, P626; Herskowitz A, 1996, ANESTHESIOLOGY, V85, P957, DOI 10.1097/00000542-199611000-00001; HESSEL EA, 1980, J SURG RES, V28, P23, DOI 10.1016/0022-4804(80)90078-5; JULIA PL, 1991, J THORAC CARDIOV SUR, V101, P303; KESTIN AS, 1993, BLOOD, V82, P107, DOI 10.1182/blood.V82.1.107.bloodjournal821107; KHURI SF, 1992, J THORAC CARDIOV SUR, V104, P94; KLONER RA, 1994, J CARDIAC SURG, V9, P397; LEFER DJ, 1993, CIRCULATION, V88, P1779, DOI 10.1161/01.CIR.88.4.1779; LICHTENSTEIN SV, 1991, J THORAC CARDIOV SUR, V101, P269; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; LOOP FD, 1977, AM J CARDIOL, V39, P516, DOI 10.1016/S0002-9149(77)80160-4; Mangano CM, 1998, ANN INTERN MED, V128, P194, DOI 10.7326/0003-4819-128-3-199802010-00005; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; Mangano DT, 1997, NEW ENGL J MED, V336, P1039; MANGANO DT, 1995, J CARDIAC SURG, V10, P366, DOI 10.1111/j.1540-8191.1995.tb00663.x; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Morse DS, 1998, ANN THORAC SURG, V65, P691, DOI 10.1016/S0003-4975(97)01425-2; Murray C.J, 1994, GLOBAL COMP ASSESSME; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; PEARSON T, 1994, CIRCULATION, V90, P3125, DOI 10.1161/01.CIR.90.6.3125; RINDER CS, 1991, ANESTHESIOLOGY, V75, P563, DOI 10.1097/00000542-199110000-00004; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; ROYSTON D, 1987, LANCET, V2, P1289; Spiess BD, 1998, J THORAC CARDIOV SUR, V116, P460, DOI 10.1016/S0022-5223(98)70012-1; Stover EP, 1998, ANESTHESIOLOGY, V88, P327, DOI 10.1097/00000542-199802000-00009; Taggart D P, 1990, Ann Thorac Surg, V50, P424; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; Unger F., 1999, COR EUR, V7, P177; VONASMUTH EJU, 1995, J IMMUNOL, V154, P1383; YAU TM, 1992, CIRCULATION, V86, P377	44	481	497	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1309	1317		10.1056/NEJMoa020798	http://dx.doi.org/10.1056/NEJMoa020798			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397188				2022-12-28	WOS:000178781300002
J	Moses, HI; Braunwald, E; Martin, JB; Thier, SO				Moses, HI; Braunwald, E; Martin, JB; Thier, SO			Collaborating with industry - Choices for the academic medical center	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Consulting Grp Inc, Bethesda, MD 20814 USA; Partners HealthCare Syst, Boston, MA 02199 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Boston Consulting Group (BCG); Partners Healthcare System; Harvard University; Harvard Medical School	Moses, HI (corresponding author), Boston Consulting Grp Inc, Bethesda, MD 20814 USA.							*BUS HIGH ED FOR, 2001, WORK TOG CREAT KNOWL; *GLOB ALL TB DRUG, 2000, DEV NEW ANT TB TREAT; Kelch RP, 2002, NEW ENGL J MED, V346, P285, DOI 10.1056/NEJM200201243460413; Kennedy D, 2001, SCIENCE, V294, P2249, DOI 10.1126/science.294.5550.2249; Kulynych J, 2002, NEW ENGL J MED, V346, P201, DOI 10.1056/NEJM200201173460312; STARR P, 1982, SOCIAL TRANSFORMATIO, P338; *TASK FORC FIN CON, 2001, PROT SUBJ PRES TRUST; 2000, HDF PARTNERS AURORA	8	55	55	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1371	1375		10.1056/NEJMsb021319	http://dx.doi.org/10.1056/NEJMsb021319			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397200				2022-12-28	WOS:000178781300014
J	Baker, N; Tweedale, C; Ellis, CJ				Baker, N; Tweedale, C; Ellis, CJ			Adverse events with medical devices may go unreported	BRITISH MEDICAL JOURNAL			English	Letter									Birmingham Heartlands Hosp, Dept Infect Control, Birmingham B9 5SS, W Midlands, England; Birmingham Heartlands Hosp, Dept Infect & Trop Med, Birmingham B9 5SS, W Midlands, England	Heart of England NHS Foundation Trust; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham	Baker, N (corresponding author), Birmingham Heartlands Hosp, Dept Infect Control, Birmingham B9 5SS, W Midlands, England.							Amoore J, 2002, BRIT MED J, V325, P272, DOI 10.1136/bmj.325.7358.272; Greig JM, 2002, QJM-INT J MED, V95, P412, DOI 10.1093/qjmed/95.6.412; MAKI DG, 1991, ANN INTERN MED, V114, P845, DOI 10.7326/0003-4819-114-10-845; Nosocomial Infection National Surveillance Service, 2002, SURV HOSP ACQ BACT E	4	3	3	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 19	2002	325	7369					905	905		10.1136/bmj.325.7369.905	http://dx.doi.org/10.1136/bmj.325.7369.905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386055	Green Published			2022-12-28	WOS:000178793000042
J	Frappier, A; Sahagian, D; Gonzalez, LA; Carpenter, SJ				Frappier, A; Sahagian, D; Gonzalez, LA; Carpenter, SJ			El Nino events recorded by stalagmite carbon isotopes	SCIENCE			English	Article									Univ New Hampshire, Inst Study Earth Oceans & Space, Durham, NH 03824 USA; Univ New Hampshire, Climate Change Res Ctr, Durham, NH 03824 USA; Univ New Hampshire, Dept Earth Sci, Durham, NH 03824 USA; Univ Iowa, Ctr Global & Reg Environm Res, Iowa City, IA 52242 USA	University System Of New Hampshire; University of New Hampshire; University System Of New Hampshire; University of New Hampshire; University System Of New Hampshire; University of New Hampshire; University of Iowa	Frappier, A (corresponding author), Univ New Hampshire, Inst Study Earth Oceans & Space, Durham, NH 03824 USA.		Gonzalez, Luis/D-5476-2011	Gonzalez, Luis/0000-0001-7600-8306				Bousquet P, 2000, SCIENCE, V290, P1342, DOI 10.1126/science.290.5495.1342; Broadmeadow M. S. J., 1993, Stable isotopes and plant carbon-water relations., P109; CARPENTER S, 1996, GEOL SOC AM ABSTR, V28, P360; CERLING TE, 1993, NATURE, V361, P344, DOI 10.1038/361344a0; Taylor AH, 2002, NATURE, V416, P629, DOI 10.1038/416629a; TROUP AJ, 1965, Q J ROY METEOR SOC, V91, P490, DOI 10.1002/qj.49709139009	6	70	87	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					565	565		10.1126/science.1076446	http://dx.doi.org/10.1126/science.1076446			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386326	Green Submitted			2022-12-28	WOS:000178634800031
J	Miltat, J; Thiaville, A				Miltat, J; Thiaville, A			Vortex cores - Smaller than small	SCIENCE			English	Editorial Material							PERMALLOY		Univ Paris 11, Phys Solides Lab, F-91405 Orsay, France; CNRS, F-91405 Orsay, France	UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Miltat, J (corresponding author), Univ Paris 11, Phys Solides Lab, Bat 510, F-91405 Orsay, France.	miltat@lps.u-psud.fr						Abo-Shaeer JR, 2001, SCIENCE, V292, P476, DOI 10.1126/science.1060182; AHARONOV Y, 1959, PHYS REV, V115, P485, DOI 10.1103/PhysRev.115.485; Bode M, 2001, PHYS REV LETT, V86, P2142, DOI 10.1103/PhysRevLett.86.2142; FELDTKELLER E, 1965, PHYS KONDENS MATER, V4, P8, DOI 10.1007/BF02423256; GUYON E, 1994, HYDRODYNAMIQUE PHYSI; HESS HF, 1990, PHYS REV LETT, V64, P2711, DOI 10.1103/PhysRevLett.64.2711; Madison KW, 2000, PHYS REV LETT, V84, P806, DOI 10.1103/PhysRevLett.84.806; MAGGIOAPRILE I, 1995, PHYS REV LETT, V75, P2754, DOI 10.1103/PhysRevLett.75.2754; MERMIN ND, 1979, REV MOD PHYS, V51, P591, DOI 10.1103/RevModPhys.51.591; Renner C, 1998, PHYS REV LETT, V80, P3606, DOI 10.1103/PhysRevLett.80.3606; Schneider M, 2001, APPL PHYS LETT, V79, P3113, DOI 10.1063/1.1410873; Shinjo T, 2000, SCIENCE, V289, P930, DOI 10.1126/science.289.5481.930; THIAVILLE A, 1994, EUROPHYS LETT, V26, P57, DOI 10.1209/0295-5075/26/1/010; TONOMURA A, 1980, PHYS REV LETT, V44, P1430, DOI 10.1103/PhysRevLett.44.1430; Wachowiak A, 2002, SCIENCE, V298, P577, DOI 10.1126/science.1075302	15	76	77	4	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	2002	298	5593					555	555		10.1126/science.1077704	http://dx.doi.org/10.1126/science.1077704			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386324				2022-12-28	WOS:000178634800029
J	Strasburger, JF; Maron, BJ				Strasburger, JF; Maron, BJ			Commotio cordis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Childrens Mem Hosp, Chicago, IL 60614 USA; Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Minneapolis Heart Institute Foundation	Strasburger, JF (corresponding author), Childrens Mem Hosp, Chicago, IL 60614 USA.								0	19	19	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1248	1248		10.1056/NEJMicm020053	http://dx.doi.org/10.1056/NEJMicm020053			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393822				2022-12-28	WOS:000178598300006
J	Ramsay, S; Ashraf, H; Frankish, H				Ramsay, S; Ashraf, H; Frankish, H			WHO Director-General elections - join The Lancet debate	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Ramsay, S (corresponding author), The Lancet, London NW1 7BY, England.							Horton R, 2002, LANCET, V359, P1605, DOI 10.1016/S0140-6736(02)08523-9; Kapp C, 2002, LANCET, V360, P695, DOI 10.1016/S0140-6736(02)09884-7	2	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	2002	360	9340					1118	1118		10.1016/S0140-6736(02)11242-6	http://dx.doi.org/10.1016/S0140-6736(02)11242-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	604QF	12387958				2022-12-28	WOS:000178632000010
J	Sigwart, U; Stables, RH; Booth, J; Erbel, R; Wahrborg, P; Lubsen, J; Nihoyannopoulos, P; Pepper, J; King, SB; Weintraub, W; Sleight, P; Clayton, T; Pocock, S; Nugara, F; Rickards, A; Chronos, N; Flather, MD; Thompson, S; Dooley, P; Collinson, J; Stuteville, M; Delahunty, N; Wright, A; Forster, M; Clayton, T; Ludman, P; Collinson, J; De Souza, A; Ischinger, T; Buszman, P; Martuscelli, E; Davies, S; Goy, JJ; Olivari, Z; Shibata, M; Bakhai, A; Perez, D; Kotsiva, K; Kamdar, R; Koutroulis, G; Ritsou, M; Nihoyannopoulos, P; Balcon, R; Sergeant, P; Sleight, P; Thompson, S; Sigwart, U; Buszman, P; Perry, RA; Illsley, C; Simpson, I; Norell, MS; Grip, L; Heikkila, J; Macaya, C; Brecker, S; Angel, J; Legrand, V; Thomas, M; Ischinger, T; Roberts, DH; Bernardi, G; Wijns, W; Martuscelli, E; Bilodeau, L; Olivari, Z; Buller, CE; Nordrehaug, JE; da Cunha, JAC; Schuler, G; Marquis, JF; Waas, W; Pfisterer, M; Mudra, H; Klauss, V; Niemela, K; Meier, B; Endresen, K; Simon, R; Ludman, P; Goy, JJ; Eckhout, E; Manari, A; Ormerod, O; Corr, L; Gomes, S; Cequier, A; Mudra, H; Knudtson, ML; Kokott, N; Golf, S; Erbel, R; Meloni, GF; Chierchia, S; Groves, P; Vassanelli, C; Valdes, M; Luderitz, B; Cumberland, D; Olsson, H; Vrints, C				Sigwart, U; Stables, RH; Booth, J; Erbel, R; Wahrborg, P; Lubsen, J; Nihoyannopoulos, P; Pepper, J; King, SB; Weintraub, W; Sleight, P; Clayton, T; Pocock, S; Nugara, F; Rickards, A; Chronos, N; Flather, MD; Thompson, S; Dooley, P; Collinson, J; Stuteville, M; Delahunty, N; Wright, A; Forster, M; Clayton, T; Ludman, P; Collinson, J; De Souza, A; Ischinger, T; Buszman, P; Martuscelli, E; Davies, S; Goy, JJ; Olivari, Z; Shibata, M; Bakhai, A; Perez, D; Kotsiva, K; Kamdar, R; Koutroulis, G; Ritsou, M; Nihoyannopoulos, P; Balcon, R; Sergeant, P; Sleight, P; Thompson, S; Sigwart, U; Buszman, P; Perry, RA; Illsley, C; Simpson, I; Norell, MS; Grip, L; Heikkila, J; Macaya, C; Brecker, S; Angel, J; Legrand, V; Thomas, M; Ischinger, T; Roberts, DH; Bernardi, G; Wijns, W; Martuscelli, E; Bilodeau, L; Olivari, Z; Buller, CE; Nordrehaug, JE; da Cunha, JAC; Schuler, G; Marquis, JF; Waas, W; Pfisterer, M; Mudra, H; Klauss, V; Niemela, K; Meier, B; Endresen, K; Simon, R; Ludman, P; Goy, JJ; Eckhout, E; Manari, A; Ormerod, O; Corr, L; Gomes, S; Cequier, A; Mudra, H; Knudtson, ML; Kokott, N; Golf, S; Erbel, R; Meloni, GF; Chierchia, S; Groves, P; Vassanelli, C; Valdes, M; Luderitz, B; Cumberland, D; Olsson, H; Vrints, C		SoS Investigators	Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial	LANCET			English	Article							FOLLOW-UP; ANGIOPLASTY; ERACI	Background Results of trials, comparing percutaneous transluminal coronary angioplasty (PTCA) with coronary artery bypass grafting (CABG), indicate that rates of death or myocardial infarction are similar. with either treatment strategy. Management with PTCA is, however, associated with an increased requirement for subsequent, additional revascularisation. Coronary stents, used as an adjunct to PTCA, reduce restenosis and the need for repeat revascularisation. The aim of the Stent or Surgery (SoS) trial was to assess the effect of stent-assisted percutaneous coronary intervention (PCI) versus CABG in the management of patients with multivessel disease. Methods In 53 centres in Europe and Canada, symptomatic patients with multivessel coronary artery disease were randomised to CABG (n=500) or stent-assisted PCI (n=488). The primary outcome measure was a comparison of the rates of repeat revascularisation. Secondary outcomes included death or Q-wave myocardial infarction and all-cause mortality. Analysis was by intention to treat. Findings All patients were followed-up for a minimum of 1 year and the results are expressed for the median follow-up of 2 years. 21% (n=101) of patients in the PCI group required additional revascularisation procedures compared with 6% (n=30) in the CABG group (hazard ratio 3.85, 95% CI 2.56-5-79, p<0.0001). The incidence of death or Q-wave myocardial infarction was similar in both groups (PCI 9% [n=46], CABG 10% [n=49]; hazard ratio 0.95, 95% CI 0.63-1.42, p=0.80). There were fewer deaths in the CABG group than in the PCI group (PCI 5% [n=22], CABG 2% [n=8]; hazard ratio 2.91, 95% CI 1.29-6-53, p=0.01). Interpretation The use of coronary stents has reduced the need for repeat revascularisation when compared with previous studies that used balloon angioplasty, though the rate remains significantly higher than in patients managed with CABG. The apparent reduction in mortality with CABG requires further investigation.	Cardiothorac Ctr Liverpool, Liverpool L14 3PE, Merseyside, England; Royal Brompton Hosp, Clin Trials & Evaluat Unit, London SW3 6LY, England; London Sch Hyg & Trop Med, London WC1, England; Royal Brompton Hosp, ECG Core Lab, London SW3 6LY, England; Hammersmith Hosp, Echocardiog Core Lab, London, England	Royal Brompton Hospital; University of London; London School of Hygiene & Tropical Medicine; Royal Brompton Hospital; Imperial College London	Stables, RH (corresponding author), Cardiothorac Ctr Liverpool, Liverpool L14 3PE, Merseyside, England.		Buszman, Pawel/AAX-9336-2020	Stables, Rodney Hilton/0000-0002-9244-7015; Clayton, Tim/0000-0002-1266-3288				Alderman EL, 1996, NEW ENGL J MED, V335, P217; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; PRINEAS RJ, 1982, MINN CODE MAN ELECTR; RICKARDS AF, 1995, LANCET, V346, P1179; Rihal CS, 1996, BRIT MED J, V312, P265; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; Rodriguez A, 2001, J AM COLL CARDIOL, V37, P51, DOI 10.1016/S0735-1097(00)01052-4; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Stables R H, 1999, Semin Interv Cardiol, V4, P201	13	399	425	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 28	2002	360	9338					965	970						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597YU	12383664				2022-12-28	WOS:000178249000007
J	Abele, D				Abele, D			The radical life-giver	NATURE			English	Editorial Material									Alfred Wegener Inst Polar & Marine Res, Dept Ecotoxicol & Ecophysiol, D-27568 Bremerhaven, Germany	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Abele, D (corresponding author), Alfred Wegener Inst Polar & Marine Res, Dept Ecotoxicol & Ecophysiol, Columbusstr, D-27568 Bremerhaven, Germany.			Abele, Doris/0000-0002-5766-5017				Chandel NS, 2000, J APPL PHYSIOL, V88, P1880, DOI 10.1152/jappl.2000.88.5.1880; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Portner HO, 2002, COMP BIOCHEM PHYS A, V132, P739, DOI 10.1016/S1095-6433(02)00045-4; TAYLOR AC, 1976, J MAR BIOL ASSOC UK, V56, P95, DOI 10.1017/S0025315400020464	4	75	77	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					27	27		10.1038/420027a	http://dx.doi.org/10.1038/420027a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422197	Green Published			2022-12-28	WOS:000179068100020
J	Mariano, NA				Mariano, NA			The changing room	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2091	2091		10.1001/jama.288.17.2091	http://dx.doi.org/10.1001/jama.288.17.2091			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413353				2022-12-28	WOS:000179048100001
J	DiGuiseppi, C; Roberts, I; Wade, A; Sculpher, M; Edwards, P; Godward, C; Pan, HQ; Slater, S				DiGuiseppi, C; Roberts, I; Wade, A; Sculpher, M; Edwards, P; Godward, C; Pan, HQ; Slater, S			Incidence of fires and related injuries after giving out free smoke alarms: cluster randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							UNDERPRIVILEGED AREAS; MULTILEVEL MODEL; METAANALYSIS	Objective To measure the effect of giving out free smoke alarms on rates of fires and rates of fire related injury in a deprived multiethnic urban population. Design Cluster randomised controlled trial. Setting Forty electoral wards in two boroughs of inner London, United Kingdom. Participants Primarily households including elderly people or children and households that are in housing rented from the borough council. Intervention 20 050 smoke alarms, fittings, and educational brochures distributed free and installed on request. Main outcome measures Rates of fires and related injuries during two years after the distribution; alarm ownership, installation, and function. Results Giving out free smoke alarms did not reduce injuries related to fire (rate ratio 1.3; 95% confidence interval 0.9 to 1.9), admissions to hospital and deaths (1.3; 0.7 to 2.3), or fires attended by the fire brigade (1.1; 0.96 to 1.3). Similar proportions of intervention and control households had installed alarms (36/119 (30%) v 35/109 (32%); odds ratio 0.9; 95% confidence interval 0.5 to 1.7) and working alarms (19/118 (16%) v 18/108 (17%); 0.9; 0.4 to 1.8). Conclusions Giving out free smoke alarms in a deprived, multiethnic, urban community did not reduce injuries related to fire, mostly because few alarms had been installed or were maintained.	Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; London Sch Hyg & Trop Med, London WC1B 3DP, England; UCL, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England; Camden & Islington Hlth Author, Dept Publ Hlth, London NW1 1LJ, England	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University of York - UK	DiGuiseppi, C (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Campus Box B-119, Denver, CO 80262 USA.	Carolyn.DiGuiseppi@uchsc.edu	DiGuiseppi, Carolyn/AAU-1341-2020	DiGuiseppi, Carolyn/0000-0002-6440-7817; Sculpher, Mark/0000-0003-3746-9913; Edwards, Phil/0000-0003-4431-8822				ADAMS L, 1999, INT J HLTH PROMOT ED, V37, P65; DiGuiseppi C, 1999, Inj Prev, V5, P177; DiGuiseppi C, 2000, Inj Prev, V6, P250, DOI 10.1136/ip.6.4.250; DiGuiseppi C, 1999, ARCH DIS CHILD, V81, P400, DOI 10.1136/adc.81.5.400; DiGuiseppi C, 2000, ARCH DIS CHILD, V82, P341, DOI 10.1136/adc.82.5.341; DUFFY SW, 1992, STAT MED, V11, P307, DOI 10.1002/sim.4780110304; GOLDSTEIN H, 1999, KENDALLS LIB STAT, V3; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; Mallonee S, 1996, NEW ENGL J MED, V335, P27, DOI 10.1056/NEJM199607043350106; MARRIOTT MD, 1994, 58 HOM OFF FIR RES D; OKOUMUNNE OC, 1999, HLTH TECHNOL ASSESS, V3, P21; Omar RZ, 2000, STAT MED, V19, P2675, DOI 10.1002/1097-0258(20001015)19:19<2675::AID-SIM556>3.3.CO;2-1; Rasbash J., 2000, USERS GUIDE MLWIN; Roberts I, 1996, Inj Prev, V2, P263, DOI 10.1136/ip.2.4.263; Roberts I, 1996, BRIT MED J, V313, P784; Rowland D, 2002, BRIT MED J, V325, P998, DOI 10.1136/bmj.325.7371.998; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; Shults RA, 1998, AM J PREV MED, V15, P165, DOI 10.1016/S0749-3797(98)00071-3; Thompson SG, 1997, STAT MED, V16, P2063, DOI 10.1002/(SICI)1097-0258(19970930)16:18<2063::AID-SIM642>3.0.CO;2-8; Turner RM, 2000, STAT MED, V19, P3417, DOI 10.1002/1097-0258(20001230)19:24<3417::AID-SIM614>3.0.CO;2-L; TURNER RM, 1999, MULTILEVEL MODELLING, V11, P6; WATSON L, 2000, HOME OFFICE STAT B, V2000; Watson L, 2000, FIRE STAT UK 1999	24	47	47	1	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					995	997		10.1136/bmj.325.7371.995	http://dx.doi.org/10.1136/bmj.325.7371.995			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411355	Green Submitted, Green Published, Green Accepted, Bronze			2022-12-28	WOS:000179415600017
J	Lohmann, U; Lesins, G				Lohmann, U; Lesins, G			Stronger constraints on the anthropogenic indirect aerosol effect	SCIENCE			English	Article							EFFECTIVE-RADIUS; SULFATE AEROSOL; CLIMATE MODEL; CLOUD	The anthropogenic indirect aerosol effects of modifying cloud albedo and cloud lifetime cannot be deduced from observations alone but require a modeling component. Here we validate a climate model, with and without indirect aerosol effects, by using satellite observations. The model agrees better with observations when both indirect aerosol effects are included. However, the simulated clouds are more susceptible to aerosols than the observed clouds from the POLDER satellite, thus overestimating the indirect aerosol effect. By taking the difference in susceptibilities into account, the global mean total anthropogenic aerosol effect is reduced from -1.4 to -0.85 watts per square meter.	Dalhousie Univ, Dept Phys & Atmospher Sci, Halifax, NS B3H 3J5, Canada	Dalhousie University	Lohmann, U (corresponding author), Dalhousie Univ, Dept Phys & Atmospher Sci, Halifax, NS B3H 3J5, Canada.		Lohmann, Ulrike/B-6153-2009	Lohmann, Ulrike/0000-0001-8885-3785				Breon FM, 2002, SCIENCE, V295, P834, DOI 10.1126/science.1066434; Breon FM, 2000, GEOPHYS RES LETT, V27, P4065, DOI 10.1029/2000GL011691; Charlson RJ, 2001, SCIENCE, V292, P2025, DOI 10.1126/science.1060096; Deuze JL, 2001, J GEOPHYS RES-ATMOS, V106, P4913, DOI 10.1029/2000JD900364; Ghan SJ, 2001, J GEOPHYS RES-ATMOS, V106, P5279, DOI 10.1029/2000JD900503; GREENWALD TJ, 1993, J GEOPHYS RES-ATMOS, V98, P18471, DOI 10.1029/93JD00339; Han QY, 1998, GEOPHYS RES LETT, V25, P1419, DOI 10.1029/98GL01095; Hess M, 1998, B AM METEOROL SOC, V79, P831, DOI 10.1175/1520-0477(1998)079<0831:OPOAAC>2.0.CO;2; Jones A, 2001, J GEOPHYS RES-ATMOS, V106, P20293, DOI 10.1029/2000JD000089; Khairoutdinov M, 2000, MON WEATHER REV, V128, P229, DOI 10.1175/1520-0493(2000)128<0229:ANCPPI>2.0.CO;2; Knutti R, 2002, NATURE, V416, P719, DOI 10.1038/416719a; LESINS G, UNPUB; Lohmann U, 2001, GEOPHYS RES LETT, V28, P159, DOI 10.1029/2000GL012051; LOHMANN U., 2002, J GEOPHYS RES, V107; MENON S, 2002, J ATMOS SCI, V59; Nakajima T, 2001, GEOPHYS RES LETT, V28, P1171, DOI 10.1029/2000GL012186; Ramaswamy V., 2001, CLIMATE CHANGE 2001, P349; Roeckner E., 1996, TECH REP, V218; Rotstayn LD, 1999, J GEOPHYS RES-ATMOS, V104, P9369, DOI 10.1029/1998JD900009; Schwartz SE, 2002, P NATL ACAD SCI USA, V99, P1784, DOI 10.1073/pnas.261712099	20	141	166	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					1012	1015		10.1126/science.1075405	http://dx.doi.org/10.1126/science.1075405			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12411701				2022-12-28	WOS:000178932000052
J	Takeda, S; Elefteriou, F; Levasseur, R; Liu, XY; Zhao, LP; Parker, KL; Armstrong, D; Ducy, P; Karsenty, G				Takeda, S; Elefteriou, F; Levasseur, R; Liu, XY; Zhao, LP; Parker, KL; Armstrong, D; Ducy, P; Karsenty, G			Leptin regulates bone formation via the sympathetic nervous system	CELL			English	Article							DOPAMINE-BETA-HYDROXYLASE; VENTROMEDIAL HYPOTHALAMUS; GLUCOCORTICOID RECEPTOR; POSTMENOPAUSAL WOMEN; FRAMESHIFT MUTATION; TRANSGENIC MICE; POMC NEURONS; DNA-BINDING; OB-R; OBESITY	We previously showed that leptin inhibits bone formation by an undefined mechanism. Here, we show that hypothalamic leptin-dependent antiosteogenic and anorexigenic networks differ, and that the peripheral mediators of leptin antiosteogenic function appear to be neuronal. Neuropeptides mediating leptin anorexigenic function do not affect bone formation. Leptin deficiency results in low sympathetic tone, and genetic or pharmacological ablation of adrenergic signaling leads to a leptin-resistant high bone mass. beta-adrenergic receptors on osteoblasts regulate their proliferation, and a beta-adrenergic agonist decreases bone mass in leptin-deficient and wild-type mice while a beta-adrenergic antagonist increases bone mass in wild-type and ovariectomized mice. None of these manipulations affects body weight. This study demonstrates a leptin-dependent neuronal regulation of bone formation with potential therapeutic implications for osteoporosis.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Bone Dis Program Texas, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.		takeda, shu/B-5195-2012; Elefteriou, Florent/P-2586-2017; Elefteriou, Florent/GMW-8429-2022	Elefteriou, Florent/0000-0002-2972-5633; Elefteriou, Florent/0000-0002-2972-5633	NICHD NIH HHS [HD24054] Funding Source: Medline; NIDDK NIH HHS [DK58883, DK54480] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058883, R01DK054480] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI JD, 1993, SEMIN ARTHRITIS RHEU, V22, P375, DOI 10.1016/S0049-0172(05)80029-0; Alaniz RC, 1999, P NATL ACAD SCI USA, V96, P2274, DOI 10.1073/pnas.96.5.2274; Asnicar MA, 2001, ENDOCRINOLOGY, V142, P4394, DOI 10.1210/en.142.10.4394; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; Bliziotes M, 2000, BONE, V26, P15, DOI 10.1016/S8756-3282(99)00232-X; Bray GA, 1998, RECENT PROG HORM RES, V53, P95; Cooper Cyrus, 1996, P419; Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; DEBONS AF, 1962, AM J PHYSIOL, V4, P743; DeFalco J, 2001, SCIENCE, V291, P2608, DOI 10.1126/science.1056602; Dellovade TL, 2000, J COMP NEUROL, V423, P579, DOI 10.1002/1096-9861(20000807)423:4<579::AID-CNE4>3.0.CO;2-#; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; FELSON DT, 1993, J BONE MINER RES, V8, P567, DOI 10.1002/jbmr.5650080507; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043-2760(01)00409-X; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HARRIS RBS, 1984, AM J PHYSIOL, V247, pR380, DOI 10.1152/ajpregu.1984.247.2.R380; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; Karst H, 2000, NAT NEUROSCI, V3, P977, DOI 10.1038/79910; KAUFMAN JM, 1992, J CLIN ENDOCR METAB, V74, P118, DOI 10.1210/jc.74.1.118; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MINKOWITZ B, 1991, J ORTHOPAED RES, V9, P869, DOI 10.1002/jor.1100090613; Moore DD, 1995, GLOB MOB SURV; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Ruffin MP, 1999, BRAIN RES, V846, P23, DOI 10.1016/S0006-8993(99)01922-8; Satoh N, 1999, DIABETES, V48, P1787, DOI 10.2337/diabetes.48.9.1787; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Schwartzman RJ, 2000, NEW ENGL J MED, V343, P654, DOI 10.1056/NEJM200008313430911; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thomas SA, 1998, J NEUROCHEM, V70, P2468; TREMOLLIERES FA, 1993, J CLIN ENDOCR METAB, V77, P683, DOI 10.1210/jc.77.3.683; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; YOUNG JB, 1998, WILLIAMS TXB ENDOCRI, P665	46	1215	1306	2	44	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 1	2002	111	3					305	317		10.1016/S0092-8674(02)01049-8	http://dx.doi.org/10.1016/S0092-8674(02)01049-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419242	Bronze			2022-12-28	WOS:000179010100004
J	Murray, SA; Boyd, K; Kendall, M; Worth, A; Benton, TF; Clausen, H				Murray, SA; Boyd, K; Kendall, M; Worth, A; Benton, TF; Clausen, H			Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community	BRITISH MEDICAL JOURNAL			English	Article							CHRONIC HEART-FAILURE; COMMUNICATION; SERVICES; DEATH	Objective To compare the illness trajectories, needs, and service use of patients with cancer and those with advanced non-malignant disease. Design Qualitative interviews every three months for up to one year with patients, their carers, and key professional carers. Two multidisciplinary focus groups. Setting Community based. Participants 20 patients with inoperable lung cancer and 20 patients with advanced cardiac failure and their main informal and professional carers. Main outcome measures Perspectives of patients and carers about their needs and available services. Results 219 qualitative interviews were carried out. Patients with cardiac failure had a different illness trajectory from the more linear and predictable course of patients with lung cancer. Patients with p cardiac failure also had less information about and poorer understanding of their condition and prognosis and were less involved in decision making. ne prime concern of patients with lung cancer and their carers was facing death. Frustration, progressive losses, social isolation, and the stress of balancing and monitoring a complex medication regimen dominated the lives of patients with cardiac failure. More health and social services including financial benefits were available to those with lung cancer, although they were not always used effectively. Cardiac patients received less health, social, and palliative care services, and care was often poorly coordinated. Conclusions Care for people with advanced progressive illnesses is currently prioritised by diagnosis rather than need. End of life care for patients with advanced cardiac failure and other non-malignant diseases should be proactive and designed to meet their specific needs.	Univ Edinburgh, Dept Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland; Royal Infirm Edinburgh NHS Trust, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Dept Nursing Studies, Edinburgh EH8 9JT, Midlothian, Scotland; St Columbas Hosp, Edinburgh EH5 3RW, Midlothian, Scotland; Western Gen Hosp, Palliat Care Team, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh	Murray, SA (corresponding author), Univ Edinburgh, Dept Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland.		Harding, Richard/G-9729-2012	Boyd, Kirsty/0000-0002-5526-1078				Addington-Hall J., 2001, PALLIATIVE CARE NONC; ADDINGTONHALL J, 1995, PALLIATIVE MED, V9, P27, DOI 10.1177/026921639500900105; ADDINGTONHALL JM, 1998, REACHING OUT SPECIAL; Carstairs V., 1991, DEPRIVATION HLTH SCO; CHAVANNES N, 2001, EUR J PALLIAT CARE, V8, P225; Coffey A, 1996, MAKING SENSE QUALITA; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Department of Health, 2000, NHS CANC PLAN PLAN I; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; GIRGIS A, 1995, J CLIN ONCOL, V13, P2449, DOI 10.1200/JCO.1995.13.9.2449; Green J, 1998, BMJ-BRIT MED J, V316, P1230, DOI 10.1136/bmj.316.7139.1230; KURTI LG, 1995, J PALLIATIVE CARE, V11, P25, DOI 10.1177/082585979501100306; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Lynn J, 2000, JAMA-J AM MED ASSOC, V284, P2508, DOI 10.1001/jama.284.19.2508; McCarthy M, 1997, J ROY SOC MED, V90, P128, DOI 10.1177/014107689709000304; RIDEOUT E, 1986, J ADV NURS, V11, P429, DOI 10.1111/j.1365-2648.1986.tb01270.x; Rogers AE, 2000, BMJ-BRIT MED J, V321, P605, DOI 10.1136/bmj.321.7261.605; Scottish Executive Health Department, 2001, CANC SCEN AID PLANN; Smith R, 2000, BMJ-BRIT MED J, V320, P129, DOI 10.1136/bmj.320.7228.129; Stewart S, 2001, IMPROVING OUTCOMES C; The AM, 2000, BRIT MED J, V321, P1376, DOI 10.1136/bmj.321.7273.1376; *WHO, 1979, WHO HDB REPR RES CAN; 1999, AGE FUTURE HLTH CARE	23	345	353	0	32	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					929	932A		10.1136/bmj.325.7370.929	http://dx.doi.org/10.1136/bmj.325.7370.929			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610XB	12399341	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000178986300014
J	Mattsson, AE				Mattsson, AE			In pursuit of the "divine" functional	SCIENCE			English	Editorial Material							EXCHANGE-ENERGY; DENSITY; APPROXIMATIONS; STATE		Sandia Natl Labs, Albuquerque, NM 87185 USA	United States Department of Energy (DOE); Sandia National Laboratories	Mattsson, AE (corresponding author), Sandia Natl Labs, POB 5800, Albuquerque, NM 87185 USA.	aematts@sandia.gov	Mattsson, Ann/AAC-1335-2020	Mattsson, Ann/0000-0002-0677-7537				ARMIENTO R, IN PRESS PHYS REV B; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; Carling K, 2000, PHYS REV LETT, V85, P3862, DOI 10.1103/PhysRevLett.85.3862; CEPERLEY DM, 1980, PHYS REV LETT, V45, P566, DOI 10.1103/PhysRevLett.45.566; *COMP SCI RES I PH, 2002, WORKSH QUANT MECH TE; HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRevB.7.1912; Kohn W, 1999, REV MOD PHYS, V71, P1253, DOI 10.1103/RevModPhys.71.1253; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Kurth S, 1999, INT J QUANTUM CHEM, V75, P889, DOI 10.1002/(SICI)1097-461X(1999)75:4/5<889::AID-QUA54>3.0.CO;2-8; Mattsson AE, 2002, SURF SCI, V520, pL611, DOI 10.1016/S0039-6028(02)02209-4; Perdew J.P., 2001, DENSITY FUNCTIONAL T; PERDEW JP, 1986, PHYS REV B, V33, P8800, DOI 10.1103/PhysRevB.33.8800; PERDEW JP, 1981, PHYS REV B, V23, P5048, DOI 10.1103/PhysRevB.23.5048; Springborg M, 1999, J CHEM PHYS, V110, P9360, DOI 10.1063/1.478947	14	118	119	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					759	760		10.1126/science.1077710	http://dx.doi.org/10.1126/science.1077710			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12399569				2022-12-28	WOS:000178791200037
J	Mannikko, R; Elinder, F; Larsson, HP				Mannikko, R; Elinder, F; Larsson, HP			Voltage-sensing mechanism is conserved among ion channels gated by opposite voltages	NATURE			English	Article							SHAKER K+ CHANNEL; CA1 PYRAMIDAL NEURONS; PACEMAKER CHANNEL; POTASSIUM CHANNEL; XENOPUS OOCYTES; SODIUM-CHANNELS; MOLECULAR-BASIS; S4 SEGMENT; MOVEMENT; INACTIVATION	Hyperpolarization-activated cyclic-nucleotide-gated (HCN) ion channels are found in rhythmically firing cells in the brain and in the heart(1), where the cation current through HCN channels (called I-h or I-f) causes these cells to fire repeatedly(2). These channels are also found in non-pacing cells, where they control resting membrane properties, modulate synaptic transmission, mediate long-term potentiation, and limit extreme hyperpolarizations(3-7). HCN channels share sequence motifs with depolarization-activated potassium (Kv) channels, such as the fourth transmembrane segment S4(8,9). S4 is the main voltage sensor of Kv channels, in which transmembrane movement of S4 charges triggers the opening of the activation gate(10-17). Here, using cysteine accessibility methods(10-12), we investigate whether S4 moves in an HCN channel. We show that S4 movement is conserved between Kv and HCN channels, which indicates that S4 is also the voltage sensor in HCN channels. Our results suggest that a conserved voltage-sensing mechanism operates in the oppositely voltage-gated Kv and HCN channels, but that there are different coupling mechanisms between the voltage sensor and activation gate in the two different channels.	Oregon Hlth & Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA; Karolinska Inst, Nobel Inst Neurophysiol, Dept Neurosci, SE-17177 Stockholm, Sweden	Oregon Health & Science University; Karolinska Institutet	Larsson, HP (corresponding author), Oregon Hlth & Sci Univ, Inst Neurol Sci, 505 NW 185th Ave, Beaverton, OR 97006 USA.		Mannikko, Roope/Q-3567-2016	Mannikko, Roope/0000-0002-8727-9184; Elinder, Fredrik/0000-0001-9125-5583				Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ALLENDE CC, 1977, J BIOL CHEM, V252, P4662; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Beaumont V, 2000, NAT NEUROSCI, V3, P133, DOI 10.1038/72072; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Horn R, 2000, J GEN PHYSIOL, V116, P461, DOI 10.1085/jgp.116.3.461; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Keynes RD, 1999, P ROY SOC B-BIOL SCI, V266, P843, DOI 10.1098/rspb.1999.0714; Larsson HP, 2000, NEURON, V27, P573, DOI 10.1016/S0896-6273(00)00067-2; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Magee JC, 1999, J NEUROPHYSIOL, V82, P1895, DOI 10.1152/jn.1999.82.4.1895; Magee JC, 1998, J NEUROSCI, V18, P7613; MALLER JL, 1979, J BIOL CHEM, V254, P579; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; Mellor J, 2002, SCIENCE, V295, P143, DOI 10.1126/science.1064285; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Rothberg BS, 2002, J GEN PHYSIOL, V119, P83, DOI 10.1085/jgp.119.1.83; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Shin KS, 2001, J GEN PHYSIOL, V117, P91, DOI 10.1085/jgp.117.2.91; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; Vaca L, 2000, FEBS LETT, V479, P35, DOI 10.1016/S0014-5793(00)01837-8; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253	30	148	154	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					837	841		10.1038/nature01038	http://dx.doi.org/10.1038/nature01038			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397358				2022-12-28	WOS:000178769800046
J	Tanasescu, N; Leitzmann, MF; Rimm, EB; Willett, WC; Stampfer, MJ; Hu, FB				Tanasescu, N; Leitzmann, MF; Rimm, EB; Willett, WC; Stampfer, MJ; Hu, FB			Exercise type and intensity in relation to coronary heart disease in men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TIME PHYSICAL-ACTIVITY; CARDIOVASCULAR RISK-FACTORS; LEISURE-TIME; WOMEN; PREVENTION; WALKING; HEALTH; MORTALITY; METAANALYSIS; FITNESS	Context Studies have shown an inverse relationship between exercise and risk of coronary heart disease (CHD), but data on type and intensity are sparse. Objective To assess the amount, type, and intensity of physical activity in relation to risk of CHD among men. Design, Setting, and Participants A cohort of 44452 US men enrolled in the Health Professionals' Follow-up Study, followed up at 2-year intervals from 1986 through January 31, 1998, to assess potential CHD risk factors, identify newly diagnosed cases of CHD, and assess levels of leisure-time physical activity. Main Outcome Measure Incident nonfatal myocardial infarction or fatal CHD occurring during the follow-up period. Results During 475755 person-years, we documented 1700 new cases of CHD. Total physical activity, running, weight training, and rowing were each inversely associated with risk of CHID. The RRs (95% confidence intervals [CIs]) corresponding to quintiles of metabolic equivalent tasks (METs) for total physical activity adjusted for age, smoking, and other cardiovascular risk factors were 1.0, 0.90 (0.78-1.04), 0.87 (0.75-1.00), 0.83 (0.71-0.96), and 0.70 (0.59-0.82) (P<.001 for trend). Men who ran for an hour or more per week had a 42% risk reduction (RR, 0.58; 95% CI, 0.44-0.77) compared with men who did not run (P<.001 for trend). Men who trained with weights for 30 minutes or more per week had a 23% risk reduction (RR, 0.77; 95% CI, 0.61-0.98) compared with men who did not train with weights (P=.03 for trend). Rowing for 1 hour or more per week was associated with an 18% risk reduction (RR, 0.82; 05% CI, 0.68-0.99). Average exercise intensity was associated with reduced CHD risk independent of the total volume of physical activity. The RRs (95% CIs) corresponding to moderate (4-6 MET's) and high (6-12 METs) activity intensities were 0.94 (0.83-1.04) and 0.83 (0.72-0.97) compared with low activity intensity (<4 ME Ts) (P=.02 for trend). A half-hour per day or more of brisk walking was associated with an 18% risk reduction (RR, 0.82; 95% CI, 0.67-1.00). Walking pace was associated with reduced CHD risk independent of the number of walking hours. Conclusions Total physical activity, running, weight training, and walking were each associated with reduced CHID risk. Average exercise intensity was associated with reduced risk independent of the number of MET-hours spent in physical activity.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University	Tanasescu, N (corresponding author), Loma Linda Univ, Dept Nutr, Nichol Hall,Room 1120, Loma Linda, CA 92350 USA.		Hu, Frank/C-1919-2013		NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Drygas W, 2000, INT J SPORTS MED, V21, P235, DOI 10.1055/s-2000-309; Folsom AR, 1997, MED SCI SPORT EXER, V29, P901, DOI 10.1097/00005768-199707000-00009; Francis K, 1996, PHYS THER, V76, P456, DOI 10.1093/ptj/76.5.456; Fung TT, 2000, AM J EPIDEMIOL, V152, P1171, DOI 10.1093/aje/152.12.1171; Hakim AA, 1999, CIRCULATION, V100, P9, DOI 10.1161/01.CIR.100.1.9; HARDMAN AE, 1994, BRIT J SPORT MED, V28, P261, DOI 10.1136/bjsm.28.4.261; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Hurley BF, 2000, SPORTS MED, V30, P249, DOI 10.2165/00007256-200030040-00002; LaCroix AZ, 1996, J AM GERIATR SOC, V44, P113, DOI 10.1111/j.1532-5415.1996.tb02425.x; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; Lee IM, 2001, JAMA-J AM MED ASSOC, V285, P1447, DOI 10.1001/jama.285.11.1447; LEON AS, 1991, INT J EPIDEMIOL, V20, P690, DOI 10.1093/ije/20.3.690; Luepker RV, 1996, JAMA-J AM MED ASSOC, V276, P241; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; Mensink GBM, 1996, EPIDEMIOLOGY, V7, P391, DOI 10.1097/00001648-199607000-00009; MORRIS JN, 1990, BRIT HEART J, V63, P325; Paffenbarger RSLI, 1996, PREVENTION MYOCARDIA, P172; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Poehlman ET, 2000, J CLIN ENDOCR METAB, V85, P2463, DOI 10.1210/jc.85.7.2463; Poehlman ET, 1998, INT J SPORT NUTR, V8, P143, DOI 10.1123/ijsn.8.2.143; Prabhakaran B, 1999, BRIT J SPORT MED, V33, P190, DOI 10.1136/bjsm.33.3.190; Prakash M, 2001, CHEST, V120, P1003, DOI 10.1378/chest.120.3.1003; ROSNER B, 1989, STAT MED, V8, P1051, DOI 10.1002/sim.4780080905; Sesso HD, 2000, CIRCULATION, V102, P975, DOI 10.1161/01.CIR.102.9.975; SHAPER AG, 1991, BRIT HEART J, V66, P384; Therneau T, 1997, P 1 SEATTL S BIOST S, P51; Walker KZ, 1999, DIABETES CARE, V22, P555, DOI 10.2337/diacare.22.4.555; Wannamethee SG, 2001, SPORTS MED, V31, P101, DOI 10.2165/00007256-200131020-00003; Williams PT, 2001, MED SCI SPORT EXER, V33, P754, DOI 10.1097/00005768-200105000-00012	34	578	595	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	2002	288	16					1994	2000		10.1001/jama.288.16.1994	http://dx.doi.org/10.1001/jama.288.16.1994			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	606QW	12387651				2022-12-28	WOS:000178745500022
J	Fisher, B; Anderson, S; Bryant, J; Margolese, RG; Deutsch, M; Fisher, ER; Jeong, J; Wolmark, N				Fisher, B; Anderson, S; Bryant, J; Margolese, RG; Deutsch, M; Fisher, ER; Jeong, J; Wolmark, N			Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AXILLARY DISSECTION; RADICAL-MASTECTOMY; RADIATION; MANAGEMENT; THERAPY	Background: In 1976, we initiated a randomized trial to determine whether lumpectomy with or without radiation therapy was as effective as total mastectomy for the treatment of invasive breast cancer. Methods: A total of 1851 women for whom follow-up data were available and nodal status was known underwent randomly assigned treatment consisting of total mastectomy, lumpectomy alone, or lumpectomy and breast irradiation. Kaplan-Meier and cumulative-incidence estimates of the outcome were obtained. Results: The cumulative incidence of recurrent tumor in the ipsilateral breast was 14.3 percent in the women who underwent lumpectomy and breast irradiation, as compared with 39.2 percent in the women who underwent lumpectomy without irradiation (P<0.001). No significant differences were observed among the three groups of women with respect to disease-free survival, distant-disease-free survival, or overall survival. The hazard ratio for death among the women who underwent lumpectomy alone, as compared with those who underwent total mastectomy, was 1.05 (95 percent confidence interval, 0.90 to 1.23; P=0.51). The hazard ratio for death among the women who underwent lumpectomy followed by breast irradiation, as compared with those who underwent total mastectomy, was 0.97 (95 percent confidence interval, 0.83 to 1.14; P=0.74). Among the lumpectomy-treated women whose surgical specimens had tumor-free margins, the hazard ratio for death among the women who underwent postoperative breast irradiation, as compared with those who did not, was 0.91 (95 percent confidence interval, 0.77 to 1.06; P=0.23). Radiation therapy was associated with a marginally significant decrease in deaths due to breast cancer. This decrease was partially offset by an increase in deaths from other causes. Conclusions: Lumpectomy followed by breast irradiation continues to be appropriate therapy for women with breast cancer, provided that the margins of resected specimens are free of tumor and an acceptable cosmetic result can be obtained.	NSABP, Pittsburgh, PA 15212 USA; Univ Pittsburgh, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fisher, B (corresponding author), NSABP, 4 Allegheny Ctr,Suite 602, Pittsburgh, PA 15212 USA.			Anderson, Stewart/0000-0001-8948-0650; Jeong, Jong/0000-0003-0596-2201	NATIONAL CANCER INSTITUTE [U10CA037377, U10CA069974, U10CA069651] Funding Source: NIH RePORTER; NCI NIH HHS [U10-CA-69974, U10-CA-69651, U10-CA-37377] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE O, 1995, NEW ENGL J MED, V333, P1444; Abe O, 1996, NEW ENGL J MED, V334, P1003; Blichert-Toft M, 1992, J Natl Cancer Inst Monogr, P19; COX DR, 1972, J R STAT SOC B, V34, P187; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; FISHER B, 1977, CANCER-AM CANCER SOC, V39, P2883, DOI 10.1002/1097-0142(197706)39:6<2883::AID-CNCR2820390676>3.0.CO;2-9; FISHER B, 1979, NEW ENGL J MED, V301, P326, DOI 10.1056/NEJM197908093010611; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; Fisher B, 2002, NEW ENGL J MED, V347, P567, DOI 10.1056/NEJMoa020128; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FISHER B, 1985, WORLD J SURG, V9, P692, DOI 10.1007/BF01655182; FISHER B, 1995, EUR J CANCER, V31A, P1567, DOI 10.1016/0959-8049(95)00461-Q; FISHER B, 1994, NEW ENGL J MED, V330, P1467; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; JACOBSON JA, 1995, NEW ENGL J MED, V332, P907, DOI 10.1056/NEJM199504063321402; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; *NAT SURG ADJ BREA, 2002, NSABP PROGR REP 2001, P84; Obedian E, 2000, J CLIN ONCOL, V18, P2406, DOI 10.1200/JCO.2000.18.12.2406; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; SARRAZIN D, 1989, RADIOTHER ONCOL, V14, P177, DOI 10.1016/0167-8140(89)90165-5; Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902; van Dongen JA, 2000, JNCI-J NATL CANCER I, V92, P1143, DOI 10.1093/jnci/92.14.1143; Veronesi U, 1983, Int Adv Surg Oncol, V6, P141; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; Veronesi U, 2002, NEW ENGL J MED, V347, P1227, DOI 10.1056/NEJMoa020989	27	4574	4819	8	184	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1233	1241		10.1056/NEJMoa022152	http://dx.doi.org/10.1056/NEJMoa022152			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393820	Bronze			2022-12-28	WOS:000178598300004
J	Schodel, R; Ott, T; Genzel, R; Hofmann, R; Lehnert, M; Eckart, A; Mouawad, N; Alexander, T; Reid, MJ; Lenzen, R; Hartung, M; Lacombe, F; Rouan, D; Gendron, E; Rousset, G; Lagrange, AM; Brandner, W; Ageorges, N; Lidman, C; Moorwood, AFM; Spyromilio, J; Hubin, N; Menten, KM				Schodel, R; Ott, T; Genzel, R; Hofmann, R; Lehnert, M; Eckart, A; Mouawad, N; Alexander, T; Reid, MJ; Lenzen, R; Hartung, M; Lacombe, F; Rouan, D; Gendron, E; Rousset, G; Lagrange, AM; Brandner, W; Ageorges, N; Lidman, C; Moorwood, AFM; Spyromilio, J; Hubin, N; Menten, KM			A star in a 15.2-year orbit around the supermassive black hole at the centre of the Milky Way	NATURE			English	Article							SAGITTARIUS-A-ASTERISK; GALACTIC-CENTER; PROPER-MOTION; GALAXY; NUCLEI; RADIO; MASS; VLT	Many galaxies are thought to have supermassive black holes at their centres(1)-more than a million times the mass of the Sun. Measurements of stellar velocities(2-7) and the discovery of variable X-ray emission(8) have provided strong evidence in favour of such a black hole at the centre of the Milky Way, but have hitherto been unable to rule out conclusively the presence of alternative concentrations of mass. Here we report ten years of high-resolution astrometric imaging that allows us to trace two-thirds of the orbit of the star currently closest to the compact radio source (and massive black-hole candidate) Sagittarius A(star). The observations, which include both pericentre and apocentre passages, show that the star is on a bound, highly elliptical keplerian orbit around Sgr A(star), with an orbital period of 15.2 years and a pericentre distance of only 17 light hours. The orbit with the best fit to the observations requires a central point mass of (3.7 +/- 1.5) x 10(6) solar masses (M-.). The data no longer allow for a central mass composed of a dense cluster of dark stellar objects or a ball of massive, degenerate fermions.	Max Planck Inst Extraterr Phys, D-85748 Garching, Germany; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Cologne, Inst Phys 1, D-50937 Cologne, Germany; Weizmann Inst Sci, Fac Phys, IL-76100 Rehovot, Israel; Harvard Smithsonian Ctr Astrophys MS42, Cambridge, MA 02138 USA; Max Planck Inst Astron, D-69117 Heidelberg, Germany; Observ Paris, Sect Meudon, F-92195 Meudon, France; Off Natl Etud & Rech Aerosp, F-92322 Chatillon, France; Observ Grenoble, Astrophys Lab, F-38041 Grenoble 9, France; European So Observ, D-85748 Garching, Germany; Max Planck Inst Radioastron, D-53121 Bonn, Germany	Max Planck Society; University of California System; University of California Berkeley; University of Cologne; Weizmann Institute of Science; Max Planck Society; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; National Office for Aerospace Studies & Research (ONERA); UDICE-French Research Universities; Universite Paris Saclay; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); European Southern Observatory; Max Planck Society	Schodel, R (corresponding author), Max Planck Inst Extraterr Phys, Giessenbachstr, D-85748 Garching, Germany.		Mouawad, Nelly/AAH-5398-2020; Brandner, Wolfgang/AFR-1606-2022; Schoedel, Rainer/D-4751-2014	Mouawad, Nelly/0000-0003-1609-5625; Brandner, Wolfgang/0000-0003-1939-6351; Lidman, Chris/0000-0003-1731-0497; Schoedel, Rainer/0000-0001-5404-797X; Lehnert, Matthew/0000-0003-1939-5885				Backer DC, 1999, ASTROPHYS J, V524, P805, DOI 10.1086/307857; Baganoff FK, 2001, NATURE, V413, P45, DOI 10.1038/35092510; BRANDNER W, 2002, ESO MESSENGER, V107, P1; Chakrabarty D, 2001, ASTRON J, V122, P232, DOI 10.1086/321104; Eckart A, 2002, MON NOT R ASTRON SOC, V331, P917, DOI 10.1046/j.1365-8711.2002.05237.x; Eckart A, 1996, NATURE, V383, P415, DOI 10.1038/383415a0; Genzel R, 1997, MON NOT R ASTRON SOC, V291, P219, DOI 10.1093/mnras/291.1.219; Genzel R, 2000, MON NOT R ASTRON SOC, V317, P348, DOI 10.1046/j.1365-8711.2000.03582.x; Ghez AM, 2000, NATURE, V407, P349, DOI 10.1038/35030032; Ghez AM, 1998, ASTROPHYS J, V509, P678, DOI 10.1086/306528; GUDEHUS DH, 2001, AM ASTRON SOC M, V198, P1; KORMENDY J, 1995, ANNU REV ASTRON ASTR, V33, P581, DOI 10.1146/annurev.aa.33.090195.003053; Lenzen R, 1998, P SOC PHOTO-OPT INS, V3354, P606, DOI 10.1117/12.317287; Maoz E, 1998, ASTROPHYS J, V494, pL181, DOI 10.1086/311194; MENTEN KM, 1997, R ASTROPHYS J, V475, pL111; Munyaneza F, 2002, ASTROPHYS J, V564, P274, DOI 10.1086/323949; Reid MJ, 1999, ASTROPHYS J, V524, P816, DOI 10.1086/307855; REID MJ, 1993, ANNU REV ASTRON ASTR, V31, P345; REID MJ, UNPUB ASTROPHYS J; Rousset G, 1998, P SOC PHOTO-OPT INS, V3353, P508, DOI 10.1117/12.321686; Rubilar GF, 2001, ASTRON ASTROPHYS, V374, P95, DOI 10.1051/0004-6361:20010640; TORRES DF, 2002, PHYS REV, V62, DOI ARTN 104012; Tsiklauri D, 1998, ASTROPHYS J, V500, P591, DOI 10.1086/305753	23	710	713	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					694	696		10.1038/nature01121	http://dx.doi.org/10.1038/nature01121			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384690				2022-12-28	WOS:000178615200032
J	Weaver, WD; Peberdy, MA				Weaver, WD; Peberdy, MA			Perspective: Defibrillators in public places - One step closer to home	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Henry Ford Heart & Vasc Inst, Detroit, MI 48202 USA; Virginia Commonwealth Univ, Hlth Syst, Richmond, VA 23298 USA	Henry Ford Health System; Virginia Commonwealth University	Weaver, WD (corresponding author), Henry Ford Heart & Vasc Inst, Detroit, MI 48202 USA.								0	33	34	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1223	1224		10.1056/NEJMp020108	http://dx.doi.org/10.1056/NEJMp020108			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12393818				2022-12-28	WOS:000178598300001
J	Bernard, L; Vuagnat, A; Peytavin, G; Hallouin, MC; Bouhour, D; Nguyen, TH; Vilde, JL; Bricaire, F; Raguin, G; de Truchis, P; Ghez, D; Duong, M; Perronne, C				Bernard, L; Vuagnat, A; Peytavin, G; Hallouin, MC; Bouhour, D; Nguyen, TH; Vilde, JL; Bricaire, F; Raguin, G; de Truchis, P; Ghez, D; Duong, M; Perronne, C			Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy	ANNALS OF INTERNAL MEDICINE			English	Article							PROTEASE-INHIBITOR; RESISTANCE; INFECTION; AIDS	Background: Suboptimal levels of antiretroviral drugs result in virologic failure in HIV-infected patients treated with highly active antiretroviral therapy (HAART). Objective: To assess the relationship between levels of indinavir in hair and virologic outcome. Design: Cross-sectional study. Setting: 7 AIDS clinics in France. Patients: 89 HIV-infected patients who received HAART that included indinavir. Measurements: Patients were classified as responders or nonresponders on the basis of viremia at the time of hair collection. in nonresponders, levels of indinavir in hair and resistance mutations in the protease gene were assessed at baseline and at the time of indinavir measurement. Results: Mean indinavir levels (+/-SD) were significantly higher in the 65 responders than in the 24 nonresponders (24.4 +/- 16 mug/g vs. 12.9 +/- 8.6 mug/g) (P < 0.001). Nonresponders with intermediate levels of indinavir in hair had more mutations in the protease gene than did nonresponders with low levels of indinavir in hair. Conclusion: Indinavir levels in hair are associated with virologic outcome in patients receiving HAART.	Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland; Virol Lab, Geneva, Switzerland; Hop Paul Brousse, Villejuif, France; Hop Croix Rousse, F-69317 Lyon, France; Hop Bichat Claude Bernard, F-75877 Paris, France; Hop Rothschild, F-75571 Paris, France; Hop La Pitie Salpetriere, Paris, France; Hop Croix St Simon, Paris, France; Hop Raymond Poincare, Garches, France; Hop Bocage, Dijon, France	University of Geneva; University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; CHU Dijon Bourgogne	Bernard, L (corresponding author), Univ Hosp Geneva, Div Infect Dis, Rue Micheli Du Crest, CH-1211 Geneva, Switzerland.	louis.bernard@hcuge.ch						Bernard L, 1998, LANCET, V352, P1757, DOI 10.1016/S0140-6736(05)79831-7; Condra JH, 1998, ANN INTERN MED, V128, P951, DOI 10.7326/0003-4819-128-11-199806010-00017; Condra JH, 1998, HAEMOPHILIA, V4, P610, DOI 10.1046/j.1365-2516.1998.440610.x; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Diggle PJ, 1994, ANAL LONGITUDINAL DA; GRAHAM K, 1989, JAMA-J AM MED ASSOC, V262, P3328, DOI 10.1001/jama.262.23.3328; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; KINTZ P, 1993, INT J LEGAL MED, V105, P283, DOI 10.1007/BF01370386; Nakahara Y, 1999, J CHROMATOGR B, V733, P161, DOI 10.1016/S0378-4347(99)00059-6; Nijhuis M, 1998, P NATL ACAD SCI USA, V95, P14441, DOI 10.1073/pnas.95.24.14441; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; TRACQUI A, 1992, HUM EXP TOXICOL, V11, P363, DOI 10.1177/096032719201100511; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; WOOLF E, 1995, J CHROMATOGR A, V692, P45, DOI 10.1016/0021-9673(94)00608-C; 1999, AIDS S1, V13, pS61	18	35	36	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2002	137	8					656	659		10.7326/0003-4819-137-8-200210150-00009	http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604WL	12379065				2022-12-28	WOS:000178644000004
J	Schmidt, LE; Knudsen, TT; Dalhoff, K; Bendtsen, F				Schmidt, LE; Knudsen, TT; Dalhoff, K; Bendtsen, F			Effect of acetylcysteine on prothrombin index in paracetamol poisoning without hepatocellular injury	LANCET			English	Article							N-ACETYLCYSTEINE	Acetylcysteine treatment reduces liver damage after paracetamol overdose, but can affect the prothrombin index, which is used to assess the progress of overdose patients. We aimed to assess retrospectively the effect of intravenous acetylcysteine on the prothrombin index in patients with paracetamol poisoning without signs of hepatocellular injury. Prothrombin index had been recorded before, and serially during, acetylcysteine treatment in 87 patients. After initiation of treatment, prothrombin index decreased (mean 0.33, 95% CI 0.29-0.38) in all patients, and was strongly associated with the start of acetylcysteine infusion. In patients with uncomplicated paracetamol poisoning, a fall in this index might be misinterpreted as a sign of liver failure, leading to prolonged treatment time.	Univ Copenhagen, Rigshosp, Dept Hepatol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Dept Clin Pharmacol, DK-2100 Copenhagen, Denmark; Hvidovre Univ Hosp, Dept Gastroenterol, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen	Schmidt, LE (corresponding author), Univ Copenhagen, Rigshosp, Dept Hepatol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.							JEPSEN S, 1994, SCAND J CLIN LAB INV, V54, P543, DOI 10.3109/00365519409088566; JEPSEN S, 1992, CRIT CARE MED, V20, P918, DOI 10.1097/00003246-199207000-00004; KOTERBA AP, 1995, ALCOHOL, V12, P49, DOI 10.1016/0741-8329(94)00069-P; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097	5	46	47	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 12	2002	360	9340					1151	1152		10.1016/S0140-6736(02)11194-9	http://dx.doi.org/10.1016/S0140-6736(02)11194-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604QF	12387966				2022-12-28	WOS:000178632000018
J	Daynard, RA; Hash, LE; Robbins, A				Daynard, RA; Hash, LE; Robbins, A			Food litigation: Lessons from the tobacco wars	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Northeastern Univ, Sch Law, Boston, MA 02115 USA; Harvard Univ, Sch Law, Cambridge, MA 02138 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Northeastern University; Harvard University; Tufts University	Daynard, RA (corresponding author), Northeastern Univ, Sch Law, Boston, MA 02115 USA.							Daynard RA, 2001, CANCER CAUSE CONTROL, V12, P383, DOI 10.1023/A:1011248512615; Glantz S.A., 1996, CIGARETTE PAPERS; NESTLE M, 2002, FOOD POLITICS, P22; Putnam J., 2000, FoodReview, V23, P2; *US GEN ACC OFF, 2000, PUBL ED COMM ACT SCH	5	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2179	2179		10.1001/jama.288.17.2179	http://dx.doi.org/10.1001/jama.288.17.2179			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413385	hybrid			2022-12-28	WOS:000179048100035
J	Lip, GYH; Hart, RG; Conway, DSG				Lip, GYH; Hart, RG; Conway, DSG			ABC of antithrombotic therapy - Antithrombotic therapy for atrial fibrillation	BRITISH MEDICAL JOURNAL			English	Review							STROKE		Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B15 2TT, W Midlands, England; Univ Texas, Hlth Sci Ctr, Dept Med Neurol, San Antonio, TX USA	University of Birmingham; University of Texas System; University of Texas Health San Antonio	Lip, GYH (corresponding author), Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B15 2TT, W Midlands, England.		CONWAY, Dwayne/AAC-5204-2022	Conway, Dwayne/0000-0001-7775-2583				Hart RG, 2000, J AM COLL CARDIOL, V35, P183, DOI 10.1016/S0735-1097(99)00489-1; Lip GYH, 1999, LANCET, V353, P4, DOI 10.1016/S0140-6736(05)74877-7; LIP GYH, 1995, LANCET, V346, P1313, DOI 10.1016/S0140-6736(95)92339-X; LIP GYH, 2002, CLIN EVIDENCE; STRAUS SE, 2002, JAMA-J AM MED ASSOC, V28, P1388; Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6	6	85	90	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2002	325	7371					1022	1025		10.1136/bmj.325.7371.1022	http://dx.doi.org/10.1136/bmj.325.7371.1022			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618JU	12411366	Green Published			2022-12-28	WOS:000179415600028
J	Wuarin, J; Buck, V; Nurse, P; Millar, JBA				Wuarin, J; Buck, V; Nurse, P; Millar, JBA			Stable association of mitotic cyclin B/Cdc2 to replication origins prevents endoreduplication	CELL			English	Article							B-TYPE CYCLIN; DNA-REPLICATION; FISSION YEAST; S-PHASE; CELL-CYCLE; RECOGNITION COMPLEX; SCHIZOSACCHAROMYCES-POMBE; NEGATIVE REGULATION; LICENSING SYSTEM; BUDDING YEAST	We show that in fission yeast the mitotic B type cyclin Cdc13/Cdc2 kinase associates with replication origins in vivo. This association is dependent on the origin recognition complex (ORC), is established as chromosomes are replicated, and is maintained during G2 and early mitosis. Cells expressing an orp2 (ORC2) allele that reduces binding of Cdc13 to replication origins are acutely prone to chromosomal reduplication. In synchronized endoreduplicating cells, following Cdc13 ablation, replication origins are coordinately licensed prior to each successive round of S phase with the same periodicity as in a normal cell cycle. Thus, ORC bound mitotic Cyclin B/Cdc2 kinase imposes the dependency of S phase on an intervening mitosis but not the temporal licensing of replication origins between each S phase.	Natl Inst Med Res, Div East Genet, London NW7 1AA, England; Canc Res UK, Cell Cycle Lab, London WC1A 3PX, England	MRC National Institute for Medical Research; Cancer Research UK	Millar, JBA (corresponding author), Natl Inst Med Res, Div East Genet, Mill Hill, London NW7 1AA, England.	jmillar@nimr.mrc.ac.uk		Millar, Jonathan/0000-0002-9930-3989	MRC [MC_U117531948] Funding Source: UKRI; Medical Research Council [MC_U117531948] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; Ayte J, 2001, NAT CELL BIOL, V3, P1043, DOI 10.1038/ncb1201-1043; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Cimbora DM, 2001, CELL, V104, P643, DOI 10.1016/S0092-8674(01)00260-4; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; CorreaBordes J, 1997, EMBO J, V16, P4657, DOI 10.1093/emboj/16.15.4657; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; GALLAGHER IM, 1993, MOL BIOL CELL, V4, P1087, DOI 10.1091/mbc.4.11.1087; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Heun P, 2001, J CELL BIOL, V152, P385, DOI 10.1083/jcb.152.2.385; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kearsey SE, 2000, EMBO J, V19, P1681, DOI 10.1093/emboj/19.7.1681; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; Lopez-Girona A, 1998, MOL BIOL CELL, V9, P63, DOI 10.1091/mbc.9.1.63; Lygerou Z, 1999, J CELL SCI, V112, P3703; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Ogawa M, 1999, J POROUS MAT, V6, P19, DOI 10.1023/A:1009628900106; Okuno Y, 1999, MOL CELL BIOL, V19, P6699; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Romanowski P, 2000, J BIOL CHEM, V275, P4239, DOI 10.1074/jbc.275.6.4239; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Vas A, 2001, MOL CELL BIOL, V21, P5767, DOI 10.1128/MCB.21.17.5767-5777.2001; Weinreich M, 2001, P NATL ACAD SCI USA, V98, P11211, DOI 10.1073/pnas.201387198; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Yamano H, 2000, MOL CELL, V6, P1377, DOI 10.1016/S1097-2765(00)00135-0; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648	54	87	91	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	2002	111	3					419	431		10.1016/S0092-8674(02)01042-5	http://dx.doi.org/10.1016/S0092-8674(02)01042-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	611HG	12419251	Bronze			2022-12-28	WOS:000179010100013
J	Braunwald, E				Braunwald, E			Perspective: Hypertrophic cardiomyopathy - The benefits of a multidisciplinary approach	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Braunwald, E (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.								0	7	8	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2002	347	17					1306	1307		10.1056/NEJMp020111	http://dx.doi.org/10.1056/NEJMp020111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607FK	12397187				2022-12-28	WOS:000178781300001
J	Huxley, AF				Huxley, AF			David Keynes Hill (1915-2002) - Obituary	NATURE			English	Biographical-Item									Manor Field, Cambridge CB3 9NG, England		Huxley, AF (corresponding author), Manor Field, 1 Vicarage Dr, Cambridge CB3 9NG, England.								0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					800	800		10.1038/419800a	http://dx.doi.org/10.1038/419800a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397345	Bronze			2022-12-28	WOS:000178769800033
J	Iyengar, VK; Reeve, HK; Eisner, T				Iyengar, VK; Reeve, HK; Eisner, T			Paternal inheritance of a female moth's mating preference	NATURE			English	Article							SEXUALLY SELECTED TRAIT; ARCTIID MOTH; UTETHEISA-ORNATRIX; SELECTION; HERITABILITY; BEHAVIOR; DEFENSE; SIZE	Females of the arctiid moth Utetheisa ornatrix mate preferentially with larger males, receiving both direct phenotypic and indirect genetic benefits(1). Here we demonstrate that the female's mating preference is inherited through the father rather than the mother, indicating that the preference gene or genes lie mostly or exclusively on the Z sex chromosome, which is strictly paternally inherited by daughters. Furthermore, we show that the preferred male trait and the female preference for that trait are correlated, as females with larger fathers have a stronger preference for larger males. These findings are predicted by the protected invasion theory(2,3), which asserts that male homogametic sex chromosome systems (ZZ/ZW) found in lepidopterans and birds promote the evolution of exaggerated male traits through sexual selection. Specifically, the theory predicts that, because female preference alleles arising on the Z chromosome are transmitted to all sons that have the father's attractive trait rather than to only a fraction of the sons, such alleles will experience stronger positive selection and be less vulnerable to chance loss than would autosomal alleles.	Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14850 USA	Cornell University	Iyengar, VK (corresponding author), Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14850 USA.	viyengar@wooster.edu						Andersson Malte, 1994; Brooks R, 2001, EVOLUTION, V55, P1002, DOI 10.1554/0014-3820(2001)055[1002:DAISSA]2.0.CO;2; Brooks R, 2001, EVOLUTION, V55, P1644, DOI 10.1111/j.0014-3820.2001.tb00684.x; CONNER WE, 1981, BEHAV ECOL SOCIOBIOL, V9, P227, DOI 10.1007/BF00302942; CONNER WE, 1990, J CHEM ECOL, V16, P543, DOI 10.1007/BF01021785; DUSSOURD DE, 1991, P NATL ACAD SCI USA, V88, P9224, DOI 10.1073/pnas.88.20.9224; Gonzalez A, 1999, P NATL ACAD SCI USA, V96, P5570, DOI 10.1073/pnas.96.10.5570; GRULA JW, 1980, EVOLUTION, V34, P688, DOI 10.1111/j.1558-5646.1980.tb04007.x; HOUDE AE, 1992, HEREDITY, V69, P229, DOI 10.1038/hdy.1992.120; Iyengar VK, 1999, P NATL ACAD SCI USA, V96, P15013, DOI 10.1073/pnas.96.26.15013; Iyengar VK, 2001, BEHAV ECOL SOCIOBIOL, V49, P283, DOI 10.1007/s002650000292; Iyengar VK, 1999, P NATL ACAD SCI USA, V96, P9169, DOI 10.1073/pnas.96.16.9169; LAMUNYON CW, 1993, P NATL ACAD SCI USA, V90, P4689, DOI 10.1073/pnas.90.10.4689; LAMUNYON CW, 1994, P NATL ACAD SCI USA, V91, P7081, DOI 10.1073/pnas.91.15.7081; LaMunyon CW, 1997, ECOL ENTOMOL, V22, P69, DOI 10.1046/j.1365-2311.1997.00033.x; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; Lynch M., 1998, GENETICS ANAL QUANTI; Opler P. A., 1984, BUTTERFLIES E GREAT; REEVE HK, 1993, PHILOS T R SOC B, V342, P335, DOI 10.1098/rstb.1993.0163; Reeve HK, 1997, EVOL ECOL, V11, P357, DOI 10.1023/A:1018472521277; Sharma Vijay Lakshmi, 1999, Bionature, V19, P65; Traut W, 1997, CHROMOSOME RES, V5, P283, DOI 10.1023/B:CHRO.0000038758.08263.c3; Wilkinson GS, 1998, BEHAV ECOL, V9, P525, DOI 10.1093/beheco/9.5.525; Wolfenbarger LL, 2001, EVOLUTION, V55, P103	24	74	75	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	2002	419	6909					830	832		10.1038/nature01027	http://dx.doi.org/10.1038/nature01027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397356				2022-12-28	WOS:000178769800044
J	Gilad, R; Lampl, Y; Eshel, Y; Sadeh, M				Gilad, R; Lampl, Y; Eshel, Y; Sadeh, M			Tonic-clonic seizures in patients taking sildenafil	BRITISH MEDICAL JOURNAL			English	Letter									Wolfson Med Ctr, Dept Neurol, IL-58100 Holon, Israel		Gilad, R (corresponding author), Wolfson Med Ctr, Dept Neurol, IL-58100 Holon, Israel.							Moreira SG, 2000, UROLOGY, V56, P474, DOI 10.1016/S0090-4295(00)00649-X	1	48	49	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 19	2002	325	7369					869	869		10.1136/bmj.325.7369.869	http://dx.doi.org/10.1136/bmj.325.7369.869			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607LL	12386039	Bronze, Green Published			2022-12-28	WOS:000178793000021
J	Halstead, SB; Deen, J				Halstead, SB; Deen, J			The future of dengue vaccines	LANCET			English	Review							HEMORRHAGIC-FEVER; SHOCK SYNDROME; JAPANESE ENCEPHALITIS; RISK-FACTORS; VIRUS; IMMUNOGENICITY; CONSTRUCTION; CANDIDATE; CHILDREN; AGE		Uniformed Serv Univ Hlth Sci, Dept Prevent Med, Bethesda, MD 20814 USA; Int Vaccine Inst, Pediat Dengue Vaccine Initiat, Seoul, South Korea	Uniformed Services University of the Health Sciences - USA; International Vaccine Institute	Halstead, SB (corresponding author), 5824 Edson Lane, Bethesda, MD 20852 USA.	halsteads@erols.com						Almond Jeffrey, 2002, Vaccine, V20, P3043, DOI 10.1016/S0264-410X(02)00246-3; Bhamarapravati N, 2000, VACCINE, V18, P44, DOI 10.1016/S0264-410X(00)00040-2; Bhamarapravati Natth, 1997, P367; BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; Chambers TJ, 1999, J VIROL, V73, P3095, DOI 10.1128/JVI.73.4.3095-3101.1999; Dung NM, 1999, CLIN INFECT DIS, V29, P787, DOI 10.1086/520435; Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405; EDELMAN R, 2003, IN PRESS AM J TROP M; Gamble J, 2000, CLIN SCI, V98, P211, DOI 10.1042/CS19990296; Graham RR, 1999, AM J TROP MED HYG, V61, P412, DOI 10.4269/ajtmh.1999.61.412; Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001; HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HALSTEAD SB, 1973, NATURE-NEW BIOL, V243, P24; Halstead SB, 2001, AM J TROP MED HYG, V65, P180, DOI 10.4269/ajtmh.2001.65.180; HE RT, 1995, J MED VIROL, V45, P451, DOI 10.1002/jmv.1890450417; Huang CYH, 2000, J VIROL, V74, P3020, DOI 10.1128/JVI.74.7.3020-3028.2000; Kinney RM, 2001, INTERVIROLOGY, V44, P176, DOI 10.1159/000050045; KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444; Kochel TJ, 2002, LANCET, V360, P310, DOI 10.1016/S0140-6736(02)09522-3; Loke H, 2001, J INFECT DIS, V184, P1369, DOI 10.1086/324320; Markoff L, 2002, J VIROL, V76, P3318, DOI 10.1128/JVI.76.7.3318-3328.2002; Monath TP, 2002, VACCINE, V20, P1004, DOI 10.1016/S0264-410X(01)00457-1; Nhan NT, 2001, CLIN INFECT DIS, V32, P204, DOI 10.1086/318479; Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7; SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932; Sullivan NJ, 2001, CURR TOP MICROBIOL, V260, P145; Thein S, 1997, AM J TROP MED HYG, V56, P566, DOI 10.4269/ajtmh.1997.56.566; Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215	29	103	109	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	2002	360	9341					1243	1245		10.1016/S0140-6736(02)11276-1	http://dx.doi.org/10.1016/S0140-6736(02)11276-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401270				2022-12-28	WOS:000178708100032
J	Bradford, MA; Jones, TH; Bardgett, RD; Black, HIJ; Boag, B; Bonkowski, M; Cook, R; Eggers, T; Gange, AC; Grayston, SJ; Kandeler, E; McCaig, AE; Newington, JE; Prosser, JI; Setala, H; Staddon, PL; Tordoff, GM; Tscherko, D; Lawton, JH				Bradford, MA; Jones, TH; Bardgett, RD; Black, HIJ; Boag, B; Bonkowski, M; Cook, R; Eggers, T; Gange, AC; Grayston, SJ; Kandeler, E; McCaig, AE; Newington, JE; Prosser, JI; Setala, H; Staddon, PL; Tordoff, GM; Tscherko, D; Lawton, JH			Impacts of soil faunal community composition on model grassland ecosystems	SCIENCE			English	Article							TERRESTRIAL ECOSYSTEMS; DECOMPOSITION; BIODIVERSITY; AGROECOSYSTEMS; MINERALIZATION; DIVERSITY; NITROGEN; GROWTH	Human impacts, including global change, may alter the composition of soil faunal communities, but consequences for ecosystem functioning are poorly understood. We constructed model grassland systems in the Ecotron controlled environment facility and manipulated soil community composition through assemblages of different animal body sizes. Plant community composition, microbial and root biomass, decomposition rate, and mycorrhizal colonization were all markedly affected. However, two key ecosystem processes, aboveground net primary productivity and net ecosystem productivity, were surprisingly resistant to these changes. We hypothesize that positive and negative faunal-mediated effects in soil communities cancel each other out, causing no net ecosystem effects.	Univ London Imperial Coll Sci Technol & Med, Nat Environm Res Council Ctr Populat Biol, Dept Biol Sci, Ascot SL5 7PY, Berks, England; Cardiff Univ, Cardiff Sch Biosci, Biodivers & Ecol Proc Res Grp, Cardiff CF10 3TL, S Glam, Wales; Univ Lancaster, Inst Environm & Nat Sci, Dept Biol Sci, Lancaster LA1 4YQ, England; Ctr Ecol & Hydrol, Grange Over Sands LA11 6JU, Cumbria, England; Scottish Crop Res Inst, Dundee DD2 5DA, Scotland; Tech Univ Darmstadt, Fachbereich 10, D-64287 Darmstadt, Germany; Inst Grassland & Environm Res, Aberystwyth SY23 3EB, Dyfed, Wales; Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Macaulay Land Use Res Inst, Aberdeen AB15 8QH, Scotland; Univ Hohenheim, Inst Soil Sci, D-70599 Stuttgart, Germany; Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland; Univ Helsinki, Dept Ecol & Environm Sci, FIN-15140 Lahti, Finland; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; NERC, Swindon SN2 1EU, Wilts, England	Imperial College London; Cardiff University; Lancaster University; UK Centre for Ecology & Hydrology (UKCEH); James Hutton Institute; Technical University of Darmstadt; Aberystwyth University; University of London; Royal Holloway University London; James Hutton Institute; University Hohenheim; University of Aberdeen; University of Helsinki; University of York - UK; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Bradford, MA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Nat Environm Res Council Ctr Populat Biol, Dept Biol Sci, Silwood Pk, Ascot SL5 7PY, Berks, England.	m.a.bradford@ic.ac.uk	Setälä, Heikki M/P-7354-2015; Tordoff, George/E-6365-2012; Prosser, Jim/F-5280-2010; Turan, Veysel/G-7722-2011; Bradford, Mark A/G-3850-2012; Jones, Hefin/A-4331-2010; Bonkowski, Michael/C-3700-2013; McCaig, Allison/F-5054-2017	Prosser, Jim/0000-0003-1757-5102; Bradford, Mark A/0000-0002-2022-8331; Bonkowski, Michael/0000-0003-2656-1183; McCaig, Allison/0000-0002-7398-0244; Tordoff, George/0000-0003-0067-2184; Jones, T Hefin/0000-0002-7874-3627; Kandeler, Ellen/0000-0002-2854-0012				ANDERSON JM, 1995, LINKING SPECIES & ECOSYSTEMS, P94; Anderson JM, 2000, INVERTEBRATES AS WEB-MASTERS IN ECOSYSTEMS, P3, DOI 10.1079/9780851993942.0003; Andren O, 1999, APPL SOIL ECOL, V13, P105, DOI 10.1016/S0929-1393(99)00025-6; Bardgett RD, 1999, SOIL BIOL BIOCHEM, V31, P1007, DOI 10.1016/S0038-0717(99)00014-0; BEARE MH, 1995, PLANT SOIL, V170, P5, DOI 10.1007/BF02183051; BEARE MH, 1992, ECOL MONOGR, V62, P569, DOI 10.2307/2937317; Bengtsson J, 1998, APPL SOIL ECOL, V10, P191, DOI 10.1016/S0929-1393(98)00120-6; BROWN VK, 1989, OIKOS, V54, P67, DOI 10.2307/3565898; Brussaard L, 1997, AMBIO, V26, P563; Hedlund K, 2000, OIKOS, V88, P585, DOI 10.1034/j.1600-0706.2000.880315.x; HENDRIX PF, 1986, BIOSCIENCE, V36, P374, DOI 10.2307/1310259; Jones TH, 1998, SCIENCE, V280, P441, DOI 10.1126/science.280.5362.441; Kampichler C, 2001, SOIL BIOL BIOCHEM, V33, P269, DOI 10.1016/S0038-0717(00)00140-1; Lavelle P, 1997, ADV ECOL RES, V27, P93, DOI 10.1016/S0065-2504(08)60007-0; Lawton JH, 1996, ECOLOGY, V77, P665, DOI 10.2307/2265488; Mikola J, 1998, OIKOS, V83, P180, DOI 10.2307/3546560; MIKOLA J, BIODIVERSITY ECOSYST; PETERSEN H, 1982, OIKOS, V39, P287, DOI 10.2307/3544689; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; Scheu S, 1999, OECOLOGIA, V119, P541, DOI 10.1007/s004420050817; SETALA H, 1991, ECOLOGY, V72, P665, DOI 10.2307/2937206; Setala H, 1996, SOIL BIOL BIOCHEM, V28, P1661, DOI 10.1016/S0038-0717(96)00252-0; Swift M.J., 1979, DECOMPOSITION TERRES, V5; VERHOEF HA, 1990, BIOGEOCHEMISTRY, V11, P175, DOI 10.1007/BF00004496; Wardle DA, 1999, AGROBIODIVERSITY: CHARACTERIZATION, UTILIZATION AND MANAGEMENT, P87; Wolters V, 2000, BIOSCIENCE, V50, P1089, DOI 10.1641/0006-3568(2000)050[1089:EOGCOA]2.0.CO;2; YODZIS P, 1988, ECOLOGY, V69, P508, DOI 10.2307/1940449	27	208	242	17	266	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	2002	298	5593					615	618		10.1126/science.1075805	http://dx.doi.org/10.1126/science.1075805			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386334				2022-12-28	WOS:000178634800045
J	Peale, SJ; Lee, MH				Peale, SJ; Lee, MH			A primordial origin of the Laplace relation among the Galilean satellites	SCIENCE			English	Article							SECULAR ACCELERATION; TIDAL DISSIPATION; EVOLUTION; IO; RESONANCE; GANYMEDE; DISK; CALLISTO; TIDES	Understanding the origin of the orbital resonances of the Galilean satellites of Jupiter will constrain the longevity of the extensive volcanism on Io, may explain liquid ocean on Europa, and may guide studies of the dissipative properties of stars and Jupiter-like planets. The differential migration of the newly formed Galilean satellites due to interactions with circumjovian disk can lead to the primordial formation of the Laplace relation n(1) - 3n(2) + 2n(3) = 0, where the n(i) are the mean orbital angular velocities of Io, Europa, and Ganymede, respectively. This contrasts with the formation of the resonances by differential expansion of the orbits from tidal torques from Jupiter.	Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Peale, SJ (corresponding author), Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA.		Lee, Man Hoi/D-3093-2009	Lee, Man Hoi/0000-0003-1930-5683				Aksnes K, 2001, ASTRON J, V122, P2734, DOI 10.1086/323708; Anderson JD, 1998, SCIENCE, V280, P1573, DOI 10.1126/science.280.5369.1573; Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; Anderson JD, 2001, ICARUS, V153, P157, DOI 10.1006/icar.2001.6664; ARTYMOWICZ P, 1993, ASTROPHYS J, V419, P166, DOI 10.1086/173470; CANUP RM, IN PRESS ASTRON J; GOLDREICH P, 1966, ICARUS, V5, P375, DOI 10.1016/0019-1035(66)90051-0; Goldstein SJ, 1995, ASTRON J, V110, P3054, DOI 10.1086/117746; GREENBERG R, 1987, ICARUS, V70, P334, DOI 10.1016/0019-1035(87)90139-4; Greenberg R., 1982, SATELLITES JUPITER, P65; Kley W, 2001, ASTROPHYS J, V547, P457, DOI 10.1086/318345; Lee MH, 2002, ASTROPHYS J, V567, P596, DOI 10.1086/338504; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; LIESKE JH, 1987, ASTRON ASTROPHYS, V176, P146; Lubow SH, 1999, ASTROPHYS J, V526, P1001, DOI 10.1086/308045; MALHOTRA R, 1991, ICARUS, V94, P399, DOI 10.1016/0019-1035(91)90237-N; OJAKANGAS GW, 1986, ICARUS, V66, P341, DOI 10.1016/0019-1035(86)90163-6; PEALE SJ, 1980, ICARUS, V43, P65, DOI 10.1016/0019-1035(80)90088-3; Peale SJ, 1999, ANNU REV ASTRON ASTR, V37, P533, DOI 10.1146/annurev.astro.37.1.533; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; PEALE SJ, 1980, LUNAR PLANET SCI, V11, P871; Pollack J. B., 1991, URANUS, P469; Schubert G., 1986, SATELLITES, P224; Showman AP, 1997, ICARUS, V127, P93, DOI 10.1006/icar.1996.5669; Showman AP, 1997, ICARUS, V129, P367, DOI 10.1006/icar.1997.5778; Stevenson DJ, 2001, SCIENCE, V294, P71, DOI 10.1126/science.1065306; Stevenson DJ, 1986, SATELLITES, P687; Tanaka H, 2002, ASTROPHYS J, V565, P1257, DOI 10.1086/324713; TITTEMORE WC, 1989, ICARUS, V78, P63, DOI 10.1016/0019-1035(89)90070-5; VEEDER GJ, 2002, AGU SPRING M 2002 28; Ward W. R., 2000, Protostars and planets 4, P1135; YODER CF, 1979, NATURE, V279, P767, DOI 10.1038/279767a0; YODER CF, 1981, ICARUS, V47, P1, DOI 10.1016/0019-1035(81)90088-9	37	61	61	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					593	597		10.1126/science.1076557	http://dx.doi.org/10.1126/science.1076557			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12386333	Green Submitted			2022-12-28	WOS:000178634800039
J	Goulder, LH; Stavins, RN				Goulder, LH; Stavins, RN			Discounting - An eye on the future	NATURE			English	Editorial Material									Stanford Univ, Dept Econ, Stanford, CA 94305 USA; Stanford Univ, Inst Int Studies, Stanford, CA 94305 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Stanford University; Stanford University; Harvard University	Goulder, LH (corresponding author), Stanford Univ, Dept Econ, Stanford, CA 94305 USA.							[Anonymous], 1996, CLIMATE CHANGE 1995; Fullerton D, 1998, NATURE, V395, P433, DOI 10.1038/26606; PORTNEY P, 1999, DISCOUNTING INTEGENE; Weitzman ML, 1998, J ENVIRON ECON MANAG, V36, P201, DOI 10.1006/jeem.1998.1052	4	42	42	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					673	674		10.1038/419673a	http://dx.doi.org/10.1038/419673a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384678				2022-12-28	WOS:000178615200021
J	Jasmer, RM; Saukkonen, JJ; Blumberg, HM; Daley, CL; Bernardo, J; Vittinghoff, E; King, MD; Kawamura, LM; Hopewell, PC				Jasmer, RM; Saukkonen, JJ; Blumberg, HM; Daley, CL; Bernardo, J; Vittinghoff, E; King, MD; Kawamura, LM; Hopewell, PC		Short-Course Rifampin Pyrazinamide	Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A multicenter clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article							PREVENTIVE THERAPY; PROPENSITY SCORE; RANDOMIZED-TRIAL; HEPATITIS	Background: Rifampin and pyrazinamide are recommended for treatment of latent tuberculosis infection in adults without HIV infection, but reports of severe hepatotoxicity have raised concerns about its safety. Clinical trials have not compared this treatment with isoniazid in adults without HIV infection. Objective: To compare the safety and tolerance of a 2-month regimen of rifampin and pyrazinamide with that of a 6-month regimen of isoniazid for treatment of latent tuberculosis infection. Design: Multicenter, prospective, open-label trial. Setting: Three urban public health tuberculosis clinics in the United States. Patients: 589 adults with latent tuberculosis infection who met U.S. criteria for treatment. Intervention: Patients were assigned in alternate weeks to receive rifampin and pyrazinamide daily for 2 months (n = 307) or isoniazid daily for 6 months (n = 282). Measurements: Primary end points were hepatotoxicity, other adverse events, and percentage of patients who completed treatment. Results: Sixteen of 207 (7.7%) patients assigned to rifampin and pyrazinamide developed grade 3 or 4 hepatotoxicity compared with 2 of 204 (11%) patients assigned to isoniazid (odds ratio, 8.46 (95% Cl, 1.9 to 76.51; P = 0.001). The rifampin plus pyrazinamide regimen was more likely than the isoniazid regimen to be discontinued because of hepatotoxicity (odds ratio, 5.19; P = 0.033). The overall percentage of nonhepatotoxic adverse events was 20% in the rifampin-pyrazinamide group and 16% in the isoniazid group. The proportion of patients who completed the study treatment was 61% and 57%, respectively. Conclusions: A 2-month regimen of rifampin and pyrazinamide was associated with an increased risk for grade 3 or 4 hepatotoxicity compared with a 6-month regimen of isoniazid. Liver enzymes should be measured routinely during treatment to screen for liver injury and prevent progression to severe toxicity.	San Francisco Gen Hosp, Med Ctr, Div Pulm & Crit Care Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Francis J Curry Natl TB Ctr, San Francisco, CA USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Emory Univ, Sch Med, Atlanta, GA USA; Grady Mem Hosp, Atlanta, GA USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Boston University; Emory University	Jasmer, RM (corresponding author), San Francisco Gen Hosp, Med Ctr, Div Pulm & Crit Care Med, Room 5K-1,1001 Potrero Ave, San Francisco, CA 94110 USA.	rjasmer@itsa.ucsf.edu	Daley, Charles L./AAC-3231-2021; Blumberg, Henry/W-2156-2019	Blumberg, Henry/0000-0002-3110-2443; Bernardo, John/0000-0002-3922-0559	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001549] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03057, HL 03078, HL 62977, HL 03035] Funding Source: Medline; NIAID NIH HHS [AI 01549] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_; [Anonymous], 1959, AM REV RESPIR DIS, V80, P371; [Anonymous], 1979, WHO ART ADV DRUG REA; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Bock NN, 2001, CHEST, V119, P833, DOI 10.1378/chest.119.3.833; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; GEITER L, 2000, I MED ENDING NEGLECT, P86; GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36; Gordin F, 2000, JAMA-J AM MED ASSOC, V283, P1445, DOI 10.1001/jama.283.11.1445; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; Little R. J. A., 1987, STAT ANAL MISSING DA; MITCHELL JR, 1976, ANN INTERN MED, V84, P181, DOI 10.7326/0003-4819-84-2-181; *MMWR, 1995, MMWR-MORBID MORTAL W, V44, P1; *MMWR, 1998, MMWR-MORBID MORTAL W, V47, P253; *MMWR, 1999, MMWR-MORBID MORTAL W, V48, P1; *MMWR, 2001, MMWR-MORBID MORTAL W, V50, P733; *MMWR, 2001, MMWR-MORBID MORTAL W, V50, P289; Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014; Nolan CM, 1999, JAMA-J AM MED ASSOC, V281, P1014, DOI 10.1001/jama.281.11.1014; Ridzon R, 1997, CLIN INFECT DIS, V24, P1264, DOI 10.1093/clinids/24.6.1264; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Schafer JL., 2000, ANAL INCOMPLETE MULT; SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494, DOI 10.1164/ajrccm/145.2_Pt_1.494; SNIDER DE, 1984, AM REV RESPIR DIS, V130, P355; *US DHHS, 2001, REP TUB US 2000	26	139	145	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2002	137	8					640	647		10.7326/0003-4819-137-8-200210150-00007	http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604WL	12379063				2022-12-28	WOS:000178644000002
J	Deban, SM; Olson, WM				Deban, SM; Olson, WM			Biomechanics: Suction feeding by a tiny predatory tadpole	NATURE			English	Article									Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Museum Vertebrate Zool, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Deban, SM (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.		Deban, Stephen/AFS-8445-2022; Deban, Stephen/AAI-7307-2020	Deban, Stephen/0000-0002-7979-4346; Deban, Stephen/0000-0002-7979-4346				CANNATELLA DC, 1988, J HERPETOL, V22, P439, DOI 10.2307/1564339; Deban SM, 2001, AM ZOOL, V41, P1280, DOI 10.1668/0003-1569(2001)041[1280:TEOTMC]2.0.CO;2; DROST MR, 1986, J FISH BIOL, V29, P371, DOI 10.1111/j.1095-8649.1986.tb04953.x; Hernandez LP, 2000, J EXP BIOL, V203, P3033; Hoff KV, 1999, TADPOLES, P215; MULLER M, 1984, Transactions of the Zoological Society of London, V37, P51; Osse J. W. M., 1999, Journal of Fish Biology, V55, P156, DOI 10.1006/jfbi.1999.1071; Sanderson S. Laurie, 1999, P301; SANDERSON SL, 1993, SKULL, V3, P37; SOKOL OM, 1962, COPEIA, P272; Vogel S, 1996, LIFE MOVING FLUIDS; WASSERSUG RJ, 1979, BIOL J LINN SOC, V12, P225, DOI 10.1111/j.1095-8312.1979.tb00056.x	12	39	40	4	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					41	42		10.1038/420041a	http://dx.doi.org/10.1038/420041a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612HJ	12422207				2022-12-28	WOS:000179068100029
J	Yang, Z; Yamada, J; Zhao, YW; Strauss, AW; Ibdah, JA				Yang, Z; Yamada, J; Zhao, YW; Strauss, AW; Ibdah, JA			Prospective screening for pediatric mitochondrial trifunctional protein defects in pregnancies complicated by liver disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE FATTY LIVER; A DEHYDROGENASE-DEFICIENCY; ACID OXIDATION; HELLP-SYNDROME; MOLECULAR CHARACTERIZATION; ALPHA-SUBUNIT; LOW PLATELETS; ENZYMES; PREVALENCE; MUTATIONS	Context Acute fatty liver of pregnancy (AFLP) and hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome are serious complications of pregnancy. Studies in families with recessively inherited mitochondrial trifunctional protein defects documented an association between these maternal illnesses and fetal deficiency of long-chain 3-hydroxyacyl coenzyme A dehydrogenase; this enzyme resides in the alpha subunit of the trifunctional protein and catalyzes the third step in long-chain fatty acid beta oxidation. Objective To estimate the frequency of fetal long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency in pregnancies complicated by AFLP or HELLP syndrome. Design, Setting, and Subjects Cohort study in which 108 consecutive blood samples from women who developed AFLP or HELLP syndrome, from their offspring, or from their partners were referred to our laboratory for molecular screening from January 1997 to December 2001. Twenty-seven women had AFLP and 81 had HELLP syndrome. We screened the DNA for mutations in the alpha subunit of the trifunctional protein. Main Outcome Measure Presence of mutations that cause 3-hydroxyacyl coenzyme A dehydrogenase deficiency in the offspring. Results We detected mutations causing pediatric long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency in 5 families (19%) with maternal history of AFLP (95% confidence interval, 9%-54%). The maternal allele carried a prevalent glutamic acid 474 to glutamine (E474Q) mutation. The paternal allele carried the E474Q mutation in 3 families and a stop codon mutation in the other 2 families. Only 1 woman with HELLP syndrome was heterozygous for the E474Q mutation; no mutations were detected in the newborn. Conclusion The association between AFLP and the E474Q mutation in the fetus is significant. Screening newborns for this mutation in pregnancies complicated by AFLP could allow early diagnosis and treatment in newborns and genetic counseling and prenatal diagnosis in subsequent pregnancies in affected families.	Wake Forest Univ, Bowman Gray Sch Med, Div Gastroenterol, Dept Internal Med, Winston Salem, NC 27157 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA	Wake Forest University; Wake Forest Baptist Medical Center; Vanderbilt University	Ibdah, JA (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Div Gastroenterol, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Ibdah, Jamal/0000-0002-5646-9014	NIADDK NIH HHS [AM-20407] Funding Source: Medline; NIDDK NIH HHS [DK-02574] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002574] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRACKETT JC, 1995, J CLIN INVEST, V95, P2076, DOI 10.1172/JCI117894; Den Boer MEJ, 2000, PEDIATR RES, V48, P151, DOI 10.1203/00006450-200008000-00006; Ibdah JA, 1999, NEW ENGL J MED, V340, P1723, DOI 10.1056/NEJM199906033402204; Ibdah JA, 1998, J CLIN INVEST, V102, P1193, DOI 10.1172/JCI2091; Ibdah JA, 2001, J PEDIATR-US, V138, P396, DOI 10.1067/mpd.2001.111503; IJIST L, 1996, J CLIN INVEST, V98, P1028; Innes AM, 2000, PEDIATR RES, V47, P43, DOI 10.1203/00006450-200001000-00010; Isaacs JD, 1996, PEDIATR RES, V40, P393, DOI 10.1203/00006450-199609000-00005; JACKSON S, 1992, J CLIN INVEST, V90, P1219, DOI 10.1172/JCI115983; KAMIJO T, 1994, J CLIN INVEST, V93, P1740, DOI 10.1172/JCI117158; KAMIJO T, 1994, BIOCHEM BIOPH RES CO, V199, P818, DOI 10.1006/bbrc.1994.1302; Knox TA, 1996, NEW ENGL J MED, V335, P569, DOI 10.1056/NEJM199608223350807; Mansouri A, 1996, J HEPATOL, V25, P781, DOI 10.1016/S0168-8278(96)80254-6; Marshall E, 2001, SCIENCE, V294, P2272, DOI 10.1126/science.294.5550.2272; Matern D, 2001, J PEDIATR-US, V138, P585, DOI 10.1067/mpd.2001.111814; Nelson J, 2000, J INHERIT METAB DIS, V23, P518, DOI 10.1023/A:1005676600975; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Riely CA, 1999, AM J GASTROENTEROL, V94, P1728; SCHOEMAN MN, 1991, GASTROENTEROLOGY, V100, P544, DOI 10.1016/0016-5085(91)90228-D; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P311, DOI 10.1016/0002-9378(90)90376-I; SIMS HF, 1995, P NATL ACAD SCI USA, V92, P841, DOI 10.1073/pnas.92.3.841; TREEM WR, 1994, HEPATOLOGY, V19, P339; Treem WR, 1996, AM J GASTROENTEROL, V91, P2293; Tyni T, 1998, AM J OBSTET GYNECOL, V178, P603, DOI 10.1016/S0002-9378(98)70446-6; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; Ushikubo S, 1996, AM J HUM GENET, V58, P979; WILCKEN B, 1993, LANCET, V341, P407, DOI 10.1016/0140-6736(93)92993-4	27	73	81	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2002	288	17					2163	2166		10.1001/jama.288.17.2163	http://dx.doi.org/10.1001/jama.288.17.2163			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611ZJ	12413376	Bronze			2022-12-28	WOS:000179048100027
J	Dalbeth, N; Callan, M				Dalbeth, N; Callan, M			Arthritis and anorexia?	LANCET			English	Editorial Material							COMPLEMENT; ADIPOCYTE		Nuffield Orthopaed Ctr, Div Rheumatol, Oxford OX3 7LD, England	Nuffield Orthopaedic Centre	Dalbeth, N (corresponding author), Nuffield Orthopaed Ctr, Div Rheumatol, Oxford OX3 7LD, England.				Medical Research Council [G116/121] Funding Source: Medline; MRC [G116/121] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		CHOY LN, 1992, J BIOL CHEM, V267, P12736; MATHIESON PW, 1993, J EXP MED, V177, P1827, DOI 10.1084/jem.177.6.1827; Mathieson PW, 1997, NEPHROL DIAL TRANSPL, V12, P1804, DOI 10.1093/ndt/12.9.1804; MATHIESON PW, 1994, Q J MED, V87, P584; WALPORT MJ, 1994, QJM, V87, P607	5	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1300	1300		10.1016/S0140-6736(02)11320-1	http://dx.doi.org/10.1016/S0140-6736(02)11320-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608CH	12414206				2022-12-28	WOS:000178827200013
J	Grimby, G				Grimby, G			Focused multidisciplinary services for young people with disabilities	LANCET			English	Editorial Material							CEREBRAL-PALSY; SPINA-BIFIDA; ADULTS; TRANSITION		Univ Gothenburg, Sahlgrenska Acad, Dept Rehabil Med, SE-41345 Gothenburg, Sweden	University of Gothenburg	Grimby, G (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Dept Rehabil Med, SE-41345 Gothenburg, Sweden.		Grimby, Gunnar/AAB-3178-2019					Andren E, 2000, DISABIL REHABIL, V22, P299, DOI 10.1080/096382800296656; CATHELS BA, 1993, MED J AUSTRALIA, V159, P444, DOI 10.5694/j.1326-5377.1993.tb137961.x; Di Fabio RP, 1998, ARCH PHYS MED REHAB, V79, P141, DOI 10.1016/S0003-9993(98)90290-8; Fiorentino L, 1998, ARCH DIS CHILD, V79, P306, DOI 10.1136/adc.79.4.306; Grimby G, 1996, ARCH PHYS MED REHAB, V77, P1109, DOI 10.1016/S0003-9993(96)90131-8; JESPERSON A, 2002, SOC MED TIDSKR, V79, P244; Stevenson CJ, 1997, DEV MED CHILD NEUROL, V39, P336; van der Dussen L, 2001, CLIN REHABIL, V15, P84, DOI 10.1191/026921501670159475; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	9	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 26	2002	360	9342					1264	1265		10.1016/S0140-6736(02)11355-9	http://dx.doi.org/10.1016/S0140-6736(02)11355-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	608CH	12414197				2022-12-28	WOS:000178827200004
J	Hanninen, P				Hanninen, P			Light microscopy - Beyond the diffraction limit	NATURE			English	Article									Univ Turku, Dept Med Phys, Turku, Finland	University of Turku	Hanninen, P (corresponding author), Univ Turku, Dept Med Phys, Turku, Finland.		Hanninen, Pekka/C-7412-2012	Hanninen, Pekka/0000-0001-5481-3275				Dyba M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.163901; Stelzer EHK, 2002, NATURE, V417, P806, DOI 10.1038/417806a	2	7	7	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	2002	419	6909					802	802		10.1038/419802b	http://dx.doi.org/10.1038/419802b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607BD	12397348	Bronze			2022-12-28	WOS:000178769800036
J	Peters, A; Pope, CA				Peters, A; Pope, CA			Cardiopulmonary mortality and air pollution	LANCET			English	Editorial Material							ASSOCIATION		GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85758 Neuherberg, Germany; Brigham Young Univ, Provo, UT 84602 USA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Brigham Young University	Peters, A (corresponding author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85758 Neuherberg, Germany.	peters@gsf.de	Pope, C. Arden/ABD-5522-2021; Peters, Annette/A-6117-2011	Peters, Annette/0000-0001-6645-0985				Brook RD, 2002, CIRCULATION, V105, P1534, DOI 10.1161/01.CIR.0000013838.94747.64; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; LOGAN WPD, 1953, LANCET, V264, P336; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 2001, EUR HEART J, V22, P1198, DOI 10.1053/euhj.2000.2483; Peters A, 2001, CIRCULATION, V103, P2810; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; Pope CA, 1999, AM HEART J, V138, P890, DOI 10.1016/S0002-8703(99)70014-1; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Suwa T, 2002, J AM COLL CARDIOL, V39, P935, DOI 10.1016/S0735-1097(02)01715-1	11	86	87	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	2002	360	9341					1184	1185		10.1016/S0140-6736(02)11289-X	http://dx.doi.org/10.1016/S0140-6736(02)11289-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	605ZZ	12401239				2022-12-28	WOS:000178708100002
J	Wilson, WA; Roach, PJ				Wilson, WA; Roach, PJ			Nutrient-regulated protein kinases in budding yeast	CELL			English	Review							SERINE/THREONINE KINASE; SENSORS; OXYGEN; TOR	The ability of cells to react appropriately to nutritional cues is of fundamental importance, and in budding yeast, a small number of intracellular protein kinases, PKA, Snf1p/AMP-activated kinase, TOR, Gcn2p, and the cyclin-dependent kinase Pho85p have key roles. A recently characterized enzyme, PAS kinase, may be a new member of this group of nutritional transducers.	Indiana Univ, Sch Med, Ctr Diabet Res, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Roach, PJ (corresponding author), Indiana Univ, Sch Med, Ctr Diabet Res, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.			Wilson, Wayne/0000-0003-2417-5756				Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; Carroll AS, 2002, TRENDS BIOCHEM SCI, V27, P87, DOI 10.1016/S0968-0004(01)02040-0; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Gilles-Gonzalez MA, 2001, IUBMB LIFE, V51, P165, DOI 10.1080/152165401753544232; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Hofer T, 2001, BIOCHEM BIOPH RES CO, V288, P757, DOI 10.1006/bbrc.2001.5840; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Moffat J, 2000, Prog Cell Cycle Res, V4, P97; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Rutter J, 2002, CELL, V111, P17, DOI 10.1016/S0092-8674(02)00974-1; Rutter J, 2001, P NATL ACAD SCI USA, V98, P8991, DOI 10.1073/pnas.161284798; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shemer R, 2002, MOL CELL BIOL, V22, P5395, DOI 10.1128/MCB.22.15.5395-5404.2002; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001	20	83	85	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 18	2002	111	2					155	158		10.1016/S0092-8674(02)01043-7	http://dx.doi.org/10.1016/S0092-8674(02)01043-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	606UX	12408859	Bronze			2022-12-28	WOS:000178753500004
J	Kasper, LH; Boussouar, F; Ney, PA; Jackson, CW; Rehg, J; van Deursen, JM; Brindle, PK				Kasper, LH; Boussouar, F; Ney, PA; Jackson, CW; Rehg, J; van Deursen, JM; Brindle, PK			A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis	NATURE			English	Article							T-CELL DEVELOPMENT; SECONDARY STRUCTURE; C-MYB; MICE LACKING; PROTEIN; CREB; ACTIVATION; GENE; MEGAKARYOCYTES; INITIATION	The coactivators CBP (Cre-element binding protein (CREB) binding protein) and its paralogue p300 are thought to supply adaptor molecule and protein acetyltransferase functions to many transcription factors that regulate gene expression(1). Normal development requires CBP and p300, and mutations in these genes are found in haematopoietic and epithelial tumours(2-6). It is unclear, however, which functions of CBP and p300 are essential in vivo. Here we show that the protein-binding KIX domains of CBP and p300 have nonredundant functions in mice. In mice homozygous for point mutations in the KIX domain of p300 designed to disrupt the binding surface for the transcription factors c-Myb and CREB7-9, multilineage defects occur in haematopoiesis, including anaemia, B-cell deficiency, thymic hypoplasia, megakaryocytosis and thrombocytosis. By contrast, age-matched mice homozygous for identical mutations in the KIX domain of CBP are essentially normal. There is a synergistic genetic interaction between mutations in c-Myb and mutations in the KIX domain of p300, which suggests that the binding of c-Myb to this domain of p300 is crucial for the development and function of megakaryocytes. Thus, conserved domains in two highly related coactivators have contrasting roles in haematopoiesis.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Mayo Clinic	Brindle, PK (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	paul.brindle@stjude.org	Rehg, Jerold E/N-8111-2018; Boussouar, Fayçal/E-7542-2019; Kasper, Lawryn/GWV-5700-2022; Boussouar, Fayçal/N-2511-2013	Boussouar, Fayçal/0000-0003-4529-4893; Brindle, Paul/0000-0001-7172-8478	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053469] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK053469-02, R01 DK053469-03, R01 DK053469-04, R01 DK053469-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Arnold JT, 1997, BLOOD, V89, P823, DOI 10.1182/blood.V89.3.823; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Goodman RH, 2000, GENE DEV, V14, P1553; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; JACKSON CW, 1990, BLOOD, V76, P690; Jacobsson S, 1996, EUR J HAEMATOL, V56, P287, DOI 10.1111/j.1600-0609.1996.tb00717.x; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kung AL, 2000, GENE DEV, V14, P272; Lecine P, 1998, J BIOL CHEM, V273, P7572, DOI 10.1074/jbc.273.13.7572; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; Oike Y, 1999, BLOOD, V93, P2771; Parker D, 1999, MOL CELL BIOL, V19, P5601; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	27	147	152	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					738	743		10.1038/nature01062	http://dx.doi.org/10.1038/nature01062			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384703				2022-12-28	WOS:000178615200045
J	Schuler, B; Lipman, EA; Eaton, WA				Schuler, B; Lipman, EA; Eaton, WA			Probing the free-energy surface for protein folding with single-molecule fluorescence spectroscopy	NATURE			English	Article							TRANSFER CONFOCAL MICROSCOPY; COLD-SHOCK PROTEIN; DIFFUSING MOLECULES; THERMOTOGA-MARITIMA; BETA-SHEET; DYNAMICS; PEPTIDES; MODEL; DENATURATION; DEPENDENCE	Protein folding is inherently a heterogeneous process because of the very large number of microscopic pathways that connect the myriad unfolded conformations to the unique conformation of the native structure. In a first step towards the long-range goal of describing the distribution of pathways experimentally, Forster resonance energy transfer(1) (FRET) has been measured on single, freely diffusing molecules(2-4). Here we use this method to determine properties of the free-energy surface for folding that have not been obtained from ensemble experiments. We show that single-molecule FRET measurements of a small cold-shock protein expose equilibrium collapse of the unfolded polypeptide and allow us to calculate limits on the polypeptide reconfiguration time. From these results, limits on the height of the free-energy barrier to folding are obtained that are consistent with a simple statistical mechanical model, but not with the barriers derived from simulations using molecular dynamics. Unlike the activation energy, the free-energy barrier includes the activation entropy and thus has been elusive to experimental determination for any kinetic process in solution.	NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Eaton, WA (corresponding author), NIDDKD, Chem Phys Lab, NIH, Bldg 5, Bethesda, MD 20892 USA.		Schuler, Benjamin/E-7342-2011; Lipman, Everett/D-1696-2009	Schuler, Benjamin/0000-0002-5970-4251; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029010, ZIADK029010] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN MP, 1987, COMPUTER SIMULATION, V192; ALONSO DOV, 1991, BIOCHEMISTRY-US, V30, P5974, DOI 10.1021/bi00238a023; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; BRYNGELSON JD, 1987, P NATL ACAD SCI USA, V84, P7524, DOI 10.1073/pnas.84.21.7524; Chan CK, 1997, P NATL ACAD SCI USA, V94, P1779, DOI 10.1073/pnas.94.5.1779; Dahan M, 1999, CHEM PHYS, V247, P85, DOI 10.1016/S0301-0104(99)00132-9; Deniz AA, 2000, P NATL ACAD SCI USA, V97, P5179, DOI 10.1073/pnas.090104997; Deniz AA, 1999, P NATL ACAD SCI USA, V96, P3670, DOI 10.1073/pnas.96.7.3670; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Hagen SJ, 1997, J PHYS CHEM B, V101, P2352, DOI 10.1021/jp9622997; Jacob J, 1999, BIOPHYS J, V77, P1086, DOI 10.1016/S0006-3495(99)76958-4; Jager M, 2001, J MOL BIOL, V311, P373, DOI 10.1006/jmbi.2001.4873; Jia YW, 1999, CHEM PHYS, V247, P69, DOI 10.1016/S0301-0104(99)00127-5; Klimov DK, 1997, PHYS REV LETT, V79, P317, DOI 10.1103/PhysRevLett.79.317; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; Kremer W, 2001, EUR J BIOCHEM, V268, P2527, DOI 10.1046/j.1432-1327.2001.02127.x; LAPIDUS LJ, IN PRESS J PHYS CH B; Mandelkern L., 1967, POLY A AMINO ACIDS, P675; MILLETT IS, IN PRESS ADV PROT CH; Munoz V, 1999, P NATL ACAD SCI USA, V96, P11311, DOI 10.1073/pnas.96.20.11311; Nymeyer H, 2000, P NATL ACAD SCI USA, V97, P634, DOI 10.1073/pnas.97.2.634; Perl D, 1998, NAT STRUCT BIOL, V5, P229, DOI 10.1038/nsb0398-229; Portman JJ, 2001, J CHEM PHYS, V114, P5082, DOI 10.1063/1.1334663; Reid KL, 1998, PROTEIN SCI, V7, P470; Shea JE, 2001, ANNU REV PHYS CHEM, V52, P499, DOI 10.1146/annurev.physchem.52.1.499; Socci ND, 1996, J CHEM PHYS, V104, P5860, DOI 10.1063/1.471317; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Talaga DS, 2000, P NATL ACAD SCI USA, V97, P13021, DOI 10.1073/pnas.97.24.13021; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; Wassenberg D, 1999, J MOL BIOL, V289, P187, DOI 10.1006/jmbi.1999.2772	31	746	761	6	291	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 17	2002	419	6908					743	747		10.1038/nature01060	http://dx.doi.org/10.1038/nature01060			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604JF	12384704	Green Published			2022-12-28	WOS:000178615200046
J	Bodenheimer, T; Wagner, EH; Grumbach, K				Bodenheimer, T; Wagner, EH; Grumbach, K			Improving primary care for patients with chronic illness - The chronic care model, part 2	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; IMPROVED GLYCEMIC CONTROL; QUALITY-OF-LIFE; SELF-MANAGEMENT; HEALTH-CARE; DIABETES MANAGEMENT; ECONOMIC-EVALUATION; COST-EFFECTIVENESS; EDUCATION-PROGRAM; GENERAL-PRACTICE	This article reviews research evidence showing to what extent the chronic care model can improve the management of chronic conditions (using diabetes as an example) and reduce health care costs. Thirty-two of 39 studies found that interventions based on chronic care model components improved at least 1 process or outcome measure for diabetic patients. Regarding whether chronic care model interventions can reduce costs, 18 of 27 studies concerned with 3 examples of chronic conditions (congestive heart failure, asthma, and diabetes) demonstrated reduced health care costs or lower use of health care services. Even though the chronic care model has the potential to improve care and reduce costs, several obstacles hinder its widespread adoption.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, MacColl Inst Healthcare Innovat, Seattle, WA 98101 USA	University of California System; University of California San Francisco; Group Health Cooperative	Bodenheimer, T (corresponding author), San Francisco Gen Hosp, Bldg 80-83,1001 Potrero Ave, San Francisco, CA 94110 USA.	Bodenheimer@Medsch.ucsf.edu	Grumbach, Kevin/L-9222-2016					BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; BOLTON MB, 1991, J GEN INTERN MED, V6, P401, DOI 10.1007/BF02598160; BYRNES J, 1998, DIS MANAG, V1, P39; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; Cline CMJ, 1998, HEART, V80, P442, DOI 10.1136/hrt.80.5.442; DEWEERDT I, 1991, DIABETIC MED, V8, P338; Domurat ES, 1999, AM J MANAG CARE, V5, P1299; Dougherty G, 1999, PEDIATRICS, V103, P122, DOI 10.1542/peds.103.1.122; Gallefoss F, 2001, EUR RESPIR J, V17, P206, DOI 10.1183/09031936.01.17202060; Ghosh CS, 1998, SOC SCI MED, V46, P1087, DOI 10.1016/S0277-9536(97)10047-8; Greineder DK, 1999, J ALLERGY CLIN IMMUN, V103, P436, DOI 10.1016/S0091-6749(99)70468-9; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Kauppinen R, 2001, RESP MED, V95, P56, DOI 10.1053/rmed.2000.0971; Kelly CS, 2000, PEDIATRICS, V105, P1029, DOI 10.1542/peds.105.5.1029; KELSO TM, 1995, AM J EMERG MED, V13, P632, DOI 10.1016/0735-6757(95)90046-2; Lahdensuo A, 1998, BRIT MED J, V316, P1138, DOI 10.1136/bmj.316.7138.1138; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; MAZZE RS, 1994, DIABETES CARE, V17, P56; Morrison I, 2000, BRIT MED J, V321, P1541, DOI 10.1136/bmj.321.7276.1541; Munroe WP, 1997, CLIN THER, V19, P113, DOI 10.1016/S0149-2918(97)80078-1; Oddone E Z, 1999, Eff Clin Pract, V2, P201; Olivarius ND, 2001, BMJ-BRIT MED J, V323, P970, DOI 10.1136/bmj.323.7319.970; Oswald N, 2001, HEALTH AFFAIR, V20, P61, DOI 10.1377/hlthaff.20.6.61; PIEBER TR, 1995, DIABETIC MED, V12, P349, DOI 10.1111/j.1464-5491.1995.tb00491.x; RENDERS CM, 2001, INTERVENTIONS IMPROV; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Riegel B, 2000, J CARD FAIL, V6, P290, DOI 10.1054/jcaf.2000.19226; Sadur CN, 1999, DIABETES CARE, V22, P2011, DOI 10.2337/diacare.22.12.2011; STEIN GH, 1974, MED CARE, V12, P885, DOI 10.1097/00005650-197410000-00008; Stewart S, 1999, ARCH INTERN MED, V159, P257, DOI 10.1001/archinte.159.3.257; SULLIVAN FM, 1991, PRACTICAL DIABETES, V8, P47; Tai SS, 1999, METHOD INFORM MED, V38, P177; Testa MA, 1998, JAMA-J AM MED ASSOC, V280, P1490, DOI 10.1001/jama.280.17.1490; Vojta CL, 1999, J CLIN OUTCOMES MANA, V6, P30; Wagner EH, 2001, JAMA-J AM MED ASSOC, V285, P182, DOI 10.1001/jama.285.2.182; Wagner EH, 2001, DIABETES CARE, V24, P695, DOI 10.2337/diacare.24.4.695; WILSON SR, 1993, AM J MED, V94, P564, DOI 10.1016/0002-9343(93)90206-5	38	1484	1491	4	132	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	2002	288	15					1909	1914		10.1001/jama.288.15.1909	http://dx.doi.org/10.1001/jama.288.15.1909			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604EU	12377092				2022-12-28	WOS:000178604200032
